<SEC-DOCUMENT>0001683168-16-000543.txt : 20161110
<SEC-HEADER>0001683168-16-000543.hdr.sgml : 20161110
<ACCEPTANCE-DATETIME>20161110171605
ACCESSION NUMBER:		0001683168-16-000543
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		64
CONFORMED PERIOD OF REPORT:	20160930
FILED AS OF DATE:		20161110
DATE AS OF CHANGE:		20161110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AETHLON MEDICAL INC
		CENTRAL INDEX KEY:			0000882291
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				133632859
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37487
		FILM NUMBER:		161989132

	BUSINESS ADDRESS:	
		STREET 1:		9635 GRANITE RIDGE DRIVE, SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123
		BUSINESS PHONE:		858-459-7800

	MAIL ADDRESS:	
		STREET 1:		9635 GRANITE RIDGE DRIVE, SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BISHOP EQUITIES INC
		DATE OF NAME CHANGE:	19930602
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>aethlon_10q-093016.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">FORM 10-Q</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Mark One)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">x</FONT></TD>
    <TD STYLE="width: 95%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the quarterly period ended September 30,
2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">OR</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">o</FONT></TD>
    <TD STYLE="width: 95%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the transition period from _____to_____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">COMMISSION FILE NUMBER 001-37487</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">AETHLON MEDICAL, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its
charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEVADA</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 48%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13-3632859</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of incorporation or organization)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">9635 GRANITE RIDGE DRIVE, SUITE 100, SAN DIEGO,
CA 92123</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive offices) &nbsp;&nbsp;&nbsp;(Zip
Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(858) 459-7800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Registrant's telephone number, including area
code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days.&nbsp;&nbsp;&nbsp;YES &nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp; NO&nbsp;&nbsp;&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant has submitted electronically
and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule
405 of Regulation S-T (ss.232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files).&nbsp;&nbsp;&nbsp;YES&nbsp;&#9746;&nbsp;&nbsp;&nbsp; NO&nbsp;&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &quot;large accelerated
filer,&quot; &quot;accelerated filer&quot; and &quot;smaller reporting company&quot; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer&nbsp;&#9744;</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer&nbsp; &#9744;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Non-accelerated filer&nbsp; &#9744;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Do not check if a smaller reporting company)</P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company&nbsp; &#9746;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp; YES&nbsp;&nbsp; &#9744;&nbsp;&nbsp;&nbsp;&nbsp;NO&nbsp;&nbsp;&nbsp;&#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">As of November 8, 2016, the registrant had outstanding 7,725,072
shares of common stock, $.001 par value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART I.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL INFORMATION</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 88%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 1.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL STATEMENTS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONDENSED CONSOLIDATED BALANCE SHEETS AT SEPTEMBER&nbsp;30,&nbsp;2016 (UNAUDITED) AND MARCH&nbsp;31,&nbsp;2016</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE AND SIX MONTH PERIODS ENDED SEPTEMBER 30, 2016 AND 2015 (UNAUDITED)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE SIX MONTHS ENDED SEPTEMBER 30, 2016 AND 2015 (UNAUDITED)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 2.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 3.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 4.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONTROLS AND PROCEDURES</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART II.&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OTHER INFORMATION</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 1.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL PROCEEDINGS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 1A.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 2.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 3.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEFAULTS UPON SENIOR SECURITIES</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 4.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MINE SAFETY DISCLOSURES</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 5.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OTHER INFORMATION</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 6.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBITS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">PART I. FINANCIAL INFORMATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">AETHLON MEDICAL, INC. AND SUBSIDIARY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CONDENSED CONSOLIDATED BALANCE SHEETS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">September 30, <BR> 2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">March 31, <BR> 2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 66%; padding-left: 10pt">Cash</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">556,352</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">2,123,737</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">193,719</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">199,471</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">66,469</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">53,294</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 20pt">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">816,540</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,376,502</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Property and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,969</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,038</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Patents and patents pending, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">89,579</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">94,161</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 1pt">Deposits</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">21,747</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">22,415</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">950,835</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,529,116</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">LIABILITIES AND EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">384,728</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">244,804</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Due to related parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58,362</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">145,112</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Convertible notes payable, net - current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">605,815</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">35,316</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">136,695</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 20pt">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,084,221</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">526,611</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Convertible notes payable, net - less current portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">500,139</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Total liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,084,221</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,026,750</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Commitments and Contingencies (Note 13)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Aethlon Medical, Inc. Stockholders&rsquo; (Deficit) Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">Common stock, par value $0.001 per share; 30,000,000 shares authorized as of September 30, 2016 and March 31, 2016; 7,711,811 and 7,622,393 shares issued and outstanding as of September 30, 2016 and March 31, 2016, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,711</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,621</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">90,811,302</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">88,047,142</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(90,886,645</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(86,502,043</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Total Aethlon Medical, Inc. stockholders&rsquo; (deficit) equity before noncontrolling interests</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(67,632</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,552,720</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Noncontrolling interests</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(65,754</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(50,354</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total (deficit) equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(133,386</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,502,366</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total liabilities and equity</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">950,835</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,529,116</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">AETHLON MEDICAL, INC. AND SUBSIDIARY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the Three and Six Month Periods Ended September
30, 2016 and 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Three Months <BR> Ended <BR> September 30, <BR> 2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Three Months <BR> Ended <BR> September 30, <BR> 2015</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Six Months <BR> Ended <BR> September 30, <BR> 2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Six Months <BR> Ended <BR> September 30, <BR> 2015</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>REVENUES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 40%; text-align: left; padding-left: 10pt">Government contract revenue</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">387,438</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">188,366</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">392,073</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">380,874</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">OPERATING EXPENSES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Professional fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">510,982</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">389,207</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,078,731</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">927,433</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Payroll and related expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,813,003</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">597,850</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,158,190</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,056,078</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">General and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">290,131</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">325,670</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">513,681</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">611,695</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,614,116</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,312,727</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,750,602</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,595,206</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">OPERATING LOSS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,226,678</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,124,361</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,358,529</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,214,332</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">OTHER EXPENSE</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Interest and other debt expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,576</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">127,245</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">78,743</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">253,933</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Loss on debt extinguishment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">616,889</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Warrant repricing expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">345,841</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Total other expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">36,576</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">127,245</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,041,473</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">253,933</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">NET LOSS BEFORE NONCONTROLLING INTERESTS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,263,254</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,251,606</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,400,002</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,468,265</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">LOSS ATTRIBUTABLE TO NONCONTROLLING INTERESTS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,668</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(27,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(15,400</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(60,623</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,255,586</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,224,606</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(4,384,602</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,407,642</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">BASIC AND DILUTED LOSS PER COMMON SHARE</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.29</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.16</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.57</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.34</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING &ndash; BASIC AND DILUTED</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,756,883</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,610,459</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,690,369</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,167,903</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">AETHLON MEDICAL, INC. AND SUBSIDIARY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the Six Months Ended September 30, 2016
and 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Six Months <BR> Ended <BR> September 30, <BR> 2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Six Months <BR> Ended <BR> September 30, <BR> 2015</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Cash flows from operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 66%; text-align: left; padding-left: 10pt">Net loss</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(4,400,002</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(2,468,265</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,612</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,676</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 20pt">Stock based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,573,991</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">101,421</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Warrant repricing expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">345,841</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 20pt">Loss on debt extinguishment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">616,889</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Amortization of debt discount and deferred financing costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,639</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">225,717</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 30pt">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 40pt">Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,752</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,533</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 40pt">Prepaid expenses and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,507</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(35,777</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 40pt">Accounts payable and other current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">125,842</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(144,533</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 40pt">Due to related parties</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(86,750</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">58,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,763,693</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,238,228</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Cash flows from investing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Purchases of property and equipment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,961</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net cash used in investing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,961</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Cash flows from financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Proceeds from the issuance of common stock, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">266,612</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,591,988</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Cash paid for tax
    withholding on vested restricted stock units </TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(67,343</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">199,269</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,591,988</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net (decrease) increase in cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,567,385</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,353,760</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Cash at beginning of period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,123,737</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">855,596</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Cash at end of period</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">556,352</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,209,356</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Supplemental disclosures of non-cash investing and financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Convertible note payable and accrued interest converted
    to     common stock</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">32,321</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Debt discount on convertible notes payable</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">75,994</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Issuance of shares under vested restricted stock units</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">30</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Reclassification of accrued interest to convertible notes payable</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">85,031</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 10pt">Cashless exercise of warrants</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">AETHLON MEDICAL, INC. AND SUBSIDIARY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">September 30, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">1. NATURE OF BUSINESS AND BASIS OF PRESENTATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">ORGANIZATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Aethlon Medical, Inc. and subsidiary (&quot;Aethlon&quot;, the &quot;Company&quot;,
&quot;we&quot; or &quot;us&quot;) is a medical device company focused on creating innovative devices that address unmet medical
needs in cancer, infectious disease and other life-threatening conditions. At the core of our developments is the Aethlon ADAPT&trade;
(Adaptive Dialysis-Like Affinity Platform Technology) system, a medical device platform that converges single or multiple affinity
drug agents with advanced plasma membrane technology to create therapeutic filtration devices that selectively remove harmful particles
from the entire circulatory system without loss of essential blood components. On June 25, 2013, the United States Food and Drug
Administration (FDA) approved an Investigational Device Exemption (IDE) that allows us to initiate human feasibility studies of
the Aethlon Hemopurifier&reg; in the U.S. Under the feasibility study protocol, we plan to enroll ten end-stage renal disease patients
who are infected with the Hepatitis C virus (HCV) to demonstrate the safety of Hemopurifier therapy. Successful completion of this
study will allow us the opportunity to initiate pivotal studies that are required for market clearance to treat HCV and other disease
conditions in the U.S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Successful outcomes of human trials will also be required by the
regulatory agencies of certain foreign countries where we intend to sell this device. Some of our patents may expire before FDA
approval or approval in a foreign country, if any, is obtained. However, we believe that certain patent applications and/or other
patents issued more recently will help protect the proprietary nature of the Hemopurifier(R) treatment technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In October 2013, our majority owned subsidiary, Exosome Sciences,
Inc. (&ldquo;ESI&rdquo;), commenced operations with a focus on advancing exosome-based strategies to diagnose and monitor the progression
of cancer, infectious disease and other life-threatening conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">ESI is accounted for as a non-controlling interest as the Company
has an 80% ownership interest in the subsidiary. Earnings or losses attributable to other stockholders of a consolidated affiliated
company are classified separately as &quot;noncontrolling interest&quot; in the Company's consolidated statements of operations.
Net loss attributable to noncontrolling interest reflects only its share of the after-tax earnings or losses of an affiliated company.
Income taxes attributable to noncontrolling interest are determined using the applicable statutory tax rates in the jurisdictions
where such operations are conducted. The Company's consolidated balance sheets reflect noncontrolling interests within the equity
section of the consolidated balance sheets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our common stock is traded on the Nasdaq Capital Market under the
symbol &ldquo;AEMD.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">During the six months ended September 30, 2016, there have been
no changes to our significant accounting policies as described in our Annual Report on Form 10-K for the fiscal year ended March
31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The accompanying unaudited condensed consolidated financial
statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for
interim financial information and with the instructions to Form 10-Q and Article 10 of the Securities and Exchange Commission
(SEC) Regulation S-X. Accordingly, they should be read in conjunction with the audited financial statements and notes thereto
for the year ended March 31, 2016, included in the Company's Annual Report on Form 10-K filed with the SEC on June 29, 2016.
The accompanying unaudited condensed consolidated financial statements include the accounts of Aethlon Medical, Inc. and its
majority-owned subsidiary. All significant inter-company transactions and balances have been eliminated in consolidation. The
unaudited condensed consolidated financial statements contain all normal recurring accruals and adjustments that, in the
opinion of management, are necessary to present fairly the condensed consolidated balance sheet of the Company at September
30, 2016, the condensed consolidated statements of operations for the three and six months ended September 30, 2016, and the
condensed consolidated statement of cash flows for the six months ended September 30, 2016. Estimates were made relating to
useful lives of fixed assets, valuation allowances, the fair value of warrants, impairment of assets, share-based
compensation expense and accruals for clinical trial and research and development expenses. Actual results could differ
materially from those estimates. Certain amounts previously reported in the financial statements have been reclassified to
conform to the current presentation. Such reclassifications did not affect net loss, equity or cash flows. The accompanying
condensed consolidated balance sheet at March 31, 2016 has been derived from the audited consolidated balance sheet at March
31, 2016, contained in the above referenced 10-K. The results of operations for the three and six months ended September 30,
2016 are not necessarily indicative of the results to be expected for the full year or any future interim periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On April 14, 2015, we completed a 1-for-50 reverse stock split.
Accordingly, authorized common stock was reduced from 500,000,000 shares to 10,000,000 shares, and each 50 shares of outstanding
common stock held by stockholders were combined into one share of common stock. The accompanying condensed consolidated financial
statements and accompanying notes have been retroactively revised to reflect such reverse stock split as if it had occurred on
April 1, 2015. All share and per share amounts have been revised accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On March 31, 2016, we filed a Certificate of Amendment to our Articles
of Incorporation to increase our authorized common stock from 10,000,000 to 30,000,000 shares. Our stockholders approved the amendment
at our annual meeting of stockholders held on March 29, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">LIQUIDITY AND GOING CONCERN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The accompanying condensed consolidated financial statements have
been prepared assuming that we will continue as a going concern, which contemplates, among other things, the realization of assets
and satisfaction of liabilities in the ordinary course of business. We have incurred continuing losses from operations and at September
30, 2016 had limited working capital and an accumulated deficit of approximately $90,887,000. These factors, among other matters,
raise substantial doubt about our ability to continue as a going concern. A significant amount of additional capital will be necessary
to advance the development of our products to the point at which they may become commercially viable. We intend to fund operations,
working capital and other cash requirements for the twelve month period subsequent to September 30, 2016 through debt and/or equity
financing arrangements as well as through revenues and related cash receipts under our government contracts (see Note 11).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We are currently addressing our liquidity issue by seeking additional
investment capital through issuances of common stock under our existing S-3 registration statement and by applying for grants issued
by government agencies in the United States. We believe that our cash on hand and funds expected to be received from additional
debt and equity financing arrangements will be sufficient to meet our liquidity needs for the twelve month period through September
30, 2017. However, no assurance can be given that we will receive any funds in addition to the funds we have received to date (see
Note 14).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The successful outcome of future activities cannot be determined
at this time and there is no assurance that, if achieved, we will have sufficient funds to execute our intended business plan or
generate positive operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The consolidated financial statements do not include any adjustments
related to this uncertainty and as to the recoverability and classification of asset carrying amounts or the amount and classification
of liabilities that might result should the Company be unable to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">2. LOSS PER COMMON SHARE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Basic loss per share is computed by dividing net income available
to common stockholders by the weighted average number of common shares outstanding during the period of computation. The weighted
average number of common shares outstanding for the three and six months ended September 30, 2016 includes 184,500 vested restricted
stock units that have not yet been issued. Diluted loss per share is computed similar to basic loss per share except that the denominator
is increased to include the number of additional common shares that would have been outstanding if potential common shares had
been issued, if such additional common shares were dilutive. Since we had net losses for all periods presented, basic and diluted
loss per share are the same, and additional potential common shares have been excluded as their effect would be antidilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">As of September 30, 2016 and 2015, a total of 3,289,606 and 2,773,483
potential common shares, consisting of shares underlying outstanding stock options, warrants, unvested restricted stock units and
convertible notes payable were excluded as their inclusion would be antidilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">3. RESEARCH AND DEVELOPMENT EXPENSES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our research and development costs are expensed as incurred. We
incurred research and development expenses during the three and six month periods ended September 30, 2016 and 2015, which are
included in various operating expense line items in the accompanying condensed consolidated statements of operations. Our research
and development expenses in those periods were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">September 30,</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">September 30,</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 66%; padding-bottom: 2.5pt">Three months ended</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 13%; border-bottom: Black 2.5pt double; text-align: right">280,860</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 13%; border-bottom: Black 2.5pt double; text-align: right">207,676</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Six months ended</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">377,843</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">424,267</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">4. SIGNIFICANT RECENT ACCOUNTING PRONOUNCEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">During the six months ended September 30, 2016, we adopted Financial
Accounting Standards Board (&ldquo;FASB&rdquo;) Accounting Standards Update (&ldquo;ASU&rdquo;) 2015-03, the new accounting standard
on imputation of interest, simplifying the presentation of debt issuance costs. As a result of the adoption of that pronouncement,
our deferred financing costs at March 31, 2016 were reclassified from current assets to an offset against our convertible notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Management is evaluating significant recent accounting pronouncements
that are not yet effective for us, including the new accounting standard on improvements to employee share based payment accounting,
ASU 2016-09 (Topic 718), the new accounting standard related to leases, ASU 2016-02 (Topic 842), the new accounting standard for
recognition and measurement of financial assets and financial liabilities, ASU 2016-01, the new accounting standard on extraordinary
and unusual items on income statements, ASU 2015-01, the new accounting standard related to presentation of financial statements
- going concern qualifications, ASU 2014-15, and the new accounting standard on revenue recognition, ASU 2014-09 (Topic 606), and
have not yet concluded whether any such pronouncements will have a significant effect on our future consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">5. CONVERTIBLE NOTES PAYABLE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Convertible Notes Payable consisted of the following at September
30, 2016:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unamortized </FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discount</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net </FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued </FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible Notes Payable &ndash; Current Portion:</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 2014 10% Convertible Notes</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">662,811</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(56,996</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">605,815</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,486</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Convertible Notes Payable</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">662,811</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(56,996</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">605,815</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,486</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">During the six months ended September 30, 2016, we recorded interest
expense of $30,794 related to the contractual interest rates of our convertible notes, interest expense of $27,641 related to the
amortization of deferred financing costs and interest expense of $18,998 related to the amortization of the note discount for a
total interest expense of $77,433 related to our convertible notes in the six months ended September 30, 2016. All of the unamortized
discount at September 30, 2016 related to the note discount established upon the second amendment to the notes (see below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Convertible Notes Payable consisted of the following at March 31,
2016 (our most recent fiscal year end):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Principal</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Unamortized <BR> Discount</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Net <BR> Amount</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Accrued <BR> Interest</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Convertible Notes Payable &ndash; Non-Current Portion:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; padding-bottom: 1pt">November 2014 10% Convertible Notes</TD><TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; text-align: right">527,780</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; text-align: right">(27,641</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; text-align: right">500,139</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; text-align: right">74,036</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total Convertible Notes Payable</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">527,780</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(27,641</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">500,139</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">74,036</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The above table shows the retroactive application of $27,641 in
note discounts representing the deferred financing costs of that same amount on March 31, 2016 due to the application of related
to the application of the new accounting standard ASU 2015-03. All of the unamortized discount at March 31, 2016 related to the
deferred financing costs noted above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">During the six months ended September 30, 2015, we recorded interest
expense of $26,390 related to the contractual interest rates of our convertible notes, interest expense of $186,276 related to
the amortization of debt discount and interest expense of $39,441 related to the amortization of deferred financing costs for a
total interest expense of $252,107 related to our convertible notes in the six months ended September 30, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">NOVEMBER 2014 10% CONVERTIBLE NOTES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In November 2014, we entered into a subscription agreement with
two accredited investors providing for the issuance and sale of (i) convertible promissory notes in the aggregate principal amount
of $527,780 (the &ldquo;Notes&rdquo;) and (ii) five year warrants to purchase up to 47,125 shares of common stock at a fixed exercise
price of $8.40 per share (the &ldquo;Warrants&rdquo;). These Notes bear interest at the annual rate of 10% and originally matured
on April 1, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The aggregate gross cash proceeds to us were $415,000 after subtracting
legal fees of $35,000, a $27,780 due diligence fee and an original issuance discount of $50,000. We recorded deferred financing
costs of $112,780 to reflect the legal fees, due diligence fee and original issuance discount and will amortize those costs over
the life of the Notes using the effective interest method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">These Notes are convertible at the option of the holders into shares
of our common stock at a fixed price of $5.60 per share, for up to an aggregate of 94,246 shares of common stock. There are no
registration requirements with respect to the shares of common stock underlying the Notes or the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The estimated relative fair value of Warrants issued in connection
with the Notes was recorded as a debt discount and is amortized as additional interest expense over the term of the underlying
debt. We recorded debt discount of $240,133 based on the relative fair value of these Warrants. In addition, as the effective conversion
price of the Notes was less than market price of the underlying common stock on the date of issuance, we recorded an additional
debt discount of $287,647 related to the beneficial conversion feature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Initial Amendment of the November 2014 10% Convertible Note Terms</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On November 12, 2015, we entered into an amendment of terms (&ldquo;Amendment
of Terms&rdquo;) with the two investors that participated in the November 2014 10% Convertible Notes. The Amendment of Terms modified
the terms of the subscription agreement, Notes and Warrants held by those investors to, among other things, extended the maturity
date of the Notes from April 1, 2016 to June 1, 2016, temporarily reduced the number of shares that we must reserve with respect
to conversion of the Notes, and temporarily suspended the time period during which one of the investors may exercise its Warrants.
In exchange for the investors&rsquo; agreements in the Amendment of Terms, we paid one of the investors a cash fee of $90,000,
which we recorded as deferred financing costs and amortized over the remaining term of the notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Second Amendment and Extension of the November 2014 10% Convertible
Notes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On June 27, 2016, we and certain investors entered into further
Amendments (the &ldquo;Amendments&rdquo;) to the Notes and the Warrants. The Amendments provide that the Maturity Date (as defined
in the Notes) was extended from June 1, 2016 to July 1, 2017 and that the conversion price per share of the Notes was reduced from
$5.60 per share of common stock to $5.00 per share of common stock. In addition, we reduced the purchase price (as defined in the
Warrants) from $8.40 per share to $5.00 per share of common stock. In connection with these modifications, each of the investors
signed a Consent and Waiver providing its consent under certain restrictive provisions, and waiving certain rights, including a
right to participate in certain offerings made by us, under a Securities Purchase Agreement dated June 23, 2015, (the &ldquo;2015
SPA&rdquo;) to which we, the investors and certain other investors are parties, in order to facilitate an at-the-market equity
program (see Note 6).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Amendments also increase the principal amount of the Notes to
$692,811 (in the aggregate) to (i)&nbsp;include accrued and unpaid interest through June 15, 2016, and (ii) increase the principal
amount by $80,000 (in the aggregate) as an extension fee for the extended maturity date of the Notes. With respect to each Note,
we entered into an Allonge to Convertible Promissory Note (each, an &ldquo;Allonge&rdquo;) reflecting the changes in the principal
amount, Maturity Date and conversion price of the Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We also issued to the investors new warrants (the &ldquo;New Warrants&rdquo;)
to purchase an aggregate of 30,000 shares of common stock with a Purchase Price (as defined in the New Warrants) of $5.00 per share
of common stock. We issued the New Warrants in substantially the same form as the prior Warrants, and the New Warrants will expire
on November 6, 2019, the same date on which the prior Warrants will expire.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The modification of the Notes was evaluated under FASB Accounting
Standards Codification (&ldquo;ASC&rdquo;) Topic No. 470-50-40, &ldquo;Debt Modification and Extinguishments&rdquo;. Therefore,
according to the guidance, the instruments were determined to be substantially different, and the transaction qualified for extinguishment
accounting. As a result, we recorded a loss on debt extinguishment of $536,889 and recognized and an extension fee expense of $80,000,
which are included in other expenses in the accompanying condensed consolidated statements of operations. The debt extinguishment
is comprised from the fair value of prior warrants issued in connection with the Notes of $287,676, as well as $325,206 related
to beneficial conversion feature and offset by debt discount of $75,993. The beneficial conversion feature is a result of the effective
conversion price of the new Notes being less than the market price of the underlying common stock on the date of modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table shows the changes to the principal balance of
the November 2014 10% Convertible Notes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="5" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Activity in the November 2014 10% Convertible Notes </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 84%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial principal balance</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 13%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">527,780</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase in principal balance under the second amendment (see above)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">165,031</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversions during the six months ended September 30, 2016</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(30,000</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance as of September 30, 2016</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">662,811</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">6. EQUITY TRANSACTIONS&nbsp;IN THE SIX MONTHS ENDED SEPTEMBER 30,
2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Common Stock Sales Agreement with H.C. Wainwright</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On June 28, 2016, we entered into a Common Stock Sales Agreement
(the &ldquo;Agreement&rdquo;) with H.C. Wainwright &amp; Co., LLC (&ldquo;H.C. Wainwright&rdquo;) which establishes an at-the-market
equity program pursuant to which we may offer and sell shares of our common stock from time to time as set forth in the Agreement.
The Agreement provides for the sale of shares of our common stock having an aggregate offering price of up to $12,500,000 (the
&ldquo;Shares&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Subject to the terms and conditions set forth in the Agreement,
H.C. Wainwright will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the
Shares from time to time, based upon our instructions. We have provided H.C. Wainwright with customary indemnification rights,
and H.C. Wainwright will be entitled to a commission at a fixed rate equal to three percent (3.0%) of the gross proceeds per Share
sold. In addition, we have agreed to pay certain expenses incurred by H.C. Wainwright in connection with the Agreement, including
up to $50,000 of the fees and disbursements of their counsel. The Agreement will terminate upon the sale of all of the Shares under
the Agreement unless terminated earlier by either party as permitted under the Agreement (see Note 14).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Sales of the Shares, if any, under the Agreement shall be made in
transactions that are deemed to be &ldquo;at the market offerings&rdquo; as defined in Rule 415 under the Securities Act, including
sales made by means of ordinary brokers&rsquo; transactions, including on the Nasdaq Capital Market, at market prices or as otherwise
agreed with H.C. Wainwright. We have no obligation to sell any of the Shares, and, at any time, we may suspend offers under the
Agreement or terminate the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In July 2016, we commenced sales of common stock under our Common
Stock Sales Agreement with H.C. Wainwright. In the three months ended September 30, 2016, we had raised net proceeds of $266,612
(net of $8,348 in commissions to H.C. Wainwright and $3,319 in other offering expenses) utilizing the sales agreement through the
sale of 50,163 shares at an average price of $5.31 per share of net proceeds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Warrant Issuances in July 2016 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In July 2016, we issued an aggregate of 2,660 shares of common stock
to three investors upon the exercise of previously issued warrants. The warrants were exercised on a cashless or &ldquo;net&rdquo;
basis. Accordingly, we did not receive any proceeds from such exercises. The cashless exercise of such warrants resulted in the
cancellation of previously issued warrants to purchase an aggregate of 19,563 shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Restricted Stock Unit Grants to Directors and Executive Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">During the three months ended September 30, 2016, 30,131 Restricted
Stock Units (&ldquo;RSUs&rdquo;) held by our outside directors were exchanged into the same number of shares of our common stock
(see Note 9).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Amendment of November 2014 10% Convertible Notes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Under the Second Amendment and Extension of the November
2014 10% Convertible  Notes dated June 27, 2016 (See Note 5), we reduced the purchase price of 47,125 Warrants from $8.40 per
share to $5.00 per share. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We also issued to the investors new warrants to purchase an aggregate
of 30,000 shares of common stock with a purchase price of $5.00 per share of common stock. We issued the new warrants in substantially
the same form as the prior Warrants, and the new warrants will expire on November 6, 2019, the same date on which the prior warrants
will expire (See Note 5).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Amendment of December 2014 Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On June 27, 2016, we and certain investors (the &ldquo;Unit Investors&rdquo;)
entered into Consent and Waiver and Amendment agreements (the &ldquo;CWAs&rdquo;), relating to an aggregate of 264,000 Warrants
to Purchase Common Stock (the &ldquo;Unit Warrants&rdquo;) we had issued to the Unit Investors on December 2, 2014 pursuant to
a Securities Purchase Agreement dated November 26, 2014 (the &ldquo;2014 SPA&rdquo;). In the CWAs, each of the Unit Investors provided
its consent under certain restrictive provisions, and waived certain rights, including a right to participate in certain offerings
made by us, under the 2014 SPA in order to facilitate the at-the-market equity program described above. Pursuant to the CWAs, we
reduced the Exercise Price (as defined in the Unit Warrants) from $15.00 per share of common stock to $5.00 per share of common
stock. At any time that the shares of common stock underlying the Unit Warrants are covered by an effective registration statement
that permits the public resale of the shares, if the Unit Investors exercise the Unit Warrants, they must do so by a cash exercise,
which could yield up to $1,320,000 in proceeds to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On June 27, 2016, each of the Unit Investors also entered into a
Consent and Waiver providing its consent under certain provisions, and waiving certain rights, including a right to participate
in certain offerings made by us, under the 2015 SPA in order to facilitate the at-the market equity program described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In accordance with GAAP, we measured the change in fair value that
arose from the reduction in exercise price and recognized an expense of $345,841, which is included in other expenses in the accompanying
condensed consolidated statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">7. RELATED PARTY TRANSACTIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">DUE TO RELATED PARTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Historically, certain of our officers and other related parties
have advanced us funds, agreed to defer compensation and/or paid expenses on our behalf to cover working capital deficiencies.
There were no such related party transactions during the fiscal year ended March 31, 2016 except that we had accrued unpaid Board
fees of $86,000 owed to our outside directors as of March 31, 2016. At September 30, 2016, we had unpaid Board fees of $28,250.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">8. OTHER CURRENT LIABILITIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Other current liabilities were comprised of the following items:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">September 30,</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">March 31,</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 66%; text-align: left">Accrued interest</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">17,486</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">74,038</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other accrued liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17,830</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">62,657</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total other current liabilities</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">35,316</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">136,695</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">9. STOCK COMPENSATION&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following tables summarize share-based compensation expenses
relating to Restricted Stock Units (&ldquo;RSU&rdquo;s) and options granted and the effect on basic and diluted loss per common
share during the three and six month periods ended September 30, 2016 and 2015:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Three Months <BR> Ended <BR> September 30, <BR>2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Three Months<BR> Ended<BR> September 30, <BR>2015</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Six Months <BR> Ended <BR> September 30,<BR> 2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Six Months<BR> Ended <BR>September 30,<BR> 2015</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 40%; text-align: left; padding-bottom: 1pt">Vesting of stock options and restricted stock units</TD><TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 11%; border-bottom: Black 1pt solid; text-align: right">1,523,280</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 11%; border-bottom: Black 1pt solid; text-align: right">50,711</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 11%; border-bottom: Black 1pt solid; text-align: right">1,573,991</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 11%; border-bottom: Black 1pt solid; text-align: right">101,421</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,523,280</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">50,711</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,573,991</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">101,421</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 5pt; text-indent: -5pt">Weighted average number of common shares outstanding &ndash; basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,756,883</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,610,459</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,690,369</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,167,903</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 5pt; text-indent: -5pt">Basic and diluted loss per common share attributable to stock-based
    compensation expense</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.20</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.01</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.20</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.01</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">All of the stock-based compensation expense recorded during the
six months ended September 30, 2016 and 2015, which totaled $1,573,991 and $101,421, respectively, is included in payroll and related
expense in the accompanying condensed consolidated statements of operations.&nbsp; Stock-based compensation expense recorded during
the six months ended September 30, 2016 and 2015  represented an impact on basic and diluted loss per common share of $(0.20)
in both periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We review share-based compensation on a quarterly basis for changes
to the estimate of expected award forfeitures based on actual forfeiture experience. The cumulative effect of adjusting the forfeiture
rate for all expense amortization is recognized in the period the forfeiture estimate is changed. The effect of forfeiture adjustments
for the six months ended September 30, 2016 was insignificant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Restricted Stock Unit Grants to Directors and Executive Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On August 9, 2016, our Board of Directors (the &ldquo;Board&rdquo;)
granted RSUs to certain of our officers and directors as set forth below. The RSUs represent the right to be issued on a future
date shares of our common stock for vested RSUs. Our Compensation Committee recommended the grants based on a compensation assessment
provided by a third-party compensation consulting firm engaged by us that developed a peer group of companies for market assessment
and analyzed compensation at such companies.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The consultant recommended beneficial ownership targets, which we
previously disclosed in our Proxy Statement filed on February 23, 2016, in connection with our Annual Meeting of Stockholders held
on March 29, 2016. In connection with the Annual Meeting, our stockholders approved our Amended 2010 Stock Incentive Plan, which
included an increase in the number of shares available for grant under the plan in part to accommodate equity awards recommended
by the Compensation Committee, and our stockholders approved our executive compensation as disclosed in the Proxy Statement pursuant
to Item 402 paragraphs (m) through (q) of Regulation S-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">To Mr. James A. Joyce, an aggregate of 634,000 RSUs valued at $6.28
per share, based on the August 9, 2016 closing price of the common stock. 158,500 of the RSUs are deemed vested upon grant and
an additional 39,625 RSUs will vest each quarter beginning on January 1, 2017. This grant is intended to increase Mr. Joyce&rsquo;s
beneficial ownership of our common stock to 9.0%, which target was recommended in 2015 and in June 2016 by the compensation consultant
engaged by us. Previously, in 2004, the Board had approved a beneficial ownership target of 15% for Mr. Joyce. However, Mr. Joyce
has agreed to the modified target of 9.0%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">To Mr. Rodney S. Kenley, an aggregate of 52,000 RSUs valued at $6.28
per share, based on the August 9, 2016 closing price of the common stock. 13,000 of the RSUs are deemed vested upon grant and an
additional 3,250 RSUs will vest each quarter beginning on January 1, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">To Mr. James B. Frakes, an aggregate of 52,000 RSUs valued at $6.28
per share, based on the August 9, 2016 closing price of the common stock. 13,000 of the RSUs are deemed vested upon grant and an
additional 3,250 RSUs will vest each quarter beginning on January 1, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">To each of our non-employee directors, Mr. Franklyn S. Barry, Jr.,
Mr. Edward G. Broenniman and Dr. Chetan S. Shah, 16,432 RSUs valued at an aggregate of $105,000, based on the average of the closing
prices of the common stock for the five trading days preceding and including August 9, 2016. These grants represent (a) $70,000
worth of RSUs representing two years of grants under the amended 2012 Non-Employee Directors Compensation Program (the &ldquo;2012
Program&rdquo;) because more than two years have elapsed since Messrs. Barry and Broenniman and Dr. Shah received grants under
the program, all of which RSUs are deemed vested upon grant and (b) $35,000 worth of RSUs representing the grant covering the fiscal
year ending March 31, 2017, of which one-quarter are deemed vested upon grant and the remaining portion will vest ratably at September
30, 2016, at December 31, 2016 and at March 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The RSUs were granted under our Amended 2010 Stock Incentive Plan
and we recorded expense of $1,523,280 in the three months ended September 30, 2016 related to the RSU grants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Changes to 2012 Non-Employee Directors Compensation Program</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In July 2012, the Board approved the 2012 Program, which modified
and superseded the 2005 Directors Compensation Program that had been in effect previously. On June 6, 2014, the Board approved
certain changes to the 2012 Program, and on August 9, 2016, the Board approved further modifications to the program. Under the
modified 2012 Program, in which only non-employee directors may participate, a new eligible director will receive an initial grant
of $50,000 worth of RSUs or, at the discretion of the Board, options to acquire shares of Common Stock. RSUs granted under this
provision will be valued based on the average of the closing prices of the Common Stock for the five trading days preceding and
including the date of grant and will vest at a rate determined by the Board in its discretion. Options granted under this provision
will be valued at the exercise price, which will be based on the average of the closing prices of the Common Stock for the five
trading days preceding and including the date of grant. Such options will have a term of ten years and will vest at a rate determined
by the Board in its discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">At the beginning of each fiscal year, each existing director eligible
to participate in the 2012 Program will receive a grant of $35,000 worth of RSUs or, at the discretion of the Board, options to
acquire shares of Common Stock. RSUs granted under this provision will be valued based on the average of the closing prices of
the Common Stock for the five trading days preceding and including the first day of the fiscal year (or preceding and including
the date of grant, if such grant is not made on the first day of the fiscal year) and will vest at a rate determined by the Board
in its discretion. Options granted under this provision will be valued at the exercise price, which will be based on the average
of the closing prices of the Common Stock for the five trading days preceding and including the first day of the fiscal year (or
preceding and including the date of grant, if such grant is not made on the first day of the fiscal year). Such options will have
a term of ten years and will vest at a rate determined by the Board in its discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In lieu of per meeting fees, under the 2012 Program eligible
directors will receive an annual Board retainer fee of $30,000. The modified 2012 Program also provides for the following
annual retainer fees: Audit Committee Chair - $5,000, Compensation Committee chair - $5,000, Nominating Committee Chair -
$5,000, Audit Committee member - $4,000, Compensation Committee member - $4,000 and Lead independent director (currently
an open position) - $15,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The RSU grants and the changes to the 2012 Program were approved
and recommended by our Compensation Committee prior to approval by the Board.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">RSUs outstanding that have vested and are expected to vest as of
September 30, 2016 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of RSUs</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 33%">Vested</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">184,500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Expected to vest</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">561,708</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">746,208</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">During the three months ended September 30, 2016, 30,131 RSUs held
by our outside directors were exchanged into the same number of shares of our common stock. As two of our three outside directors
elected to return 40% of their RSU&rsquo;s in exchange for cash in order to pay their withholding taxes on the share issuances,
10,957 of the RSUs were cancelled and we paid a total of $67,343 in cash to those two outside directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Stock Option Activity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">There were no stock option grants during the six months ended September
30, 2016 or September 30, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Options outstanding that have vested and are expected to vest as
of September 30, 2016 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weighted</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Average</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Price</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weighted</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Average</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Remaining</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contractual</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Term in</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Years</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 58%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">417,047</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.20</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.77</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected to vest</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,500</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.00</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.00</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">434,547</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">There was no stock option activity during the six months ended September
30, 2016 other than the expiration of 4,000 stock options during the period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On September 30, 2016, our stock options had no intrinsic value
since the closing price on that date of $5.02 per share was below the weighted average exercise price of our stock options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">At September 30, 2016, there was approximately $3,509,367 of unrecognized
compensation cost related to share-based payments, which is expected to be recognized over a weighted average period of 2.87 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">10. WARRANTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">During the six months ended September 30, 2016, we issued 30,000
warrants with an exercise price of $5.00 per share.&nbsp;Those warrants were issued in connection with the Amendment of November
2014 Investment Documents (see Note 6).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">A summary of warrant activity during the six months ended September
30, 2016 is presented below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Range of</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Price</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weighted</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Average</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Price</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 58%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants outstanding at March 31, 2016</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,164,094</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.10 - $15.00</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.68</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,660</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$6.25</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.25</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$5.00</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.00</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancelled/Expired</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(19,563</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$6.25</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.25</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants outstanding at September 30, 2016</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,171,871</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.10 - $15.00</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.37</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants exercisable at September 30, 2016</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,171,871</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.10 - $15.00</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.37</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following outlines the significant weighted average assumptions
used to estimate the fair value information presented, with respect to warrants utilizing the Binomial Lattice option pricing models
at, and during the six months ended September 30, 2016:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(238,238,238)">
    <TD STYLE="width: 70%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk free interest rate</FONT></TD>
    <TD STYLE="width: 30%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.70%&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average expected life&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5 years</FONT></TD></TR>
<TR STYLE="background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">91.5%</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected dividends&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The expected volatility was based on the historic volatility. The
expected life of options granted was based on the &quot;simplified method&quot; as described in the SEC's guidance due to changes
in the vesting terms and contractual life of current option grants compared to our historical grants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Based on the above assumptions, we valued the 30,000 new warrants
issued during the six months ended September 30, 2016 at $111,900 and classified that fair value as equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">11. DARPA CONTRACT AND RELATED REVENUE RECOGNITION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We entered into a contract with the Defense Advanced Research
Projects Agency, or DARPA, on September 30, 2011. Under the DARPA award, we have been engaged to develop a therapeutic device
to reduce the incidence of sepsis, a fatal bloodstream infection that often results in the death of combat-injured soldiers.
The award from DARPA was a fixed-price contract with potential total payments to us of $6,794,389 over the course of five
years. Fixed price contracts require the achievement of multiple, incremental milestones to receive the full award during
each year of the contract. Under the terms of the contract, we performed certain incremental work towards the achievement of
specific milestones against which we invoiced the government for fixed payment amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Originally, only the base year (year one of the contract) was effective
for the parties; however, DARPA subsequently exercised its option on the remaining years of the contract. The milestones were comprised
of planning, engineering and clinical targets, the achievement of which in some cases required the participation and contribution
of third party participants under the contract. We commenced work under the contract in October 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In February 2014, DARPA reduced the scope of our contract in years
three through five of the contract. The reduction in scope focused our research on exosomes, viruses and blood processing instrumentation.
This scope reduction reduced the possible payments under the contract by $858,469 over years three through five.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In the six months ended September 30, 2016, we invoiced the U.S.
Government for the final two milestones under our DARPA contract in the aggregate amount of $387,438.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The details of those milestones were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Milestone 2.6.1.3 - Quantify the degree to which the MERS virus
can be extracted from circulation in vitro using miniature Hemopurifiers. The milestone payment was $193,719. Management considers
this milestone to be substantive as it was not dependent on the passage of time nor was it based solely on another party's efforts.
We quantified the degree to which the MERS virus can be extracted from circulation in vitro using miniature Hemopurifiers. The
report was accepted by the contracting officer's representative and the invoice was submitted thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Milestone 2.6.1.4 &ndash; Prepare and present Final Report for DARPA.
The milestone payment was $193,719. Management considers this milestone to be substantive as it was not dependent on the passage
of time nor was it based solely on another party's efforts. We prepared and presented the Final Report for DARPA. The report was
accepted by the contracting officer's representative and the invoice was submitted thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In the six months ended September 30, 2015, we invoiced the U.S.
Government for two milestones under our DARPA contract in the amount of $372,328.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The details of those milestones were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Milestone M6 &ndash; Define Aethlon&rsquo;s GMP manufacturing process
and revise and upgrade Aethlon&rsquo;s quality procedures and policies to the current state of the art. The milestone payment was
$186,164. Management considers this milestone to be substantive as it was not dependent on the passage of time nor was it based
solely on another party's efforts. We demonstrated that defined our GMP manufacturing process and that we revised and upgraded
our quality procedures and policies to the current state of the art for a company of our size. The report was accepted by the contracting
officer's representative and the invoice was submitted thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Milestone 2.5.1.1 - Complete Aethlon&rsquo;s GMP procedure and establish
and maintain all GMP documentation for the company. The milestone payment was $186,164. Management considers this milestone to
be substantive as it was not dependent on the passage of time nor was it based solely on another party's efforts. We demonstrated
that we completed our GMP procedures and established and maintained all GMP documentation for the company. The report was accepted
by the contracting officer's representative and the invoice was submitted thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">12. SEGMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We operate our businesses principally through two reportable segments:
Aethlon, which represents our therapeutic business activities, and ESI, which represents our diagnostic business activities. Our
reportable segments have been determined based on the nature of the potential products being developed. We record discrete financial
information for ESI and our chief operating decision maker reviews ESI&rsquo;s operating results in order to make decisions about
resources to be allocated to the ESI segment and to assess its performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Aethlon&rsquo;s revenue is generated primarily from government contracts
to date and ESI does not yet have any revenues. We have not included any allocation of corporate overhead to the ESI segment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following tables set forth certain information regarding our
segments:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid">Six Months Ended September 30,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Revenues:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 66%; padding-left: 10pt">Aethlon</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">392,073</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">380,874</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt">ESI</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Total Revenues</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">392,073</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">380,874</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating Losses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt">Aethlon</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(3,281,530</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,911,219</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt">ESI</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(76,999</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(303,113</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Total Operating Loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,358,529</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,214,332</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Net Losses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Aethlon</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(4,323,003</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(2,165,152</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt">ESI</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(76,999</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(303,113</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Net Loss Before Non-Controlling Interests</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(4,400,002</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,468,265</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Cash:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt">Aethlon</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">553,884</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,208,554</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt">ESI</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,468</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">802</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Total Cash</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">556,352</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,209,356</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Total Assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Aethlon</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">914,179</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,677,989</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt">ESI</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">36,656</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">27,486</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Total Assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">950,835</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,705,475</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Capital Expenditures:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt">Aethlon</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,961</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt">ESI</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Capital Expenditures</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,961</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Depreciation and Amortization:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Aethlon</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,822</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8,886</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt">ESI</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,790</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,790</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Total Depreciation and Amortization</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">20,612</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">18,676</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Interest Expense:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt">Aethlon</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(78,743</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(253,933</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt">ESI</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Total Interest Expense</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(78,743</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(253,933</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">13. COMMITMENTS AND CONTINGENCIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">LEASE COMMITMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We currently rent approximately 2,600 square feet of executive office
space at 9635 Granite Ridge Drive, Suite 100, San Diego, CA 92123 at the rate of $6,054 per month on a four-year lease that expires
in January 2019. We also rent approximately 1,700 square feet of laboratory space at 11585 Sorrento Valley Road, Suite 109, San
Diego, California 92121 at the rate of $4,394 per month on a one-year lease that was recently extended to an expiration date of
November 30, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our Exosome Sciences, Inc. subsidiary previously rented approximately
2,055 square feet of office and laboratory space at 11 Deer Park Drive, South Brunswick, NJ at the rate of $3,917 per month on
a one-year lease that expired in October 2015. In October 2015, ESI relocated to a different suite at the same office complex.
That new suite was comprised of approximately 541 square feet of office and laboratory space and is located at 9 Deer Park Drive,
South Brunswick, NJ at the rate of $1,352 per month under a month to month lease basis. In January 2016, we exercised our 30-day
notice to terminate the ESI lease in New Jersey as part of a consolidation of our laboratory operations in San Diego and the ESI
lease was terminated effective February 29, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Rent expense, which is included in general and administrative expenses,
approximated $79,000 and $90,000 for the six month periods ended September 30, 2016 and 2015, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">LEGAL MATTERS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">From time to time, claims are made against us in the ordinary course
of business, which could result in litigation. Claims and associated litigation are subject to inherent uncertainties and unfavorable
outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting us from selling one or more products
or engaging in other activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The occurrence of an unfavorable outcome in any specific period
could have a material adverse effect on our results of operations for that period or future periods. We are not presently a party
to any pending or threatened legal proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">14. SUBSEQUENT EVENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Management has evaluated events subsequent to September 30, 2016
through the date that the accompanying condensed consolidated financial statements were filed with the Securities and Exchange
Commission for transactions and other events which may require adjustment of and/or disclosure in such financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In October 2016, we collected $193,719 from DARPA. That amount had
been invoiced to DARPA for the achievement of a milestone in September 2016 and was classified as an account receivable as of September
30, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Subsequent to September 30, 2016, we continued selling common stock
under our Common Stock Sales Agreement with H.C. Wainwright (see Note 6). Between the period of October 1, 2016 through November
8, 2016, we raised net proceeds of $61,265 (after deducting $1,919 in commissions to H.C. Wainwright and $799 in other offering
expenses) utilizing the sales agreement through the sale of 13,261 shares at an average price of $4.62 per share of net proceeds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On October 5, 2016, we entered into an amendment of the lease for
our laboratory space at 11585 Sorrento Valley Road, Suite 109, San Diego, California 92121. Pursuant to the amendment, the lease
term will be extended to November 30, 2017 and the rent will be $4,394 per month.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following discussion of our financial condition and results
of operations should be read in conjunction with, and is qualified in its entirety by, the condensed consolidated financial statements
and notes thereto included in Item 1 in this Quarterly Report on Form 10-Q. This item contains forward-looking statements that
involve risks and uncertainties. Actual results may differ materially from those indicated in such forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">FORWARD LOOKING STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">All statements, other than statements of historical fact, included
in this Form 10-Q are, or may be deemed to be, &quot;forward-looking statements&quot; within the meaning of Section 27A of the
Securities Act of 1933, as amended (the &ldquo;Securities Act&quot;), and Section 21E of the Exchange Act. Such forward-looking
statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance,
or achievements of Aethlon Medical, Inc. (&quot;we&quot; or &quot;us&quot;) to be materially different from any future results,
performance, or achievements expressed or implied by such forward-looking statements contained in this Form 10-Q. Such potential
risks and uncertainties include, without limitation, completion of our capital-raising activities, U.S. Food and Drug Administration,
or FDA, approval of our products, other regulations, patent protection of our proprietary technology, product liability exposure,
uncertainty of market acceptance, competition, technological change, and other risk factors detailed herein and in other of our
filings with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;). The forward-looking statements are made as
of the date of this Form 10-Q, and we assume no obligation to update the forward-looking statements, or to update the reasons actual
results could differ from those projected in such forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Overview</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We are a medical device company focused on creating innovative devices
that address unmet medical needs in cancer, infectious disease and other life-threatening conditions. At the core of our developments
is the Aethlon ADAPT&trade; (Adaptive Dialysis-Like Affinity Platform Technology) system, a medical device platform that converges
single or multiple affinity drug agents with advanced plasma membrane technology to create therapeutic filtration devices that
selectively remove harmful particles from the entire circulatory system without loss of essential blood components.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In June 2013, the FDA approved our investigational device exemption
application to initiate a ten-patient human clinical trial in one location in the U.S. to treat dialysis patients who are infected
with the Hepatitis C virus. The principal investigator of that clinical trial recently began recruiting patients. Successful outcomes
of that human trial as well as at least one follow-on human trial will be required by the FDA in order to commercialize our products
in the U.S. The regulatory agencies of certain foreign countries where we intend to sell this device will also require one or more
human clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Some of our patents may expire before we receive FDA approval to
market our products in the U.S. or we receive approval to market our products in a foreign country. However, we believe that certain
patent applications and/or other patents issued more recently will help protect the proprietary nature of the Hemopurifier treatment
technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Through Exosome Sciences, Inc. (ESI), our majority-owned subsidiary,
we are also studying potential diagnostic techniques for identifying and monitoring neurological conditions and cancer. We consolidate
ESI&rsquo;s activities in our consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our common stock is traded on the Nasdaq Capital Market under the
symbol &ldquo;AEMD.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">WHERE YOU CAN FIND MORE INFORMATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We are subject to the informational requirements of the Securities
Exchange Act and must file reports, proxy statements and other information with the Commission. The reports, information statements
and other information we file with the Commission can be inspected and copied at the Commission Public Reference Room, 100 F Street,
N.E., Washington, D.C. 20549. You may obtain information on the operation of the Public Reference Room by calling the Commission
at (800) SEC-0330. The Commission also maintains a Web site (http://www.sec.gov) that contains reports, proxy and information statements
and other information regarding registrants, like us, which file electronically with the Commission. Our headquarters are located
at 9635 Granite Ridge Drive, Suite 100, San Diego, CA 92123. Our phone number at that address is (858) 459-7800. Our Web site is
http://www.aethlonmedical.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">RESULTS OF OPERATIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">THREE MONTHS ENDED SEPTEMBER 30, 2016 COMPARED TO THE THREE MONTHS
ENDED SEPTEMBER 30, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Revenues</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We recorded government contract revenue in the three months ended
September 30, 2016 and 2015.&nbsp;&nbsp;This revenue arose from work performed under our government contract with the Defense Advanced
Research Projects Agency, or DARPA, and our subcontract with Battelle Memorial Institute as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Three Months<BR>
 Ended 9/30/16</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Three Months<BR>
 Ended 9/30/15</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Change in <BR>
Dollars</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 55%; text-align: left">DARPA Contract</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">387,438</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">186,164</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">201,274</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Battelle Subcontract</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,202</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,202</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total Government Contract Revenue</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">387,438</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">188,366</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">199,072</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>DARPA Contract</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We entered into a contract with DARPA on September 30, 2011. Under
the DARPA award, we have been engaged to develop a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection
that often results in the death of combat-injured soldiers. The award from DARPA was a fixed-price contract with potential total
payments to us of $6,794,389 over the course of five years. Fixed price contracts require the achievement of multiple, incremental
milestones to receive the full award during each year of the contract. Under the terms of the contract, we performed certain incremental
work towards the achievement of specific milestones against which we invoiced the government for fixed payment amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Originally, only the base year (year one of the contract) was effective
for the parties; however, DARPA subsequently exercised its option on the remaining years of the contract. The milestones were comprised
of planning, engineering and clinical targets, the achievement of which in some cases required the participation and contribution
of third party participants under the contract. We commenced work under the contract in October 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In February 2014, DARPA reduced the scope of our contract in years
three through five of the contract. The reduction in scope focused our research on exosomes, viruses and blood processing instrumentation.
This scope reduction reduced the possible payments under the contract by $858,469 over years three through five.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In the three months ended September 30, 2016, we invoiced the U.S.
Government for the final two milestones under our DARPA contract in the aggregate amount of $387,438. In the three months ended
September 30, 2015, we invoiced the U.S. Government for one milestone under our DARPA contract in the amount of $186,164.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Operating Expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Consolidated operating expenses for the three months ended September
30, 2016 were $2,614,116 in comparison with $1,312,727 for the comparable quarter a year ago.&nbsp;&nbsp;This increase of $1,301,389,
or 99.1%, was due to increases in payroll and related expenses of $1,215,153 and in professional fees of $121,775, which were partially
offset by a reduction in general and administrative expenses of $35,539.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The $1,215,153 increase in payroll and related expenses was due
to a $1,472,570 increase in stock-based compensation, which was partially offset by a $257,417 decrease in cash-based compensation.
The increase in stock-based compensation was the result of the RSU grants to our officers and directors in the three months ended
September 30, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The $121,775 increase in our professional fees was primarily due
to an increase in our non-DARPA-related professional fees of $144,307, which was partially offset by decreases in our DARPA-related
professional fees of $22,166 and in our professional fees at ESI of $366. The $144,307 increase in our non-DARPA-related professional
fees was due to a $112,596 increase in scientific consulting fees, a $51,000 increase in business development expenses, a $9,665
increase in our accounting fees, a $7,127 increase in investor relations fees and a $5,942 increase in our public relations fees,
which were partially offset by a $43,044 decrease in legal fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The $35,539 decrease in general and administrative expenses was
the result of decreases of $59,065 in our non-DARPA-related general and administrative expenses and of $31,945 in our general and
administrative expenses at ESI, which were partially offset by a $55,470 increase in our DARPA-related general and administrative
expenses.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Other Expense</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Other expense in the three months ended September 30, 2016 and
2015 consisted of interest expense. Interest expense was $36,576 for the three months ended September 30, 2016 compared to $127,245
in the corresponding prior period, a decrease of $90,669. The various components of our interest expense are shown in the following
table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Quarter Ended</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Quarter Ended</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">9/30/16</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">9/30/15</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Change</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 55%; text-align: left">Interest Expense</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">17,578</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">13,968</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">3,610</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Amortization of Deferred Financing Costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,139</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(20,139</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Amortization of Note Discounts</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,998</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">93,138</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(74,140</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total Interest Expense</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">36,576</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">127,245</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(90,669</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">As noted in the above table, the most significant factor in the
$90,669 decrease in interest expense was the $74,140 decrease in the amortization of note discounts, which related to the amortization
against the discount on the convertible notes that we issued in November 2014. Other smaller factors in the change in our total
interest were a $20,139 decrease in the amortization of deferred financing costs and a $3,610 increase in our contractual interest
expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Net Loss</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">As a result of the changes in revenues and expenses noted above,
our net loss before noncontrolling interests increased from approximately $1,252,000 in the quarter ended September 30, 2015 to
approximately $2,263,000 for the quarter ended September 30, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Basic and diluted loss attributable to common stockholders was ($0.29)
for the three month period ended September 30, 2016 and ($0.16) for the three month period ended September 30, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">SIX MONTHS ENDED SEPTEMBER 30, 2016 COMPARED TO THE SIX MONTHS ENDED
SEPTEMBER 30, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Revenues</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We recorded government contract revenue in the six months ended
September 30, 2016 and 2015. This revenue arose from work performed under our government contract with the Defense Advanced Research
Projects Agency, or DARPA, and our subcontract with Battelle Memorial Institute as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Six Months<BR>
 Ended 9/30/16</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Six Months<BR>
 Ended 9/30/15</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Change in <BR>
Dollars</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 55%; text-align: left">DARPA Contract</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">387,438</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">372,328</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">15,110</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Battelle Subcontract</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,635</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,546</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,911</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total Government Contract Revenue</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">392,073</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">380,874</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">11,199</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>DARPA Contract</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We entered into a contract with DARPA on September 30, 2011. Under
the DARPA award, we have been engaged to develop a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection
that often results in the death of combat-injured soldiers. The award from DARPA was a fixed-price contract with potential total
payments to us of $6,794,389 over the course of five years. Fixed price contracts require the achievement of multiple, incremental
milestones to receive the full award during each year of the contract. Under the terms of the contract, we performed certain incremental
work towards the achievement of specific milestones against which we invoiced the government for fixed payment amounts.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I></I></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Originally, only the base year (year one of the contract) was effective
for the parties; however, DARPA subsequently exercised its option on the remaining years of the contract. The milestones were
comprised of planning, engineering and clinical targets, the achievement of which in some cases required the participation and
contribution of third party participants under the contract. We commenced work under the contract in October 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In February 2014, DARPA reduced the scope of our contract in years
three through five of the contract. The reduction in scope focused our research on exosomes, viruses and blood processing instrumentation.
This scope reduction reduced the possible payments under the contract by $858,469 over years three through five.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In the six months ended September 30, 2016, we invoiced the U.S.
Government for the final two milestones under our DARPA contract in the aggregate amount of $387,438. In the six months ended September
30, 2015, we invoiced the U.S. Government for two milestones under our DARPA contract in the amount of $372,328.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Operating Expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Consolidated operating expenses for the six months ended September
30, 2016 were $3,750,602 in comparison with $2,595,206 for the comparable quarter a year ago. This increase of $1,155,396,
or 44.5%, was due to increases in payroll and related expenses of $1,102,112 and in professional fees of $151,298, which were partially
offset by a decrease in general and administrative expenses of $98,014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The $1,102,112 increase in payroll and related expenses was primarily
due to a $1,472,570 increase in stock-based compensation, which was partially offset by a $370,458 decrease in cash-based compensation.
The increase in stock-based compensation was due to the RSU grants to our officers and directors in the three months ended September
30, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The $151,298 increase in our professional fees was primarily due
to an increase in our non-DARPA-related professional fees of $202,114, which was partially offset by a reduction in our professional
fees at ESI of $4,918 and in our DARPA-related professional fees of $45,898. The $202,114 increase in our non-DARPA-related professional
fees was due to a $160,924 increase in scientific consulting fees, an $85,000 increase in business development expenses, an $8,851
increase in investor relations fees and a $5,942 increase in our public relations fees, which were partially offset by a decreases
of $39,909 in accounting fees and $19,953 in legal fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The $98,014 decrease in general and administrative expenses was
primarily due to decreases of $103,221 in our non-DARPA-related general and administrative expenses and of $49,373 in the general
and administrative expenses at ESI, which were partially offset by an increase of $54,580 in our DARPA-related general and administrative
expenses. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Other Expense</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Other expense during the six months ended September 30, 2016 and
2015 consisted primarily of losses on debt extinguishment, warrant repricing expense and interest expense. Other expense for the
six months ended September 30, 2016 was other expense of $1,041,473 in comparison with other expense of $253,933 for the six months
ended September 30, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table breaks out the various components of our other
expense for both periods:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Six Months <BR>
Ended</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Six Months <BR>
Ended</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">9/30/16</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">9/30/15</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Change</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 55%; text-align: left">Loss on Debt Extinguishment</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">616,889</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">&ndash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">616,889</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loss on Warrant Repricing</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">345,841</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">345,841</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Interest Expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">78,743</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">253,933</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(175,190</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total Other Expense</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,041,473</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">253,933</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">787,540</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">Loss on Debt Extinguishment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">This loss on debt extinguishment arose from the Amendments (the
&ldquo;Amendments&rdquo;) to our November 2014 convertible notes The Amendments provided that the maturity date of the notes was
extended from June 1, 2016 to July 1, 2017 and that the conversion price was reduced from $5.60 per share of common stock to $5.00
per share of common stock. In addition, we reduced the purchase price of warrants issued in connection with the notes from $8.40
per share to $5.00 per share. In connection with these modifications, each of the Investors signed a consent and waiver providing
its consent under certain restrictive provisions, and waiving certain rights, including a right to participate in certain offerings
made by us, under a securities purchase agreement dated June 23, 2015, (the &ldquo;2015 SPA&rdquo;) to which we, the Investors
and certain other investors are parties, in order to facilitate an at-the-market equity program described in the liquidity and
capital resources section of this report below. This loss also included an $80,000 fee to extend the November 2014 convertible
notes from June 1, 2016 to July 1, 2017. The $80,000 amount was not a cash payment but rather was added to the principal of the
notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Loss on Warrant Repricing</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On June 27, 2016, we and certain investors (the &ldquo;Unit Investors&rdquo;)
entered into Consent and Waiver and Amendment agreements (the &ldquo;CWAs&rdquo;), relating to an aggregate of 264,000 Warrants
to Purchase Common Stock (the &ldquo;Unit Warrants&rdquo;) we had issued to the Unit Investors on December 2, 2014 pursuant to
a Securities Purchase Agreement dated November 26, 2014 (the &ldquo;2014 SPA&rdquo;). In the CWAs, each of the Unit Investors provided
its consent under certain restrictive provisions, and waived certain rights, including a right to participate in certain offerings
made by us, under the 2014 SPA in order to facilitate the at-the-market equity program described in the notes to the Financial
Statements. Pursuant to the CWAs, we reduced the Exercise Price (as defined in the Unit Warrants) from $15.00 per share of common
stock to $5.00 per share of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On June 27, 2016, each of the Unit Investors also entered into a
Consent and Waiver providing its consent under certain provisions, and waiving certain rights, including a right to participate
in certain offerings made by us, under the 2015 SPA in order to facilitate the at-the market equity program described in the notes
to the Financial Statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We measured the change in fair value that arose from the reduction
in exercise price from $15.00 to $5.00 and recorded a charge of $345,841 to our other expense to reflect this change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Interest Expense</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Interest expense was $78,743 for the six months ended September
30, 2016 compared to $253,933 in the corresponding prior period, a decrease of $175,190. The various components of our interest
expense are shown in the following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Six Months <BR>
Ended</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Six Months<BR>
 Ended</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">9/30/16</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">9/30/15</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Change</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 55%; text-align: left">Interest Expense</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">32,104</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">28,216</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">3,888</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Amortization of Deferred Financing Costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,641</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39,441</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,800</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Amortization of Note Discounts</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,998</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">186,276</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(167,278</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total Interest Expense</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">78,743</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">253,933</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(175,190</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">As noted in the above table, the most significant factor in the
$175,190 decrease in interest expense was the $167,278 decrease in the amortization of note discounts, which related to the amortization
against the discount on the convertible notes that we issued in November 2014. Other smaller factors in the change in our total
interest were an $11,800 decrease in the amortization of deferred financing costs and a $3,888 increase in our contractual interest
expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Net Loss</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">As a result of the changes in revenues and expenses noted above,
our net loss before noncontrolling interests increased from approximately $2,468,000 in the six month period ended September 30,
2015 to approximately $4,400,000 for the six month period ended September 30, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Basic and diluted loss attributable to common stockholders were
($0.57) for the six month period ended September 30, 2016 compared to ($0.34) for the period ended September 30, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">LIQUIDITY AND CAPITAL RESOURCES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">At September 30, 2016, we had a cash balance of $556,352 and negative
working capital of $267,681. This compares to a cash balance of $2,123,737 and working capital of $1,849,891 at March 31, 2016.
The primary reason that we had negative working capital at September 30, 2016 was the presentation of $605,815 in convertible notes
as a current liability rather than as a long term liability as we did at March 31, 2016 since those notes have an expiration date
of July 1, 2017, which is less than one year from the September 30, 2016 balance sheet date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Significant additional financing must be obtained in order to provide
a sufficient source of operating capital and to allow us to continue to operate as a going concern. In addition, we will need to
raise capital to complete the approved human clinical trial in the U.S. We anticipate the primary source of this additional financing
will be from proceeds of our at-the-market offering program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We raised $5,591,988 in net proceeds from a financing in June 2015.
That amount, coupled with previously existing funds on hand and revenues from our government contracts, has financed our operations
through the second quarter of the fiscal year ending March 31, 2017. However, we will require significant additional financing
to complete the current and expected additional future clinical trials in the U.S., as well as fund all of our continued research
and development activities for the Hemopurifier and products on our Aethlon ADAPT platform through the twelve month period ending
June 30, 2017. In addition, as we expand our activities, our overhead costs to support personnel, laboratory materials and infrastructure
will increase. Should the financing we require to sustain our working capital needs be unavailable to us on reasonable terms, if
at all, when we require it, we may be unable to support our research and U.S. Food and Drug Administration, or FDA, clearance activities
including our planned clinical trials. The failure to implement our research and clearance activities would have a material adverse
effect on our ability to commercialize our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Future capital requirements will depend upon many factors, including
progress with pre-clinical testing and clinical trials, the number and breadth of our clinical programs, the time and costs involved
in preparing, filing, prosecuting, maintaining and enforcing patent claims and other proprietary rights, the time and costs involved
in obtaining regulatory approvals, competing technological and market developments, as well as our ability to establish collaborative
arrangements, effective commercialization, marketing activities and other arrangements. We expect to continue to incur increasing
negative cash flows and net losses for the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Going Concern</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The accompanying condensed consolidated financial statements have
been prepared assuming that we will continue as a going concern, which contemplates, among other things, the realization of assets
and satisfaction of liabilities in the ordinary course of business. We have incurred continuing losses from operations and at September
30, 2016 had limited working capital and an accumulated deficit of approximately $90,887,000. These factors, among other matters,
raise substantial doubt about our ability to continue as a going concern. A significant amount of additional capital will be necessary
to advance the development of our products to the point at which they may become commercially viable. We intend to fund operations,
working capital and other cash requirements for the twelve month period ending September 30, 2017 through debt and/or equity financing
arrangements as well as through revenues and related cash receipts under our government contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We are currently addressing our liquidity issue by seeking additional
investment capital through issuances of common stock under our existing S-3 registration statement and by applying for additional
grants issued by government agencies in the United States. We believe that our cash on hand and funds expected to be received from
additional debt and equity financing arrangements will be sufficient to meet our liquidity needs for fiscal 2017. However, no assurance
can be given that we will receive any funds in addition to the funds we have received to date (see Note 14).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In July 2016, we commenced sales of common stock under our Common
Stock Sales Agreement with H.C. Wainwright. We raised $266,612 under that sales agreement during the three months ended September
30, 2016 (after deducting $8,348 in commissions to H.C. Wainwright and $3,319 in other offering expenses) through the sale of 50,163
shares at an average price of $5.31 per share of net proceeds. Subsequent to September 30, 2016, we continued selling common stock
under our Common Stock Sales Agreement with H.C. Wainwright (see Note 6). Between the period of October 1, 2016 through November
8, 2016, we raised net proceeds of $61,265 (after deducting $1,919 in commissions to H.C. Wainwright and $799 in other offering
expenses) utilizing the sales agreement through the sale of 13,261 shares at an average price of $4.62 per share of net proceeds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In October 2016, we collected $193,719 from DARPA. That amount had
been invoiced to DARPA for the achievement of a milestone in September 2016 and was classified as an account receivable as of September
30, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The successful outcome of future activities cannot be determined
at this time and there is no assurance that, if achieved, we will have sufficient funds to execute our intended business plan or
generate positive operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The consolidated financial statements do not include any adjustments
related to this uncertainty and as to the recoverability and classification of asset carrying amounts or the amount and classification
of liabilities that might result should we be unable to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Cash Flows</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Cash flows from operating, investing and financing activities, as
reflected in the accompanying Condensed Consolidated Statements of Cash Flows, are summarized as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid">(In thousands) <BR> For the six months ended</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">September 30, <BR> 2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">September 30, <BR> 2015</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Cash (used in) provided by:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 66%; text-align: left">Operating activities</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(1,763</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(2,238</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">199</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,592</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net (decrease) increase in cash</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,567</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,354</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">NET CASH USED IN OPERATING ACTIVITIES. We used cash in our operating
activities due to our losses from operations. Net cash used in operating activities was approximately $1,763,000 in the six months
ended September 30, 2016 compared to $2,238,000 in the six months ended September 30, 2015, a decrease of $475,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">NET CASH USED IN INVESTING ACTIVITIES. We used approximately $3,000
of cash to purchase office equipment and fixtures in the six months ended September 30, 2016. There were no investing activities
in the six months ended September 30, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">NET CASH FROM FINANCING ACTIVITIES. In the six months
ended September 30, 2015 we raised approximately $5,592,000 through the sale of common stock. We raised approximately
$267,000 through the sale of common stock in the six months ended September 30, 2016, which was partially offset by
approximately $67,000 in cash paid for tax withholding on vested rights, for total cash from financing activities of
approximately $199,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">At the date of this filing, we plan to invest significantly into
purchases of our raw materials and into our contract manufacturing arrangement subject to successfully raising additional capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">CRITICAL ACCOUNTING POLICIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The preparation of condensed consolidated financial statements in
conformity with accounting principles generally accepted in the United States of America requires us to make a number of estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities
at the date of the financial statements. Such estimates and assumptions affect the reported amounts of expenses during the reporting
period. On an ongoing basis, we evaluate estimates and assumptions based upon historical experience and various other factors and
circumstances. We believe our estimates and assumptions are reasonable in the circumstances; however, actual results may differ
from these estimates under different future conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We believe that the estimates and assumptions that are most important
to the portrayal of our financial condition and results of operations, in that they require the most difficult, subjective or complex
judgments, form the basis for the accounting policies deemed to be most critical to us. These critical accounting policies relate
to revenue recognition, measurement of stock purchase warrants issued with notes payable, beneficial conversion feature of convertible
notes payable, impairment of intangible assets and long lived assets, stock compensation, and the classification of warrant obligations,
and evaluation of contingencies. We believe estimates and assumptions related to these critical accounting policies are appropriate
under the circumstances; however, should future events or occurrences result in unanticipated consequences, there could be a material
impact on our future financial condition or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">There have been no changes to our critical accounting policies as
disclosed in our Form 10-K for the year ended March 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">OFF-BALANCE SHEET ARRANGEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We have no obligations required to be disclosed herein as off-balance
sheet arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">As a smaller reporting company as defined by Rule 12b-2 of the Exchange
Act and in Item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are not required
to provide the information requested by this item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">ITEM 4. CONTROLS AND PROCEDURES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">DISCLOSURE CONTROLS AND PROCEDURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Under the supervision and with the participation of our management,
including our Chief Executive Officer and our Chief Financial Officer, we evaluated the effectiveness of the design and operation
of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of the end of the
period covered by this Quarterly Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Based on such evaluation, our Chief Executive Officer and Chief
Financial Officer concluded that, as of the end of such period, our disclosure controls and procedures are effective in recording,
processing, summarizing and reporting, on a timely basis, information required to be disclosed by us in the reports that we file
or submit under the Exchange Act and are effective in ensuring that information required to be disclosed by us in the reports that
we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer
and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">There have been no changes in our internal control over financial
reporting during the last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal
control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">PART II. OTHER INFORMATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">ITEM 1. LEGAL PROCEEDINGS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">From time to time, claims are made against us in the ordinary course
of business, which could result in litigation. Claims and associated litigation are subject to inherent uncertainties and unfavorable
outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting us from selling one or more products
or engaging in other activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The occurrence of an unfavorable outcome in any specific period
could have a material adverse effect on our results of operations for that period or future periods. We are not presently a party
to any pending or threatened legal proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">ITEM 1A. RISK FACTORS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">As a smaller reporting company as defined by rule 12b-2 of the Exchange
Act and in Item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are not required
to provide the information requested by this item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">During the quarter ended September 30, 2016 and subsequent thereto
through the date of filing this report, we issued the following securities which were not registered under the Securities Act of
1933, as amended. We did not employ any form of general solicitation or advertising in connection with the offer and sale of the
securities described below. In addition, we believe the purchasers are &ldquo;accredited investors&rdquo; for the purpose of Rule
501 promulgated under the Securities Act. For these reasons, among others, the offer and sale of the following securities were
made in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act or Regulation D promulgated
by the Commission under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On July 26, 2016, we issued an aggregate of 2,660 shares of common
stock to three investors upon the exercise of previously issued warrants. The warrants were exercised on a cashless or &ldquo;net&rdquo;
basis. Accordingly, we did not receive any proceeds from such exercises. The cashless exercise of such warrants resulted in the
cancellation of previously issued warrants to purchase an aggregate of 19,563 shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On August 12, 2016, we issued 6,464 shares of common stock to the
holder of a convertible note in exchange for the partial conversion of principal and interest in the aggregate amount of $32,321
at a conversion price of $5.00 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On September 1, 2016, we issued an aggregate of 27,122 shares of
common stock to our three outside directors in settlement of an aggregate of 27, 122 restricted stock units, or RSUs, previously
granted to them, which RSUs vested on August 9, 2016. On September 30, 2016, we issued an aggregate of 3,010 shares of common stock
to our three outside directors in settlement of an aggregate of 3,010 RSUs previously granted to them, which RSUs vested on September
30, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">ITEM 3. DEFAULTS UPON SENIOR SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We have no disclosure applicable to this item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">ITEM 4. MINE SAFETY DISCLOSURES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We have no disclosure applicable to this item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">ITEM 5. OTHER INFORMATION.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We have no disclosure applicable to this item.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">ITEM 6. EXHIBITS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(a) Exhibits. The following documents are filed as part of this
report:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Articles of Incorporation of Aethlon Medical, Inc., as amended (1)</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bylaws of Aethlon Medical, Inc., as amended (2)</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DARPA Contract dated September 30, 2011*</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2012 Non-Employee Directors Compensation Program, as amended August 9, 2016 (3)</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock Unit Agreement by and between Aethlon Medical, Inc. and James A. Joyce dated August 29, 2016*</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock Unit Agreement by and between Aethlon Medical, Inc. and Rodney S. Kenley dated August 29, 2016*</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock Unit Agreement by and between Aethlon Medical, Inc. and James B. Frakes dated August 29, 2016*</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock Unit Agreement by and between Aethlon Medical, Inc. and Franklyn S. Barry, Jr. dated August 29, 2016*</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock Unit Agreement by and between Aethlon Medical, Inc. and Edward G. Broenniman dated August 29, 2016*</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock Unit Agreement by and between Aethlon Medical, Inc. and Chetan S. Shah, MD dated August 29, 2016*</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fourth Amendment to Standard Industrial Net Lease by and between AGP Sorrento Business Complex, L.P. and Aethlon Medical, Inc. dated October 5, 2016* </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Executive Officer pursuant to Securities Exchange Act rules 13a- 14(a) and 15d-14(a) as adopted pursuant to section 302 of the Sarbanes-Oxley Act of 2002*</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Financial Officer pursuant to Securities Exchange Act rules 13a- 14(a) and 15d-14(a) as adopted pursuant to section 302 of the Sarbanes-Oxley Act of 2002*</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Executive Officer pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002*</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Financial Officer pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002*</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interactive Data Files*</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</FONT></TD>
    <TD STYLE="width: 88%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Instance Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Schema Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Calculation Linkbase Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Definition Linkbase Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Label Linkbase Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Presentation Linkbase Document</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">* Filed herewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed with the Company&rsquo;s Registration Statement on Form S-3 (File No. 333-211151) filed on May 5, 2016 and incorporated by reference. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed with the Company&rsquo;s Annual Report on Form 10-K filed on June 26, 2015 for the year ended March 31, 2015 and incorporated by reference.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed with the Company&rsquo;s Current Report on Form 8-K filed on August 10, 2016 and incorporated by reference.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AETHLON MEDICAL, INC.</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 30%">&nbsp;</TD>
    <TD STYLE="width: 15%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: November 10, 2016</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    JAMES B. FRAKES</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JAMES B. FRAKES</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHIEF FINANCIAL OFFICER</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHIEF ACCOUNTING OFFICER</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<!-- Field: Page; Sequence: 27; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>aethlon_10q-ex1001.htm
<DESCRIPTION>AWARD CONTRACT AND MODIFICATIONS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 10.1</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="award_image1.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 2 of 40</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Section B - Supplies or Services and Prices</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%"><FONT STYLE="font-size: 10pt">ITEM NO</FONT></TD>
    <TD STYLE="width: 17%"><FONT STYLE="font-size: 10pt">SUPPLIES/SERVICES </FONT></TD>
    <TD STYLE="width: 17%; text-align: center">QUANTITY</TD>
    <TD STYLE="width: 17%; text-align: center"><FONT STYLE="font-size: 10pt">UNIT</FONT></TD>
    <TD STYLE="width: 17%"><FONT STYLE="font-size: 10pt">UNIT PRICE</FONT></TD>
    <TD STYLE="width: 17%; text-align: right"><FONT STYLE="font-size: 10pt">AMOUNT</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">0001</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center">1</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Lot</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">$1,975,047.00</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">$1,975,047.00</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">RESEARCH</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">FFP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Research IAW the SOW (Contained in section C).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">FOB: Destination</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0">&nbsp;</P>

</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">NET AMT</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">$1,975,047.00</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%">&nbsp;</TD>
    <TD STYLE="width: 17%">&nbsp;</TD>
    <TD STYLE="width: 17%">&nbsp;</TD>
    <TD STYLE="width: 17%">&nbsp;</TD>
    <TD STYLE="width: 17%">&nbsp;</TD>
    <TD STYLE="width: 17%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">PURCHASE REQUEST NUMBER: 1300211787</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0">&nbsp;</P>

</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">000101</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Funding Information</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">ACRN</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">$938,583.00</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">AA</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%"><FONT STYLE="font-size: 10pt">ITEM NO</FONT></TD>
    <TD STYLE="width: 17%"><FONT STYLE="font-size: 10pt">SUPPLIES/SERVICES</FONT></TD>
    <TD STYLE="width: 17%; text-align: center"><FONT STYLE="font-size: 10pt">QUANTITY </FONT></TD>
    <TD STYLE="width: 17%; text-align: center">UNIT</TD>
    <TD STYLE="width: 17%"><FONT STYLE="font-size: 10pt">UNIT PRICE</FONT></TD>
    <TD STYLE="width: 17%"><FONT STYLE="font-size: 10pt">AMOUNT</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">0002</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">NSP</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>CDRLs</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 3  of 40</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%"><FONT STYLE="font-size: 10pt">ITEM NO </FONT></TD>
    <TD STYLE="width: 17%"><FONT STYLE="font-size: 10pt">SUPPLIES/SERVICES </FONT></TD>
    <TD STYLE="width: 17%; text-align: center"><FONT STYLE="font-size: 10pt">QUANTITY</FONT></TD>
    <TD STYLE="width: 17%; text-align: center"><FONT STYLE="font-size: 10pt">UNIT</FONT></TD>
    <TD STYLE="width: 17%"><FONT STYLE="font-size: 10pt">UNIT PRICE</FONT></TD>
    <TD STYLE="width: 17%; text-align: right"><FONT STYLE="font-size: 10pt">AMOUNT</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">0003</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"></FONT>1</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Lot</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">$835,124.00</FONT></TD>
    <TD STYLE="text-align: right">$835,124.00</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">OPTION</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">RESEARCH</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"></FONT></TD>
    <TD>FFP</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD></TD>
    <TD COLSPAN="3">Research IAW the SOW (Contained in section C).</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"></FONT></TD>
    <TD>FOB: Destination</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">NET AMT</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">$835,124.00</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%"><FONT STYLE="font-size: 10pt">ITEM NO </FONT></TD>
    <TD STYLE="width: 17%"><FONT STYLE="font-size: 10pt">SUPPLIES/SERVICES </FONT></TD>
    <TD STYLE="width: 17%; text-align: center"><FONT STYLE="font-size: 10pt">QUANTITY</FONT></TD>
    <TD STYLE="width: 17%; text-align: center"><FONT STYLE="font-size: 10pt">UNIT</FONT></TD>
    <TD STYLE="width: 17%"><FONT STYLE="font-size: 10pt">UNIT PRICE</FONT></TD>
    <TD STYLE="width: 17%; text-align: left"><FONT STYLE="font-size: 10pt">AMOUNT</FONT></TD>
</TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">0004</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>NSP</TD>
</TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">OPTION</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">CDRLs</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%"><FONT STYLE="font-size: 10pt">ITEM NO </FONT></TD>
    <TD STYLE="width: 17%"><FONT STYLE="font-size: 10pt">SUPPLIES/SERVICES </FONT></TD>
    <TD STYLE="width: 17%; text-align: center"><FONT STYLE="font-size: 10pt">QUANTITY</FONT></TD>
    <TD STYLE="width: 17%; text-align: center"><FONT STYLE="font-size: 10pt">UNIT</FONT></TD>
    <TD STYLE="width: 17%"><FONT STYLE="font-size: 10pt">UNIT PRICE</FONT></TD>
    <TD STYLE="width: 17%; text-align: right"><FONT STYLE="font-size: 10pt">AMOUNT</FONT></TD>
</TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">0005</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
</TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">OPTION</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center">1</TD>
    <TD STYLE="text-align: center">Lot</TD>
    <TD>$782,322.00</TD>
    <TD STYLE="text-align: right">$782,322.00</TD>
</TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="5">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Human and Animal Use</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">FFP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Tasking in SOW section 2.3.2 will not be funded until the contractor obtains all</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">necessary IRB documentation and obtain both institutional and Government (SSC-</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Pacific) approval in accordance with IRB documentation submission guidance</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">prior to conducting human or animal testing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">FOB: Destination </FONT></P>

</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>NET AMT</TD>
    <TD STYLE="text-align: right">$782,322.00</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 4   of 40</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%"><FONT STYLE="font-size: 10pt">ITEM NO </FONT></TD>
    <TD STYLE="width: 17%"><FONT STYLE="font-size: 10pt">SUPPLIES/SERVICES </FONT></TD>
    <TD STYLE="width: 17%; text-align: center"><FONT STYLE="font-size: 10pt">QUANTITY</FONT></TD>
    <TD STYLE="width: 17%; text-align: center"><FONT STYLE="font-size: 10pt">UNIT</FONT></TD>
    <TD STYLE="width: 17%"><FONT STYLE="font-size: 10pt">UNIT PRICE</FONT></TD>
    <TD STYLE="width: 17%; text-align: right"><FONT STYLE="font-size: 10pt">AMOUNT</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">0006</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"></FONT>1</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Lot</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">$1,534,009.00</FONT></TD>
    <TD STYLE="text-align: right">$1,534,099.00</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">OPTION</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">RESEARCH</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"></FONT></TD>
    <TD>FFP</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD></TD>
    <TD COLSPAN="3">Research IAW the SOW (Contained in section C).</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"></FONT></TD>
    <TD>FOB: Destination</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">NET AMT</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">$1,534,099.00</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%"><FONT STYLE="font-size: 10pt">ITEM NO </FONT></TD>
    <TD STYLE="width: 17%"><FONT STYLE="font-size: 10pt">SUPPLIES/SERVICES </FONT></TD>
    <TD STYLE="width: 17%; text-align: center"><FONT STYLE="font-size: 10pt">QUANTITY</FONT></TD>
    <TD STYLE="width: 17%; text-align: center"><FONT STYLE="font-size: 10pt">UNIT</FONT></TD>
    <TD STYLE="width: 17%"><FONT STYLE="font-size: 10pt">UNIT PRICE</FONT></TD>
    <TD STYLE="width: 17%; text-align: left"><FONT STYLE="font-size: 10pt">AMOUNT</FONT></TD>
</TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">0007</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Lot</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>NSP</TD>
</TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">OPTION</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">CDRLs</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%"><FONT STYLE="font-size: 10pt">ITEM NO </FONT></TD>
    <TD STYLE="width: 17%"><FONT STYLE="font-size: 10pt">SUPPLIES/SERVICES </FONT></TD>
    <TD STYLE="width: 17%; text-align: center"><FONT STYLE="font-size: 10pt">QUANTITY</FONT></TD>
    <TD STYLE="width: 17%; text-align: center"><FONT STYLE="font-size: 10pt">UNIT</FONT></TD>
    <TD STYLE="width: 17%"><FONT STYLE="font-size: 10pt">UNIT PRICE</FONT></TD>
    <TD STYLE="width: 17%; text-align: right"><FONT STYLE="font-size: 10pt">AMOUNT</FONT></TD>
</TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">0008</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">1</FONT></TD>
    <TD STYLE="text-align: center">Lot</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
</TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">OPTION</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>$892,922.00</TD>
    <TD STYLE="text-align: right">$892,922.00</TD>
</TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="5">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Research</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">FFP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Research IAW the SOW (Contained in section C).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">FOB: Destination </FONT></P>

</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>NET AMT</TD>
    <TD STYLE="text-align: right">$892,922.000</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 5    of 40</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%"><FONT STYLE="font-size: 10pt">ITEM NO </FONT></TD>
    <TD STYLE="width: 17%"><FONT STYLE="font-size: 10pt">SUPPLIES/SERVICES </FONT></TD>
    <TD STYLE="width: 17%; text-align: center"><FONT STYLE="font-size: 10pt">QUANTITY</FONT></TD>
    <TD STYLE="width: 17%; text-align: center"><FONT STYLE="font-size: 10pt">UNIT</FONT></TD>
    <TD STYLE="width: 17%"><FONT STYLE="font-size: 10pt">UNIT PRICE</FONT></TD>
    <TD STYLE="width: 17%; text-align: left"><FONT STYLE="font-size: 10pt">AMOUNT</FONT></TD>
</TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">0009</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>NSP</TD>
</TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">OPTION</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">CDRLs</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%"><FONT STYLE="font-size: 10pt">ITEM NO </FONT></TD>
    <TD STYLE="width: 17%"><FONT STYLE="font-size: 10pt">SUPPLIES/SERVICES </FONT></TD>
    <TD STYLE="width: 17%; text-align: center"><FONT STYLE="font-size: 10pt">QUANTITY</FONT></TD>
    <TD STYLE="width: 17%; text-align: center"><FONT STYLE="font-size: 10pt">UNIT</FONT></TD>
    <TD STYLE="width: 17%"><FONT STYLE="font-size: 10pt">UNIT PRICE</FONT></TD>
    <TD STYLE="width: 17%; text-align: right"><FONT STYLE="font-size: 10pt">AMOUNT</FONT></TD>
</TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">0010</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">1</FONT></TD>
    <TD STYLE="text-align: center">Lot<FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
</TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">OPTION</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">NSP</TD>
</TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="5">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Hardware Deliverable</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">FFP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">50 Prototype Optimized Cartridges</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">FOB: Destination </FONT></P>

</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>NET AMT</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%"><FONT STYLE="font-size: 10pt">ITEM NO </FONT></TD>
    <TD STYLE="width: 17%"><FONT STYLE="font-size: 10pt">SUPPLIES/SERVICES </FONT></TD>
    <TD STYLE="width: 17%; text-align: center"><FONT STYLE="font-size: 10pt">QUANTITY</FONT></TD>
    <TD STYLE="width: 17%; text-align: center"><FONT STYLE="font-size: 10pt">UNIT</FONT></TD>
    <TD STYLE="width: 17%"><FONT STYLE="font-size: 10pt">UNIT PRICE</FONT></TD>
    <TD STYLE="width: 17%; text-align: right"><FONT STYLE="font-size: 10pt">AMOUNT</FONT></TD>
</TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">0011</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">1</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Lot</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
</TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">OPTION</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">RESEARCH</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>$774,875.00</TD>
    <TD STYLE="text-align: right">$774,875.00</TD>
</TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="5">FFP<BR>
<FONT STYLE="font-size: 10pt">Research IAW the SOW (Contained in section C).</FONT>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">FOB: Destination </FONT></P>

</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>NET AMT</TD>
    <TD STYLE="text-align: right">$774,875.000</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 6   of 40</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%"><FONT STYLE="font-size: 10pt">ITEM NO </FONT></TD>
    <TD STYLE="width: 17%"><FONT STYLE="font-size: 10pt">SUPPLIES/SERVICES </FONT></TD>
    <TD STYLE="width: 17%"><FONT STYLE="font-size: 10pt">QUANTITY</FONT></TD>
    <TD STYLE="width: 17%"><FONT STYLE="font-size: 10pt">UNIT</FONT></TD>
    <TD STYLE="width: 17%"><FONT STYLE="font-size: 10pt">UNIT PRICE</FONT></TD>
    <TD STYLE="width: 17%; text-align: left"><FONT STYLE="font-size: 10pt">AMOUNT</FONT></TD>
</TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">0012</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>NSP</TD>
</TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">OPTION</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">CDRLs</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Page 7 of 40</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Section C - Descriptions and Specifications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>STATEMENT OF WORK (SOW)</U></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Statement of Work</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Aethlon Medical, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>DATE: 23 September 2011</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>TITLE: Broad Spectrum Countermeasures for Viral and Bacterial
Sepsis using Dialysis-Like Devices</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>1. Scope</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The scope of this effort is to use Aethlon&rsquo;s ADAPT System
as the core technology within an extracorporeal blood purification device that would simultaneously remove: viruses, virally-derived
immunosuppressive glycoproteins, and multiple classes of exosomes; complement activation, activation of virus growth (e.g. cytomegalovirus)
and TLR activation, all of which have implications to the promotion of the well-being and recovery of wounded warfighters and the
prevention of sepsis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>1.1 Introduction</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">This effort will use the adaptable dialysis-like platform (ADAPT)
technology that allows for the selective removal of harmful agents from the entire circulatory system. This revolutionary advance
overcomes the limitation of devices that indiscriminately adsorb or solely capture particles by molecule size. The platform will
provide an expansive therapeutic filtration mechanism to immobilize multiple affinity agents directed toward precursors to sepsis,
bacterial toxins, viral pathogens, and disease enhancing particles transported by exosomes. To insure benefit to wounded warfighters,
this effort will advance an innovative strategy that will allow therapy administration without systemic anticoagulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The ADAPT platform has been previously used to create a broad-spectrum
antiviral device that immobilized one lectin affinity agent, resulting in the effective capture of all tested Category A pathogens,
as well as exosomes underlying tuberculosis and cancer. In human studies, this same device, known as the Hemopurifier, consistently
provided greater than 50% average viral load reductions during four-hour treatment periods in both hepatitis-C and HIV infected
individuals without antiviral drug therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The resulting device would save thousands of military and civilian
lives each year. Each of these technology advancements will be integrated into a single cartridge that will provide decision-free
and life-saving medical care for the wounded warfighter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>1.2 Background</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The goal of the DLT program is to develop a portable device that
removes &ldquo;dirty&rdquo; blood from the body, separates harmful agents, and returns &ldquo;clean&rdquo; blood to the body in
a manner similar to dialysis treatment of kidney failure. While the device could have an impact across multiple areas of medicine,
the target application for this device is sepsis. The envisioned device can also provide early identification of the presence
of a pathogen. Once the presence of pathogens has been confirmed, the DLT device will provide continuous &quot;label-free&quot;
removal of pathogens, toxins and activated patient cells without pathogen identification or use of pathogen-specific binding chemistries.
As a final step in the treatment process, the DLT device will enable closed-loop therapy based on continuous, reduced dimensionality
modeling of patient health. Predictive modeling in this fashion will allow us to identify sepsis early, learn what we need to
remove, and direct the most effective intervention to improve patient health. This cycle of sensing, adjustment, estimation, computation,
and manipulation will modulate key health parameters faster than the underlying disease process and drive the patient towards
a stable, healthy state.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 8  of 40</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2. Technical Requirements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2.1 Human and Animal use</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Human use <B>is </B>anticipated in this effort, specifically
related to the use of human blood. The contractor shall obtain all necessary Institutional Review Board (IRB) approvals, show proper
assurance documentation, and obtain proper approval from the Government officials prior to human use testing. Funds associated
with human subjected testing shall not be released until IRB documentation has been provided to SSC&rsquo;s HRPO and approval to
release funds has been obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0">Animal use <B>is </B>anticipated in this effort. The
contractor shall obtain all necessary Institutional Animal Care and Utilization Committee (IACUC) approval and demonstrate this
approval to the Government (<B>both </B>ACURO and SSC-Pacific) prior to beginning experimentation with animals. If animal use is
no longer anticipated, or changes significantly from the approved IACUC then the Principal Investigator (PI) must submit a letter
stating the discontinuation of animal use for this effort and/or receive appropriate authorization for IACUC changes of previously
specified protocols. Unless prior approval by DARPA is given IACUC documentation must be provided prior to contract award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2.2 Base Effort (Year 1)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>2.2.1 Subtask 1a: Anticoagulant-free Hemopurification
Device </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left">2.2.1.1</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Write requirements definition for the extracorporeal blood purification system and
acquire necessary equipment.</TD>
</TR></TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left">2.2.1.2</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Fabricate breadboard prototypes for anticoagulation-free anti-sepsis extracorporeal
system (ASEPSYS) device. Fabricate prototype blood tubing sets. Acquire anti-thrombogenic surface-modified hollow fiber plasma
separators.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left">2.2.1.3</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Assemble and test breadboard ASEPSYS devices <I>ex vivo </I>with bovine blood. The
test will most likely be conducted using a porcine model where the elapsed time to reach a pre-defined degree of clotting in the
blood treatment device will be compared between the new device and two control groups; one using standard anticoagulant therapy
and one using none. Determine contribution of the following techniques and approaches to eliminating anticoagulants:<BR>
<BR>
(1) Backflushing at regular intervals, (2) Turbo
loop, (3) Continuous pre-dilution loop using re-captured hydration fluid, (4) Linear vs pulsatile blood flow, (5) Elimination
of air/blood interfaces in extracorporeal circuit, (6) Anti-thrombogenic derivatized plasma separation membrane, and (7) Ultra-short
half-life anticoagulant nafamostat mesilate.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left">2.2.1.4</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">IRB Documentation Generation: The contractor shall obtain all necessary IRB documentation
and obtain both institutional and Government (SSC-Pacific) approval in accordance with IRB documentation submission guidance prior
to conducting human subject testing.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Milestones </U></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left">M1:</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Demonstrate the effectiveness of the prototype device in preventing platelet activation
or clotting in at least a 2 hour blood pumping experiment at 100 mL/hr blood flow.</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>2.2.2 Subtask 2: Removal of Sepsis Precursors</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U></U></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left">2.2.2.1</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Begin to develop a device based on Aethlon&rsquo;s ADAPT system to efficiently capture
sepsis precursors identified as potentially important in killing patients undergoing sepsis. The strategy is takes advantage of
the flexibility and rapidity of modification of our ADAPT platform system to test any sepsis precursor candidates that circulate
in the blood. The sepsis precursors that will be targeted are shown in Table I, in order of importance. No test for the removal
of bacterial toxins. No testing for removal of cytokines, since the evidence to date does not support a role for them in death
due to sepsis. Additional factors may become known during the grant period and those will also be tested as time and budget permit.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 9 of 40</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: right">2.2.2.2</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Screening Capture Agents: Perform initial screening of the different proposed capture
agents by measuring binding affinity and kinetics using surface plasmon resonance (SPR) or biolayer surface interferometry (BLI).</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: right">2.2.2.3</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Perform quantitative real time PCR will also be used to measure viral load, and specific
DNA or RNA targets.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><B><U>Milestones</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left">M2:</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Target capture &gt; 50% in 24 hours for at least 1 target in blood or blood components</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Table I Potential Target Sepsis Precursors
and Broad Spectrum Binding Agents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 33%; border: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Group</B></FONT></TD>
    <TD STYLE="width: 32%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Factor</B></FONT></TD>
    <TD STYLE="width: 35%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Proposed Binding Agents</B></FONT></TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Sepsis related Exosomes</B></FONT></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>1.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>iNOS exosomes [1-3]</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Inducible NO synthase containing exosomes implicated in sepsis</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">GNA lectin or iNOS Specific antibody</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>2.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Platelet derived exosomes [4, 5]</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Exosomes isolated from platelets associated with sepsis</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">GNA lectin or antibodies</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>3.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Macrophage derived exosomes [6]</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Exosomes from cultured macrophages</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">GNA lectin</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Other Potential Sepsis Factors</B></FONT></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>4.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Complement Activation [7-9]</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Humanized Cobra venom factor (CVF) from Incode, <B>CVF is not a toxin</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        CVF is a stable analog of human complement
that neutralizes C3a in animals</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>5.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Bacterial DNA [13-15]</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">CpG rich DNA activates macrophages via Toll Like Receptors (TLR)</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Antisense nuclease resistant DNA analogs, TLRs or specific antibodies</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>6.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Common Sepsis associated Viruses including CMV</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Virus blooms in trauma and burn patients [10]</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">GNA Lectin</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>7.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Protease leakage through <BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ischemic gut (e.g. trypsin) [11, 12]</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Ischemia in the gut leads to protease leakage into the blood and the symptoms of sepsis (reperfusion injury)</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Lima bean trypsin inhibitor, Soybean trypsin inhibitor</FONT></TD></TR>
</TABLE>
<P>&nbsp;</P>

<P>&nbsp;</P>

<P>&nbsp;</P>

<P></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 10 of 40</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2.3 Option 1 (Year 2)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>2.3.2 Subtask 1a: Anticoagulant-free Hemopurification
Device</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left">2.3.2.1</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Demonstrate the effectiveness of the prototype device in vivo in animals preventing
platelet activation or clotting in at least a 2 hour blood pumping experiment at 75 mL/min blood flow.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left">2.3.2.2</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Formulate initial design based on work from previous phase. Begin to build and test
selected instrument design and tubing sets.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left">2.3.2.3</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Write and test software. Conduct ergonomic research. Begin discussions with System
Integrator.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Milestone</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left">M3:</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Demonstrate the effectiveness of the prototype device in preventing platelet activation
or clotting in at least a 8 hour blood pumping experiment at 500 mL/hr blood flow.</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>2.3.3 Subtask 2. Removal of Sepsis Precursors</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left">2.3.3.1</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Build the ADAPT capture cartridges with the identified affinity agents. Measure the
rate of capture of the specific targets from in ex vivo recirculation experiments from cell culture and blood.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left">2.3.3.2</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Cartridge construction with optimized affinity matrix design for each potential target.
Complete all capture agents screening. Initiate <I>ex vivo </I>capture studies from blood using the optimized cartridges.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Milestones</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font-size: 10pt">M4:</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Target capture &gt; 50% in 24 hours for at least 5 targets in blood or blood components.</TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font-size: 10pt">M5:</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Milestone 5: Target capture &gt; 90% in 24 hours for at least 3 targets in blood or
blood components.</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.4in 0pt 0"><B>NOTE: TASK 2.3.2 SHALL NOT BE EXERCISED
AND TASKING FUNDS RELEASED UNTIL IRB DOCUMENTATION AND PROPER IRB APPROVAL HAS BEEN OBTAINED.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2.4 Option 2 (Year 3)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>2.4.1 Subtask 1a: Anticoagulant-free Hemopurification
Device</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U></U></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left">2.4.1.1</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Collaborate with System Integrator to build final prototypes for <I>in vivo </I>pig
testing.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left">2.4.1.2</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Perform animal tests to confirm the performance of the device <I>in vivo.</I></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left">2.4.1.3</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Document all adverse events and long term effects of treatment.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Milestones</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U></U></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left">M6:</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Demonstrate the effectiveness of the prototype device in preventing platelet activation
or clotting in at least a 24 hour blood pumping experiment at 1250 mL/hr blood flow <I>in vivo </I>in pigs.</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>2.4.2 Subtask 4: Target Capture in Combined Agent Cartridge</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U></U></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left">2.4.2.1</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Candidate cartridges that demonstrate &gt;90% capture in 24 hours efficacy in binding
to individual sepsis precursor targets will move to the next stage. These capture agents will be combined into a single cartridge
and retested ex vivo in pig blood or blood components.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left">2.4.2.2</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Optimize cartridge design in regard to fiber length, diameter and the use of prototype
ASEPSYS system. Demonstrate increased capture rates 2-7 fold from the current system in blood or blood components. 2.4.2.3 Perform
basic biocompatibility studies to confirm that the combination cartridge does not present any new patient risks that need to be
addressed.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Milestones</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left">M7:</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Target capture &gt; 50% in 24 hours for at least 5 of the 7 targets ex vivo in blood
or blood components using the combination cartridge.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 11  of 40</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left">M8:</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Optimize cartridge composition for target capture in a single cartridge demonstrating
increased capture rates 2-7 fold from the current system in blood or blood components.</TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left">M9:</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Target capture &gt; 90% in 24 hours (12 months) for at least 5 of the 7 targets ex
vivo in blood or blood components using the optimized cartridge</TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left">M10:</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Pass biocompatibility tests for the combination ADAPT device.</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2.5
</B></FONT><B>Option 3 (Year 4)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>2.5.1 Subtask 1a: Anticoagulant-free Hemopurification
Device</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B><U></U></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: right">2.5.1.1</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">System integrator implements design modifications emanating from pig experiments.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: center">2.5.1.2</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Collaborate with System Integrator in conducting verification and validation testing
and collecting all remaining data required for IDE submission (e.g. biocompatibility, electromagnetic interference, electromagnetic
susceptibility, software V&amp;V, etc.).</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: center">2.5.1.3</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Make additional cartridge or device modification as required by system integrator.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Milestones</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> M11: Demonstrate the effectiveness of the newest device design in preventing blood clotting in a 24 hour blood pumping experiment at 1275 mL/hr blood flow <I>in vivo.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>2.5.2 Subtask 4: Target Capture in Combined Agent Cartridge</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U></U></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left">2.5.2.1</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Determine the <I>in vivo </I>efficiency of an optimized combined clearance cartridge
incorporating all the successful capture agents.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left">2.5.2.2</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Finish construction and delivery of 50 prototype cartridges for testing by the system
integrator. The</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: right">cartridges</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">will need to be made available (packaged, labeled, sterilized and qualified) to the
system integrator.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left">2.5.2.3</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Perform basic biocompabability tests for the combination ADAPT device to confirm the
combination cartridge does not present any new patient risk.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Milestones</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left">M12:</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Complete studies in septic pig models with optimized combination cartridge for &gt;90%
clearance of at least 4 of the 7 sepsis marker targets in 24 hours (12 months)</TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left">M13:</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Construct and deliver of 50 prototype cartridges for testing by the system integrator.</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2.6 Option 4 (Year 5)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>2.6.1 Subtask 5: Testing of final product by System Integrator</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left">2.6.1.1</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">System Integrator approval of ASEPSYS device for portable blood pump without the need
for systemic anticoagulation.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left">2.6.1.2</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">System Integrator testing of the ADAPT treatment cartridge for reducing sepsis related
death by &gt;20% in a septic animal pig model.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left">2.6.1.3</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Prepare and submit IDE proposal for sepsis treatment based on previously approved
IDE.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left">2.6.1.4</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Prepare and present Final report for DARPA.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Milestones</U></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left">M13:</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">System Integrator approval of a sepsis precursor ADAPT treatment cartridge for reducing
sepsis related death by &gt;20% in a septic animal pig model.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left">M14:</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">System integrator acceptance of the ASEPSYS anticoagulation device as the blood pump
that can avoid the need for systemic anticoagulation.</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 12 of 40</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>3.0 Program Management and Reviews</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>3.1 Program Management Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">The contractor shall develop a Program Management
Plan. A graphical representation of this plan (Gantt chart is one example) identifying major tasks and their task leaders, milestones
of the major task and their completion dates shall be generated. In addition, a graphical representation of budget shall be generated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>3.2 Kick-off Meeting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">The contractor shall participate in a kick-off meeting
within 60 days of contract award. The purpose of this meeting is to introduce key program personnel, discuss the proposed tasking,
present the program schedule and milestones and the initial Program Management Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>3.3 Quarterly Reviews</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The contractor shall hold quarterly reviews for the duration
of this effort. The purpose of these reviews is to present a summary of work completed and milestones met, discuss any problems
encountered, update the program schedule, present the program financial status, and discuss remaining work.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>3.4 Final Contract Review</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0">A final contract review held in place of the last
quarterly review shall be hosted by the principal contractor. The purpose of this review is to present a summary of all work completed
and milestones accomplished and to discuss any relevant future efforts similar to the contract that may be pursued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>4.0 Deliverables</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The reports and presentation materials are to be delivered in
accordance with the contract CDRLs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CLAUSES INCORPORATED BY FULL TEXT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.6in 0pt 0">5252.227-9211 PROCEDURES FOR CONTROLLING TECHNICAL
DOCUMENTS UNDER SPAWARSYSCEN PACIFIC CONTRACTS (NOV 2008)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.6in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0">The Contractor shall comply with DOD Directive 5230.25
and the information provided herein when the Government provides the Contractor with technical data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a) Location of distribution statement, export warning notice,
and destruction notice (classified and unclassified technical documents).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0; text-indent: 0.5in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Standard written or printed material with covers and/or title pages: Statement(s) to be printed, typed, or stamped on the
front cover and title page.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Technical documents without covers or title pages: Statement(s) to be typed, printed, or stamped on the first page of the
document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Deck of punched or aperture cards: Statement(s) to be typed, printed, or stamped on face of first and last card and on
top of deck.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-indent: 0.5in">(4)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Magnetic tape, cassette, or disk: Statement(s) to be typed, stamped, or printed on a label applied to outside of material.
The first page of the resulting hard-copy report or computer printout is also marked with applicable statement(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-indent: 0.5in">(5)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Microfilm: Statement(s) to be typed, stamped, or printed on outside of jacket or canister housing the material. The first
page of the resulting hard-copy report or first frame is also marked with applicable statement(s). The headers for microfiche must
carry an abbreviated version of the statement(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(6)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Drawings: Applicable statement(s) to be typed, stamped, or printed near the title block.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b) Safeguarding of Unclassified, Limited-Access Documents (for
classified documents see NOSCINST 5500.1A).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Normal working hours: Limited-access documents and those that have not yet been reviewed cannot be left unattended in work
areas accessible to non-DoD employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-indent: 0.5in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>After normal working hours: Limited-access documents and those that have not yet been reviewed should be placed in locked
files, desks, or similar containers. If this is not possible, locked offices or buildings are adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 13 of 40</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-indent: 0.5in">(3) Additional guidance for safeguarding
limited-access media processed by an IT system, activity, or network can be found in OPNAVINST 5239.1A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3in 0pt 0">(c) Destruction of Unclassified, Limited-Access Documents.
Destroy by any method that will prevent disclosure of contents or reconstruction of the material. Examples of such destruction
methods follow:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-indent: 0.5in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Printed document, deck of punched or aperture cards, computer printout, and drawings: Destroy by tearing each copy into
pieces to preclude reconstruction and placing the pieces in regular trash containers or send to the Mail Room Branch for destruction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Magnetic tape, cassette, or disk: Destroy by erasing the magnetic storage media.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Microfilm: Destroy by cutting into small pieces or send to the mailroom for destruction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Safeguarding of Classified Documents: See NOSCINST 5500.1A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(e) Destruction of Classified Documents: See NOSCINST 5500.1A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(End
of specification)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>5252.237-9601 KEY PERSONNEL (DEC 1999)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>The offeror agrees to assign to this contract those key personnel listed in paragraph (d) below. No substitutions shall
be made except in accordance with this clause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>The offeror agrees that during the first 6 months of the contract performance period no personnel substitutions will be
permitted unless such substitutions are necessitated by an individual's sudden illness, death or termination of employment. In
any of these events, the contractor shall promptly notify the Contracting Officer and provide the information required by paragraph
(c) below. After the initial 6 month period, all proposed substitutions must be submitted in writing, at least fifteen (15) days
(thirty (30) days if a security clearance is to be obtained) in advance of the proposed substitutions to the contracting officer.
These substitution requests shall provide the information required by paragraph (c) below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>All requests for approval of substitutions under this contract must be in writing and provide a detailed explanation of
the circumstances necessitating the proposed substitutions. They must contain a complete resume for the proposed substitute or
addition, and any other information requested by the Contracting Officer or needed by him to approve or disapprove the proposed
substitutions. All substitutions proposed during the duration of this contract must have qualifications of the person being replaced.
The Contracting Officer or his authorized representative will evaluate such requests and promptly notify the contractor of his
approval or disapproval thereof in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>List of Key Personnel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%"><FONT STYLE="font-size: 10pt"><B>NAME</B></FONT></TD>
    <TD STYLE="width: 55%"><FONT STYLE="font-size: 10pt"><B>CONTRACT LABOR CATEGORY</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Richard H. Tullis, PhD</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Science Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-indent: 0in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>If the Contracting Officer determines that suitable and timely replacement of key personnel who have been reassigned, terminated
or have otherwise become unavailable for the contract work is not reasonably forthcoming or that the resultant reduction of productive
effort would be so substantial as to impair the successful completion of the contract or the service order, the contract may be
terminated by the Contracting Officer for default or for the convenience of the Government, as appropriate. In addition, if the
Contractor is found at fault for the condition, the Contracting Officer may elect to equitably decrease the contract price or
fixed fee to compensate the Government for any resultant delay, loss or damage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 14 of 40</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(f) If the offeror wishes to add personnel to be used in a labor
category he shall employ the procedures outlined in paragraph (c) above. Adding personnel will only be permitted in the event of
an indefinite quantity contract, where the Government has issued a delivery order for labor hours that would exceed a normal forty
hour week if performed only by the number of employees originally proposed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(End of clause)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 15 of 40</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Section D - Packaging and Marking</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CLAUSES INCORPORATED BY FULL TEXT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">252.235-7010 ACKNOWLEDGMENT OF SUPPORT AND DISCLAIMER (MAY 1995)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>The Contractor shall include an acknowledgment of the Government&rsquo;s support in the publication of any material based
on or developed under this contract, stated in the following terms: This material is based upon work supported by the (name of
contracting agency(ies)) under Contract No. (Contracting agency(ies) contract numbers(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>All material, except scientific articles or papers published in scientific journals, must, in addition to any notices or
disclaimers by the Contractor, also contain the following disclaimer: Any opinions, findings and conclusions or recommendations
expressed in this material are those of the author(s) and do not necessarily reflect the views of the (name of contracting agency(ies).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(End of clause)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 16  of 40</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Section E - Inspection and Acceptance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">INSPECTION AND ACCEPTANCE TERMS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Supplies/services will be inspected/accepted at:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 6%; text-align: center"><FONT STYLE="font-size: 10pt">CLIN</FONT></TD>
    <TD STYLE="width: 23%"><FONT STYLE="font-size: 10pt">INSPECT AT</FONT></TD>
    <TD STYLE="width: 26%"><FONT STYLE="font-size: 10pt">INSPECT BY</FONT></TD>
    <TD STYLE="width: 23%"><FONT STYLE="font-size: 10pt">ACCEPT AT</FONT></TD>
    <TD STYLE="width: 22%; text-align: right"><FONT STYLE="font-size: 10pt">ACCEPT BY</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">0001</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Destination</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Government</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Destination</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">Government</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">0002</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Destination</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Government</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Destination</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">Government</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">0003</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Destination</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Government</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Destination</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">Government</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">0004</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Destination</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Government</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Destination</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">Government</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">0005</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Destination</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Government</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Destination</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">Government</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">0006</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Destination</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Government</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Destination</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">Government</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">0007</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Destination</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Government</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Destination</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">Government</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">0008</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Destination</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Government</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Destination</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">Government</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">0009</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Destination</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Government</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Destination</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">Government</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">0010</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Destination</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Government</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Destination</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">Government</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">0011</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Destination</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Government</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Destination</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">Government</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">0012</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Destination</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Government</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Destination</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">Government</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CLAUSES INCORPORATED BY REFERENCE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 17%"><FONT STYLE="font-size: 10pt">52.246-7</FONT></TD>
    <TD STYLE="width: 53%"><FONT STYLE="font-size: 10pt">Inspection Of Research And Development Fixed Price</FONT></TD>
    <TD STYLE="width: 30%"><FONT STYLE="font-size: 10pt">AUG 1996</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">252.246-7000</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Material Inspection And Receiving Report</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">MAR 2008</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 17 of 40</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Section F - Deliveries or Performance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">DELIVERY INFORMATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 6%; text-align: center"><FONT STYLE="font-size: 10pt">CLIN</FONT></TD>
    <TD STYLE="width: 25%"><FONT STYLE="font-size: 10pt">PERIOD OF</FONT></TD>
    <TD STYLE="vertical-align: top; width: 15%; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 41%"><FONT STYLE="font-size: 10pt">SHIP TO ADDRESS</FONT></TD>
    <TD STYLE="width: 13%"><FONT STYLE="font-size: 10pt">UIC</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">PERFORMANCE</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">QUANTITY</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">0001</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">12 MONTHS AFTER</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">SPAWAR SYSTEMS CENTER</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">N66001</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">DATE OF CONTRACT</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">RECEIVING OFFICER</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">AWARD</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">4297 PACIFIC HIGHWAY, BLDG 7 SAN DIEGO CA 92110-5000</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">619-553-1251</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">FOB: Destination</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">0002</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">12 MONTHS AFTER</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">(SAME AS PREVIOUS LOCATION)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">N66001</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">DATE OF CONTRACT</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">FOB: Destination</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">AWARD</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">0003</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">12 MONTHS AFTER</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">(SAME AS PREVIOUS LOCATION)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">N66001</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">DATE OF OPTION I</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">FOB: Destination</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">AWARD</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">0004</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">12 MONTHS AFTER</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">(SAME AS PREVIOUS LOCATION)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">N66001</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">DATE OF OPTION I</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">FOB: Destination</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">AWARD</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">0005</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">12 MONTHS AFTER</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">(SAME AS PREVIOUS LOCATION)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">N66001</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">DATE OF OPTION I</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">FOB: Destination</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">AWARD</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">0006</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">12 MONTHS AFTER</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">(SAME AS PREVIOUS LOCATION)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">N66001</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">DATE OF OPTION II</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">FOB: Destination</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">AWARD</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">0007</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">12 MONTHS AFTER</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">(SAME AS PREVIOUS LOCATION)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">N66001</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">DATE OF OPTION II</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">FOB: Destination</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">AWARD</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">0008</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">12 MONTHS AFTER</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">(SAME AS PREVIOUS LOCATION)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">N66001</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">DATE OF OPTION III</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">FOB: Destination</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">AWARD</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">0009</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">12 MONTHS AFTER</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">(SAME AS PREVIOUS LOCATION)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">N66001</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">DATE OF OPTION III</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">FOB: Destination</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">AWARD</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">0010</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">12 MONTHS AFTER</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">(SAME AS PREVIOUS LOCATION)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">N66001</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">DATE OF OPTION III</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">FOB: Destination</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">AWARD</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 18 of 40</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"><TR><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">0011</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">12 MONTHS AFTER</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">(SAME AS PREVIOUS LOCATION)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">N66001</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">DATE OF OPTION IV</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">FOB: Destination</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">AWARD</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">0012</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">12 MONTHS AFTER</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">(SAME AS PREVIOUS LOCATION)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">N66001</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">DATE OF OPTION IV</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">FOB: Destination</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">AWARD</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CLAUSES INCORPORATED BY REFERENCE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 17%; text-align: justify"><FONT STYLE="font-size: 10pt">52.242-15</FONT></TD>
    <TD STYLE="width: 53%; text-align: justify"><FONT STYLE="font-size: 10pt">Stop-Work Order</FONT></TD>
    <TD STYLE="width: 30%; text-align: justify"><FONT STYLE="font-size: 10pt">AUG 1989</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">52.242-15 Alt I</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Stop-Work Order (Aug 1989) - Alternate I</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">APR 1984</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">52.247-34</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">F.O.B. Destination</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">NOV 1991</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 19 of 40</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Section G - Contract Administration Data</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ACCOUNTING AND APPROPRIATION DATA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AA: 9710400 1320 595 0P1D1 0 2525DP AM 179166 1101E S12136</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AMOUNT: $938,583.00</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CIN 130021178700002: $938,583.00</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CLAUSES INCORPORATED BY FULL TEXT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">252.204-0007 CONTRACT-WIDE: SEQUENTIAL ACRN ORDER. (SEP 2009)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The payment office shall make payment in sequential ACRN order
within the contract or order, exhausting all funds in the previous ACRN before paying from the next ACRN using the following sequential
order: alpha/alpha; alpha/numeric; numeric/alpha; and numeric/numeric.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(End of clause)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5252.201-9201 DESIGNATION OF CONTRACTING OFFICER'S REPRESENTATIVE
(MAR 2006)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.95in 0pt 0; text-indent: 0in"><B>(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>The Contracting Officer hereby appoints the following individual as Contracting Officer&rsquo;s Representative(s) (COR)
for this contract/order:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.95in 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>CONTRACTING OFFICER REPRESENTATIVE</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name: John Rockway</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Code: 52260</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address: 53560 Hull Street, San Diego, CA 92152-5001</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phone Number: 619-204-0988<BR>
<FONT>E-mail: john.rockway@navy.mil</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT></B>It is emphasized that only the Contracting Officer has the authority to modify the terms of the contract, therefore,
in no event will any understanding agreement, modification, change order, or other matter deviating from the terms of the basic
contract between the Contractor and any other person be effective or binding on the Government. When/If, in the opinion of the
Contractor, an effort outside the existing scope of the contract is requested, the Contractor shall promptly notify the PCO in
writing. No action shall be taken by the Contractor unless the Procuring Contracting Officer (PCO) or the Administrative Contracting
Officer (ACO) has issued a contractual change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 20 of 40</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>5252.216-9210 TYPE OF CONTRACT (DEC 1999)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This is a Firm-Fixed Price (FFP) Completion contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(End of clause)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5252.227-9213 PATENT MATTERS POINT OF CONTACT (OCT 2008)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">The Point of Contact regarding Patent Matters for this contract is:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">OFFICE OF PATENT COUNSEL / CODE 360012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SPAWARSYSCEN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">53560 HULL STREET</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SAN DIEGO, CA 92152-5001</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(619) 553-3001</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0">Do not submit interim and final invention reports
to this address. See the clause at 5252.227-9206 for the proper address.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(End of clause)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">5252.232-9208 INVOICING INSTRUCTIONS FOR SERVICES
USING WIDE AREA WORK FLOW (WAWF) (APR 2009)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Invoices for services rendered under this contract shall be submitted electronically through the Wide Area Work Flow-Receipt
and Acceptance (WAWF). The contractor shall submit invoices for payment per contract terms. The Government shall process invoices
for payment per contract terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>The vendor shall have their Cage Code activated by calling 1-866-618-5988 and selecting option 2. Once activated, the vendor
shall self-register at the WAWF website at</FONT> https://wawf.eb.mil<FONT STYLE="font-size: 10pt"><U>.</U> Vendor training is
available on the internet at</FONT> https://wawftraining.eb.mil<FONT STYLE="font-size: 10pt"><U>.</U> WAWF Vendor &ldquo;Quick
Reference&rdquo; Guides are located at the following web site: </FONT>http://acquisition.navy.mil/rda/home/acquisitiononesource/ebusiness/donebusinesssolutions/wa
<U>wfoverview/vendorinformation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="color: blue">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Cost back-up documentation (such as delivery receipts, labor hours &amp; material/travel costs etc.) shall be included and
attached to the invoice in WAWF. Attachments created with any Microsoft Office product or Adobe (.pdf files) are attachable to
the invoice in WAWF. The total size limit for files per invoice is 5 megabytes. A separate copy shall be sent to the COR/TOM.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Contractors approved by DCAA for direct billing will not process vouchers through DCAA, but may submit directly to DFAS.
Vendors MUST still provide a copy of the invoice and any applicable cost back-up documentation supporting payment to the Acceptor/Contracting
Officer's Representative (COR) if applicable. Additionally, a copy of the invoice(s) and attachment(s) at time of submission in
WAWF shall also be provided to each point of contact identified in section (g) of this clause by email. If the invoice and/or
receiving report are delivered in the email as an attachment it must be provided as a .PDF, Microsoft Office product or other
mutually agreed upon form between the Contracting Officer and vendor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 21 of 40</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>A separate invoice will be prepared no more frequently than for every two weeks. Do not combine the payment claims for services
provided under this contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>The following information is provided for completion and routing of the invoice in WAWF:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 47%; border: black 1pt solid"><FONT STYLE="font-size: 10pt">WAWF Invoice Type</FONT></TD>
    <TD STYLE="width: 53%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">2-n-1 (Services Only)</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Issuing Office DODAAC</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">See Block 5 of the SF26</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Admin DODAAC</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">See Block 6 of the SF26</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Inspector DODAAC (if applicable)</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">N66001</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Inspector Contact Information</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">See Clause 5252.201-9201</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Service Acceptor DODAAC</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">N66001</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Acceptor Contact Information</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">See Clause 5252.201-9201</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">COR Contact Information</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">See Clause 5252.201-9201</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">DCAA Auditor DoDAAC :</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Service Approver DoDAAC :</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">See Block 6 of the SF26</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">PAY DODAAC</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">See Block 12 of the SF26</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>After submitting the document(s) to WAWF, click on &ldquo;Send More Email Notifications&rdquo; and add the acceptor/receiver
email addresses noted below in the email address blocks. The contractor shall, at a minimum, include the COR, Receiver, and Acceptor.
This additional notification to the government is necessary to ensure that the acceptor/receiver is aware that the invoice documents
have been submitted into WAWF:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD COLSPAN="4" STYLE="border: black 1pt solid"><FONT STYLE="font-size: 10pt">Send Additional Email Notification(s) to:</FONT></TD></TR>
<TR>
    <TD STYLE="width: 30%; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Name</FONT></TD>
    <TD STYLE="width: 25%; border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">Email</FONT></TD>
    <TD STYLE="width: 20%; border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">Phone</FONT></TD>
    <TD STYLE="width: 25%; border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">Role</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">See Clause 5252.201-9201</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">COR</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(End of clause)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>5252.243-9600 AUTHORIZED CHANGES ONLY BY THE CONTRACTING
OFFICER (JAN 1992)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Except as specified in paragraph (b) below, no order, statement, or conduct of Government personnel who visit the Contractor&rsquo;s
facilities or in any other manner communicates with Contractor personnel during the performance of this contract shall constitute
a change under the Changes clause of this contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>The Contractor shall not comply with any order, direction or request of Government personnel unless it is issued in writing
and signed by the Contracting Officer, or is pursuant to specific authority otherwise included as a part of this contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>The Contracting Officer is the only person authorized to approve changes in any of the requirements of this contract and
notwithstanding provisions contained elsewhere in this contract, the said authority remains solely the Contracting Officer&rsquo;s.
In the event the contractor effects any change at the direction of any person other than the Contracting Officer, the change will
be considered to have been made without authority and no adjustment will be made in the contract price to cover any increase in
charges incurred as a result thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(End of clause)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 22 of 40</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><U>ADMINISTRATIVE INSTRUCTIONS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><U>INCORPORATION OF REPRESENTATIONS AND CERTIFICATIONS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">All representations and certifications and other
written statements made by the contractor in response to Section K of the solicitation or at the request of the contracting officer
which are incident to the award of the contract or modification of this contract, are hereby incorporated by reference with the
same force and effect as if they were given in full text.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(End of Instruction)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><U>MARKING OF SHIPMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Each shipment of material and/or data shall be clearly
marked to show the following information:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">SHIP TO:</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">MARK FOR:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">RECEIVING OFFICER</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Contract #: N66001-11-C-4188</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Item #: ALL</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Receiving Officer Code: 56506</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The receiving office is located at 4297 Pacific
Highway, Bldg. 7, San Diego, CA 92110-5000 and is open for deliveries Monday through Thursday from 6:30 AM until 4:00 PM and Fridays
6:30 AM to 3:00 PM.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(End of Instruction)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><U>AGREEMENT TO LICENSE--NO IMPLIED LICENSE</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(a) Except as provided in paragraph (b) below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>Aethlon Medical, Inc. shall obtain a license from the U.S. Government under the following U.S. patents, patent applications
and all patents issuing thereon, and under all patents that may issue and patent applications that may be filed on the following
invention disclosures, on reasonable terms and conditions, consistent with law, regulation, and Navy policy prior to any manufacture,
use, sale, lease, license, or conveyance of any kind of any process, machine, manufacture, or composition of matter that would,
absent such license, infringe any claim of such patent(s)/application(s):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">NONE KNOWN AT THIS TIME</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>Nothing in this contract shall release Aethlon Medical, Inc. from any obligation of or duty under any other Government contract;
nor shall it grant to or confer upon Aethlon Medical, Inc. any rights, express or implied,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-indent: 40pt">(i) to any invention other than
a Subject Invention,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-indent: 40pt">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>under any patent application or patent assigned to the U.S. Government that is dominant over a patent protecting a Subject
Invention,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-indent: 40pt">(iii) under any patent application
or patent assigned to the U.S. Government protecting an invention other than a Subject Invention, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-indent: 40pt">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>under the U.S. patent(s)/patent application(s) identified in paragraph (a)(1) above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(b) No license from the U.S. Government shall
be required for research, development, test and evaluation to be performed by Aethlon Medical, Inc. under this contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(End of Instruction)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><U>APPLICATION OF DFARS 252.227-7013 AND 252.227-7015
TECHNICAL DATA CLAUSES</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The DFARS 252.227-7015, Technical Data--Commercial
Items, clause applies to technical data that pertains to a &ldquo;commercial item&rdquo; as defined in the DFARS 252.227-7015 clause.
The DFARS 252.227-7013, Rights in Technical Data--Noncommercial Items, clause applies to all other technical data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(End of Instruction)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 23 of 40</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">DISSEMINATION NOTICES FOR TECHNICAL DOCUMENTS
PREPARED UNDER SPAWARSYSCEN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><U>PACIFIC CONTRACTS (NOV 2008)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3in 0pt 0.1in">(a) Unless otherwise specified, all classified
and unclassified technical documents generated under this contract must carry the following statements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in; text-indent: 0.5in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Do not distribute to DTIC or other data depositories.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0.1in; text-indent: 0.5in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Distribution authorized to DOD components only; premature dissemination <I>[Contractor to insert a date which will be determined
by the Program Manager and affixed by the Contractor]</I>. Other requests shall be referred to the Space and Naval Warfare Systems
Center, Code 2015, San Diego, CA 92152-5001.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0.1in">(b) The Contractor shall place the above statements
on the original and all copies before being delivered to the shipping address in Section F as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0.1in; text-indent: 0.5in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Standard Written or Printed material with Covers and/or Title Pages: Statement(s) to be printed, typed, or stamped on front
cover and title page.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0.1in; text-indent: 0.5in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Technical Documents Without Covers or Title Pages: Statement(s) to be typed, printed, or stamped on first page of the document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in; text-indent: 0.5in">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Drawing: Applicable statement(s) to be typed, printed, or stamped near the title block.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.4in 0pt 0.1in; text-indent: 0.5in">(4)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Magnetic Tape, Cassette, or Disk: Statement(s) to be typed, printed, or stamped on a label applied to outside of material.
The first page of the resulting hard-copy report or computer printout report is also marked with applicable statement(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0.1in; text-indent: 0.5in">(5)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Microfilm: Statement(s) typed, printed, or stamped on outside of jacket or canister housing the material. The first page
of resulting hard-copy report or first frame is also marked with applicable statement(s). The headers for microfiche must carry
an abbreviated version of the statement(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0.1in; text-indent: 0.5in">(6)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Deck of Punched or Aperture Cards: Statement(s) to be typed, stamped, or printed on face of first and last card and on top
of deck.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0.1in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">(End of Instruction)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><U>EXPORT CONTROL (DARPA)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Should this project develop beyond fundamental research
(basic and applied research ordinarily published and shared broadly within the scientific community) with military or dual-use
applications the following apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0.1in; text-indent: 0.5in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Contractor shall comply with all U.S. export control laws and regulations, including the International Traffic in Arms
Regulations (ITAR), 22 CFR Parts 120 through 130, and the Export Administration Regulations (EAR), 15 CFR Parts 730 through 799,
in the performance of this contract. In the absence of available license exemptions/exceptions the Contractor shall be responsible
for obtaining the appropriate licenses or other approvals, if required, for exports of (including deemed exports) hardware, technical
data, and software, or for the provision of technical assistance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0.1in; text-indent: 0.5in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Contractor shall be responsible for obtaining export licenses, if required, before utilizing foreign persons in the
performance of this contract, including instances where the work is to be performed on-site at any Government installation (whether
in or outside the United States), where the foreign person will have access to export-controlled technologies, including technical
data or software.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0.1in; text-indent: 0.5in">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Contractor shall be responsible for all regulatory record keeping requirements associated with the use of licenses and
license exemptions/exceptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.65in 0pt 0.1in; text-indent: 0.5in">(4)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Contractor shall be responsible for ensuring that the provisions of this clause apply to its subcontractors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(End of instruction)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 24 of 40</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Section H - Special Contract Requirements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">CLAUSES INCORPORATED BY FULL TEXT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>5252.209-9206 EMPLOYMENT OF NAVY PERSONNEL RESTRICTED
(DEC 1999)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">In performing this contract, the Contractor will
not use as a consultant or employ (on either a full or part-time basis) any active duty Navy personnel (civilian or military) without
the prior approval of the Contracting Officer. Such approval may be given only in circumstances where it is clear that no law and
no DOD or Navy instructions, regulations, or policies might possibly be contravened and no appearance of a conflict of interest
will result.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(End of clause)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">5252.227-9205 RIGHTS IN MASK WORKS (DEC 2002)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(a) <I>Definitions</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">As defined in 17 U.S.C. &sect;901--</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&ldquo;Semiconductor chip product&rdquo; is the final
or intermediate form of any product--</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(A)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>having two or more layers of metallic, insulating, or semiconductor material, deposited or otherwise placed on, or etched
away or otherwise removed from, a piece of semiconductor material in accordance with a predetermined pattern; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(B)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>intended to perform electronic circuit functions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&ldquo;Mask work&rdquo; is a series of related images,
however fixed or encoded--</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(A)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>having, or representing the predetermined, three-dimensional pattern of metallic, insulating, or semiconductor material
present or removed from the layers of a semiconductor chip product; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(B)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>in which series the relation of the images to one another is that each image has the pattern of the surface of one form
of the semiconductor chip product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(b) For any and every mask work generated in
the performance of work under this contract, the contractor grants to the Government a non-exclusive, irrevocable, royalty free,
worldwide license to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-indent: 0.55in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-indent: 0.55in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>reproduce or have reproduced the mask work by optical, electronic, or any other means; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3in 0pt 0.05in; text-indent: 0.55in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3in 0pt 0.05in; text-indent: 0.55in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>import or distribute or have imported or distributed a semiconductor chip product in which the mask work is embodied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(c) The contractor shall include this clause,
suitably modified to replace &ldquo;contractor&rdquo; with &ldquo;subcontractor&rdquo; in all subcontracts, regardless of tier,
in which a mask work is likely to be created in the performance of the work under the subcontract. The contractor shall not obtain
rights in the subcontractor&rsquo;s mask works as any part of the consideration for awarding the subcontract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(d) This license is specific to mask work rights
and shall not be construed to broaden any proprietary rights to technical data or computer software.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(End of clause)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 25 of 40</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in">5252.227-9206 SUBMISSION OF INTERIM AND FINAL
INVENTION REPORTS AND NOTIFICATION OF ALL SUBCONTRACTS FOR EXPERIMENTAL, DEVELOPMENTAL, OR RESEARCH WORK (OCT 2008)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>This contract contains either FAR 52.227-11 &ldquo;Patent Rights--Ownership by the Contractor&rdquo; clause and DFARS 252.227-7039
&ldquo;Patents--Reporting of Subject Inventions&rdquo; or DFARS 252.227-7038 &ldquo;Patent Rights--Ownership by the Contractor
(Large Business)&rdquo; clause, or FAR 52.227-13 &ldquo;Patent Rights--Ownership by the Government&rdquo; clause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Under these clauses, the Contractor is required to submit interim and final invention reports and notification to the Government
of all subcontracts for experimental, developmental, or research work. The interim and final invention reports and notification
of all subcontracts for experimental, developmental, or research work may be submitted on DD Form 882 &ldquo;Report of Inventions
and Subcontracts.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>The Contractor shall submit interim and final invention reports and notification of all subcontracts for experimental, developmental,
or research work, including negative reports, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 60pt">CONTRACT CLOSEOUT / CODE 23100</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 60pt"><B>SPAWARSYSCEN PACIFIC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 60pt">53560 HULL STREET</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 60pt">SAN DIEGO, CA 92152-5001</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>The SPAWARSYSCEN Pacific Office of Patent Counsel, Code 360012, will represent the Contracting Officer with regard to invention
reporting matters arising under the contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(End of clause)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">5252.227-9207 LIMITED RELEASE OF CONTRACTOR CONFIDENTIAL
BUSINESS INFORMATION (APRIL 2010)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Definition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&ldquo;Confidential Business Information,&rdquo;
(Information) as used in this clause, is defined as all forms and types of financial, business, economic or other types of information
other than technical data or computer software/computer software documentation, whether tangible or intangible, and whether or
how stored, compiled, or memorialized physically, electronically, graphically, photographically, or in writing if -- (1) the owner
thereof has taken reasonable measures to keep such Information secret, and (2) the Information derives independent economic value,
actual or potential from not being generally known to, and not being readily ascertainable through proper means by, the public.
Information does not include technical data, as that term is defined in DFARS 252.227-7013(a)(14), 252.227-7015(a)(4), and 252.227-7018(a)(19).
Similarly, Information does not include computer software/computer software documentation, as those terms are defined in DFARS
252.227-7014(a)(4) and 252.227-7018(a)(4).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>The Space and Naval Warfare Systems Command (SPAWAR) may release to individuals employed by SPAWAR support contractors and
their subcontractors Information submitted by the contractor or its subcontractors pursuant to the provisions of this contract.
Information that would ordinarily be entitled to confidential treatment may be included in the Information released to these individuals.
Accordingly, by submission of a proposal or execution of this contract, the offeror or contractor and its subcontractors consent
to a limited release of its Information, but only for purposes as described in paragraph (c) of this clause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Circumstances where SPAWAR may release the contractor&rsquo;s or subcontractors&rsquo; Information include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(1) To other SPAWAR contractors and subcontractors, and
their employees tasked with assisting SPAWAR in handling and processing Information and documents in the administration of SPAWAR
contracts, such as file room management and contract closeout; and,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 26 of 40</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(2) To SPAWAR contractors and subcontractors, and their
employees tasked with assisting SPAWAR in accounting support services, including access to cost-reimbursement vouchers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(d) SPAWAR recognizes its obligation to protect
the contractor and its subcontractors from competitive harm that could result from the release of such Information. SPAWAR will
permit the limited release of Information under paragraphs (c)(1) and (c)(2) only under the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>SPAWAR determines that access is required by other SPAWAR contractors and their subcontractors to perform the tasks described
in paragraphs (c)(1) and (c)(2);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Access to Information is restricted to individuals with a bona fide need to possess;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Contractors and their subcontractors having access to Information have agreed under their contract or a separate corporate
non-disclosure agreement to provide the same level of protection to the Information that would be provided by SPAWAR employees.
Such contract terms or separate corporate non-disclosure agreement shall require the contractors and subcontractors to train their
employees on how to properly handle the Information to which they will have access, and to have their employees sign company non
disclosure agreements certifying that they understand the sensitive nature of the Information and that unauthorized use of the
Information could expose their company to significant liability. Copies of such employee non disclosure agreements shall be provided
to the Government;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in">(4)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>SPAWAR contractors and their subcontractors performing the tasks described in paragraphs (c)(1) or (c)(2) have agreed under
their contract or a separate non-disclosure agreement to not use the Information for any purpose other than performing the tasks
described in paragraphs (c)(1) and (c)(2); and,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in">(5)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Before releasing the Information to a non-Government person to perform the tasks described in paragraphs (c)(1) and (c)(2),
SPAWAR shall provide the contractor a list of the company names to which access is being granted, along with a Point of Contact
for those entities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(e) SPAWAR&rsquo;s responsibilities under the Freedom
of Information Act are not affected by this clause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(f) The contractor agrees to include, and require
inclusion of, this clause in all subcontracts at any tier that requires the furnishing of Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(End of clause)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>5252.231-9200 REIMBURSEMENT OF TRAVEL COSTS (JAN
2006)<BR>
<BR>
(a) Contractor Request and Government Approval of Travel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Any travel under this contract must be specifically
requested in writing, by the contractor prior to incurring any travel costs. If this contract is a definite or indefinite delivery
contract, then the written Government authorization will be by task/delivery orders issued by the Ordering Officer or by a modification
to an issued task/delivery order. If this contract is not a definite or indefinite delivery contract, then the written Government
authorization will be by written notice of approval from the Contracting Officer&rsquo;s Representative (COR). The request shall
include as a minimum, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Contract number</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Date, time, and place of proposed travel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Purpose of travel and how it relates to the contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in">(4)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Contractor&rsquo;s estimated cost of travel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in">(5)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Name(s) of individual(s) traveling and;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in">(6)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>A breakdown of estimated travel and per diem charges.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 27 of 40</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The contractor shall submit the travel request in writing
to the Contracting Officer&rsquo;s Representative (COR). The COR shall review and approve/disapprove (as appropriate) all travel
requests submitted giving written notice of such approval or disapproval to the contractor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>(b) General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.45in">(1) The costs for travel, subsistence,
and lodging shall be reimbursed to the contractor only to the extent that it is necessary and authorized for performance of the
work under this contract. The costs for travel, subsistence, and lodging shall be reimbursed to the contractor in accordance with
the Federal Acquisition Regulation (FAR) 31.205-46, which is incorporated by reference into this contract. As specified in FAR
31.205-46(a) (2), reimbursement for the costs incurred for lodging, meals and incidental expenses (as defined in the travel regulations
cited subparagraphs (b)(1)(i) through (b)(1)(iii) below) shall be considered to be reasonable and allowable only to the extent
that they do not exceed on a daily basis the maximum per diem rates in effect at the time of travel as set forth in the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in">(i) Federal Travel Regulation
prescribed by the General Services Administration for travel in the contiguous 48 United States;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Joint Travel Regulation, Volume 2, DoD Civilian Personnel, Appendix A, prescribed by the Department of Defense for travel
in Alaska, Hawaii, The Commonwealth of Puerto Rico, and the territories and possessions of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Standardized Regulations, (Government Civilians, Foreign Areas), Section 925, &ldquo;Maximum Travel Per Diem Allowances
in Foreign Areas&rdquo; prescribed by the Department of State, for travel in areas not covered in the travel regulations cited
in subparagraphs (b)(1)(i) and (b)(1)(ii) above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.45in">(2) Personnel in travel status from
and to the contractor&rsquo;s place of business and designated work site or vice versa, shall be considered to be performing work
under the contract, and contractor shall bill such travel time at the straight (regular) time rate; however, such billing shall
not exceed eight hours per person for any one person while in travel status during one calendar day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(c) Per Diem</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>The contractor shall not be paid per diem for contractor personnel who reside in the metropolitan area in which the tasks
are being performed. Per diem shall not be paid on services performed at contractor&rsquo;s home facility and at any facility required
by the contract, or at any location within a radius of 50 miles from the contractor&rsquo;s home facility and any facility required
by this contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Costs for subsistence and lodging shall be paid to the contractor only to the extent that overnight stay is necessary and
authorized in writing by the Government for performance of the work under this contract per paragraph (a). When authorized, per
diem shall be paid by the contractor to its employees at a rate not to exceed the rate specified in the travel regulations cited
in FAR 31.205-46(a)(2) and authorized in writing by the Government. The authorized per diem rate shall be the same as the prevailing
locality per diem rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Reimbursement to the contractor for per diem shall be limited to payments to employees not to exceed the authorized per
diem and as authorized in writing by the Government per paragraph (a). Fractional parts of a day shall be payable on a prorated
basis for purposes of billing for per diem charges attributed to subsistence on days of travel. The departure day from the Permanent
Duty Station (PDS) and return day to the PDS shall be 75% of the applicable per diem rate. The contractor shall retain supporting
documentation for per diem paid to employees as evidence of actual payments, as required by the FAR 52.216-7 &ldquo;Allowable Cost
and Payment&rdquo; clause of the contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 28 of 40</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(d) Transportation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>The contractor shall be paid on the basis of actual amounts paid to the extent that such transportation is necessary for
the performance of work under the contract and is authorized in writing by the Government per paragraph (a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>The contractor agrees, in the performance of necessary travel, to use the lowest cost mode commensurate with the requirements
of the mission and in accordance with good traffic management principles. When it is necessary to use air or rail travel, the contractor
agrees to use coach, tourist class or similar accommodations to the extent consistent with the successful and economical accomplishment
of the mission for which the travel is being performed. Documentation must be provided to substantiate non-availability of coach
or tourist if business or first class is proposed to accomplish travel requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>When transportation by privately owned conveyance (POC) is authorized, the contractor shall be paid on a mileage basis not
to exceed the applicable Government transportation rate specified in the travel regulations cited in FAR 31.205-46(a)(2) and is
authorized in writing by the Government per paragraph (a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(4)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>When transportation by privately owned (motor) vehicle (POV) is authorized, required travel of contractor personnel, that
is not commuting travel, may be paid to the extent that it exceeds the normal commuting mileage of such employee. When an employee&rsquo;s
POV is used for travel between an employee&rsquo;s residence or the Permanent Duty Station and one or more alternate work sites
within the local area, the employee shall be paid mileage for the distance that exceeds the employee&rsquo;s commuting distance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(5)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>When transportation by a rental automobile, other special conveyance or public conveyance is authorized, the contractor
shall be paid the rental and/or hiring charge and operating expenses incurred on official business (if not included in the rental
or hiring charge). When the operating expenses are included in the rental or hiring charge, there should be a record of those expenses
available to submit with the receipt. Examples of such operating expenses include: hiring charge (bus, streetcar or subway fares),
gasoline and oil, parking, and tunnel tolls.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(6)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Definitions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(i) &ldquo;Permanent Duty Station&rdquo;
(PDS) is the location of the employee&rsquo;s permanent work assignment (i.e., the building or other place where the employee regularly
reports for work.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.45in">(ii) &ldquo;Privately Owned
Conveyance&rdquo; (POC) is any transportation mode used for the movement of persons from place to place, other than a Government
conveyance or common carrier, including a conveyance loaned for a charge to, or rented at personal expense by, an employee for
transportation while on travel when such rental conveyance has not been authorized/approved as a Special Conveyance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.45in; margin-left: 60pt">(iii) &ldquo;Privately Owned
(Motor) Vehicle (POV)&rdquo; is any motor vehicle (including an automobile, light truck, van or pickup truck) owned by, or on a
long-term lease (12 or more months) to, an employee or that employee&rsquo;s dependent for the primary purpose of providing personal
transportation, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in; margin-left: 60pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>is self-propelled and licensed to travel on the public highways;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in; margin-left: 60pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>is designed to carry passengers or goods; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in; margin-left: 60pt"><I>(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>has four or more wheels or is a motorcycle or moped.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.45in">(iv) &ldquo;Special Conveyance&rdquo;
is commercially rented or hired vehicles other than a POC and other than those owned or under contract to an agency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.45in">(v) &ldquo;Public Conveyance&rdquo;
is local public transportation (e.g., bus, streetcar, subway, etc) or taxicab.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.45in">(iv) &ldquo;Residence&rdquo;
is the fixed or permanent domicile of a person that can be reasonably justified as a bona fide residence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.45in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.45in"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 29 of 40</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">EXAMPLE 1: Employee&rsquo;s
one way commuting distance to regular place of work is 7 miles. Employee drives from residence to an alternate work site, a distance
of 18 miles. Upon completion of work, employee returns to residence, a distance of 18 miles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><I>In this case, the employee
is entitled to be reimbursed for the distance that exceeds the normal round trip commuting distance (14 miles). The employee is
reimbursed for 22 miles (18 + 18 - 14 = 22).</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">EXAMPLE 2: Employee&rsquo;s one way commuting
distance to regular place of work is 15 miles. Employee drives from residence to an alternate work site, a distance of 5 miles.
Upon completion of work, employee returns to residence, a distance of 5 miles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><I>In this case, the employee
is not entitled to be reimbursed for the travel performed (10 miles), since the distance traveled is less than the commuting distance
(30 miles) to the regular place of work.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">EXAMPLE 3: Employee&rsquo;s one way commuting
distance to regular place of work is 15 miles. Employee drives to regular place of work. Employee is required to travel to an alternate
work site, a distance of 30 miles. Upon completion of work, employee returns to residence, a distance of 15 miles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><I>In this case, the employee
is entitled to be reimbursed for the distance that exceeds the normal round trip commuting distance (30 miles). The employee is
reimbursed for 30 miles (15 + 30 + 15 - 30 = 30).</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">EXAMPLE 4: Employee&rsquo;s one way commuting
distance to regular place of work is 12 miles. In the morning the employee drives to an alternate work site (45 miles). In the
afternoon the employee returns to the regular place of work (67 miles). After completion of work, employee returns to residence,
a distance of 12 miles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><I>In this case, the employee
is entitled to be reimbursed for the distance that exceeds the normal round trip commuting distance (24 miles). The employee is
reimbursed for 100 miles (45 + 67 + 12 - 24 = 100).</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">EXAMPLE 5: Employee&rsquo;s one way commuting
distance to regular place of work is 35 miles. Employee drives to the regular place of work (35 miles). Later, the employee drives
to alternate work site #1 (50 miles) and then to alternate work site #2 (25 miles). Employee then drives to residence (10 miles).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><I>In this case, the employee
is entitled to be reimbursed for the distance that exceeds the normal commuting distance (70 miles). The employee is reimbursed
for 50 miles (35 + 50 + 25 + 10 - 70 = 50).</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">EXAMPLE 6: Employee&rsquo;s one way commuting
distance to regular place of work is 20 miles. Employee drives to the regular place of work (20 miles). Later, the employee drives
to alternate work site #1 (10 miles) and then to alternate work site #2 (5 miles). Employee then drives to residence (2 miles).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><I>In this case, the employee
is not entitled to be reimbursed for the travel performed (37 miles), since the distance traveled is less than the commuting distance
(40 miles) to the regular place of work.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 30  of 40</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Section
I - Contract Clauses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CLAUSES INCORPORATED BY REFERENCE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%"><FONT STYLE="font-size: 10pt">52.202-1</FONT></TD>
    <TD STYLE="width: 60%"><FONT STYLE="font-size: 10pt">Definitions</FONT></TD>
    <TD STYLE="width: 20%"><FONT STYLE="font-size: 10pt">JUL 2004</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.203-3</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Gratuities</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">APR 1984</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.203-5</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Covenant Against Contingent Fees</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">APR 1984</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.203-6</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Restrictions On Subcontractor Sales To The Government</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">SEP 2006</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.203-7</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Anti-Kickback Procedures</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">OCT 2010</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.203-8</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Cancellation, Rescission, and Recovery of Funds for Illegal or<BR>
 JAN 1997 Improper Activity</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.203-10</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Price Or Fee Adjustment For Illegal Or Improper Activity</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">JAN 1997</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.203-12</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Limitation On Payments To Influence Certain Federal Transactions</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">OCT 2010</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.204-4</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Printed or Copied Double-Sided on Postconsumer Fiber Content Paper</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">MAY 2011 </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.204-7</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Central Contractor Registration</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">APR 2008</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.209-6</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Protecting the Government's Interest When Subcontracting DEC 2010</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"></TD>
    <TD STYLE="text-align: left">With Contractors Debarred, Suspended, or Proposed for Debarment</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.215-2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Audit and Records--Negotiation</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">OCT 2010</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.215-8</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Order of Precedence--Uniform Contract Format</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">OCT 1997</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.215-15</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Pension Adjustments and Asset Reversions</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">OCT 2010</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.215-17</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Waiver of Facilities Capital Cost of Money</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">OCT 1997</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">52.215-18</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Reversion or Adjustment of Plans for Postretirement Benefits <BR>
JUL 2005 (PRB) Other than Pensions</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">52.215-19</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Notification of Ownership Changes</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">OCT 1997</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">52.215-20 Alt II</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Requirements for Cost or Pricing Data or Information Other OCT 1997<BR>
 Than Cost or Pricing Data (Oct 2010) - Alternate II</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">52.219-28</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Post-Award Small Business Program Rerepresentation</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">APR 2009</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">52.222-3</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Convict Labor</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">JUN 2003</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">52.222-21</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Prohibition Of Segregated Facilities</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">FEB 1999</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.222-26</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Equal Opportunity</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">MAR 2007</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.222-35</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Equal Opportunity for Veterans</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">SEP 2010</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.222-36</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Affirmative Action For Workers With Disabilities</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">OCT 2010</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.222-37</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Employment Reports on Veterans</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">SEP 2010</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">52.222-40</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Notification of Employee Rights Under the National Labor DEC 2010 Relations Act</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">52.222-50</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Combating Trafficking in Persons</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">FEB 2009</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">52.222-54</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Employment Eligibility Verification</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">JAN 2009</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.223-6</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Drug-Free Workplace</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">MAY 2001</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.223-18</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Encouraging Contractor Policies To Ban Text Messaging While Driving</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">AUG 2011</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.225-13</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Restrictions on Certain Foreign Purchases</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">JUN 2008</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.227-1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Authorization and Consent</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">DEC 2007</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.227-1 Alt I</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Authorization And Consent (Dec 2007) - Alternate I</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">APR 1984</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.227-2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Notice And Assistance Regarding Patent And Copyright Infringement</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">DEC 2007</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.227-3</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Patent Indemnity</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">APR 1984</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.227-11</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Patent Rights--Ownership By The Contractor</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">DEC 2007</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.228-5</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Insurance - Work On A Government Installation</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">JAN 1997</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.228-7</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Insurance--Liability To Third Persons</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">MAR 1996</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.230-3</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Disclosure And Consistency Of Cost Accounting Practices </FONT></TD>
    <TD>OCT 2008</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 31 of 40</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%"><FONT STYLE="font-size: 10pt">52.232-2</FONT></TD>
    <TD STYLE="width: 60%"><FONT STYLE="font-size: 10pt">Payments
    Under Fixed-Price Research And Development Contracts</FONT></TD>
    <TD STYLE="width: 20%"><FONT STYLE="font-size: 10pt">APR 1984</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.232-8</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Discounts For Prompt Payment</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">FEB 2002</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.232-9</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Limitation On Withholding Of Payments</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">APR 1984</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.232-17</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Interest</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">OCT 2010</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.232-23</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Assignment Of Claims</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">JAN 1986</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.232-23 Alt I</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Assignment of Claims (Jan 1986) - Alternate I</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">APR 1984</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.232-25</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Prompt Payment</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">OCT 2008</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.232-25 Alt I</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Prompt Payment (Oct 2008) Alternate I</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">FEB 2002</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.232-33</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Payment by Electronic Funds Transfer--Central Contractor OCT 2003 Registration</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.233-1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Disputes</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">JUL 2002</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.233-3</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Protest After Award</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">AUG 1996</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.233-3 Alt I</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Protest After Award (Aug 1996) - Alternate I</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">JUN 1985</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.233-4</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Applicable Law for Breach of Contract Claim</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">OCT 2004</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.237-2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Protection Of
    Government Buildings, Equipment, And Vegetation</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">APR 1984</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.242-13</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Bankruptcy</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">JUL 1995</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.243-1 Alt I</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Changes--Fixed Price (Aug 1987) - Alternate I</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">APR 1984</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.243-1 Alt V</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Changes--Fixed-Price (Aug 1987) - Alternate V</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">APR 1984</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.244-6</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Subcontracts for Commercial Items</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">DEC 2010</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.245-1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Government Property</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">AUG 2010</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.245-9</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Use And Charges</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">AUG 2010</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.246-25</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Limitation Of Liability--Services</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">FEB 1997</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.247-63</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Preference For U.S. Flag Air Carriers</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">JUN 2003</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.249-2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Termination For Convenience Of The Government (Fixed- MAY 2004 Price)</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.249-9</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Default (Fixed-Priced Research And Development)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">APR 1984</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">52.253-1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Computer Generated Forms</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">JAN 1991</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">252.201-7000</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Contracting Officer's Representative</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">DEC 1991</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">252.203-7000</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Requirements Relating
    to Compensation of Former DoD Officials</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">JAN 2009</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">252.203-7001</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Prohibition On Persons Convicted of Fraud or Other Defense- DEC 2008 Contract-Related Felonies</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">252.203-7002</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Requirement to Inform Employees of Whistleblower Rights JAN 2009</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">252.203-7002</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Requirement to Inform Employees of Whistleblower Rights JAN 2009</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">252.204-7003</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Control Of Government Personnel Work Product</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">APR 1992</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">252.204-7004 Alt A C</FONT></TD>
    <TD>entral Contractor Registration (52.204-7) Alternate A<FONT STYLE="font-size: 10pt"></FONT></TD>
    <TD>SEP 2007</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">252.204-7006</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Billing Instructions</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">OCT 2005</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">252.209-7004</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Subcontracting With Firms That Are Owned or Controlled By DEC 2006 The Government of a Terrorist Country</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">252.223-7006</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Prohibition On
    Storage And Disposal Of Toxic And Hazardous Materials</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">APR 1993 </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">252.225-7012</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Preference For Certain Domestic Commodities</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">JUN 2010</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">252.226-7001</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Utilization of Indian
    Organizations and Indian-Owned Economic Enterprises, and Native Hawaiian Small Business Concerns</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">SEP 2004</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">252.227-7012</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Patent License And Release Contract</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">SEP 1999</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">252.227-7013</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Rights in Technical Data--Noncommercial Items</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">MAR 2011</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">252.227-7014</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Rights in
    Noncommercial Computer Software and Noncommercial Computer Software Documentation</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">MAR 2011</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">252.227-7015</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Technical Data--Commercial Items</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">MAR 2011</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">252.227-7016</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Rights in Bid or Proposal Information</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">JAN 2011</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">252.227-7019</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Validation of Asserted Restrictions--Computer Software</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">JUN 1995</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">252.227-7027</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Deferred Ordering Of Technical Data Or Computer Software APR 1988</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 32 of 40</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 20%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 60%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 20%; text-align: right">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">252.227-7030</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Technical Data--Withholding Of Payment</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">MAR 2000</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">252.227-7037</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Validation of Restrictive Markings on Technical Data</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">SEP 1999</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">252.231-7000</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Supplemental Cost Principles</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">DEC 1991</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">252.232-7010</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Levies on Contract Payments</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">DEC 2006</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">252.235-7011</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Final Scientific or Technical Report</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">NOV 2004</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">252.242-7004</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Material Management And Accounting System</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">MAY 2011</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">252.243-7001</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Pricing Of Contract Modifications</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">DEC 1991</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">252.243-7002</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Requests for Equitable Adjustment</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">MAR 1998</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">252.244-7000</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Subcontracts for Commercial Items and Commercial</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">NOV 2010</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Components (DoD Contracts)</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">252.246-7000</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Material Inspection And Receiving Report</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">MAR 2008</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CLAUSES INCORPORATED BY FULL TEXT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">52.215-19 NOTIFICATION OF OWNERSHIP CHANGES (OCT 1997)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a) The Contractor shall make the following notifications in
writing:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-indent: 0in">(1)  When the Contractor becomes
aware that a change in its ownership has occurred, or is certain to occur, that could result in changes in the valuation of its
capitalized assets in the accounting records, the Contractor shall notify the Administrative Contracting Officer (ACO) within
30 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-indent: 0in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>The Contractor shall also notify the ACO within 30 days whenever changes to asset valuations or any other cost changes have
occurred or are certain to occur as a result of a change in ownership.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b) The Contractor shall--</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Maintain current, accurate, and complete inventory records of assets and their costs;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Provide the ACO or designated representative ready access to the records upon request;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-indent: 0in">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Ensure that all individual and grouped assets, their capitalized values, accumulated depreciation or amortization, and remaining
useful lives are identified accurately before and after each of the Contractor's ownership changes; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-indent: 0in">(4)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Retain and continue to maintain depreciation and amortization schedules based on the asset records maintained before each
Contractor ownership change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0">The Contractor shall include the substance of this
clause in all subcontracts under this contract that meet the applicability requirement of FAR 15.408(k).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(End of clause)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">52.217-9 OPTION TO EXTEND THE TERM OF THE CONTRACT (MAR 2000)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>The Government may extend the term of this contract by written notice to the Contractor within the period of performance
of this contract; provided that the Government gives the Contractor a preliminary written notice of its intent to extend at least
30 days before the contract expires. The preliminary notice does not commit the Government to an extension.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>If the Government exercises this option, the extended contract shall be considered to include this option clause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 33  of 40</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(c) The total duration of this contract, including the exercise
of any options under this clause, shall not exceed <FONT><U>five years.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(End of clause)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">52.232-32 PERFORMANCE-BASED PAYMENTS (AUG 2010)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0">(a) Amount of payments and limitations on payments.
Subject to such other limitations and conditions as are specified in this contract and this clause, the amount of payments and
limitations on payments shall be specified in the contract's description of the basis for payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b) Contractor request for performance-based payment. The Contractor
may submit requests for payment of performance-based payments not more frequently than monthly, in a form and manner acceptable
to the Contracting Officer. Unless otherwise authorized by the Contracting Officer, all performance-based payments in any period
for which payment is being requested shall be included in a single request, appropriately itemized and totaled. The Contractor's
request shall contain the information and certification detailed in paragraphs (l) and (m) of this clause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(c) Approval and payment of requests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>The Contractor shall not be entitled to payment of a request for performance-based payment prior to successful accomplishment
of the event or performance criterion for which payment is requested. The Contracting Officer shall determine whether the event
or performance criterion for which payment is requested has been successfully accomplished in accordance with the terms of the
contract. The Contracting Officer may, at any time, require the Contractor to substantiate the successful performance of any event
or performance criterion which has been or is represented as being payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>A payment under this performance-based payment clause is a contract financing payment under the Prompt Payment clause of
this contract and not subject to the interest penalty provisions of the Prompt Payment Act. The designated payment office will
pay approved requests on the 30th day after receipt of the request for performance-based payment by the designated payment office.
However, the designated payment office is not required to provide payment if the Contracting Officer requires substantiation as
provided in paragraph (c)(1) of this clause, or inquires into the status of an event or performance criterion, or into any of the
conditions listed in paragraph (e) of this clause, or into the Contractor certification. The payment period will not begin until
the Contracting Officer approves the request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3in 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3in 0pt 0; text-indent: 0in">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>The approval by the Contracting Officer of a request for performance-based payment does not constitute an acceptance by
the Government and does not excuse the Contractor from performance of obligations under this contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Liquidation of performance-based payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-indent: 0in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Performance-based finance amounts paid prior to payment for delivery of an item shall be liquidated by deducting a percentage
or a designated dollar amount from the delivery payment. If the performance-based finance payments are on a delivery item basis,
the liquidation amount for each such line item shall be the percent of that delivery item price that was previously paid under
performance-based finance payments or the designated dollar amount. If the performance-based finance payments are on a whole contract
basis, liquidation shall be by either predesignated liquidation amounts or a liquidation percentage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>If at any time the amount of payments under this contract exceeds any limitation in this contract, the Contractor shall
repay to the Government the excess. Unless otherwise determined by the Contracting Officer, such excess shall be credited as a
reduction in the unliquidated performance-based payment balance(s), after adjustment of invoice payments and balances for any retroactive
price adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 34 of 40</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(e) Reduction or suspension of performance-based payments.
The Contracting Officer may reduce or suspend performance-based payments, liquidate performance-based payments by deduction from
any payment under the contract, or take a combination of these actions after finding upon substantial evidence any of the following
conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0">(1) The Contractor failed to comply with any material
requirement of this contract (which includes paragraphs (h) and (i) of this clause).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(2) Performance of this contract is endangered by the Contractor's
--</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Failure to make progress; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Unsatisfactory financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35in 0pt 0">(3) The Contractor is delinquent in payment of any
subcontractor or supplier under this contract in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(f) Title.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">(1) Title to the property described in this paragraph
(f) shall vest in the Government. Vestiture shall be immediately upon the date of the first performance-based payment under this
contract, for property acquired or produced before that date. Otherwise, vestiture shall occur when the property is or should have
been allocable or properly chargeable to this contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(2) &quot;Property,&quot; as used in this clause, includes all
of the following described items acquired or produced by the Contractor that are or should be allocable or properly chargeable
to this contract under sound and generally accepted accounting principles and practices:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Parts, materials, inventories, and work in process;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(ii) Special tooling and special test equipment
to which the Government is to acquire title;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Nondurable (i.e., noncapital) tools, jigs, dies, fixtures, molds, patterns, taps, gauges, test equipment and other similar
manufacturing aids, title to which would not be obtained as special tooling under subparagraph (f)(2)(ii) of this clause; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-indent: 0in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Drawings and technical data, to the extent the Contractor or subcontractors are required to deliver them to the Government
by other clauses of this contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0">(3) Although title to property is in the Government
under this clause, other applicable clauses of this contract (e.g., the termination or clauses) shall determine the handling and
disposition of the property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35in 0pt 0">(4) The Contractor may sell any scrap resulting from
production under this contract, without requesting the Contracting Officer's approval, provided that any significant reduction
in the value of the property to which the Government has title under this clause is reported in writing to the Contracting Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(5) In order to acquire for its own use or dispose of property
to which title is vested in the Government under this clause, the Contractor shall obtain the Contracting Officer's advance approval
of the action and the terms. If approved, the basis for payment (the events or performance criteria) to which the property is related
shall be deemed to be not in compliance with the terms of the contract and not payable (if the property is part of or needed for
performance), and the Contractor shall refund the related performance-based payments in accordance with paragraph (d) of this clause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.45in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.45in 0pt 0">(6) When the Contractor completes all of the obligations
under this contract, including liquidation of all performance-based payments, title shall vest in the Contractor for all property
(or the proceeds thereof) not --</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.45in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.45in 0pt 0"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 35 of 40</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.45in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.45in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Delivered to, and accepted by, the Government under this contract; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-indent: 0in">(ii) Incorporated in supplies delivered
to, and accepted by, the Government under this contract and to which title is vested in the Government under this clause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0">(7) The terms of this contract concerning liability
for Government-furnished property shall not apply to property to which the Government acquired title solely under this clause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(g) Risk of loss. Before delivery to and acceptance by the Government,
the Contractor shall bear the risk of loss for property, the title to which vests in the Government under this clause, except to
the extent the Government expressly assumes the risk. If any property is lost, stolen, damaged or destroyed, the basis of payment
(the events or performance criteria) to which the property is related shall be deemed to be not in compliance with the terms of
the contract and not payable (if the property is part of or needed for performance), and the Contractor shall refund the related
performance-based payments in accordance with paragraph (d) of this clause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0">(h) Records and controls. The Contractor shall maintain
records and controls adequate for administration of this clause. The Contractor shall have no entitlement to performance-based
payments during any time the Contractor's records or controls are determined by the Contracting Officer to be inadequate for administration
of this clause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">(i) Reports and Government access. The Contractor
shall promptly furnish reports, certificates, financial statements, and other pertinent information requested by the Contracting
Officer for the administration of this clause and to determine that an event or other criterion prompting a financing payment has
been successfully accomplished. The Contractor shall give the Government reasonable opportunity to examine and verify the Contractor's
records and to examine and verify the Contractor's performance of this contract for administration of this clause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(j) Special terms regarding default. If this contract is terminated
under the Default clause,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.45in 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.45in 0pt 0; text-indent: 0in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>the Contractor shall, on demand, repay to the Government the amount of unliquidated performance-based payments, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>title shall vest in the Contractor, on full liquidation of all performance-based payments, for all property for which the
Government elects not to require delivery under the Default clause of this contract. The Government shall be liable for no payment
except as provided by the Default clause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(k) Reservation of rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1) No payment or vesting of title under this clause shall --</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Excuse the Contractor from performance of obligations under this contract; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(ii) Constitute a waiver of any of the rights
or remedies of the parties under the contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(2) The Government's rights and remedies under this clause --</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3in 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3in 0pt 0; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Shall not be exclusive, but rather shall be in addition to any other rights and remedies provided by law or this contract;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-indent: 0in">(ii) Shall not be affected by delayed,
partial, or omitted exercise of any right, remedy, power, or privilege, nor shall such exercise or any single exercise preclude
or impair any further exercise under this clause or the exercise of any other right, power, or privilege of the Government.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">(l) Content of Contractor's request for performance-based
payment. The Contractor's request for performance-based payment shall contain the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 36  of 40</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1) The name and address of the Contractor;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>The date of the request for performance-based payment;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>The contract number and/or other identifier of the contract or order under which the request is made;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(4)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Such information and documentation as is required by the contract's description of the basis for payment; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-indent: 0in">(5)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>A certification by a Contractor official authorized to bind the Contractor, as specified in paragraph (m) of this clause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(m) Content of Contractor's certification. As required in paragraph
(l)(5) of this clause, the Contractor shall make the following certification in each request for performance-based payment:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I certify to the best of my knowledge and belief that --</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>This request for performance-based payment is true and correct; this request (and attachments) has been prepared from the
books and records of the Contractor, in accordance with the contract and the instructions of the Contracting Officer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-indent: 0in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>(Except as reported in writing on_________&#9;), all payments to subcontractors and suppliers under this contract have been
paid, or will be paid, currently, when due in the ordinary course of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0; text-indent: 0in">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>There are no encumbrances (except as reported in writing on_______&#9;) against the property acquired or produced for, and
allocated or properly chargeable to, the contract which would affect or impair the Government's title;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(4)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>There has been no materially adverse change in the financial condition of the Contractor since the submission by</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">the Contractor to the Government of the most recent written
information dated____________&#9;; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-indent: 0in">(5)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>After the making of this requested performance-based payment, the amount of all payments for each deliverable item for which
performance-based payments have been requested will not exceed any limitation in the contract, and the amount of all payments under
the contract will not exceed any limitation in the contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(End of Clause)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">52.252-2 CLAUSES INCORPORATED BY REFERENCE (FEB 1998)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">This contract incorporates one or more clauses by
reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their
full text available. Also, the full text of a clause may be accessed electronically at this/these address(es):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">http://farsite.hill.af.mil<BR>
http://www.acquisition.gov</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: blue">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(End of clause)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">52.252-6 AUTHORIZED DEVIATIONS IN CLAUSES (APR 1984)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">(a) The use in this solicitation or contract of any
Federal Acquisition Regulation (48 CFR Chapter 1) clause with an authorized deviation is indicated by the addition of &quot;(DEVIATION)&quot;
after the date of the clause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 37 of 40</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b) The use in this solicitation or contract of any <FONT><U>Defense
Federal Acquisition Regulation Supplement</U></FONT> (48 CFR <FONT><U>Chapter 2)</U></FONT> clause with an authorized
deviation is indicated by the addition of &quot;(DEVIATION)&quot; after the name of the regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(End of clause)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">252.204-7008 EXPORT-CONTROLLED ITEMS (APR 2010)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0">(a) Definition. Export-controlled items, as used in
this clause, means items subject to the Export Administration Regulations (EAR) (15 CFR parts 730-774) or the International Traffic
in Arms Regulations (ITAR) (22 CFR parts 120-130). The term includes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-indent: 0in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Defense items, defined in the Arms Export Control Act, 22 U.S.C. 2778(j)(4)(A), as defense articles, defense services, and
related technical data, and further defined in the ITAR, 22 CFR part 120.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-indent: 0in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Items, defined in the EAR as &#783;commodities, software, and technology,&quot; terms that are also defined in the EAR,
15 CFR 772.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0">(b) The Contractor shall comply with all applicable
laws and regulations regarding export-controlled items, including, but not limited to, the requirement for Contractors to register
with the Department of State in accordance with the ITAR. The Contractor shall consult with the Department of State regarding any
questions relating to compliance with the ITAR and shall consult with the Department of Commerce regarding any questions relating
to compliance with the EAR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0">(c) The Contractor's responsibility to comply with
all applicable laws and regulations regarding export-controlled items exists independent of, and is not established or limited
by, the information provided by this clause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.55in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.55in 0pt 0">(d) Nothing in the terms of this contract adds to,
changes, supersedes, or waives any of the requirements of applicable Federal laws, Executive orders, and regulations, including
but not limited to--</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>The Export Administration Act of 1979, as amended (50 U.S.C. App. 2401, et seq.);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>The Arms Export Control Act (22 U.S.C. 2751, et seq.);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>The International Emergency Economic Powers Act (50 U.S.C. 1701, et seq.);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(4)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>The Export Administration Regulations (15 CFR parts 730-774);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(5)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>The International Traffic in Arms Regulations (22 CFR parts 120-130); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(6)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Executive Order 13222, as extended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.45in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.45in 0pt 0">(e) The Contractor shall include the substance of
this clause, including this paragraph (e), in all subcontracts. (End of clause)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.4in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.4in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.4in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.4in 0pt 0"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 38 of 40</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.4in 0pt 0">252.232-7003 ELECTRONIC SUBMISSION OF PAYMENT REQUESTS
AND RECEIVING REPORTS (MAR 2008)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a) Definitions. As used in this clause--</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35in 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35in 0pt 0; text-indent: 0in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Contract financing payment and invoice payment have the meanings given in section 32.001 of the Federal Acquisition Regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Electronic form means any automated system that transmits information electronically from the initiating system to all affected
systems. Facsimile, e-mail, and scanned documents are not acceptable electronic forms for submission of payment requests. However,
scanned documents are acceptable when they are part of a submission of a payment request made using Wide Area WorkFlow (WAWF) or
another electronic form authorized by the Contracting Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0in">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Payment request means any request for contract financing payment or invoice payment submitted by the Contractor under this
contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">(b) Except as provided in paragraph (c) of this clause,
the Contractor shall submit payment requests and receiving reports using WAWF, in one of the following electronic formats that
WAWF accepts: Electronic Data Interchange, Secure File Transfer Protocol, or World Wide Web input. Information regarding WAWF is
available on the Internet at <FONT>https://wawf.eb.mil/.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(c) The Contractor may submit a payment request and receiving
report using other than WAWF only when--</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>The Contracting Officer authorizes use of another electronic form. With such an authorization, the Contractor and the Contracting
Officer shall agree to a plan, which shall include a timeline, specifying when the Contractor will transfer to WAWF;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>DoD is unable to receive a payment request or provide acceptance in electronic form;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-indent: 0in">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>The Contracting Officer administering the contract for payment has determined, in writing, that electronic submission would
be unduly burdensome to the Contractor. In such cases, the Contractor shall include a copy of the Contracting Officer's determination
with each request for payment; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-indent: 0in">(4)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>DoD makes payment for commercial transportation services provided under a Government rate tender or a contract for transportation
services using a DoD-approved electronic third party payment system or other exempted vendor payment/invoicing system (e.g., PowerTrack,
Transportation Financial Management System, and Cargo and Billing System).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35in 0pt 0">(d) The Contractor shall submit any non-electronic
payment requests using the method or methods specified in Section G of the contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.4in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.4in 0pt 0">(e) In addition to the requirements of this clause,
the Contractor shall meet the requirements of the appropriate payment clauses in this contract when submitting payments requests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(End of clause)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">252.247-7024 Notification of Transportation of Supplies by Sea
(MAR 2000)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a) The Contractor has indicated by the response to the solicitation
provision, Representation of Extent of Transportation by Sea, that it did not anticipate transporting by sea any supplies. If,
however, after the award of this contract, the Contractor learns that supplies, as defined in the Transportation of Supplies by
Sea clause of this contract, will be transported by sea, the Contractor --</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1) Shall notify the Contracting Officer of that fact; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 39 of 40</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(2) Hereby agrees to comply with all the terms and conditions
of the Transportation of Supplies by Sea clause of this contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.55in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.55in 0pt 0">(b) The Contractor shall include this clause; including
this paragraph (b), revised as necessary to reflect the relationship of the contracting parties--</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>In all subcontracts under this contract, if this contract is a construction contract; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>If this contract is not a construction contract, in all subcontracts under this contract that are for--</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Noncommercial items; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Commercial items that--</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-indent: 0in">(A)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>The Contractor is reselling or distributing to the Government without adding value (generally, the Contractor does not add
value to items that it subcontracts for f.o.b. destination shipment);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.6in 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.6in 0pt 0; text-indent: 0in">(B)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Are shipped in direct support of U.S. military contingency operations, exercises, or forces deployed in humanitarian or
peacekeeping operations; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0; text-indent: 0in">(C)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Are commissary or exchange cargoes transported outside of the Defense Transportation System in accordance with 10 U.S.C.
2643.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(End of clause)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">N66001-11-C-4188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Page 40 of 40</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">Section J - List of Documents, Exhibits and Other
Attachments</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">Exhibit/Attachment Table of Contents</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 22%"><FONT STYLE="font-size: 10pt">DOCUMENT TYPE</FONT></TD>
    <TD STYLE="width: 22%"><FONT STYLE="font-size: 10pt">DESCRIPTION</FONT></TD>
    <TD STYLE="width: 16%"><FONT STYLE="font-size: 10pt">PAGES</FONT></TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-size: 10pt">DATE</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Exhibit A</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Base Period CDRLs</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">4</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">26-SEP-2011</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Exhibit B</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Option I CDRLs</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">4</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">26-SEP-2011</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Exhibit C</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Option II CDRLs</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">4</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">26-SEP-2011</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Exhibit D</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Option III CDRLs</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">4</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">26-SEP-2011</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Exhibit E</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Option IV CDRLs</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">4</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">26-SEP-2011</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Attachment 1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Performance Based</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">5</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">26-SEP-2011</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Payments Schedule</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Attachment 2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Clause 252.227-7017</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">28-SEP-2011</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0">AMENDMENT OF SOLITICATION/MODIFICATION OF CONTRACT</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;<IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">SECTION SF 30 BLOCK 14 CONTINUATION PAGE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">SUMMARY OF CHANGES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">SECTION C - DESCRIPTIONS AND SPECIFICATIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 313.8pt 0pt 25pt; text-indent: -20.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 313.8pt 0pt 25pt; text-indent: -20.05pt">The following have been
modified: <U>STATEMENT OF WORK (SOW)</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 192.8pt 0pt 191.95pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 192.8pt 0pt 191.95pt; text-align: center">Aethlon Medical,
Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify"><B>DATE: 11 December 2013, <FONT STYLE="color: red">Revised:
12 March 2015</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify"><B>TITLE: Broad Spectrum Countermeasures
for Viral and Bacterial Sepsis using Dialysis-Like Devices</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5pt"></TD><TD STYLE="width: 15pt"><B>1.0</B></TD><TD STYLE="text-align: justify"><B>Scope</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 5pt; text-align: justify">The scope of this effort is
to use Aethlon&rsquo;s Hemopurifier as the core technology within an extracorporeal blood purification device that would simultaneously
remove: viruses, virally-derived immunosuppressive glycoproteins, and multiple classes of exosomes; complement activation, activation
of virus growth (e.g. cytomegalovirus) and TLR activation, all of which have implications to the promotion of the well-being and
recovery of wounded warfighters and the prevention of sepsis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5pt"></TD><TD STYLE="width: 15pt">1.1</TD><TD STYLE="text-align: justify">Introduction</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 5pt; text-align: justify">This effort will create an
adaptable dialysis-like platform (ADAPT) technology that allows for the selective removal of harmful agents from the entire circulatory
system. This revolutionary advance overcomes the limitation of devices that indiscriminately adsorb or solely capture particles
by molecule size. The platform will provide an expansive therapeutic filtration mechanism to immobilize multiple affinity agents
directed toward precursors to sepsis, bacterial toxins, viral pathogens, and disease enhancing particles transported by exosomes.
To insure benefit to wounded warfighters, this effort will advance an innovative strategy that will allow therapy administration
without systemic anticoagulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 5pt; text-align: justify; text-indent: -0.05pt">The ADAPT
platform has been shown previously to create a broad-spectrum antiviral device that immobilized one lectin affinity agent, resulting
in the effective capture of all tested Category A pathogens, as well as exosomes underlying tuberculosis and cancer. In human studies,
this same device, known as the Hemopurifier, consistently provided greater than 50% average viral load reductions during four-hour
treatment periods in both hepatitis-C and HIV infected individuals without antiviral drug therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 5pt; text-align: justify; text-indent: -0.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 5pt; text-align: justify">The resulting device would
save thousands of military and civilian lives each year. Each of these technology advancements will be integrated into a single
cartridge that will provide decision-free and life-saving medical care for the wounded warfighter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5pt"></TD><TD STYLE="width: 15pt">1.2</TD><TD STYLE="text-align: justify">Background</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 5pt; text-align: justify">The goal of the DLT
program is to develop a portable device that removes &ldquo;dirty&rdquo; blood from the body, separates harmful agents, and
returns &ldquo;clean&rdquo; blood to the body in a manner similar to dialysis treatment of kidney failure. While the device
could have an impact across multiple areas of medicine, the target application for this device is sepsis. The envisioned
device will persistently interrogate the entire blood volume, providing early identification of the presence of a pathogen.
Once the presence of pathogens has been confirmed, the DLT device will provide continuous &quot;label-free&quot; removal of
pathogens, toxins and activated patient cells without pathogen identification or use of pathogen-specific binding
chemistries. As a final step in the treatment process, the DLT device will enable closed-loop therapy based on continuous,
reduced dimensionality modeling of patient health. Predictive modeling in this fashion will allow us to identify sepsis
early, learn what we need to remove, and direct the most effective intervention to improve patient health. This cycle of
sensing, adjustment, estimation, computation, and manipulation will modulate key health parameters faster than the underlying
disease process and drive the patient towards a stable, healthy state.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 5pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5pt"></TD><TD STYLE="width: 15pt">2.0</TD><TD STYLE="text-align: justify">Technical Requirements</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5pt"></TD><TD STYLE="width: 15pt"><B>2.1</B></TD><TD STYLE="text-align: justify"><B>Human and Animal use</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 5pt; text-align: justify">Human use <B>is </B>anticipated
in this effort, specifically related to the use of human blood. The grantee shall obtain all necessary Institutional Review Board
(IRB) approvals, show proper assurance documentation, and obtain proper approval from the Government officials prior to human use
testing. Funds associated with human subjected testing shall not be released until IRB documentation has been provided to SSC&rsquo;s
HRPO and approval to release funds has been obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 5pt; text-align: justify">Animal use <B>is </B>anticipated
in this effort. The contractor shall obtain all necessary Institutional Animal Care and Utilization Committee (IACUC) approval
and demonstrate this approval to the Government (<B>both </B>ACURO and SSC-Pacific) prior to beginning experimentation with animals.
If animal use is no longer anticipated, or changes significantly from the approved IACUC then the Principal Investigator (PI) must
submit a letter stating the discontinuation of animal use for this effort and/or receive appropriate authorization for IACUC changes
of previously specified protocols. Unless prior approval by DARPA is given IACUC documentation must be provided prior to contract
award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5pt"></TD><TD STYLE="width: 15pt">2.2</TD><TD STYLE="text-align: justify">Base Effort (Year 1)</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5pt"></TD><TD STYLE="width: 22.5pt"><B>2.2.1</B></TD><TD STYLE="text-align: justify"><B><U>Subtask 1a: Anticoagulant-free Hemopurification Device</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5pt"></TD><TD STYLE="width: 36pt">2.2.1.1</TD><TD STYLE="text-align: justify; padding-right: 5.75pt">Write requirements definition for the extracorporeal blood purification
system and acquire necessary equipment.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5pt"></TD><TD STYLE="width: 36pt">2.2.1.2</TD><TD STYLE="text-align: justify; padding-right: 5.8pt">Fabricate breadboard prototypes for anticoagulation-free anti-sepsis extracorporeal
system (ASEPSYS) device. Fabricate prototype blood tubing sets. Acquire anti-thrombogenic surface-modified hollow fiber plasma
separators.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5pt"></TD><TD STYLE="width: 36pt">2.2.1.3</TD><TD STYLE="text-align: justify; padding-right: 5.8pt">Assemble and test breadboard ASEPSYS devices <I>ex vivo </I>with bovine blood.
The test will most likely be conducted using a porcine model where the elapsed time to reach a pre-defined degree of clotting in
the blood treatment device will be compared between the new device and two control groups; one using standard anticoagulant therapy
and one using none. Determine contribution of the following techniques and approaches to eliminating anticoagulants:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 41pt; text-align: justify; text-indent: 0in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Backflushing at regular intervals, (2) Turbo loop, (3) Continuous pre-dilution loop using re-captured hydration fluid, (4)
Linear vs pulsatile blood flow, (5) Elimination of air/blood interfaces in extracorporeal circuit, (6) Anti-thrombogenic derivatized
plasma separation membrane, and (7) Ultra-short half-life anticoagulant nafamostat mesilate.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5pt"></TD><TD STYLE="width: 36pt">2.2.1.4</TD><TD STYLE="text-align: justify; padding-right: 5.75pt">IRB Documentation Generation: The contractor shall obtain all necessary
IRB documentation and obtain both institutional and Government (SSC-Pacific) approval in accordance with IRB documentation submission
guidance prior to conducting human subject testing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt"><B><U>Milestones</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 40.95pt; text-align: justify; text-indent: -0.5in">M1:
Demonstrate the effectiveness of the prototype device in preventing platelet activation or clotting in at least a 2 hour blood
pumping experiment at 100 mL/hr blood flow.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 40.95pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5pt"></TD><TD STYLE="width: 22.55pt">2.2.2</TD><TD><U>Subtask 2: Removal of Sepsis Precursors </U></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5pt"></TD><TD STYLE="width: 36pt">2.2.2.1</TD><TD STYLE="text-align: justify; padding-right: 5.75pt">Begin to develop a device based on Aethlon&rsquo;s ADAPT system to efficiently
capture sepsis precursors identified as potentially important in killing patients undergoing sepsis. The strategy is takes advantage
of the flexibility and rapidity of modification of our ADAPT platform system to test any sepsis precursor candidates that circulate
in the blood. The sepsis precursors that will be targeted are shown in Table I, in order of importance. No test for the removal
of bacterial toxins. No testing for removal of cytokines, since the evidence to date does not support a role for them in death
due to sepsis. Additional factors may become known during the grant period and those will also be tested as time and budget permit.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6pt"></TD><TD STYLE="width: 36pt">2.2.2.2</TD><TD STYLE="text-align: justify; padding-right: 5.85pt">Screening Capture Agents: Perform initial screening of the different proposed
capture agents by measuring binding affinity and kinetics using surface plasmon resonance (SPR) or biolayer surface interferometry
(BLI).</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6pt"></TD><TD STYLE="width: 36pt">2.2.2.3</TD><TD STYLE="padding-right: 6pt">Perform quantitative real time PCR will also be used to measure viral load, and specific DNA or
RNA targets.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt"><U>Milestones</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt">M2:&#9;Target capture &gt; 50% in 24 hours for at least
1 target in blood or blood components</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">Table I Potential Target Sepsis Precursors and
Broad Spectrum Binding Agents</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 70%; border: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Septic Exosomes</B></FONT></TD>
    <TD STYLE="width: 30%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Removal Agent</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">INOS exosomes</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">GNA</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Viruses Associated with Sepsis</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Dengue Fever virus</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">GNA</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">H1N1 Flu virus</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">GNA</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Cytomegalovirus **</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">GNA</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Herpes viruses &ndash; e.g. HSV 1</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">GNA</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Poxviruses - e.g. Vaccina (model for small pox)</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">GNA</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Activation of Innate Immunity</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">LPS endotoxins</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">GNA</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">LTA endotoxins</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">GNA</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6pt"></TD><TD STYLE="width: 15pt"><B>2.3</B></TD><TD><B>Option 1 (Year 2)</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6pt"></TD><TD STYLE="width: 22.5pt"><B>2.3.2</B></TD><TD><B><U>Subtask 1a: Anticoagulant-free Hemopurification Device</U></B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6pt"></TD><TD STYLE="width: 36pt">2.3.2.1</TD><TD STYLE="padding-right: 5.85pt">Demonstrate the effectiveness of the prototype device in vivo in animals preventing platelet
activation or clotting in at least a 2 hour blood pumping experiment at 75 mL/min blood flow.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6pt"></TD><TD STYLE="width: 36pt">2.3.2.2</TD><TD STYLE="padding-right: 5.75pt">Formulate initial design based on work from previous phase. Begin to build and test selected
instrument design and tubing sets.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6pt"></TD><TD STYLE="width: 36pt">2.3.2.3</TD><TD>Write and test software. Conduct ergonomic research. Begin discussions with System Integrator.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6pt"></TD><TD STYLE="width: 36pt">2.3.2.4</TD><TD>Complete fabrication and testing of prototype instrument.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6pt"></TD><TD STYLE="width: 36pt">2.3.2.5</TD><TD STYLE="padding-right: 5.95pt">Research literature and patent database for technical options for an on-line/in-line sensor with
the ability to quantify the clearance of citrate and/or calcium in effluent dialysate.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6pt"></TD><TD STYLE="width: 36pt">2.3.2.6</TD><TD>Collect feasibility data on at least one sensor option.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6pt"></TD><TD STYLE="width: 36pt">2.3.2.7</TD><TD STYLE="text-align: justify; padding-right: 5.85pt">Conduct a series of 21 experiments aimed at characterizing the contribution
of several alternate fluidic designs and methods of perfusing plasma filters and affinity columns in the performance of affinity
plasmapheresis.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt"><U>2,3.3 Subtask 2. Removal of Sepsis
Precursors </U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6pt"></TD><TD STYLE="width: 36pt">2.3.3.1</TD><TD STYLE="padding-right: 5.85pt">Build the ADAPT capture cartridges with the identified affinity agents. Measure the rate of capture
of the specific targets from in ex vivo recirculation experiments from cell culture and blood.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6pt"></TD><TD STYLE="width: 36pt">2.3.3.2</TD><TD STYLE="padding-right: 5.8pt">Cartridge construction with optimized affinity matrix design for each potential target. Complete
all capture agents screening. Initiate <I>ex vivo</I> capture studies from blood using the optimized cartridges.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt"><U>Milestones</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt">M4: Target capture &gt; 50% in 24 hours for at
least 5 targets in blood or blood components.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt">M5: Milestone 5: Target capture &gt; 90% in 24 hours
for at least 3 targets in blood or blood components.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt">NOTE: TASK 2.3.2 SHALL NOT BE EXERCISED AND TASKING
FUNDS RELEASED UNTIL IRB DOCUMENTATION AND PROPER IRB APPROVAL HAS BEEN OBTAINED.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt"></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6pt"></TD><TD STYLE="width: 15pt">2.4</TD><TD>Option 2 (Year 3)</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6pt"></TD><TD STYLE="width: 22.5pt"><B>2.4.1</B></TD><TD><B><U>Subtask 1a: Anticoagulant-free Hemopurification Device</U></B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6pt"></TD><TD STYLE="width: 36pt">2.4.1.1</TD><TD STYLE="text-align: justify; padding-right: 5.85pt">Design and fabricate optimized configuration(s) of hemopurification device(s)
that contain(s) a combination of hemofilters, plasma filters, and affinity columns.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt"><U>Milestones</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 41.95pt; text-align: justify; text-indent: -0.5in">M6:
<FONT STYLE="color: red">Define Aethlon&rsquo;s GMP manufacturing process and revise and upgrade Aethlon&rsquo;s quality procedures
and policies to the current state of the art. <STRIKE>Demonstrate the safety of at least one prototype device within an optimized
fluidic circuit architecture preventing clotting in a 24 hour experiment <I>in vivo</I> at a blood flow rate of 200 ml/min using
either pigs or dogs.</STRIKE></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 41.95pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6pt"></TD><TD STYLE="width: 22.5pt">2.4.2</TD><TD><U>Subtask 4: Target Capture in Combined Agent Cartridge</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt"> 2.4.2.1 Evaluate contribution of manufacturing process variables to binding capacity of affinity resin.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt"> 2.4.2.2 Determine capacity requirements of affinity resin to multiple simultaneous targets.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt"> 2.4.2.3 Perform basic biocompatibility tests for the combination ADAPT device to confirm the combination cartridge does not present additional risk.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt"> 2.4.2.4 Finish construction and delivery of 25 experimental cartridges for testing by the system integrator.</P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt"><U>Milestones</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt"> M7: Target capture &gt; 90% in 24 hours (12 months) for at least 3 targets ex vivo in blood or blood components using the optimized cartridge.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt">M8: Pass biocompatibility tests for the
combination ADAPT device.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt">M9: Construct and deliver of 25 prototype
cartridges for testing by the system integrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6pt"></TD><TD STYLE="width: 15pt">2.5</TD><TD>Option 3 (Year 4)</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6pt"></TD><TD STYLE="width: 22.5pt"><B>2.5.1</B></TD><TD><B><U>Subtask 1a: Anticoagulant-free Hemopurification Device</U></B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6pt"></TD><TD STYLE="width: 36pt">2.5.1.1</TD><TD STYLE="text-align: justify; padding-right: 5.7pt"><FONT STYLE="color: red">Complete Aethlon&rsquo;s GMP procedure and establish
and maintain all GMP documentation for the company. <STRIKE>Revise and upgrade Aethlon&rsquo;s quality procedures and policies
to the current state of the art and establish and maintain all GMP documentation for the company.Develop additional optimized configuration(s)
of hemopurification device(s) that contain(s) a combination of hemofilters, plasma filters, and affinity columns.</STRIKE></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt"><U>Milestones</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 41.95pt; text-align: justify; text-indent: -0.5in">M11:
<FONT STYLE="color: red">Develop a strategic plan for developing an alternate method of producing GNA by cloning the gene into
an alternate vector and identify potential partners for such production. <STRIKE>Demonstrate the safety of an additional prototype
device within an optimized fluidic circuit architecture preventing clotting in a 24 hour experiment <I>in vivo </I>at a blood flow
rate of 200 ml/min using either pigs or dogs.</STRIKE></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 41.95pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6pt"></TD><TD STYLE="width: 22.5pt">2.5.2</TD><TD><U>Subtask 4: Target Capture in Combined Agent Cartridge</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 41.95pt; text-align: justify; text-indent: -0.5in">2.5.2.2
Finish construction and delivery of 50 prototype cartridges for testing by the system integrator. The cartridges will need to be
made available (packaged, labeled, sterilized and qualified) to the system integrator.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt"><U>Milestones</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt">M13: Construct and deliver of 50 prototype
cartridges for testing by the system integrator.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt">2.6 Option 4 (Year 5)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt"><B><U>2.6.1 Subtask 5: Testing of final product by System
Integrator</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt">2.6.1.1 System integrator acceptance of the hemofilter
device.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6pt"></TD><TD STYLE="width: 29.95pt">2.6.1.3</TD><TD>Prepare and submit IDE proposal for sepsis treatment.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6pt"></TD><TD STYLE="width: 30pt">2.6.1.4</TD><TD>Prepare and present Final report for DARPA.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; text-align: justify"><U>Milestones</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; text-align: justify">M12: System Integrator approval
of a sepsis precursor ADAPT treatment cartridge</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 7pt"></TD><TD STYLE="width: 15pt">3.0</TD><TD STYLE="text-align: justify">Program Management and Reviews</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 7pt"></TD><TD STYLE="width: 15pt"><B>3.1</B></TD><TD STYLE="text-align: justify"><B>Program Management Plan</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.75pt 0pt 7pt; text-align: justify">The contractor shall develop
a Program Management Plan. A graphical representation of this plan (Gantt chart is one example) identifying major tasks and their
task leaders, milestones of the major task and their completion dates shall be generated. In addition, a graphical representation
of budget shall be generated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.75pt 0pt 7pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 7pt"></TD><TD STYLE="width: 15pt">3.2</TD><TD STYLE="text-align: justify">Kick-off Meeting</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.8pt 0pt 7pt; text-align: justify">The contractor shall participate
in a kick-off meeting within 60 days of contract award. The purpose of this meeting is to introduce key program personnel, discuss
the proposed tasking, present the program schedule and milestones and the initial Program Management Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.8pt 0pt 7pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 7pt"></TD><TD STYLE="width: 15pt">3.3</TD><TD STYLE="text-align: justify">Quarterly Reviews</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.55pt 0pt 7pt; text-align: justify">The contractor shall hold
quarterly reviews for the duration of this effort. The purpose of these reviews is to present a summary of work completed and milestones
met, discuss any problems encountered, update the program schedule, present the program financial status, and discuss remaining
work.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.55pt 0pt 7pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 7pt"></TD><TD STYLE="width: 15pt">3.4</TD><TD STYLE="text-align: justify">Final Contract Review</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.7pt 0pt 7pt; text-align: justify">A final contract review held
in place of the last quarterly review shall be hosted by the principal contractor. The purpose of this review is to present a summary
of all work completed and milestones accomplished and to discuss any relevant future efforts similar to the contract that may be
pursued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.7pt 0pt 7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; text-align: justify">4.0 Deliverables</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 25.45pt 0pt 7pt">The reports and presentation materials are to
be delivered in accordance with the attached Data Delivery Matrix.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 25.45pt 0pt 7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 25.45pt 0pt 7pt">(End of SOW).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 25.45pt 0pt 7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; text-align: justify">SECTION G - CONTRACT ADMINISTRATION
DATA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; text-align: justify">The following have been modified:</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; color: Red">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; color: Red"></P>

<P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">SCHEDULE OF PAYMENT MILESTONES</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">12 month duration base period (Year
1)</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: silver">
    <TD STYLE="width: 13%; border: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Milestone</B></FONT></TD>
    <TD STYLE="width: 8%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Month</B></FONT></TD>
    <TD STYLE="width: 55%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Payable Milestone</B></FONT></TD>
    <TD STYLE="width: 24%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 25pt"><FONT STYLE="font-size: 10pt"><B>GOVT CONTRIBUTION</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Subtask 1a</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Anticoagulant-free Hemopurification Device</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>($908,384)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">2.2.1.1</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Write requirements definition for the extracorporeal blood purification system and acquire necessary equipment.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">($358,284)</FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 13%; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: center">2.2.1.2</P></TD>
    <TD STYLE="width: 8%; border-bottom: black 1pt solid; border-right: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.8pt">3</P></TD>
    <TD STYLE="width: 55%; border-bottom: black 1pt solid; border-right: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 18.6pt 0pt 4.9pt">Fabricate breadboard prototypes for anticoagulation-free
        anti-sepsis extracorporeal system (ASEPSYS) device.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 36.45pt 0pt 4.9pt; text-align: justify">Fabricate prototype blood
        tubing sets. Acquire anti- thrombogenic surface-modified hollow fiber plasma separators.</P></TD>
    <TD STYLE="width: 24%; border-bottom: black 1pt solid; border-right: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 30.7pt 0pt 30.65pt; text-align: center">($183,367)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: center">2.2.1.3</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.75pt">6</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Assemble and test breadboard ASEPSYS devices. Evaluate the use of different techniques and approaches to eliminating anticoagulants.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 30.7pt 0pt 30.65pt; text-align: center">($183,367)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: center">2.2.1.4</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.25pt">12</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Obtain all necessary IRB documentation and obtain both institutional and Government (SSC-Pacific) approval in accordance with IRB documentation submission guidance prior to conducting human or animal testing.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 30.7pt 0pt 30.65pt; text-align: center">($183,367)</P></TD></TR>
<TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.55pt 0pt 6.5pt; text-align: center"><B>Subtask 2</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.55pt 0pt 6.5pt; text-align: center"><B>&amp; 4</B></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Removal of Sepsis Precursors</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>($1,066,663)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: center">2.2.2.1</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.75pt">2</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Begin to develop the Aethlon&rsquo;s ADAPT device to efficiently capture sepsis precursors and acquire important equipment and supplies</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 30.7pt 0pt 30.65pt; text-align: center">($416,424)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: center">2.2.2.2</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.75pt">5</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Perform initial screening of the different proposed capture agents by measuring binding affinity and kinetics using surface plasmon resonance (SPR) or biolayer surface interferometry (BLI).</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 30.7pt 0pt 30.65pt; text-align: center">($216,747)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">2.2.2.3</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">8</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Perform preliminary quantitative real time PCR to measure viral load, and specific DNA or RNA targets.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">($216,747)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">M2</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">12</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Target capture &gt; 50% in 24 hours for at least 1 target in blood or blood components</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">($216,747)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>($1,975,047)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD"></P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD"><B>12 month duration option #1 period
(Year2)</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: silver">
    <TD STYLE="width: 13%; border: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Milestone</B></FONT></TD>
    <TD STYLE="width: 8%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Month</B></FONT></TD>
    <TD STYLE="width: 55%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Payable Milestone</B></FONT></TD>
    <TD STYLE="width: 24%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-indent: 25pt"><FONT STYLE="font-size: 10pt"><B>GOVT CONTRIBUTION</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Subtask 1a</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Anticoagulant-free Hemopurification Device</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>($782,322)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: center">2.3.2.1</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.85pt 0pt 3.8pt; text-align: center">15</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.5pt 0pt 4.9pt">Demonstrate the effectiveness of the prototype
        device in vivo in animals preventing platelet activation or clotting in at least a 2 hour blood pumping experiment at 75 mL/min
        blood flow.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 30.7pt 0pt 30.65pt; text-align: center">($195,581)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: center">2.3.2.2</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.85pt 0pt 3.8pt; text-align: center">18</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Formulate initial design based on work from previous phase. Begin to build and test selected instrument design and tubing sets.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 30.7pt 0pt 30.65pt; text-align: center">($195,581)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: center">2.3.2.3</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.85pt 0pt 3.8pt; text-align: center">21</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Write and test software. Conduct ergonomic research. Begin discussions with System Integrator.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 30.7pt 0pt 30.65pt; text-align: center">($195,581)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: center">M3</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.85pt; text-align: center">24</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 22.05pt 0pt 14.95pt; text-align: center">Complete fabrication and
        testing of prototype instrument.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 22.15pt 0pt 14.95pt; text-align: center">Research literature and
        patent database for technical.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 30.7pt 0pt 30.65pt; text-align: center">($195,581)</P></TD></TR>
<TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Subtask 2</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Removal of Sepsis Precursors</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>($835,124)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: center">2.3.3.1</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.85pt 0pt 3.8pt; text-align: center">15</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Build the ADAPT capture cartridges with the identified affinity agents. Measure the rate of capture of the specific targets from in ex vivo recirculation experiments from cell culture and blood.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 30.7pt 0pt 30.65pt; text-align: center">($208,781)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">M4</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">18</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Target capture &gt; 50% in 24 hours for at least 5 targets in blood or blood components.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">($208,781)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: center">2.3.3.2</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.85pt 0pt 3.8pt; text-align: center">21</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Cartridge construction with optimized affinity matrix design for each potential target. Complete the capture agent screening.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 30.7pt 0pt 30.65pt; text-align: center">($208,781)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">M5</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">24</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Target capture &gt; 90% in 24 hours for at least 3 targets in blood or blood components.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">($208,781)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>($1,617,446)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD"></P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD"><B>12 month duration option #2 period
(Year 3)</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: silver">
    <TD STYLE="width: 13%; border: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Milestone</B></FONT></TD>
    <TD STYLE="width: 8%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Month</B></FONT></TD>
    <TD STYLE="width: 55%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Payable Milestone</B></FONT></TD>
    <TD STYLE="width: 24%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-indent: 25pt"><FONT STYLE="font-size: 10pt"><B>GOVT CONTRIBUTION</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Subtask 1a</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Anticoagulant-free Hemopurification Device</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>($372,328)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: center">2.4.1.1</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.85pt 0pt 3.9pt; text-align: center">27</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Design and fabricate optimized configuration(s) of hemopurification device(s) that contain(s) a combination of hemofilters, plasma filters, and affinity columns.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 34.3pt 0pt 34.25pt; text-align: center">($186,164)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 6.45pt; text-align: center">M6</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.85pt; text-align: center">36</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Define Aethlon&rsquo;s GMP manufacturing process and revise and upgrade Aethlon&rsquo;s quality procedures and policies to the current state of the art.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 34.3pt 0pt 34.25pt; text-align: center">($186,164)</P></TD></TR>
<TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Subtask 2+4</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Target Capture in Combined Agent Cartridge</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>($720,726)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: center">2.4.2.1</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.85pt 0pt 3.9pt; text-align: center">27</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.4pt 0pt 4.9pt">Evaluate contribution of manufacturing process
        variables to binding capacity of affinity resin.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: #E6E6E6">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 34.3pt 0pt 34.25pt; text-align: center">($197,362)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: center">2.4.2.2</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.85pt 0pt 3.9pt; text-align: center">33</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Determine capacity requirements of affinity resin to multiple simultaneous targets.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: #E6E6E6">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 34.3pt 0pt 34.25pt; text-align: center">($197,362)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">2.4.2.3</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">30</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Perform biocompatibility tests for the combination ADAPT device to confirm the combination cartridge does not present additional risk.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: #E6E6E6; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">($78,641)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">2.4.2.4</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">36</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Finish construction and delivery of 25 experimental cartridges for testing by the system integrator.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: #E6E6E6; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">($50,000)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 6.45pt; text-align: center">M9</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.85pt; text-align: center">36</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Target capture &gt; 90% in 24 hours (12 months) for at least 3 targets ex vivo in blood or blood components using the optimized cartridge.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: #E6E6E6">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 34.3pt 0pt 34.25pt; text-align: center">($197,361)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>($1,093,054)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD"></P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD"><B>12 month duration option #3 period
(Year 4)</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: silver">
    <TD STYLE="width: 13%; border: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Milestone</B></FONT></TD>
    <TD STYLE="width: 8%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Month</B></FONT></TD>
    <TD STYLE="width: 55%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Payable Milestone</B></FONT></TD>
    <TD STYLE="width: 24%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 25pt"><FONT STYLE="font-size: 10pt"><B>GOVT CONTRIBUTION</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Subtask 1a</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Anticoagulant-free Hemopurification Device</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>($276,172)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: center">2.5.1.1</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.85pt 0pt 3.8pt; text-align: center">45</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Complete Aethlon&rsquo;s GMP procedure and establish and maintain all GMP documentation for the company.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">($90,008)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: center">M11</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.85pt; text-align: center">48</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Develop a strategic plan for developing an alternate method of producing GNA by cloning the gene into an alternate vector and identify potential partners for such production.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 30.7pt 0pt 30.65pt; text-align: center">($186,164)</P></TD></TR>
<TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Subtask 2+4</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Target Capture in Combined Agent Cartridge</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>($296,964)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">2.5.2.2</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">48</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Finish construction and begin delivery of 50 prototype cartridges for testing by the system integrator.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">($296,964)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>($573,136)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD"></P>

<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; color: #4F82BD"><B>12 month duration option #4 period
(Year 5)</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: silver">
    <TD STYLE="width: 13%; border: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Milestone</B></FONT></TD>
    <TD STYLE="width: 9%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Month</B></FONT></TD>
    <TD STYLE="width: 54%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Payable Milestone</B></FONT></TD>
    <TD STYLE="width: 24%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 25pt"><FONT STYLE="font-size: 10pt"><B>GOVT CONTRIBUTION</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: #E6E6E6; text-align: center"><FONT STYLE="font-size: 10pt"><B>Subtask 5</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: #E6E6E6">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: #E6E6E6"><FONT STYLE="font-size: 10pt"><B>Testing of final product by System Integrator</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>($581,157)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">2.6.1.1</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">51</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">System integrator acceptance of the hemofilter device.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">($193,719)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">2.6.1.3</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">57</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Prepare and submit IDE proposal for sepsis treatment.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">($193,719)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">2.6.1.4</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">60</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Prepare and present Final Report for DARPA.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">($193,719)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>($581,157)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt">(End of Milestone Schedule)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt">(End of Summary of Changes)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt"></P>

<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt">&nbsp;</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="image_002.jpg" ALT=""></P>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 1; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SECTION SF 30 BLOCK 14 CONTINUATION PAGE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">SUMMARY OF CHANGES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SECTION A - SOLICITATION/CONTRACT FORM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt">The standard size code 1,000 has been added.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt">The NAICS code
541711 has been added.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SECTION C - DESCRIPTIONS AND SPECIFICATIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">The following have been modified:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt; margin-left: 20pt"><U>STATEMENT
OF WORK (SOW)</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Aethlon Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>DATE: 12 March 2015; Modified: <FONT STYLE="color: red">15
July 2016</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>TITLE: Broad Spectrum Countermeasures
for Viral and Bacterial Sepsis using Dialysis-Like Devices</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt"><B>1.0</B></TD><TD STYLE="text-align: justify"><B>Scope</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The scope of this effort is to use Aethlon&rsquo;s
Hemopurifier as the core technology within an extracorporeal blood purification device that would simultaneously remove: viruses,
virally-derived immunosuppressive glycoproteins, and multiple classes of exosomes; complement activation, activation of virus growth
(e.g. cytomegalovirus) and TLR activation, all of which have implications to the promotion of the well-being and recovery of wounded
warfighters and the prevention of sepsis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt">1.1</TD><TD STYLE="text-align: justify">Introduction</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This effort will create an adaptable dialysis-like
platform (ADAPT) technology that allows for the selective removal of harmful agents from the entire circulatory system. This revolutionary
advance overcomes the limitation of devices that indiscriminately adsorb or solely capture particles by molecule size. The platform
will provide an expansive therapeutic filtration mechanism to immobilize multiple affinity agents directed toward precursors to
sepsis, bacterial toxins, viral pathogens, and disease enhancing particles transported by exosomes. To insure benefit to wounded
warfighters, this effort will advance an innovative strategy that will allow therapy administration without systemic anticoagulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.05pt">The ADAPT platform
has been shown previously to create a broad-spectrum antiviral device that immobilized one lectin affinity agent, resulting in
the effective capture of all tested Category A pathogens, as well as exosomes underlying tuberculosis and cancer. In human studies,
this same device, known as the Hemopurifier, consistently provided greater than 50% average viral load reductions during four-hour
treatment periods in both hepatitis-C and HIV infected individuals without antiviral drug therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The resulting device would save thousands
of military and civilian lives each year. Each of these technology advancements will be integrated into a single cartridge that
will provide decision-free and life-saving medical care for the wounded warfighter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt">1.2</TD><TD STYLE="text-align: justify">Background</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The goal of the DLT program is to
develop a portable device that removes &ldquo;dirty&rdquo; blood from the body, separates harmful agents, and returns
&ldquo;clean&rdquo; blood to the body in a manner similar to dialysis treatment of kidney failure. While the device could
have an impact across multiple areas of medicine, the target application for this device is sepsis. The envisioned device
will persistently interrogate the entire blood volume, providing early identification of the presence of a pathogen. Once the
presence of pathogens has been confirmed, the DLT device will provide continuous &quot;label-free&quot; removal of pathogens,
toxins and activated patient cells without pathogen identification or use of pathogen-specific binding chemistries. As a
final step in the treatment process, the DLT device will enable closed-loop therapy based on continuous, reduced
dimensionality modeling of patient health. Predictive modeling in this fashion will allow us to identify sepsis early, learn
what we need to remove, and direct the most effective intervention to improve patient health. This cycle of sensing,
adjustment, estimation, computation, and manipulation will modulate key health parameters faster than the underlying disease
process and drive the patient towards a stable, healthy state.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt">2.0</TD><TD STYLE="text-align: justify">Technical Requirements</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt"><B>2.1</B></TD><TD STYLE="text-align: justify"><B>Human and Animal use</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Human use <B>is </B>anticipated in this
effort, specifically related to the use of human blood. The grantee shall obtain all necessary Institutional Review Board (IRB)
approvals, show proper assurance documentation, and obtain proper approval from the Government officials prior to human use testing.
Funds associated with human subjected testing shall not be released until IRB documentation has been provided to SSC&rsquo;s HRPO
and approval to release funds has been obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Animal use <B>is </B>anticipated in this
effort. The contractor shall obtain all necessary Institutional Animal Care and Utilization Committee (IACUC) approval and demonstrate
this approval to the Government (<B>both </B>ACURO and SSC-Pacific) prior to beginning experimentation with animals. If animal
use is no longer anticipated, or changes significantly from the approved IACUC then the Principal Investigator (PI) must submit
a letter stating the discontinuation of animal use for this effort and/or receive appropriate authorization for IACUC changes of
previously specified protocols. Unless prior approval by DARPA is given IACUC documentation must be provided prior to contract
award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt">2.2</TD><TD STYLE="text-align: justify">Base Effort (Year 1)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt"><B>2.2.1</B></TD><TD STYLE="text-align: justify"><B><U>Subtask 1a: Anticoagulant-free Hemopurification Device</U></B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt">2.2.1.1</TD><TD STYLE="text-align: justify">Write requirements definition for the extracorporeal blood purification system and acquire necessary
equipment.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt">2.2.1.2</TD><TD STYLE="text-align: justify">Fabricate breadboard prototypes for anticoagulation-free anti-sepsis extracorporeal system (ASEPSYS)
device. Fabricate prototype blood tubing sets. Acquire anti-thrombogenic surface-modified hollow fiber plasma separators.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt">2.2.1.3</TD><TD STYLE="text-align: justify">Assemble and test breadboard ASEPSYS devices <I>ex vivo </I>with bovine blood. The test will most
likely be conducted using a porcine model where the elapsed time to reach a pre-defined degree of clotting in the blood treatment
device will be compared between the new device and two control groups; one using standard anticoagulant therapy and one using none.
Determine contribution of the following techniques and approaches to eliminating anticoagulants:<BR>
<BR>
(1)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Backflushing at regular intervals, (2) Turbo loop, (3) Continuous pre-dilution loop using re-captured hydration fluid, (4)
Linear vs pulsatile blood flow, (5) Elimination of air/blood interfaces in extracorporeal circuit, (6) Anti-thrombogenic derivatized
plasma separation membrane, and (7) Ultra-short half-life anticoagulant nafamostat mesilate.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt">2.2.1.4</TD><TD STYLE="text-align: justify">IRB Documentation Generation: The contractor shall obtain all necessary IRB documentation and obtain
both institutional and Government (SSC-Pacific) approval in accordance with IRB documentation submission guidance prior to conducting
human subject testing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Milestones</U></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt; text-align: right"></TD><TD STYLE="width: 0pt">M1:</TD><TD STYLE="text-align: justify">Demonstrate the effectiveness of the prototype device in preventing platelet activation
or clotting in at least a 2 hour blood pumping experiment at 100 mL/hr blood flow.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt">2.2.2</TD><TD STYLE="text-align: justify"><U>Subtask 2: Removal of Sepsis Precursors</U></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt">2.2.2.1</TD><TD STYLE="text-align: justify">Begin to develop a device based on Aethlon&rsquo;s ADAPT system to efficiently capture sepsis precursors
identified as potentially important in killing patients undergoing sepsis. The strategy is takes advantage of the flexibility and
rapidity of modification of our ADAPT platform system to test any sepsis precursor candidates that circulate in the blood. The
sepsis precursors that will be targeted are shown in Table I, in order of importance. No test for the removal of bacterial toxins.
No testing for removal of cytokines, since the evidence to date does not support a role for them in death
due to sepsis. Additional factors may become known during the grant period and those will also be tested as time and budget permit</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt">2.2.2.2</TD><TD STYLE="text-align: justify">Screening Capture Agents: Perform initial screening of the different proposed capture agents by
measuring binding affinity and kinetics using surface plasmon resonance (SPR) or biolayer surface interferometry (BLI).</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt">2.2.2.3</TD><TD STYLE="text-align: justify">Perform quantitative real time PCR will also be used to measure viral load, and specific DNA or
RNA targets.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Milestones</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">M2:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Target capture &gt; 50% in 24 hours for at least 1 target
in blood or blood components</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Table I Potential Target Sepsis Precursors and Broad Spectrum
Binding Agents</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; border: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Septic Exosomes</B></FONT></TD>
    <TD STYLE="width: 20%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Removal Agent</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">INOS exosomes</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">GNA</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Viruses Associated with Sepsis</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Dengue Fever virus</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">GNA</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">H1N1 Flu virus</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">GNA</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Cytomegalovirus **</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">GNA</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Herpes viruses &ndash; e.g. HSV 1</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">GNA</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Poxviruses - e.g. Vaccina (model for small pox)</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">GNA</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Activation of Innate Immunity</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">LPS endotoxins</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">GNA</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">LTA endotoxins</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">GNA</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt"><B>2.3</B></TD><TD><B>Option 1 (Year 2)</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt"><B>2.3.2</B></TD><TD><B><U>Subtask 1a: Anticoagulant-free Hemopurification Device</U></B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt">2.3.2.1</TD><TD>Demonstrate the effectiveness of the prototype device in vivo in animals preventing platelet activation or clotting in at least
a 2 hour blood pumping experiment at 75 mL/min blood flow.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt">2.3.2.2</TD><TD>Formulate initial design based on work from previous phase. Begin to build and test selected instrument design and tubing sets.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt">2.3.2.3</TD><TD>Write and test software. Conduct ergonomic research. Begin discussions with System Integrator.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt">2.3.2.4</TD><TD>Complete fabrication and testing of prototype instrument.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt">2.3.2.5</TD><TD>Research literature and patent database for technical options for an on-line/in-line sensor with the ability to quantify the
clearance of citrate and/or calcium in effluent dialysate.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt">2.3.2.6</TD><TD>Collect feasibility data on at least one sensor option.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt">2.3.2.7</TD><TD STYLE="text-align: justify">Conduct a series of 21 experiments aimed at characterizing the contribution of several alternate
fluidic designs and methods of perfusing plasma filters and affinity columns in the performance of affinity plasmapheresis.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>2,3.3 Subtask 2. Removal of Sepsis Precursors</U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt">2.3.3.1</TD><TD>Build the ADAPT capture cartridges with the identified affinity agents. Measure the rate of capture of the specific targets
from in ex vivo recirculation experiments from cell culture and blood.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt">2.3.3.2</TD><TD>Cartridge construction with optimized affinity matrix design for each potential target. Complete all capture agents screening.
Initiate <I>ex vivo</I> capture studies from blood using the optimized cartridges.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Milestones</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">M4:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Target capture &gt; 50% in 24 hours for at least 5 targets
in blood or blood components.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">M5: Milestone 5: Target capture &gt; 90% in 24 hours for at
least 3 targets in blood or blood components.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOTE: TASK 2.3.2 SHALL NOT BE EXERCISED AND TASKING FUNDS
RELEASED UNTIL IRB DOCUMENTATION AND PROPER IRB APPROVAL HAS BEEN OBTAINED.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt"><B>2.4</B></TD><TD><B>Option 2 (Year 3)</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt"><B>2.4.1</B></TD><TD><B><U>Subtask 1a: Anticoagulant-free Hemopurification Device</U></B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt">2.4.1.1</TD><TD>Design and fabricate optimized configuration(s) of hemopurification device(s) that contain(s) a combination of hemofilters,
plasma filters, and affinity columns.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Milestones</U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 36pt">M6:</TD><TD>Define Aethlon&rsquo;s GMP manufacturing process and revise and upgrade Aethlon&rsquo;s quality procedures and policies to
the current state of the art.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt">2.4.2</TD><TD><U>Subtask 4: Target Capture in Combined Agent Cartridge</U></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt">2.4.2.1</TD><TD>Evaluate contribution of manufacturing process variables to binding capacity of affinity resin.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt">2.4.2.2</TD><TD>Determine capacity requirements of affinity resin to multiple simultaneous targets.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt">2.4.2.3</TD><TD>Perform basic biocompatibility tests for the combination ADAPT device to confirm the combination cartridge does not present
additional risk.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt">2.4.2.4</TD><TD>Finish construction and delivery of 25 experimental cartridges for testing by the system integrator.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Milestones</U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 36pt">M7:</TD><TD>Target capture &gt; 90% in 24 hours (12 months) for at least 3 targets ex vivo in blood or blood components using the optimized
cartridge.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt">&nbsp;</TD>
    <TD STYLE="width: 36pt">M8:</TD>
    <TD>Pass biocompatibility tests for the combination ADAPT
device.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt">&nbsp;</TD>
    <TD STYLE="width: 36pt">M9:</TD>
    <TD>Construct and deliver of 25 prototype cartridges for
testing by the system integrator.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt">2.5</TD><TD>Option 3 (Year 4)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt"><B>2.5.1</B></TD><TD><B><U>Subtask 1a: Anticoagulant-free Hemopurification Device</U></B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt">2.5.1.1</TD><TD>Complete Aethlon&rsquo;s GMP procedure and establish and maintain all GMP documentation for the company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Milestones</U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 36pt">M11:</TD><TD>Develop a strategic plan for developing an alternate method of producing GNA by cloning the gene into an alternate vector and
identify potential partners for such production.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt">2.5.2</TD><TD><U>Subtask 4: Target Capture in Combined Agent Cartridge</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">2.5.2.2 Finish construction
and delivery of 50 prototype cartridges for testing by the system integrator. The cartridges will need to be made available (packaged,
labeled, sterilized and qualified) to the system integrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Milestones</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">M13:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Construct and deliver of 50 prototype cartridges for
testing by the system integrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">2.6 Option 4 (Year 5)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>2.6.1 Subtask 5: Testing of final product by System Integrator</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2.6.1.1 System integrator acceptance of the hemofilter device.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">2.6.1.3<FONT STYLE="font-family: Times New Roman, Times, Serif"> </FONT>Quantify the degree to which the MERS virus can be extracted from circulation <I>in vitro </I>using miniature Hemopurifiers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 2.6.1.4 Prepare and present Final report for DARPA.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Milestones</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">M12: System Integrator approval of a sepsis precursor ADAPT
treatment cartridge</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt">3.0</TD><TD STYLE="text-align: justify">Program Management and Reviews</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt"><B>3.1</B></TD><TD STYLE="text-align: justify"><B>Program Management Plan</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The contractor shall develop a Program
Management Plan. A graphical representation of this plan (Gantt chart is one example) identifying major tasks and their task leaders,
milestones of the major task and their completion dates shall be generated. In addition, a graphical representation of budget shall
be generated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt">3.2</TD><TD STYLE="text-align: justify">Kick-off Meeting</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The contractor shall participate in a kick-off
meeting within 60 days of contract award. The purpose of this meeting is to introduce key program personnel, discuss the proposed
tasking, present the program schedule and milestones and the initial Program Management Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt">3.3</TD><TD STYLE="text-align: justify">Quarterly Reviews</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The contractor shall hold quarterly reviews
for the duration of this effort. The purpose of these reviews is to present a summary of work completed and milestones met, discuss
any problems encountered, update the program schedule, present the program financial status, and discuss remaining work.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt">3.4</TD><TD STYLE="text-align: justify">Final Contract Review</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A final contract review held in place of
the last quarterly review shall be hosted by the principal contractor. The purpose of this review is to present a summary of all
work completed and milestones accomplished and to discuss any relevant future efforts similar to the contract that may be pursued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.0 Deliverables</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The reports and presentation materials are to be delivered in
accordance with the attached Data Delivery Matrix.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(End of SOW).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SECTION G - CONTRACT ADMINISTRATION DATA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following have been modified:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">SCHEDULE OF PAYMENT MILESTONES</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #4F82BD">12 month duration
base period (Year 1)</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: silver">
    <TD STYLE="width: 13%; border: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Milestone</B></FONT></TD>
    <TD STYLE="width: 8%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Month</B></FONT></TD>
    <TD STYLE="width: 55%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Payable Milestone</B></FONT></TD>
    <TD STYLE="width: 24%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 25pt"><FONT STYLE="font-size: 10pt"><B>GOVT CONTRIBUTION</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Subtask 1a</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Anticoagulant-free Hemopurification Device</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>($908,384)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">2.2.1.1</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Write requirements definition for the extracorporeal blood purification system and acquire necessary equipment.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">($358,284)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2.2.1.2</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">3</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fabricate breadboard prototypes for anticoagulation-free anti-sepsis
        extracorporeal system (ASEPSYS) device.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fabricate prototype blood tubing sets.
        Acquire anti- thrombogenic surface-modified hollow fiber plasma separators.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">($183,367)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2.2.1.3</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">6</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Assemble and test breadboard ASEPSYS devices. Evaluate the use of different techniques and approaches to eliminating anticoagulants.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">($183,367)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 13%; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2.2.1.4</P></TD>
    <TD STYLE="width: 8%; border-bottom: black 1pt solid; border-right: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">12</P></TD>
    <TD STYLE="width: 55%; border-bottom: black 1pt solid; border-right: black 1pt solid"><FONT STYLE="font-size: 10pt">Obtain all necessary IRB documentation and obtain both institutional and Government (SSC-Pacific) approval in accordance with IRB documentation submission guidance prior to conducting human or animal testing.</FONT></TD>
    <TD STYLE="width: 24%; border-bottom: black 1pt solid; border-right: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">($183,367)</P></TD></TR>
<TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Subtask 2</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&amp; 4</B></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Removal of Sepsis Precursors</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>($1,066,663)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2.2.2.1</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Begin to develop the Aethlon&rsquo;s ADAPT device to efficiently capture sepsis precursors and acquire important equipment and supplies</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">($416,424)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2.2.2.2</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Perform initial screening of the different proposed capture agents by measuring binding affinity and kinetics using surface plasmon resonance (SPR) or biolayer surface interferometry (BLI).</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">($216,747)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">2.2.2.3</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">8</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Perform preliminary quantitative real time PCR to measure viral load, and specific DNA or RNA targets.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">($216,747)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">M2</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">12</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Target capture &gt; 50% in 24 hours for at least 1 target in blood or blood components</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">($216,747)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>($1,975,047)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #4F82BD"><B>12 month duration option #1 period (Year2)</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: silver">
    <TD STYLE="width: 13%; border: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Milestone</B></FONT></TD>
    <TD STYLE="width: 8%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Month</B></FONT></TD>
    <TD STYLE="width: 55%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Payable Milestone</B></FONT></TD>
    <TD STYLE="width: 24%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-indent: 25pt"><FONT STYLE="font-size: 10pt"><B>GOVT CONTRIBUTION</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Subtask 1a</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Anticoagulant-free Hemopurification Device</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>($782,322)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2.3.2.1</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">15</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Demonstrate the effectiveness of the prototype device in vivo
        in animals preventing platelet activation or clotting in at least a 2 hour blood pumping experiment at 75 mL/min blood flow.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">($195,581)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2.3.2.2</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">18</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Formulate initial design based on work from previous phase.
        Begin to build and test selected instrument design and tubing sets.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">($195,581)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2.3.2.3</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">21</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Write and test software. Conduct ergonomic research. Begin discussions
        with System Integrator.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">($195,581)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">M3</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">24</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Complete fabrication and testing of prototype
        instrument.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Research literature and patent database
        for technical.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">($195,581)</P></TD></TR>
<TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Subtask 2</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Removal of Sepsis Precursors</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>($835,124)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2.3.3.1</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">15</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Build the ADAPT capture cartridges with the identified affinity agents. Measure the rate of capture of the specific targets from in ex vivo recirculation experiments from cell culture and blood.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">($208,781)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">M4</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">18</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Target capture &gt; 50% in 24 hours for at least 5 targets in blood or blood components.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">($208,781)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2.3.3.2</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">21</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Cartridge construction with optimized affinity matrix design for each potential target. Complete the capture agent screening.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">($208,781)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">M5</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">24</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Target capture &gt; 90% in 24 hours for at least 3 targets in blood or blood components.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">($208,781)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>($1,617,446)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #4F82BD"><B>12 month duration option #2 period (Year
3)</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: silver">
    <TD STYLE="width: 13%; border: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Milestone</B></FONT></TD>
    <TD STYLE="width: 8%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Month</B></FONT></TD>
    <TD STYLE="width: 55%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Payable Milestone</B></FONT></TD>
    <TD STYLE="width: 24%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-indent: 25pt"><FONT STYLE="font-size: 10pt"><B>GOVT CONTRIBUTION</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Subtask 1a</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Anticoagulant-free Hemopurification Device</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>($372,328)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2.4.1.1</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">27</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Design and fabricate optimized configuration(s) of hemopurification device(s) that contain(s) a combination of hemofilters, plasma filters, and affinity columns.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">($186,164)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">M6</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">36</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Define Aethlon&rsquo;s GMP manufacturing process and revise
        and upgrade Aethlon&rsquo;s quality procedures and policies to the current state of the art.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">($187,164)</P></TD></TR>
<TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Subtask 2+4</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Target Capture in Combined Agent Cartridge</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>($720,726)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2.4.2.1</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">27</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Evaluate contribution of manufacturing process variables to
        binding capacity of affinity resin.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: #E6E6E6">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">($197,362)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2.4.2.2</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">33</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Determine capacity requirements of affinity resin to multiple
        simultaneous targets.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: #E6E6E6">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">($197,362)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">2.4.2.3</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">30</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Perform biocompatibility tests for the combination ADAPT device to confirm the combination cartridge does not present additional risk.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: #E6E6E6; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">($78,641)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">2.4.2.4</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">36</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Finish construction and delivery of 25 experimental cartridges for testing by the system integrator.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: #E6E6E6; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">($50,000)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">M9</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">36</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Target capture &gt; 90% in 24 hours (12 months) for at least 3 targets ex vivo in blood or blood components using the optimized cartridge.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: #E6E6E6">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">($197,361)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>($1,093,054)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #4F82BD"><B>12 month duration option #3 period (Year
4)</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: silver">
    <TD STYLE="width: 13%; border: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Milestone</B></FONT></TD>
    <TD STYLE="width: 8%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Month</B></FONT></TD>
    <TD STYLE="width: 55%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Payable Milestone</B></FONT></TD>
    <TD STYLE="width: 24%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-indent: 25pt"><FONT STYLE="font-size: 10pt"><B>GOVT CONTRIBUTION</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Subtask 1a</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Anticoagulant-free Hemopurification Device</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>($276,172)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2.5.1.1</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">45</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Complete Aethlon&rsquo;s GMP procedure and establish and maintain all GMP documentation for the company.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">($90,008)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">M11</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">48</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Develop a strategic plan for developing an alternate method of producing GNA by cloning the gene into an alternate vector and identify potential partners for such production.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">($186,164)</P></TD></TR>
<TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Subtask 2+4</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Target Capture in Combined Agent Cartridge</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>($296,964)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">2.5.2.2</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">48</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Finish construction and begin delivery of 50 prototype cartridges for testing by the system integrator.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">($296,964)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>($759,300)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 60 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #4F82BD"><B>12 month duration option #4 period (Year
5)</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: silver">
    <TD STYLE="width: 13%; border: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Milestone</B></FONT></TD>
    <TD STYLE="width: 9%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Month</B></FONT></TD>
    <TD STYLE="width: 54%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Payable Milestone</B></FONT></TD>
    <TD STYLE="width: 24%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-indent: 25pt"><FONT STYLE="font-size: 10pt"><B>GOVT CONTRIBUTION</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: #E6E6E6; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Subtask 5</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: #E6E6E6; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: #E6E6E6; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Testing of final product by System Integrator</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>($581,157)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2.6.1.1</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">51</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">System integrator acceptance of the hemofilter device.</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">($193,719)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2.6.1.3</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">57</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt; color: red">Quantify the degree to which the MERS virus can be extracted from circulation <I>in vitro </I>using miniature Hemopurifiers.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">($193,719)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">2.6.1.4</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">60</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Prepare and present Final Report for DARPA.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">($193,719)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>($581,157)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(End of Milestone Schedule)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(End of Summary of Changes)</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 61; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>aethlon_10q-ex3101.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>EXHIBIT 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a),
AS ADOPTED</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY
ACT OF 2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, James Joyce, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">1.&nbsp;&nbsp;&nbsp;I have reviewed this Quarterly Report on Form
10-Q of Aethlon Medical, Inc.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">2.&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not
contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light
of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">3.&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results
of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">4.&nbsp;&nbsp;&nbsp;The registrant's other certifying officer(s)
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 5%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="width: 94%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">5.&nbsp;&nbsp;&nbsp;The registrant's other certifying officer(s)
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors
and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: November 10, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 33%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&nbsp;JAMES A. JOYCE</FONT></TD>
    <TD STYLE="width: 62%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JAMES A. JOYCE</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHIEF EXECUTIVE OFFICER </FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(PRINCIPAL EXECUTIVE OFFICER)</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>aethlon_10q-ex3102.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>EXHIBIT 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a),
AS ADOPTED</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY
ACT OF 2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, James Frakes, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">1.&nbsp;&nbsp;&nbsp;I have reviewed this Quarterly Report on Form
10-Q of Aethlon Medical, Inc.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">2.&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not
contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light
of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">3.&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results
of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">4.&nbsp;&nbsp;&nbsp;The registrant's other certifying officer(s)
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 5%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="width: 94%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">5.&nbsp;&nbsp;&nbsp;The registrant's other certifying officer(s)
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors
and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: November 10, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 33%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&nbsp;JAMES B. FRAKES</FONT></TD>
    <TD STYLE="width: 62%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JAMES B. FRAKES</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHIEF FINANCIAL OFFICER </FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(PRINCIPAL FINANCIAL OFFICER) </FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>aethlon_10q-ex3201.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>EXHIBIT 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION
1350,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">AS ADOPTED PURSUANT TO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In connection with the Quarterly Report of Aethlon
Medical, Inc. (the &ldquo;Registrant&rdquo;) on Form 10-Q for the six-month period ended September 30, 2016 as filed with the Securities
and Exchange Commission on the date hereof, I, James A. Joyce, Chief Executive Officer of the Registrant, certify, pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1. The Quarterly Report on Form 10-Q fully complies
with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">2. The information contained in such Quarterly
Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Aethlon Medical,
Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: November 10, 2016</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ JAMES A. JOYCE</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James A. Joyce</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aethlon Medical, Inc.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">A signed original of this written statement required by Section
906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the
electronic version of this written statement required by Section 906, has been provided to Aethlon Medical, Inc. and will be retained
by Aethlon Medical, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>aethlon_10q-ex3202.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>EXHIBIT 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION
1350,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">AS ADOPTED PURSUANT TO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In connection with the Quarterly Report of Aethlon
Medical, Inc. (the &ldquo;Registrant&rdquo;) on Form 10-Q for the six-month period ended September 30, 2016 as filed with the Securities
and Exchange Commission on the date hereof, I, James B. Frakes, Chief Financial Officer of the Registrant, certify, pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;1. The Quarterly Report on Form 10-Q fully
complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">2. The information contained in such Quarterly
Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Aethlon Medical,
Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: November 10, 2016</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ JAMES B. FRAKES</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James B. Frakes</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aethlon Medical, Inc.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">A signed original of this written statement required by Section
906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the
electronic version of this written statement required by Section 906, has been provided to Aethlon Medical, Inc. and will be retained
by Aethlon Medical, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>award_image1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 award_image1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" /+ N8# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ>H6]UJ=M9:1;7D6D6&G10 4444 %%%% !1110 4444 %%%% !1110 4444
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M/0@Y'YBEH ***:K*WW65O]T@_P C0 ZBBB@ HI,@D@$$CJ,C([\CMP0?QI:
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MM?+=V>GZA-<SW]HMRWY&_P#!.+_@H6O[6O[/WP+_ &U/&/C3QEX/^ /[/?\
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M>TT*VL]&M_\ A(D01W>J#5-5U$ _-&ZTG]F:;Q+XC\*67[1O_!273O&7@O\
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M?P\\0_"?6M6E^/\ K/C?PUXI\,WL<_A:]T>TM['1T:2*2R\4U[_@FYXB\3?
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MM?\ QQU70Y]%\-W&CW.C#Q3^S[X2_P"%E^%/B%H%N;'XA6/C;1/'O@_Q%?\
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MG[4_@VRTK1? W[(GBK0[CX,_ 3XR^%OA;<_&N\DUW]@[XC6/A+P;X(T_QO\
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M]-.\&?%I?%7CK2X_!\OPROO#7BGC_P#X))_\+:L(M9\:>+O"VC_&#P!^Q/\
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MOP[U!K*RU61[*&?PZ1?W&@+:75Q'XF\3/J$5KIH!J6/_  3J^ OAC]@GQ?\
M\$X?AK>>/_A;^S?XM\#_ !5^%QM?"OB33-8\::!\,OC3XF\6:]X_\$Z!XE^(
M_AKQ[!!IE_I?CCQ-X)TR^U31]7\0Z#X2OH#HVN6/BG3M,\467/?%?_@F]X ^
M*/[&'P2_85M?C7\>/AK\'O@G>_ (V'B'X=:C\+--^*GB?0_V9]7\/>+/A+H6
MJ>,M8^%&M6'A^32/'/@?X>>+=1\3^ _#7A/QAJ=UX.AL6UZ&SUWQ"NI6TUO_
M (*@0Z??3OH?_!/G4;QYY+;3MGQ!_:*T?3K2^@N[#3X=*O;MOAYKTFI7.IW;
MZE#+-;V^F3Z%>16.G+I?B*6>XN+6W:ZE_P %3#%$EYX-_8#$WV*\6>>V^)7[
M1HC.H064T.GR0VDWPG#BSU34?(U"\A:],^@67G:1!/XDGV:Z0#S/4_\ @DW\
M%+;]JS]I;]L#X5_%_P#:-_9]^)7[7/P:UGX0?';PY\&?&?P]TWX<^*+[5_#\
M7AR'XSZ5X>\;_"7QYJ7@[XWZ-;:=X?U#3/&7A#7M%TV;7/#\.LZUX=U>]\0>
M-W\5)\8/^"3'P,^+OA?]A/0(OB5\8OA5J_\ P3UUOP#XE^"'CSX3V_P*T[QE
MK.N_#?P1HO@'P]<?$*Z\>? OXAZ9K%@VBZ.9-1T/0=,\,Z)J%[?237>GS#3M
M 31]?Q]XB_X*K^$= \1>)1>_\$U])\-^';#5?$&L>)O&.J_M-:1IOASPQHUO
M;:CJ>HZM%:V=U%-%IVDQZY?7M^=5TRWA72;,M$D6KW4NA\'JW[1W[=EQH?PQ
MO_"7Q!_X)8WES\7O!/C'XP?#O5KWXI_'^_\  GCGX+>%/#W@;Q'>_$7PCXQT
M;PS+I>K>%M/TCQUI6NZKXLCE_P"$=CT+5O#%]I\]U!K$T^F 'J/@K_@FG\/O
M@OX[^/GC/]F3XY_M _LM:1^TQXXUKXJ_%OX8_!VX^!-_\-M4^+WB30O[!\0?
M%3PWIGQB^ GQ:\1> _%VL1QV&J:E!X(\4:!X7OM7TC2Y[CPX]O!);2:_[7?_
M  3D^&'[8WQ!_8O^)7C3XJ_';X>Z[^PQ\6K3XT_">S^%_B;P%%8^)_&FG77A
M*;3U^)^J?$KX8_$SQ9XFT>"T\*-I5Y8:5XB\-MX@L?$?B%_$\^M:@VB7VA^8
M?!OXV?\ !0;XL7GB>TT#Q9_P34\8W'A#4XM(\8Z3X.\4_M(P>*?A_?7VIVCZ
M3'XJ\*:WH)UJW76O!5I?^-O"LVKV_A6U\<V'B+0+GPU<S^#["V\>>,_2+T_\
M%8HM90:>G_!/*_\ #[_V8LLMY)^TOI.LP"#3]#CUIXX((M:LKHZGJC>)+G2X
MVN+/^P["#0[&ZF\17-Y?ZC9@'Z(@8 ''  XZ?A[>E+7P3'-_P4[NF7SM/_80
MT%)+>"1S%J_[1'BYK2[:ZMKBXM41M#\%#4+=+."\T6&_+:7(]SJ]KXHDTV*'
MPY+X2\48&DS?\%8XYKFUU[3?^">-Y;[;&&RUK2-:_:8TV8O!)'%J6HW7AF\T
M#58U35(;.6ZL=%B\7L="DUV.RN->\1KX6?4O&8!]-_M4Z1'K_P"S!^T?H4TL
ML,.M? 7XP:1+-!>R:;-%'J7P]\16;RPZC"KS:?+&LQ:.]B1I+5P)T5FC .Y^
MS[#K%M\!O@G:^(=*30M?M?A'\-K;7-%BM?!]C%I&L1>"]$74]+AL_A[%#X M
M(M/O1/9I;>!X8O!]N(/)\-11Z*ED@_-W]M/QE_P4M\&?LD_M.>,(?"7[%%SI
MWA7]G;X^Z]K5O8^(?V@?$>OS:;X<^$OB35K>\\-^'AX1T&WU[7-5NX)[6+P7
M>:[H<$8AMHX_&UY+J3_V7C_LS?&[]N3XA>&KOX3^ _B'_P $SO$'Q+^ 6D_"
MCPK\6O 7A[Q?\>O$'BKX873^'K^WO_"/C[PW%8:+K'AK7=4DT632M,UR_P!.
MM+;0?$WAGQ[X6U'PKJNN>%]7L=* /JCQE\6/'7AC_@H=X!^$][XYUS1O@IXX
M_87^/WQ3U?1=5\/^!H/!&D_$'X.?'']G;PO9^--&\>7WART\5V7B*/PG\;M6
MLO%WAO5?$_BSP1/I5GX*UB+PUX&U.RU+4/B1^/S?MU_MF_"CX*ZGXD^,/Q=\
M5>(="\5_!+]CCX,^*_B3X-^%_P )+SXN_L@?\%!_BI^SU\#_ (A:8WQ"\&:;
M\'Q\.=3^"G[4OBWXNZ3X-M?%E]X8\6>%OA5\9-1\.^$;'4++PMX^NS\$ON3X
MV?%?]HFR\1V'@3]H6'_@CQ!=^'?"C?&R\\)?&_X^^/;/7] \):%XLN]!A^(V
MF^'_ !S\('-CX7TCQ'+X'T>;XGM#:Z?I/BEY;$VZWEWH<2[MW^T'^T9X;'C#
M6HQ_P24\":S>?$C5=*^*=U??M>>/93/XN^'>C_#+P]K4?C+6_P#AGKPC>77Q
M)\.>&I-'L-5T/Q)9+JGP]T@_#'P_=7^IV#6EV #S^Z_:'_:%_P"$5^%/BSPQ
M\9+GQYKOQ5_X*E?M(?LD1?#G3;;X-QW^H_ >R_:7^.OP3O\ 6? 5F?AGI>O6
M7C?]CKX>?!KQ)\9C/)J?Q"C\1^#_ (4?%7Q!\38?%MKJUO#\._'O!7[1W[4[
M_P#!/W]F#XP^*OVA/BI?_'WXJZ+_ ,$D;;Q7#:W'[!$;^,M8_::_:,^ NB?M
M&WOPQ\+Z=\,]&T_P[+J^C_&/6_@OI;>/]4L-(AN/#WA1_!EE:^*(]5\=^//=
M?!?QS\=^%?$WQ \0>'_ '_!'#PE\1)=(\0>+/C1XM\*?MI>(O#?BM-$T?6KZ
MY\:>+OB+%#^QOIWB 6>EZ_9^+D\5IXO\0PIH&MZ-=WNO:U]NO]0LM&E\9^)/
MB5\%K:$?$'P'_P $;?A,OAZY\ ):Q^,_C3XB\ 0:'J?P^TW6O$?PWCCDUOX$
M:7_8T_@6PT.UUKX?2I%%-H&G+JVK^'TTV'P_ VL %GP3^T?\=?B#_P $V_AI
M\8[3XK+<_&/QK^T9\%?AU>>*?">D_"N3QY\/O WQ(_;Y\"?!NX^'_P 8?!U[
MX(\5_#+PW^TG\,?@5XHMO!7[5O@#1?#+Z-X5^/VB_$_P[\.M:T'3;/PIXBTW
MQ/QC^TS^TKHW[7'@[]F_0OVC?%/Q,^&?A_\ :9M/@</B7\--&_9GC^)_Q.\7
M^-?V"OVW_P!H'QC^SC\3I]>^&]O\)=&^/W[.7Q#^ ?P$\>Z/J_@W2?@[X6D^
M&7Q]\">#OC#X;\2WW]O:SXA[;4/'7[1?Q1\$?&>1O W_  19U+X36'B6+XA?
M$ZR\0_&/XH?$3PPVO>"?'T&AR_%WXT6-[^S[X.T;3O%/A_XD? ;QA! GB&PU
M'4?"'Q*^&8\#M\0[OQ1\&M9UF_UM(^-O[2D&F^+];N;'_@C5HW@3]F_XS:EX
M5\2?$6T_:*^(UIX?^#7QSU33K+P-XA\/>(+.Z^"6F:5\+_C1+!\4O$.EZUH-
MYXRL?$VK^'O&WAWPI/<M;?%V^U+00"WX@_;:_:D_9Q^$'[*C_M(>%/"2_$CX
M:^!?V??B+_P4]\6:186%W\+_ (7^!?B_J.K_  HUR_T?Q/X=\0"+PIXC\!>+
M8==^/GC7Q#_PBNL?!RR^$7P+^*FBCQ7HFM^-_A#_ ,)#Z3\&?VA?C#8_MM?&
M?X1_%_QSJ/CGP9XHU7X\>*/V6[[X66GPI\6_!75/"7PFM?@OHGCKX.>.-2\'
M>&[OXS_#']I3X#>+-1UNW\1>%_'>J:EX?^)5G\2+W5_"6J7^J>#M1^'?P[BO
MKS]M'XPZ%\7/!^E>!?\ @E5\5;'QWX/L;?Q]X,O?B%\7/&GAOQKX2\=>$KWP
M_IWA_P"+44'PFU2Q\5>%?'/ABWU*QMKS6M&NM/OO"5L^B#P]K&G7AO;;E_A7
M\1/VF_BOXC\0?$'X,3?\$C?B-\8-5\#Z'JT_Q"^'OQ ^)VM>+;_X4^,M1C'P
MTU+Q-?>'O!FK>*[KP/JLO@CQ99Z;=R>))?#/B/Q#X-ET_19["]\*:Q;68!I?
M#K]J#XW^*OA+_P $9_B9X@\6:;INJ_MV?&.QU_XU:'I.D^#[W0U\#?%G_@G=
M^VE^UGX7^#F@ZO!IM\K:'\,O'G@WX5>'M#\>Z!?6'BSQKI_P\MKO7?$%U;>+
MO%-EJGT/^RKXP^-.M_'3]KGP[\8/&H\6V.D^,-%U[X067@;Q'X$\9_ WPE\'
MM2\<?&?P)X0\/:%K^D?L]?!SXC:!\?K?_A5E[)^TU\+OB%\1?VCM*\$>(F\'
M:M\/?B9I&C>,]1\"^'?E=_$_Q[^"'P^\$7.O7/\ P2_\$_"KP5\0/%I^%5OX
MT^*OQUU:Q\(ZM\/M&^+OC+XQ>%O"'C'QEX<ED\$>(/AA\./"?QFNDT[0M$AT
M_P""/P_^%GC7P6_A+1O FD7EKX R+CX__&SX7ZGK-C\.?'O_  1L\!Q^/_&?
MQ'^(7BU=.^+7Q!T_7/&&L^"])^'?B7X_>,]8T#P?X<L9?%/CCPAX(UK2=8\=
M^*M2OI;]$\:?"S_A*YM*MGTJ3Q4 >4_$+]J_XX^+O^"13?MVZ5^T3XW^%GQ=
M'@.R\0_%?P5X5^'WP[\./\+/BIXE^)/@FQU'X*77AGXM^%O&.N?#SQ%\ _$J
MQ_"#Q+>^)9];;Q5X'N_B-KVN>"]1\=>*_AWXP^'6+^W]^TI^U/\ LM?%'PQH
M'@_XS?'70?#FM?!?XF_%6Z\5>.M&_9&U_P"$?P5UCP[^U?\ L^_!7P5\0?VE
M]4'PSTKQ>O[(>B^'/C=<>*_C5+X$\2W?QNT7X6:;-XALM?\ #.K>"_%7CSPC
M]W^$_"G[94<WB#QYX(^%7_!-G4;;XQ+I?BSQ-XI\,W_Q:\/WGQ(WZ3;GPQXA
M\3^(M-^&FOGQZT6F1V46GZOJOFN=-O87LI((M)C@U?LQ8?\ !0?5GN=3U?X9
M_L$:?X@EMCHPU/\ X37XX>+I9= MM1%_9V5W<77PC\)WTUM+,7OCI)N&LM.U
M)Q=1SW[QF20 M?MJGXJ6-S^SS?\ P@^,/QC\"^+O&/Q_^$WPGM_!OPSTCX,:
MUX4\9>$O$WQ/\"?$#XU>)?'T?Q5^&GC2[M!\/_V9_A3\;[C0]2\/^(-!CM[;
M7M?5-'\0^+KCP5<Z'^56I?MY?M6Z'XOUG0IOB!_PG&@_%CXJ>)-#\=0:=X6\
M(^&;?]AKX6Z?_P %F?#W_!/JQU6W\60^'-"U>3Q#??L]:]\0=5FOOB';>/\
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MU"^.BSWL^A7,<6EV$?BR&3P4 ?H=17P(?$7_  5"34+QQ\(/V"[C2?MT4]A
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M,M7U+Q5XRFT6[\0 'ZXT5^/7A_\ ;H_:DFE$?B.7_@C\$U?PW#XU\,R^'_\
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MNWNLV=IHMU?R64WVP _5>BORM^'O[4'[?7C<Z%I6G_"#_@F-XI\1>,/#^O\
MC?P7'X#_ ."EGQAUJ'Q)X$\)ZWIGA7Q;XBTK14_X)YW6KZSHWAKQ?KWAWPQJ
M'BO09-6\,P:CK-O'J5SI.HW&A:3XA2P_;#_;,OM)T_5K'X'_ /!.G4(/%R6_
MB#X:S?\ #T7Q1;V/COX?S68OKKQ9HU]8?L(>(;:_BT6&+4_[3DT>?5M%GCT#
M6+O3]9GMX;1[\ _5.BOSDG_:+_;<TF+5K3Q/^SQ^Q5H'BGPU%!K_ (B\(?\
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MG3_!NKW+Z*?#^FZ_+<?L-)8V5[JEMKVE2WEA?ZOI=_8OJVBKIEMX@CU2VEH
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M_P#K;10!X-^SGH'Q3T/X60+\9+_[1X_\1^./BWX^OK!=4@UO_A#-#^)'Q?\
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M?"_P!\?_ !=KOAS7-"^)?[2<W@G1OBIXAU+QUX@\ 2_LD^(Y=+M@#^N?Q?\
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M2>)-6"W'PQ\1^'O$]QXQN;P>R:W^RG^T1XU\4?MK_"OQ'H^H7?PL_:Y_:_\
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MOB]\)_VN]<_;M;P_XQ\=> OC4_\ P4+\=2?"WRK+PO\ $OX0V?Q[?_@GW?\
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M_C-X7\1>)/V]?V'+[3-3\.VFA> OA=^V;X\\3:?>^=_PDVK1-8_L_?#C28]
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M?\?M&^,=GJUMXN^&;WGB:'PEJ^LV?P^U_P 5:1-'_P )3X;O?!'BNWT#Q%:
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MGEZ=_:5](;JZM/,U..*PE.H?.GQ<\3?\%,/A!\4/V5?#>N?M)?\ !/7Q'/\
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MWU>]L(K?1[@W<H?XDZM9V,UWJ5GK=A<Z/#]I,&AZY;26WB)-7T-+K4_TRHH
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MG[0_Q^TAM&MU?0@=WB.+]F#61XEFDB_X25^/"OA-8'_L.,+=8OV;C]2\>?\
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MMC?V0F*-=0!X9O$&AV\B0W&L:7;S2-LCBGU&RADDDWVD9C1))U9I%?4+!60
MLK7UFI&ZZ@$@!^8O@/Q#^U;=_P#!0#]GY?VH?AW^SIX#@O/V2/VR+/P/-\#/
MBK\9/BS<WNK7GQ._8*UC7]"\0:CX]_9V^#OA[1(-&71KW^R+T:Y+KOCZUB;5
MK#P3H5KX>\11Z?\ JE7Y[?%N*TUO_@HQ^PQJVASV6J7?A_X$_MYVFM?8A87]
MQI?AZ[US]E72=5N+J<7YN=-M+?QMHOA_0;XP:?,QULPZ9=7^G2PS6.H_H30
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M&ZK^U5^S]X:^"'A[5?VDO$_PH_;*?X$77Q<\*_M6:/\ !GX5_L<?%[2/A/\
M"GPC\*_C;;V_Q3\<Z.GQK_:0\'^+?#'PC-C\3/BO'\ I#\$O#T?B#P7\8QHG
MG^H?\%??VCO!_P 7U\'>+O WA'4O#/PO_:*_;8TKXE)X2T'7[[Q+\6/@O:_!
MG]L'XI?L$>%OA)9^((/"%K<_$SQWXT_99^+/P%\0ZCI-[XA\*^*?B7\"K[1=
M%U]=6^*FBV.D>M6O_!1C]K<^+?%WPV\5:/\ !3P#\5-'T/P9HW@CP7XU^$HL
M6\??'NYB_9T\27?P-U?4H?VY;JR^$7C_ ,5VW[6_P5^'>E6OBK^U?!7A;Q)J
M>B^./ 7Q._:8@^()^&'P[]/U[]O3]I6W^'/Q?F'A?X=^$OB7'^T/^QQ\,/@5
MK.N^"+#X@?!?6_@S^UO^WCH7[&/@[]H&+Q)\(?VM_%DGQ7M-;TBXUSXL67PY
MFUK]G3QGX.O(+#P-XCM]8LS:^/-3 /'OB3_P4+_:D\'?L3?!?Q+\1M4\"_LS
M_M):)^TAK?[.O[1NH_%[2/AUH\/B*Z^%WP*^)OQL;Q-\/(?&7Q(\,_ 'X6:I
M\;O"7A'P#\6=(\-?M*_&7X*^&IOA[XA\5?#/PM\2?#7C?Q3\)OB6. B_X+ _
MM,_&>_D7]GGX+>%X;;XG>*_A_P".OV+=!^*&G:QX*N_VN/@U\&_&7@CP;^VK
M\//"/CAM6\7^'M!^*L_C?Q7I?PY^%7B+XH:#\$O"OAG5?&GAO6?$;:YX8T3Q
M%XP7LO&__!77QC\/M-_9ZG\=> /A9\2O"L'B+]H_PM^VGXF^%?A?XU>*_#&D
MP?#OXN_$S]FW]E7QM\+]33PUXD^&/PM\*?M5?'SX=QZCX?7]H?XJ#3M)TL>)
M_A_\)_%?QW\8^$?$/B?3.QC_ &_/VM+35?#_ ,*M?^(7[&DWQ.^+_A?P/\7/
M!'CKX<? 7]K'XJ_#KX=_#3Q9\"OCK\8O^$-T7PGX?\?65U^W9\0_%%]\$M7\
M,_ 75/V<?BMX!U'X[^#=!^+'Q3@^$W@:_P#AYX9^%OQ/ /+]=_X*E?'.Q_9;
M_9E^/NM?%7X*_!)OC'\-/^"AOQBLM4^/'PA\5>%=*\>^(O@)\6=*TW]F7]ER
MS\":AXV\.>,;+XK?$/X<>([_ .U^%/"FJ^(/BOXPO_AKXHUWP%X1U^SL-;LK
M?I[#_@I!^V!XO_:GN/AII>B_ SPY:^$OAIXS\=S? "?Q/X3T;XF_$[QQX,^)
MG[2/PFO/@[\/]:^)?C7POXS^*MOJWBCX.^#=%L?BI\./A'H'A_P?XS\9ZMH?
MC32Y=6\&7G@K7,32/^"I?[37QH_9U_;%_:9^!>K_ +/VD^$/V4O@5KWQDLH_
M&'[+O[3OBKX8>/I?"G['7P!_:LN;.S_: \3_ !E_9RUK0X/&]M\:+_1O"NF:
MW^SMIGCC0O"6BMXS\3>%&5(-"U?ZS_;&_; _:0_9/LOV4;'Q)!\#-=36O WC
MGXI?M<>/[;P5XCU7P]X=T3X.:O\  C3?%5[X*^$&E_'>?XW_  ^^%%_??%;5
M+OQ%^TEH/A_]KJT_9TU#1_AY9^//@[XOC^*>DZYH0!\.?#[_ (*D_%/XF_8_
M@W/^U3\*](U;Q1X6L?B'K/[8GASX(?!W3O@SX('C?X,?$W4/ WP3\!WVI?M>
M?%KP5X6^,.J?&_X5_$FQT/1?VHK/POK^D^&/@;\6?A_\0_"FF>)O%?P6^)?B
M_P#>C]F/XD^)/C+^SC\!?B[XPTR#1O%/Q1^#OPV^(7B#3+70?$'A2VL]6\8^
M$-(\0WL5OX4\637'BOPK 9]0=X?"_BFYN?$GAV-UT;7KFXU:QNYG^!/^&D_V
MN_"?[,?[=_Q(\8^(OV6?$7Q0_9]\=^//A=\'[?3/#][^SOX O?$>A1Z;<Z!K
M_CSQ!\:/VD?&?@MM4\5KX[\'C0?"FL^._AAX>?Q5I\FA>(_BAHUAXT77O ?S
MW\*O^"L_Q4\4?![6?$VK_#[P+KWCGPG^U%^RQ^S9);:%X7^+WPYOO'+_ !>_
M;"UO]F+XS^)K_P""WQ&M;WXD_ _Q'\)+;PKXSO?$?@C5];^+^E>$OB9X&\=>
M!K;X@?$_P7H^B_%;Q. ?OA17\]/@C_@I!^W=XAT#5/B5K/AW]D73_A;XETO_
M ()PW/P:O=+\-?'2[U/Q?K7_  40\:^#-#T7P[+K.O\ C;PWX>UW7?A?HWB:
M":]T#P8=5UWQ5<:_X9U.\T[P-IDPM]3^M?VG/V\OB]^S1\,/A1X]3X;>'/BY
MXOU3P4?&'CSX&^&M)\?^&/B[XCT32I)+'XE?$71M$>+QEI?P ^"7P2@DTWQK
MX]^*OQOUG4O#&H66H:3\*;6ZT3XN>,OA]HWC  _6&BOR7^!G_!1/Q!XW^/6B
M?L\>-+/X2ZGXAT#X]3_L<_$/Q9X#UOQ9IK^*/VB?#/[-7QA_:1\6^//AG\/M
M8T[Q++I?[/LEI\"_B1\*K*\\6_$"^\2:9\;? 7Q@^&SZEKI^%<7B;QQ^M% !
M1_G\^M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7C
MGCW]G;]G_P"*FN0>)_B?\#?@]\1O$EM9VNGV_B#QY\,?!'C#6X+"Q.HFRLH=
M6\1:'J.H16EF=8U<VMM'<+!;G5-1,4:F^N?-]CHH ^,A_P $Y/\ @GL+G1;T
M?L)?L:B\\-R3R^'+L?LO_! 7.@2W6I1ZS<R:+./ OF:6]QK$4>JSM9-"TVI1
MQW\A:[1)E9_P[?\ ^">9^U9_80_8U;[<(Q?;_P!E_P""$AO1#9WNGP"[>3P,
M[W(@L-2U&QA$[.(K._O+1 MO<S1/]H44 ?(4O_!/K]@N>&2VF_8E_9%EMYM?
MM?%<T$G[-?P7DAF\46+ZS)9^))8G\$M&^O6C^(_$+VVL,IU&W?7M9:&Y1M4O
M3.EQ_P $^?V"[M;9;K]B7]D6Z6SO]1U2T6X_9K^"\RVNIZO%HT&K:C;B3P2P
M@O\ 5(/#GA^'4;R+9<7L6AZ/'<R2II=BMO\ 7U% 'QM-_P $Z?\ @GW<S17%
MQ^PM^QS<7$%M<V<$\_[,7P1EFAL[RXL;NZM8I7\#,\=M<W6F:;<W$",(IY]/
ML9I4>6T@>/*?_@F9_P $X9-)AT"3]@#]B630;8W9M]$?]E+X"MI$'V^UL+&]
M\G3F\ &TB^UV6E:99W7EPJ;BUTZQMYC)%9VR1?;U% 'PZO\ P3'_ .";L=KI
M]E#_ ,$__P!BFVM=)L+K2=*AL_V6/@98II>DWVHW&KZAI6G?8O EN;'2]2U.
M[N[_ %+3K4Q6>H7-Y>2WD$[7=SYMN[_X)K_\$[+YKJ2Z_8._8WFEO=577;J8
M_LS?!A9Y]=C>XDAUV2=/!:S-KEO+=W,]KK&_^TK6XGEN+>ZBG<R'[7HH ^4M
M/_80_8BTF&ZM]+_8]_9>T^WOIFN+Z"S^ ?PKMX;Z0O=R 7L<?A55NXHGOKLV
M\%P)(+8SN;>.(A"O%S?\$R_^"<]SIT&CS_L(?L@3:);:Q8^(8="D_9S^$C:$
MNO:9I5IH6FZRVBGPE_9<FIZ?HEE%HUC>RVCSV>E27NGVSQ6FI:C#=?<-% 'Y
M7VOP%_9T_9D_X*$_LJVWP"_9R^ _P7O?BY^SU^V/HGC?Q1\+OA#X-\!^)?$U
MMX3\1_LJ>)-#T37O$/A'2]+NM9M/M9U+5Q;Z_#J#/>6;75KJNG3_ &FSU[]4
M*^#?C?H]U<_M]?L&:W%J6F6=KI/PZ_;/L;JRNH+FZU+5GUC0O@;);V^EQV\\
M"6 MCI4M]?:W?+=V4$-M'H@L_P"T/$.GWMC]Y4 %%%% !1110 4444 %%%%
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M;P9\6/ D>G7=A=6@ SX;?L\?\$RK[X.?LO7_ (X^,_Q)^,OP]^(]KX4^!?[
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M^O?&G]H?5/B5H\FF^,/&NJVVIX?^!O\ P2O^&^C>.=3^$_[0?Q=^%WB[X>?
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M[71=%^&O@?\ :=L/"W@;P_=)JGAVWTS]G+]GLZ]I&O76D?$RX^* !]!>)_\
M@F_^SQ\2-5\:Z[\1=>^/7Q%A^*5[/;?$SPYXZ^.GQ+UGP;\1?AE)>:_K>G_
M/QSX"O=9C\+ZY\%?#7BKQ5XF\3^%/!FI:*;_ ,)7/B3Q3X6T36=/^'WBSQ5X
M+UGZG^#7P4\&_ OPWJOAGP9?>/-6@UWQ+J'B[7-:^)7Q,^('Q:\7ZQKVHV>G
M:9)=ZCXQ^)?B3Q3XEN(;;2-&T?2;"Q.IK865AIEND%LLSW4]QN_##PCXE\">
M!=!\*>+_ (H^,?C1XCTE+Y-2^)OQ TGX=:'XP\5-=:G>WUM/K>E?"7P-\-?A
MY:3:=9W-OHUN/#7@?0()[+3K:YO8+K59KZ_N^^H **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\]_V_P#QEXB^'"?LN_$?
MPCX!?XK>+OA]\:OC3XR\'_"^#5SX?O/B/XNT'_@GG^W#>>'O =IK[6VI6^AR
M>+KY1H']K7/A_P 4_86OTEM?#6JWPMHT_0BOD;]JWX3^ ?C7J7[-WP_^*%EH
MOB'P'K/QK\:V/B;P!XCT[3]6T#XE:1K?[(_[47AC4/!VK6&H'$MJ++7;GQ.&
MM$DO(KCPU!+'Y4:37, !^5WC7_@M?\ ?"_BJVTSQC\&_AKK7Q.M_@K\?_B/\
M1-!T[XBFW^)7@[5_V<]5^(/C/]FWX5ZI\.OBK\&OAO\ &VV\5_&'4?A)\:=<
M@T#Q;\/O"?B']FWQ_P"'_!VD>+?#-UXD^,WPWN-?ZZ3]MOX)_&+]GK]K[6H_
MV'/@OXIGTW]J']DG]F'XK_!CXEZOX)F\,?$+]I3]H+XB?L[_  ?\2>%OVD[_
M $KX1_$"TL->_9H^/?Q3N_!_CW6+/P?\;K;7-(^&-EX[^'&I:^GB'2='TO\
M4AOV/OV:7^$NM? Q_A'X<?X7>)KO2-2\5^&I)M8>7Q?J^B^,U^(UOKOC'Q"^
MIMXG\6>(M0\??:?&?B7Q#XBUK4];\8>)]3US6O%E_K6H:]K4]_H^)_V4OV=/
M%VA_%;P]JWPA\&VME\<?&7A7XC_%F\\,Z<?!7B/QQ\2/ MUX4O\ P/\ $;5O
M%W@R30/%:?$'P5J?@7P;J_A#QO8ZU9^*/#&L^&=%UC0]5L-3L8;M0#\;+_\
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M*QD+X"! #N+EOE"A<[L\8SGBOY^KS]A[]H'QS\(O^":_Q'_93L?V<#K'P/\
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M[5W_ .$B_;\_9GTV5WN542Q6Z:#IWBR.1K"193>-<3VL;6YM9;![Z::XM;(
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M_P $Y+==4>2WB<V=G.G[<UR(;N&Z%U!.=1CLK(0+97-O>W+W5U;:< ??]%?
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M^TVP%LES.=1L;WQ+9VYU?,=U86EAI>IZIIL^I/I2W.O6&EW>I:MHDMC^T/\
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M*C_'OQ%XIE^'/CC]JCX+?LO_  ;L_A]X4NK7_@H--\,O#7B'X:^(KV?XB_\
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M67P7@_8K^&&KV?PTT:^^*_A#5_C_ .!/#%SJDEG87OQ<^(3:=XJLO!%FWCP
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M"M._9W^'G[07Q$\7_!_Q' OP&_8M\!_M@7G@35?$VAZ3\1=3E\8ZU\4-"O\
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ME\+3Q?#^S\/_  = /H_P?_P5<_X)O6;:QH7@[XG7?AZ1+CQ+XUUG1K?]F_\
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M9HO['^K_ !)M? 5O>QZ#;>.(/V;-$A^%6EZA)!<:98Z5>ZGK0T>7Q;=CQ#$
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MHVEKJ^F:=X0N_$D^I0^(].L8=?\ #^DV8E\3RV&IV&G:GH.E^)OMN@6?044
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M8IQX>^"/PIT,307DVH0S?V3X$T&P\V&_N8XKB^BD^S[X[R>**:Y0B:6-'=E
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MXJTG_@EK_P $S-"DN)M%_P"">'[#>ESW<#VMS<67[)OP$@N)[1YH+@V4DZ^
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M+S39K>X\.7WB;Q!>:+)9W&M:E)<_G-\ _A'H'AW_ (9K^"FC?MRZ/\7O%/P
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M]^+GQ*T76O$7A7]@30?$_P 9]2U6[^,<?C71?BM/\-/A!\7]:\%+JES+\,O
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M'6;W3-'O]3U&_P#A_P#!/PQXW^(>IW%A!;ZS\8?&7Q)UW2H+71M5L+2'[CH
M**** (Y?NC_KI%_Z-3V/^>XZC\O/V'_AGX3_ &I_^".?['?PK^,-IK&H>"/C
M7^P+^SKX8^)&D:-XBU;PM?:_X7\2?!+P9:^)/#S>(?".HZ9J":1XDTM[G1=8
M?1;S3['6_#^H7UE;VEAI&HKIT'ZB2*'1D8$JXVG#%3AB%)#*0RD Y#*0RGE2
M" 1\ ?\ !)RY^V_\$M_^"<%ZTQN9[S]A+]DF[OKII1/-=:G<_ /P!/JUW=7
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MRZ?IM_\ 8[DW4>M-J]UIMHWA@:)XN^]$!"(",$*H(R#@@#(R  <>H !]!3J
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M'PWXW^"/ASXFGQGXJL/AQ\3O#_PHM=/_ &:/%2:+JEC\4/%]U==[^U'\:?\
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M-'TL?9Y[A[S6=4_:=^%]K8V4:P1RM$90TLLEQ(%@@AAE:>2.,M(GV#7Y^?\
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M9W%XRPNMI!<_#7Q-#-<E+G_1V$$;M*5N/W+!,2_NRU?1"]/Q;OGJ30 M%%%
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MM/&/PZ\1^';C5HM.U.XM--U"33H=1>\2RU"[M;&[:$07=Q#!))*OORDD'/\
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M1Z&G4U?NK_NC^7T'\A]*=0 4444 %%%% !1110 4444 %%%% !1110 4444
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M=RCJR] >HZ'H?H>QK\6_C5\!OV6_A_XL^(Z>/_VC?^"E[2? SX%:3\=OBZ?
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M (B^'WPRD\(Z]XUT/XHW5GH7[4%Y;>)?#?B[PCX+\7ZG9_$7P%=>([K6-?\
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M/^"F7_!22>*QL;N+RL:3IU[^UC=Z1I=Q9-MN]*N+'3X)=*U&*#4+ P7<22@
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MFTW0/8?''[/_ .SKX9^)_P )_"7ASXJ?\%2_'UQ\9OC#X<^"OA#5O!?_  5
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M7^*)O@R_C#0+/P!:^'?'/@3Q'X^U/4;70-= /Z;-Z9QO7/IN&?YT!T/ 92<
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MNY[F75?@)J%YX<BTC4=<\3P>%M+\ 77@[1/#&A:W8>%M%TNS\+_#WX1Z-\/
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MP]H6K+\5M&^$-YX3\5:SJ[_&R#QQ8:#X)_1*B@#\IO@C_P $Y?$7P,\"^//
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M'.C2_M/^'_@=#X0^-OANT^( \-:OXOU?_A=OABS\)_%?7?C'XE^,7ZS44 ?
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M^AE% 'Q%\-_V*]%\ _#K]A_X<3?$#Q!KVF?L)^+IO$'PYO[S3X'U3Q+H^F?
M/XV_LU^!O#/B74=5O]>U46_A7X7?&BXM+S6[34U\0>*=7\*Z7<ZM?QZ1JWB+
M0=3R_P!I/]A'P?\ M(W/C/Q!K?C;Q1X>\?:MXU_9;\>?#WQMID%E/+\*=:_9
M&^(=[\5?A2=%\/F:RT/Q4ECX\\2>/_$,A\;6NM[;SQQ=H!)::'X=MM-^\:*
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M;7\[_P!DO]L/3?VOOVE?B3X U3]F/PGX;^+/[(?A_P 3_#/]IWXF3>)O#'C
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MBT#2YV\::EI3^%+?4]"OO$?B;XG^)O[?]Y>?!#4_B3KGP)^&_C#Q#X0\:_\
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M'^+G[5WPM_9L_::\+>&/ 7ASX"_M >#]=^)K>&M?NO$"_%SPQ\./%::GK?P
MU.2YTZ6_\&W_ (O\1>#I?"MS\7?!J#^R/ 'B?4M9T?P;X\^)>D:3:>)=2^)?
MAY^W)_P0Z\0>.Y=3\&_MK?L^6OC;3/&NM?M"0'Q-^T;XA\-GPWXZN-*T3P;X
MU\6:%:?$#Q;I>E^%]9\1:-I\^B_$;P_HL.G2>*K?7OB?<>,-%U&Z\<_$Z]UO
M6^$W[77_  12\,>#M:\(_"3]O'X'> O!=QXC^(&K0>#=%_;B\8?#S3=+U7XG
M?$'P[\2_&#_#?PI>?%W0I-#\//\ $"XM[/0+#X=Z?:>$O <MU\0/A1X(MO#6
MBWGQ*\%S 'VQ^T%\6OVB/AK\:/@#HWP]\.?![QA\,?B9XZ\)?#W7O!NJ:[XB
MT?XZZW-K=UXEO_B1X[\$ZC=&R^&^@^$_V??AKH:_%OQ!IOB >(M8^+&F6/B3
MP!X;?P9XX7P!:_$CYB\$?M7_ +9WCWPY^W#H^K_#SX=? 3XR_ /QC<Z_\,O
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M8:M-XE33-6O3+H.K$:=I-W>Z@8;-KD6IMY;>64 ^_**^#_\ AZ)_P3GV0/\
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M4\.6UK_9S:K<^'WU!KN:Z2U2PM_$EE>^%[V]>9;:P\5V-]X7O9;?7[*ZTZ(
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M7[4/P8T&YM+>![2*6[N;'7O&6FWT%BLU]9P?;I+9;-KBXC@6=ICL !^A=%?
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MGB'4%N&C-GHD<NJW'EV$4DZ 'UI17AWA?]IW]FSQQIEWK7@O]H3X'^+]&T^
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M@[4=;TK2M7\(P^(/#VI:GH,NIP:S$WB6UGUC2H+?^PKN[_3*@ HHHH ****
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MUK?B6STN[^'7AZW\91V.IZOK7BK2_"\/C;7_ !)8:9I6NZWX:T6V33!;65F
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MXG.ME;^-V\6^![KX1:=9Z[H.A>)O!_@CQYX6\3>+-"^*O@;QGI7_  C,7A@
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M-W>V_@#4W\.77PUT?]L6.Z\1^#K6S\2V5]?_  PU.SN?&7A==?O7\&^41_\
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MJM_J?T-\,?VX-0^-.H^'O ?PW^#^GWWQ:\2#]I[Q(FB^)/'EQI'PY\-?#/\
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M_P"$*\V&+4O#UG::#?QQNJ7FC6MMI=P)+&"*!7V7_!/K]@G33=G3OV(OV0[
MW\@FOC9?LU_!FU-[,+B[NQ+=F#P7&;F07>H7]T'FWM]HO;N;/F7,S/\ 7E%
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MNZRM[^T-?(7[3WPTOOB%\2_V%M6LI])B3X5_M>77Q*OH=6MK^Z6[L;;]DO\
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MA?L/17$@AD69K6+XT_\ !1.2R1[DVB0SHDT^H-';QWUQ+;/+/)-:V:W,4NH
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MB_>SU'P)X1MK;4]8L=+T'4O$^GPQ:]JGU=_P3Z_X*H?MZ?MA?'73/AK\<_\
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M/#FC^*]6\>>$O#G@;QGJWAOPEX_?P]J-E#^>O_!:OPHWAW_@@O\ $+P%?_\
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MV;],FUFU&E2PWD6J^'H+R37M%N_,%I8ZQIMC>:BKZ=!=HWVS0 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MNA^P?^VU,\UM'"RQW4S6<-U T%T)(%MYKBY5!<V]LZ?7-?#7[6NO3Z+\=?\
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MM2EL?BE#;V:2P/:W%C)JX>>"YCLXKH ^[**** "BBB@ HHHH **** *M[/\
M9;2XNO)GN/LT3W!M[6/S;J<0#S3!;0X)FN)0ACAB&TRRLL:NA8.OP1_P2A2U
MB_X)C?\ !/RWL+R/4+"T_8Z_9VLK#4(]).@_;["Q^%?ABSLKV;0V'F:/=W=K
M!%<7VEW$EU=V-Y)/;7E]J%U%-?7'W^Q( P<?,@Z9X+ $=NHXSVZ\XQ7YY_\
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M^ OAF[CC:^=(3J$UKJ\T.DHA-Y)JKV2:>DE^UM&WTW0 4444 %%%% !1110
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M+X?8X]&TZ.UQJES]LU,?9UMA%C4;LFZOOD_TNY_?W'F2_-0!\KZU_P %%O\
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M[5?P):/7C>:@^DV@T60>/"FJ_:M5BETRW^P&X\_48I+&/==1O$M:[_X*>?\
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M\;_$7@7XF0Z7;Z-\0?'-[X+?5_A_J'CFQTJ?QKX[@^&'2_LJ?M4?LX_M8?M
M?%[]G;P5^Q+^R;INK_ G]MG]JSX*?%_0KKQ#X,E^(OA[P9^S7;VFE>&?VK+'
MX;O^S_9Z/KD7Q"^(7Q@M/ ]WX;?Q_IOB+P>GQ$U77-'\0^/)$^(NA>&@#]'+
M[_@HC_P3^TN=+74_VY_V.M.N9+>2[CM[[]IOX*VD\EK$EV\MRD-QXVCD:WB2
MPOGDF53&B65VS,!;S%)XOV^?V!_M'FQ?MJ?LA&ZO-/MKSS4_:.^#)N+G2AJG
M]E6=T''C(R3:<-:U'^S;:8%K4:I?_8XF%W=>7)\6?LI?&KP)^U/X-O\ XX_L
M]?L$_LZI^R[XC^/&K? C0?B)<>*_ <?Q#^)OP_\  'Q%T;X2_$+XQ:'\.?AA
M\%/B'\.M:^'GA_XO_#P2^$[&Y^/GD^*_AA\,M.^*<^H>&+O3_#W@^O!?@9^U
M1^R7\9? O[''QG3_ ()S_ ;PG^S5^WY^T9XK_9X^!7B2Z\)?#^\^*:^(O EC
M\6];^#?CKXE_"%_@SI?A?1O!/CO0_P!GOQUKFA:GX8^+?CF^\$Z=<_"Z\M+3
M6X?%&O2>  #]:/\ AN/]BG^VG\-_\-@?LM_\)%'<:O:2:!_PT#\)O[:2ZT"3
M0XM=MGTK_A+?MRW&B2^)_#4>KPM )--D\0Z&EXL+:M8"XNZM^VA^QWH$D<6N
M_M8?LTZ++-"MQ#'JWQV^%VG22V[V\%XD\:7GBF%GA>TNK6Z6504:WN8)PQBF
MC9ORF\+?M%_ +XN_$7]HW]D2]_X)Q?LR6/[07PB^(WQ6M_@7\"?B3JWPG@\(
M?M/? 3P1=_$7X:>"_P!H_P !^*K3X+>)M$TK2=6^->B^(?A)\7/ &D>'_&_C
M']G>RUK6/$7C;^T"T_AG4?E'Q)^WK^RUX \17$GB;_@E/^QQHWP6\%_\%@M1
M_P""6?C_ .*L'C3X+1+\/_'"7?PV\8:#^T0WA?4/V<=(TZ[\/&P\5:CXL\;:
M)'XPL->^'>M^ M1_M;6+PQ2ZUI@!_1Q_PT;^SU]H@M/^%[_!K[5=6NHWUM;?
M\+0\$?:+BRT>.PEU>\@A_MSS);72XM5TN34;B-6BL8]2L'N7B6\MS)2_X:?_
M &:A'!*?VA_@:(KF:*WMI?\ A;7@'R[BXG$)@@@?_A(-LLTPN(#%%&6>03PE
M%82)N_$C1OVH?^";>D?\$_/A?^V[XB_8%_9@\*^ ];^/WA+]G^72M"^%'PWU
M#X7:1!:?'67X%^,/CI\-_BA<_!KPY#XY_9P\'> M-\7_ !K\(_$ZS\!>&D\2
M_"[1%L]0T7P/JESJ]EX?^A-*\)?L,W_[8_Q4_8S_ &:O^";O['/B;QE^SI\&
M? WQ"_:(\:ZG\*_A#\+/!OP_D^*OA#Q'IG[/'PDT&3PW\&/'FK^)O&7BW2/A
MU9/XCL]6T[P;X9\ _"!=$UK0=8\>:M9#X>V@!^H5A^T3^S]JNHZ5I&E_'3X.
M:EJVO:@NDZ'I=A\3O!5YJ.LZJ]Y=Z<NF:596^MR7.HZ@VH6%]8K96<4UR;RS
MN[41F>WF1-^Y^+WPFLIWM;SXH?#NTNDV;[:Y\:^&H)T\Q$DCWPRZFDB^9&Z2
M)E1N1T9<JP)_"3XS>(?AAX-_:!_9Y_9H\8?\$3?V0]5\7?M3^'/VA=6_9[@\
M5:Q^S[/:2>(OV;_@K\,?CUXA\+_$^YTK]GWQGX4^'%WXE\::C)X'\'WOAWQ3
M\1/M.N_#.7Q[J%IIOAR#3]0M?UQ@_85_8C&GW%C_ ,,:_LIQ66HZ;=Z7J.GQ
M?L]_"4V%WINIV(T[4]+N8#X-BCN]-OM/_P")?=VMQ;B"]L0+>XMS"?) !Z9<
M_M$?L_V<TMM=_'3X.VMQ I>:WN?B;X*@FA0?9\M+%+K:R1J/M=KEG4 ?:;?)
M_?1[L%/VLOV5Y8;>YC_:7_9_DM[LV@M)T^,OPZ>&Z.H7]KI=@+>5?$928WNI
MWUEIUIY;-]IO[RUM(=]Q<0QOCW7[%?['%\Q:^_9,_9FO&;3;;1BUU\!_A9<,
M='LK+7],L]))F\*N3IMIIWBOQ1I]M8G_ $6"R\2:_:11)!K&HQW-ZV_9 _9+
MLIWNK/\ 9=_9UM+J47"R7-M\$_AI!/(MW?7>IW2O-%X921Q<ZE?WVH7 9B)K
MZ]N[N3=<7$TC@'PG^U#^UK^S7J?[3'_!-%=+_:#^!>M^'9OV@_C[XBN]5TKX
MI_#_ %NPT\^%OV'?VFC<:QJ5W8^+H5T'0M'T;4]=O=1\77\6I>'=-OX=)\.:
MC;VFM^+?#6JZ=]O7?[:7['.FR_9=0_:R_9GL+E!?;K>\^._PMM9U_LK7M1\*
MZGF*;Q5&X_L[Q/H^K^'+_P"4"SU[2M2T>X\O4+&YMXFR_L4_L:S-$\W[)/[,
MDKP6FG6$#R_ ;X5R-#8Z/:SV6D643-X4)CM-+LKJYM-.MD*PV-K<SV]LD44T
MB-<7]CS]DN.QL-,@_9@_9YM=.TRUM[#3K"V^"WPXM[.QTZUTWPUH]MI]G:P^
M&XX+:RM])\%^#=,M[6*-8+:R\(^%K>".-/#NC"Q -]?VFOV;GG-JG[0?P0>Y
M#6B&W7XK^ VG#ZAK<_AJP4PC7S(&O?$=M<^'[1=N;G6[>?2H0]_%) M2Q_:I
M_9@U.^32]-_:0^ NH:E)8MJ<>G6/Q@^'MW?/IJZ9H&MMJ"6D'B*2X:Q71O%?
MA;5FNUC, TSQ+H%^9!:ZSITMSRUM^P[^Q59+*EG^R!^RY:). )TMOV?_ (3P
M+,!I/C'00)5B\)() -#^(GQ T8!P<:3XZ\8Z=_QY^)M;AOHK[]AC]BK5-2L]
M7U/]D+]E[4=2TZ\?4+"^OOV?_A-=7EGJ#Z]XD\5&_M;J?PD\T%\/$_C+QAXC
M6\B=;E==\6^*-6$OV_Q#J]Q=@'K%E\;_ (+ZEJ,FD:=\7OA??ZM%97.IRZ79
M>/\ PI=:C'IMFFL27>H264&K27*65K'X=\0/<W;1""!-#UAI9%73+TP6G^,7
MPCBU&'1Y/BG\.8]6N3JZV^EOXW\,IJ,[>']7_P"$?UY8;)M3%S*=$UXC1-7"
M1,=-U?\ XEM[Y-Y^YKX:_:._9I_81_9=_9U^.G[0&E_\$]?V<O&H^#'P[\:?
M&V;P!\.?V;O@]:^+/&^K?#;1[CQW9V&BBU\%'/B*YU7PYI]UIVJO;W=WI6I6
M=GK=K%+?Z9:;?R*^#W[2?[ /CW]GO]ACX\>)O^"4G[#VOZ[^UA^U1\*/V;--
M\5? KP'\"/C+\!_@O:^,_%WPA\$^ /$7BOXS^'_@Y<>(?!GC;2]&U7X3>"-!
M^!WC?X>?#_XDP_$OP/\ \(OK&G> ?AMX#?XF:" ?TLZ;\8_A%K,:2Z/\5/AQ
MJT4OV\1R:;XX\,7T<ATK5M#T#5 CVNJ2J_\ 9NN^*/#6BW^TG['JWB+0].N/
M+O-6L(;B:]^+7PJTVRM-1U'XF?#ZPT^_>".PO[WQGX<M;*]>ZBTJ>V2TNI]2
MC@N7N(->T.:!89',L6LZ5)&&34;-IOPH_;'^)?\ P3__ &8/VHOA%^RYJ_\
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M\6_"'P;XB\,?L_:QXTMO@+\6-"T6[B\3>#O NF^,@#]?_P!D[QCIGCKXS_\
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M7BN&&]35?AX/C7X!\3>+/!_[1'BO3/#GP^\;^*/C+X?^%GA#QWX\U>;PA%>
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MTBVUNV_(_P#:R^'_ (U^*WQCTCQI\!OA+\1- _9FUCQ7_P $]_A+X\\!Z_\
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MQ^PU^V%^T!^TI\4/CI\:?V8_V*OB2/BC^Q!JG["/CGPAK7[:'[1.@_"_Q/\
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M672M:T7Y\\*?\$__ -J'X;:W\"H_ '['?['5O\&_V8/C+\4OC[^SC^S;J?\
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MB]L[01M=W5O:B9_*B-S-';B678\GEQF9DWR>7&[E%RP1&;&U20 ?#UW\0/\
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M:MH?PN\.W/AW3M$MA\1O'#Z7_6!)-%$N^618DW*N^4^6@9W6-%+/M4,\C*B
MD%W957+, 88K^QGN)K2"\MI[JWAMKBXMH9XY;BWM[SSOL<\\*,TD,-W]FN/L
MLLBK'<>1-Y+/Y3[0#XO_ &.;7XRS^(?VL/%'QV\!>!?AQX]\5?M >&[F;PW\
M.OB"GQ2\+'2]*_9D_9YT;2]5L?&=UX0^'WB.YFO[:S4:MHOBKP+X>U#PWKT&
MKZ3HMSXR\%P>%_B'XO\ MNO(_AM?^'[[Q=\>TT34=-O[W3_BYIEAXHBL-1EO
MIM+\01_!'X-3C3M5A>U@BTO4ET&XT*\.G6T]_%]@O;&_ENHKR^NM/L?7* "B
MBB@ HHHH **** "BBB@ HHHH _/7_@I8GP@_X4%X<O/VA;=-3^ _A[XM>$O'
M7Q:\.W&E^)=:LO$GA7X9:/XI^)=O876F^'8]DUQI?B7PAX?\5:!<:Y?:3I>F
M^*O#N@ZI9ZBGB6R\/VUU\J^/K/X1_LT>(?@S\$[G]C?P%X6\&_M%_#5_#'[.
M%SH?QH^(@^'FH_MCWO\ :7B.V_97\=R>#O!GB.3P!X:\0^&9]9^(.A?'CP]H
M/C+2)O"OP^^+^HZAX+TO4?#'@W2/'OTC_P %1O >I_%/X >!OAGHGAG3/'&K
M>/OC_P#"WPLG@76?&6A_#S2_&WA_49-<_P"%A>&9?'.J6.L:IX6U+4?AE'XT
M/AC6/".A:UXDM?%T6@'[+9Z =>UG2_-?B-\ ?BW\9_"NH^'_ (I?LD^'/B7J
MVJ?![P+\*+SXF>-?VK[GX?\ Q+TA/!7B+P)\0+7Q/\,-4\ ?#_QY?_"'Q@GQ
M4\-Q_%]/&GA+Q>GC6^^*'PU^">K:IXGEA\"^"]0^&P!\G?MT_ #]EJ__ &+/
M^"N>IZ?^S=9_#?XX_LK_ ++_ .TA?^&OB';:UXGN;O5[[5?V3O\ A=?@'XP_
M#SQ2=6M=6C>QUB1_!-S>:E:V.M:1XH\ ^._"]L;WP5J<5YXEZKXZ:E_P39^!
M?B3XQ_ GQ7^Q%X2\;W'[,W[*_@G]JOXC>'M L?AQX>MC\*;]O'4>H^,OA]X>
M^+_C;X<1^-OA?\--4^!GA_0OBY\2M!N+GPG\/-9^*?PTT3Q!)<0ZI\79_A_U
MOQ\^#?[=WQ@_9X_;C^$-M^R[\,X/'W[;WP>^-7PKU[X@ZK^UI9W&B>!M&\1?
M 'Q1\%?A/:VWA^V^",$]Y<:>#H^K^-+:S^R:;_PDGC+QUXKTC4+K3X-%\!6W
M%?MU?L?_ +7'[8/A;5M,UK]G;P5JUK8MXZU'P/'/^UAX7\(?$'P3=>+?@+\1
M?V;]8\)?#WQA;?LM^+(?"WPR\<>&M=LOB1X^\&7VIZI:?$#Q#K-U\/\ QM/>
M_"V[\4>%;\ ]AT[X9?L6Z7XW^%WP#U#]BKP,/%'QH/CY/@9IVF>*M+\;^"=4
M^&'A'X0S^)_''CW7=1GU!?$_PO\ #/A,>)_#GPVUBQ3P'J$^E^/OVAO"#^$Q
MK6G_ !,^)WB7PWI_&K]BW]DE/V1?VF?BEHO[+-A\)/'^C_"/]H'48&O_ +?H
MOC'1/&?PS\-_%#1]#\::5K%EX@NH&V:Q%=>./A?XVAEBN'TN[\$>.-/32-5T
M[15T?G]:^&O_  4!UKQW\,OC%IO[.GPL\&_&/X:^)_$T/AO4-)_:4\ KX+7X
M6?$JT\'>%_C1\./'<UM^RK'K/C"S^)FN_#SX;?'_ %+6?#_AOP;XNMO%'@VQ
M\'Z)XH\*Z#X4ET?XP]A\68_^"G?Q2^#_ ,=?A#J7[./P-A@^+WP#^(?PM\/Z
M^O[8-O?2^$/%.N>#-5\%:7XOU%;;]C[PG]HF\67/C.P\2>*-*M]/UC2O!MO\
M/?%S^&QXAFU[PGX6U$ ZW]GO]@+]B[XH_LO?L]:]X_\ V4O@U<:WXJ^"OP2\
M5>)XW\*:,MS<ZX_PH@TZ:TU+4=!NY8-6L+;2?%?B3PNVG+J6I^'KCPYJE_H2
M+>:!<_9Y/KVV_9+^ =M:"R;P7?:A;_8X=.9=<\=?$3Q%)+8VT&B6]I:SSZ]X
MMU&XN(;./P]IHLTGED%HSZM);>5+X@UZ34OF;X<:S^WU\*/AK\+OAMH'[)'[
M/VH:+\/_ (;^%/"5M&?VO=;M[IK/P/X'CTB+3+BY?]FN.VT_6M2O;71=/T@6
M5GK^A*]CK4NKZOI-G=Z7=1]2/BY_P4>?5)[(?L6_LW16,$5]'#JTW[;WB46.
MHW5K;>(WANHTB_9(EU:RTK4+O1="MM+\_1I=2EM_&]M>ZS:>'Y/"6K:?JH!T
M&O\ _!-S]AKQ3J]EK_B+]FOX=ZSK>G---9:OJ%OJ]SJ4%W<VDUE<:A]M?5C<
M2:G-;2^7)J<COJ+&"TD-V9;*R>WCU#_@FE^P+JD307W[)/P.FBDC>*5#X(TZ
M/SU*OY3W#0"%KB>RE,%[I=U<&6YTG4M-T/5-,EM-0\/Z'<Z?0B^*'_!1=KG4
M(9_V1OV9X/)T/46TV4?MD>,)M*O/%9OH;;1K*ZU(?LKIJ]AX1-M=6FH:SXD3
MPG>Z_;6T'BF+3O!&HWV@>%K/XD\?I?Q7_P""JUU%9W&J_L8_L::1YLJ1W.G6
MW[=/Q-UC4(8+B'3[F&ZEF/[%NE:=#<65S<W&BZKIEK=:K&EO:ZMXHTO5M4ET
MO1/!_C4 [J#_ ()E_P#!/JVBNK>+]CG]GDVEY=V=[+93?#+PY=6$4VGI=PV4
M=CI]U:36.FV5M;W]]91:;86]MIRZ;>WNEFU.GW<]N].[_P""7?\ P3SO_LJ7
MO['?P%NK6QGTVYL]-G\!Z;+H\$^D>2MA(NBN#I)*112VMR#9%=0LM2UZQOUN
M;/Q'KL&H\HOQB_X*C)J6BP']B#]E:[L+RXM(M>NG_;I\7:6FA17 AOY[K3'C
M_9%UR[\30V5K<MH$RSZ5X9N9=?TN_P!1M;:?0[JP=YE^+/\ P5'DTBS9OV,?
MV1K773<2+J</_#</Q!O=+@MH+K4+4R:1-_PQW87&J/?6VE2ZO9#4%\/^5_PD
M/@K1;Q(9+WQSJWPY .YT#_@FI^P#X5M[VU\-?L>_L^:#!J<MG<:LFD?#/P[8
M'6+S3A,=.U+6GMK2.36-7T^:5+NPUC4VNM3LKVSTR_MKN*]TC2KBSS;C_@EY
M_P $Z[V>2XO_ -BO]FW4WEO1J135?A1X5U6"/4%6*-+ZVM=0L+FTM+N.&STB
MUCGM8(9(['PSX.L(V6S\&>%(='MP?$[_ (*$3:8+F7]DO]G:TU :XVG36)_:
MZ\3W<@T.;4+>QM?$UF8_V:(;.\>TM+U=<U/PY=:EI-R;;1]9TO3M6N[Z;1)=
M3X.7XH_\%6;N*Q&G_L@_L7:5/?VNH37K:Y^VM\4;N'PU>6LWARXLM.":/^R!
M+)XKBU33)/$EG'JD+>%VL_%"P6-SI0\/:1!XI\7@'9W7_!+S_@G+?-*;W]AO
M]E:\6:TUFP>*[^!_@"YMQI_B._.I^(M/BMIM$>WAT_Q!J$E[=Z[8PQ1VFL3:
MOX@?4H;G_A(M=_M'Y?\ B'^S'^Q-\+_VF_A'\#/AY_P3.^ _C?QK\0_A'\:/
MCC8^/K+PU\,/!4?A33?A!XV^ 7@SQ5:V&J:KHLNK2>.=9NOB_P"%-4T.YL+O
M37FO-.OKG4=;TQKW4M;B]?F^)O\ P5R@TBZN&_9#_84N=96W26WTW2OVW?C)
M=PY^QZBSK'=:M^Q?X=2]OGO8H5_L^X.BZ=#&FD1CQ)=?\)/K=W\-/FSXA?"S
M_@I[\:_B/HWQNU+X!? SX$?$_P +_!'XL? ;P7K7PG_X*!W-KKNF>$?C9X\^
M&OC/QS+KU_XZ_P""87QPTG3]0M;SX(?#*#PUKWA#39=3LK,>)=>N-/FUC6]%
M\-^ @#QC]G=_^"9/[67C2>P^&?\ P3S_ &?+/P[K/PM_9"^(JZE\9;3X?^!_
M$][<_&WXE?M'^ ;KP#X8\"-HGBS0[GXD_ ;Q%^RCX]MM?@\-^,X[+QMJ/PS\
M)_\ "O\ Q#XB\,_#KX<>*+6+P,/^"9WQVG^&7P?\+?\ !/O]G[6_$/C_ .,/
MQQ^"7@3X41:;;Z'!\+W_ &=;KQS+\7K']I3P;<?#G1-?_9TM=,\):5X?NT^'
M=]X%\76_BZ\^)_PB\-6]O>^&=0L_$^B=5\,?V2_VY/@KK[WWP'_92^ ?P'\,
M-\//V;OAS%X)\&?\%)/$/BK0]3\&?LR_$OXG?&#0= \2ZG\2/^"6OB_Q^NO_
M !6\3?M#_$ZR^.7Q*@\<^*/B3XV>QU/6M(\;^&/%ESI/CS7KE[^Q9^V-K/Q/
M\&_M2:I^SC^SS8?M>_#OX/Q?"CP'^T5H_P"V]K&I_&#0=(G3XAQ:^VIWVK?\
M$X;#P5\1)M7\.>-['1XM!^-^E?&7PIIFL^&],A\,P>$]>&K?'S70#S[7/#/_
M  3U^%?QI7X<>,_^"3?[-/@KXE1:W^R5X8UF&33_ (+W?CO6X/VR_P!KSXZ_
MLH?#K6_!,$GA".3XE:/8'X">-_C_ .-DN]>TG7['X2>)_P#A)K[0I?$FI?$C
M2]$Y[QDO_!,_P[XBF_X2#_@E]^Q3:27_ ,6OV[?@]K_Q"^)U]\#O DNF6?[&
M/A;QSXJ\9>,/%OC+XA> +34+?PWX]\%>'-/UJSO1K.HV'@Z6]TO5O%VKZ9X>
M\'6/C*W]2\<_LI_\%#/&/BSQ'\0+O]G7]GVZ^)VJ^&?@AH6G?%B3_@HQXZO_
M !OX-\3?LV?%K]H/XL_"SXN_#U-9_P"";-SH>G?$B/Q-^T/\2]-\1>$+S3=+
M^ _C+X1Z[IWPJU+X8>&_AEJFO_!WP^ME^QU^V7HGC'P-\1S^R3^S?XK\5^"O
MVB?VEOVD+'PCK_[<.IWW@'6?%G[6>G>,M"^*VE^-O$&I?\$_I=9N?"6C_P#"
M5:!>?#;PUX<^'UIKVEZ;X1GN?%/Q,\2WMDGA+Q\ >P^%/$_P5UGXC_ +P3\+
M?V!=&BT_]I/]G#QU^T'\-/%T7C+2_A=XXM_V>?#^H?L^:-\1;==$OM(TCQ/X
M"^(9T_\ ; \":>OPXU+Q%X2@U$:/XX\+ZKXNT?2_"_A*7Q+MWGQ"_9_^(7Q6
MN_@'I7[(.B>+?BW/\?/BM\'(="\9^,;&S\*S?"[X!>$OAGXH^)/QRUOQ/96?
MC*>R\"V>@?'7X>^#--\!6_AW6O$VM^-_B'8^"M<TG1O"T_B[Q9HGH.J>!/VZ
M/$?[3OP^_:5O/@/^SUIGB#X5_!KXP_ WPOH+_MJ>.+CPGJ7A+XX_$#X=?$'Q
MEJVK>'8OV"[O7%\4-+^SO\ ]+L]7M/B#::;H$^K?$2%_#/C*QT;P_JWB+P/2
M?V4_VT_ WB_Q'XS\$_!/]GAO&OB/]H3XR?M$0_$J^_;!O+'QW\.=8^..AQ>'
MO'W@SP)XAD_X)PZGH.N^!==T3POX#T>+P)\2/A=K\N-+TK7-8^)FK^*/!OA#
M7-' ,33_ (E?\$UOB/XCT?P9\3OV*/ACX4N;CXC?%GX%Z2_QB^'OPWUCPUH?
M[6?PC\:^+O".I_L__$O7=/3QEX8^'OB;XTZ'8:5\3/V9O$WBZ_-A^T5X%\?7
MZ:%96?CG4/\ A#/%?U[\#/V+_P!@7XS? ;X2_$RV_81_9U\ :9\6/A=X!^)*
M^!V^#'@'3-2\+2?$#PSX!\:RZ9J<NE>'-(+^*=+N-!\&V.KZ^EM:ZM>W?@G0
M&N90-$TN&Q^-+K]CG]KV/PA\2? FH_L?_LK_ !8^'/QK^'VM>!/C9\/?B=_P
M40^-#WOQ'U[Q?XW^(7Q.\=?%S4/'-O\ \$_KW6;/XEZ]\1_'9UWPEXH\*_\
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M_P!G?P+X[OK'P1X'T;XOZOX]^)4OP'@^''C#6O!4>A>,O&/A2_U!M&\.>/\
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MII&5I)9&?C!\9/\ @K>UE,K?L&_L2Q:HD;M;;/\ @HY\4[JPG>3[0L:72O\
M\$];*ZL5M=UM.TD)U(7[6MS9!-.%]'J.FZ;_ !@_X*NJTJ+^P?\ L2SLD(=2
MG_!2SXM)&9FDO=L!,G_!-'S6"P6ULS3-#;*UQ?V\21F&.\N;, Z_6_\ @EI_
MP34\16MI8:U^P!^QC?Z=IYNFT[39?V9O@VFG:;)?G2QJ4^GZ?#X.BLK*YU:'
M1-(L]9NK>".XUC3M+TW2]3ENM,LK>S3\S;[X-_\ !-OX/>,?VP/%,W_!(_\
M8GT3X/\ ['OQI\"? CXV_%#P1\+_ (9ZG\1+?PM\4O@M^S7\9=6^*UC\)+3X
M%V%I=?#;X<>%OV@?#6K_ !7AB^)*^)K#PGX%^)GB3P9H/CC6X].\(>)OT"MO
MC%_P58<//=?L(?L6VUK!;2SND/\ P4F^*-Y>74BCS4AL"W_!."RL6,D$4D4<
MM_<:=";V[M5ED@L;>YO7_.SQ?^R'_P %$/&_C3XY>(O%G[*/P+\5>$_VBOCA
M\-/C[\8_A!J?_!32UL/A;\0/&'P:\)?#+PE\,?#NNMX=_P"".GA_XL7OPT\+
MP?!KX:74W@^7XI6P\;)X8.D?$*Z\1^&O$OB_PYK8!QFH>#O^"9/_  @WQA^(
MVF_\$=O^"?\ \0=0^#5G^WO'H_P3\*_#KX+>,_VA_$7A?]A+]I3Q5^S;XC\3
MZ3\&;K]G4Z'IW@77O&ND'6;J/0/%OB;Q/X6TSQ5X=M/!?@CXG^(+Z]T:PZ[X
M-V7[ '[4EE\5/#GP!_X)=?\ !/#]H#Q!\+?A/X5^*MZWPNU+X)>)_A)XU\+>
M,OB%\0;/]GSPWX6^*5U\ M(DUWQK\0] \%?&OQ5XCT/7/"&GZ-\-=;@B^'?C
M+Q/=ZAXVUZ3P]M^&OV5_^"L7@SPY:^$_ 'AKX8>!O"NJ_$7XZ_%SQ#I5O_P4
ML2Q\26?CSX\?M&ZA^U/XRN_#?C3PM_P13T_5]+L;SXDZMJ^CQ^%;Z;Q+\.]5
M\!>(?$?A#Q9X+U>2/P]XMTCB? O[)W_!2GX$_%;XF_%SX,_LI_!CPS\3_C[J
M7B/Q-^TYXY\(_P#!2+PLFD_M0Z_<Z;XP;X<W/Q?T&\_X)+>![_P?J/P=;Q-K
M>E^!/$?[,3_L^>(O$%[KVF:I\8]<^*^H6NH>*;( X>P\6_\ !,N[\2_M#:=#
M_P $<_V9K37OV??!_P"V[XM\6Z/HGP_^ NK^)/!.I?LCZS>I)#\?O#G@7P!K
M+?".T_:4T-X-2_9[\4Z6_P 4KOQX-*^(>C6NEQ:'X4L=9\5_2GAKXA_L6_!_
MXY>#OANG_!-W]G+X26NO?$+]D'P?X&USP5X:^'!^(.M^+_VI/ASXAUBTU#X>
M_#CP[\)+'^TM"^#^N:79>'?BYK5CXRTL:)\/&\4_%'7K"T\+^&TTO7O%=6_8
M3_;GN+7QZ9/V/_@];W/QBU+]N1?B]J_@/_@ISJ6C>-/%G@+]O[7O%NI_$SX3
M7EYXB_X)C7&EZ]X*^%FI7WA;QM\(;^XO_#GC'PMXJ\)^%8;+Q%_PB5]\2O!G
MC+[*^%7A;_@I;\,O&OC_ .)FC?LB?LKR^)_B9HWP6\$ZUX?\2_MS-'HGACP1
M\$K/QIX4\/V7A#5OAU_P31\(>);I=3L]9D\97EAXZU3Q58:+JGB[78O!D?AO
M3=/A\"7@!?\ "SVVIO\ ';0_$?\ P36_9MTI_@;+:V_B2+0OBEX1\80W7B^T
M_9X\-_'_ ,)-K7V_X!>'=9D\.RSP> _A;J_B/1-.\<>(K/Q?=MJ.F>"_%O@O
M3M:\2'B/"/QJ^ WQ=^%,_B'X!_L#?"GQ]/\ !K]GGX-_';XP_"W7-7\$?#G7
MOAK9_'OX":W\5O"_P8^$-JOP]\06GBOXM:5\.O\ A'K:73_%9^!?PSTSPUXW
M\#6/AWXF'4M$\3^#O #]/\/?\%+M/T?]I6_M?V+_ (5Z=X[_ &P/LFN_$N^T
M_P#X*-"#1/AQXQTKX(?#WX!R77PETO5OV(O$NG^&]/N?!_@C0==TS7->TOXB
MZC/XZ@UZ^\5^'KOPQIWA/PSJ?B]A^QY^VSX%\!+X9\$_L[Z3X%\0_$+]GWX2
M?LO_ +2_B[X#_MZ^"O#/B+XX^"_@GX3D^'_P\^)5YKWB+]@[PO)\//C%#X!T
MS6? &L_$KX/Z3\.O$NE^ OB5I?A_P[;WWB3X>?!KQ]^S. ;FD?M3_P#!/[XU
M6OQ9GLOV"OAOXUOM'\$_"#XN?![6-=^&OPP\/>$_VH?V9OCYH?P0UF\^*OPI
M\=_$[PKX+O/#FI?!_P"&?[37PQU;]H_P!X\T;P4WPBU'QQX4TJ]\2ZEX;\1:
M3XTK]6M3_8/_ &)=<OI-4UO]D/\ 9CUG4Y3?^??ZM\"/AAJ=U.=3MKJQU%IY
MK_PS<2SM?V=_J5I>/.\LES9ZIJME.\EIJFH07/Y76O[(G[1/B?P[K/@O4_\
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MN])U/Q5X+US4-'M]$O["T?Q//I.CW5SX<U77?CA/AG_P2CF_8F\5?M^^$?\
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M)OB#H-IJ\WC9_#7AOXX7/B>R^*MYIVD^.?$6FSZD=-^(=]=>.;[PC=S6YO\
MX>:AJ+W"7?PVO?!U[9.NF75B@]TNO%GA6RB\^\\3>'[2'-\/.NM9TZ"+.F1S
M3:D/,EN43.GQ6\\M]S_HD<$SS^6L;E?@>V_X)$?\$P+07Q@_8*_98$NIF4ZI
M=2_!WPC<7VJB:QL=.E35;^XL)+W4X9+;3K4O#?7%Q$UV)M0*?;[N[N9^DO?^
M"7'_  3KU/Q-X@\9:G^Q;^SEJ?BCQ7:6MCXCUS4?A?X;OK_5[2RT?5?#MM#>
M2W5I,'6+PYK-[X<5E56/AV/3-"<MI.B:-9V !]P?VYHGGFU_MC2_M2LZ-;?V
MA:>>KQB],B&'SO,#(--U$NI7*BPO2P'V6?RYTU+3I'>)+^S>6,A9(EN83)&Q
MFN[<*\8?>C&XT^_M\, ?/L;R''F6TZI\$C_@E+_P392^@U*W_8@_9JL[RWU!
MM6BEL?A5X9L%&I/JL&MR7C0V5G;P2S2:I;K=2M+$_FF:]AD#6^H7T5QHO_P2
MX_X)PR7IOV_8:_96$[ZY;^)9D3X'_#^.UN?$-KILNCP:W=V,>B+97FIKI=Q?
M:>;R\MYYGM-4UJ%F*ZYK O@#[@M=9TB^69[+5=.O$M]AN&M+VVN5MQ)!%=1F
M=H9'6$26UQ!<(9"H>&>"124FC+5M*\3>&]=>>/0_$&B:S):MMNH])U6QU)[9
MO/N[7;<)9SS-"?M-A?V^) I\^RNXO]9;3*GPI+_P2>_X)FS6YMIOV#OV4IT^
MU:=>K+<?!+P+/>Q7.DW N],>#4)=(:_@%C=@W5K'!<QQ0W+R7"QB:21WO/\
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M/BM9_$CQ-I5K8:Y<^#3X\LOC+=:I:^$-:U[5=?N]!U0:WXUATK7?%NN^$](
M/VPCN[66**>*Y@DAG*B":.5'BF+Y">3(K%)=Y!";"V\@A<D'$C2QHK.[;$16
M=W<,J(BC+,S, JJHY+$@  G.%./@5_\ @E3_ ,$V-[SVO[#'[+6E7CH(_P"T
M="^#'@GP_JB(L6@10K%JFA:5IVI0BU'A7PS)8B&[C&GS^'M#N;+R+G2K*:&3
M_AU=_P $V\:9C]AG]EM&T1]6ET1H_@OX'C;1IM>LQI^M3Z4R:0&TZ?5;)+>T
MOY[)K>:ZM['2XI9&72=-^R@'WNLB,,HP<;V0E,L Z,4=25R%*.&1P<;&5E;!
M! _.6UTK3G_X*V:WX@0NNIV'_!.KPKHVH&26X$ L==_:>\8W6A*D'SVJ3S76
MB:XIDF^QW,Y6&.S&J)%=#2NBOO\ @EA_P3CU*2XDOOV)OV;;H7BV,=[;R_"O
MPRUC?P:;)8M86FH:=]C%CJ%E9P:;8Z7;6-Y;SV<.@6T7AQ(/[!!TYO@W1?\
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MACQ!XN^$5AX$U7Q'\/M-N-5L/ 4\UMX!FU#5IO!UOJ+ 'ZMM(B<L=H)506!
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M" ?U';A_M=_X6[?A^7KVHR/?_OEO?V]OY>HS^ G@3]C#]@F^^,GBO]EW0O\
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M  QQI_[.'A3P!^Q[^S'^V?<WNN_%[Q7JW@?PG^SS^T0OQ<^,O@FX\1:QH7Q
MBTCX?>-?!/B?X<_$KX@^//"^IVELNGWFKZ3\3-)U_P 07'B+5[W20#^D#[3;
M^88?/B\Y616A$BF8-(DDB Q ^8"\<,LB#;\T<4DBY1&8-NKRULK:XO;VXAL[
M.T@FNKN[NY%MK6UMK>-IKBYN;B8I%!;P1(\LTTKI''&K.[*JDC^?/X:_!?\
MX)N>+_A[^RCXJ^'G_!/SPA8_M!?M1#Q[X:TWX$^-?&,WA+Q9\-KKX)S^)_\
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M=\='X8_%74-/U?PDNB7FL?L[_L_ZIJEM-XF\,Z/9?#[J/V^OVL/VR+[]@/\
M;!T#QM_P3.^/7A;PG>?L2_M%6WQ+^+^N?'O]BE="\)65Q^SOX[_X27Q9!X-\
M.?'[7/&>M6.BWMS9W-WH\&AZ7JTFGV?B]]/L;B^T;PMI'COI_P!O+Q+^T=X>
M_: _:9UCX-^(_BZ^J^#?V;/^";?C/X.^"/!OC;XJ0VNL^,=/_;6_:@3X^:3\
M,_A-H9/PK^)_Q1\?_#"3X;^"_$'A3XASZ!X1URWN/AA;_%CQ?X,^&ZWGB[P_
M]R?\%2KRRT__ ()D_P#!1:]U'28->TZQ_83_ &N;O4-"N[B_L+/6;"V_9_\
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M\7?%_P#9_P#CMKGCOQ+X/\56OQ$\+^._%DGP?^(=]^U>]O8? 3QOKG@*\O\
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M5^TA_P %+;I8Y-8_X)H>!]'6:6RC%O:?MV?#[6[ZTA?^S[K4[VXA;X0Z/97
MM+ ZW9V5E;:HK7_BNV\,Z7<7NG>&/$FN>-? OR=9K^V#J_\ P2^^-'[0WPO\
M+?M*?"O]H3XJ?#7X+W?A;]GOQY?>//''[2'[/OP.^#WAWX;_  _^+GPO^']K
M\1;""Z\;_M/>(O"&@?M%_%#X9^/O$7P\T3Q?\1?BY\4OAQ9>-[+5[?PUHHCZ
MKXN:3X.TK]JK]G_6_#WASXMZI^Q'JY^+/AG]JV[NXOC7'\+/"OQT\*^#-<U7
MX#:GX[T+6/L9\6^ OB!'\=_VBK?X]^*M4TSQK\-[+]H'X?\ P(_X6AKO@GXP
M>!=(AU8 ]KG_ &D/^"KO]EVLEG_P3 ^!DFMB[>UU.QNO^"D.E0:3#'#;PW;W
MVDZO!^R3=WNHV=U'<QV&G_VCH6AZ@VM6NK1W^F6&AV^D:YKU'4_VFO\ @K1!
M=W$&F?\ !*_X(7T$%SK$,-Y=?\%*M TZUOH[6+PU-HMU!C]DZ^O8H]8.L:Y:
M307-A%<:=>^$]0#B>RU#0KW5OS%\9^"/C5!\8K_3_&'@;XZ?$GX32?'BU\%?
M#+]EO5XOVR? NIWO[*_BC]K^_N?A=\8/V:_VB_ /BCP1X3^#?[0OP*^+>EZ_
MXR\1^%O'VF6%OI_[#MQ^S_\ #8_$KX/?#R[/B7QQ]IV/[/NIZ_\ L;_M:)=>
M*OVP/@K\7?B3^T]^V/\ #_P]\1_"&A_'7Q3\3O"'ACXA?M]:_I?P=\<:'\&=
M.\16FNZI\"M.\'Z)\-M1U:_\ ?\ "#/XG_9EB\:^+-'\6^'CXMUKQQ( ?1MS
M^T'_ ,%2%%J]I_P3=^ \@N+*Z:2"Y_X*(VUO>6.IRI:IHT%W'%^R1<VC:8MW
M/,?%%_8W][>:3IEK/=^'M+\7ZBUIH]T7_P"T)_P5%AT_2)]._P"";OP-OK^;
M?!KUG/\ \%#K&VCTVYB-CYEUHUP/V3F3Q!I$L9UDZ?/?#POJMQ<VVAP:AHND
M6^L:K>>&/6_V ]2\:W7P 6S^('P\MO 'B/2OB/\ %"WGNO#U]XRD^&/Q,2_\
M7WWB.?XN_!'PY\2=1U'XD_#KX/\ C[4-?O=3\(_"?Q@6/PJ*WW@+P;K7CSX9
MZ%X&^)GC;[79U4$L=JJ,LQ!"@#J2Q& H');. ,DD 9H _FX\-_%7_@H#/_P5
M\^(WC<?L&?#N'XC6?_!./X'>$_&7@VU_;0TF?P2GP]U7]KG]I"Y\ ^*X/B%+
M^S_!>7GC8/IWBN2/P'<>#=&TX::GC.Y3QI>WFD>&].\3_4GP[N?^"FWP4\9?
MM$^+_!W_  3T_9]\277[1_QZ\/?&SQ=#JG_!2>\2/3-6E^&WPH_9UOXO#BM^
MPGILD.D:)\/_ (#^"O'%QIVJW%_?2W'BG5].TG4;RYTFU\/2=!?:X/#W_!:3
M]H"34SXBM=#U;_@CY\$=;:\\*>'?%'B+Q'(OPY_:O_:G;7?[ L/"WA[7M2O?
M$FF6/Q"TV7P_X=L8+SQ/XBO]16'PKX=U^:PU1++YX_X(^6&EZ5\._P!K/XH_
MLY?![QQ\.9=8\'?#G1/@I^R/\<?B)\7- UF=OACX>^)EYX3^)_[3/BGQ5X#\
M7^"_AC^U7^UOXU\7ZAXP_:4U/X3O\4Y]!\*GX4Z]\3/#>I_&:W\>3>+P#[PM
MOVA?^"CDCV"W7_!.;X>6RZA'JLK>7^W7X.N)-*"2SR:!#K,?_"BH5%U=Z>^G
MCQ&N@R>(+/0=9.KV&D7OB[2M/TSQ#X@Z,_';]O9[V[L8/V"/!L86[2"PU74/
MVRO!MOHDMO-JJ".ZU!['X1:KKUAY'ATS7E]!:^'M5EC\1K;:!8C4M&GF\8VO
MRK_P4?M/VH?B5^R_^R^GBRSF_9UN+K]J+P[JO[7D'P6G^-'[47@GP1\(O"GP
MY^/6O>%[[Q!JOPDT']G3XR^.?@\GQNT#]GCQ/\39]%7X.QVGAMM6TGQGK$?@
MBT\41ZQ]>?\ !-FW\5Z9^Q5\%?#_ (O\%WW@&Y\&Q_$#X?\ A;P]>>'_ !7X
M0AE^%7PZ^*?C?P)\%?$VA^!_'=]K/CSX>>$/''P>\/>!?&O@;X:^._$/BOQO
M\-_!GB#0? WB[QEXR\0^']2\4ZL 1W'QO_;J:/43IW["O@UIH/M+:8FJ_M@>
M$M/BU$1- ]NMQ+IWPDUY]/:[MVN8HP(;Q8M2CM;:>1-/NIM7LO@KPQ\:?V_(
M_P#@I]\1Y&_9&\(II/B3]A#X$3ZGX"7]JC3%L/"\/@S]HC]I&*/Q5JGB23X)
MOHFM^-_&(\6ZYIW@CP9X5N[W3--\/>&)=9^*/B_P9?\ B_PSHFG_ +M2W$$$
M4D\\J001(9)9ISY,44:C+/))+L1%4<L6( &2<8-?F#X?FT-?^"T7Q8AFA^S^
M))O^"8'[/DNF2JHE;5M#MOVL?VG$UV.?&E&2P7P]?W?AZ2SW:XJ:O_PD]Z8]
M)/\ 8LEV@!Y%^U9X'_;,_:MTKX2>%OB/^P?X&\6?#7P%\8-&^)WC'X*WW[=F
M@Z#\,/C)K7@&REU/X767QF6W_9J\0:GXW^$W@[XEC3_B<?A^+.S@U[QCX(^&
MFI^+M!\3:#9>(/ YT?V6+#]O']ECX;>$?@+X7_8=\+ZA\(_!NI:['X,7Q%_P
M4(T3QWJOPP^'6J^)_$.K^&O@QX"DU#]ESP9J6I?#SX,^&=0\+^!?A3IOB[5[
M[6-'\$Z#<>#K[Q5>6'A#PKK/BK]C]P]_^^6]0/3W_+)Z FOQT_X+*>+/C'X;
M\$?L"V7P5\0_%GP_J?C+_@J=^Q9X0^(B?";Q3\1_!=YKOP6U3Q-XDF^*>@>/
M?$'POO['Q/8_"N^\.VC-XXE>WU;2(;2"VN=3TN2*W6[L@#@?V9- _P""AW[.
M'C7]M?Q9!^PA\,_$X_:C_;&\;_M%:+%#^VEX7TW4-%\+7?PK^!WPMT'1M=>Y
M^#M["-7U&+X9Z[XK>PTV6?3-$O=:'A\ZA?1I+XFO=+]HOQW_ ,%$OC_X*G^#
M7C+_ ()>ZS9^$+_Q?\/O%5_XR^%/_!0/]G*&9]0^%OCWX:?%'PU#:3?$+X3P
M:G'H6I^*-!OK#5[NW\+Z?XG@L/#I?1WTR\U^RU+2?CC]IWXN?MY?\$\/V>OV
M5_"G@_X[>,?VS/''_!/23X9?'K_@I!XPUC1=4'B3XY_!+XS_ !"\8_"KPM\.
MUUC4/$GB#Q-J%_X=\)WGQ,\76 BC^(?Q"N)?@Q\*/''CC1=4U#Q=$^N<-\8/
M&W[;2?\ !3_XZ>+/"OB/]I/2/V0/#?\ P4!_X)C:OJOQ/\+^-OCKXG\/>#/@
M!XW_ &0M/T[Q=X7^'W[-MI+IWPG\=?L]?&OXO7R>"/VB/B1I_B+^TO@'XKUK
M2/C7>_"OXBZKX3D\0^!@#]=M8_:=_P""G6GQPG3_ /@EQX+UN46D5Q=K9_\
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M0^$%EI?@B^\6:5\-/#6M:AI7A[P/KMIXI\8ZF-,TWQ3\"O"'B;5-5^&G"?\
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MOP/\!_V6_AE\4_C;^TU\7/A[HW_!17_@E_XZ^%/[1.IZM\0]2U']H/\ 9_\
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MAWT?Q%^(&M>' #]@]4^+W[24-L7T;]DN^U"Z&HZI9?9]1^.GPOTE6MK:&?\
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MJ>?!IO[+W[+NDP7<K:G9V4MC-<Q6"R/IELMQIUB"(=-O+JS\F5OM:@ HHHH
M**** "BBB@ HHHH **** /C[]LGX,^'OV@/#7P=^%7BS4/%NG^&_$'QX\*WV
MLGP#\1?B)\(_&]W8>%O"/CSQ;-;>&?B3\*O$/@_QUX2NE70_M>IWF@^,/#-W
MJ'AZUUG0X[^\DU6/0]6_*_\ :I^!W[%'[)OB/PQX.^)&F_\ !4OXBZ[\5-!N
M-(_9^?2_^"D/[?VK^%/C7\;[S4M)\.67[*'A?7KC]L/3-&\(?&7XA?;9/'.F
MV7Q(M?"7@_6_!>H?%3QAHOC!_#WPJ\=6_@'])/VWOB5XQ^$^L?L;^+O!7PE^
M)7QROE_:NNM%O_A?\([?X>MX\\2:?X@_92_:FTB&32M0^+'CWX7?#?0K/0]:
MN]'\0Z]K'B[XA^%+"#0-*U.WM+S4-8N]-T/5?S&_;%^&'Q0_; ^+5C\3/B+^
MP]_P4AL]1^$_PKT*P_8^\*>&;7_@FVVG?LT_M4ZSXV@\<7_[95EXAO/V_#IG
MC_XL_#O5_ GPB\.>%]!\8:OI/P\\+^%?#GQ(TJQL_B'X5^.WBFZLP#N?^"@7
M_!.K]G;P+^P)^V?XWTF[_:N@UG4OV;_%][K>CZW^W7^V?X\A:;2]!\/7UQ'K
M#>)?CSXCA\3^2/!7AZTO9O$I\1:*NE:9JME]A/AWQ5XWTWQ+][W7_!-S]F#5
M+BVO+_4?VJ]2FMK Z7YFH?\ !0+]OR]%W$+.VTN2\U);K]IJ5-8UNXTJRL]'
MNO$FJ+>Z]?:-;0:3=:E/IL<=JGP5^WE^T?\ M&>//^">O[1GPW^(?_!.+]LC
M2_%&N?LZ>*;'7_&=_)^P_#X(U#Q%IFGZ%9ZEJFF>$OA'_P %$?BU\0-,;7->
MU 7G@KP#H7B#6O&]\8SI6A^)+F[L)?$T7VYI'[:'[0][;1SI_P $H/\ @H+%
M!*+9H3?^.?\ @F-I]XT=S:V]P9KVRU'_ (*-V5W:3HTK)<6IADDA<>5*$O4N
M[2U /F[QW^R3^QKX%U?X@_"#PU\.?V]OB9?^#_ =E\:OBYI_PR_;8_;RMM5T
MW1M6L-8\+>$HO#<\O[4GA2;QU\0?B/:>$?%]G9?#_P"%UQ?75]X>\&>*+3Q1
M'IFK:O\ #OPI\1N6_P""CO\ P3E_9F\.?L(_MZ_$GP=X?^,,'Q,TO]B']LR3
M0=8;]J+]JG7UN=2\2_ ;QPVHPZIX<USXVWWAOQ;:ZO)9Z5IMYH_B?2]4TO4-
M$T[3O#=S:OH-G::?;W].\5?M"^ ?VGOB?^T7\)_^"='[=W@RZ_:33X,V/[0_
MA#Q-<_\ !.SX@:5XDUGX*6MEH?ASQGX)O],_X*<:(OPR\0ZO\)]:OOAIXVOI
M[;X@^&?$(\#^!-3T+PSX-\1^%?%%_P#%_._X*$?MB_M$7W[!_P"VGHMS_P $
MO/VV?"!\0?LI_M+Z'I_B[QGXU_X)V:KX#\,FX^!'CR>3Q+\1Q\/?^"@'BCQ5
MI7@S14M[Z\UR?0=#UK5;K3K2*Q\.66L>*]9T3P[? 'F?Q#^&'_!/#PDOQI\,
M>)O O[?3>$O@#\9O@-\)OC;\5_#/[<_[96MZ3\)M>^(_PP^'WQ*\(?$WQ3K-
MU^V%#\0K+X:>$/#/Q=\$Q_$7XG:-X4U_0_#NFFPUKQ)?2:'\,/$-_P##RAJ_
MPW_8#^%?P$^//[1?CGPA_P %''^!7P'B^/WP[\3_ !"\8_MW_M(:E+J%U^RM
M^T)KWP.\2:3X3TR+]M*W\6HNM_$:QU33OA[XK\::7H.@KX$^&NFWWBO7/ OA
MW2_!;:\OQ!^%'QY\>>)?VM/"FO?L/?MN:]^SC^V)\3/ 7B[XT?"W0/#?_!-+
M1_$-_P""_AI\&/A/\#9/V?M$^)/CK_@IR;?3/A7\1="^#6FW'BF_\.?"BR\2
MPV'Q"\:'X<_$+X=>*[V'QCX8M^$-)_:O\#7/B77O G[ OQ\TCXEZYXN^-NMR
M^.I?V;_^":$&L>(Q\>OC>_QD^*/A'XAZUK7_  5"U/5/%7P4\2Z\C6=MX0\.
M^+?A?XQ'A[2?"&KZ_P#$#Q+XO\-VR>+0#HKKX7?L9>,=$U[3]!_9+_;9\;:_
M\(/ ?_"=?&/P;X'_ &G_ -I"P\7_  V1;_6+[PIHWA3Q W[3GAS2?C;XV^($
M?A#Q)XZ\#0_"?Q7XKO=>\%7%AXQU:^TJ+XR^!+'Q_P"1>-_$_P#P3F\*>%_B
M]>>(O@M^VGKNG?#G2?VK?&^FZ=8?MN?M*7O_  GOAC]B']IF?]A#X\:GX47Q
M)^USX=@\*^)_A[XR\6:7)X2TGQ OAC3M2\ ZAX$N/AGXEU#Q#X''AKX?'['O
MP9_:._8BU[Q%JO[/_P"PA^WUX6\)_%'Q':^)/BU\%TM/^"6?_"E--6Q^*'C/
MQW9:7^S+X"N?^"M$MY^S3I1\*^.;SX7W/AV+7_B)X,_X1C1=!U_3?"FD^.XM
M5\2ZUS?CW]CCXN>(? 'QWT;3/V/?V]M"\5?M/>%/VE_AQ^T#J?@6'_@EI%X:
M^)/@GXW_ +6'QI_:;\$RP_#SQ;_P4=?2/#7CGX%^+/CI\6K;X;>/XO$^I^)-
M:\'_ !4\47'Q"FUCQH/!MM\*P#W#QQX&_8:M?BY\1/@3KW[+_P"UKK%UX6_:
M"TO]FKP7XT\._M@_&6V/C/XUZS^RA!^V-H7PX\ :A<?M<>'?&O@#0==\ >)K
M/PE&@D\/^ =,U>Q\&1>-AX9^'GA/0M?\*P:=X?\ V7)/"?[4/B_4_P!E[]LF
MYT#]D_P#\2KKXYZSXR_X*%_''QE<Z!\2O@K\,O@W\:M<^ <5YKG[7FO:S=:K
MXG^'_C#3_P"P?$-FLGPT\3:!;?$#PSXVUO1?#/Q!UFU\7?1WP_U#XE^#?BS\
M9/CCJW_!,#]J#QO\1OBG\9[#XLZ-XBU[5?\ @FOI_B7X5V<OP(^$O[.L/A?P
M'K<O[?/C#4H(+;P7\-9=1\9ZE::UX8CUR]\6^+8]'TFXL]432CX';>'_ -I2
MV^%?[>GPBM/^"?W[<*-^W=\4OC7XWUKQ1J'B'_@F"VD_#33?C-\,_#/P;N].
MT73Q_P %(=7O-<FTKP7X.T?4'O=6T.YM[;Q7?^(M:?P]XITBVTWP5J !1\=^
M$?\ @G[+X:^-'Q)?X*?M5R_"[]F70?"'B;]K_P =>$_VSOVDO!VC_ VXD^'E
MK^T1XL.L^'O!/[4UGJ'Q?^)'P0^%WQ5T_P"-/Q3OOAOIWB_7KA?$&CV?PSUW
MXH?&'2X?!.AU/@QX2_X)H?$6X\8Z=9_ KXKV?Q(^ W[3W@7]F#Q-X U+]I[X
MW>,H_"MSXR\=ZA\+OA/\<_ U[JGQZ;2]3^ ?CVWL]6A\!^.]'TK3-;O[WP1K
MGPSNO#>F>-?A7J_AKPJSQ+\)OV@?%'@#]ISX1#]AO]M/P[\)OVU?!OAG0_VE
MO!^@:Q_P3(LEO;M/@-\./V9/'=_\$-6F_;\U.X^$&H_$'X(_#OPOX5\0^%]?
MM/BUX9\-:MX9TW6OAYXHT;7=8\2>*M7J>*_A%\;/$C:??VG[ '[?^B_%/X;?
M$?\ :G\2?!_XY:/\0_\ @FS;)H_AK]H/XQ:U\=M!\"^(OAYJG_!1S6=+^(_@
MOX6_$J+X>^.O!-UXGN-+\3Z5XX^%'@J]\+K\/-&\2>-M'TX [_XJ> ?^"?/P
MU^'?[//Q#T[X(:WXPL/VD?VA=(_98^ UUKG[4OQHT+X=:IJGB.S\9Z?\/O&M
MYXX\0?$C5="T#P3\0=$^$HM?A]K&D:3KFM>-+WX@:%X<\$VOB/6OBS<6?B7C
M/ FH?\$W;KQ+8^%8/V1]<\(33ZQ\>?A[H&I>+/C#8ZKK4WQ:_9,^$>D^,OB)
M\*]7T31?CAXO^(5AJWASP;)K^D>)?%]IHWB/P)H'CSX8WNC^+?%$6NZO\#=3
M^(_K7Q=@^.WC7X$?#?\ 9G\"?\$W/VKO"'P0^'WASPYX%\2?#OQ;<?\ !+#X
MN^"/BK\(-,\!:W\*K/X*^+/!?C7]N;[!<:9I6D7WAWQQ)K-IJWARZTOQ%X.T
M1K.Z\::)!K?@3QGY/^SQ\'/B5^S'^S?XZ^ WP[_X)H?MG^)9O$'A_P :Z!I7
MQ5^(?Q8_X)G7_P =[6T\4?"*P\ &XU'QS8?M>36_BW79F\*Z!"^NZG-X>749
M[U(]3TV'3- CN=1 *'@KP]_P3^U;P#\)O'.B_LC>)&O?VB?%?P5^%_[.7A7P
M'^TO\1/&WB;XAZ_\<? 5W^TU<Z;XO/A/XDSI\&X/@S\&/!T_QM\;:K\1IM/M
MO#O@SX=6%O\ #>[\07FA_#'1]:[N_P#A!^Q#I/[0/AO]E74_V%/%7@[Q+=Z%
MI7BK1_"/_"X_$?A[0O%_PQT?Q+X0^$,_CKX/^#/"WQ+F\&_%C2?A8E[;ZW\1
M_"]I<Z3X]^%_P<TOPQXCUSPA9:SXR\$>!-4\\T[X-?M%:=\-?@AX*T+]B_\
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M!?A=XFTSQGXA\;KX-T&;5=1GT;2;7QOX<U[5/$-Y]!_LX/\ M8?L\?"'QO\
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M:^)GCV]U*X2]^WR:A\+O!]MX?T86OC;Q'HP!\NS+_P $R_AI^Q%:_MZ^/?\
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MM;T[5O'][H\6I^'&^*.K>.=2\->)O%EIJ1\9^(6?';Q'\<_C1XU^!>O^._\
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MA9?M::O86DNK>3>66BV%SK09]1ET1=<N= TN^UC5O#L>H_M>?M<6-Y+;0?\
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M*^%+/]I6#PP#JVK:G>ZEJL?]CF#4[Z=KJ]AFG2*2/(\,_MD_M=ZCJ9B\2_\
M!)3]L+PYH[F*WBO[7X[_ /!-W7[^.ZDFD#7-]I</[;.G00:-;6RQO=75GJVI
M:P+F46]KX>NX4>\&I?\ [7O[5-A.J)_P2L_:_P!7A\W5S)+HOQG_ ."=1E%K
M!'8SZ#)'%KO[:V@0M<ZBNH"TUJVEN8(]#U+1O$J:;=^)]+MO#FK>*@#5N_\
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M3Z]=M!Y4L7FW$.EZ1J$\<,HEBD$3AXF(#+^1O_!6[XS_ !(\(_'72]&_9_\
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MJ5C^T;K-[X9\.^+/BU8Z)#\,/"W@KP+;>)O&'B;Q"GAZ._T'X<>&_BYKW@T
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M_P#!3#Q#\+?B+JFNVFJ21?#N^\5Z-^U7?:3X,UCXA^$/!L?B_P"%/BFTDO\
MPOXZB\*WNGZ3JFC>,]/^'/A_QQ\CP:W^RCI'PQ^,'QKMOA)_P5&T7X,_LNP_
MLY>)OCC8>$?^"LG_  43N?$/P]^%GQW^ 7PE_:$N_C)JO@Z?]IZQNM5TSX ?
M"WQ78:?\3?"W@CQAJ_BW1+?0M<N= \+:[HUOHGB%0#W#XI?M'?MC_#_]K/\
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M!N0)0 ?HON&<8;.<?<?'?OMQCCKG'3GD4%E&<GH<'@\'WX_^M7YM_P##I?\
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M2\0_M4:CXDT/5H_AO-?:?JGQ3\1Z';^#O$?CU-)^"=G\5?%'CCP[:>#=+ /
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M_P %#_VB?BBO_!+C_@HM=:O??L6?L<>!=4\#Z?:?L-W?C32-*T;XY?M]^(-
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M\+_$-IX'\7K\1=-U3PQ%X8^$.GZ1;:^OCW7O 'AO]//@G\=_B)K_ .S_ /\
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MYT+]M_XI?"+Q5\3/$E[\./@]^S7^R1^TC\6!K?[8OQHO-.^$7C3XR_MA?\%
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MM6_M(:/\:=#^)'C'XN_&CP;\$/"FH?L-7?C+XT?$;XI?$_1O"/PY_9G\5?\
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M=I'F2RI#>O<:?X6\1>']%N$O;:$VLVEO9Z7)?^'[;1]4OOH*@ HHHH ****
M"BBB@ HHHH **** /SV_;[\!7'Q2OOV-/AYIWQ(^*7PAUCQ7^U;J^FZ5\2?@
MMK'AS0?B7X3=_P!C[]K1M5U#PSJOB_X>?$KPU9S3>'QK&GWDVI:'9S16%[<R
M:-K-GKZZ5%<_GM^TC:_"_P#91\3>-OAQ\3?^"D/_  5QL?B3<?!?P#\3/AUI
M?A35?@WXL\0_'Z2X^+2_ K1?A;^SK!-^S3<^$?''Q^O/B=X\^$/P]\7^$)K;
M2];9?BS\$?$7B+6(]'U76O%6D?HM^W7X]U/X3ZW^Q7\58OA_\4?B/X6\!?M9
M:O?>/]%^#7PF\9_&KXA67ASQ+^QW^UOX TC5M(\"_#[2==\67-I%\0/%_@G3
M];U33]*GM=#T?4KW5=;N-.T"TU34;7\1_P!M/XU0?M<?M"^#_C)I?P6_X*:^
M!/$7[*>@>$_&'[!5\/\ @E-^W#J'AGPO^T_+\1+;Q!\4_B%\=M/_ .%7^"]7
M\8?#[X@?#GPEX*^!%AX'@\4Z1I.C_#GQK\;O%.JFV^)5Q\+?$/PX /K/_@H-
M^QY\0OA'^QC\7?'-S_P4,_X*&^/8K1?!^B>(-!\5^,?V8K_3]2\&_$?XS>']
M$\:6,FD:7^S%X?\ #\-[I.@^-]8D\+:UFP?PPVA^&K=-8MO#6B/:-]B:W_P3
M;\:ZY%'!)_P4^_X*>Z9#;ZYIVN6:Z)\7_P!G_2I;8:7>6EY::-)>6W[,*WVJ
M:&_V*&UU&QURYU1]:LVNX-:GU#^T+][GXR_;V_X*/_#_ ,9_L;?%;X?Z]^RI
M_P %$=)\0>,_ VD::-2/_!/[]K6#P-HOB^]UCP]-X56\\2ZA\-]%1],U/Q,L
M%OI]CJ,,5Y,T$.@^,]!TJ_US3]!U;[5F_P""I7PVCCDN(?V2?^"FMW9PZB-,
MGN8?^"<?[6$4D=Q]FFNWFCTJ^^&]IKM[IT<-GJ8.JZ=I5YIDES80V$%W+?\
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M_P $S_\ @H%X9M?V8?\ @H3X?G\5_L9?M0>%=/O_ (A?L!?M/>"?#VF7.N?
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M6_$/6X_ *_&779;_ ,2Z9X6\/ZXE]HFJ '?_  4_X)J?"'XS::WB'0/V]_\
M@N!>Z0L2:I:Z_P",O^"@_P"TAX2T7Q=9W?B/Q7HV_09]!UC1M'NX;6[\+WGG
M6VBPZ=<6NAWGAC5I(A8^)-+OM0\N\7_LC_L7^"])_:[EU+_@J%_P6$U#4_V
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M^.7CS_@F/J<GC'5/$'Q \8?"_P 5>%_B_P#$?X@_"'XI)X:\7VGPQ^!'P4^
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M6]'_ &+/^"FVA?#;]F/]OGX9_M5_"75M5_9:^#GB[4X_A'\)OVH[+]I?P/\
ML[WDFN?M@7_BCS-&LKW4_A%X:^+=BT-]IO@SP7HMSXJT2^O]3:P\<>D?M P1
M?M1?&SQO\<]5_91_X*._#G6O&_PA_9@^&_A;P[>?LB^'=;\2^!?B3^Q#^VYX
ME_:E^$'Q$;5F^,>J_#C5/"7C?QGK>E0Z_P"&=3O?#ES=> K<2ZGXKTB*_P#$
M$?@P OZU\-?^"?\ \!/'T'PD^)G[2/\ P5@^".L^)?''@'X;:W_PL7_@HS^V
M9X<\(_"OQ%\;]$^).O\ P%\1ZWXMMOVC9_#G_"(_&MOAK\1_ /P]^(>A:MXX
M\!Q_%'P-J7PI\?:KX4^+]C;Z!/ZM\1_V4?V./A5\,?VF_C;XN_;'_P""N4?@
M#]DO5-1M/CB]O_P4=_;_ &O/!]MX.\$_#[XE^*;S2M%;XO6>N>)]&M? 7B?3
MO$=Y>Z0NKW6L:5K.M2^#WU"\3PZ+?S#XB>/=;^,?Q0\1?%[XL_\ !/'_ (*!
M?$"'QYX0^&WP6\>_"2R_9/\ A=;>%?$OPA\/>'?VHO"_B'P+J5UXQ_:VT::]
MB\;/^V=KL7BWQ%?7,_A%_"OA""&3P=8:E#XJO/#GB5]XM^.=_P#L3?MO_LL7
MW["'_!8WQ[<_M>7WQ<T#P]\6/BI\#/V//$OC?P!X:\5_ OPS\+/ 'AWQNH_X
M*!:3XQ^,4_PZ^'GPST/0KGXO^*-9T+QW\2]3MK"7Q=XIU+XLZU/K_B$ ^R+'
M]FO]C'P_XJ^-EOXB_;>_X*E?"KQ-^R]\*Q\:/C=X5^*__!1C]M^UTKPQ\%_%
MVA^)]4LOBL+OQA\4?$G@[QU\/=/TSP/X_P!'C\>?#;7O%.C^&/$GAKQ1I.J:
MM8_$#PQ;KI'*^.O@M^QMX>^$/P<^/MW^UE_P6$\8?";]H[3?A?XU^&OCKX>?
MMT_MW:CI6JR?'/Q1\+? OP:\+_9/"OQ,TN;0M;^,7C/XW?#G0?!?@E--MKDR
MS:OK(LO#_A;P?X]UO2?GSXN_$+XI?&K]H_\ X7A\<O\ @G+_ ,%7KRRCL_ ?
M@;P;X=^'7[._P!\+2^"?@K\(?C#I7[37B+PD?%O@3_@IAXNU:_\ 'GQA_: ^
M''[/=[XX\?7N@?V)XC^$/P;_ .%3_#;X8^&=2^(/COXDW;[/6O'EI^SUX<_9
MH\&_L!?\%-M)^'/@+_@H)\,/VJ/@S)%^R5^S9I5GX&\!_#_]LOP%^UYHOP.E
MT36/VX_"5^WAR7Q4+KP3H_Q+N(O#J^#? GBBT?6_"#CX6_$&'3P#[6\<_L=_
MLQ^#[GX$^#/'?[5/_!5OPMXA^/\ X[OOA-\-] ;_ (*&_MMS^*KKQ3I/AKQ?
MXSU&Y\40:%\6M3GTOP_;Z-X0N(+WQIJ\DOA"&YO?"6G7>K0W?C6Q&M_33_\
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MX6QW/[-W_!0#X>?&;QI^S_\ 'SX8?'O4O"O_  33^.>J_ KQ]XB\:_ 'X[>
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MNI\>>(=*\1_ K]D3X+:9^R/_ ,%"]"^$_P"PY/X3U36K+3_V.;R\OOC5\,O
MO[+7Q0_9LD^&O@+0_P#A=EC\1? VN^(M ^*UMXI\/>)-)?Q%X\\&WWANWTC3
M[:/QA]IUWPIXO=?%;XHWO["/A7]B[Q9^S5^V5JG@_P"&>@_!?P#X,UKQM_P2
ME^(WQ-N_&?@OX">-?AQXP^%^C?&WX=Z9\7?%/A2]U'6/"GP!^)7P<^+OB+P
MMWI7B#Q;J?A/XY^!+'X(Z#XW^ W@GXJ@'K?Q)_9P_9<^$OQ!^&'AKX@_''_@
MM[IOCKXN?\+PE\$?!W3/^"B/[8'BGQ#XCT']G'P'9^,OBIXQ\/:%X)_:)UOQ
M-XS'V&[T[7/#/@GX::SXK^)7CK7=0-OX#^&NIZ+I]_9Z9VWQ2_8V_9A^%WB#
M0/!&K>-_^"RWC2X^)'CN;X>>&5\/_P#!0/\ ;,?2O&'C33O@+KWQ?O\ 3=%T
MOQ5^TIX3?6SX.^%?@'7?&\7B"PT2ZT[_ (3+P7-\-/#FL:S\1-)A^&8^4?C[
MXCUG]J+]G;4/A)XD_8D_:/\ AE+XAM_B1K'PROOAO_P3:_:-T37_ -EWXY7O
MA[P!IGPL_:9^#'Q.E\<>&OB!X4^*'PGG\/\ Q'\4P66A> /A3IOQQNOB5X0^
M'?C'7OAC;>'_ (O>+?'7WS<?MW> _BQX]^ 6M^(/V9_^"DO@BP_9O\>ZU\1/
M^$E^(O\ P3-_:WU&\^)>IZQ\ OBM\(((?".G^ ?A#XYU;PYJ-UIWQ7F\3:KJ
MGB.Q\&FTABN/ X2;7+[Q#H>B@'DLWPH_8C^&FM?%:UF_:S_X*L1^'_@AXL\'
M?#7]H?X\^(_V\?VV-6^''PK\8?%70O"OB_P)X!^(?B#QO\5+E=#/@O0OB1X&
M\3^)_$WA/PBV@?"#3?B#IMW\?_&OAS2YM:33>Y^)/[('[.7@7X@:WX,7]IG_
M (+!_%3Q_P"#O!]K\6O'_P /_A)_P4"_;.\0:GX$^'WB/3/B>OA7QIXCT30?
MB]X?,]EXU\0?"/Q-X4^'_@3PU)KWBWQ7XMTB4>'/ 5[H,/CW5[3Y.^)^L^"+
M#X:?MZ?L[_"_X<_\%!]!^"?[?_Q=\??&7XKWMA_P2W_;5\7>/? ^D?%_PIX=
M\(?M4_#GX:6OB;X2-X1UR^_:"TGX<^.M2\#^)O%$^E#X/^)OC#/K,?ACQQ:V
MOP_\&:I[9J_[77B[P_\ M3_&K]H[X&_LK?MYIK/QR^!GP:^!7BCPY\5_^"=7
M[0<6A^#]1^ WB[]H#7/ GQD\-:[X<N-(O/']E9+\:_%5IXA^!>L_\(/+X^M[
M/PS>Z-\>OA/%NA\3 %/PS\%OV0/$%WJ5W\,?CC_P6-_:)\):3HG@7Q1?^/?A
MU_P4[_;+UCP#'X4^+/PBE^+GPG\76FK#]K/P3JNJ^#_'VFRZ=X?TSQ;I6G7W
MAOPSXCU"#4OB-JG@[X>:;XD\:Z1R>E? G]BSXE:)\ ?$;?$/_@M9':_M&:1\
M/;K]GB[U7]OK]M_5K7XQCQQ\"?C9^U%X5O/#WB*U_:5\3>%=(UZ^^'7P@\;V
M.NZ+X@UWP?<^#-1T+P5=>)=&\*:/X]T/QGXP^>OV=/B9X!_99T/XEZ+\/_\
M@FC_ ,%4?&NO^"/A_P#![P!^SQXP\9?L"^-G\3:5X<^!O[(6A_LP:;:_$O5+
M7Q=X1TKXI0ZG=:IXY\877AK2;P:#K/\ PFLR:19Z1J_AF"]\,0?"C5_"6F_
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M[C1K>>P\5W/A0ZM%<1_#,W6J>'+QK.Z\16&O:)9ZGI]SX42VUM95CU/2(M0
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M2/#O@E=0LK'5;[Q]H?NRZ!\?='T"_P!/\-_LG_L<V[-H^MZ/:Z"O[0GC31-
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M:\\4^-/"6B::7\-:#;:3=2:Y;7]G+XQU7P9HERYMO^"DG@S6+_3_ (;>!?\
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MX-\$^"_"_P!+_P#!/WXJ?$OXD>"/C3H7QD;QYIWQ3^#GQ\UWX4^//!?CW4/
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MGT*PU/5-&/B*'1/&.J3:-I]OXFAM;.?50#]1:*_+FSN/^"OT'B*\T;5/&/\
MP3 6.0S1:2EMX=_:D'B":QET#4I=-\2W7AVZ\>.B;_$]B]O<>%K35989/#]M
MJE]#XY%_IS:>]>ZN?^"N\MZ+&W^)/_!+G3=5>^5+_1KGP1^U%JMWH%EJ%GXC
MOM+8/'\7=!GU^]6T@TZ9+2;2O"4&M6OA/Q/J=M/I:>(H[?P0 6=4UK_A&?\
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M;XT^&OVC_B1INH>-/VGM#\.ZI\=M(\3?#[XE77Q:UC4;CX>:I;ZQXDO/B-X
M\.6>C"6QT*/1;_1O#OQ(OKOQ)=P7/PNOJ]S\)O\ @J%/IGA_3KG]FG_@D-J<
M?A;XN:E\=?#V@:?\;/VL? ^@7OQVO]1\8^(M4^)E[%8?LX:]:7'BFY\?>)M:
M^*=U)JFC^*;H^(S<HUU_PD^G:5\3-+ / ?BE_P %:/C#X2_8S_92^+MSJ/A3
MP5\7-7\7_MH_ #]LW2=)^#^J?&C7?AY\?OV'_P!E']K;Q3\6;[X:_"3PW\4M
M"U"X\(G]H3]FW3O$/A[0_&WC#P]J5_\  ;QQX;UOQEK7PQAOM4\0>'_>O'O[
M9'[7.B_ []J;X]6&L?!72YOV;?V+/V;_ -M<> ;&+_A9W@3Q%JFO?#WXE_$_
M]H/X(Q?%WP5*LGBSX?W_ (0^&<^D?!3XL> ]#EUBT\5^*=&\?:I!\1/!^GM\
M,]<Y^R^!?_!3*S^)UY\6M7_9?_X)%:5\3!\5O&'QJ\'^-8OVF?VRM3U#_A<_
MBS]G^V_9HB\<7VAW_P"S;I.G-XAN?A%X>\*?#_4FTRY+3^!['7-!T:'2M1UJ
M[\0UQNE?L%_M9^%/&VJWVD?L(_\ !+'Q1\*/$7A7P1\-/$OP:U[]LW]MK3O!
M^N?"SX-+KK_ 3P+?>#M>_99^*'P-N/"GPAN];>_\(>#;KX%7/AOPYK<FO>)O
M"4'AS6_$9GTD _>SPOK+>(_#/AWQ"^G7^CMKVAZ3K3:3JL?DZGI;:K86]\=-
MU&( >5?6)G-K=QX&R>*1>U;M?G;J'C+_ (*S2P78TK]G'_@G;87)LV>QDU#]
MM3]I35X$U N8DMKN&V_8%T226S6)!?M?0SPSN]R=)&GQK9#6K_S'5==_X+EN
M=0ET3X6_\$H+91;1C2K#5/CU^U[?L]Y(MA%(=0U:U_9PTP16ML[:G?*+;1II
MKQ(['2_]":6?5X@#]8**_'O0]8_X+]VVM65WXD^'?_!'O6?#L<[2ZCX?T/XS
M?MI>&M:O+9HK798V7B^_^ _BRQTV>*>:]#:I/X'U6.XBTVU(T>V?6IAH'IP\
M0?\ !965'E/PD_X)DV,BZ9ID$=B/VB/VJ-52368C>'6=4?5#^R_HS0:9?K8V
M$>F:"NCW%UI)\47DUWXDUH> X8/B, ?IM17Y?WWB#_@M%%?7TFF_"3_@F!?:
M:T$\.F65[^T/^U9I=]#=6TVG_9K^_P!4@_9@U>">WUFVL]5\_2;;1[>7PW<>
M(=.5-9\5Q>#[I_'%H>(?^"RQ2[1OA#_P3(5YGB>QN!^T;^U0Z:<CH)Y[:[LS
M^RS&=:>UDO3I<5]#?: +Y/#0UU]/TYO''_".?#T _3:BOSONO&7_  5D)E:R
M_9R_X)WJOFWMK##=_MI?M)LWD-%I"Z=KDMQ#^P0 )H9EUZ6]\*I;M'<QSZ1;
MP>,K5K2\NKWH/#_B[_@IR4$?BG]GO]@]9#J=NQO/#_[8W[04B#1GN-,ENH!I
MFH_L+1LVIV]HFL65O='5EM;NXN-,U22SLHK2ZTB] /O"BOSUL_$W_!5RZN]*
MGU#X)?\ !/30K"-X)];TJS_:D_:0\5W=XEN(9+G2]*U^?]C[P9#IKZN8;BT@
MUV[\-:J/#@U&'4)/#GBDZ+)IFO\ 0KX@_P""F&GW-O;O\)/V%O%MI%#'%=ZP
MO[1'Q^^'=S>SF;6%EO[?PX?V7OBA%ID*6\^@31Z3)XJU9Y9M,UBU;6H4URRN
M_#P!]TT5\4^%O&7_  48N;O6)/&W[.'[%.CV$4!_L"T\+?MK?'3Q)=W]S)(K
M@ZQJ.K?L!>%(=(@M(5> K9:7K<FHR2K=AM+6W-E<Z6E^-O\ @H!-=7":W^S+
M^QWI]DND0S6MQI?[<WQJUBZFUYK29[C3;BTN_P#@G?H<5KI$5\L%O#K<=[=W
ML]I+->OX?MIH$L+@ ^Q*_.?X1WT]U_P57_;JMI--FL8]/_8>_P""9\4-Q-"4
M_M9+CXR?\%/KN2^MIW0--:0RS/I02*1[6&]TV_\ +5+J2\+^W+XO_;>.FV<K
M?L]_LJKK#OC4+%?VQOBX^FVL>R,[[/53^PK'=7SB0RIY4^C:<I18Y/.#.T4?
MREX&^&?_  4:\/?M)?'C]HB]^'W['T;_ !K^%_[-GP]L_ ]U^U#\8O%MG\/X
M_@2/C'J^L6NC^)(?V*? .I:QHWBWQ+\;-;FL8]3LHY- FT2]\0K;WLGCN;PW
MX- /U7HKXRU'Q#_P4,-C.VD_"']C*/4GL=86V@U']HSXWRV-KJ4DVJR>'YI[
MJV_9:AN+ZQM+=-$M=8MH[/3I]1FN=5O[*ZTM+*TTV_-$\2_\%#5,S^(_@M^Q
MC*KA7@MM$_:>^-\!@)(W6\U[??LBW(NQ&')6[33[,S&V -E +W=8 'V;17PY
MJ&O?\%*9]7L6TOX5_L.:5H44VLKJ<.H?'WX]^(-6O;:/3]<_X1Z:QN;?]FSP
MS9Z7/=ZJ/#8UFUN+36(]/T^37&LKS4KF#3UN>3T[Q#_P5BC6_?5OA!_P3PO&
MEO+&33+?3OVCOVD].6RL)-)MKC4K2_O;G]E?53J=Y9ZY->:18ZC;V&D0ZEI.
MG6WB*XTS2KS69?"^@@'T#^R]?6USX%\=6=O:6%FVC_M'?M4V-U%IVM?VW;RW
M-W^T=\3]>:[DEFAL]0T^_O8=9ANM5T74+"T&D:G+>66C2ZWX9BT/Q-KGT=7P
M%_P3<T3Q!I?P"\>ZIXOT[3]%\9>+_P!L#]NGQ-XRT#0_%6M>-O#.A^+C^V%\
M:_#_ (ELO"7BCQ#H_AO5]3\*7.LZ!>:MX>^V>&/#4UEI>IVVGRZ+:36LC2_?
MM !1110 4444 %%%% !1110 4444 ? ?[8EJDO[1?_!*6Y>XM(/L7[>?Q)=$
MGBN&N;MY_P#@E_\ \%'+<6UG/#'+%$P61KJ9+LV]O-%:G9="[CMK2\^^MZ'&
M&4Y.!\PY/H.>3["OR-_X*V:A\.])TW]B/6OB?+\78_"?A+]J;XS?$K4!\#/B
MSXU^"OQ+DMOA)_P3 _X**_%&]AT+QW\./%'@?QO:"\L?"-SIDFF:/XU\+Z?K
M\]_::'XOOM1\$ZCXC\.ZWO>#?V<_V>/BGXIO/A_I_B#_ (* V=AJOPL\ ?&"
M'Q%/_P %'_VXK.RN_"'CY]:3PG&+GP[^UG<^*-!O-8:3QAH(M;\Z3/JW_"OM
M2O8)KW_A'-"UV4 _57<O3(STZCKD#'YD#ZD>HHR..1R,CD<CU'J/>OYW_BM#
M^PU^S]\)_A[\:?C;XA_X*H>!?AS\3/%WQQ^&=AXHU#_@I[^WAK\]CXU^#:_%
M*^\%^ ]8TS1OVWKWQ!?^*/VA]+^&/CF#X!:#I.CZY/XC\9:UX;^%_BV3PK\6
M_%?PU\)W_P!!V?[/_P"S-J,7P>U'XBZM_P %+/A%J'Q/_96\;?M+>)- \;?\
M%+?^"@6BZG\(-+^$T?P0F\9>'_B1I?AW]K6]GTOXH>%I_CE;66K6'A2/4_"M
MY=>'O&5OK$EY-%X<6] /V=R,9R,$9!R,$<<Y].1S[BE) ZG'0<^I. /Q/ ]Z
M_G0U2\_93\#^ -$^+/Q$\,?\%2/ _AMOV1_B5_P40AA\4_\ !43]N77O&T/P
M"^#GPP\,:W\2TU#PD/VS-;?PO\2O!&G_ !_\$Z!K_P -DN= TW5OB#<ZK8^%
M/%'C/PCX(?Q%=<N]_P#L0^$9_P!L+6O#&@_\%4=8^*W['OP_^-6N?&+P_KG_
M  4:_;PTGQIXF^$WP7FO8O#_ (T\ ZAXO_:];PQXF\/_ !1_L_QK<_":^EO/
M#YE\1?!CXM>#-?&@>-?"&O\ AK7P#^E<$'D'(]130RGHRGZ$=P"._<,I^C ]
MQ7\ZES=?L8)^UA\3_P!EGXO7O_!2?P#KOP]\,_$'Q=XS^)X_X*M?MO3_  )T
M+X>?!CX*_ WXO?$OQMXJO/#/[:.@^*?AW\/=)\+?'CX3Z3#XT\7_  Z\/:=X
MA\77=YI=UJ%IJ$EZ=:]8^#^A_LI?M#:;X6'P6U;_ (*;^+O$>H_!#1_BOXM\
M"3?\%'_VQ?#GB;P'I.J?$?7_ -G_ %/X:^-=5\3?MD6_A>+XPZ!X]\ _':RU
MQOA]XQUB'2?$_P %?%AN_B3IUMX@^%$OC$ _=6F[EZ;ESTZCKG&.OKQ]:_FN
MUB+]CGPIHGB36X++_@H_XHG\#?"_]O?XT:GINE?\%>?^"@&IWFO_  U_X)T?
M&[1OV;/VG+[P9?:/^U\VBWOQ-U;QCJ>F:C\(O">O:IX%L?%>A:\]CX\\8_"3
M6])U7P=X8VO#NK_L\_$JY_:.O?"GP>_X*R^.T^ E]\;]0\32?"/_ (*H_P#!
M0KQ/_:6G_"CXC?MS_#6RM-$\&Z-^V]H/B^7QI\0?&?[%E]I?A/X5> _!/BS7
M+:#]H7]GJ4VJZ;J7B=O!0!_1P"#T(/T.:6OYQ"G[(6H?!GX/?&3P_JG[='BG
MPS^T%\+OCAXK^'7BRR_X+5?\%+&^#*^//A7XI\.^#?A5\//&?CZ3]J@^// T
M_P"T9XU\7Z5X'\'W.N_"?_A*_!7Q,GT/X*?$7X:^%OCYXET#X6ZS7L?@-^Q!
MXRU?P=I&I_"S]N=_B'\1_P!J+QS^RCX$T36O^"IW_!3FZ%S\1/A?IG[1?B^_
MUWQ+XKE_:1ETK2/",7@W]G#XH^/+?4O#L_C36-+TR2PT_4]$T[QGJQ\-T ?T
MAT5_+%IG[/W_  2MUJYO?$'@K]FO]JKQQ\.M,\>_!SX)_$[Q]J/_  4 _;RT
MO5-"^+7[57B.S\!?!71?"'A/XH?M&Z'K7BO3O%OC7Q-\+-'O_'TUWX+OO LW
MQH\$ZH+%KWPY\;K?X2>E_#?X0?\ !.;]GSQ9J&MO\.OVNOV>-,UOX7?MX_$G
MXF?$CPQ_P4U_X*":[8+X;_X)B_%[2_@A\6T\4Z?X-_:;FUGQC8"^\?>(O&_P
MAMKO3[S5+/P@FJ3ZUX=\!?$F_N? ]L ?TH!E;HRGDC@@\J<,.#U4\$=CP:=7
MX*>!/%W[,GQP^%'[(7CKX3K^U[X@\*?MN?%KXG_ ;1+[6_\ @JY^VWH]OX'^
M*WPO^&W[4_C'X@^&)/''@+]I;XBV/BC3=%\4_LQ?$3X?Z9XT^#VN>)O _B::
MZ\.^,_AQXA\3^"AH^KR?)_A7XG_LE>)O@;X/^/VN?!?]O*\\+:_^Q;^T)^W1
MXL\'_$G_ (*>_P#!3WQ'J.A_!S]GW1_V+O'_ (V\,:?IOQ:^*]M\/OB3X\\0
M_"']JA=3\+VFAZY/\+;[QSX'OO@]J_Q-T>+Q#\2?$?PQ /ZFZ*_GI^+O[*__
M  20\._$/]C;X3>.+;]I'7=4_; U:[M?A)]I_P""A/[=EC=Z1&OPR\:_%;P]
MXL\?^%O$_P"UUH?C6/2/&>G>%M6\#6&M'0]<UN7Q?/X4\(ZUIL.C:=<7GA?Y
M-^(&@_\ !(_PA^SM\-_CUXV_9O\ BG<_#?XK^#?A5\2? &DZ)^VS^VEJ_B&R
M_9R^+WPP^(6N_"[X]_&[29OB1I+:%;W>B_ R]F\0Z?X6G^-'C_P#XEUR[\<>
M*CI>M:QXQ\0W(!_6117\HG@_X8_\$M_AD?BLW@W]F3X_^!])\!_M%?L]_L]^
M*-'N/V^?V^-,N;[5OCII?_!/WPOX)\;ZMI-C\5]=^&]I=_#_ %#]OSP7X2^*
MMAJ'C27QWX>T[PO\0;SP5!\2+/7]9B.I\?M*_P"";'P\B\>>'?&7[//[5&L^
M.=-T/X#^*/@5X3\6?M__ +?GPRT']I27]I[7O#.E:]IGAC4OBO\ &7P9KFFZ
MW^S98^(O!'C7]HC2?%7@.>Y_9V\">+?AUJMS#HVIZHOA_2 #^J>OPE^-OQ7_
M &8]'_X* _M5^#?VXM;_ &8OB?\ #_Q=^SW\!_@Q\!?!/BGQI\#M:\0_#NU\
M;:7\6;_]H/X/?$;P7\0?&]EKOP?UGXZVGB/P%XHO?'GB#3?!/PN^+_P_M/A-
MX*U+QE?^+O!/A31+WX[TKX9?\$XK7X0Z-\2/%7[)W[3WAGX-WGQ%^(/@;Q9\
M0Y_V[OVYM1\+?"G0_AEXMM/ VF?%_P#:'U3Q3\:?"7B"?X+6GBC2M'TS7/B+
MX(MOC5X4^#?@KQ'XAU;QGJGAKPA%\:$\/^N?LW?\$Z_V(/CI\6?%GASQ-^QW
M\7/AO!_PH3]F7]I>+7?$W_!2+]O3Q7\4TTS]I71/B%;Z?\/?''A:[^*-I9^&
M?$/@SQI\,/BKIWBW0M&^)/BCPC<Z99?#'Q7:O=^)]5U?PS\,P#RSPY\<?A!<
M_!CX;> ?BI\=?V?K#]L?PA_P4)T/XM_%SX_:_P#&?X,3>&/&WP/\0?M*:3XV
M^('BNS^(5IXGU/\ X2?P-^T5^Q1XSA_9-^&_P2\,VFJZO!J_BWPA\"(O WA?
MX:^#KCQ#X3[[]ECX.?#WX7W_ .R/\,_VK-8_9L^)W[-?PQ_987QUX-L/C]XD
M^!&L_$O]E3X_ZO)\!=:\<_LW>(?A]XJ\1:Y+8^!]"^(_@%OB+^SI?_#B[\7Q
M_"K6/!?B;X-ZB/"_AKX6? +5O$GZ)3?\$;OV!+FPU73+SX??&C4K#6$M([JT
MU;]M/]N'5H+:+3[>UM+"UT5-2_:/NO\ A';&RM+#2[2VL?#YTRTAM-'T>UBB
M2#2=,CLOG:P_80_X)C?"'XH_$[X*_#_X4_'30-5^&WP2^$'CCXWZSX0_;-_:
MP\'Z#X5^%GQ@^(7Q \&^"[SQIKE]^U%X<.KVJ0?"_P",7CSXAW-S/>WVD?#C
MPEK^HZ]-J5QXU\/Z'XI /C3X.^#?!]I_P2__ &!O#_A'1_@3X>_:B@_:)_8I
M3XT^,?%GA'X7_M$^(= \1?L]?M#WWBG7OBC\==2T7XD^#X)?$6BV=MXS\0^)
M_&DWQ#O?%'AR3QEXNM_"/B&X\1WEKXKM>%MO%OQ"\#_L-_ WX'?#OXI?#GX%
M_%7]B+POX@_:1U#^VOVJ_!'AOX*_M(?M3^$?C)K/Q4^'_P (?@]\4[;QMX>M
M?''[+7QGTO2OB#YOPQU2[\$^'/A'\%/V@O@)X7\?R:?K/PX\7?",_7-EH'_!
M#GX>W.A_"OPG\8_&EGXHM?%_@&P?X6>$?VU_VY;/XB>&?$_Q!^/_ ,-?@I;:
MO\1/!Z_'ZQ\5>%M3T'XY?$OP_:_$^]^(-MIVO>"O$'B;XCZMXWBL]4UWXC/J
M73>%_P!GO_@ASXJL;@Z;\;QXJT+3? /@'7)9?&O_  4:_;"\2>$_^$+U+2?"
M?CKX?:RD_C_]IF]\.W]_HWAWQM\-?&6DZE#)<^)O!&@>+_A#XCDFT/2]=^'5
MY> &-\!OB?\ LP>,OCC^U%8?M9WG@SXEV7[1W[1/P?\ VE_V2_C3XZO_ (8^
M*O!;? O1/A/\'=6^$GPXT?QC9>)];?X):S^S)\<- ^(\47PR\>GP4OB?QIXX
MUKXA_#>Q\=WWQ,^)T>F> ?$*^_99\(_LK?\ !<S0-"\4?LI^&?&?QOUO]I;P
ME^QOI5GX_P#V?=$U'Q'X:\<?\$WOV=/@/X6T#X90Z9XEL8O"OA'7?B[X-\8>
M&I;*74-!TY'TC5O%'B)M(T>XN+VV^J? ?[*W_!%51H=CX*\<ZI!+J/Q&?PWH
M"M^V[^V5;ZIJ7Q3^'W[4=Y\+=/L[:34_C_;ZE=>-/#_[5?B6XT/P=/*TNMM\
M0+RRU_PM=7B1Z?JZ==X=_91_X)86OQ_D_9UO=#\4Z)\7M$\?:[I/P\\ >(OV
MROV@_$C>,_$6A_L^_"WXE^,Y_#/@2W_:.\3/H=MX6^&'Q$\.OJ/A_P <>'/"
M=W+%JGB+Q?H&AZCHWC*^\4>(@#\_?CUXJ^#]A#^U3\3?@+^U[^RQHGB+XP?!
MSX?? WXM? ;X@?M-_LQ?#;X(?M)?#RP_9]^&_P -]4^('PW\6Z?X[FT#P=\6
M?V8KN\UU8/B)K'AVWT7QSH%AJ?[//C7P;:>#;+X-?%'P1K>#_P!M/]FSX*P0
M?#GQ/^TM_P $_P"U_:$M_P#@J]XW^.'[0WQ2\5?M%?LEK>_$#]FWQ9\;/BAK
M_A+XR>'?&.G_ !@T/6/#7C;X;? _4OA;^S/>^&/&>FZ;\5-'TGX<^(/A;I/P
MWUGX5>(O!'BWQ%]:Z+\&/^"*&O>&/"6N^'OBAK-SH6M^&[[7O!B:9^VC^VQ:
MZIXETC0?'6C?LZZ9=^'-!M_CG;^(?%>J:Y\3M9T'X6_#2UL=.U'Q%\1?'LMC
MIWPSA\2^(K1&MNVT3X?_ /!(SX9?#/0?%7@;Q/::W\'-!B\4>(M0U32/VQ?C
M#XD\,?#[P3\ ?!^N_$#Q%XTU3POXI_: GU;5/!/PMMO@,FCG2_"'A_Q3>^&I
M[62TLO#5OX=3QK>V8!\G2_%WX(>*_A=^TYIOAK]L']DC4/CM\0_^"A.A_M%?
M"']L<_'WX!:]X=\)?!2X^)_P^O?AO\8],O+_ .(3:7;/^S1\ ?#_ (K_ &4]
M)^#L\NG77QKN_A-K]OK?A^?X1?&GQIXXO_C_ $WQ%^S"W[*'['4&E?&O]E?P
M3\3(/VX_A'X@OOAMI?BW]B_4)O@7\'_A_P#MS_''XE_$_P"(/C?Q1;_%#1_$
M'BKX#ZSX8T7PAJ>L0Q_$"\L;D_#OP!_8NAWFM:QXE\/:G]_?$[3?^"(_POT;
MXY>-+6_\:^-O%?P@UF/P;\5?A%\,?VDOVL9/B#9>*O%5AX[:?PWJ'PKNOC?X
M>L8=2TOPY\+OBQ?:W_:5C8Q>!_"GPU^*9OKG1[3PUXDLD^FX/V8?^"4]Y\2H
M? MI?ZI;?%'Q?\7]=^%::%9_M)_M8Z3XHO\ XP?#;P!8^+]6\-W0M_BS8SV&
MJ:=X!\$VGBBTGNYK73O$,/VS7])O-6U/Q7?W&M 'YR_M ?$GX"P_&7XSZS^S
M]\9_V/O%'AO2O!?_  2CC^/6B?!7Q[^SGX:M_P!H_0O@G^VY^V#\2/VSO@?X
M/\':1\<AJC>./'6@?$'3?$VI_"K6M.U/3OBHW]I_ _Q+K_C:Z^(%W:V/9?'W
MXH?L4?%/]K;X)_'KX4>./V7]'^!'BO\ 9M_;^\/?M5?$?Q59?L\_$KPN/%/Q
M:\*?L9I\#=5^)W@'Q9\0;>32H-0T#]G:U\8V=OXDT:PTU]$\.:9IGC73M#_X
M6.VH7?V;XJ^"_P#P2HMO%^IZIKWB36K&YTGP?\/X;?XB>'?VTOVBA)?:%XP3
MX\^%_#?A6R'@#]H>Y\;Z;H\=E\ ?B=!I-[K&AZ3X$\4WVEWVG> ]8\3^*_#W
MBG3O#_B/QJ^#W_!#SX>_!+Q1^V1X[DUCXK^ _!;^);2#Q?IO[2?[6GQ@UG6_
M$OPR^!^H?$J#P[X<^W?&?Q +G4[_ ."7P\MO%O@G5+NXL/#OB'P;'X3\9:/K
MUQH.O^'=<U  ^0_"?Q8_9"M?V]?%/[0NJ?$W]G?PK\%#^WK\&OVI_@]<>%?B
MI^RWX,US7_#_ ,1_^"7/@G]DO3?BG9_$VX^/5EHOB?X%_#7XD^&_VC?#'QX^
M#/@7PUJ7C>X\<3>$?BNGBV/P'X \>>$_B#T7_!2'Q7^SGX_^.'C'XE_LQ_M2
M_P#!/34M:\<?##X/_''Q5K6N_'K]EI/%/A;]LK_@FG\1Y?C)^P@_A^2[^*6F
M^*V\2_M1:Q\4KCX!?$OXC2>'_&5SX8^ WPUTWX?62Z2_CW1[^P_0#P]^R;_P
M1^^._B:U\+>&'TSQ]X@\=ZAXLTG1M-\)?M3?M'ZW)KC_  LT+P3?^.(Y[?PW
M\8Q#X=E\&0:SX&L?$EGJPTN>VN%\#K>HTTGA:)?HWPQ_P2._X)_^#M0T76O#
MWP0U>#6] DMI=)UO4OCC^T/K^L6[6L'V6W\S5=>^+.HZC>+!9G['"E]<W,<=
MHJ6JI]G1(E /PG_;"\6_LA^-O!.G7?@CX^?LZ:X?$/\ P3 _X+/Q?&2\^%_[
M17[/?C22+]J__@HQIG[+OQ T3P197L'CJ9/&GBOXD:A-\4?^%4Z)X2O=0U+5
M/#GA7PY8Z0'\)2:5#>?87QK_ &U_V.KWX??\$Z_#^C>)_A/J&C_LL_&S]F+X
ML>+V\.^+?@/?^&_A)X&\(_L^_&GPGXU\1Z!!X1^*<MGH%M\#I-1\-^#/'R>$
M=*U^TT*Y^)W@3X<^'+#5;_QW:2:1^G>H?\$P?V+=;BLH?$GPT\8^*$L7N9HW
M\4_M _M)>*+FXGNM?3Q-)-J=WXB^+VJ76LR1:M%;&RDU>6]?3M+T_2- L&MM
M!T;2]-M?BO5?!7PX^$O[>WQ9^&L>A_$BX^%'AOX*_P#!*O1O '@+2_VA_CAX
M*\->'?&7[0'QX_;C^!_BOX@?8M/\:-I_B_67\*_!CX/:7J=AXB9WU?3_  )!
M;VE]%KNJZE_;X!S7[;__  4#_9K^/'[/'PM7X7_M)_ R".S_ &E?@UXY^._[
M-/BW]H[]GSX?_&'XT_LL_#;XP0GXI_#M/!_B3QGJNFWJ?$3P_8:#XJU+X+>.
M=6\":I\1_AO?77P:^)/_  AVM>-]:\$MY.GQR_X)^^)_V]='_:S\.^/_ -EK
MXB?L^^)_@!\4KWQ!X%C^(?P0U'QIX>_:R^(WQ'^"O@#PW\=];^%'B+XAV']C
MZK^T=\(_A)X>^$^B?$#4_#H\0>&+;X?:K:>/KOX4:)JWQ0OM8^B/@Q\=?V?O
MC%^QU^TW^V=K'P0^)6@7G[,%A\8)O$W@/4?VL?BCX_O-8N?@I\#="^([Z>GB
M^R\97=LE]!H>J6'AB#Q#;Z+KGA2^\1:.?BE\#O%WQC^"VN_"3XZ?$C],;W]E
MKX*>*X(KR[LOB";2]C@OH8M-^./QXT.WW2WC:O#=)::5\1M+BAG:2?9YOV2W
MNETZ.TT:3;I=C:V,(!_,'\"_C&WP1^)_PW^(6@?MM?LI_#3QFO[)WPP_9Z^/
M7A75/VK?V=O&7PD\&?!GQGX__:[^(OPOU;P7X]\1?$CP#!\9_BY_P2TT'Q1\
M#++Q!KVK2^(=)\0?L^>/?&_AWP]-XF\5^*]*\6W7BW[$_P '?V1?C]/\//A9
MXB^,7P=^%.B^$_A5\3#+\2?$GQ%_9J\1?%^TM?"O_!8+X_?M:>#/A=X4\9R_
M&;QI\3/"OQETOX8Z+I?CW7O'>DZ[XJC^&F@_$[3?'-U;:+XQ\4Z+]F_J*T#P
M/\)M1_:0^*/P!'@?Q3867P^^"7P)^+L?B^'X_?&1IKY_BSX_^/G@VT\-P^%&
MUZUMO#L?AH? -KRTUS2O$NH2:O;>(KG1[C1= M--CD\1? GBOXQ?LGW'C+XR
M:9:?!?QCXI@_9V_:H^#/P!\?:KXN_:D^/FE1:3\-/C]XSTOX0:?^T%#H=Y?Z
M_!!X0L?VQO"'CGX0>-/#6LMI13PW\,?&/[1^J:X?A]XDTB?Q2 >2>)?VROV8
M](_9R_X* ?LM:=X_\#>(_B=^T)X]_P""@A^'7@_X:?%3X/:;J7BS2OC)I'Q$
MN_">OZ'XAE^(7A_3Y==^('C&\F\.:7#I>HWWC#2=?U:W\=^-['PC\+--\3_$
MKPYYC\3/%7[.FM_\$M?VK_!GB_2/AWK/[0'CC]B+2O@MX#3Q#X0_9M^!VN:=
MXLU[]FC7?@SX4^ _P_U^;_B<:?H_PD\1-XBU9/B7\0] TKPMX,T3XLVGAVP\
M7SIX<U[1?!WN'A/Q'^QWI?[(W@K]J[XB?L7IX#TCXTZG\%XM2\#K^T/\0_'/
MC3P[X.U3X9^![G]KOQ=\68M6&A^(/#]S^P]'>_M)^&_C+X2ET75/%^H0? 3Q
M-JNH:?X7USX@OH>C?-&MZI^PKXS_ &B?C[X)'_!-7P1XRUKX)?M+_LT?L=WG
MBQ_CU\3H-/\ [)^(O[07@;]D_P )>(_%*ZA\,;>+PC?Z5%\24\?^&O!7@37/
MB-I'B.S^%DNJ?$SQ;\._B-X<_9IN/' !]3?M9_%3]C;QQ^V!^RYXA\&?%K]D
M/Q)\*+;]E?\ X*+>%_'WB.PT_P"%G[2/AGP1XL^+/Q(_9(^,,>MCX3^&O$ES
M"?&OQ"M/A!\?]9MO&VJZ-K/A_4?$6E^)H/&6G>*=1UBST?4.Y^/7[4_["?C[
MXI?\$RKFV_: _9N\,^$?@K\:OB+K/Q*^'U]^T-^S!+I_P8\'^)/V&_VK_@=I
MGA/XIQZ%\<M1T721:>//$VE_"FSA\(R^/M%N_%T-UX?@O%TR.;5X_2/V>?V"
M_P!@?]IG]G?4;BX_9D\=_#72;_XJ?%3P)XW^'VI_M ?'I-1\-_%+]FWXP^/O
M@7XW_P"$+\8^&?C!9ZK#X%7XE_#OQ-XI^'VJZ#)X+'BBUN- ^*.J>#O#'C?4
MY[73?CKX0?L_?\$R?%'C6]TOX)_LV?$ZW\/?#OX3Z)^U1XS\>>/OVU?VPO!_
MPZL/@^GQ6\??L[_"SXB"TD^*?C>V\;R^*?"?[)_Q$^(^@:;X@TBVM++X>>%_
M#M])J4VM>/-2@L0#S/X\P?L.I^S+_P %DOAS\-M3_9$;XD?&J?XV>"/V/I[+
MQG^S3X<36;#XO?\ !/']D[3?#NF?#;Q7)XUT#2M*\#Q_'OX>Z'I,7FZMI6G>
M$O'OP]\ ^*M6TBVLO"7@OQ(.A_:L^)?[/'Q$\?\ AKQ;^RU\:OV78_VA/@=\
M:K[]K+X3>)+;QI^S_P#L^6=OK?A7]CKX267PV^$FMZTWQ.T_XAZQ\(/VC?#.
MO_#;]G;XNZOXOL-,L-=\"?'_ $F?1+ZWTSX0_#>#2:'C_P *_P#!"B[\2Z,W
MBOP+\7_$GC3X<>)?AC/XF^#?Q$\;_P#!03Q=K^AP3_!O]I?Q;\&=!MOAMK7Q
M4U/X<6>IK\._AAX^\1Z-X<\71KH&F?!;3;"WO-.TVRU'X9V]>_:/XA_X(N^)
M[7P%X<T&^^.>NZCXB^$'P]^-?PI\&-XY_P""@Z^.?'GPW^*7C#X7Z'X*\9^!
M/#NO>,=/\2^)_%?B_6_&7PT\1W5O#%<?$_4+7Q.?%>NV4T\WC.:T (_V#/VI
M/V?O '[4O_!17XD?'7]H_P#9A\'^)_C+<?LP_$F[\6:A^T]\ ]5T(PV_PR\6
M^&=?^&^C:U!\7?$&I6>C?LZ>*?#VO_!O4+-X](\(WNN>%M6\=^&X8M4\;^+]
M-T7Q!-#_ &"_BM_P3=^-7[/7CCQ?^R'XEU#Q'^V%_P %!F^"&E7OQ<_9D\4^
M'O@;X=_:>_X*(?M,>#/AA^U9\.O"_C;QV?A=X<U;X+?!WQAK7Q5\"ZKI5JGC
MO0/#?A#Q_P"&_AWIL_BG5_$'A'6O:;&'_@C?ID.NKXE\$_M(Z5K/@S6?BSIM
MWX)\?^(?V^/%7B^6\MM._:(F\3Z_-X3N_'GC"\6[^)'@[]F+X^W6CW_B>WTW
MQ1JWA+X9:EH&O0Z,;/1O#S>N77[-O_!-B3]IC3/V:/$?PY^*MGXK\;^'OA9X
MD\':3K/QT_;JM/#NLWWB#PY\?_B-H_AOQ'I7B7QCHGPCTO4M+T+X*_$37=$\
M V?BSQ%\0=2:/Q_?ZW\-/"FA:%J7B+7@"C^UY\>?V9H/V@_^"?/QBM_VEOV<
M?%7[*'[*7B3XWZK\5_A]H?QC^'_C'7?"_P 0-;_9[\56?[.'QKMO!5EK>MZU
MXWLOA=H7@OXVZ*MEH4&I>+_#C>.6^+$>FMX1^&GC[Q;X,_$KQ/X6AAUWPWXK
MTGQ3\"O 7P6N;7XR?%7P/X,'[1G[,'PW\5^"?@K+_P %(?AW^U+\!_V=_P!F
M'XF7_P 5=/\ !WP7_:XT+X/ZFWQ<^&2ZQ++X"^$7AGQ_;_ ;PW\1/A?::SX2
M^)7P;_5#6? __!#'X;0?&#Q%-\/OB#HOB?X)^"/'5SXHT-/%_P"U]H'Q.M_A
M=X ^,UG\ ?&/B+P=H^N?$#1?$-A\.-!^.4!\&S^)H7\/^'-/U+3KOQVE];^"
M%'C6;V;QY>?\$J/#5O9:=\3M>_:'T2RU[X9_!+XOZ+:^)?CM^W;;6NN^&_C1
MX7^/GCOX:V^AP3_%F5-0\9>'_!7[.?QS\7MX3L$?Q'X#TOPWKS:7:6NJZI/8
MW@ ?MJ?M4_LC_%+XG_\ !,OXF>%OVH?V7;OPO\$_VX;OXF_$OQ1)\;/@O%J_
M@7P*_P"Q]^TEX/O[JX_MOQWIEQ#H4?C#XF_#31_B!!HSZAJ?AO\ MC2_$.I:
M:=*\,:U<:=\K?\$D_BO\)_@]^T!^UYXS^,/Q\^!&@6?[0NL>(_&GP?M_%7[0
MGP.D\;>#_"VL?ML?ML_$W_A26KWFG^.]0\1?&R^MXOCGX;^/ND?%C79[CQ'I
M6A?M':+\&-9T/POJO@"-/$WT]XKUK_@D3\/6^*&D/I?B(:U\.+%=1\87TGBO
M]JBYM$D\*_'*Q^ 'A;5=9\;:=K.MZE)HMG\:OB8_@#0/%Q_M*VT+PIX-O=1L
MI+?X8?"+P]<Z)YWX5U/_ ((\^./!WAS4?$_A#XHZG9ZGX<^./BS7]4L]:_;V
M^('PX:U_90FTS2?CM>1^(+^=+_Q)\/K'5]7L/"7AO_A)/#6FV_QCT\^"O"5C
MX9U0ZCX+\-2@'SM\3/V@O!?A;XK_ !P^,/Q9\?1^*OA__P %&_V:?CG\"_CE
M\+?!?[5_[,/A#XI_ 'PEX(N_B-HG[%'A&RU+Q5\0_"/@SX->,)/ ^F_MY>%O
M%>N:'\7/%&CI^T_>7-MXGU'3-!^&WBCQYX4]^^!'[3WA/]G3]A_XV_#W0/VA
MOV1_#_Q9O?BQ9?!_]GWXWZA<?"G]EJY^+^G7/PT_9\^';?M4?%'X/:KKVM^'
M]!\6_!*UU;6&^)$_AK0Y?"_CWPS\#-/^(.A^ /#-A\0--\ :;TWA/5?^"=-W
M;?#K2_'O[/7Q/^%>L_%7XJ?M8_#3P]9O\9/C2DVI:I^S5^U7X*_8<L].\<^)
M&^(OABYOO'_Q[^)GQ*^%?A[P]X0U&3Q%9Z_J_P 1O&$>H^+O$6E/XF\7>)E^
M+6I?\$>O _A3X5Z[J7A/3?'OACXC_"KX3_M)^$K[QQXH_:Q\0:/K'[-'CW7;
MK4IOCMX*O=1T7Q_!XBUKPHDNF^+O'FF3_P!@^(?#]AJ_P^U;XK>(O!MCK7@6
M^N@#Y8^%>L_!6>[_ &2OV6(_&/[,OC_P%^R;^V=^TZG@'XO^,_B'^SO^T%X!
M_P"&'?CO^R9^V,W@6PT5]2^+5AXU;X;_  F\3_%'X:?LB>*AJ6B^&].UK4_
M/@32)=#UC1]3MYM,N:#^SK^Q=X-_:OT'2M3_ &S_ (&?#G]G?]D7X-?\$CKG
MPE\7-<\<_LVP_%WXL_%;]ASQ3^V[I5GX/U?XMZS?6:^"+-O#,>A:)\=-0\%>
M#=+N_'/PTUSQ#\$/!?BWX=^!?#OQ(\*2>^^#?AQ_P0D_:4^)5E\"O /PCNO$
M'B>ZA^*OB:[M-&T;]J/X9^!/%UWX \2>*M$\=>&-:\:S:GX&^'_QICO-4\*?
M$0V/AN+7?B'X.UCP[X8\0ZO &\):GHU[KWS'\.?C-_P1';X3>"_'.H?L8Z%\
M*/ WQ(L?^$ZO-/UCP9\?-9US5?@I=>#?VK-7\$ZUX4_X03X>^*],^('C"W\-
M_ [QQJ7Q=^'\7B73/AG\+M-UOXJZ@_Q?\;ZYX5O]-\: '5:U\>O@];_\$JOV
MG?V4/"ESX(UKXA_'KPY_P4Y\1>#+.+Q_^S9XAT>\\7?&S]IO]H7Q)\%_!FN:
M1J/Q0.FZ]\2_'(\:Z3JE_P##K41<W'A+0/!WQ*M/B?K_ (?U[P/<Z?J7O7P1
M_:(_8OM/C[^V-X?^/7C3X+_&>;XE?M5:'^TC\'/VAM'^-OP)^)7A&^^%/A;X
M1?!+XM? W3[+Q+IGQ=U7Q?\  *Z^"7BSPPVB> _!'B5/"&F>.?%0C^-7PHM]
M6TSXE>*_^$>Y/]H#X9?\$</A;\8? 7@F[_9"\(^)+[]H?6] \>^._%GAA_C9
MHGC!OB#\19?!/_#/^D^&=0T+3!H'COXC_&OXEZCX"\+ZCX:B^*?@V?P@?%N@
M>+?B.T'ASQ_'>:OS&G^ ?^#=+7/ ?@'X_>&/ 5EIGPN^($/B?Q!\,_B9X-LO
MVQO!'A;Q)9Z3X2^.WQ=^(1\.P^&K[P[+;Z9\,_ _P(^+6K>+=*DTNPL/AKIN
MC>%O!45CIUUXI^'GAG5@#Y7^,WQIU/Q)^SY^WH=?^+O[.<H_X*??L+?'[Q#X
MR^&]M^T]\*?$]]^S_P#M66&D7G@GX(?#3Q*GCGXU?"GPEX>\6>._V=/%.A?!
M2_U/P]>WG@<^-OV0]%N8=6UR"]M(_']GX3_&#]F?2OVX8_'UO\>/@KXT^'2_
M\%,_A'^T2^I^#/&7P%\"^$+W5[W_ ()G?M@_L[^/_%/AS]F7PA\:?$_B/P_-
MX=_:"\5>"_!?BGXW^)/"UG\3OBOX_&G^'-;N/'G@[X#6WQ+C^KXO O\ P0'B
M^'>I^+O^$"\?:OH/PW'B\V^F>(I?V]+[QG<WNDZ[^S]X1USP7X;L?&FOMKOB
M'4T\<_M6_ 'P3X<\%Q33VI\3^/-.M?#5A':^&=<U#0?1-"^"?_!$OQC\2?"G
MP!\&?"SXH>'?'/BW5O#OPTTOPMH>M_MM? &]9O%WPLN?VF[?3+]+[QE\+M02
MTTCP'XWM-8\9VTD-S?>!M7^(&@^!_%MGHVM^(+?0G /GOXE_M/?L(?%G]M+X
MS?%+7?B#^S!K?AGXL?LR_P#!-+0+WP#J%O\ LT?'CXC?$'XA_!G]I7]JOXO^
M+?@W=V)^,EMH/P_\0ZEX=\4_L]:5;?%CQC<-X*\.Z_+X&CB\;Z1XK^&DNC67
M]3U?CE^SS^P1^P=\3_"/QA\#VWP+\;^ C\,?CS\:_A7\0_AWIG[57[36H>'1
MXCU+5?#GBO4?$L$-C\7-,M8H/C?\/KWX5_$OQ%I<VEV=S<6NO:?X>\0'7(M(
MCU&^]]U?_@E9^P_XAUG4-?U_X6>+=:U75)VN+VYU/]H+]I:]3<YN"4LK2Z^,
M4UGIENIN9FCL]/M[:TB9\QPHR1LH!^B%%?F['_P2,_X)\Q3K<?\ "A[^5Q<7
M%V\=U\:/C[>6MQ<7FE>*M#NY;VRN_BE-9W[7>D^.?&-E="]@G6XB\2ZR9@\E
M_.[_  ]HOP7_ ."2&M>*O'^B^-/@5XT^&.M?"GXB_$;PY\7K'Q[\7/C=IV@>
M"_'&A?%SPWX=^&OA[Q-HMC\9;BQUP_M<Z3XKTKXP_L_>$K'0];A^+'P?O[Z3
M7-!TRYO+CPI= '] =%?S\^'OV:_^"%>M6OPB_P"$(\0#QAX<^('C3P-\-O@E
M<?#_ /:F_;*\;> O&GC/QYK_ ,:?"^@M\/;[PC\8M;\$^(]3\7:W\!?CE<>.
M_'^CS7<>N1^ ?&/BSXF^)+C3Q)K5RGQX^&/_  2A_9JTFW?3O 7QH\<?8=;\
M7:7K7AKX'?M2_M+0Q_#GP=\)O"_Q.\=?%?QM?)<_M(>#O#6E^$/AWIGP/^*]
M[>Z'X.N]1\1^+OBU\)?$GACP9X5\2_%7X=>(8?" !_0/17XA_"#X!_\ !+#Q
M!)HGPVDTWQ'\,?B_X'UWP-\/M6_9L\;?MD_&W6OBC\-_&/C_ .$'BOXR^"OA
M9JGA?PQ^TEXTTG5;KQS\%M*\3^---\-:!J?B#1O&G@[P6\5U9W=S\,_['\):
MWC#X:_\ !)S1?B/>:7KWQY\;WWQ+T[QE>>;X&T3]OS]MGQ/J.C>*O"NC^.-)
MU>73_ACX2_:&UBVT:S\%V'P;^(>B^(YM+\-VF@>#-5^&7B72=<ETG7?"-Y:6
M8!^TU%?A/K?@W_@DS\)_C'\2/AAXZC^)'PT^)OP0L?#LMYH_BW]H/]JB/6_%
M7A'Q)I'P]\9:7X]^&?@>V^-NK>//BA\.;/6#J']H?$_P_P""-5\)>&OB%\.?
MVA]3U77]-U;0/BEK%VOPH^%/_!+CQQI=CKEUX=\1>!%\2>+M=\,^#] OOVSO
MC;XOU75IM2_:1^*?[.FA:WI>G_#G]H#QEX2T7P-XX^(/A'0]*^'VOZ7X@;PU
M9RZC\*/A]YWAK6? '@3P[HH!^Z]%?A9K7P[_ .",?A+P_K_Q'U[7I=.L;6XU
M#4-:T_2_CW^U5KVIV\FI^+--\ W+^'O!'@SXE^(9]7T>77(M,T_P_<^ =(U/
MPI-X9T6T\0^#;VY\ ^'K?7+'EC\"?^")FO:/H5UXK^)$WPX7Q5\([7XA3Z3K
M7_!0;]J3P%I9\$^.?#]MXAU6XU7Q'X?_ &G;'P!XDU3P]HWCNTU+Q!J.G:_K
MM]X)T_Q?I'B1M0TK1O%^A:KJ@!^_E&0>ASW_  /0U^$NI_L[?\$ROAM\;O%W
M[+OB[X9?M%:+XTTZ+X:?&/1];\:?M6?M1ZUH?Q%L?'>OZEX%U_QM\/\ Q_XE
M_:>U75I;CX/7>MWU[\?=%U*X\/>(?#/AGQU#XXFT/Q%H'C\ZMJGLOB/X?_\
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M5_'&STWQB_A3P7I_A*VU/X+^.=#OF^!/[0?PR^&/PI\&Q:BW[.'B>W\ 7_P
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MC>VEQ\1_$^M7&E>.?%WQ2U8:I#XVNJ^8[K]J'_@EU\0;?PIIEG'I7B#1=?\
M$VJ?$SP_H?C73/CU\._B19?$RU_:MUC0/A?XM^#W@SQ]X2\/SZ%XN\<?M>>(
MO''ACX5^,++Q-\+-1C\3:=K6C_#N_P!6\->']>L/"_7?%G]DC]A?4-4_:)^(
M?B/XX>)]2\4:/>:=\0?VHM*\'^//A3KOC_Q9XG^$?A.]O_!;_$W0[#P5JGC+
M5/%O@WPGXDT_2?A_X>OI=/N=.\+W/@WP9H>GIX1AT'0D6V_X)V?L%:7!/X,\
M3?%W6]2U+Q_KGQ*\.#3O&_Q&^&FE_$75M8_:'^+]S\=]2\#Z7JO_  AGA[XD
MZ'J2_$+P3KVK^ O">@ZCI6K>&-2TCQCK&C6L?C$>)-?8 [*#XE_\$T_AKX5\
M0?&OPAX4\/SZ!^SQKG[-?PV\:>(/AY\-?&>OKX"N=<O1)\#8/&-GHVEW-O>W
MOPHT?]H74/B3>67B.+4_&OP3\*?$6X\9ZMI7AJY\4:,^K^BZ]XV_8UL?AI<_
MM%Z5I_A671/A%XSUOX4:[K/BJY\?>"YO"@_:2^,GPL\0_%W1O%>FW&A:MK3M
M\5=<U_X?_%74]&\=>'$\._$2\F\!ZSXVUWPWX4O3XTT+P[2?V$OV,M!\#^'O
M VH?M5?%3Q+X6^(FJ:'JO@U/&'[17@CQ%/XO/[,OBW2/BA\/K#P_XBU30AJ'
MC&S_ &<M<\'77B>P@DU#6[VWU&Z\:^-?B7/XK\6:EKGB@\OKGP;_ ."=_A7]
ME?5/#VF?M+_$SQ]\ ]+\7_#S2['PW\-?VD+OXHWFM?$SX^^+H/C?\"/"^AZ=
MX9U'6KSQ7\1_B=KW[0GP]\<?!J'4O[2\0^)M(UGX):YI%]>Z#HG@>^M #I='
M_;D_X)5Z;K>A>.K&XT&S\1:UKGQH_:V\-:[:? _Q_JNIZ3XG\*_"7X]>#_C'
M\88FTKP9JL_PS\9ZS\%_@!\=]+\0PZRG@_QAXOCTCQ7X,O-%OOBKXDU7PMJ/
MEG@3XQ_\$?=5T&[^&\OPL^'ECIO@+PIXP_9O7P9>?!KXI:AX;L? /@CXR?L[
M^#+G]FN[L_B!\.O#$NP>,OB#^S-<^./@IJNA2>"=/U_5]3CN+CQ5X>\$>/?%
MUOGZ_P#LA_\ !(#6->UJ\^)/[0G@/XG:KKFK6G@#7O"?Q%^.7PH\<_;/$/C+
M5OAUX?F\,WGP\GT^YEMO&WCK7M3\!67C2[30;;Q]X[U7Q+H8\?:EK<TOAW[%
MDZ9^P5_P2J_:X_9<^'7QK\$?$_Q!X/\ @S^TS<^'OB#X4\9:%\4?!/@C_A+/
M$?B[Q!\-_B3KO@?Q?H'B+0]5\%^*=7U;Q#\#O"^C?$CX%>/_  YXHT30;SP+
MK/A >"=#F\-/9:8 ?6/[0/[:_P"PKX>GTD^/?#MUX_\ &'C3PY^R[\4?#VD1
M?"3Q;?>*O$\D.O\ Q<_:,_90T:SFC\+RZO=^/]+F^!'Q^^-GPX\&31->>!-2
M^'6OW/BX> =4\9^$(_%GSW\%?'_[(UG)/=?%#]BSX4_"#Q/K7QH\>?![X2?#
M'X90^+?CWXQ^(GQ7^ 'C?]M+X6?%*P\ _#^S^"?@K0- ^%VFV?AC]HCQ[X(O
M='GCL?%?@_XF_%7Q;\0? ?PQU^_URW\1=_K_ /P3T_X)Q_$CPCX!USQ'\4M9
M\<>'/$.A^&/@-\*?&UU^T=!KD6IZ1X,UCQ-X4\!?#+PAXRCU.6/Q5J/@W6O%
M'CGP-X+BN;_7O$VAW/C[XG>"=,OX3\6_B;I/C/R?2OV2O^"2NMZ/\0=!U[X^
MS^(O!EOXOT*XU2+XR?M+Z7XI\&:OXN\:1:;^TMIGQ)\&ZO\ $O5M5L/&-UX[
MU/\ ;'E\>2?$;2M1UN'7_&?QIU:_&J/XJU5+A0#TGPW+_P $VH?V8?BY\<?@
MS\$-,O\ ]G_X,^/_  9XK\?6+Z/\3OA]\+9;?]F_5/A+X?TOXY?#"SU.T;X=
M_$%?@?X&^ '@:Y^'7CKP+;W&G:#+\(6^$MYXT^'WB/P[\0-&\-_HGXC_ &1_
MV:?&=C'9>+O@I\/_ !+Y::?#_:&MZ'#JFOO#I=]\'M1BM9O$]X9/$EQ97FH_
ML]? N_UNSN-4DMO$=]\(OA[>>((M3N?"VERP?GA'^R/_ ,$R-.M/&%KX;_:6
MC\(K?_$GQ%\4/BROA+]K[3-&T;Q7\2-*\5)\5OB%XG^+W@R/Q.W@#Q1XBU#6
M/V._%^M_%C5?%_A.\UGQ5I/PF^-D?Q#O-6TRS^*"G] _AK^UA^SMXX\-:1=:
M1\8_!27Z:AX6\'ZEH/BGQSX+L_'.C>,?$\VN:9X7\+^,-'AUMFTSQ?XNO/"G
MB,>'[%@J>+)M(U*;PP=3MX@U 'F_Q'^&W[(G[)/PAO/%-U\!_#$_A"TU(_"[
MP[\/_#/@C2O$][XF\3_M<_&:S\'GX7^%-"\2WMOX8TYOC]\;?C%;:-XC_MO5
M/#/@6[U7QK=:S\1M=TCPI;:OJ]A@:5^T;^Q#\ M>\23^/-2^#O[+GQ5T[P%X
M9\$>-/"GB+5O ^AZWI/P]^#>LZUHGPD^']AJ'AO4+W1)O#EM;?$"Y\7_  -^
M$VE7-EXID\-?%ZW\0:;\-] UKQUK&EGLOVAOBI^RKXIM8/@;\>-5T'RO$OQ)
MN_#=GI>L>+=#\):KH7BGX1?#>U_:8F^+.@ZNWBO0?$/AH_!#1=(T+XDV?Q.\
M+W%OXE^$_C'2_#/C33;C0=2T?3/$-C\@>,M&_P""1\GQ$USXX:Y\??A!KWQ.
M\0ZI\$_%=U/8_M9:5KNI:_XY^'MU\-?!7PU\>VOA0_$JYT.Y\<>);+PM\*/A
MQKGC:YTQ#XA\-:;HND^(-4ATJ_UF\OP#[:T[]NW]D'4]-U768/V@/A[!H^B7
MGC*RU?5M2U.72-+T]_ 7QE\?? #Q)<76HZI;6EE%I\7Q8^%GQ)\-:3J;3C3_
M !);>!?%?B;PY<ZKX4T'4M<MOS>_:1TW]A;X_P#QI\?3>+/VQM%T6\_:+\$>
M-OV.?%OP]\)0^,+3PO\ %CPU\,O[:L+SX9>/=;\'>(-'M/&^L>#OB)XR^*F@
M_#J_34](UJ]\5?$#XC?!7P'J6M>*[6]TK3V?#+X,?\$L?B);_&KX&:5\,?'^
MD?!WPSICW'Q#\:>)_C/XQ\*_ WQ'K_@GXM?'_7O'WA'PEXLTOXWVUYXD\3^
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MA;6-K;V=N'=Y'$%M"D$(>21F>1A'&H9W9G<@LQ+$FOS$MOVNO^"BWDW4]_\
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MFEC6)WL;::[LYM4?PO86VK2Z7JWBKQ'X! .:\0?\$F_@=XMUW7/%'BSXM?M
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M51Z;#J,4.N:]+-?KID<>E6K06TLLTTEV]]J=_=7NJZEJ%]<^Z444 %?-FO\
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M65E\3]0^)?CSQ;XSBMM+C?5OB#XB_P"%B&2+QMH/A37= ^V** /DSXB?L4?
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MY5KZ_H **** "BBB@ HHHH **** "BBB@#X4_;;_ &?? ?[3<OP(^$?Q)O\
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MVVK:EX@\*?"W5Y-"TN&XOOB/K^K<Y\7?V(/V*/V;_P!DW1_"/Q"\5_%#X?\
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M<&J_VIXCO=(TK2M7OK7],*_(;QU;_ 36OVVOV^],_:?_ .$8\+_!O1OV7O\
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M%KX'EGU/P9K.J?%/]J3X;?$W3]?\/0:%K_C#XD_&[X,:[HVH:UXL\6_"V2Y
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MZ\)^'_ /PK\%_!O1/#&D>$?&-]:> /A':?!;4O /@#2/"UW\)]?T'PX =_\
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M&MZE^SIX^^.L?CWX;>+?#/A;X?6VKZ7\-_A##\0/#'B;XF_"3PK\8)O0+?\
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M\!G1FT*ZT#1[._\ #NF?M(>%[$^#-*\#7/BG5_&/PA^('Q(U3Q#J7P^ET"0
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MF@^"?A/7/$,OA/\ :=O?V=_%'PCEMOBMX0T7Q)\'],DM?B'X7TSQ2GC31=7
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MA^#\OBCX?60F\.^*_BMX$\?^"?$5KXQT36/B/;>&OC9I_C?3M9T&^\%#2;
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MX9:O\?O!G[:G@W6O#'@W0;KQI:Z=\=/@UXH\.S:&? ]EXR^$P!]BR_\ !/\
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M^L>)?#7QG\'?'[Q-X^TG5],\3:/XPO?%,L?@^7P[X U7PGX%^&WH'Q@\+_\
M!4[4M/\ AAXQ^%'C7P_H7B&W^'_PJ\=_$3X31ZE\,M;\&WGQ$T7QCXU^)GQ^
M^ S>-/%'PS\)^*[OPK\2= N?AW^SW\%/B5I5CX4UWP'HFB:]XV\:3VOB#5+K
M7[P ^RK_ /8T_9TOM4TC5!X %BNB>'OA]X<L=#TWQ#XFLO!K0_"7QNWQ+^%6
MN:AX%CU?_A#=7\:_#?X@O)XP\&>/-5T*]\9:'KD]U<6VN>7>7<,_G^J_\$[?
MV.-1\IM4^%%D+)?'MK\1VTRW\3>*-$\/WOQ&.M?!O6T\5ZIH.C:WIFB:YXBU
M#QK\ ?@OXSO+S6K'4)]4^(/@BR\8W?VCQ3KWBK4O$'#> ?A=^WCX=\!_&72O
M'GQTNOB)XOU'XR?LZZ3\)M;:Y^&.ES67[./A32O@#9_'C5V'AWX&^!+'1_C#
M\1+A?VC-1NO[8A\5:4NNW'@Z?P7?_#_P_)IV@>&_BSP-^Q?_ ,% -#^(.E?%
MSQYJWPE^*_Q@UG2_%OC+QAXL\6>*IK;P?-\5/#WP+_X)]>!_A3>WOP_LO!ES
MX6T_5;/Q=\#/VGKGPEK7@3PSI6C_  E\4_%'5_B]X-T;P\OQ&\;_  KU@ ^V
MM5_X)2?L+>(O!]SX$\5_"CQ;XR\/7^CZ7H>J#QG\?OVB?%>N:S9:+IWQWT73
M'UOQ9KWQ7O\ Q5K%]9:#^TK\9?#MKJ.I:U=7UKX;\3:;X=M9X=%\%^!;#PWT
MNJ?\$V_V1M8\0^*_%VI>"_&G_"6^-M(^*/A[Q#XETKXU_&?POJ]UH?QE\9_'
M/Q_\0],M)O"?C[0HM+&L>*OVC_BYJ%E?Z5!9ZQX<BUGPY8>&M1TC3_AQ\-K;
MPB_]FNU_:E^'FK7?AK]H36?&WQ8N?&&K:#8>#O$"V_P]B\.>!/"'@K]G/X1R
M:YK7CR[\)Z!I$\/B[QU\<S\4;'4WM+G5;#5]6FAU7P=X6\,^!4M-*T+YGT+P
M!_P5UTKX;_!?69_B;\+Y_B?X1\.?$0_%GP+KNN^$_B#X;^)FO:QX8\6W/ABX
MU#QI:?!#X-W46O6'C/5O#6I:5+X'T;X4>!-+_P"$:B\(2^#H_!US<ZQ<@'U/
MX"_X)[_LC?#RZTC5_AOX"UGPU#;>$G\&W-GI'Q6^*M[X6\9^"KGX$?"S]G2S
MT#Q[X7U/QOJ?A7XBZ3I_PC^#'PQTG0/^$PTG7)=&U70+_P 8:1<6OBGQO\0-
M9\6?6'@/P/X7^&7@GPC\.O!&DV^@^#/ GAK0_!_A/0K3<+/1/#?AK3+71M#T
MBR1B?*LM,TRRM;*SMTQ%;VT$4$"1PQQQKYC^S)X)\6?#KX)^#/!_C>!K7Q/I
M7_"22:C:G7;KQ*+--5\8>(M;T^Q36;RZO9+J*RTO4K*VBBAN7LK".)=-TZ.W
ML+.VMXO>J "BBB@ HHHH ^'_ /@G_H&H^'_@W\4X=0D9UU/]M_\ X*+Z_IZ2
M6E[8RV^G:W^WK^T;?0Q26US>W5J \TEQ=6]UI4&FV6J6=S;:Q<64FKZAJFHZ
MA]P5\,?\$]?$#Z_\$_BB)I89KC0_VY_^"DWA^9X'L]@73O\ @H-^TPUC$]O;
MRM<VLUOI5QI]O.FIV]E=W4T4FI6\-SI5]INJZE]ST %%%% !1110 4444 8N
ME>'="T.\\1:CI&D:;IM_XMUF'Q#XGO;&QM;2Z\0:Y;Z#HGA6VU?6KBWBCEU3
M4K?PSX:\.^'H;Z]::YCT70='TU9!::?:Q1[5%% !1110!XK\47MK7Q)X%U>+
MPW)XG\5:+IWQ)U'X?Z? ]JER?&$7@NZ$$,+WE[I=G;'5M$.N^'Q?:CJFGZ9!
M)J\4%W=VLEW;7EM^>?PD_:I_;PUGPQ;>*_B7^SMJ,EVOPO\ VF_&4/PZ\+_
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MX3\':_\  37]!^,NIZ(C7?A;Q?XE\)^"_!&F_$WQ'=:I9Z5^R-% 'X6>#O\
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M P(8!@>H(!![\@\=>:6BB@ HHHH 3:N[?M&[&W=@;MN<[<]<9YQG&>:6BB@
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MJ)J?CKQ%XO\ "?A@:!I;_P!@^/-0G\(_;UU&'3-&OM-ZOX;?L+Z]JGQD\:^
M[SX\_P#!-_4_B-\"_"O@:V^*/@3PG^Q-^V!X4\6>#?A_XW-UXR^'CMJNL_\
M!574(!X.\1WW@V&YLM1&BZQX;O!\-&\($QW/A$P>'>A^*G[!WC_4_P!FBT^
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M&GA#1_%FD?$:X\<>#P#X.T[]BOQ!X9^)MC^SQIG[;7P\L_%0\.:M&G@O3O\
M@B\FC>'M7C\)WOP[^&E_XD\)>)_!D_ASX:^,/#'@7Q-\2?@A:^.]8\17WQ1?
MPKIGA;X7V6I^,?!_A&'XOM\1^-UW]F3X<Q6NIZ;KOQ[_ &,-/\(^%_BSJ/[.
MMA;VW_!%_P"/UOX/TWQK9_$34_V<IOAOK7BWP=^U)'HFM6?C[XJ?M(V/P@\-
M6HUO2/"?Q*T2?QG\,-$TWQ):Z9\69-+_ ']U[X(>*-6_;/\ A7^T?%K-G%X+
M\!?LP_M ?!#5/#DFO>)7U#5?$WQ?^+'[-/CW0M;@\,,LO@V.Q\/Z1\$O$5A=
MZXCV7B>>;Q'9Z=+'J>E6]NVD_,7CC]BWXNZS^S)X\^#=KXH\#^,_%-Y_P4.\
M*?ME^"9O%^M^(?#V@S^!?#W_  4:\!_MRK\,_$&NZ?X.\7ZYHNH6GAW0=;^%
MVF7UGHOBNT@1-&EMGT[0VCT?0@#QSP%X5_;,N-?^&7[/7@C_ (*:? 3P5K7A
M/X4>%_'DWPM\/_\ !-7Q'X-\77'P-\-7VG_"B.;1;#XK?M0^)Y/!$T'B/P_J
M^E7L>OZ3X@U30=<O-,CN_#=MHUM;Z?K#/AK>?MK>.M;_ .$<T7_@J'X:\<:L
M?B%\6/@I>ZEX?_X):^(]+\&>'/BO\%K32[+XGZ'XH\17'Q6U+1/#$FEZA9^-
M+KP+J/B/Q1I_A;Q9J#>'=,\.ZS\1/^$7UJR\>_6/Q&^!W[0L?[9.H_M+?":V
M^!&HZ-<?L>:C\ =-M/B5J_C+3O$^E_$27XEZK\0=)U_/AOP3K(E^'5N4T>T\
M4>&[#Q'I&K^,KBX@N_M_AZ3P/I+^).9_9Y_90^)?PF^,'Q#\?^++'P#XAA\6
M_M8_M%_&'0-=T[XN?%99/"?PL^-7AJS@LM,T_P"$D_A"S^'Q^(']N^$_!MIX
MBN;S6=2@MK+4O'GB/PYXEM;G7;CPMJ !\8:_I?[6VC^+?$7A;6/^"WOC'3]7
M\"^*O 7P/\;ZAH/_  3Z_9RO?AQX-^,WQ$\.:%8_"_PYX_\ $G_"*>);+PGX
M^\>3?%'X*>+]3TC6?&&A>'-7UOQ3%IOAVQ\":5\1?!GA;PCM?"[P#^W%\8YX
MK+X:?\%D_C#XAT[3-<^,FCW'B_5?^";O[/>B:-?:W\#/CI\0_@)\2/ &N:SK
M7@+POI</C7P3\2?"I\*:M;:=IOA\>*-/\-:KXP\(6LGASQ'I^KZ+ZS\4/^";
MWC#XD?##]L']E?4_&WA.\_9D_;:^/VK_ !D\>ZPP\1V/QD^&_A;QSK?@#Q-\
M9?AAH,6IKXP\-^/S\2]0\(>(]'\(>-_[9^%$OP/T7QM9S:3X5\>7/@+1[75?
MK']D7]E2#]F_1/'U[K6M3^(_B!\1?BY^TMX_US4-,\1^-CX/MO#7QK_;'_:5
M_:K\)>&]&\$:SKL_A/2-:\(+^T5JGAGQ!XQT;P[H_B#QI-I=H^MWUUI.C^&=
M.T8 _'SX4>.OVG?C!XY^&>B>&/\ @O-XIU"X^,NJWGA;X+:;9_\ !,WX#Z)X
M+^-4NC>'OC5XGUOQ7\._&.J:#KUAKVE#1_@!\9]1M=5@\6V>E:=8^"O#LNI:
M9>0^,?!MW\2+VO?%O]H3P1X/;XV_$'_@M'\5[/X,ZA\/[/Q[H_Q=TK_@E;X.
MNOV5/$_A33+W1;75_&_A3X@^%O!?BO6T\(ZQ:WMUXJLM1U+XP6]OXE^%$US\
M7OACK^K_  S\%^*OB)!ZAI__  2B^,FM_M._#+XK^+?'?P_\%?!RRU'Q7XY^
M.OP-^$/C'XC1?"KXD_'[XI?LP?M7_L_?&O\ :0^%WPB\:>&-7T;]GOQI\4[G
M]I*UUC7/!_@WQKJ?AO4)_#^O^,O'&H?$'XE>+M0\3UZ7>?\ !/O]INY^&O[+
M?PA;XJ>")/#_ .Q[\'-1^#/@SQ+)XX^*J#XYZ59:K\"M#\!^*?C3\-X-(CT>
MT\8^&?AI\*]7;5M57QAX_L]<^(.LZA?Z1I7A+PQXOUG1=( .#^+R?M,_"/XB
M>&_AYK?_  6G^)MGXU\6^(_@AX:\*^ H?V!OV</'&IZWK7Q%L/B_;?">T?4_
M"WPSTW3(=-^,&E? ;XO^(/BM?W.I:1;7WC3P/<2_"S5?@!X=U;P_\,]=Y?Q?
M\2?C)\(?'NK^"?BY_P %H_B=X-\26O@_PAK4_AWQ;_P3Q^#^G6WAG2/BE\=U
M_98^'GQ*\1ZWI7PPN=+T7P7JGQET">S&M>(M4T?PUIMAXI'CCQ)JNC?#FZT>
M^TGU;QO_ ,$J?$-KJWP\L?AOXW\.^(/AY\*?VP_A%^T=\*O#/CZ^UKP1K/P9
M^"_P8\$_&K_A!/V.OA?XE^&'A];C3?A%X!^*7QC\7W_P4U34+:>[^"OPK\=:
MA\+=$T+7O#7PU^']A+D^,O\ @EE\4OB/\5=%^/6H^._A1\/_ !G\-/V>OV6?
MA#\%OA-I\'Q<^+/P-T/6/V4OVH?BW\<O!L7Q4TOQ7XV\%'XT^#=8\">*?A]X
M*O&\:>&+SQ-X8^*GA+2OVC?AW=^#?B7\//AO/I0!]0:C^RW^W^MY<W/A[_@J
M1XG@M[B;5DBT[Q;^QY^S9XAM['3]1M+D6)MI?#FG>!;Q];T'48=&ET[4;RZO
M-(N=,?Q9I^L>'=4O=:\-:UX'\K^)OP._;P\%6O\ ;6M_\%G_  U\+-)@\-^,
MX?M7Q _8X_9?M])?4[?PMJOB6P\47M[JWB/PT6MO!*>$[GQ'KNG6M[8V6H_#
MZV^)5K=W&CZC-X:\=_#;]<;5KE[6W:]B@@O&@A:[@M;F2[MH;EHU,\5O=RVM
MC+=01RETBN9+*SDGC597M;=F,2?@E\3_ (V?LY?#_P ;^.O@+XE_;)^"FL?M
M%?M$?M]_#[XB_$#3&\81^*/BX/V=O#GC/P')X9^%/AOX7_!Z#XFZYX%\.M\-
MO".B_LI&7QY<_"[PMKR^+/BA\9=;U72/&WC_ %#PYX@ /H&S_9?_ ."G6M:E
M/K'A?_@L9X7U/PT=0DTZXT\?L _ ?7DM=3T'2=6\%^,-,M=<TGXE::MO=67C
MJ/4M9%E>6U]=>&_$'AS3/#.L_P!KV-AXJL?$TJ?LB_\ !5FV_M*&W_X+#:->
M?VB+R>WDUW_@G7\"KJ\T.XN[C0V6'1'T3XC>&[1M'TRWL]>@TRTU^QU_5A-K
MEI<:OKVL+HPM]1\G\7?L:_M/_&SQ/\(?#$7[0W[47P?^#>O6W[:_Q-OO''@#
M]H+]H/P!\5?!?@[XR6.D>&?V=O@EXQ@UOQ^L5Y\4?AF_Q_\ BY\:O!^H:YX$
MUJP^&>O_ +.OP@^#6HKJOA/P^=6UW[5^'O[.7[1&D>#/&<'BG]H7Q-;?$_Q=
M^T;=^.]4\<V7B;4_'UAJ7[/VB?M2^-?B?X6^"F@^&/%.@^'M!^$1U[]G?7]-
M^ OB;6?AYI7]L>'T1O$>D>(=>\5:)IWC&] /(+/]EG_@J-%!?_VG_P %8/"5
MS-,+]K.:Q_X)[_"?3X=/\R_U.]T\&"X^+FJ/=1V5OJ,.E70EN%>^T[0=!>.6
MQU;_ (2/5?$M&+]E'_@J@FNRWG_#W'PS<: ][+LT.Y_X)X?!W[=#H\PMD$0U
MJV^*MKNUZV6WF>TU>32VT@3WMT][X7OH$L[:TR]=^"/[77[+G[,/[27Q(T;X
MP_%_]L;]J+P[\!T\+?LS^$)_%7C'3O"$OC33O@YX>\/6\;?#B35?$%AX@UOQ
M'\=;GQ7XKA\6?%W6?BCXLTKX>CP?HWBCXHMJ&C>,_'FNYMI_P38^,&CZ)K%M
MX6_;&^/VGW.A?!+XS>&_@WI\_P"T3^U%<^%?#_QN^*GP9^"GP:\,?$7XB0Q_
M&B/Q)\5/#WP>MO@?<?$+P?H'B[Q+JMI<_%']H#XX>/=.TSPCXJ;PGK=B =5?
M?LD?\%/;FWNQ!_P5W;3;VZTFTLH)K/\ 8&_9[EM+#5;?4(KJ?5[.RU#Q'?2O
M]NT^34M.N-/O;V\A0KH=[:R6\FFZK'XCS[?]DC_@I_>P +_P6,:6"&:2(WFD
M_L!_LVI>27=GJEO-?6MW/=:]JVG&.&[MM7\/36UOIMG>6NAR6EE+=GQ5IEYX
MJU3E/&G[ W[4'CC5OC)>?$+]ICQ#XK\#>/\ Q_\ #G7D^'T?Q&^--]87OPK\
M ?M>V'Q2N_A'X?\ #+^/?!/@?X<:UXC_ &9?A7\,/AK+\2-  \2ZO\5OBM\>
M]6\4:Q/\/+/P/H1_1_\ 9L^&WB[X4_"33?#'C[Q*_BKQOJWC'XL?$OQ;J'VN
M>_L=.\1?&CXM>./C%J_A'0;ZZAM;B[\*> K[QW-X&\'W$UCIKS>%O#NCO_96
ME!AIUL ?"7C#]CK_ (*>:O)X?_X0[_@L7X@\&V]C)O\ $2W7[!G[+/BB[\01
MB6V"Q6EQ<QZ9;Z$#:VS+*ZV.I.U[?ZA=1F&U.FZ=I=30?V)O^"EMI+!-XE_X
M+1?%373#9V\!33/V(OV,/#T,UTEC>6]U>RQ-X"UE&:\O9K&_\C BM?[.6UM?
M+AO;XS_K=10!^9\O[&_[;]^99[W_ (*\_M,:7<SSM,;;PC^S/_P3^T[1K5#+
M<R+:6%IXL_9<\=:NELJW"6Y.H>(-3O&@LK(_:Q<?VA<:AAR_L:_\%#(X[Y[#
M_@L'\8#>R6NI1:=)K/['O[%VHV%O<R>((=8T2;4;#3/A9H$E]#INFP-X6U&'
M3[W1+C6M$U#4KD7NG>(AH>NZ#^IE% 'Y3WO['O\ P4KDNI%T[_@L)XOM=,&C
MVEI E[^PW^RA?ZV-9ANY;J[UFZU.#1]-TJ>&\BMM(T[^RK?PY8QV]C<>+FCN
MFU+6?"VH^ \73OV+_P#@J):7.EM>_P#!:#Q?JEG9G3H]0@G_ &!_V1K:YUBW
MA@A&IR3W=EI4$5GJ-_=7FN26MS8V4&GZ=:V?@.U?2;^?0/&M]\3?URHH _,7
M_AE__@I8@>"/_@J;HKVR>'-'LK6XNOV#_@_+K+>*;30;BPUCQ!J-W:_$.RTB
MZTK6-=-GK\7ARP\/Z3-I<4=[H\>O7,%Y:W.FTKG]D3_@HW)Y*VW_  5S\:6R
MAKG[2S?L4?LI3S2(UO="R6U<Z!'#;/#>-82WKSV]ZMY:07]I;1Z;/?6M_I?Z
MCT4 ?D#I_P"Q)_P5)MK>T^V_\%LO'^I7L=QI9O9)/V!OV,K6PN;.SUW2[W4(
MK>SM?"R7=G>ZQH%OJVASWDFJ7EO9W>IVNM6.G0'3&TZ__,5_A7^VM\%_VW_V
MZ+Y_^"DG[0VL>-M ^"__  39T_Q_\2?A=^P7^S_\;_BK\4M!\=?%+]K72?AO
MX;M/@WX*^%</AWP"GP[@T_QO'XK\=V>@Z_9>+M(^($]Q%%X=UKPAX?T>OZN*
M_&#QYX ^/?Q)_;P_X*(_#3X3_$2R\ GQ]^R9_P $TK6]\37VO>/;+5_#WPXU
M[X@_\%&?#GQ2M/A=K'A2^TZZ^%WQ<U72]$\KPC\0M)AU:3P?J6HZ;XUDM=9U
M72-*TBS / -'\7_'WQE%\%M)\+_\%T/&FN6W[1O@SX9_$[X<>--,_8=_91TV
M.RT#]I/1/$[_ +.UEXNT[5_"VFZSX+T+XT'1?$MS\$M%\0^&-,\=ZUXG^&?B
M;0]=\:W,]E?>'[SW_P )?!G]LOXC^.?CC\+_  E_P6G^*$_C3X):]\/?#7Q
MTO3?V(_V5]-USP3KWBGX1Z?XTLDN[OQ?\,+_ ,+>+=(\9:5XE\$>,M/U/P9I
M"Z+HNI6'C7P8^KS:\VKZ?X+TKW_@F9XUOOB5\-_B GCGX9>'-#TBP_8F\1_$
M'X4?#CP?XD^'?A&;X@?L!6?QPUOX&^$OAUK5IXCUW5M+^!E[X^^)?PRFUCPA
MXSL?%;>'?#'P6U"+0-/N/$'Q7N-8\ ^F?!3]A[XI_L^?$7PY\7?AOX_\$GQS
MXP_9C\?_  ^_:<LO$.G^)[WP;\3?VB-4^*WB/]H[P%\5/"^E6>HV>H^'O">E
M_M#?'K]L?Q?XKT.YU%]:U+0/C['H.DZA86?@[PU9Z. ?.?Q*^'G[6GPQ_: _
M9W^"OB/_ (+B?$[PQ\2?VD;WXS2?"+X9>)/V%_V8-?TOXFW?PQ\(Z=XG\5Z7
MIGBKPU\+-#TWPL_P]\#S-XEL]'\3>*K2]\7:L]_JMFFOV6E7OANUQ=%C^-'A
M[0_A%J?C3_@MK^T#:+^U5\;]9^#'P7TOQ?\ L2?LX>"=>U/XF:=>^*[CQ'X
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M7[,GBS4KCPQH'C7XM^#?'>M>*O"_AK4/!C?"CQ+XC\:Z3K>G>$?"MYXF\/\
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MP8;_ (*(?\%-O$7Q'L/A_P#$OXBGP]K_ .P?^RMK]AXA\(?!SQ0OPVU+6_!
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M!$FEZC:W5U;6LWAG]E+PJ\$/B+3K0:)KP569+2]U'4/#;>'-=FM-6L?T5HH
M_.#4OV-?VOKN&T2P_P""N/[8&D2V\-Y'<36_P'_X)Q78OY9KMKNTNKF/4OV*
M;L12V8N;G36CL6M+6XTFTT)#;Q:O9ZWK7B7+F_8P_;:\RRFMO^"OO[4ZO9:;
M<P-%>_LW_P#!/:XM-3U-X]4:UOM6AL_V3],EDM(KIO#S75AI5SH]Q<6>GZ[:
M6FIZ=-XAM+WP]^F=% 'Y4/\ L0_\% 1>++!_P6D_:=^Q)=V\BVEU^R9_P3KG
MEDLD74VN+:XN[;]EJQ#7$\TNC!+NWM[5(+6PU.'[)+<ZO:WNB>@V/[)_[:EG
M97MO+_P5+^-FH7>HWKW$^HWW[-?[''G:7;&WTBR2T\.6UG\%[.PL1';V6I7H
MDUNU\2*^NZHM]) ^EV;Z%>?HM10!^>EA^RO^VA%?QSZI_P %0/C+>V*V[(]E
M8_LV?L?:;*]S)#;R22B[F^#FI*L$>HRZF+2!K5YX=$C\-Z;<7EWJVF>(O$?C
M+7L?V8_VN;+5H=0E_P""E'QIU:R-A;0WFA:O^S[^R#_9K:AING:K#:7VGW&B
M_!/1-9LX=9U2YT>_\96-[JNJ_P!H6>EW>F^#;KP!+JBZEI_WI10!\$7/[+G[
M6E[+<E_^"F7Q^TR%M<GO[*/0?@+^Q9!)#HWVYS9Z!>2Z_P#L[^)5O%32;?3H
M+[4[>'3KV[UJX\2ZK:_V;INI^'O#O@^2T_9>_:OTR2XEM/\ @I-\==6:^$CW
M4?BWX%_L@ZE!:7"OI]O:RZ''X:^!?@TZ=$-,TX"^M;U]6M[O6]3UK6+=-/MK
MG3]'TK[SHH ^#-*_9>_:PBB5M=_X*7?'^_O6>]\_^QO@1^Q;HFEK'<M,MJME
M97_[.WB/4()-/ADB:&2[UK44GO(!/=PSVLDE@;FI_LL_M(W;B>R_X*7?M8:2
M[:Q<:A+;6WPG_8%NM/73Y]0EU*+0;6*__8WN=1BL;-WAT*WNKG5;W5W\*1-;
M75_=>+9?^$T3[GID@RA'R\X&&&5.2 0PR,@@X(SR.#UH ^ /^"8_B#Q7XC_9
M1,_C;XAZS\6O$FA?M/?M\> KWXG>(H/"%KKOCVV^&?[>W[3'P[TCQ7K%E\/O
M#_A3P+I^I:UH_A>POKW3/!WAK0_#6F3S/8:+IEII]O;Q+^@5?G[_ ,$T(9(/
MV<_B!'+/+=NG[=__  5,A%U<7[ZK=306G_!3K]KZQL!=:E--<7-W-;:9:V5D
M6NI6N8([6.UF$;P&&/\ 0*@ HHHH **** "BBB@ HHHH **** /ESXS)<1?M
M ?L>WH;R[.7QY\6]%F8.1YM[?? GQWJ]G:[1RQ>V\.ZC= MA5^Q=0S(&^HZ^
M1OCG8)??M'_L2O)/:PC2?B+\9M<A1](%W>75PO[/'Q#\/K:VVK#5+-]'A%MX
MAN[RZ!L-7@U%K2UMY+:UFCMM0M_KF@ K#\21^()="U6/PK=Z+8^(6LIAI%WX
MAT^_U71(;W;F)M3T_3-2T?4+JT."LL=IJ=G.-PD24E/+DW*Y;QSXR\,_#KP3
MXQ^(/C75(M$\&^!/"WB'QEXMUJXAO+F#2/#/AC2;S6]>U2:WT^VO-0GBL-*L
M;N[DAL;.[O)4B9+:VGF9(G /EO0?V1/V>+3QCXJ^/_Q7T_1/CU\6=0L=6TB_
M^,GQMM_"WB^Z\#^!]'UOQ1?_ /"O_AYI=WI\/@+X.>!O"R:KJ&DZYI_@/0_#
ME[XL.BVVN?%S5_&WC"PG\0GAO^":OAC_ (1[X ^,-1\.ZAX=N/@G\0?VCOVC
M/BG^S%I7A2QM=/\ #N@?LZ_$3XK>(?$WP^@\/V^GZ7I6F+X5\2SWNN?$'P,F
ME0SZ9;^!/&7ABTL;I[>W2.+\^OV:](FUC3_@I\*?VW[&]^''A;]MWQ)IO[8'
MAOPQK>K>)_$6F_M+?M2?%VXUO]IOXC_LR_%?69+3Q+X1\#^#OV5/#2_##X3_
M  D^!^K_ !!TJ/\ :8\'?";Q1J.F>&_$7@KP/XR\':?^SOQ7\!_%/7/"'A[P
MW\!/BMX<^ UWIU\UIJ.KW'PFTSXEP'P:W@CQ1X;M=&\)^'[OQ/X3T7PQKV@Z
M]J7A/QAX:UR_MO%'AZTE\%Q>'=:\#>(/#VN:C9H >W45EZ+8W>E:/I>FZAK6
MH^([W3M.LK*\\0ZQ%I-OJVNW-I:Q03ZSJL&@:7HF@PZEJ<L;WM]%HFBZ/I$=
MU/*NF:5IUD(+.&1-5TZ6._E@O[*=-+GEMM2>*[@9-/N8(HY[BWOW5V6SGM[>
M:*XGBN#')#!)'+(JI(C$ XS0_B3HGB#XD>/?AEI]I?'5OAUX?\ Z[KVJ277A
M\Z8\WQ!D\8-IVAVMA#KLWBV'4M+T_P )1:MJ5_JWAC2_"U]:>)='M/"WB+Q)
MK6E>.=)\'^AU^/?[)_Q;^$_PL\%_MD?\%)_VB?BG\//@K\(?VOOV@'^(WPU\
M6_$/QZWAOPZ/V:/A)\.O!7[/O[/?B)W\:0>&K?3=6^-F@_#C4_CEH/A/2=.&
ML_V-\7/"OAR^M;[QI9:P;K]/]7^+OPMT'X9GXS:U\0_!NE_"4>&=-\9K\2+_
M ,1:7;>"9?"NM6UI>:+X@@\22W(TJ?2M9M[^P?2+N"YDBU,WUG'8FXENH$D
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M1?7NHV/@?P;IU_?W&N:I/K/Q(\>Z]XT^)7B_Q/XOU;\VOCK^SC\6?A5^VO\
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MQ%H'B.XEL$L_VA[>>R^W3>%M"TZ[AM[A+;^S(M;2W@M[[QMX]O\ Q0 ?G/\
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MAL[FV.BZ1';R:?%9B.#3;&':4M(!& ?I/N&[;@Y(SG:VW&<8W8V@^Q()'(!
M./E#]LG]F[4OVF_A3HGAKPGXU;X;_%'X:?%7X8?'GX,>/)[*\US0O#GQ7^#_
M (JL_%?A;_A,?"%OJND6WC7P/KZ6^H>$_&'AV_N5<Z!K]]J_AZXTCQGI'AGQ
M!I'X(W7[*,/PE_:X_P""I?Q@_:B\2_MRZS\%OA1^R7\$OVE/A+X"_9T_;6_;
MBT[QGX3^#'A/QM^VS9>)?AM#\2K#]IOP&GQ0\9^+4^%$OQILO@]K&M#PU\([
MGQOI?PT^$[66BZ9>W_BO[0\=?#[]@?X/?&CP;\,/$GCK_@HEXWOW^)_P7\':
M]XE@_P""A/[?GQ+\#_"GQK^U)>ZSI'P \,?&2RN/VL[[QG_PCGQ.UOP0G@JP
M75/"'C'PAI=OX]T4?%:[T+P/XIEUFU /TK^&^C?MF0ZY%>_%OQY^S-<>')+G
M4I)/#OPV^%7Q6L]7L++^VM"DTBQ3Q9XI^--]8ZQ=KX=MO$UEJ&K'P9H%N-9U
MG1-4@T&2S\-W>D^)O$?BA\"?VX+_ $7XV:9\.?VM[+PEHWBVR^(^M>$-2T7X
M/6'B_P".^D:WK^J>)]<\):#X-\0_$CXI67P/\(67@[1[OPE\,_#D$OPS%EJF
ME^'+WQAXGU>U\<^+K[Q=X?\  _V??@I^S!^T3;_#OXD_#O0/^"C^G?"SXN?#
M:?QY\'OC+?\ [=W[:7ACP+XY^&%WI>B:EX3\52:5HW[7D?C_ ,)7/Q-TKXD3
M>+?!NF_$SP3X:\6:Y:Z$FO\ B+3M*\0>$/#5KI/ _$_X$_L<?!CXZVG[/VG>
M _\ @I;\2_B%-^S#\4OVB%N/ /[>O[;?CTP?"'P)XP^'W@SQCX:\,V_C']M!
M?%%]\0Y_$&J?#T^!O"GA3P^=?AEMK?Q#\+M8TSQWX<MFA /1_P!@WQ?H?P;_
M &?/!7P-^ O[*'[34OQWAU^&]_:;_P"%^^ /BE\*(KK]H+QA91:_^T!\>/C3
M^U;\8_"<?A;]HB^UOQY]JM;_ .('[/&J_M$ZAXSDU#PK)\,?#UU\%],3Q#X2
M^^?@S\)O&WACQK\5_B[\4O%D.N_$+XO/\/K:3PUX<U+Q)<?#KX8>#?A]X9N+
M/0_A]X+MM?O -3,'BWQ-\0_%&O\ CX>'?!^I>.+WQ3;OJ'AG1;/1-'TC3ORR
MT']F[_@F/XB^(W[,WAWP;KW[7_Q*A_:V\%^/?B-\*/BGX/\ V[OVZ_$/P<UC
M1=/\.V/C2?P[XO\ %.C?M.0>%K:+XK^%K7Q=J_@?X7WVF7_A3QCH'PP^*MI!
MX<M-*\'ZK9MA?#?]E']DOX@>./%?A6;]G#_@I?\ #/6_ ]E/XQ^)?B/Q'_P4
MB^/S6GP]G^(?A_4_BI9^'-;U2Q_X*'>(/&%MXD\:V-[*_BJP^'6CZQX>M/$6
MN:GH_B?Q/+X:FU#6+H _1[]I#Q9\,_B#\7?@S^QWXC^&WC7XD>)_B3I_BKXT
M:CK7@GQ5-\/9/@%\//A5)I>BW'Q=U/XB:/XK\)>.O#FK>(/&7C3PY\+/!VC?
M"V]N/B%XIC\5>,KF*"T\ ^%?B'K6D?0MO\-;'X??"K7?A[^SWHWPW^#US#HG
MC,_#NVMOA[!<?#7PGXV\3RZSK<'B+6?ASX2UKP WB#29?&NL3^*/%NB:3XG\
M):GXLFNM7 \3:/J>J/K,'Y1?LV_L;_L2_M ?!;P+^T=X<\$?\%"/A'X$^,'P
M"^%?Q"\.7OC?_@H[^VSX=\0'X5:SHVL^+O"'A#4K/X6?MT^,9O#Y\$:-K^H:
M]-X3NKNVTC0)OB5X@M?#[76LZW\1-.LOG;X:>-OV ?B#X1_9/\=::G_!3/PW
M\#/VN1\0M7^$W[0.I_\ !57]J&/X7:)IG@7X:_&3]H+Q3K?Q0\3Z-_P4DU+Q
M]X,<^"O@]XUU7QMI&O>'KW5O!GBK1K7PC\5=,\,>(].U*TM #]._A7^Q!K?A
MS]EKX&?L\?$O]ICX^>(_$/PW\7P?$KXI?%7X7>.-2^!GBWX]>.-2\5>*/B)X
MTTWQCXC\"SQ>/].^'_BGXA^++OQ!K&E^'O'&D>,_$UKI>GZ/XW\=>*=,U;QK
M:^+?GS1?^",?P4TWXS_$7XNZK^UK_P %+_%=E\3?!_@GP)X@^&^M?M\_'S3M
M!7PM\-_^$A/@70$^)/@[Q%X5_:/U7P]X:G\;?$34K/PUXH^./B#P]=Z]\2_'
MOB35],U+7M?.HVWS]\1?"7[%WPU^'_A;X_\ B/X6_P#!5M/@-\2I?A]XIC^-
M'AG_ (*!_MUVGA[1?#GQ3^+'P[\ >"OB?\1/ $G[>^@_%[PK<W,WQ;TGXGW4
M%U\+KKXF^$/AEI/B/5?$>@>'O%G@[6O VB=OK'PQ_8EM_&/AWPUX2TC_ (*(
M?%.Y^,WQM?X6>$-6^&O_  4@_:UU+P!X^UBT_8N3]K?3OB%H.KZA^WCX=\(V
MOPTU?X2,W@7P_K,?]D2WWCUK:SLO#R>"ET/QVH!^QWP\^&OA/X6Z')X>\'V^
MKPV%Q?SZK>SZ_P"*O%GC;7-2U.Y@M;6:_P!5\4>-]<\1^)]6NC:6-E9QRZGK
M%VT%G9VMI;F*W@2,?G/\#K2]U3_@J[_P4OMK_2XY-%M_V;?^"84^C2W]K)?Z
M/<>(--U[]N36&U%;:=ELCK&CWD?AVY<VKV^HVPL= NVNH&3398OBKQE>?L:?
M"+4?B#=>._V>_P#@KAH^@_L]_"CX&_M)?M%>*=4_X*#?M+>,]$_9X^&7Q*L?
MB=KYUCX@>$[+_@I7XF\:^+K'X46WPB\=)\8?!GP>\"_%E7TN%IO#FA_$+PIK
M$U[+P6O_  ,_9L^'7[2G[=OBK1/ '[='QO\ !/PQ_9Q_81^+N@:)^SY_P4*_
M;*TWXC>/K;XC+^U':ZYXCUCQ%XV_;I^%W@GQ)X-\'^"_A1X=\1Z%JWCGQQIU
MII:Q^+;?P;8ZAXOUQK?Q0 ?HW\%OV'?B1\$K_2-4\)'X&Z)>:3^Q3^S1^RM/
M%X9;XNZ-HVHZE^S]8_%^#4M:T;PQ<>)]2\,>$HO%P^)FEZ1X6\9ZEHWQ ^)O
MPW\-^'M7TC4]>^)UCXFM+'PQ]+_"+X2_&OPPGP[3XH^(OA+XHC\ ZA86>A:=
MX#\+^,? _A[P7X5A_9_\#^ [^V\&:'-XMUBSN;Z7XJZ+X\UG2AXSB\2:AH'P
MU^(DGA;2?%%K=Z!<GQ3^0_AEO^"85[J7PYT7X;>'_P#@H'XAB^+OPI_9L^+N
MB>*=#_;@_;8T*306_:[\.?$JU_9>^''B*_\ ''[:'A?QKX(^('QE7X0:II.B
MZ8;"T\)^%/$-I\*?$?Q&\5^!_.^'7BF#H?V;O!7_  3X_:G\=_#;X<67PU_X
M*&> =>^+W[)F@_MB^$/#7Q:_;]_:DU7PYK/P5\1>+?\ A74%IK^D?#G]O7XK
M:%IWB2VO/$>A_:?"_B2RM;632FT6QTJ\O]0\ ZIHWA  _<SQY\)_A9\4X])A
M^)WPU\ ?$:+0;F>]T*+QYX-\.^+X]%O+E(X[F[TE/$&FZBNG7-Q'##'//9B&
M65(HUD=E10*FB_!CX/>&O!&M_#/PY\)_AKH'PW\26^H6OB+X?:)X$\+Z5X(U
M^UU;38-&U6VUKPG8:5!H.JP:GH]K;:5J$-]83QWNFV\%C<+):Q1Q+^7'C#]A
MS]A2X^.MG^SM<_"#]KQO%DOP7U_]H/PSXI\*?MF?M;>$O!VNQ^$/'?A_P;K?
MAK2/$FC?M;>&=;A^+%AXA\3^'/$CW&M:9I.CN_C2Z\3-XW_MS6?%SC\6/VDO
M'G[+_P 5+NP^"'['GPB_;M\$?M+>(OV>?!'[1_Q7^(GCO]LG]H;7M3_9=_8G
M\8:9\-O&)_:9^&?A#4?VYM0\!?%3]H[4M:^)5CX(^"GA^RO+[Q)H'Q0T'Q#X
MF^*=E:?#S1O#^F_%$ _87]L?]H/XD?&+Q;JO_!*G_@FWX(^'%[\2X_ VA^'/
MVDOCIXQ^'WA?QQ^R7^P'\"]=TY]'3P_XP^'EU;W7@[XG?M#>)/!\4=K\%/V1
M]1TJ+2+_ $:^T_QQ\2K?2/A-I&IRW7T5^Q7_ ,$J_P!E?]B_6KCXL:1H6K?&
MC]J_Q/I6CV?Q*_;!^.U^_P 1?C[XTNM,\.1^%7CTKQ/KSW\?PP\*/H,-MX=L
M_ ?PRB\,>&+3PGI/AOPQ<VNI:=X:T<VWYK^'OA5_P3I^"OP^TW4?AK^R+^VU
M)\,?%G[7OBW]G/QA\3/"?[4_CSPK9>+?VNM&_;D\/?L,GQK\:K>#]M'PKXI\
M8>+OB=^T1X#\)>--)^+L?A'Q3XC/A:._\8^*QX-U2XUGPMJ?HWBSX$_L'Z%\
M4M0^"-W^QC^UKXN\>^%_@C\'_P!IR_\ !6O?M=^,;@6UC\6?B5XE^$FB>!?#
MFF?$#]N*'PWK7Q&\(>,O">HV-[X;T>\_X0B6XN= MOAQXK\5ZOXA\/6>J ']
M +V-D]Y;ZBUG:MJ%I:W=C:7[6\+7EK97\ME/?6=O=%#/#:WL^F:;-=V\;K#<
MRZ?923([VD!C_ __ ()Q>#M$_8N_X*D?\%,_V _"MMH7ASX,?$O1/A%_P4C_
M &:/AYHMIJL$7@/3OC=<ZU\+/VG-!TN&X@MM T/P>GQG\ ^'M2\'^$O!UI;^
M'/#.C:K'IUM(SPRZ5H'/^$O O_!.>[BM;&X_8T_:2^&7P1U7]L'XH?L5?\+/
ML/C5\1[#X::?\;O WQFD_9M\.KXI\,?#K]I6[\9^&?AU\9_C%<>*?A-\(/%&
ML>"(-%FL-4TSP[XSL_ &D?%S1=#UKX-\7_LM_L=6?_!P3%^SU\+O@G^U7XWU
MGP5_P3)\1^(/'UKX6_:-^.OPYUW0/&_B?]J?P!\0_AWX_P#"OQ\^)/[2GP^^
M)^J>%/"D6NZ[_;%_\%/$WB31/!'BK5_#>CZ!I6I>*_"?BS2/A\ ?V%,%"[2H
M*C VA<CJ,?+C& <'I@8SQC-96AZUHOBG1M(\2:!J%EK6A:[INGZUH>L6$L=U
M8:II.J6L&HZ9J>GW49:*YLKZSGM[NTN8F:.:&2.6-B"#7X*_L^?LS_L!_&S]
MG35_VF;?P!_P4,^&/P8M_#OB3Q;H]_K?_!23_@H!K&H^(-'\/^+_ !UH.OZ;
MH'@GX4_MM^-/$,GC.TU3P7<21>&M%T>^C\0Q>+/"FF^ ]9\9ZCJ6LZ5HWG_A
M7P9^QCI?[&_[%_Q]TCP!_P %)/C;\)OCW\,OV7-"T+7?AK_P42_:KTGPIX8\
M3_M%^/\ X'_ OX;^#=<^'OC#_@HSX<TOPEXCG^)OQFT6S;1_"X\0Z#\,]&\,
M>-(9O%=A+X6TBPUD _I!KQ_XR?M!_ +]G'PY9^+OV@OC;\(/@/X0O;Z+2;#Q
M1\9/B3X+^%WAJ[U.4#RM,L];\;ZUH6EW%^X(*64%R]PP*E8B",_R3?&?0O@?
M^TYXCO/V;/\ @GC\'_VO?$/CO38?AV_QN_:7^,/_  4]_:A^)'P.^!6E^/?%
M4/@];;X)Z/>_\%2?#7P^_;)^-?@CXEVEKX/U?PK\/_B;-\*/"'Q/TFV\#>-?
M%FO>,U?X97?JG[,__!+?_@B_\9]*^*7A3]H[P7^T!^V+XT_9#U/XZ?#SX\_M
M?_M4_M!?%:^.A>(?V=?'5UI?Q0\)^,=*\%_'&QC^"WAZ34[_ %;XM?";P5XB
M\'V.@^.?A)J<7Q'T7Q5XS\0V_C7^P0#^I/X0_&_X*_M!>$(/B+\!/BY\,/C=
MX N[V^TJV\>?"'Q[X4^)7@VXU+2Y?)U+38?%/@S5M:T26^T^<^5>V:7QGM)C
MY<\<;D*?4J_A"^/'[/O_  3M_8'_ &J_V)?CI\,?V4_VN?AW^Q=^UO\ LV?M
M=_$3XI_"CPC^T=\6_#VI>.M _9$_9QMOVI/A-\=M(L[#]J#1/B+8?%.#P=-X
MT\$VWPL^*/CK2?#]QX"\2-=2Z+X5\=6_BC0-5_H^\%?\$X?V(?&'A;XG6WB3
MX??M@>!/"OA;QWXCMM=O_B7_ ,%)?VN-?L_%EQ8>'='UKQ+X^MO$7@_]N3XB
MM::/I&M:QJ^AZ@/'.I^%?%VA>/\ P)KNNR^&;"WTWPEXNU< _7N2**9)(Y8X
MY8YHVBECD1726)@RM'(K J\;*S*R,"I#,"""<O*J0054@D$@@$$@@@D=R" 0
M>H('H*_F7A^%'_!%[Q+\$_V;?VC?$OP:_:K\*?#+X^_M":W^S_I>L>,_VH/V
MN/#L7P'\?Q-\5_LFO?'6.+]K!]*^$W@JYUSX=RZ%X*\30W>I0Z-J7Q$^&%SI
M-KH>@>()-8T9Z^-O^"0FIZQXZF^#?@']JW]J3P1X>^*G[&GP8\;?M"?"_P#;
M"^//Q)^".I>)/VP/BQ=?"WX=WFF?&+XA?MG:3I_Q*TCX4>/? /A#2?C'JO@J
M?Q;/\-U\:>'=,@CU**;XFVOA0 _IB6&)9&E6*-97CBA>5442/%"TK0Q,X 9H
MXFGF:)"2L;32E0#(Y,:V=HD\]TEK;K<W2P)<W"P1+/<);"06R3S!1),MN)I1
M LC,(A+)Y87>V?YD?C#\'?\ @E1\#?&-^OQ9_98_:Z3QGIOP\\/_ !SUS6-%
M_;-_:%^)&N7S^/?VDO W[#QM_#4FD_MHZEXT^)?C[Q+J>J>&[VTTGPQH^K^,
MOB!\/KNR\!6FBZE\8/%5I\'=6]NF^#O_  30U[XUWGP+T3X%_'7Q3^T'H_QO
M^)_PX^'VAI^UE^T+<_VAKG[/'P:^%GQB\9_%K0/B-IW[1NLVGP[\/>#['XZ_
M"_P)>ZS>76@_$C2_BQJOA_PU/X6$GABUUC10#][=&\->'/#CZO)X>\/Z)H3^
M(-:O/$FOOHVE6&EOKGB+48[:'4->U=K&" ZEK5]#96<5YJEZ9[ZZCM+9)YW6
M"()2\*^!_!7@6QNM,\$^#_"_@[3;W5+S7+W3_"OA_2?#UC=ZUJ+B74-7NK32
M+2SM[C5+Z0"2\U"6-[NZ<!YYG89K\0=-_9]_X)_^"Y/V:_!GB7]G3]LC]G[6
M/VJ?CM\9O"-E\-?&O[5/[3'A6U\ ^,O"$'Q)CU[QK\4KGP%^UGXF^$D?A_XO
M^*?#^@^#_A?)X=\7>*[CXN:O\>/ S^'-)U.P\4>+9=,\ _:^^%O[)?@WXG>-
M/V+/V(/V6/BG^UW^W5XW\'Z+=?$OP_KG[4_[9!^ /[.GA'Q[;7M[X:^)?[9_
MQFD^-5W!X1EUK3O"VK^+_!7PTTC5G^.?Q0N-/@O/#\/AX>-]&\::D ?O-^T[
M\$;K]HCX.ZK\*;/QIK7P_FU3QE\(_%+>*/#NJ^,]!UJWMOAE\7_ GQ0O=*L-
M>^'7C;X<>.]!E\36?@V?PP^N^$O''AK7]&AUB34M-U)+FU2.3XQ\4?L#?%'Q
MCXBU+Q[K/QS&G_$3Q'X[T6_\2:UX2O/B[8>#'^%%O\/O GPL\5_#_0_A%X[^
M*OQ-^&EA\1/&_@?1/%VB:I^T1K'AWQ%\1['2]>M=)M(I($FN8OST\ ?\&[$/
MB'PEXY\1?M,?\%'?^"@OB/X__%M;C4?%GB/]G_\ :)\3_!+X3?#V]OM;USQ"
M-!^%'PSGC\:-<>'=.N?$FKV,K_$GQ!XWEUPWNJ>(%M-$U_7M7O+CDO\ @ES^
MPE\&9O'O[6W[%?[6/@W7/C+\?O\ @G7\9?AYIG@[]J2T^(/QN\'7WQH^!'QI
M\'Q_&7]FOQCK]UH/CSPO83_&OP%X>N->^'WQ'O/#^@P:18WNER0V7B3Q?J'B
M+QIXB\0 '[P:'\%/B#X2\=:7XDT;QKI/B/3M*D^/L6FW7CV/QCJGBK2]-^.O
MBC0OBC<:<9=,\8:;X4U?2_"GQ+\,:=IFA:9-X7T^XTGX5RZ?X2\,:YX9?P[J
M#>-L+X2_ 'XJ^&9?@%K/Q9^(W@GXE^+_ (1>$M6\-:IXAL/!?B_PU,O]K?#;
MX?>"M3M_A^Q^)VIW%GX?\2^(O!%UX]\3:=\8)/C5XAEUC7A;:/XPTJ'P_HLD
M'FUE_P $M_V/-+U33]:TG2/VA=&U71]/O],T*^T7]N']N'1[CPY;ZMIUSI6K
MS>&6TS]HNT'AO4]8L;J:/6-9T(:?K&JR^5=:A?7-W;V\\7;6'[ '[/.DOJ$N
MEZS^U-I4NK2^;J4VF_MZ_MUZ?+?-EQ#'<RVG[1\,DMO:++)#IMJS&VTV"1[;
M3X;:!C&0#[5HK\Z?AM^RY^Q1\?\ P'I_C?X8_$GXV_%SX>3Z[XVTBP\5Z#^W
MU^V=XPT+4=>\->,+KPMXULSK(_:*OH]5N="\9^$-2T>Z6XN+E=/U&PU6&S,2
M7U^;O?E_X)H?LESV TVYTS]H"ZL_[/O=+DCN_P!M7]M6[DN;34+AKFY^VW-S
M^T'+<WUT"[V]MJ%Y-/J%EI[-I=E=6^FDVE 'WO17YN>)?^"27[!_B]YV\0_#
M+XEWZ7%I?V4EJG[5'[6ECIXAU*\L=0O'BTS3OCE::?;W;W>D>'Y8K^WMHK^U
M'A7P=%:7,$/@[PO'I&1H'_!'/_@GMX8:T?1?A%\0[9M.\71>/=*,_P"U/^UM
MJ)T;Q?'JMKK4FO:'_:?QTO/[$O+W4+.)M5&E?8X-8M9+S3M5BO-.U"_M+D _
M3JBORYN_^",W_!/*[;0MGPJ^*VF6_A6X6Y\*:9X>_:__ &S/"^B>%)8KF2_M
M?^$6T'PY^T#I6B^&XM/U*6;5=+@T2PL(-)U>XN-6TV.UU*XFNGK1?\$5O^";
M5G8MINC? ?Q7X7M7BU6!QX*_:3_:H\#SO%KB7<>K(]YX0^-FB7C"_BNT@G+7
M!9H-*\-P K#X5\-)I(!^I]%?F[H7_!)G]B3PWKX\4Z/X:_:!M_$?GQW)UFX_
M;C_;FU'4'ECNA>$R7&I?M'7;RI-,-EW%)NAO;7_0;M)[(FWK3TC_ ()9?L=>
M'Q;IX?TG]H?0(K>RO-.$&B_MQ?MPZ7;S6&H6)T^_M;J"R_:*ABNH[V-I+J\,
MZO+=:K<WVL3R2:IJ6HW=V ?H?17\V?Q#^ W[+7[-N@_M4_$_Q]^SG^U7\6_A
MG\*OCKXIL/&FL>$/VK/VB+*/X(? KPO\.?@KXF66Q\/^(_VD="\3^.+F&Y^*
M7B#Q?X \'?#K1?$&HWNC0:QHGAZ]T5] \#^%]0W?B'XR_P""5'P]@^(]QXQ\
M-_MB:;X$^''CCX__  V\.:EX1_:4_;1US1_BS\6O@AX__9[^$7Q'^&7P?^'W
MP^_:.OM>\1^,-6^.7QB\'_"/P%X2D\*:9JGB'Q]\#_'VNP:9HG@/X3>!OB!K
MP!_1?17YM_"']CKX(#Q+XQTN;X)_M1_"2[\/S^&_$-AXKUK]L7X]ZSI/CP>+
M;>XO[J+2-<\*_M/>)M8DUGPS>:+!I?Q+\.^)K'3-.A\1+97?A^_\>^&;S2O%
MU_\ /OC/Q#^S_P# SQU^U/+XI^%O[1.B?!?X%Z[^SQX3^+'QQ\"_MI_M#W^J
M:!:_$'1=%UJ^\<^.?!,WQB\,:SX$^#?PD\/?$'3/$/Q3\<>'O$?B:]G\+:=J
M_BKQ!X2DT+P+_:&G@'[345^3UO\ \,O^+?C/^U'^S)H?PS_:Y\;_ !$_9Y\$
M^ _B'>Z->_M"?&?2]+^.>H^*[+2_&5SX/^ 'B_XE?M*^&?#OBOQ'X#N-&^&>
MF?%N;5];\&^"O!^J_%_P9H'BOQ/%:?$#Q2D_SGI'CC]E70?@5\3/VH/&/[,'
M[6GPT^'_ ( ^/WB;]G?6KOQ%^UQXCFG_ +>T3]M*']C+Q+XDL0O[74FB>%M!
M\(^,] A\;ZUKU_>:#I>C^!K?Q;=>%-?UB.[SXQ /WMHK\;O'7PT_8S\ ?LI?
M$?\ :6\=?LL^,O$7AGX6OXBMM;\)^"/C5-\7]6U33_!WB+2?A?XK\6^&/%$/
MQQ'A67PG9MX3@UO6-0\2>(?"?C73?!?@.PU'XC>#/"?C[PNW@30/&M%TW_@F
MYX)\22>#;GX5?M'Z;'=^#?V6KKX=VUM^T_\ 'KXO:#X^L_VT?BM^TK^SQ^SG
M'X0F\'?M,_$+P)8#QUJ7PT^(7C;0OB/=:[IWA+P]X1\=^'_B%XA\=>#_ !)_
M;D'AT _?:BOP:UWP+_P3[T_X^>#_ -E+XO\ [.7Q9\$:]XR\2^,]*TCQK>?M
M$?$_Q3X2TCQ+::#\!_\ A&;K7_&/@WX]:KXP^&,'QCG^._AOX5> ?$OQ%T[P
M##XP^-MOK'PBTE]7UKXE?"V_^+5'X,:)_P $_?CMXR\4_"[P%^S-^T1:ZDO@
M?]D[XH>*YO'/[3/B?06OO"_[3'BWXAZ;\-X]'O4_:TUO4M5\0>!;;X,_$?QC
MXY\&I-IFJ6WA?2;Y/!=IXXUGQ9'X>U@ _?.FL#M..HP??@@\<CGCC)QGKQ7X
M:_#KP'^P;\?X_@WXS\3?LW_M$>!;/X__ !A^,/PC^'7B;7_VAOB?;>'M#^*7
M[/5_\6;>+0="@\%_M*7.J_#_ $+Q>O@_]HO7O@3J/A'PMI'A.?PZ/&JZTWPX
M\6?&_2O!OC_[]?\ 8%_9P9]0:5/CY/#JRZI#J=A<?MB?M@W.D:A#KMQ;W&KV
M]YHL_P =I-)N+74)H"US;2V36[K=ZI'Y7E:QJR7H!R?_  36UB/Q!^S=XNUJ
M*VBM8[[]M+_@I7Y*02WDT4MG8_\ !1W]JW2].N$EOY'NF2;3+&S:&-DM(+:V
M$%I8Z9I%A;VNE67WW7PM_P $Y?A]K?PM_9B;P3K]G<V-YIO[1_[<.HVD=YXL
MD\;W4^@>)OVW_P!HKQ1X6U&;Q+=Z]XFUB]?5O#&LZ/JIM?%&M7?C31Q>C1O'
M$=EXOT_6K"U^Z: "BBD!!Z$'Z'W(_F"/J".U "T444 %%%% !1110 4444 ?
M(WQHEUN']IW]C3^S;F6?2YM>^.\/B/11&DL"V0^#>HW-CXG.9HY8+S1]7MK#
MP[;7"I-;"W\;7UM-&L]W;3Q?*.K?\$LO OC[]E;X8? GQWJUCI/Q&\'_ +/'
MBW]D'Q3\8/!!\5:9=Z[^R[\8_%O@/4?VC/A7IGA_3/$/A70F'Q<\'?#K1O#^
MB:MXNTCQ3;_"+Q!>R^*_"FBZB]KJ.E^)?J;XE:)8W7[;'[*FOZC;23_V-\&/
MVN-/T22$ZFK6?B36]6_9BFBN;HV1CL)-/;POH_BZRDAUF>2!M0O-+FM--N+Z
M"VU/2/L&@#\<KS_@G1\2].^+.C?M"^&O$WP^N_C'\*_VSOVL/VL/A;-K^J^/
MI/#7B#PI\>?@5XG^$FE_ 7Q':7UGXETWX:1^)M3USP]J/Q%^,?@KPMXE\3^'
M- \ P:/X/\+Z_:>/?$-CIGZ!?M ? ZQ^/UEI?@7Q;8VUS\-=2TSQ;IWC2ZTS
MQ!KOA#XC:5-?:?I\_@[6?AMXM\-6L>N^&O$7AKQ?INF^+],\1Z'XE\(^(/"O
MBOPWX/\ %_A[5O[8\.VL9^BZ* /PPG_X)2_&R[_9[T;X9ZY^TWH7BKXP?"/P
M-K/B'X(?&A/AM)X,M=3_ &K-<_;5M?VZO$/QM^,G@+3=8URPU32O%_QH^$_[
M,.O:EH/A#5-)N-&U/P5\5C97%_X9^*EUX1TCT?XS?\$U_B'\2/%O[0OQ0\,?
M%CPQX5UG]H#X<_&[P=XW^#NLZ/XM\6_#+Q[KKZ9X;N?V._$'BKQ9<Z]I^L>&
MH/V;OB5:_$[XL7%M\/\ X?Z-<^*-5^-VO>&KN[N8_!MAXE\4?L17B?[0'B'X
MV>$?AOJ?BKX"> -"^+/CKPY>Z7J[_"O5M?M/"&I?$CPW;7)'B;PAX)\9:QJ^
MC>%?"GQ#O],=I_!&J>.;E/ UWKUK;:%XKU#PSI&KW'C'PX ?'/[/_P"QA\5_
M@AX_\=^+O^$\\%>+;CQ?\1_V;?&T'B+Q2/B9J^I6%C\+_P!E3X7_ ++/Q8L8
M/"5AXI\,>'_[;\;>&_AE?:UX$\2>(-6\6R^#_$/Q(\3:SX@L?%\&F:5H%SJ_
M%?\ 8<\4?$'0/^"C?PX@^*&G+\+?^"DFAMI/C#3+CPN=/\6_!75?$_[+_@C]
MD3XF^)_"7B.VNM3L/'Z>(/A9\-_ FL^$O"_B/0_#*^$?'.C:W>W_ (F\5Z!X
MH@T+PQ]3?L]?M'?"O]IOP1=>-_A=K&HSIHGB'6/!?C?PAXI\/:UX)^(WPR\>
M>'9Q;:]X$^)?P_\ %%IIWB?P9XHT\O!?VUKJUA'9>(_#>HZ%XV\(W_B#P/XF
M\->)-7S_ -I7]H#3_P!GWP%;ZM9>%=8^)WQ4\<:E>>"/@-\$?"]U!8>+?C?\
M77\->(/%&A?#S1-5O8Y-(\+65QI?AG6M<\8_$/Q1)8^"/ACX%T3Q+\0O'&K:
M3X5\-ZK?P@'BW[+?[,?A3]D^#XQ>+_',/P=TR^UCXQ?%[6/ OQ"TO3I=%UCP
MW\#OB7XWTOQ+X7\ ^,_&GBZ=]2U'Q!%K$.FV?B"^&J/9:\^C>#+-I+L>'=&C
MLO.-._8K^(.K_LT^-?V2Y/CQH!^"T>HV/BG]G#XE^#_ ]DOQ3^&EMX=^,NE?
M&?X1^$/$EGK&H^(?AS\3?#7PEO= T;PE9>)I;+2?$/Q+\#V>G6?C%8?&]EX@
M^(WC6_\ #7]@W2_BOX9A\??\%&=.\#_M7?'#QWHVDZCXU^'?C/P]!XN_91^#
MFHR:3JUG-X"^ 7P-\:3^*?"NG:5X=TGQ+KG@[4OBAXIC\2?%/XF6UYKVJ:[X
MDTS0/$J>!M%3]AKX>^&/A-\=_P!OKX<_!?0]*\+_ +-OA_XQ_"JX\(^#] TK
M3]!\'^ _C=K/P*\$ZA\>?!GPUT33?$FHZ=I7P_ATQ_A#XNN=/T7PKX)T'3_B
MWXR^+>F6VG:AJ]AKEZ #;\;_ +$/_"U?CK%^T/\ $.]\ :MXU\1_"7P!^S9X
M^\+:CX'_ .$K\ 2_LWZ3XV\2_%3XS_#C1].UN^MWUQ_VC?'TW@"U\<S^-[;5
M]!T'P!\/]#\,Z+X;N=3E\8ZWX_XGPC_P3E/P@^!7B[X$_"GXF&Y\+ZK^V=^R
MW^TCX#;Q_HVI:U=_#'X5?LT>/OV4?$'A?X#Q7MAX@M=1\=V7A+P%^S!IOPJ^
M&?B?6+W0M6TWP=<>#HO'=QXZ\1>$_$7BOX@?J)7RQ\8/VK?"WPZ\3:C\+?A]
MX+\:_M&_'W3?#L?BN_\ @1\%9?!=WXR\->&[V"^DT+Q'\2M>\<^+_!'P]^$N
MA^*YM,U.V\#R?$7QAX?UOXE3:'XH@^%F@>.[WPAXGLM* /GW]L+_ ()U:7^U
M5\3['XUV/Q3N?AC\5/ ?@/P!8_!3Q1;^"K?QG:^ OBM\*OB^?C%X'\;^)_#&
MK^)=.\-_$_P%-JV=#\9_"/7M.T^/7=/D@\2>'/&W@CXD^&/A[X[\$\?J7_!-
MF\\2?&?X2_M'>)?B=IDOQJTKXV_'_P"(GQUU2RTKXHQ^!?BQ\(OV@O@MX;_9
MY\0_LVV/@"W^-&G:;HGA?1?A?\,?@)>:'XVUZY\5QZ?\5/@A9_$S3/AUI-[\
M3/%^CV?VC\%_VC?#/Q>\5?$WX:7>B:I\//C%\&KGPG%\1_A3XKU'PW<^)]*T
MKQSX7T_Q/X1\;:0?#VMZO;>(OAQXE,VO>&="\<61CT?4_&?@/X@^&K5Y+_PC
MJ:Q_1% 'Q?\ LK?LU_%3]F[X :1^S9JOQ?\ AW\2?AW\*_ .G_![]GRZ?X&Z
MOX1\3>&?A-X+\*Z=X)^%VB_&>YM_C5KOAOXO>*_#_AK2K.Q\9>)O _A;X#Z-
MXWEC:XTSP;X(,DD;^9^%/V!+KP+\._\ @G)I_A?XL:>GQH_X)Y?#KPA\(M'^
M*NM?#S4]2\,_%CX:3_!WPQ\&?C=X6U_X867Q,T>3PXGQ/L/"'A?QYX4U:Q\=
MZKK'PP^(O@KP3=SWOC[P3#X[\"?$/]'*\ \ ?&/4_B#\=/CM\.=)T.R'@3X&
MVOPU\+ZKXP74M-N[W4?C%XP\.3_$3Q/X'.GV&KW=YI \%_#/Q)\(?$-Y'KVD
MZ3?7C_$>REL/M>GPB=@#\V_B%_P19^#OQ/\ $NL^+O%GQ&UV\\0^)=2_:Z^*
M.IZU)X9TNYUCP_\ M+?M'?';]C#XY?#'XT?#V9[^'0_#.G?LT7/[%'PY\%>&
M?AWJGAOQ-IGQ4\,2NOQ7UC7I]0^((^(_[$^&H/$=KX<T"U\8:KHNN^+;;1=*
M@\4ZWX:T"^\*>'-8\1PV,$>MZKH'A;5/$OC/4_#6BZAJ:W5WI6@:CXP\5WVC
MV,T&G7?B77;BVDU2ZY3XO?%KX=_ 7X6?$3XU_%SQ/9^"OA?\*/!OB+X@?$#Q
M9?V^H7EKX>\)>%-+N=9UW5'L-)M-0U?47M=/M)Y(-,TC3]0U;4K@16.EV%[?
MW%O;2][:7<%_:6M]:N9;6\MX+NVD*21F2"XB6:%S'*J2QEXW5MDB)(N=KJK
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MG\&_"/PW^'OBO4C\0?$>@^*/$OP%TCXZ^/OCOKOAGX&^)=*UF?Q!X:U;XO\
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MC_XF> ?A:;>>72?B9JGAO5[?QO#X9T+Q#X.\;P> -:C'_!5S]K#P_OF,D_\
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M?!/B;Q/X1\*6^O>'?&7[=?\ !1/]K>W_ &%_V*_V@_VI!HL?BGQ!\,O!#_\
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MMHLWQE\'VNMW7Q,^&_P>71+RXO++6[?XC_&+0#XH^$OAO4='NK.'4M*?XFZ
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M\.M(M=6TSP%+\0/B+\:?\%<]7A^.'[+7[8WP!^W7N@_!?X=_LP?%OQO^TO\
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MAWX2\=>$O&'QQ\9_$'6/"/PJM/AA\$H/BQXCM_B9XS\/6MTEO\,!X@^+GAX
MYC]L--+_ &W?VHOA;_P3VT66TUSX9?!_4OAO^UM^W9&VH:6^A'P=H6OZAJW[
M-'[/VL6T<.IZK?\ BOXI_%7PK9?%F]T*T'A:Y\*^ OA?I/C75?%=M'XF\#^#
MOB;^L.K3ZC;:7?SZ5:0ZAJL-E<R:?8W%VUA;7U_';R/:6EQJ"VE\VGP75PL<
M$E^+"^^QK(;@V=RL9@?\M_\ @F)^S_\ MA?"/X5^/O$?[8MO\)M*_:0_:!^+
M^K?'3XX>-/ASXF\3^._$WB+7M5TG3_#>E^#=4N/$]K/X1\.^'_AWX8\+>$O
MOPTT;P-<ZEX5\(?"31='\#)I6I^.[+Q!\:O%_P"K(R ,G) &3C&3W..@SUQV
MH ^=/@U\#-1\'6GA[QE\9O%UI\;_ -H2PT77](U3XR7O@WPYX6FTS1O$OBO5
MO%UUX&^''A[1+-+?P3X"T=]2L/"^GV\=SJ7C+Q5X8\(>"S\4?&/C[Q!X?L];
M3XB^(@U/_@HY\??$W[/9\,^&-;_X)V_ #6I-._:3\1:_:Z)XLT/]L;]H+2U$
MFG?LR>#[1K;6=$NO@K^SQK2CQ#^TOXJ:[L]9U+X]>'?"'P!TF,VG@KX^:8/7
MOCG\7/&/QY^+_B/]B']G7Q#K/A'6_">F>"?$G[7WQYT>[N-'G^!/PL\<K<:C
MHWPQ^&NKVQ&J7'[3GQN\.V-ZOA6]TD65E\#_ (;7&L?&G7?%.C^.%^"/@KXH
M]_X7\;_LF?L<:O\ LX_L(?"O1-(\#:QXB\+ZE:?!?X _"GPCK6LR^&/AIX.+
MR>(OB-XLM/#]AJ,7@7X<V.KWHMM?^*WQ%O\ 2M/\4_$'7X=+_MOQ#X]\1"SO
M #[(BC2&*.*-$CCBC2-(XD6.-$10BI&B@*B*H"HJ@*J@*   *@O[VTTVRO-1
MO[F&RL;"UN+V]O+B18H+6TM(7GN;F>1\+'#!#&\LKM\J(C,W -6$=74,",8&
M><X) ;!/T(.>A!!'!%?B]_P46T;6?^"A?CFR_P""6?PRU>_T?X?#6OAC\3/^
M"C/Q%LFMFL_"_P"S8+N\\4:-^SKHE]I&O6'B_P /_&O]H?6M'\,3Z!J8M]+T
M70OA;IOC?Q5-J'BG^S;KP%K8!H?\$OK/Q'\:[_\ :'_X*H?&.'4-"O?VPIM*
MT_\ 9\T/QWI6DZ)XA^$/["'P=UOQQ)\#--O9FU;5E\(#XIVWB36?CMX]\++J
MRV=AX@\5V]WK4LVI6FZR^J/ 7[8GB3XJ?M-Z%\(/A_\ !\:M\%]9^$GB'XG'
MX[7?CRQM-62UTCQ?=>$/#VN)\*(-!O;^U^%/Q5U"WGB^!GQ&UWQ9HEY\:4\*
M?%KQ!X(\&W7@3X9-XP\4?%'QU\9:[^TW^UKXB_8Q^ 5EX4U[P-^PY\//AQXY
M\6?!G2_%_C'X<_#SQ#\:/B,NH:;\#]'_ &@_$'PSTBX\.VG[*_PB\$^'_%VK
MZO\ LSQ:G=_$WXW_ !$_X1.._P#A;9?![X<7_BS7_P!2?@%\#+3X*Z'XEFU+
MQEXI^)OQ-^)'B.'QU\8/B?XMO;G[?XW\=KX;T+PJ;W1_"T=Y/X:^&_@_2_#_
M (<T71/"?P[\$6>F^&] TFPCN;A-:\5ZIXG\6>(@#WJBOE?]ESX]?$'X[+\>
MQ\1?@_;_  5U7X/?M'?$SX(Z1X<_X3Z3Q]JWB7PEX+B\/W_A#XFZ\\?@?PCI
M'A.X^)OAOQ#IOC71/!^A:Q\0[/2_"FLZ#)J?C,>)KC7O"WAGZHH _.OX3ZA;
M7?\ P51_;?MTDU$W>F?L-_\ !-C3;J*ZL8X;*)5^-7_!3W5X'TR\1_-O+>5-
M=42O<PILU"'4+:TNKI+2>WT[]%*_-;X2Z-!!_P %:?VX=71W2>?]A/\ X)OF
M:%+?2(8YC?\ QJ_X*56AEN)K2%M2NI+6/PO;):2ZE/;WBK>7EO+!=:3;^'9;
M7]*: /D;]J']J&Y^".I_"[X3_#?X=Z[\9OVE/V@[CQMIOP4^&&C7.G:/HEO9
M^ =$L]3\=?%SXO>,M7O+33_A[\"/A=+KO@^U^(7BZ"+7_%,^K^-?!?@GX>^"
MO'7Q#\9^%O">J^$>$_VJ_C#\"/VCOV8/V/OVSO$'P4\<_$W]KCP?\8-9^#WQ
M/^ OASQ;\.=)U7XD?!C2]1^)?Q*^&.N?!'QIXN^)_B#PMX2\/_"B[TZ\\ ?%
MV/XK>*;/QKJ?A7Q9H_CKPY\+_$&H?#^S\?<)^W?\)/AU\#]?^+O_  4"O/VM
M_P!HK]EO7=;^!?@S]G_QI!\#?!OP/^*'B7XE'0O&OB34?@QX<^&'@_XM_!#X
MO>)+GXP:IXR^(VM^%/"7A?P3<6NE^)[_ ,1VTT^@VNLPW'B>/G_V!/V%==^"
MQ\1_ML_M$^#?'WC;]O'QIX3^)'A&?3_%GQ<M?BGXT\*?!DZWX>D^&_P8@\9Z
MKXIC^%U]X_US1?AGX/\ %/Q+\:>%9/ OP_U3XN>-_'</A_3_  9\)[/P?X4\
M( '[%$X!/H">W;ZD#\R!ZFOS9\=_\%$/%'P[-YKFM?\ !/#_ (*':O\ "^V\
M3>/M(_X6IX/^%OP:\36</AOX>:IJ.EZC\0]2^$EE\?4_:3TSPEX@32KW7/!%
MO-\$I/%_BOPU)IFIV'A=;K5K72Z^V/A#XQ\?>.? FF^)?B=\)-7^!WBV]N=7
M-[\.M>\7>#/&^IZ)I\&J746AS:AXC\ ZMK?A2?4-2T1;'4-5L-)U74K31=5F
MO]'MM6UNRL;37M5_-+_@HS\(/V>?VT/!WQ-^'/Q4_P""C4GP&^#'[/5AH6J?
MM0_"'P)\1_@%HGA"WO-2\WQEX2A_;#N/%VD:OXUL/AEKNB:09'^%6H^)_AQX
M7^(?A9/$$^KC7I#HFI^& #]/_A9\3?!7QJ^&7P[^,7PUU>7Q!\.OBMX%\(?$
MKP#KT^D:UH$VN>"O'?AW3?%7A76)=!\2:=I'B/1)-3T+5K"]?2/$.D:3KFFO
M,UGJNF6-]#/;1][7X<?\$Z?VM/CK^TSX/U[X0V-M>^!OA[^S-XL\8^$O&W[7
M$GP1T[X*Z!\3_A*NBIX@_9DMO@E\%?%]G%X?^$?B;Q/\*/$OP\^*_B2]UWPQ
M\0?AYH'P'MO &IZ'X<M]8_:8T.Z^ GV?X6^/7QTT;XL^,OA9!X3L/VJO O@_
MX.^//'EG\6_A&FG>!_&!\>_#_P 8ZMX!L_V=O%EGXRU#2/V?O$GQS\:ZSHFK
M6,7B'PW\7/AEX4T#Q;X2^(=M\5_AI^S[X>M/ <_C( ^^*\9\2_M#_ _P;XUU
MCX>>+/BAX.\-^+?#?P>U[]H'Q58:WJ]OIEEX0^"?AC6%T'6_B?XRU^\,/A[P
MCX/L]56^MX]6\2:KI<-\FA^)[K3OM=IX4\23Z5^;'[1/_!0#]KG]DCX2^&/B
M3^T7^S%^S;X4\4_&+XF^!/V<_P!GOX1>!/VOO'?CW5/&?[1?Q=\4^&=(^&?A
M_P"('Q+\3?LG?"GX?_#7P##X:A^*_C7XE>+WEUZ#PII/P_TFTT"7QAK'C(:?
MH/S;\)_V*[OXN_&_XZ?LQ>,(-/U[X1Z-XO\ A=\3_P#@IC\?[+P?<>#M<_;Z
M_::U;PC'XY\+_L9V%G-IT-KH7[#7[/WPT\4?"DP> ](\5?$2XF\ OX9_9Q\5
M^*+E;GX^WWQ/ /W]\(^);/QGX6\.^+M-LM:T[3?$^BZ;K^G6?B/1[[P]KT&G
M:O:17]BNL>']5AMM7T+46M)X7N]%UBTLM9TJ=GL-7L+#4K>ZLX/E+X-:=$O[
M9W[:VM6=QIT]K=^&OV6-%U&.W58M1L_$VC^$OB+J5[;:C';P-;SHWAKQ)X/O
M+&_NK\ZS+'=S6%UI%AH^E^']2U[[,CCCA1(HD6.*-52.-%"I&B *B(B@*B(H
M"JB@*J@*H  %?E_\?OVA?$_[,'QE^.7CK1/ .E>-[;Q3JW_!,[X2V.DZ[XLF
M^&FB1^)?VG?VE/B1^S1:^,KWQA9> ?'MW=V_AS5_%?@.X\06PT6]DB\-Z+<"
MS>&[ABM;X _4.BOQ^\!?\%9?#NO_  ?^#'[1WBCX8Z38_LY_$+XK_M'_  *\
M:?''X>_%RR^*OPX\,_$;X&W'Q+L/!?B#X;^)-,\!>'](^,GP0_:#\1_"7Q'\
M-/A)\3K34?!FMZ_\:_%?PF^$FD_#O6O$GQ'L#IOZ>_"+Q=XF\?\ PK^&_CGQ
MIX*F^&_B[QEX%\*>*O$OP]N;[5-2N_ VN>(-#L=6U+PC>WVN>&?!>LW%_P"'
M;N[ETB^?5?"7AO4!>6DZ7>BZ=.KVL8!Z)7X-_MMWO_#5G_!8?_@G-^PA+>+/
M\.?V9?A[X\_X*N?'?PK=:6/LOBO5_A]XD3X$?LB+::X;F(R'PG\:/$?BSQIK
M7ATP7EM>1:-H5[>6RO!8:AIW[R5^(/[(T<4O_!<S_@L%<ZS'I,NL6O[.W_!-
M"T\&7-Q!H[:]:>#KKPC\?+CQ-::5<(AUFWT:[\5P6=SKMLSQQ7%_!H$M_&\=
MMX?:, _;Z@D 9)  ZD\ ?C17YU_\%)/VKOB;^SG\'= \$?LR>$++XG?MK?M,
M>*X_@K^R9\.K\74FC+X]U*W-YXF^+WQ!^Q:=JDNF?!_X >#4U/XH_$C6[ZU@
MT1[?2-%\(W^K:-<^,M.U&$ ^1_B7]M_X*1_\%.O#?P/L74?L@?\ !)CQQ\//
MCE\<;B:"ZET[X[_M]>*/"NIZ]^S[\,="U6U\/MI=UX>_9*\(W\GQ;^*-K:^/
M?MB?$_Q[\,?#7BCX>3)HEGKUK^V7B'Q)X<\(:+J'B/Q7K^B^&/#NDQK-JNO>
M(=5L=%T73(9)8X$FU#5-2GMK&SC>>:&%9+F>-6EECC!+R*#^1OC;XO\ ['O_
M  0F_8U\$^$/$^M^*?B#\0/%^M>*+SPAX0T+3W\7?M3?MW?M3^/-8M==^(WB
MC3/#EA]KU?QC\2?B;\0O%-IJ7B75"/\ A&_ UCKOA[PY;2Z3X;TWPIH8_E,N
M_P!F+]J?_@N3_P %B/ OPZ_;Q\=S:;H/P'UCQ#\7?VH?V,_@]XQ/C?X&?L/?
M"GPE+8>$OAI\!=0^+.B>.O%?@OQ5^U7^TIXBT+2KCXRZ?X&GTJ3P3X1N/$GB
M&SUN+QC9>(O@[\$@#_0^R.!D9/ &1R>>!^1_(TM?S^_%+_@HKX[\ _'SX4_M
M_?\ "W_#>L_\$:==\67G[&6NZ]HFB7,_AC0O&OBK6]0M;/\ ;_U_X@KX;$LO
MP*M/C[X,T']D;PKKTVK+\,=5T+QK<_'#PQXDO_"/B;P[J?BW]M_'GQD^%?PJ
M^&_B+XP_%7X@>$OAA\*_"-I-?^)OB'\0]<L?!7@[0]/BU)-'CU'4?$'B:72]
M-M].U#4Y;:UT2_><6FOM?:;+H<VH0ZIITER =-XS\9^$?ASX0\4_$'Q_XGT'
MP5X%\#^'=:\7^,_&/BG5;+0O#/A7PKX<TZXU?Q!XC\0ZWJ4UMIVD:)HNE6EU
MJ.J:G?7$%G8V5O-<W,L<,;N/QX_9'\%>+O\ @H-^T9H/_!3_ .-.CW6D?LZ^
M$_!_]F_\$NO@MJ\XE$?@?QQ'J%QXE_;Q^(GAW4-+%UI7Q>^/7A&Z\/:9\%-'
MEN;&Y^%?P*O+RWUC1V\:^.=6O-+Y6QE\?_\ !93QQX<O_$?PX\5?#C_@DGX#
M\2^$?'ECX5^-7PWO_#?C#_@IGXAT*\E\3^"-2U?X<^-&TCQ7X%_8U\)>(]*\
M&?$/3]$^(O@V&]_:5<:38:[X>M_AV=5TJ^_=;I0!^,?_  7I\9_M<Z+_ ,$[
M_''PV_8;^$?Q3^+7[1G[1'CWX<_ 3PO%\+_!A\:#P5X:\7:Q+K7Q$\5?$"WN
MM$UCPUH7PWU3P%X6\0?#7Q'XE\;3:!X1TBX^(6ES:IKUIF.&X]D_X):?\$]_
M!O\ P3/_ &3--^&^I>(-%\9_&OQ1<:I\3OVI_P!H&Z6XCU#XK?%;5Y[[5=9U
MK5-?UV0ZQ/X-\"V-W_PB/@5-7DL_LGA/1HM9U&RMO$&N>)+R]_3BOR6_X+M?
M%KQG\$?^"1'[>WQ \ /XD@\4Q_ ?5O!]E?\ A/3Y-1US1K+XH:]H'POUWQ#;
MK #<Z;:>'- \9:IKNK>([4I=>%-'T^_\36TL-QI,4J@'EW_!)(WG[5?CO]K3
M_@K%XNM;>Y@_:\^(MS\(_P!CN[O-$U#3-1T#_@GY^S=X@\1^#_A%?:7I_BS3
M;+QIX-;X_>/)/'WQX\;>';V.SAUF\UOPAJIM?[.T[P];Z=^W5?A+^SK^S#^V
M'\6OV9O".G_#/]I+XM_\$Z/A)\'O!'PY^&'_  3Z^&?A+X=> /&OC5OA3\&_
M FH_#KP)\;_VW?"_QU^'ESXP\6WWQKT^?3O%LO[*]OJ_PLU'X:^!]-\)_P#"
MP?$5O^T!J'B'_A6OO/[&'_!17Q!XU^+4O["/[=/@O0OV;_\ @HUX0\/ZEK4O
M@32+S6-1^"G[4W@/PU#;Q3_M$?L@^/M7TVSM_%WP\\5QQZCX@G^%VM7J_&3X
M6)IOBGP]XUT*XD\">*-9LP#]8:_G@_X.5_CGXG\/_P#!/_6OV0O@]J=\?VA?
MVX1XN\$>$O#WA[Q ^A^*KGX)?!;PM<_'+]J;7K*"":*^U_P__P *I\(R?##Q
M-X=TV+4KW6H_BYIVE2:/J6F7NI)'^_GC#Q?X7^'_ (3\4>._''B'1?"/@OP5
MX=UOQ=XO\5^)-2M=&\.^&/"WAK3;G6?$'B+7]8OI(;'2=%T32;.[U+5-2O9H
MK2QL;:>YN)$BC=A^'?\ P35TS5/V_/VFOC?_ ,%?/B-_:;_"WQ'X>UK]E'_@
MG-\-M=T*^T_2]#_9%T_6-+\3^-OVC;W3-8OV \=?M7^-DMKDQ7GA'PWXJ\'_
M  U\&:1X1UK5_$=CK2Z5X9 /N_\ X)7WVF:C_P $U/V!KK1?LRZ+)^QU^S8^
M@Q6]I::;/#X;F^#G@VY\+)J^D:?-<:=HWB%_#,VD3^(])TRXN=*L==FU"'2+
MN]TM;.\N/OBOYZ?^".DLO["WQH_:Z_X(P^+K6ZL;7]GCQ5XK_:O_ &%GDO+J
MX7XE_L*?M!>-M3UVVTG1+C6KEY=0U_X$_&35?$7P]^(.MZC>Z3;:QXD\26TN
MFV<MIIVJZW=_N'K/QG^&WASX.:_\>O$_BBV\*?"GPKX \0_$[Q;XL\16M_I$
M?A#P7X2T2^\0^+=5\3Z;>VD>K:%<^$]*TS4I/$NCZC80:OHEYIM_INHV$&H6
M<]J@!^07_!9K]I/X+:'#\$?V2_C'\2?"_P /?@WXXU7_ (:B_;L\2>)76[T;
MPG^P%^S)XI\,Z]XO\-^(M(L=03Q!JO\ PU7^T!J7P._9-\.>"=(T'Q5JOQ<L
M?B7X^\ >'_#7B#5)VTJ?] /V-OV[O@E^V]HWQ'N?ACI_Q*\"^-/@]XLL/"/Q
M7^#7QS\ ZG\)OC5\/+GQ%H5GXM\!ZSXM^&^OROK6D>'/B5X,U"Q\5^!M7N!Y
M>IV#:CI-\FF>+/#?BOP[H7\Z'BWPAXDU'XD?L-?\%'/V_/"MQ\(/A_\ MY_\
M%$? /CGXS:-\0'U:PM?V7/@#\(?@3\>;;_@E#^SE\4=.&O\ B71_#&@^+OB_
MK?A/XR?M&7OB+3M!\)Z=^TEXVT>Q\;6O@*7P[IUI'PG[4W_!16<?MX?M;_M!
M? GQAJVL_"/X,_M#_P#!*GX%_'GXH_"+Q'JNB+\./V.OV.OVF/&WCW]MOXG?
M$VWT2>[N_$GP_P!<^,7[0NF?LYZ#!+I=IJOQE\)>%?VC5^&]IXN^$_P7^,NL
M@ _HC_X*T?M=:]^PQ_P3P_:@_:2\%VUW??$OPGX!C\+?!VPT_3+77;VX^-/Q
M5\0:+\*_A)/#X?NG4>(+?2/'WC/0=>U7184N+G4-%TK4H;>UNI2MO+_.!_P:
MH_LNR_LL?M"?M^?#/7K?6+KQ)X1^$O[-.D3^+KF>V30O''C.T^+/[6?P\_:.
MU?PS:VFJZW::AX<\'?M!_!WQ9\"O"_C.TODM_B+X8^"FE?$N"ULK3QO9Z1H_
MT=_P77\2?M2_MQ_M5?L=?\$Y?V(_A3XX\<6WPD_:*^&OQR_:0_:3\*Z>U]\,
M?V6?BY'X/\9:E\!X/BMXDDTW4?#6F3_##0K^;]I+QG\.]?NK/6/'>@2_"+P5
MX>MI?$/Q0\*PZC[WH?Q%^ /_  2D_P""J[?#+XN^+M-^!7[*?C#_ ()!_L_>
M _@?\6?BWKD5AX9U;4OV#OB1\3-&\3^ +KQQ?ZQ:VNJ?$/3_ (>?%[1/%VI6
M4_A^ZU;Q/-J$#Z;>VFKZI::3XL /Z3?Z]*3(R1D9 !(R,@'H2.P/;UK\&[?5
M_B__ ,%I]2M1HL/Q?_9L_P""3.G:C!K,'C6RUCQ]\#/VE/\ @HJ]BWAS5_"X
M\+V3Z%X:^(/P1_8OUF.?5+_4/%-OK7AKXN_&NRA\/P^'QX*\+7NMSMJ)_P $
M??C[\$K7Q'X:_8$_X*S?ME_LH?"W7)-.;1?@O\1]'^&G[:GPZ^&%E82:F%\.
M_"&Z_:-TC6OB3X$\+?9]2D*Z9!\1+^]N-0 U#6-6UC[-I-MI0!^Z 93T(/?@
M@\>O%?E[\8O^"M/[,?@[XB:G\!/V?[/XA_MU_M/:9I,6L:A\ ?V,?#^G_%[5
M_"5E=:E<:-!>_%[XHC6-(^!7P+L;?4(!)J,7Q9^)GA?Q#'8364VF>&]8NM9T
M&QU7R>__ ."-FC_%JYFB_;*_;^_X*)?MC>"-4T_5=(\6? SQE\>]+^!W[/'C
MO2-6TNVL)M,\<_"_]E3P3\#I_%NG0W-G9ZK%I6O>*+_1I;VT$=WIES9:IXEM
M=?\ T]^"7[/_ ,"_V:O UO\ #/\ 9Y^#OPQ^!WP]MKVXU5/!7PF\#^&_A_X9
MDUB\M[.UO]<NM&\+Z=IEE?:[J,&GV2:EKE[%<:MJ7V6!KZ]N'C#4 ?.WP1U_
M_@HC\2=?\/\ BGXZ^ /V7OV6?AV-.T[4=5^$7A7QIX^_:G^-.L7-\FEWLFCZ
MU\5%T/\ 9]^%'PNU#P^T&IZ1KMIX9\&_M$Z7XA;5(YM \::"FAPZCXB^YZ**
M "BBB@#\._V@/^"BO@C]@#P?^UE\3KWP%XP^-WQ:^+7[>^F?!GX!_LX> ;9T
M\=?$_P"*%Y\"OV:_A]HV@V5_IWAS6+ZW\.:CJEEI$]]XR/A;7O[,USQSX-^&
MVG6_B;QEX@\':9XD]Z_8A_X*<:1^TM\-?VH-3_:'^!?C[]B?XY?L.^*->\-_
MM?\ P8^(]U/XXT+X76NG^&]0^(&B>,O!WQE\/^&]'\(_%WP-XC^&=FOC2SUC
MPMIUOJ26#Q:A!HE_X+\1?#CQQ\0.A\"^)OAQ\#OA1^W]\0O$?Q2^&'P'LK']
MI_XP^)O$7QO^,>NZ-K?PE\'>.]9\+_#33? OB_Q7!?\ B7X>:9+IGAVYF\ Z
M#=^!_P#A*O"6IWOB'1IO#5MXEB\07Z>(KG^9W]CKX.?%GQ[\.?\ @LE_P39_
M8F_:F\!_\%%/ G[0?[(_C#XL^)O^"C>G^$O#G@Q;O]NGXO:IXD^'OQ)_9;^(
M/Q-TC7/%^F_&U/C+X*AU/XA^%_B*/&VL6'P=\*Z])X>GN?$.GZC8ZK( ?2GP
M]_X.0OVK_$VH>,?VT?%'_!.#Q-X5_P""-/ASQMX$^'FI_'R]UZV7]ICX=V7C
MF?2FTGXV^-?AMIOB/7K/Q%X&N=-\3>"M5U+P7X-\.-_8.E>-?#FJ:/\ %;Q]
M#JNCQ:M^ZO\ P4C_ &V_'?[)7PO^%^B_L\_#&P^.G[5G[4WQ(B^"7[+?P]U3
M5]*TGP+<^-9?!WB?X@Z_\0?B+JEYXE\+WEU\//AYX"\'Z_XCNO#?A'5#XS^(
MWB(^%/AUX:FT*;Q=+XQ\-?C/IGQ.^)7_  5)_9*_98_X)>? 3]B_]I#]F;]G
M[6/AC\%?AE_P4>^*GQM^%FI_!6']E7X5_#7PU9:O<_LW_ _3/&ND^ XOBC\5
M?BM'\.M/\):?\0O G@GQ%X&^%7P_^('@OQ3XA\#C4_%TVE?#C[D_X+I>'O&7
MC3X)?!CX<_LZ_ ;]KOXB?MM'XAW/C;]B#XN_LI:;>>'-"_9?^,_A'3K?P^WC
M[X^?&/4+JR^&'P^^"_B7PAXVUOP#XQ\&?$>'6]/^*OA'6/%&AZ+H=E?Z.WC;
MP6 >8?#7_@I)_P %,?A-\)--^#7[87['_P )T_;SN?VPO"W[''PR\1MX_P#B
M)\)OV3_VI&^(/PE\2_&#P;\:OA)XWT3X/_&K7+^P\/\ ACPMK,/Q6T9O#_A[
MPOHVJZ5+IUUXL\">/=2O/A#X/^</VFO^"AW[;&B?L9?!37M?_:M_94\9ZI^V
MC_P41_9U_P""?>L?'3_@G3X8U?P/X=_9%AU_Q_XGM/VA]1^&/Q@_:>\=?%+P
MI\?->UOP1X,O/!?A3XDZAX$^"_A_X4>*=5\1^+;?6M5FTWP]/X?Z;_@KQ^R;
M^V[^T5JG_!(_Q/XX_8@TC_@H1I_P&\%_';7/VRO@=\)OCMH/P3^%?C+]IOQO
M\"/A]X)^'MF=7^(?C+X=:V_P(E^+,OCC5[_4[C0-?B;X<V.H>&O'OA^#0_$V
MI^%_%W5_\%I?V(OC3\3O^"#%O\&O!OP7\)V7[3GP,?\ 9N^)/ACX%_\ !/WX
M8:E'\.K/XF>&OB+X<T'QMH'[/O@(^';OQWI7@KPOX<\<>/?$?A^[\-VWASQ?
M%!H<6I:@\6C7'B+P]J !]:?L0?M$?M!_#WXS?\%$OV3OBGX_\7_MN> ?V#_"
MWPE\7?"WX^:%X4\':C^T'X[B^(OA'XB>-]5_9K^*UOX'U+P_X+^(?[1_@'2/
M#/AC3=#O/#?@WP+J?BW3/$7A[6_B+I>@ZQXNT2]UOM/V;?\ @JUJGQ"^-/[/
M?[.'[6/[%'[27["7QM_:V\)?$#Q[^S-H?Q6F^'WQ!\)?%/P[\-_"%I\0/%>A
MWWB3X9^)=6\0_"CXJ^&?!4MSX@\7?#'XS>!? &I^&4AMM%N]2F\4ZGIN@W/N
M?CCPI\,_^"6W_!/[XV:M^QC^S'9:AI'[/OPC^(7Q1\'_  .\ ?;6UGXE>+_#
MOAN?4Y;[Q1XFU&?6O&?C;Q/X@DTNVN_&OC?7;[QA\2?$EI:7-UYGB?Q%]BLK
MO^<G]D?P5_P6J_:D^(WPG_X+ W6I?"[]K_1_@1H_Q>\.?LK?LS_M(>"D_8EU
MKXH?#SXP_"SPA=?&'XP?LI>(?!'AK5O^$$TKXF>-_#5C\)/V9M2_;(TSQ _Q
M%^"]I)\9/B#_ ,*JF\7>&DTP _9+_@HQ_P %R/V=/^";WQLT7X'_ !%^#/[2
M/Q6U6S^&O@GXY_&#QI\&? ^B>)_A_P# 7X(^-?B9JGPIL?'/Q*U>Y\366KVM
MX/$VDW#6OARPT&XEO["6TE74K>>_T^VN_7_CI_P44F\,?M?_ /!+']F7X&:%
MX/\ B+H7_!0K_A=GQ)UGXA:Q=>*+:U\,_L^_"#X#7'Q4M/$OA2#3=+\G^WO'
M.J:UX5CT"]\1R_V?%;6-YX>OM%@N_%=EXG\)_BE\>_V0_P#@J)\;?C__ ,%#
M_#:_LA^&/!I_X*\_LX_L$?#CQI\9KCXI_#'XL?"C]AKP!X#\'_$GP1^U!\/]
M8U+Q1;>%O%GQ(^)&GV>LV\_A)/A'\.[G1=4\5W.D>.-*UO0+NRTW7],_0'5_
MV4O&7A+_ (+'_P#!+^R^'WPV^)^K?LV?L8_\$X?CKX$L_B=K6AWQ\#^#]2O'
M\$_"#P=H.J?$JVL](T7Q)\4?$7AC3+0WG@6ZO]6OSHEO=>.-)\'Z9:6FL>(+
M$ ^Z/V$/VV]=_;.\>?M\Z9_P@FG^$_ G[(?[;?Q$_8W\(:];:O%J6I^.-8^#
M_A'P+=?$36-=MXKN>/3;BW\7>)[F/2X+>&VA&A7&FVMT'URQUN.V_0]@2I .
M">A]/S!'Y@CU4C(/Y)_\$<OV5?C-^S1\!_VAO%W[1'A2#X=?'+]LO]NK]JW]
MMSXF?"VT\2:%XPT_X9:I\</&UG9>'O!^G^)O#=Q>:1JL$'@;P7X6UFXEMK^]
M:'4-;O;2XEAN+:2SM?UL9MJEL$X[#J>>@]SV'<\4 ?)G[%=_-J'P;\4/-NW6
M/[47[<VA)OF><FW\.?MN_M#^'[4K)(JR^6;;3(C%%,UQ/!&5AGOM0FC>]G^M
M:^0?V(8);?X->,A+!]G,_P"UK^W[?1+YSSK-::C^WE^TI?V5XDDE[J!,=_:7
M,%]&J7"0QQW*Q6]GIT"1Z?:_7U !1110 45#;SBXC\T1RQ@M(FV:*6!\QNT;
M'RYDCD"%E;RW*!94VRQEXG1V* )J*** "BBB@ HHHH _-W]N#X5:]\<?&FB_
M"#1=8&CZA\5/V,?^"@7PO\%ZE=WWB>QTKPQ\5?B)X4^!_A3P=X[N[WPR/MFA
MS>'?#>J?$'3(O%&G2Q>*M)L?$^JV/AE';6]1DC\1O?\ @GW\8;;X0_MLZ5;>
M*W\0>-?C1^R)^SA\,/@98^+_ (X_$OXC>*/"?[1?[*/PZ^(5E\-/C)>?'+QI
MX?LO%?A2_N?B-=_"+QO9OI>DZ_?:#\5/ _C+X[WFLZ[XU^*>O:?IOW1\0-&;
M5_VN?V;KFXUB]ALO"_PH_:<\46N@6]ZL-KJ7B ZI^SKX/LM9O[(0.]^FA^'O
M&7BVQML7%O\ 8[KQ'%<NL\8*I]44 ?*/C/XGZE^R]\#? VKWWP5^,7QAU\1Z
M#HWB3P9^SKX'TSXA^,3XOUG1=4UOQ+XFO-)35O"%C+IFK>++*_BUOQ5YL$+>
M)?%%CJVLI::?>ZIJMAX0W_!1B^.H-I\'[ G_  4@N',16"X7]FS1;:QGU,:;
M_;8T@7^H?%"SM;>230_]/76K^2S\))J)_P"$)F\2)\10?" _27 SG SZ]_7^
M?-)M7T'KT'7IG\N* /S$U#_@IA>:79^9=?\ !/+_ (*<2:J=2UG3!X?T[]ES
M2M8O#)IEE9WEA=_VUH_Q1O\ P8FF^)6NI;/1M1D\4K:6EY87D7B:3P\ALY;S
MRWXL?\%2?BMI>ER>'OAE_P $QO\ @IAJ?C_Q&GAFQ\(:OK/[/7PV3P=ID_BF
MQBU6[UW5#=?M$>'TU:[\!^'GN]=U+P!?ZYX,GU_7=.7P#JGBWP(9?$/BOPA^
MQN!SP.>O'7ZU^1UA^VW\4?!6O?MQ3^-/A)\8_'?Q=\%?%+Q-X<_9B_9,^%WP
MU\>>*_%'BKX)?#_P986'@CXN2ZQK?P\^''@^STKX[_$V#XE:_-\1+WX@ZC\+
MK;1;#PG\(?#_ ([U/XJ^$=9\-7H!\8_%+]J:WL?@?X#_ &-/#'["G_!5S5$\
M6>,]:^(WQ7\2>+_@;X5\4?%GQI\-_A[\6/!GQR_:%\=>7:_%?3?#'C36?CM\
M1O'^A^"M5\(Z ?#OA/P_8?%OQ6?"_P -7\/> -+^"FL_?NM?\%*O$.B/?"/_
M ()K?\%.=8@LI[6*6]T7]GWX;W4=TUW<V=MYEG9O\=(=5O(8GNYWEE@L98[>
M#3KZXO&MK-]/NK_Y-\1^._VW?V2?&GQ/_:=^)_A0?M"^)_B1<Z9\/K?P_P"#
M? 6F?"WP=H\7@OP?\0_!_P &O@/H%SXJ\>>+?$<L'QE_:2\,:!<?L\^.?#6L
M7VJ>.?BQ^V1K?@SXQ_!WP+X1U+X.>-OAIZOXM_:Y_P""A=A+IGB+PA^P];Z_
M8>/='_:!\0^#-?M_"/CB3Q1X=\.>$OAY\$OB#^S7\/\ XF>"_$FN> /$F@^/
MOC#XQ\;_ !/^"7BZ/Q!<>"?"_P ,?'7AJ+Q_J[)X \/>++Q@#U!_^"E/Q'-W
M!9Z/_P $HO\ @J3K FMI;F2YA^&/[*GA^SM9!J<.G6]M<2^-/VP_"Q>YO+>[
MTO6(UMDN8K;2]1D74YM/U/PYXRTWPYPO@3]HS4OAAXD\3^+? 7_!#3]MOP)X
MG^(GC/4+GQ-XN\'>%O\ @FCI7BWQIXE^(&HVFO\ B3Q#XYUK2?V[+/4I4U;Q
M D%UK_B#7]5NM'@>RL;O5M5LQ8"VTWH?"7[0_P#P4[UGQ9X#\-ZE^R+X$M="
MUWQ3$OB/Q_JTTGA.'1_AY-^T_P"$;)]=N?!Q^*WBX:'X@L?V+O%;^,KCPU<>
M.-9U6Y_:!\*>,O"%GIKZ'I&GV6M>A6G[1G[;*_LT>%OBUXG_ &6="\*?%'7M
M56\\;_#BY\6^%Q9? OP9HGP2UOX@^+;_ ,3ZSXV^(GPTTCQ[,_Q<\,3? +0]
M<M/$/P[\/VD_CCPS\9M>-O\ "?P]XCUF< \*\!_MB?'OX9_%_P"/EQXF_P""
M6?[>FC:#\:_&?@7XG>#&3Q3^P9XD\1:KKUK\(_AK\(?$WA]-"T3]N2^T^U.E
MZ7\,O#7B"VTCPUJOB+5+?3)O&GBKQ58^&])T6]N4]PM?V_\ XRWOG1VO_!*7
M_@I)]J@2W,EO?6/["VE1K)=B3[/&NH:C^W3!IMT"]M?1W4FG7=\FF_85DU#[
M/'K7AEM;\4M?CQ_P45L++6X?"7P:^%WC_P#:6U_1O$WQ*\7?"3Q1XY\4>%_A
ME\-_ 'AO]HWX>?!+X'>'-(D:_N]?\$1_M&?!;PW^U1^T39>+]3\%^+O$6G^.
M/!DGPZU[3-=71?"/A>7UW4/C=_P4'BU2QO?#'P'\*>,O",6A_LLWUS%?^ ;S
MX<>(?$.J?$_XL^,9/VCM+LXO$W[0M[?>#3\"/@CX;\.Z'X?;6/"WB*/QM\;_
M (C>']4UFX\&_!SP_P"+O%>F %>__;Z_:<6\33]'_P""/W_!02\NKFWNY[1M
M5\;_ /!//1]/8VHTZ5DO=7M_VY=8TS32]N=<,4=S=?;+JZL=&L]/L[V77;EM
M#_']_P#@IW\1O^"DOQUTRV^'?_!.C]M;XY_LO_L_KX-^-7PZ\ _"CQI^SYH'
M@SXQ_M(^ O%.CZ[X.U#]K#XKW7[0WA?PG\/-"^"GQ(T#1_%/PE_9NN-2\?:K
M\7],U3PU^U5XN\%W/@?PK\+]*U7]?/ GQY_X*.>*?''AS0-=_92\,^&?!MQJ
M_P !+'QCXUOI-%L[/1=*\9>$/ASXU^-'B#0=/U'XX6GB+7=$^'>IZ9\>O@BZ
MGP[:^-[+XDW?P'\=Z)\/?B7\(M>\<Z_X>X+7/VB/^"E?AS7Y[7P'^Q+X9U3P
M?JOAS3M7M[".PT/0#X<^)LO[06MZ3\<](U+Q)+\=[>Z\:PZ5\+/&/A[XB_#?
MQ-'\+_ NB_'OQ=\-/BW=OXE\$:?\3OALVF 'A/AC3?C+K/QH\6?'[]HG_@G)
M_P %*_VD_BA>IXO\,^ ='\6>+?\ @EWX/^!GP/\ AIJ?B72-1C\$?![X6I_P
M4MU&RT34O$>@:+X8T/XR_$;7?$?BWQ7\=)(?$UCJUU9?"2[T?X1^$.?^(_[0
M'[4OQG_:E^$5G8_\$?/VK]2^ 7[$LD?C;1?!-SX__8!\.:^G[8/B'PM-X;^%
M.J:;J-E^V+=_#>S^&OP>_9\\9>/)[B+PQXY\1W4OCGXM^&H/$_A3PJGP_P##
M^I>(_4/ 3?\ !:7POI7Q$OKOPU\&?%/CSX@>$XO&%I?_ !$DQX+\%_&G1_A)
M\7/A7HO@#PGX5\+_ +0&L1>&O@9XC^+'PA_9Y^.?BF\TG2SXJL? /[3'Q,\-
MM/KOQ1\'7OB?P_;\+^-?^"B?P8T+QUHOPR_8^_X2WQ1XV^$VM_M!6@TW0/AC
MH7@?5_VN/B_HWQU^)_CKP!XH\1>/?VOO!^N^'_#O@WQEJ7P#^'[ZW_96KWGQ
M!\40>.+?3M(^$'P\:W\:>$@#Z?T+]LS]K&[MKA-<_P""2'[9OAZ^6_F@LDB^
M.'_!-+5=(;3VDBBL;[4+^#]NVVU&QF)D>XU2QM-!U3[%:0ROI]UK5X8;&;XW
M^/'_  4N_P""AVH6_B?X%?LQ?\$EOCH/VMK[P$OC#1]-^)?[07[#-WX)^&7A
M6]UJ3PH/B)\0;WP1^U!XFT[3)KC61=/\(/ GCC5O =U\?I/"WQ!D\"ZA>Z%\
M+?B7J/AOT;]H+XU?MM^&OC#\,?##>"VU?Q!IOQ"^+&H? 7PY\*-:M?!EK^T=
M?6?[-OPY\*>&M0^)_@?4?B/XKN=/^ W@7X@?M4_%+7?BNOQ!UC1K;PWXH_8V
M^'OC[0_+UWXD?#/P?XJO_LT^$_V\?"/P=^.GB#5?@G\&?"7[6OQ!^&5QJT/Q
MIU[3W\01?&/]H>Y\>?&'2? E_P#$BU/Q'L/']I\$/!?@]? WCC1_AO?ZKIMU
M\!O 7Q;7X$?#Y/%]W\'_ !!J&L 'Y9_!/2_^"W?P<^"OB[]GKP;^Q!^TSX5\
M!^&O%OQA\;_##Q;=_M._\$^_%OQO^,^O^*_%Z>-?#-O^TM\;M6_::NM?\/\
MA_QKK&I>+9OC[%\)O#I^-?B#6==?5/@S^TA\#]$LM'\)Z!'\.?#?_!9'X;?#
MOQSH?P\_X)=>//@;\3_CEXAU:^_:(^+OPM_;+_8:\1_%;XBW^I-X:M+SXKW_
M ,;OC5XZ^)WBG7/BA:Z(/']A\--(M/ 7P[^&?P>UOQ98>,M)\)>(])T"7X5Z
M_P#J!HWQ4_X*8'XE^(/!MA\/+:[BT;X_>'AX@UZ^\.>%]3T'4OASJOQ9U3X?
M2^#+6_G^+=I8^&F\/_LS77PM_;6\1^.-%TC0O"?B"T@\5_LL>"=*UO\ :K\4
M^+=4^&_V/^PSXL_:G\??#"Y\8?M6:#:>$O&.IVGP]MK/PK9:9X>LK"RU:U^%
MW@ZY^)]WH]WH>IZK-JWAZW^+6H>-?!VCZ_J-T;+QPG@JX^*G@6"P^%_Q#\#:
M3IP!^,>K_$#_ (+C^(_@\_PGT/\ 8%^//P+\+Z+X/C\">#HOAU^VU^QG\2_V
MA]033+3PVFG>/OBA^U]\<_C)XUU+7/%.K.+X>,%T;X')XRUJ]'CF]7XN0ZO-
MX/\ %&H>3?L]_"W_ (*[?"GP3\-/A_K7[%7QV^&7POT^XTWQ+\:]&_9K_:R_
M8GUO]IO]I'QY)X?U]?B;XX_:3_;!^+_Q4T+QKX[\3?'GQ=<ZKJOB77/AEI?P
M=^(/PZ_MKPM=?#KXM66HQ&Y^$G]9N!Z#\AWZTN!Z#KG\?7ZT ?SC>*/@OXJU
M;7_#FJ>'/^"'O[5'@+7O!?A_PU\*]#^*7PA_X*6_!?\ 9Y^*7B3X>Z'J[^+K
M*+XA_$+X'_MD^&?B%\2--MO$.FKJVN7?Q+\4>,_&&J>(_$-YKA?5M0U;Q#K,
M7-?"[PI^WI\)M:N]6T'_ ()X_P#!2[QGI.G^+_ OB7P3X/\ BQ_P6:^"5SX4
M^'FF:%J$FMV/@CP_I&E?'+Q%<>/_  CI]YJFJ6'Q4LOCOX@^(UYXJTNSM;#2
M+SQ1X>M/#_AO0/Z7<#T'Y"C ]!^0_P ]S0!^6^C?M=?\%%[W1=-NM4_X)+>(
M] UV>PT;^T=*N/VV_P!EZ_TS2]5O#I2ZS!'K6EW]U<W^AZ*]WJ)CU6'0X]5U
M5-&E,'AF"6\LH9>HMOVI_P!O:?5[:VE_X)=>+8-%=M'M+O5O^&O?V99KNUOK
MF2W76[Q-)BUYEN/#6E)/)-8:A_:,7B36([2Y$G@_2I6LXKO](<#T'7/X^OUH
MH _)K]EKQ?XM\5_\%+/VJ-6\?^!+_P"&'CCQ5_P3C_X)B^*/%OPOO]1\/>)+
M[X5>(C\7?^"D/]K?#[6/&O@V?5O"/C35-&O-6G \2Z!K4ND:A$SP:2M[::>U
MW%^LM?F5\#M5COO^"LW_  4,T^,R@Z/^QQ_P3*M9T^Q1VT'VB?X@?\%&]1:<
M3PZI?_;)I;;4+.%KF[L]"NO+M8[*/3+FTTZ'6=2_36@#YA^.'[*/@3]H'XL?
MLS?%7Q[XI^(RQ_LL^.O$GQ/\%?#/0_$.GZ;\+O%WQ'U;0(O#WA?QM\2="?0[
MG6]?UWX66[ZQ>?#>32?$OAVTTR]\3>(TUZT\1Z=J7]GP_3H& !DG  R>IP,9
M..,FEHH *^3O"W["?['?@KXK:_\ '#PS^SC\)M-^+'B;QQK/Q,U?QR?"EE>Z
MT_Q#\0WJZGK7C>P?4?M=MHWBG4=5-WJMQK>C6VGZ@=5U77=36=;_ ,0:Y<:A
M]8T4 ?)GC[]A']CKXI?&6U_:$^(G[.7PJ\8_&.U70L^.-?\ #%KJ%_?W'A>X
MTFZ\-ZCKEA,3HOB'5] G\/>&7T?6=>TS4M6TX>$_!Z6E[%'X2\.)I?U=!;P6
MT4<%M#%;PQ+LBA@C2**-,YVQQQJJ(N>=J@#/.*EHH XKQE\-_A]\16\,MX_\
M#^$/&X\&>('\6^$E\7^&=%\2KX8\52>'?$'A%O$OA\:S97HT;7SX4\6>*O#)
MU?3A;:@= \2Z_I!N#8:O?03=DL:*2RHBEB68JH!9CU)( ))[D\GO3Z* "OS@
M\<_L^>$_VB?V@/V@_ ?C?Q+XNT&3P_XJ_P""=G[0FA:GX*U73X]<MV_9W^+_
M (F^,WPLT"^;Q3X1U_14\(W'Q?\ A1KM[KWA:UAOUNM/UC6]1L;SPYK_ (@;
M4H?T?KYX\#:%X9M?VC/CSK>D3J=:O_!7P,T_Q)9VUR1:VESIMS\7M3L6FTY(
MXK>WU2^MO$\E[?7^V:]U*UFTQ+J\EAL+2ULP#R"7_@GM\!!\.OB!\.--N?'>
MAV'Q:_;(\"?MU?%+7=,UW2FU_P =?'CX>_&WX5?'71;K4%U+P]J/A[0O"UWX
M@^"GPW\-ZQH/@OP_X7DOO"NA7$BZA!XPUS7_ !?J>K^T-X>_X*%ZGX_T6Y_9
M0^*7[&?@GX6)X9MX_$FB_M"? ;XY?$SQ]=>,X]3UN>]O="\2_#3]I3X1>'+'
MPSJ&DR^'K"WT^_\ "-_JVE:I:ZWK$VJ:W:W]AHNG?:!('4@=N3CGTI: /S\@
M\*?\%34T&X6X^.7[ 5QXICM[TVUS#^RU^T?9^'[N[>XUF73Q/I\G[95_?Z=;
M06L7A^PO/+U#5)+JXO\ 6=7@%G'I%EHNM_BQ^UUXH_X*.?\ !/#]M;X8_MY_
M&+XW?L=:%\"OVH/!7@G]A7]HWX@:)^S_ /&>7X#_  !U;PQXZ\9^/_V6?CS\
M8M N?VA(O'=O83Z[\2?B3\'-9\=O\2/#/PS\*0:YI,OB\177C+PX_A'^JD$'
MH0<<'!S@C@C\^*R/$/A[0?%V@ZWX5\4Z+I/B3PQXETG4M \1^'-?TVRUG0?$
M&@ZS93Z;K&AZYH^I076G:MH^K:?=7-AJ6F7]M<65]9W$UM=0RPRNC '\]7QX
M_P""G_Q\^#VOZ/\ #WX;_M-?L+?MH?M,?$?PZ=8^"?[%_P"QQ^SG\:_BS\8_
M'-[J^APZWX.OO%OQ T/]LO7_  '\%_@_J.F>+_ 'C3Q'\=/BYH/@OPEIGPJT
MSQSXT\*V?BZYETW2]+],_9[_ &&_^"IWA_XQ_$3]L7XQ_M:?L6Z_^TK\:? W
M@_PF- U_]E?X[?%;X=?LN^!X18WGBOX'_LY7UG^V5\)I-.^'^LZ[I&@>+O'F
MNMH.F>(?C-XPT#0]3\6SZ>?#GA^]M?UQ^"O[,O[-W[-EAJFD_LZ_L_?!'X!Z
M5K;6[ZQI?P6^%'@+X6:=JKVDEW-:MJ5GX%\/Z#;W[6TVH7\UNUW',89;Z\DB
M*-<S%_<* /YW_P!J/_@E!_P4<_:-_:F\+_M3Z5_P4G^"7P:^(>A?LU^*OV8M
M \3_  P_8I\8P:G\&/#'C+Q;HWBKQU\1O@=H_P 1OVOOBC8^'/C?\3K%-<^&
M_B3XG#5=,U'PM\,?["TKPC9Q^+[%?','@EG_ ,&_O[6_@R^UVU^!G_!27X:_
MLT_#SQ[\*?@9\'_B]\,OV=OV,?B!\,E^,7A7]GS7/'GB_P ,R>-OC&W[</B7
M]H32/$OQ,\5>/=?E_:(\;_";XI?"OQ=\;;3Q'XLOO$VJ0:[K^KWVJ_U-D@8R
M0,G SW/H/4\&C(/0YH _-"V_9@_;7TWX*:/\!M%^-O\ P3RL?AQI/@>/X7_\
M*ZN_^";/Q3O?@[/\,+70KCPC8?#BV^%T/_!16RL=/\&6_A)--TF;0I=9U33K
MI(KZQ6TMM#FMM*M_RV^ W_!$;4M*U;PQ\0-%U7]@WQ;:_![QW\4[+X1^$?BW
M^RU_P4)^*?PB^%OB?PCX^\:^"[IOAK^SC\;/^"N/C_X*_#^WM-?T9=>\'>)?
M"7@^UF\)1(\?@FW\B]TGQ'I_].Y91C+ 9Z9(&?IGKU%8/AR\U>[TZXFUVSFT
M^\37O$]K!!<V^G6COI%GXEU6T\.WBQZ7X@\36K0:EH$.F:A:W$NI6VI7EM=0
MW>L^'O"&L3W_ (2T0 ^";KP;_P %8(EMH[3]H;_@GA.YL].^W:K<_L=_M+60
MBU!5OUU:6WT2']NN^-W9'?I<NFVT_B&VG1;*_M[JYE;4X+O2KFD:'_P4BDO[
MBPN/VJ/V =9U&U@2%]%TS]C?X^:=>V^HVL6B2:Y]M:7_ (*!Z[.L6FP:Q97,
M<+:5!(T>NZ&;TV0N;6XO/K'X\^'?B%XQ^!OQG\(_"'QM<?#;XL>*OA/\1/#O
MPP^(UEIFF:W>> ?B%KGA#6-,\%>-K31M:N+31M7N/"OB2ZTS78-,U:ZMM,OY
M;%+6_N(;2:61?RQ^(O[#'Q\^&=]XY^*?[+FN>$?A7K.G^!=8\!_#3X<?"JS_
M .)-HGD_#'Q;\!?AIXUTR'QA8B]\,6>@^!-"_91USX[_  QTO5O&W@?XGP_L
MN>!=2\"_#6'XM>!/"FK>. #ZV/A#_@IK/<0.WQ^_84LK:"<M<PK^R1^T)J,^
MI6L=_;LMO!<+^V]H\6BW%WIJ7:->R6GB!-.OKBW?[#JEM9RQ7W9Z=X2_;UCO
M+=M9^/O[(E]IYV+=1Z9^R%\9-+OXBT$K236TUW^W#JT$PCN$AM4ADBMFFM[J
M6_-Q!+8II>H_G9X@_8;_ ."GWB"RTV3P[^WE)\/H]2\2?'[6O&GA6Y\4>/?'
M=P+/XL?L_P#PUM_ GA;1/BFFC^"_$S>&/@3^V'X+\0?$SX6R:%X>^'FJ/\"?
M%=S\+/%7]I6VN_$#1/%GJB_L)?MF2^.-*34/VYO&MQ\'K7Q9<)K'A73_ !/\
M7]"\;^(OAN?B!\,?$=G9:G\0=,^($?B:'XA'X=6/Q@^$&M>+=!UG0+.]M-=^
M&OQ#\,Z1X)\7>$-?B\5 'T3>> /^"F\M_<_V?^U1^PI8:4;>/[&MY^P/^T+K
M&H+=/901R_:FA_X*6Z';O;P7XNKF,PJDMW:R06;_ &.>*349?BK]LW]@G]J_
M]L7X;:+X&^/7[9'[#WAV_P#!OB=_%/PS^+W@']AOX_?"OXW? WXJ:+I\?B;0
MOB-\#?BI9?\ !5-_$?PU^('AC3-*N_$$E]:W.IZ?J>@Q3?\ "2>'M;\,I=6C
M?3&L_LS_ +6EC\!=+T6U_:.U;6/BU8?$CQ%XT\<ZC:R>*/$T7C_P1I/PH\<_
M#;X:^!/"ECXT^(WA31_#NO:?KK_";XS^)].?6_!WP[^)WQ.\'^)O#?B]_#WA
M+XBZ[XFTVE^S'^P;J_P4\9_"'XFZEXXO/$VN^'8/VKM9^)LGQ9,/Q0^)WCCX
ME?';5_@-H'PI^)>J?%B22POKGQI\&OV?_@1I7[/C:A>+XBUW7?AYXAN- OO'
MVM-I%QK?B< _)_XA_P#!"O\ ;L_:IL?AM9_M2?\ !:BZ_;/_ &>O"T-MJNC_
M  $^*O[(VN:%\#_BE8-J%EXE\)ZQ\7T_9A_;;^ .M_&^;1;RUTC6_#6N^*O%
M.H[;NSM[FV8Z3>7NG7WZ_P!A\#?^"DVA^%-*\+^$OVPOV(?!5KX>M+;1O#MA
MX5_X)K?$K3?"FD>'-+M]/LM#T6T\+/\ \%'[F*SM=+L8-0M5BTG4=*L%CET6
M/3M,TRVTB]MM;^8?%_\ P3E_;AU_0;[3/#O_  4!\=>!]5B^&7ASX>Z'JVB:
M_P#$33='A\0^$_BS\+OBK>?%BZ\!>!]=^'W@W2]8^)(^"ND_#=O O@_3O#FA
M?!?X/?&#XF?#7P7KWBW1M+O9_BA\6_M:?LK_ +5_PD\5?LU_L7?L:_MB_%[_
M (6G\4O',WBF&^T74-4^Q?LW?LZC6?VM/#GQI^+7B[X>6_QQ\(>$_"GPF^&'
M@7]H/]G+X?\ [-G@WP3X-L;*[\<_LN^&? O@N]\":_XNMO$7A( YW_@JQ\)/
MBQIOB3]ECQS^U5_P5S_9>_9L_:"^$?Q$/BO]BOQ[\!_V!/C5K7[8S^/?$1TG
MPK\2O"7PN^#'@W]L3XJ:U\8/A=\3-'DTKPI\5/!$_P 'OB'X7U^Q?0/#GBZ,
MZ5J=U;:Q^"^O?%C_ (+M?\%0/VG_ !W^Q[KOPLO(_@;\']5\-?$+]K3X$_"_
MX8:M^R)\!M07Q/K/A#X[^#/%/QC;]KM_!WQ:\+ZQ\6/'>C:3XL\6?#JXTOPI
MXGU?P;IOCCXC> O"/BR[\??$/QKXA_=S]J?]AW3?^"9,5]^U'\)OBK\2_P!H
M']LCXX>)O#7P3^"'AO5KGQAJ'[2?[8_QZ\7>&_V>=.\!>$?BU\6]/^(>A7M_
M\#_ASKOP)^)OQ0\>_"73T\&_LVZ/\!_'?B;POJGPZD'P=^$D<OUY_P $[_\
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MCUJ]U"_GU)=?NM-UWXFRK<M'=>'KKXB3^!@UWI_A+3KR?Z#$B$9#H1R<AAC
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MINK>)9M4UUCH N]%M-4U;4=,%[<ZK9:HP^[]Z<?,O.2/F'(&<D<]L'/I@^E
M#J:RJWWE5L<C< <'UY!I0RG)!! Y)!' ]3^1_*D\Q,XWIGTW#/Y9H =2,JM]
MY5;&<;@#C(P>OJ.#[4TR(.KH.W+ <C&1U]Q^8]12AT/1U/!/##H.IZ]!W/2@
M!<     #&!C@8Z8';&!CTI:9YD?/[Q.,Y^=>,#)SSQ@<G/0=:7<ISAE.,YY'
M&#@YY['@^AXH =2$ D$@$C."0,C/7!ZC/?'6DWIC.]<>NX8[CU]0?R/H:-Z9
MQO7.,XW#./7&<X]^E #J" >",CT--WIS\R\'!^8<'.,'G@Y!&/7CK06 !(^8
MC^%<$D\'') '4=2  020.: /C[]AO;_PIGQOL*E?^&O_ /@H5]P?+O\ ^&_?
MVFO,&0 -X?<)!U#@[N3D_8=?%W[!.NZ;XE^!'BK6]&NSJ&EWW[6__!05K*^$
M%E;Q74,'[??[3-KYMNM@\D$MJQ@)M+QV%W?VIAOM02+4+BZC3[1H *SI)=5&
MJVD,5CI[Z&^GW\E[J+ZG<1ZK;:K'<:>NF6=MHPTF2TO-.O+235IK[4Y-=LKK
M3KJRTVUM](U2'5+J]T;1HH **** "BBB@ HHHH **** /CS]J7X9?M.>(]6^
M''Q&_9(\;? ?P9\5_!=GX\\):@_[1'PY\<?$7P)J?@/X@1^$M6U>TM[+X<^.
MOAWXMLM;C\5?#?P3);2VWB:TTQK!]2NM0M=1FT^RTZ]^7+KXX?MJVUPNA:M^
MU;_P2E\*^);/X?\ C7XQ:U#<:%\8?$$>G_!OX::C9>&/B'\4)-.G_:)\&3VW
M@7P7XPU:RTCQ;XPO]1M_#7A>\@_L/5M174=0EFT3],/B3HGB[Q+\/?''AOP!
MXP_X5YXX\0^$?$FB>$/B!_8>G^)SX%\3:KHUY8Z%XP7PWJTD>EZ^_AO5)[75
MX]&U(MI^HR6BVM]'+:R2Q/\ FC:_\$R;[PK9>'/"'P_^-YM?ACH/PB_:\_9T
MM/"WC3X;V>KZIX;^ '[8'BSX*^.]>\ ?#JZ\!^,?AGX \#P_"#Q#\+M>T;X'
M:99?"VZ\"?#[X7>)O"?PFT/P78^%?AAI1UT \[L?CU^W-J>LZKX''_!13_@C
M38^/_#?Q"\-?"WQ'HEG\"?C/K.HZ5X_O/#?B#QOX@\$WWA^Y_P""A.B:A8?$
M./PUH&K:EHOPRGN6\0WW@SPYJ7Q&O=0T;3-5ATC0+,OQY_;QFT.\\>:)^W;_
M ,$<-4\":'X!@^)OB2^U3X4?'#PS9Z)X'F\(Z]XPL?%^M^*S^VYKMGX:\%ZO
MI/A_5M4E\6ZUX=BL/#WA;0O$7BIX-?BT:\TR#Z+NOV&+^;X\^/?B\?B%%/HW
MQ)_;.\*?M:ZIX>L[3QWX.\3>%CX7_8%\+_L2#PKX=\;>$/BG8/<WFJ1^$QXL
MO=;M='\))<Z/XGO?"&O6/B;3-!C3Q#\KZ+_P2*\16O[+%W^S/JO[0-W>#Q?X
M/TZ;XB>/KS3/&7B/7;WXM:7_ ,$U]._X)PP^(= ;5?B'::G_ ,(5?>'_  [X
M1^+VJ>&?$VNZ[/=^(-(\0^#[VZU'1O&G]I^& #N/$7Q1_P""@NA:)J\TW[<'
M_!*.QU-+3XF>*_#6H7O[/7QUU.WU[PY\-O$V@> /%^AMX%TS]MFV\0BZ^&/Q
M,\6>$/A_\0/%^@>*?$\L7BSQ_P"#/"-W\.O"WBJVM=/^)7F_A;]HK]O37U75
M[G_@H[_P15N?#<%OX/\ $SW7@_X%?''5([[P1\1H-'U/X97T?B.^_P""@#:1
M87GQ(T/XD_ /4/#<RZ9J\4]K\9_#FJZ1!XETV]\#I\2O5[3_ ()H_$#PQ\.-
M:^#?P\_:1MO#'PZ\0^-OC7?:_J.K_#/Q;XN^+GB3X5?M/?'7X;?'+]HKX8^(
M_BU<_'[2?%6I>*O'C>%O'WPSTW]H&2X;XOZ)X!^(VG:M/J^J?&7X?0?&'Q;H
M>*O^">WQG\0^./CEK>G?M#>"/"OA3XM_'?X,?&[2/#_A[X6_%+1T\'Q_!NR_
M89LM)\$1:!X=_:6\.> M0CND_8HLHD^)-QX5?XN>%]+^)WB+0?A5XT^%VG6M
MY_;X!Y[??%/_ (*:6'AGP'X_U/\ ;+_X(ZR?#SQAXGMO#NG>)IO@!^TM8Z7X
MDU/3O[8NM?L_".I-^VMJ-E<>(-'/AKQ%!J.B2+</X1M?"_B/Q9XAU"&#P]JV
MBV'%>+?VI?VS/!'AMK_6_P#@IA_P1GTV[TN3PS'JVJ:O\&OBWJ.E1P7_ (:\
M<6IO[^ST/]MRQNM-7Q?X^^&'C[1/"D#W45M-=^"/&NCZ=JFN^)XT\)>%_M#2
M/V%KW3M'\+Z*_P 6M4TVUF_:^^/?[67Q7;X8:=XA^!C>+KGXU^ /CEX03P%X
M&/PG\?>'-6^'BZ5X@^*WA?XA^)?&U_XC\<:W\0O&G@CQ/XF\5V%[XL^*5_XE
M\+?,OQ*_X(W^"?BUH/[->A>,?B[X@2]_9=L?B[\/_!7Q"\+:)>^!_BEXA^"W
MQTU[4K_XE^'O$7BKP#XU\'V0^)6L^&[+X?\ AV#XG_V'?PP>)-#^(_Q0F\&W
M'B?XKVEK\. #I=%U?_@I]XE\87?PJT;]O_\ X)6WWQ(TGX;^&OB/J/A/0OV,
MOCGK_CB+P?XQEOO#WA?Q[=^'XO\ @HG!+#X,\2:QHWB.ZT#Q-'I"Z1=ZOI*Z
M7##?6+W$<?D&D_M(_MDMX=\0^++O_@J!_P $P]7T?PSX[NO!-VMC^Q=\;-(N
M)];DT/7_ !W!86-C+^V]K&N^*;*\^%/A'7/B/X1F\(Z+=Z?JW@2+Q)\7+?QI
MXK^&WP_NY?%/VO<_L3>*YH_"NAVWQGTW1_ UK^Q[X:_8]\:>&_#GP@T/PC=W
MGAG3&FA\3>+_ (5:AX+\7>&M&^#>J^*]+>UTBTT"U\+>,?#7@6RTG2#X(L='
MGMKB2[\M\+?\$RD\*?%;]G/X_P"B?%72O#GQK_9Y\ V/P1L]7\*_"Z/2/AUX
MQ^!_AKX9?%SX9^#=(U;X4/X_N?#^D?%'3K;X@>"];U;XHZ'=VT-W%\*M$\"Z
M/X.T3X>ZE<>'X "G_P )3^WEH>AM>ZE_P4,_X)G:IJ%CXO\ AKX*UJ2[_8>^
M-%EHVF>-_CAJ_@RV^$W@O^U](_X*5N+.]^(-UX^\-^&_AO<ZGI?VSQ=+XF\!
MPV=IJ&KZG,==H?$7XM?M=_"SXE_#CX._%G_@HE_P3S^&?Q+^+=A/!\*/#NJ?
ML/\ QH\+K\1-=N[SP[X+LK+2[OQ9^W_K&E2WT?Q,\3>$O#FCZ#9:^=:\0ZGX
M]\,^$K>RE\1:UX:_MK0\9_\ !,6]\1?$;6OB[HWQPM="^(GQ.\;_  2^(_[1
M.NWGPBL-:B^./B_]E+]L/X(?M._LEWFH:3#\0-$T_P %V7P.\"_#7Q_^SU%;
M>&$CN_&?ASXLW'C[7-3A\:>$-/GU;J_VG?\ @GOXI_:@^(W[,'QJ\1_'^Y\)
M?%S]E;P_XZE\&:EX3\"ZY8_#[Q)\1/%'QW_90^.6BZSXU^'$?Q>@A\6_#'1)
M?V6;'P?J?PD\6>(?$3:G%XP@^(GAKQQX&^+_ ,._A_X_T0 ^7K3]IC]J:?2O
MA1*O_!5[_@FZNF?%'2K'4?AGXFU7_@GS\;M)G^*HGTOP5J6GW&EZC>_\%!;+
MPSXET-[;QGH>H>./$?A'2O#=KX;M-0VSV/ADWLDOA+9@^-?[2^OW?B^PT7_@
MJ[^REIU_X:\>:5\.=6T*X_X)_>-;WQ7H?B/Q5XM^*7P7\,Z+9^&[[]IK0=:\
M2:G>_$;X5>,;"+Q5I^E3>%+/XB?!GX^6]_I-QX4M;GPA\$_H#X:_\$UM*T'P
MO\$? _Q;^)U]\9O!OP,46^D>']2L?B)86GC/38OA]9_#B+1/&=MXM^-WQ*TB
MS\)76DZ#X0U;7?AG\.=&^'OP?\0:_HNL3W_PY&E^*;_28>>\!_\ !*GPE\*?
M'VE?%;X??&CXB1_$'0/VC/'?[2>B7/CM/^%A>$].\5^.?&7[6KR>'-/\,ZGK
MFGW?AOP!H7P;_;8^.WPKT7X?^ M?\%> [3Q+JMA\<8/"MO\ $N_\=W7CH \1
MF^-WQP\0ZYX9MK#_ (+,_LJZ?8^.1!J>@77@K]AZPN?#VOVESX&US]H86O@+
MQ=K_ .TAXT\.?9KO]GO_ (2CQ)X?DU+6_&M_?Z)X&\+^)5;4YO WQ:T[XJ=9
MK7Q9^/W@+PWIWB.__P""K_[/NJ:0WP]M/BP+KQ+^P+JOBO5]6^%?B+P%=^+=
M'^(4>B_#+]H/P?J;>'-)TKPWXL\<:WXDL-%70]%\-16T'B:'2([!]5UCTCP9
M_P $HOAWX6^'GBGX&2_%_P"*5W\"-<\5?"SQQI?A&R.A:)XSTOQ5\*/ ]AH_
MAZ_NO'-E;S:1;VME\3].T_X]^'-+^'O@+X:V/@/XE>&_ >G^"(]"^'?A"+P3
MJ'IOPC_X)^>'_A-K7[.'CJT^)/B?7OBK^S/\+O!W[/G@_P ;ZCI\=KI.N_L[
M^'?"FA^%M9^''BKX?V.MQ^$[S7_$L^A6OC5OBM96EGX\T#QG;V=EHE]!\+;C
MQ/\ ##Q0 ?%D?C3XG:U\2?"OB=_^"HG[/W_"UH/%&I?LR>#+Z_\ ^"=OC+1]
M0T+QSXI\"VG[3NO_  Z^)VFW_P"T%8C1H_$/P8^%%AX\C;7S\.YK#2['Q1JN
M@^*-/3Q-9:)IN_#\:OBYXA@^&VE:+_P64_9]L]4\?_$CX7_!WPCJ9_8L\,Q)
M\0/'WQ)^&5Y\>/A3H^EC6/C/#IHNOCC\&-'UWQ!X1\06;1>$/B'J":78_"N:
MSUR-_">O?7/QJ_X)[>$OCOJ.ICQU\4_B->^'O$W[1WC?X]>*='MKV+2;NYT3
MX@?L,?$+]@CQ%\'O#FO>'IM"U+P9X1/PN^(-YXCTG7M!\OQAI/C:WN_$D.LR
M>(=5.N6/(G_@F-X$\8Z_)XG^/OQ8^(GQ[UG5/"7PD^''BJ[\2Q:/X&FUOP)\
M OAK^TQ\//A(^E7GPJC\&:IX+^(]CJG[5?Q-^,?B;XH^%-1TO7U^.,FC>-/A
M-:_!K1_"_@SPIX8 .7^%OPA_X*#_ ! \&^'?B3X8_P""JW@'Q[X0\;^&-"\5
M^"=7B_8$\!Z/IM_::O8VNJVEW?V/_"W+76WT2^/V=9?#TEQX=\4:9IMSK&BW
MNNV_B)['7/#O9:O^S/\ \%)]1GU7[#_P4_\ #.@V=X8?[-CTS]A'X77%]HZQ
M17,#B*\UKXHZK:WK7 DM;N9KW39 NH6SO;K!IUP=+B^]OA=X#M_A;\-/AY\,
MK3Q%XI\7VOP[\#^$_ UMXM\<ZC::OXV\40>$M T_0(O$?C#5K#3M(L=4\5:X
MFGC5/$6HV>DZ9:WVL7=Y=6^GV4,J6T7=4 ?GKH7[-G[=NDW$E]J/_!2;5O%,
MYTN]6'2M=_9+^ ]MX8CU^W\0:?K7AV]DM/"W_",^*9O#[:?%JOA7QMH \9Q:
MGXB\/7FG2>%O%/P^\3Z;=^)]9]"7X<?MWV=M.FG_ +6'[.>H7ESK.GWK7'BW
M]B[QKJ=M8Z/!9W$6HZ+I5IX4_;)\"RQOJ%X+&[AU/5[S6Y[%$U*U$-R+VQFT
M?[(HH ^/M8^%W[:5[;V\&D_M<_"O1'37K.>ZO%_9-DU&[G\+17337NDP"[_:
M ^Q6WB.\MV%I%XEDL;K2K142;_A#[B7>7\QN/V</V_+O3YXY/^"DR:?JLMM;
MQQ7NB?L<?!J#3[:[MGTYS<1Z9KGB'Q%<O#?"#4X=1M9M7D9H=0MAIESI4^GM
M<7OZ'T4 ?F3H?[+'_!1K33/=ZI_P54O/$=\UY9S6UE??L1_L_6/AB*SL-/T*
M-;.?3M'U*P\2W#:OJNFZM>>(;J/QE:M-IWB.\TSPY'X6N;#2=7L^!M?V??\
M@HYJ'COQ%X8U#_@IK\6/".BV6HOI?@[5+K]B?]DS64\=:#IGA7P1J>K>-K+Q
M3H-IKVC>'#'JGBJX\'+I7Q#\*^!=;UCQ_P"$?&WB+PMX*O\ X8W/AB$?KI28
M!() )'0XY'!'![<$CZ$^M 'XO67_  3:_;;T/XY^._VA/#'_  51\1Z+\1_B
MK\+_ ((_"?XD:X_[&7[/&I76M^'/@GK?C?Q#HTFDVMS,OAS0KZ34OBS\54TZ
MX/AS4I+#3];\)V>MOXK/@QI_$'H&I_L;?\%-+N+05L/^"Q_C'2YK&XFN=?>/
M]A7]DVZCUTW6G_/96L5QI!?1=-T_7%CNM%C6?4-1BT W&B:]JOB/4Y8O$]O^
ML5% 'YIP?LB?MU_9[BUN_P#@K'\:=H\+Z=INFWNG?LL?L96VIP>*8;;0K75/
M$VI3:C\'=9T[4[&]_L:]O;+P[%I6F_V=J/BOQ+)<ZQJMC%X0T[PBEY^QQ^VS
M*+6>R_X*T_M&6E['JMC=7<4O[.'[#]WHE[IMKKCWT^G_ &#_ (9[M]5M+B\T
M>]O]*DO;7Q!';K=V'A34&TV6PTOQ+H?C3]+:* /S1TS]CC]MJTTW3["__P""
MM7[16IS6L^FO?7K?LW?L06LVK6UK)K#ZC:W#Q_L^R7%I_;BW&A1W=SIEU9W&
MGII^L_V$^E-K.EMX8SKG]B;]MI+*<Z5_P6!_:HM];N7L;9]1U;]G7]@;5]-M
MM+MQI NVL-!A_9?TJW@\17HTJ=1K-Q=7FFVXUW6F_P"$=FF;2)='_3^B@#\K
MO#?[$7[>6D/9'7/^"Q?[2/BF*"Q>TN[6[_9A_8<TR&]FGBMEEU+S]+^ EOJ4
M%]975QK>H:,JZA)817$7@ZSUZQ\2:'H?BK1_B!TM[^QU^VN]E]DTS_@K%^T)
M921Z;%IL5Y>?LY?L7:G<W/E:.;+^T-58_ JT674WU;4M;UF2ZT9= 5Q9>!-.
M:(P>'?%,OQ!_2RB@#\^H_P!E+]KI[.TMK_\ X*=?'V[EL7UT+>0? 7]CK3+C
M5(=5N!+IW]O"P^!$,4]UX?MH(-+L)M!3PW;W%CJ'B&[O[*X\03>$]=\%QZ_^
MR3^UIK$-C!I__!4G]IOPT;2'[-<7FD? S]A>:^U6$W.B"2>_.K_LO:GIT6HS
M:<OBI&NM*TS3(8=7O/!NHV5G::=X8\4Z#\1_T)HH _.K3OV./VK(-/N;/5_^
M"JW[7&O3S^=)%>R_![]@W1I;"[;2+JRM+NS_ .$=_9*TF60V.M:G=>*DT_4Y
M]3T2]U'0O!&B:KI5_P""[#QWX7^)/):1_P $^OCUX=\6_%3QOX>_X*A?MAZ9
MXB^+]_X7O?%%W+\-/V&-86RC\(Z#IGA_1=-\-#6_V2M1DT33+33[2^L(K2.:
M<-:ZC-K%X][\0KOQ!X^\0_J%10!^?TO['W[2=W</-=?\%1_VRK=)_MR7-MH_
MPR_X)_65N]O=V=IIMNEL+_\ 8KU>:PGTVVM7U>RO+*:&=O%E_J&HWAN_#G]F
M^$=,T-3_ &4?VEY8='M-"_X*:_M7:3;VD4,>L75_\)_V#M=UC4VMO[*=9[*]
MF_9"L[#39[^6SU--7^UZ1K5O)9:W+!HUOH-WI^G:C!]XT4 ?FQ_PQ1^UC#XF
MFUVR_P""M'[8R:=-?:;<'PWJ'P@_8(U+3$L;;3=2@OM+B=_V18+B&&XU!]%D
MLKR)DU&WTJSUFVU:[U_Q'K&G>+O#LFG_ +%O[6<=O>QZI_P5K_;(N)KR>TNE
MFTGX,_\ !/;3EMI8%/VB&WCU;]C3Q&\5A?R3W$D]I%/&\*V^CQ6=Q;1VNK#7
MOTCHH _-Z;]B_P#:P6:9-/\ ^"K7[6MM8R6+:>)KSX0?L/:EKK(;"TL%U&:]
ME_9>B\/IK1+ZIJ$EUI?A32M..IV_A2:#2;>UTWQE9?$.#4_V(/VI;J_FN]/_
M ."N?[=.GPRM%ML9/A?_ ,$YKNWAC,6J&Z\HQ_L+V3"9[^ZTZ[M'8M!:P6-U
MILUK>V5W91Z/^E%% 'YG#]A']I=VTQ;K_@KG^WU<VD-_*=:LT\#_ /!/>Q&J
MZ&MYJ%Y8Z5:7^G?L/6FL:-?(;R*VU'7H=2NKV_LH#;6\6FJFG'2])?V&OVAH
M(U@L_P#@J_\ M]PPQW,5U&]SX6_X)_:G>;K<F>WBENM0_8<N%FMGN_)AOK>2
M Q7NC6=O8E8=3N=<US6OT?HH _,[4_V!OV@-3LK>W?\ X*T_\%#K*[@L)[4Z
MAIFD_L%6,MS/?6L]I?W%U;0_L0"S9!"NFII/V>"VU#1WL)[^WU.36M6U/59\
M30_V!OVF8T5[_P#X*R?M\V_V7Q!X[OXK&'PI^P%!%J%OK_B[Q+J%A_:SZ;^Q
M1:Q3VDNB:R97@L(]+O\ 3]4NS/H]]X?MM$\*Z)X6_4RB@#\VT_87_:.M;A;C
M3O\ @KA_P4(C:2>\N;M-3\&?\$W=9@DGNAK$P-I;W7_!/Q(+"WBO]:NIX[%$
MEL(;*#2M*LK6RL]"T$:9);_L-_M'6MZ;N/\ X*X?\%!W$?V6.TANO!'_  36
MNXHX4B@L[P7<%Q_P3WDL[ZXFL;:$6ES)9QFTU,W.K7$>HW%[>)/^D%% 'Y\V
M?[&?[1<=S;3ZG_P59_;QUB)+98KS3W^'W_!-?2;*[N"4:2:.30?^"?.F:K9Q
M*Z^9;10ZH9XW5(KR\O[)KNSO&6'[%/QXTU;D6W_!4C]O-GO$"R3WGAS]@35I
MK,"2]E\O2(];_8;U2PM8F-[%&\M_8ZKJ/DZ+H:)J",_BA_%7Z$T4 ?G3)^PY
M\>[JYCN+_P#X*O?\%#)UCE1EL[3P]_P3JT>R\E;B!S;NNC_\$_K*\F62SMTL
M9)YKV2Z_>W=['/'?3BXC(OV%_C9#%"J_\%3_ /@H7+=0>:T6I7-K^P=-=K--
M#+;-,]E'^PS!X=N_+@GE$%MJ.@WUE%<,E_\ 9GOK6PN+/]%J* /SVL_V'?B]
M;6VJP7'_  4[_P""A&I2ZA (;*\O9?V'X;G0)!;SP_:]*33/V(M/L[FX::6*
M[*>(;37+3S[6!!:BS>ZM+G\$?C;\-?VS?A1^V_\ MY6?BKQG_P %@?CAXJU?
MPW^S!IW_  3<N/V5K/PQX;T7XN> [GPW\4M5^)WPT^+O[3D_P/U?]EOX%^$/
M!'[0OBZ&Y^(OB/XJ6G@3XBZ!X-T_P-K6E6?Q<\/7&D>"]2_KWII1#G**=V"V
M5'S$'()XYP>1GH>10!_-;^S/_P $)_CAJ=[X<_:+_;K_ ."EO[;WCK]L33M'
M\9^&O".L_"#XU>'[?PM^SW\-_'6KZ+K>J?#?X8>,/'?PAUGQ;>>)+Z71H-+\
M=_&#PQI_PJN_'7AWR?!Y\'Z;X8M;Q/$'Z+_\.U?$:W6G7<'_  4H_P""G<+6
M-OXD@FA_X7[\+[JUU0>*?[4EOI=1MK_X!WD7GZ?>:O<W?AJ6P6P;PL+?2]-\
M/#3=#T?2M*L_T]HH _*R'_@EYK(NK:XO/^"F7_!5+48K/<UM8S?M+^!+"U\Q
M=2U"]LY+I]"^"&D7NH_8;*]M]#6'5+R^MM1TW2M/NM<@U77WU+6]1U;/_@FW
MXUMO#FL>')_^"GG_  4\U$:S:W%I-KMY\8O@%'XCL5-U%=:=/H^J:?\ LQ6!
MTJ[TAXC%!<V4,,NJVLDMKXG;7X'$:_I]10!^9>O?\$W->\0V,EC<_P#!1S_@
MICIYD:Z<WN@?'WX<>'K]7O;/Q9I-P5N-'^!EGP-"\6SZ5:*R,FFW.A^$_&&F
M)9?$/PQI/C""*/\ X)M>)/MCW5W_ ,%)O^"F]]$\DTGV&3X\_"RRM%63^U(H
MHT.C? +2[Q8[:QUB\L8@+O?)Y>EZK=O<^(-!T+6=-_3FB@#\Y3_P3W\0RS3W
M-Y_P4+_X*,W=W)<W4UO,/C7\,=.AL;:[U0:I+I\&F:)\#-+T:XMHVW6-K<:G
MIM_JEGI9^P6FHPPA=G*6O_!,[Q)8VTUM:?\ !3'_ (*B )HMCH>CSW?[0'PK
MU2YT*#3HI3;7T,VK_L_ZB?$.LO?SRZG?:SXY'BW4M5D,6EZK<7OARTLM#MOU
M%HH _,34_P#@FUXJU"_^TVO_  4K_P""F>C6%O)8'2M$TSXX?"F2RTVWM-<7
M6)K:74-6^ NJ>(=?%[:^;X?GNO%.LZY>_P!BR_\ 'PVJPV^J1:VD?\$]_'NC
MVD%C#_P4P_X*1WELL9-Y_:WQ&_9MU:\U&];59M2?4)M4O_V5Y]6LI&M[J\T8
M:;HE_I.@1:5<Q&#1X=3TC0-2TK]):* /S'U'_@G!XUU*>.>7_@IS_P %-[8P
MVFHVD,.F_%WX!:=;H+[^U/(N)([7]F1#>76DB_L4TV?4'O)"N@:6^I-J4MUX
MB?7L@?\ !,'6V\.ZEX5NO^"F'_!4Z[TG5-?F\133-^TGX!L?$=K=S:A-=&PT
MSQIH_P #M-\::;H"Z:;'P]%X>LO$,.BPZ=I<&J16*^+=3\1^)-;_ %/HH _
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MU[PK>>'FT^\L=?T:RU.UWZF6EE /Q)O?CY^S3?Z]-X0M_B7_ ,%=/$WC#1_
M/CKQ'??#[PG\5_&D?CL7GPS'[96E?$_P6WA#2/&>A^/-1\2-XF_8R^/GPWT_
MQI::=<?#G4OB#\0/A#H?P8^)L7B2Z^$=S\..P\,6/P&^+GB7XPZ9\ /VK_\
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M%BW'CCX=P>+^W_9@_:Z^#/[67A.SU_X6^([:^UJW\"?#'QQXV\(1WNEZW?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!<F>\O/M5W'$/](O(A90S2']U86ZK\UZ@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>/[0L-=\=^'-&U6#[>/@^-4M?M6FW]W;>;97MM-!YOG6TD-Q'%*G]!_[5?\
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E10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -2 IP# 2(  A$! Q$!_\0
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MMK.CCKUTF4^O_3Q]/R/KP ;E%8WV;Q+\O_$VTGK\W_$LDY'M_I'':I1!KWF
MG4M-\OG*_P!GR9/3'/G=N<\<^U &I16:(=:W'=J&GD=@+%Q_[5^E.\G6/^?Z
MQ_\  -__ ([0!H45G"'6<G-_8$9XQ9/P/^_M1M;Z_LPNIZ8&QU.GR$9X[>=]
M?S'IR :M%9!M_$6S"ZII8?U.FR$?EY]-EMO$QW>3J^DIG[N_2Y&Q]<7 S^E
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M.?ESI$IP/?\ TGGM3?L?C#_H.Z'_ .":;_Y*H Z"BN?^Q^,/^@[H?_@FF_\
MDJC['XP_Z#NA_P#@FF_^2J .@HKG_L?C#_H.Z'_X)IO_ )*H^Q^,/^@[H?\
MX)IO_DJ@#H**Y_['XP_Z#NA_^":;_P"2J/L?C#_H.Z'_ .":;_Y*H Z"BN?^
MQ^,/^@[H?_@FF_\ DJC['XP_Z#NA_P#@FF_^2J .@I",CO\ @:P1:>+L'.N:
M(3CC&CR\'_P*I4M/%H;Y];T0CT&CRC_VYH WJ*PFM/%93"ZUHP;/4Z3*1CZ?
M:?I36M/%Q8[=<T0+G@'1Y2<?^!5 &_17/_8_&'_0=T/_ ,$TW_R51]C\8?\
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MD\\-UXK\.0/$65DEL60J0%8YS<\X62,G_>![B@#JJ*YZ]N]2L&B%WXBT*U+
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M/(K.$7<0#M(!P#VZXKIZ "BBB@ HHHH Y_P3_P BA8_]M/\ T8U=!7/^"?\
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MM@'BKP^S2)')&1;-@JY 0_Z_G<64#UR* .IHKEAKDIA>4>*-!\N,$NWV-L*
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M?#\_FQ>='Y5R[;X\XWC Y7/?I0!TE<_9D?\ "Q-9&>?[)L/_ $;=U-N\4?\
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MLW;@X[9KI** .0D\%R%=-@CO]MO9I:1/\I#RI"LH."I&PDR@@CIMXZ\6M/\
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MT+76MTL%G&HVDWGB6;;%#-!"5 6"/"XPW0MU '<XK?\ L_B#_H)Z9_X+I/\
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MM;BW6VDNHVE#R+#\Q9LAH]T1^7CAB-NTE#V1\)Z,3_Q[2?A<R_\ Q5 \)Z*
MP%HP#')Q/(/_ &;_ #QZ4 <7>>#]=>TMK(6-M<):7IOW9IE"3_OX9?)08XR$
M=1N  P@SC.-./PO?/=Z/J<ME"MW'KDU[*NY2T%NZ3*%W9Y.61F XR3UQFNA_
MX1+1?^?:7_P)E_\ BJ/^$2T7_GVE_P# F7_XJ@#:HK%_X1+1?^?:7_P)E_\
MBJ/^$2T7_GVE_P# F7_XJ@#:HK%_X1+1?^?:7_P)E_\ BJ/^$2T7_GVE_P#
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MV%S$Q_TYF\HB6)YI#EOG5TC=1D;@7QM"DM0 0_#ZYFO)KN^CMO.2V=;8*PD
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M]=08W+*&]",JP]L537P?IL%UY%YJ22Z2K22QVLLNUE#1)$B[P02B)YP .?\
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M#$ES([,%QN.%!P!D9)XY [BIK;1;:[MX)XM7UG9/&)4#W4B,5(!Y5@".HR"
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MECD?@*!E_*0$]L<8YRC>$;!/#^MZ-:O)!:ZL)0RKC;!YD8C(C&!A>,X]2>W
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M;^3MP,@DT )8>!-=T[68M4N)--NGDN9;FX$MR0/,F%GO"[X7^7?!*% P=K(
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MTR[*X&NZ@#SR$M\_^BO\XK2HH YS7--OAX>U#.N7I LY=V8H,D[#S_J^*O\
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MY ?.&*\''&><#FIK/1O"VHRW<5CI4LSVLRQ/F5T# N49U);E5*R#W,;8SP2
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M/^C2\?\ CM'_  ENB_\ /S+_ . TO_Q-;5% &+_PENB_\_,O_@-+_P#$T?\
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MUUO4!I<:6WV>T^R.L2_ZQ%F#E.^[;)@GN&QDY($>BZ=J:ZI'-J^GI-'J]O\
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M:!5&XM@ 8ZGDUA^._P#DGGB7_L%77_HIJWU4(H50 H&  . * %HHHH ****
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M&Y/K0!JKHFFM,\*W>H&5 &=!JMQN4'."1YG&<'\C4G_"/67_ #WU/_P:7/\
M\<KESX,\0[?.3Q#(EZ(I8S-YTI#J3=%$89&0OGQ8;[P\HXQG-:8\-:O'.]Q!
MK]RDQM;F.,22O)'%*TA:!MA.&V*[*=WWMJ'@B@#5_P"$>LO^>^I_^#2Y_P#C
ME'_"/67_ #WU/_P:7/\ \<K+D\/ZU)<:7*NK/$+6(+/&)Y2LI^T0R$]?F_=I
M(F6R?GYR,UD6W@WQ3&EA]H\3SRM;O$9 +F8"4*+0$$YYW?9Y\Y[SD\Y.0#IH
M]&TN:2:.*]OWD@8)*JZM<$QL5# ,/,X.&4X/8@]ZE_X1ZR_Y[ZG_ .#2Y_\
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M)(KF^>,X9674IR#^._D50T_2=>M==+W&HBXTK>[QQ&9O,C;+XR2OSJ5<#:6
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MF1V??EP8FR5RP5004X!W=>!E+/PS>V+6MPBVDMQ!J=]=[6D904G>5E^;:2&
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MVR@7 8GDDHI*L/[PS\V2*MO9^.'2UN]1MXI]3M+3,<J&(#<RV_FH!D#S"4N
M#C8-Z=!G !TO_"/:I_T.>N?]^;+_ .1Z/^$>U3_H<]<_[\V7_P CUGZ19:[%
MXI^WZI;O.J60M4G7RE+9>,Y*@\'[Q8#C*MC/RBNPH Y__A'M4_Z'/7/^_-E_
M\CT?\(]JG_0YZY_WYLO_ )'KH** .?\ ^$>U3_H<]<_[\V7_ ,CT?\(]JG_0
MYZY_WYLO_D>N@HH Y_\ X1[5/^ASUS_OS9?_ "/1_P (]JG_ $.>N?\ ?FR_
M^1ZZ"B@#A/&>AZC!X%\0ROXKU>X1-,N2T,T5IL<>4V0=L"M^1%=W7/\ CO\
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M%K:2*$P0LURR9!&!B.:-<'/(.2>IMI8>)C#K\=Q=LZSV\@L-DP5HY#-<%<$
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M !1110 4444 <_X[_P"2>>)?^P5=?^BFKH*Y_P =_P#)//$O_8*NO_135T%
M!1110 4444 <Q\.@1\/=#W')-L"3L*]23T/-=/7.^!8TB\&:='&BHB!U55&
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M.F14MYJ'AY-0>VOI;%;J5/+=;A5!9<JNTEAR,S* ._F8'6@#%O\ QE=V$MO
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MPFXL2<L?M 8]BT8..:C\.Z/K-CJT+7UI<- +6WC+M)&X619+IG/^LRH_>1=
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MYE(RK(,$ <8'.,U)X>T368VM;?5?/\DZ4T&I.UP&^U7+./G5@=PP/,Y^7AU
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M<ES-%>);RW)F>4!"59FBCC7(R-R@0J&4\,"1Q6GJNB7&I7T-RM\T/V:2*2!
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M;HLZGS@Q)\Q"[YRH^\NZX?/;]YSVJY<^'M(O+J6YN+"*2:90LC-GY@"I&?\
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M7C^*M9CMKRX%K;O).4+REF4)@H"#D,.?3Z4[[-82:B=/_P"$@\1_:5S\O[P
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MEB4P']R<2CKOY/[Q.0!CREX)Z%UX"NII76+6G6T-R)TMRCA81YPD*( X7:0
M.F>#@@,16O\ \(]JG_0YZY_WYLO_ )'H_P"$>U3_ *'/7/\ OS9?_(] %!O!
M5R=4T^^&LLS6NU7#PY,B#[,2N[=\H+6Q;IUD/OG+M_ASJ5GI4%G!X@W;$.\M
M'(OS_9HH RE9!S^Z)^8-Q(W&>:Z/_A'M4_Z'/7/^_-E_\CT?\(]JG_0YZY_W
MYLO_ )'H BTOPU=:5K=_J,=ZDBW3'$+H<1J9FD;!SZ.W&,9/YTW\%WG]J3W2
M:N3'+<"X6-E;Y&\^*1L?-UV1;<C ^8\ 9!TQH&I!-I\7ZT3G[QBL\]/^O>G?
MV%J//_%6:QS_ -,K/CG/_/#\/_K\T 9VF>#KJPTLVTNK_:+AIK&22X\IE:3[
M.8L[OG))<18)SCYNAYR?\(?=3:)ING7.K2'[+=-<-)'N!;]VZH =W\,C*X)S
MR@SD_,=/^Q-0 _Y&G5CSGF*T]>G^H_"D@T348GW/XIU:8?W9(;4#_P =A!_7
M_"@##'@K5O\ 6?VTGG&%U8A9P-[3B5L8FX1P-K Y(_A('%:%AX4FM7M&FU.6
M8P33,Q!<%T=E< DN22'C0Y).1E3P3G032-01V;_A(]1<'.%DBML+TZ8B!['\
MZ/[+U3>#_P )!=8Q@C[/#ZG!'R>GUZ=J ,>V\):FE]I=Q=:P;C[',EPZLK$-
M*$G1F4$G;O689'0%<BJ^D^%M8&I75]?:A=)&][.PM!<L T?FW1C;<I)7*S1<
M#& @!&0,;O\ 96M?]#'+_P" D7^%']E:U_T,<O\ X"1?X4 8R^#]7:7%SX@N
MIX2(0ZF5U+A6MRPX(QD0R\YR?/;.>\FL^%-4OFOO[.U@Z?\ :IUE$B[V92(4
M0,0&&YE:-2,\$9![8U?[*UK_ *&.7_P$B_PH_LK6O^ACE_\  2+_  H RM>\
M(7NJ:A-<VNHK;%W:16VMOC<VDUN""#V,JMGKQ["K!T'6A!J&-89YI;U;BW<R
M2*!$)2_DL WRC:2F5QD!20>E7?[*UK_H8Y?_  $B_P */[*UK_H8Y?\ P$B_
MPH YV/PQXD>\OA_;=Y$L<<202/.Y6=A%"&.T.=JEHVR<!LNY'7)MR>%=:_M.
M.XAUR46X>V9H7FD;B)H"W4X)81R@DCG>"<]M?^RM:_Z&.7_P$B_PH_LK6O\
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M?^"Z3_X_1]G\0?\ 03TS_P %TG_Q^@"EX>T?4]-OK^[OYH;B6]="[K(V0%#
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M\%TG_P ?H U:*RU@UX,-VI::1W T]Q_[6H$>O+$6-SILDG9! Z#_ +ZWG^5
M&;\15W_#CQ&,@?\ $OFY(R!\IKIJX?QV=;'P^\1&Y>PCC%C,<P[RQ&T],]#7
M<4 %%%% !1110!QVAZ?-?Z/;F&2-!;>(;^>3>"=RB[N!@8[Y(_6K^F:7K=G?
M75W--IKRWETCSLL<G^J52NU<L0#@1X[9WDY)IW@W_D!W/_85U+_TMFKH* .=
MU+P_=WUY/>"Y@%PDUM)9DQD",1,Q(;G+9$D@[<'M40\+W/\ 8TVC?;8X[..9
M;BRE2,F2.19_.3?DD,JL%&.-PSTKIZ* .=ETC5WU*SUE;BS_ +2AMY;:2+:X
MA='PP[YR'5#G'3<,#.1DKX$N;8:C%;7\31ZOI_V2_D>+8X?=(QE0+QSYT@V\
M8PO)Q@]Q10!R]OX1,5]%>B[6.9;R:>4)$&6:-II)44YY#*7.&'9F'(-.N?#5
MW-X<U;3$NH5EO+N2XAD9"50-(' 89!..>A%=-10!RA\&+//>RS71C>XO&D_<
MD[9(&*$QR*3@G*MAARN>.I!=HWAB]TZ^TEI]026VTFRDLH=JD/<*VS:TG.-R
M+'CC.XLQ^7I74T4 <@OA+4;>TC6UU14N);*Y@OF9&99I92T@D49RH61Y"!S\
MKD>AJ5O!J1:R]Y9SB*V:X@N%MR#B-E>1Y=O/ <N&QV;<?XN.JHH YP^';N/1
M=0M(KNV:YU.Y:6\F^S"-2KX5@J#/.Q0,L22>2::_A=GN7B9H&TQ[Z6Z>W*D$
MK+ Z2+D>KR,W_ C72T4 <Y9^%(+?Q/>ZG(D#VS1VPL[<*0+=HE=20OW1PR@$
M#(Q61IW@.ZL6M9%OX%FS%)<L(=V7BDWJ$)P=A5G4@G@X88);/=44 <@_@Z2_
MUPZKJ3VSF>1Q<6ZJQ7R3 T2H&X)/SDDD8Y( '6IKOPK/+K+ZE;W$4<D=Y%<V
M\;!BA B$3*ZYP?E!*D#*D^G%=310!R<7A"7^QVTZ>YC,8M;J*,JGW'FD+A\$
M8RN%Q@#!SZ\:D6G7[Z[8:G<SP_N=/DMYXX@P5I7:-MP!/W1L8#//S=>M;%%
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M&<#()QVKI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HI-PW%><@9Z<?G2T %%%% !1110 4444 %'?&/
MQHHH **** "BBB@ HHHH :R*[(S#)0[E]C@C^1-.HHH **** .;^(">;\/M>
MCV;]UE(-N<9X]<''UKI*YWQX"? >M*" 3:L!E=W7V[UT5 !1110 4444 <AX
M?U9=.L+FV;3=3D8:C?.6BM69"6NI6X.!D<]:U?\ A)$_Z!.L?^ 35'X,8OX5
MM9&QND>:1L  %FE<DX' Y)K>H Q?^$D3_H$ZQ_X!-1_PDB?] G6/_ )JVJ*
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ML=KZ]N!K4-M);PS6<RQPN\+S8!BC<EHU8%C\S  $9X_$ >GB"TD!*VNI_P#
MM.G7/YH/\_C3?^$DL>/W&J<C/_(*NO\ XW[4N@:E<:SX7L]0)@6ZN( QVH^Q
M7QR-K8;@\$'GBL6XU_6K6P\4W;OI\@T-)0JB!T\YQ:0S*23(=HW.X(YXV\C!
M) -;_A*=/QG[/J_7'_('N_7'_/+_ #UJ/_A+],RW^BZW\O7_ (D=[ZXX_=<_
MA65>^*]2@DM5CCM09H-/=@\3Y5KBZ6%_XAP%8X'J.<CKIZ1K=Y<ZW>:9J,45
MM<1/*\46Q@9(0RA)$;)60$,-Q&"K,%([D /^$RTO_GUUS_P17O\ \9H_X3+2
M_P#GUUS_ ,$5[_\ &:S--UWQ!J.CZ%<B33(Y]8LEFC!MI"L3F%9.?WF6&=PQ
MP<$<G',)\7Z@L^OS2RVL%GILEW&@-A,^/)A23<\JMM'+$[=H+ $ Y!H V?\
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M01>/FDOVM1IX9I6LUM29&3S/M'F,N\,N4VI&21C.>W(H UO^$V\._P#00_\
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M<JRI*K8P01G!.UMMZ/7;PVVJR26$"R:9E9E6Z+!G%O'-A3L&1F0KD@<*#CG
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MDD#9[>6O)Z4NG>&-2MHO#PN9K1Y=/U*[O;IT+#S?-6X *@C@DS D9P.<$X%
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M)"7 YX9AGG-6;SP?#+I?B"TM)UMO[8LFMW58\QQR-YN^0+G^(RY(SC(SU))
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M]0OI0 U]*\$I?I8^1NNG("QQM,Y;*[LC!.1@@D]!D9QFF0Z5X*GN6CBL[EY
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M]MIS3Y?"EU)_:($T*?:M<MM37:S ;(V@+*P[L?(.,<<CWS<OM"NKK6-2O%:
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M HI]% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSE@NT$YYP6XYQE2Z1J7V#6?L5H8]3EDOEM)D@\J5%>0MD3$X&X9V\?>(.<4
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M"\LK:Y6SMA<0V[M(\4@5F=(VEB4ACM9<RX)X^7'56( .@_X2'5/^A,US_O\
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M?[+D&U5;:?\ EZX 8$>Q&*==)XC1'BN_$?AM59<.DND2 %2#U!NNA"M^1]*
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M!3IR&X.[<MOX;OF\(PVSV*"Y34Y)9X&<(T]N+N20*6&<Y4A\$X).#C)KNJ*
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MD?,>IQG)%;E[IKOXP@A:.233+Z,W5P/*)1;BW:/ROF'3<&SAN#Y Q_%GIZ*
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M:QQ&;@ 9[+SG!.G>GQ0VAZE!MOY;T6,C64GD6Y2=FA4!94Y"N)2>/NX[D;L
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MZ].L0]*WZ* ,(>+='CB&^XNLA<Y>RF#-[XV#T["G_P#"6Z+_ ,_,O_@-+_\
M$UM44 8O_"6Z+_S\R_\ @-+_ /$T?\);HO\ S\R_^ TO_P 36U10!R'B/Q%I
ME_H-S:6T\CSS[8XU,$BY8L !DK@<UU]8OB[_ )%74/\ KF/_ $(5M4 %%%%
M!1110!S_ ($_Y)YX:_[!5K_Z*6F:.K_\)MXE8[-A6T P/FSL;.3Z<C'X^M9?
MA#7S9>"- MFT?5Y'ATVVC9HK4LI(B .#GD<=?>I-/UB:W\0:S>R:'K/DW0@,
M6+0Y.U2&[\8- '9T5@CQ0"&/]B:V,' !LS\WN.?YTO\ PDZYQ_8NM=>OV,^W
MO_G% &[16(/$J$?\@C6!];)J7_A)$_Z!.L?^ 34 ;5%8O_"2)_T"=8_\ FH_
MX21/^@3K'_@$U &O'%'$"(XU0,Q8A1C))R3]2:?6+_PDB?\ 0)UC_P  FH_X
M21/^@3K'_@$U &NT4;NCO&K/&248C)4D8X]."12R1I+&T<B*Z."K*PR"#U!%
M8_\ PDB?] G6/_ )J/\ A)$_Z!.L?^ 34 ;&Q-RMM7<HV@XZ#CC]!^5.K%_X
M21/^@3K'_@$U'_"2)_T"=8_\ FH VJ*Q?^$D3_H$ZQ_X!-1_PDB?] G6/_ )
MJ -JBL7_ (21/^@3K'_@$U'_  DB?] G6/\ P":@#:HK%_X21/\ H$ZQ_P"
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M)_PA<-E'IDB:A:?VA,&>:,^:TB3K&HP_.3*K'=Q\O3., '8O;W%O&K7'B65
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MF39@Y&0%()(QGY3QFH8M;L-)U*ZT^_:.VF::-UD57*RB7"J[MR$+2!T4,W\
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MA$36Y4PQ)%$JH%0H%#!-^T D[=V,GI4T/@W0H[R^NY;"&YN+V21Y))XU8@.
M&4''3Y1[\=>!6]10!RVH?#_0K_R5%NMO%&02D4,66.5).]D+*QVC+*03U^\
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M7,9DB8LH=XR2"/F5BK=?<&I%SCY@ <GH<\4M% !1110 4444 %%%% !1110
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,KQ#_ ,@V'_K^L_\
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ML1N.,XG0_P!*TJ "BBB@ JIJG_()O?\ K@__ *":MU5U,$Z5> #),#\?\!-
M$.A?\B]IG_7I%_Z *T*SM (;PYIA!!!M(B"._P @K1H **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** &JZONVL&VG!P<X/I3J0* 20 "QR<#J:6@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***BMIUN;=)E21 P^[*A1A]0>10!+1110!DZ[.\
M1TQ%QB:_B1LC/'+<?BHK6K%\0_ZW1O\ L)1_^@O6U0 4444 %07DS6]C<3H
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MU:M9/BCGPEK0SC_09^?^V;4 4+_Q.^G7EX)E0PV\S1I$BJ99\0QR;$W.,O\
M.S  '(C(X.*JM\1=)"NR13NJA,$%!O,FTQX!8'#;P,] V5SNXJS*WB.6YW'P
MYX=DD1MZL^JR;AR,'_CUX/RC_OD>E-9?$LBD/X7\.$$!2&U60Y .0/\ CUZ
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M;$V64B- 0<@A>G/,FJ>'-+UN6XFO]#O7DN4"28N0O CEC_ADP/DGD4^N?84
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M^"*]_P#C- '045S_ /PF6E_\^NN?^"*]_P#C-'_"9:7_ ,^NN?\ @BO?_C-
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MLMG?CP^T,]G=OJ<<]^]Y(;=Y/.C*38VL!\RMNBVH.> -OR$#T6B@#E&TSR?
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M@N3<10(DIA2#*\ 1J254#H -QZ?T%6* "BBB@ HHHH RO$/_ "#8?^OZS_\
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MEY&"D9YYWMC: M96M>+].A\6B#PWJML+6YTX"]NK%%F6(1L=GED?+OVF0<G
M"Y/W: /1O$.JIH7AS4M6DVXL[:2?#?Q%5) ZCJ<#&>]2VOVFUT6(W*O/=QP!
MI54Y+R!<D#GN<X[5Y[<G4=4^'>E:-?--/=>([M41+AMTD%JS>:V\@*6(B4_W
M2"P'&*]&O]0L]+M&NKZYCMX%(!>1L#). !ZDG@ <D\"@#DI?'FI6&G?VCJO@
MG6+6S)C576>V=\R,J("AE# DL!C''?OCH=*\0Z?J\TEO"TT%Y%DR6EU$T,R@
M8^;:P!9>1\RY7GK6/XD\O4O$'ARW=L6=J\FK70<%=JQ)B/<"./GD5@#_ '#Q
MQQE:/XZN/[%UB^U^2W@ L_[5L A*JUD^[RLGKYF0 0/[R8&30!Z%3))HHHC+
M)(B1CJ[, /SKQAY-0O[G2O":W/GZK;Z EM<1W$AEDCGN K3.ZEAGRXXSMR<;
MI4&1FLV\T[7M8@BCGTUDMWC@L;$ZE#-!#IS.K)Y/EMDRLP,:M,% ^]M/3(![
M5K3ZL=+;^P#8F_)4I]LW&/9D;CA2"3CIR!G&37#:)XL?5M=.KR:5<RW4,EOI
M(@4 -$KL//N@N6'E>853*L_$0)..F9!I6H+K5SI+)YOBD00HNK6EU*\>GV[L
M05*X18\*K,B#.\@;NQ.SH,\EMH6J^(([)$CT=+G3]'BFD$2M;1[ 6=O5Y(NI
MZ!1C&22 >BUC'Q+9'5[G385DFGM #=$%$$((R"=[*2-O.5!&*\KN]1\9C1X/
M%>K7FI6R2S!HH[*(JD%OMW^8\.\J20-BJ^>7)8GY0+)TR'6-+BL?$E[97]Y9
M.U[K.IMLE.FPABRV\<F 0QV8)7IM<]QD [CPD3KMU=>+9D=4O0(=.CDZQ6J_
MQ#T,C9?Z;!SBMG6?$&F^'XH)=2N5A2:01J3SCU8^BCJ6Z <G KQ5M7U2.YM;
MSP[)K8MWO/(TNSNI=VW(<M$L? ; YPS%8U103N.$];\/^')[.)[K6[O^T=3G
M@6"1W&4CB'_+)1W&<EF(RYY.!A0 =""& (((/((I:R]&T*UT&%K;3WEBL<LT
M=ID&.(LQ8[.-P&2>,X'8"M2@ HHHH Y[2SGQMXA]H;3^4GM_C_0=#7#ZI:7.
MHWGC>UTTRIJ+6$(MGBF,3";RI/+^88QAL<DG].*S^'==@U/4FMVOF@DO;.:
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M=<'3QE7 _P!HEVEZY^51V KDI9Y/"MKH?A_6'<W,C6%Q;VL+*1-+&T?V@LQ
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M\HSLT^1<GC)_UQXZ\?K6K10!G^3K'_/]8_\ @&__ ,=H\G6/^?ZQ_P# -_\
MX[6A10!C:A)K5CIUU=BZL)#!$\@0VKKNVJ3C/F''3%%O+J]Q;6[B]TY998UE
M\HVSY"G&?^6G.,^GY59UW_D7M3_Z])?_ $ USMSI>IW6+BQ5AN\/26T,@D"X
MG;:5 YR#QUQQCK0!K27.KK!YR:EHQCSMWM&ZKN'!&=YZ'-(\NOK ;@7FC>0
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M<_:44GDK&<!78#@@9 SRP(Q74:#X6TWP\9IK<2W%]<'-S?73^9/,?]IO3T4
M*.PJBVK:ZT#6^B^%C;QPQE$?4)T@087Y B1[RPZ#!V>F:SO#"^/M5LVFU^XA
MT</,[^5'%'+.$*C:JMRB@<_>#L3_ '1P #N:BN;F"SM9;FYE2*")2\DCG 51
MR237)3>"=2BO;B]TSQAK$$\OEOY<^R:%I$7;EDVC(8!<@$=SZ8H>)K#Q7J6F
MV=GJ@TM[(W<+W+V5K-<'" N"82?F7S%C!7+<$YZ4 :NFVDOBR6WUO5$']EY2
M?3-/=2"I!.V:7G#,0595(PG'\7(MZEXTTBQCD^SS#49HVV/%9NC"-L$_O'+!
M(^G\;#MZBN7N-$U3Q/<F.X@U6XA'S"35Y!;6R$@CY+>'#R<=I".IYSP=C_A%
M-#T30FFUN\5H;6W:/SY&$$-LA!4^5&N$C.&(R,L>,DG% &!+XN37K^W_ +<F
M@TSPM<L;6,?:&!U*5U7 #  ^4,N"PPI..6%=YIVM:'<7;:3IE_92SVL?S6UM
M(K>2BX !"_='( ''MT-<3IGA*QO(&MM#TWR--G1$N=2U:V$\EQ&@ 2.*.7[J
M@="RA<*,*V<UVVA>'=*\-6/V32K1848[I')+/*W=G8\L>3R?6@#4HHHH ***
M* "BBB@#%\+*%TB< D_\3&^/)!_Y>I?2MJO-]9\8S^%K&W2&XT.#[1>WY+ZI
M=21]+E@ JHC$_>Z]!BNF\'>(;CQ-I5Q>S6\$<<=W+!#+#*66=$.-X! *\Y&#
MS\N>,B@#3UG6+30M+EU"\+^7'@*D:[GE<G"HB_Q,Q( '<FJGANTU.&SEN]8N
MI);Z\?SFAS^[M5_AB0#CY1U;JQR2>@%&(MXG\2^?NBDT329?W.$#?:+P;E9M
MW]V,' P/OD\_(*U=.UZPU:]N[:Q=YOLCF*694/E"0'YD#="R\9'OWP< &G16
M1)XDL(-873+E;N"9Y1##)+:2+#,Y7=A9-NTG /?J#6A>7EMI]E/>7DR0VT"&
M261S@*H&230!C>*]3O+:SBTW2'0:SJ),5H6Z1 8WRMP?E0$=NI4<9S6EI&E6
MVBZ9#8VH.R,99V.6D<\L['NS$DD]R:Y>R_MJ6"?Q;%HHN=5N]L5KI]Q<B'[/
M: G'S%3M=L[VX]%_AJ*+XF6=KINH77B"V729[*Y^QFT$OVAYIS&C[8V48;[^
M#C..IVB@#NZ*XKP_XKUDKJ]UXMM],TJRL(H2[13[_)E()>-WS@D QGCIO RQ
MZ5KSQ1J3L;<WB65_?.&T[2XH-UX;<%P)&#@^66(!)92(U4Y!.10!WU%<]!X5
M*Q!;G7M;N9"/FD:\,>3MQTC"@>O Z\U;M]"^QL/LVJ:FB8 V27'GC'UE#'\<
MYH IZ5C_ (3CQ'@$'R;3.1U^63I715PFN330IX_DLG>.[32D,3PG$@D\F7;M
M( .[.,<GMCTJO)+K O-?U&"ZN472[N&:W@,TLD,RB+;+"<@$L<DXP0K;",\T
M =[#=VUQ/<00SQO+;,$F16!,;%0P!';*L#^-35R7_"&W=E*;O1O$%U:7\J@7
MDUQ$MPMVP)(9U.,$9(&TKA<+T5<.?P;<:G'CQ#XAU'45)^>V@86ENP]"L?S$
M>S.U %'Q'XWF;3=7'AKRY!I]M)+=:K(-UO;E0<HG_/67 /R@X!QD]CFZ?JMC
M\/?!FD:=;6 NO$VI)$[V,7^LGNI%R[R$#*KD-R1T7 Z<7/&]U;+I]KX'TBW6
M.:],$#"*$-%96[2 99>ARJN O?!)P :Y#4;5G^(-UX?T:9SJ<(6!KB5U,\C7
M"![B\<@#[D)5$X !;"C'% '4Z'X]OYM";4KR.VNGNM4BTS3XX6\I9W&Q)74D
M$[-XE<9&=H .*ZL^)K,>*Y_#YCG$UO8"^FN2 (8T+[0I;/#'!/3& >:\MTWP
M;XDM-(TZZET9A)X6N533;".Y4&[7S&,TN0,9<%, _P!UCU:L343X@GO?$FC:
MI)/#KNOFT-Y]G4A+>$J5C@5AD$%Y%C)!.5#DYP<@'5^%/C':WFGWL-Q'J6KZ
ME#<7,J1V5F/^/57^1R?E4* 0,G!R,$9(W9NG:EKU]X.\*"XT^,QW6K'44NKS
M4]JOM::Z <[6*J G7!^Z.!FH[3P3-:?#^'Q'%J*Q6NEZ/>W.G0QVX64B59'"
MR2$G='ALA<?Q?GM_8X?$FD^!]$@:2WL;K0;Q4>:/,B@6\<"L!G^[,Q]QCIDT
M ,\+>/O$4NK:O?:\L)TS^QVUJ*V@P39P@GRXV;:"SN@9N>V#@9P(_B!XVM]9
M^&T%AF6QU765MO,L8@TLL<4A5VQM'S?)VQG!QBK7_"G)5L)K*+Q-<Q1:C:K%
MJS+"&:ZD3?Y;*2<1H-^-@XVHH&#S5Z^\&7<&K:#J%T\VM:K_ &A")K[R4BCM
M8(U8[4CS\BEL$XR2>I^Z* )4^*.AV^F*+*PU!Q9OY%U!)$(9+-%*J'D#D8!W
MKM'5N<#Y3BCJ_P 0KRU\9:F]O+OT/0H)?MT"6^3(XCSDR_PGS#&BKW_>,>%&
M<7PYX-C\>:AXKOK_ %6YATJ37Y0;2T01&=H2!&S2$EBN"?EP/FYSP*TX?A/?
M2:3JGARZU.!/#9EGFL8(%?S9)'R4:=R<MY9(P!]XJ"W3% '4VGC9$T_PRVJV
MAMK_ %Q2ZVR,#Y""-I"S%L<*H&?3/2L1?&NC^(_"6JZWXBT6U'AV%F?34O=C
M27NQ3EEC<8!)X7!SR>G>E)\(+S5)8;[5_$DBZAY+6DK6<151;;-BQ1[F^0=6
M8\EMS#C)SB7?PJ\3W&@W\]U<V[WJVMO9P:?9;=L\4!50/,E!\L.J@E5VJ2 6
MSTH I:5J,%MX9FEAT2^BU>\O_LNE6NG7=Y;6Q4H"%,HD1) K+*"RMCY<C (J
M<ZPUWXBT672[_5;;3]6O);"WMY]>N6>18V4&X&XR ?,)$ SS\O3YJZ ?##6M
M8N=&U/5]>DMKF*VD@GMH8HBMK&R[5CM\*%1@I(9\') ( P*O:9\&]'L(K,OJ
MFHO<6CAX9HQ%$8R-VW;A,J!N8XS@LQ;J: +-UX(\1W*@6OBR]TUN#N-S+=D>
MN,F,?F#]*ZCP]I-_H]G+#J&N76KR/)O66X1%*# &T;0/3/XUGR^"+:=@TNN>
M(RX !*:O-'G\$('Z4U_A_H<Z1K>2ZQ>>6<J;G6+I^?IYF/;I0!U-%5M/T^UT
MNR2SLH1#;H6*H"3@L2QZ^I)/XU9H **** "BBB@ HHHH **** ,_7?\ D7M3
M_P"O27_T U+I?_()LO\ K@G_ *"*BUW_ )%[4_\ KTE_] -2Z7_R";+_ *X)
M_P"@B@"W17"Q>*->.DZK=V>F)J%P-7NK2%7G6&*WAB)3?(Y' RA..2=V,UT7
MA773XF\+Z?K1M#:&\B\WR"^_9R>^!GUZ#K0!L45Q?A[QXNJ^&-9UR[MUCBLK
MZ:VBABR7<*0$7W=B0 !W(KF+SX@^(++X<:!?QQ+)K>JW,K2"2, 00HTDDGR\
M?<10O/89/- 'K=%>;?$GQMJ?AN_L+33[BVMH;VSGE%W(JNL;1E#N()Y&PL !
MR69>O0]);W^OZUX#TW4-*%E;:O>6L$S?;$<QQ[@I?A>20"<#Z9H Z6BO.]*\
M=W-GX.\0ZAJMS;7\^DW%S!;7$:"!;\Q1AOE7)[[@2N1A<\X-7O!GB'Q#?:K/
MI?B)=-:X%C!?*;%77R?,+?NI Q/S#''/(% ';45XQ??$+4(+_4(Y=3.F6]QX
MDN--;4FB$L=E#;PH0H5AC>[$GD$?>ZX!KU'P]96MKIGFVFI7&I1WCFZ-W/,)
M#*6 Y7 "JN ,!0%]!0!GZEC_ (61X>R"3_9VH8QV^>UZUTU<SJ4;/\2/#K+T
M33M09OIOM1_,BNFH **** ,BZ\+Z'?74]S=:9;S2SD&8NN1)A0OS#H?E '/8
M8JIK&CZ9I/@W6HM-TZTLHS83C;;0K$/N,?X0.Y-=%65XH5F\):RJ!RQL9P B
M[F)\MN@[F@"S<Z5I]Y<?:+JR@GE"! TJ!L $G'/U-1?\(_HW/_$JLN?^F"_X
M573Q7H<CA$U!&8] JL2?TKG+[XA1WUR+7P]);^4"1+JE['(+<$$ K$ /WKC/
M(! '<Y.* +^O?\(CX;-L=1LK:-KN5DB41;BQ +-A0"3QT !.2 !7$ZM>+JFD
MWDND:=I6A%(97,NIRJ9@4."GED[86 *$E\D;^%;DC8T_3?"^G:K;ZNOB.YN]
M425FFN[QB[RQLFPQ @#:HX9<<@CJ<FJ^HZ3X?FL[UX/%%S/J-QI1TDS7A4[X
M2,$.PBR6/)W')SZCB@#,TKPV/,LK&^U#0[><R;7NHD>\NVDW2!PKNJQPC='(
MNPHP&S')%366B>#K#Q/;W$A_M+2XM)E,=Y.6G<31L)9"2.=YC=&4*H^4-MX.
M*V-,CT1(3/J'B%_MSLDC-!Y8",K2MP5A0,2T\C%M@)R.X)-:+P[X(CTR.Q;7
M[Z5(V+))))\ZDQ1Q9!"#!Q$ISCJ6SPQ% #_$,/AV_A72-!DL(+NYE-O-=O(P
M-FO\3A3U;'"Y(&64Y.0#HOX<\'OX4M9&NYU@E/F?;EE?SII%!:1FSDEB(V+9
M&>#TQ7.QZ+863:L;+Q=:A[_:PFELV\R)U*E64JP&054YQCY0"*V)Q8ZL(1KG
MC>6X2)?ECLK<6JEBK(S'AF.5<C&<?KD @U9-"N==;2[:P$B6 AFU35;J9V2&
M!-DN&D).2R[,#.>"<8&1O"V\#GR^+3,DWD(I=LL^Y4&!G."SH W0[UYY&<>X
MMO#%IX5\0:1HFHV\']IV;6\,3KLBA/D^4.53//WB3DDDU+;0>&K;4+;4HO$=
MQ;WT8VS/ %"S+MC78P,>-H\I,8P>O/- &E%!X&FB655M1$W1W+JN-K-NR< +
MA&(;H=IP>#31'X&+VZ&.%)+AMD:.LBMN\Q8R"#RIWNBX..6'K6?=V7@^]M+"
M"?7)RUC:_989P$$FPQO&V6$?=7Y'W254XXJOJEIX.EN7U&77+]IO,,I2",2-
M(_FPRX"^42WS6\8"CC /')- &_>6'@O3[MK2[CM8;A8O.\IG;=LP[9 SSQ%(
M>/[AK%UV_P#"&D2W5M;:/_:%W;0^=*D+X2)<@9=R<+U'KUK U._L/$NHG5K^
M^F5)4\NUT_3[C."HGC+32E=L?RSLK*A//3=MJU!H/AZ\BD.K^(V7SXHXY;6S
MXC(18QM9BF9 ?+R?E4'<<KTP 1Z@NG7NII96HM(SD>8MG+MBA_>&+$MQ(#\Q
MDPH1(PP)YX.1>T7P[X5<1&[N4U3[0SR9$LZQJT11?W,?.\*TG+EB03Z#"Z;0
M>#V9,:Q,B"21WCC;8L@:X^T;6 4<!\@8P2"02<U4NM*\(7FFVUA/XCO6B@@F
MML@H&>.65)'5L1]_+5>,?+D=3F@"[;6'@H72R0WT$UM/&T@225I=[ML(*R$D
MDX8'9DY#J0 #S-8IX5N["UN+C3(K<W>H3:? @W-ODBDE3J ,96)FYQZ<G&:T
MD/A:5KXOXBN]MZ8Y)4!4+YT9C\N91Y>%=1$@&/E(7D$\U./^$7BM;&!M:E9[
M/47U.*20?,9)&D=L@(!M(F<=.A'I0!?MM*\'WAG%M#:R^0BR2%78@(V=K9SR
MIVM@CCY3Z&H%L?";ZC]G%K9^5Y:GS3,PRS.J*H'0@EEP0>21ZU#I,OA318W2
MUUAS_HRVD1D /DPJ6*HOR8P-Y^]GH,YK&DL= L;&1='UM/.\])HTE58HTQ<1
MS$+MB(7E/[IY)]> #>MK7P9J*[=,CL;N=D+1QI,1N.Q7"DYX.&4X/.#G'!K2
MT[1]!U#3+6[M;3_1Y8Q)$/,;Y0<'H#P<@9]Q7+Z!;^&]%DCO1K.Z\WB61-J!
M"P@$(7*1)QM53T'.3@9(K>T76_#VC:-:Z<FK)*($VF1E8%VZDX[9))Q0!J-X
M;TEY/,:TW/@#<9')P#D<Y]:R]=B;07T_5K9I$T^WN=VI('=B8F5QYG7D([[V
M!XQN;JHJ^?%N@@D'4HN/0$_TH'BW03_S$HOR;_"@##LF\,BP;7]:73 ++4;L
M6M[<!#MS.[#8QZDGICGTJAI\E_JE_K$-C#+ITVMR)<NX&R2RM@B('?'263:^
MT=1US\M066I>']&%_J-M9Z9-X@DOKJ.T)V)(T;2G#,_41 8)89X( R6 ._H6
MJ^'M'M95.KQ7%W<RM<75RR%3-(>IQV  "@=@ * "\5HG@\'^&&.G>7");BZB
MCW"SA+=%+ @RO\V,\@!F/;.3#KNN:7<-HGA_PG*;6QF\B..5'C$J!AN?SFPG
M*EG!RQ.>>2:Z:'Q+X;CDF>*]MHWE;S)6"%3(P4+DG')VJH]< #M4\?BC0Y6*
MKJ=N"/[S;1^M '*:/JW]H:]9S:V9!KQNFABT@.52Q7RW)FVG[Q,9(\SH=P4;
M23FKK/B*/7];LK=I[6WT@EI;8WL_DPW;1NH\UN\B!BNR,$!^68X"UIZQK>FZ
M]J@TN"]A@LEC/VW4DGC5G7(/V>,_>^;^(\8 P,L?EZ2+7M#CC6.+4K%$1<*H
ME4  <8 _I0!Q&M:_X@M=(GU73[N_GTB!,75T]C&DI!V@R6Z$ D+R<N,8Y&\#
MG.\)6]U)#>ZIY#Z?$-^=7O0&6*,DAA;+P68@#,S_ 'C@[6'RUZ4/$.C,<#5;
M/MUF4?UK-EN=#OM;COKK6[26.T ^S6S2JL<<G.9.OSMC@'^$9QR2: .=M%BA
M;39M6TJ_LM 3=/:VTT!F;SBPQ+=D%F\QF<LH/1LECOP%EU345UOQ5HMSX7M;
MUM1BGB6^O3;/#$++)+QN9% ?.2549(;D8YSUYUW17 !U2Q(SWG7J/Q]J3_A(
M]#W,O]L6&5SNS<IQ@ ^ON* -.BL0>,O"Q) \2Z.2" ?].BX.<?WO7BHO^$[\
M'_\ 0UZ'_P"#&'_XJ@!EI;K=^)O$4$KSA&6U_P!7*T; ;2?E92"!GT([BKW_
M  CUE_SWU/\ \&ES_P#'*YG3/&7A>+Q3KLTGB/1TAF^S^5*U_%M?"$$ [N2.
M_P!16W_PG?@__H:]#_\ !C#_ /%4 6_^$>LO^>^I_P#@TN?_ (Y7+^+-5T/P
MO97A:;4IKZ&.(QV_]K7"AVE9E0%C)P/D=CZ*C'M6[_PG?@__ *&O0_\ P8P_
M_%5Q5[K7A6[^)W]I0>+M'@$>G1-YYN8642K(ZC:S'&3&\JD#D!@>.,@%"ST[
M34\3Z':WU[=J;9;B^U6^NM09//G5/+B<-YAPI1G9.0WEJ.<*PKN;?0?"2:K=
MW=O<[=1D*Q7,T>J2B5CNV*KL),GYEV@'N,=J\PA;PYJ-[J\P\0:,MG)J<L4<
M-SJ:1CR!%,H**&7$9>YG&/[N2 ^0:ZR.3PDM^+X_$/2UN249O*OH45B+MKEA
MC>3M8OLQG[H[\T =5%#X=F,OEZO=$1,JNW]L7& 3&)!SYF#\A#<=N:Y?X@-8
M:?HL=Q8:E</+;-+,X_M:5BNRVFECR&<]9%C&>OS<4R#3?!MOIJZ=_P )GIK[
M9X) S7D6_=':BU(.&YRJ$\YP<\<57U'1/"6IZ;IUBWCC2PEE>_;'!GA9944*
M71EW]-R DYX'!]: .LT_P]H]MH>G:/>7$X=K*. VSZA,@=0FT@1[^G48Q[=J
MXRW-K)XFMM2AL-4B\-Z?9R6-@(KIU,LK3QP+'&?,&.8FX! VA#WKLK^3P_J>
MH)=-X@T_RW:W9D%PA)-O,9$*L&X^9L-UR...]6VT[0[3PS!HR^)+59(;UKR&
MX6:-2)//:?&T'!7DJ1W7/3L 7H!HSR-!=S:II]PLGE"&\U29&<L%;Y")2''S
MJ,J3@Y7CI4HM_#S;-FKW+[Y%B79K,[9=LX'$G4X/Y&L[4X=*U6ZD\_Q1IR-<
M01Q3I$T8+(DN\%<L2O5@>HY'<5EZ3X7T329()$\46+O%/%-SY>&VS7,A'WNI
M^U,,]MH/- &AX8\-Z-HNA_99=<DN9%NIO-FBU26-3(\I(4JLF W[Q%/<DCN:
MV!8Z(UXEFNI7K7+ABL2ZO<%CM )X\SL&7\Q6#)HFD/I5KIX\4VBQPS22EA(N
MYBUVER,'?E2/+VY![Y&,"I]*TW2-,ET9QXCTZ0:1;26D'W%+Q,D:+O.[E@(E
MR1@'T'& #3M+71;NTCG%]?1[X_-,;ZS,60;58YQ*1PK*3@XPP/>G7EEI%G8_
M:C<ZI,AD$2+#JEPS.Y;:%'[SDY_+!]*Y&+PUIFD:%/%:>(-/NKD6GEJ Z1M*
M5LH[8#=YG'^K+#G@L1D=:UK"'29M!C234[6RN?[2?4U662(LDK3&0APLK*02
MQ'#=".A% %H3Z&9/($FL_:Q.T#VIU*X$B,JJ[$YEQ@(ZMD$Y!&,DXJ33'T34
MX'NHIM6BM/)CG2XGU29$DCD&4<9ER 1_> /T-4H]+T=-=NM8/B2P^U71E:4J
MRK]Z*.) /GX"B/.#G)8GC JA;>&M(M1I[KXGTR26PL[.VB$J(T;^1%/$Q==_
MS!EN&XR,$#D]* .MDL-*AR'U*ZB*(&;=JDO"D, 3E^AYP?5?:F6UG;7WVB&#
M5=3\VWE,<A\\AE) 8<$8(VD$'!Z]>M<Y+H6CO]G1-?T2&*VOHKJ$Q0HLBQI<
M>>82WF8V;N%P!M [\YW=+O[&+4]8OY]1L42YG18U%TA^1$"ACS@%B&./0#\
M"VWA]F.1K6K+P!@3KZ=>5I/^$>?_ *#NL?\ ?]?_ (FM!=3L'B,J7ULT:J6+
MB52  <$YSTS4OVF#Y?W\?S[=OSCG=]W'UP<>M &5_P (\_\ T'=8_P"_Z_\
MQ-'_  CS_P#0=UC_ +_K_P#$ULJP=0RD%2,@@\$4M &+_P (\_\ T'=8_P"_
MZ_\ Q-'_  CS_P#0=UC_ +_K_P#$UM44 8O_  CS_P#0=UC_ +_K_P#$T?\
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MBJ'^\'PH))SQNZA:T-5\<S:5(IN-/AM[<ZA-:">YF=$=$MVF\P?N\XRI1N"
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M=;I&,TWDQ[EXV9;G/(QGG(Q70V_A?3K._@NK420>3/-<")&&PO*N'R""0.^
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M.HVFM^LO1]'_ +*FU28W#3R:A>M=N2H4)E$0*/8+&O/<Y^E:E  <X..M%%%
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M4 %%%% !1110 4444 %%%% !1110 4FT!BV!N(P3CG'^2:6B@ HHHH ****
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M_?7&>=H!L4444 %%%% !1110 4444 (<X. ">V32T44 %%%% !1110 4444
M%(V<?*0#D=1GBEHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
944 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" *[ A@# 2(  A$! Q$!_\0
M'  !  (# 0$!              4& P0' @$(_\0 6Q   @$# P("!0@&" ,%
M!0 3 0(#! 41  82$R$B,0<4%D&5%2,R459AD]0W0E5UL](D,S54<8&TTU)B
MD1=EE*'A)4-3@K$T<I*BT29CH^+P1$9F=*2RP<+$_\0 %P$! 0$!
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MY(KCOCGG&/?WQQU>M-2++-U"@.[4CC4P3] 4TD#D2(9>L06$P#$CB,*H!?\
M6.1COK9VS37Y+JSW9:H0!60#K%E/GAN[G (QVP6!QXCW)NFF@YU;J7=7.B%6
M*T<!S?YWDI.(L D2 DY$I.<J,X QC4M:9;Q)#7P54=9U12(K<B WK/%B[(V?
MH'P@8[ Y[#OJWZ:3I1:WJI$-/N=5D]:ZTHPX5H9E5G<1Q]-\$X4<NIR4=LX[
M%=7&B:9J2+UI0LX7$F/(L.Q(^X^8^[6;35JS30TTTU%---- TTTT#33305K=
MG]O;+_>TG^@J]?)4O HMP*%J7DE$AHFY*K*>/A48; &<8/;/?('F?N[/[>V7
M^]I/]!5ZLNBQ-%"KJ+=5/5+\G3S3**?L[N.(=NKA>+,<\<Q L<GM[\G2^4NX
MJB.*.BCN$<*UBR(WK #K#Q4,K\9 6RQ8@9\AYCL-7W31%(:DOLMOK4F^4UJD
MB)I7BJ%57Q$.*L.6>74R<_5C)QVU[NM%N-*AULLLIAZ4? 5,Q\$@#GEG.6'T
M593Y]B.X.;IIH0J;/>(H)$:*L6EDEC +NK2HO$<^X)P"Q !]PY'L,:@JJNWC
M9K/)5PT;5,H0&3UI@XC58H^X42#)+F3..YQ_@#TG32#HH<=RW365,L!IX>,$
MT9)@7@W#DA&<R'.4+$@>7EG/GYN%=O7U!(:.THSM'&C-R0%,H.;!S+DL&+>8
M_5\VSJ_::;4(ZJ/%4;LCJ4,U*I@<QK-)X<(@9^3!>IV)7@2<G!QV/<"V662I
MEM-')7*5JFB4R C!Y8[Y'N/W:W--6J1%#5:](7]@TO[VMG^O@U9=5KTA?V#2
M_O:V?Z^#459=---!6O2;^C;=G[IJ_P""^K+JM>DW]&V[/W35_P %]0WL[LP;
ME>UR;0L$2K$&$K6Z##L<=AVR!W SC!)QG([A9:K;E'5UESJ*II937TPI9$/$
M!$ 8>$@<@3R/O.M1]GT,CN\U15R23$^L.S+FH!*'BX"XQ\VH\(';/UG7/IXM
MLQ3-&-G;4D/4:)"M!!W82,N,'R.%R < YP&SVU[-'MI[=%40[3VF9'89C-JC
M#!6:)5[-QQ_6Y[XS@>6=(N4V7^+:%'%2K!'55H"-3E&Y(65(&Y1Q]U^B#GS[
MG/GJ3IK6D5TEN$M1/45#(8T,H0")"W+@O%1D9 ^ED]O/SUSVBL^UI+A3PR;4
MVI()7BC,<5MAZ@+H6+>\$+CN/</?V[Q])1V"=7QLG:S%9(X^7R?  QE9T0C!
M/8,HSD@X8G P,V\SG<3I=V+35938.T."\]J;>+8[D6V$#/\ ]SK[[ [.^R>W
M_AL/\NH++IJM>P.SOLGM_P"&P_RZ>P.SOLGM_P"&P_RZ"RZ:K7L#L[[)[?\
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MWV3V_P##8?Y=/8'9WV3V_P##8?Y=!9=-5KV!V=]D]O\ PV'^73V!V=]D]O\
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MO5^$<19(TR!U.S'B"<^98:O_ *SHQ&S.NU=TQ7&%Z:_EZ%9(FD1ZJ0EU2=G
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M2 Y;/A+R*Q&,Y4X(SVNMY9BUFQ3V*_PVBYT\M4*JLGF#1S&XRQX4NQR.*Y7
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M&KYA?FAR,^%L#(^HX&L%RL]LNE/%!<[=15D$3!HXZB!9%0CR(!! .MX
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M=B[9N%=;J>.?HK#3H\I9U5DX],\2 Z$9^D3CMC.M.]5FU8*L"R>CS;5QHC'
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MJKWDB2-!0T;C@I0<06R6(.5,@'90"1R'T\ GCWMR2(Z!U8%2,Y^[0R( 277
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M?S[>1^)<MZ-6JC6RF%&21UD16)7]5B#,""?>!G'GD^6K?%6T\I812<RLIA;
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MUZ-2G5B]9+-+&[1HSL%+&1B1XP/?V7OG)(O!/LF*395L2UK20U$QINOUQPX
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M BR%WZ<I8RIT501GPCMS!?/N]P\1UABV[=IJ:6.[R4M<SUD54A9F B4LIEC
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MH&IX*B%G98\2LW$QXSU(PJKQP_8$]LYR1D#.Q#MFJ;;T%#7QTU5-'5))EG/
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M6TL42OU89D=2^&3!5B@7R+8&06(Q]^IF^[DN5LJ7CBL<]4B0=0R1<V!?B3P
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M-AJY;E)#*35-3R9C/.3BH581E1Q7L>_B7/+NVI&C6Z3CWO=WK)H6VO5(D4G
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MRJO#YH<R.L3@\?+S[Y$;;-HUM)'!'+MVG2N9EDIZREDB6.VGF6<+W# -DGP
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MEI)JF)Z:G]9)*8\#+'2L5^DF6/A&3W.._NX-M"ENL=JBV+M2:YM:S<&AX0J
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MD.2C@(?$W$X!QJ,N4^PZ2NBA79%H>(RD32/8Y5,$:I&[,ZBF)#?.KV.%QW+
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M.RE<#M@DY'EG6"T&P7&Y6>G_ .S;:Z07"-)A.L'4"HSLH;M2\1D)D!V0G(&
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M[@_&H/S.GM'=/L7N#\:@_,Z1;02EMLU#;16BECDXULS3SK+,\H9V !P')XC
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ML'\3X<\^X[:1M.9;U)S/'^-"+9=L?=%CKTV7#20\97E9N@QI6 3I#LYXXX'
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MV)K>._W^<LR5&RZ__P!BM)M@5M'3E6CIIO5FFH?Z1&[QY9^/3XH_$*QQR*X
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MA5D[R@'Q\<$$ZEK[L**6Y[3IXK7ZQ0VBED#S1TU)AV#1LJ%'QCD4?N@&"WF
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MP.SOLGM_X;#_ "ZLNF@K7L#L[[)[?^&P_P NGL#L[[)[?^&P_P NK+IH*U[
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M-43I-0;QN-4 T,D2.C \,',P]Y^B01H.GZ:JT^T+3"@=ZG<9!95\%\N#G)(
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M%O>^R(21R6*@(['!_P#V;Z]1:HZ_[%J+HU 4NL"-2T<=,)9Z+K2NZ.K"0DN
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M#06733305KTF_HVW9^Z:O^"^K+JM>DW]&V[/W35_P7U9= TTTT#3330----
MTTTT#3330---- TTTT#3330---- TTTT#3330---- TTTT#3330---- TTTT
M#3330---- TTTT#3330---- TTTT#3330---- TTTT#3330---- TTTT#333
M0---- TTTT#5:](7]@TO[VMG^O@U9=5KTA?V#2_O:V?Z^#06733305KTF_HV
MW9^Z:O\ @OJRZK7I-_1MNS]TU?\ !?5ET#3330---- TTTT#3330---- TTT
MT#3330---- TTTT#3330---- TTTT#3330---- TTTT#3330---- TTTT#33
M30---- TTTT#3330---- TTTT#3330---- TTTT#3330---- TTTT#3330-5
MKTA?V#2_O:V?Z^#5EU6O2%_8-+^]K9_KX-!9=---!6O2;^C;=G[IJ_X+ZLNJ
MUZ3?T;;L_=-7_!?5ET#3330---- TTTT#3330---- TTTT#3330---- TTTT
M#3330---- TTTT#3330---- TTTT#3330---- TTTT#3330---- TTTT#333
M0---- TTTT#3330---- TTTT#3330---- TTTT#3330-5KTA?V#2_O:V?Z^#
M5EU6O2%_8-+^]K9_KX-!9=---!6O2;^C;=G[IJ_X+ZLNJUZ3?T;;L_=-7_!?
M5ET#3330---- TTTT#3330---- TTTT#3330---- TTTT#3330---- TTTT#
M3330---- TTTT#3330---- TTTT#3330---- TTTT#3330---- TTTT#3330
M---- TTTT#3330---- TTTT#3330-5KTA?V#2_O:V?Z^#5EU6O2%_8-+^]K9
M_KX-!9=---!6O2;^C;=G[IJ_X+ZLNJUZ3?T;;L_=-7_!?6I7WF[T5WNK14TU
M730$"&G"$=3PQDX(C^MGP2V,C!QYZ+1<--<_DWW=!'22#;LJ1SM&K//UX@G-
M@N.\&<@D9!P#D8)/;6_/NJYTMCAKI;!5RU$E5TFIHHY"T4>,\CA23CMY#_#Z
MM.47'35,K=W7.GI*62.P/)4RTTD[4QD<.I1L<<",^?8Y^_MGMG/'N*\R-&OR
M Z\IC$[=1N*8Y'EDH,C">>,>)![^R;14B]ELTU09]W7FGDA9+%73H:="R=&3
MZ956)++']Y7 ![^8'?&9-RWGU:FJS;:A@]8T<E.8)%98BBD8)3)()\\ '![Z
M)5>--4&DWI?)Y0'VO+%&TBIS9I\KR&>XZ';'?ZQD>8U)63=-34!X[E;9:5Q$
MI@+<R9WX%BN.FN&['L,Z*MFFJ58MQW>YU?.6W55&A$@]7F@88*J<>(J.Q(S_
M )^_6O[97WICI[:=Y%52W5::+/@Y,0.BW^ &<^XXTWF$K:J^Z:I%LWE=JIKJ
M*C;55#ZG$LD1!D85#%4/%<QCN"Q'_P I^_&O3[SO-=2Q$;>K**21XCEHI9"J
MF0A@5,0(;"D_5@YSY91=5_TU5J_<MPI[A-3PV.>:.-^(D^< ;N!Y\".X/(8)
M[*<X. 8MMVWF=J0BRU5-G/541R.#YXPQCP,8'GC.<??I%[DVU7W35.HMRW9I
M8TGLT[,Y0,0KJJ9*@^:9[<F/<D80]^X&OMKW7<ZM"9MNU,3"F><JI<^,*&$8
M+(O<YQ_B#]V47*+AIJC5NX+\QJ)H*&2*-(PJQ]!WR291S'AR?H1X'N#]_<=;
M5NW3<Y_6%GL52A@IWDY8D^==6( 7YO&"!GSS]2GST%OTU2*'==W]7 GL=5(X
M9EZK12H#XAQ)41EN)Y8R 3X22,=]:U=OF\T]/420[6JIGAC=NG\ZI=EC#<5^
M:[Y)*@_6-!T#35%H]X7BJ, .WY8%DZ9+,)F*AI%5LJ8E((4D_P"7U:P;HWA?
MZ*.MCH=O5$AC8K%+"))&<"0J>(Z6 V!GN<>(?2\M)L1>*N@Z:YVN^-P+!R.U
M9'(D,8;G..0 3Q8]7R,\C[L>$]_?K>J]XW2&!'CVW5RN0N442Y[IR."(B//*
MC[QWP#G0BZ[::ID>X[LENIZEK9-++)/*G2*21A5#@+G,?+'$YS@9Q_T^U&XK
MM'54L\5MJ9()J2.9Z80L61RDK%0W'Z7)(U[^7+R[C18BNBY::HEOW??*Z5H3
MM_U9F9XXY7:8J"$RK,&A4X)('^1P3K:M5^O4EQML-7:ZA:23FD\S18968L8B
M0#V\*#E@8S(/HX(U:(N.FJ[;K[<*RY14[VAZ>)FD#2R,XXA0N.W#!))/OQV[
M$^Z--^OD0C?U":?,/:-:=EY.>8!)/EXA&,'& Q)[=Q!=--5&3=573;9%2]KJ
M*J\PJHJ*&*-@^>3*6  ;PDHQ!&>V.Y[9\2[ENAH;;6QV>H3JU#1S4Q1^73QV
M;Z&1[C@@?4<'L'47'37.SO?<#P2M%M256& G(SDY*YPR]'/;&.V1GWC6:Y;K
MO@]1%-9*I5>J2.5Q$Y\!ZF21P) \"GR/9QY'N OVFJC3[HNLES6GDV]-' 0Q
M$G)R<A.7'^KX@Y..[ ?43Y:C9MYWBE]:E-@JZM"O.&.**8$8"97O$#WY$^7F
M"!GMD.@::H$._P"K:KIJ6:PS1U,T;R"+DX)"QAP!RC&6+'@ <=P?J.MZQ[IK
M:ZYA+C;YK?"T;)&LD4H623(XX=HU\P3@?<=";+CIKG\>]KZT\$;[6D02*I9C
M)-X>2J?/H8..1![@Y4]M8K;OR]5UNCK&VK74TI4YIINHO?YOOGI9_6;ZOHG_
M "4O0=%TU4Y=T7".WR57R%5'C5- (PLC,R!"PD "9P2 OEYG6@^[;S/3<8K'
M-33\T\3+*ZD'@3@]+_F(.<8[XR1C307O35#I=\W.:X102;9K(8&6)GFD$H"\
MF4-CYO!XY).2.PSY=]:]+Z0*^XT,$]#8:@I.I^<42OTR<XR!$>X[$@X[,,9S
MI-EHZ)IJBU^\;M0RT=.FW:RK,E(L\D_"1%#\.13 C.&SVP<=^WGVUMP[@N;T
MMPJ6MU2O3JXHXH6B=3TSQY=RAY=^62 0/KTFR1=;]-42Z;JO:6RTUE/9YU>6
M=Q4TZ)([!5';'S><$X]P^X_7ECOEZ>@NTJT\_4CCY4Z-3,IR9Y%[97N> 0^7
MWGSTFU>!=M-4F#==YQ K[?G*E$YR,9 <D$_1$7U@*?+!/U=]>*O>EU@M]!.F
MV:N26I+AXP)?F<8X\OFLC.<>6.WGCOH+SIJG4>YKG/+52O9ZM(X*)IA3])\R
M2#B<!B@'?)  R>Q[>[59CWMNE-SU/5L57+;A"ICABIY@H;MR\9AY,W?('884
M_=I%R;5X=7TU#[=N=5<4J/7J4TTBR811'( 4XJ<Y=5SW)]P\O+L=3&@::::!
MIIIH&FFF@::::!JM>D+^P:7][6S_ %\&K+JM>D+^P:7][6S_ %\&@LNFFF@K
M7I-_1MNS]TU?\%]0URCKZ":XQ/N?=LST5*M61!2V]S,K%@%0"GSRRA\P!W'?
MSQ,^DW]&V[/W35_P7UOU%E,EVJKA%<JV"6>E6EXQB(K&%8L'7DA/+Q'S)'?R
MU%A32[5%78Z.?=>Y2]VCZT'*GMKI&0I<!F6 CD0K8XD@\3WU[ODU79;AZI5[
MIW6SO325$#I!;>,Y09:-28!A\=\-Q!]Q.#B3J_1];ZB>GJ4KJV"NI7C:EK$2
MG::G1%(Z:.\3'@<DD'.2?/';4E?=K4U]#I<ZNKE@>E-,8ATU&2P;J@A.0D!4
M8(( QY:LD:W4NZ7%[?4S]7<&[Y:V"W^NLD5);&D,>5Y1J>C@NO-25!QW&"2<
M:UK]N86EHR-T[LJX&@AJ&J(DM,<4:RDA SRQH 3_ .61G&1JSU?HZH:BK2M2
MYW"GN0,@DKH8J833(W$"-V,)RJA0%&.WUG7D^CFEBGCDMU[O%O5&YK'!ZNRA
M@Y<'YR%CV)P!G   QVTG;,V3;G^?OFTKC/46[;M#>*O=FZDIZOI<8Q!;F= ^
M.[8@XX4')()[ XSJ-NM\J+;%<.IN#><M10S&*>GC@M74"<"XE'*(*4*J<8.<
M]B >VK;?=D4-^ML5#>*JHJZ>*E:G19(:?PN1CKJ.EA90.P*@ 9/;6I7>CRCN
M%"8;A=KK45/*0K6L8%F57CZ;)X8@I4@ ]U/< Y[:MJRL4M5%K/=#;ZZ=[SO9
M*NC"-)0-!:C,4;.'!$1C*]F[\_U3[^VM-+I=I(*"2.NWZ[5D3311B"T<@HX]
MSX,=PZ^1.,G.,'%XH]N+3T5?%+<J^IJZV+HR5LW2ZH4 A0H5!&./(D>#S/?.
ML46UUB^2NG=KBHMU(]&@Q">HK*%Y/F/Z0XJ1C R.X/<&3O3-?Q(VKF75*PUU
MRO,ML6.\;VIH[A$T\4M1#:0HC55;D>,9.#S4# /<]\8.L=@O,EX:\?\ XU;I
MHUM(8U1F6TN4XE@05BB=@? W9@,CN,ZLXV7TZ.T4]'N"\T@MM,U)%)%ZOR=#
MQ^D6A/?"J,KCR^OOK-9MHQV^EK*2INUQN5)5))&\-6L ^FS,Q#1Q(W<LWF2!
MG5FE9HL44>^;EGL=.DETON]::1G5.E+':(R%97*/R9 F#TV&.7+(P0"1G<OU
MTKK/4=!KYO2KF6GCJ)4IX;3F)7) Y!HUSW4Y*Y48\^XU:#LN"2KHZJKNUSJJ
MBFF60/-T3S55=1$P$8'#$C^6&/+NQ[:^;QV33;ID@:IN=RI%@=9$6E,. R^1
M!>-BOO! (!!P<C2R?7JJU;>*NCXSS7W>_P F&;H-<5I;88(V#<6+#H\PH8$%
MN./>"1WUJ5.Y*JGO,-M>];SZ\\K0TY_]B**@J_ E RAF&2#Y9QWQJT5?HXMU
M5=K?727"X$4-0U33P,E.Z([-R?!:(N Q[D!@![L=M98M@P4<J&TWN[6Z% RI
M!"M-(B R&3 ZL+D8.,=^P48U(Y6=+(';=UDOMGKKE'NK=E+3TAP_6@MCECCR
M4QPN"V>Q7/('L0,Z4ESK7KZJ"XW[>-H@I4#SU=?':4AC#9X\BL9(SQ."1C_#
M(S/4FQ(K=:ZBEM]TK3U8T\,XB*-,A4I*P1%/(<%4X(! [C/?4DUDF22[UP?U
MJLN-/'%)1SR*M,I52,*PCYX/)NYY?X#2>$0*ST354U*OI1JC4P\NI$)K9S3B
M,MR'J^1@#)SY:V98%AIZ.>7TCW)(*P@4TC-;@LY(R.!]7PW;OVU&OZ-EK[A/
M'=*J;Y+%%!!%ZO48E>9!(&F8E.08=5B,.1DDD'MB9&PZ!;5;:%*^Y\:)'C,S
MRI))4*[AV$A93G+*K9 ![>>,C5D:#S4<=!%7/Z4*M:*5BD=09;8(W8#) ;U?
M!..^-:S7*W+5FG_[4:HE%8R-ZQ:L1D,%PPZ/($DD>6.Q!P<9D;WLZIJ++MZT
M6^ND]6H*D--4RNBSF+IR(0H$10L>>/HCM[P>^L51Z-Z62&FCCOEY@2FDDDCX
M"F..4B28/*$Y :-,>_MWSJ;K:S#2S)67!*2B](%[JF,G19X([>Z)(4#JK$4_
M;DN2#Y'!&<]M3?LY=/MIN#\&@_+:U;/LT69:"DHZV>:@@F2>3UDH9"T<2QH%
MX(HP0H))_P"'L.YQ;]6:;(K7LY=/MIN#\&@_+:>SET^VFX/P:#\MJRZ:@K7L
MY=/MIN#\&@_+:>SET^VFX/P:#\MJRZ:"M>SET^VFX/P:#\MI[.73[:;@_!H/
MRVK+IH*'O"WWJR[1O=TI=XWQZBAH9ZF-9(*$J62-F (%.#C(]Q&LEPI:RWU\
M=-5[QW)'&]/+4FH,-OZ:+'QY _T?.<,#Y8['OJ3])OZ-MV?NFK_@OK<OFWJ>
M\U<<M74U(B6GFI7IXR@21)0 W(E2P/88PPU)6*;J137A:BU6FY1;QW0U)=*D
M4T#K#;6QEN(=N,!XJ6*COX@6 (!SB4O<599JRWPUF[=SB*MD,*5"P6[II)C*
MJ^8,CEW .,9[$C(SEK/1Q;:VG=*ZOKZF;(DBJ98Z<RP2\PQEC/2\+GBH)QC
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MJ?2=6Q3K'UC'));581\>7/!I\\<=\^6.^M6EN%!4R.L?I/JSB0QH146INJ0
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MW)16WVDM=3<7GIZ6">EZ]]N*@%S(&YD5'B^AD8X^>"1YZLGI-_1MNS]TU?\
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MM*U;#BTXHXPY&,8+8SY ?]-;=79[965T%;5VZCGK:<$0U$L"M)&#YA6(R/\
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M-4HY!F)#9QQ)P#YZ[A+L+;=1,9ZBW4T]8]0:B6JDAC::8EBW!WXY*>0X]NP
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M+)*?DOJ4X2)C%PBE&)",C&6/8@MV!XYU/46_?7=U4-MI113PRT+3.(Y0)7F
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M^8"./T<+C.,^(:ZP/+OYZ<CCUZV+9:ZJ@EI;9?H4ZYJ*@S-5S222$!1(K^L
MJX P&/(8/<'MJ5CVGM9.7_XN;B?D"#U*FI?S4K[Y3^J2/\]=,TTBVAJH$EHL
M,EU2XR6#<#52MSR99RI/'B<IU.)R!W!'?)^LZ\T5CVW06-+10[8N]-0),:A4
MA65&$A!!(</R[@D$9Q@X\NVN@Z:"EQ4]ICH*VB6Q7PTU7+UI$;JMA^V"A+YC
MQ@8X8Q@8QK2J;)M^J1EGV_N!^4?3=NK.&D&".3MU,L^"1S)+8)&<'70=-!SV
MCL=@HVB:GL6Y%:.19@345+<G#LX+9E/+Q.Y\6<Y.=8J?;>V:=)4AVW?U26,Q
M2+U:@AU*A<,.IWP ,9^B>XP>^NCZ:5'.*_;U@K:V2MELNYO7'8/U/6JK'->'
M%N(EP<&.,^7Z@^K6':M@H;+MQ[146R\3QM.:@-3Q3P\'_P"-&,SNC'ODJX[D
MX R==-TTX'/IK+890X-CW(G,1ANE45,>>FQ93X91X@Q+<O,DDDDZTZK:.TJN
M@:BJ]K7NHI6*L8YGGD')?)QF0X;';D.Y'8G';73=-!5K'4T=CM<-NMEEO45)
M#RX(\;R$<F+'Q.Q8]R?,ZW_E_P#[IN__ (;_ -=36F@A?E__ +IN_P#X;_UT
M^7_^Z;O_ .&_]=36F@A?E_\ [IN__AO_ %T^7_\ NF[_ /AO_74UKD.[]E27
M&]7&L.U$N9D<2+)-ZNSDF6+(1F=<CA&W:097.%8@D:;T5T:.^AFPULNJ#ZVI
MC_\ X.O)O^"?_9-V/W^K?^NJ9N.PW/Y>M55;+$TMGM)]36VJL&9Z>2-A(5+3
M! G=!P9<DH,8&H2;9=:LMCDN&TUO5%31(!!**62>G7N6A8R2!60'NN&/9L>[
MN)T=.^7_ /NF[_\ AO\ UUXFW$T<,CI9;S*RJ2(TIQR8_4,L!D_>0-<_J-O[
MB62T5$-FD]5L]4S1V[G"YE@F+AXT<S!0$C8+Q8=R,*>(R8>P[%J+9%01W/8G
MRI")34/&%H0(P8F3ILID"\@V#R7)*\22671)LZI-=*::3J36&XR2=-HN3T8)
MX-CDN<^1P,CWX&M"2*Q24\<$FSY'@C!"1M;(RJ@DDX'D.Y/_ %U W[9,]Y3:
M-%<:#K+1K+UZGA!4+ "!QC;K99AV RHY=LY&H6_['KKA;*>DBVYTZI6C2LJ_
MZ+**N42(?6>,C8?"K)],<O'Q ()T6+NB5%?15/#UG;M=-P0QKU*%6XJ<949/
M8'BO;[A]6M9?D=8)8%VG.(97$LD8MJ<7<>3$>1/WZY^=GWZ&T7>FMVWYJ1:R
M@%#50K4PGU@I$%C>,]3R+!E//B>##WKC5NW78*RY5MK:TVV2DGIZ":(5!Z")
M$'B91%R5NH&#<>P^;P2>Y"XLPD9Z?:P5-W@J:9Z>IL=SF@D7B\<E(&5A]1!.
M"-8Z6XTE($%)M^O@"((EZ5$%XH#D*,'L,D]M5\VUJ+;-!2U]J]7L\EP8SVP\
M'6*%E?IQM@E.)DX9&>(Y8)P#JHV2P[WVO:H:/;5B:GEJYTFJ)5EHXA$@7CP=
M1R5B#DDJO)E(RW(:FYMF;.CR36N5ZIY-KU3O5@"H9K>I,P'D'_XO\];E/>8J
M:".&GLETBAC4*D:4@55 \@ #V&OFUEO,,)COCU-1-DH)7Z(4A.P?P $<\YQC
MMCW>^H3[<N<PIEALK0K%<*IX0TD(%,SSK(E2 KGL%#C \7B(Q@DZ;T-JKI\O
M_P#=-W_\-_ZZB=RU51>J&DHZ.U7)9/E&AG+2Q!%5(JJ*1R23[E1C]_EJ*O=C
MO,N[+7<*RW0W?H4[QRSTT<<*8(DRBI+*65B"@[$J^3SX@+C-L.V36BNM]"L#
MTYCHYS4Q'AX%,P, <1_-A\&3LGA'<#MC5B*YW_1-I7_3334#5 ](-OOMQN]N
MJ[5;WFAL\\50L1$6:SFW&0(S3*$XQ\@>:]^6!]>K_IIO$G6'#(/1C7/;[86M
M-!#+/5?.TTENIVBHX@LPYR()\2N>HGB0@X5?#E<:S0;$NEKO=PJ**R5%3!*Z
M4Q8R4T4D\:]'J2,P<%UE$<@(<D@L"%')L=MTU8FFBS-7+GV=,LL%TMVWH*63
MK24\5OD,/]%I98@C]@Q0 ..?!21@L!W8C5;M6Q%M[ 2[ JZR(UO5,,L-K*)$
M'E*JIZH9LJZYYY\NQQ@:[KIJ9F;R5M3,^G(=V[.KJ_;E@I!89YS35-3,(:?U
M.9J.)U?IQ?TD\" 60$*"!P['LIU+[4V=ZA?J1JZR1+#ZI#5RN@B>!;@HX,ZY
M/4+\?UL8SDYR<ZZ/IJQ-,S^I,5S/XY)N3:=75T]6GLN:RK,\CU-5SIV^449B
M8U\;@GAE3AP O#"YU$0;#J@MU1=I3TM-<ZA3"E/ZG$] %GYACPE 8<2"I!9E
M*LO92-=RTU(LLS5SJRVB[N=SU%_LIEKJ^WQ1-Q>%XYV".#$F7R%[K]/B,ECY
M=]2%NH+JEQHY::WB@J?D:.G>LJ4CF1)58'INJ2AFP.7D>/?SU==-7>N;Q\I2
MU,V^G*+IM/<-5<=V&B@@I37PX-5(BL*KPXZ:\95< GWR'P>0Y*QUT^VQS16^
MFCJF1ZA(E61D7BI8#N0,G S[LG_'6QIJ1:*$WFN;?1IIIH&FFF@::::!IIIH
M&FFF@::::!IIIH&FFF@::::!IIIH&FFF@::::!IIIH&FFF@::::!IIIH&FFF
M@::::!KDM3[44>X[S=;1)5I1Q5_0$56E=5B=7Z8/"G/%51"9&$B,1[L8QKK6
MN>^U.X8;SN5:BGIWMEN+Q4SQ4+LTLI6,HA*RLS'YSN!&,X\/O D6FO$_!.GC
M]HZGWKO(3U,=3MFI;HU$L*\;?(HE(1BI4]0CAE1XSY\@H&1G6E?+WNRZVZLI
M85JF! BA>FLE?03.[Q.597,O@"L%SRR.X!QK?LV^[Y<;QMJ,Q4,=)<8(S4J]
M+(K0S9D62/F9,J>43<08SY$$@X)F=R;SJ+2]0T5')+3I6QTBM'233X[IU&8Q
M@X[2 *#C)4G)R!K5-LM,0L32<WNJ@WKO<S5%#-MZK-*8L)<4M50%"$@=4IU.
MH6[D=( -V#9P<#:BJ=XTM#MN>U"=JRHM,,-0ETIJF5.LI',N.:])P"26?NV,
M=SC4_:-WUTUIOE56K1&6CE A1%:,"-F*H[$LW).V>8QD!O",:B[S<-W37\V"
M1MNW"DE@$D\@M;RI&I/_ +V-JH$ ^[ ;W$X&LUI3-I^R(M/3]A*W2LN==MVU
M5M;'7+15,QEJ8[8DJ3I 48QJ>FS29SPY&/O]V,ZHMLK-U5=-5T<='N"&ONJS
M"*6IGK52C0-X>4AAXJ2JMP955^X#C)Y:MWH_WC>+O!127F&A1*FH-+P@B:&2
M)C )5+*9''$@-@ANX*G [@;MYO\ N"WM>&,= 5HIH95586<"D<L"SMU5/+PD
MG"G&.ROG.M=KLWIU2M([OW/)/;,N%1=-KVVJK:>IIZQH%%1%4PO$ZR 8;PN
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C0L"B0*S%F ;&<$DDCWDDZWM- TTTT#3330---- TTTT'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>10
<FILENAME>aemd-20160930.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.15b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: aethlon_10q%2D20160930.xfr; Date: 2016%2D11%2D08T22:13:26Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-roles="http://fasb.org/us-roles/2016-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:AEMD="http://aethlon.com/20160930">
    <link:schemaRef xlink:href="aemd-20160930.xsd" xlink:type="simple" />
    <xbrli:context id="From2016-04-01to2016-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-11-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-11-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-04-01to2015-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-04-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-01to2016-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-01to2016-09-30_custom_December2014WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">AEMD:December2014WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-01to2016-09-30_custom_AethlonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">AEMD:AethlonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_AethlonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">AEMD:AethlonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-01to2016-09-30_custom_ESIMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">AEMD:ESIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_ESIMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">AEMD:ESIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-04-01to2015-09-30_custom_AethlonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">AEMD:AethlonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-04-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_custom_AethlonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">AEMD:AethlonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-04-01to2015-09-30_custom_ESIMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">AEMD:ESIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-04-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_custom_ESIMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">AEMD:ESIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-01to2016-09-30_custom_Milestone2613Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AEMD:Milestone2613Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_ConvertibleNotes10November2014Amend2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AEMD:ConvertibleNotes10November2014Amend2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-01to2016-09-30_custom_ConvertibleNotes10November2014Member_custom_FairValueWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AEMD:ConvertibleNotes10November2014Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">AEMD:FairValueWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-01to2016-09-30_custom_ConvertibleNotes10November2014Member_custom_BeneficialConversionFeatureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AEMD:ConvertibleNotes10November2014Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">AEMD:BeneficialConversionFeatureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-01to2016-09-30_custom_ConvertibleNotes10November2014Member_custom_DebtDiscountMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AEMD:ConvertibleNotes10November2014Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">AEMD:DebtDiscountMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_WainwrightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">AEMD:WainwrightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_UnPaidBoardFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">AEMD:UnPaidBoardFeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-31_custom_UnPaidBoardFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">AEMD:UnPaidBoardFeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2016-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-07-01to2015-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-07-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-01to2016-09-30_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-01to2016-09-30_custom_ConvertibleNotes10November2014Amend2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AEMD:ConvertibleNotes10November2014Amend2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-01to2016-09-30_custom_WainwrightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">AEMD:WainwrightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-01to2016-09-30_custom_ThreeInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">AEMD:ThreeInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-01to2016-09-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2016-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-01to2016-09-30_custom_JamesJoyceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AEMD:JamesJoyceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-01to2016-09-30_custom_RodneyKenleyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AEMD:RodneyKenleyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-01to2016-09-30_custom_JamesFrakesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AEMD:JamesFrakesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-01to2016-09-30_custom_NonEmployeeDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AEMD:NonEmployeeDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-04-01to2015-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-04-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-01to2016-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-01to2016-09-30_custom_Milestone26143Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AEMD:Milestone26143Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-04-01to2015-09-30_custom_MilestoneM6Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AEMD:MilestoneM6Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-04-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-04-01to2015-09-30_custom_Milestone2511Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AEMD:Milestone2511Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-04-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Percent">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Integer">
      <xbrli:measure>AEMD:Integer</xbrli:measure>
    </xbrli:unit>
    <dei:EntityRegistrantName contextRef="From2016-04-01to2016-09-30">AETHLON MEDICAL INC</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2016-04-01to2016-09-30">0000882291</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2016-04-01to2016-09-30">10-Q</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2016-04-01to2016-09-30">2016-09-30</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2016-04-01to2016-09-30">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2016-04-01to2016-09-30">--03-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2016-04-01to2016-09-30">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2016-04-01to2016-09-30">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2016-04-01to2016-09-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityFilerCategory contextRef="From2016-04-01to2016-09-30">Smaller Reporting Company</dei:EntityFilerCategory>
    <dei:DocumentFiscalPeriodFocus contextRef="From2016-04-01to2016-09-30">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2016-04-01to2016-09-30">2017</dei:DocumentFiscalYearFocus>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2016-11-08" unitRef="Shares" decimals="INF">7725072</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Cash contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">556352</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">2123737</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">4209356</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2016-09-30_custom_AethlonMember" unitRef="USD" decimals="0">553884</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2016-09-30_custom_ESIMember" unitRef="USD" decimals="0">2468</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2015-09-30_custom_AethlonMember" unitRef="USD" decimals="0">4208554</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2015-09-30_custom_ESIMember" unitRef="USD" decimals="0">802</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2015-03-31" unitRef="USD" decimals="0">855596</us-gaap:Cash>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">193719</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">199471</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">816540</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">2376502</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">22969</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">36038</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">89579</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">94161</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DepositsAssets contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">21747</us-gaap:DepositsAssets>
    <us-gaap:DepositsAssets contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">22415</us-gaap:DepositsAssets>
    <us-gaap:Assets contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">950835</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">2529116</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">4705475</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2016-09-30_custom_AethlonMember" unitRef="USD" decimals="0">914179</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2016-09-30_custom_ESIMember" unitRef="USD" decimals="0">36656</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2015-09-30_custom_AethlonMember" unitRef="USD" decimals="0">4677989</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2015-09-30_custom_ESIMember" unitRef="USD" decimals="0">27486</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">384728</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">244804</us-gaap:AccountsPayableCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">58362</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">145112</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2016-09-30_custom_UnPaidBoardFeesMember" unitRef="USD" decimals="0">28250</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2016-03-31_custom_UnPaidBoardFeesMember" unitRef="USD" decimals="0">86000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">35316</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">136695</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">1084221</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">526611</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">0</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">500139</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:Liabilities contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">1084221</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">1026750</us-gaap:Liabilities>
    <us-gaap:CommonStockValue contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">7711</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">7621</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">90811302</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">88047142</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">-90886645</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">-86502043</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">-67632</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">1552720</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">-65754</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">-50354</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">-133386</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">1502366</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">950835</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">2529116</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2016-09-30" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2016-03-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2016-09-30" unitRef="Shares" decimals="INF">30000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2016-03-31" unitRef="Shares" decimals="INF">30000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2016-09-30" unitRef="Shares" decimals="INF">7711811</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2016-03-31" unitRef="Shares" decimals="INF">7622393</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2016-09-30" unitRef="Shares" decimals="INF">7711811</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2016-03-31" unitRef="Shares" decimals="INF">7622393</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ContractsRevenue contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">392073</us-gaap:ContractsRevenue>
    <us-gaap:ContractsRevenue contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">380874</us-gaap:ContractsRevenue>
    <us-gaap:ContractsRevenue contextRef="From2016-04-01to2016-09-30_custom_AethlonMember" unitRef="USD" decimals="0">392073</us-gaap:ContractsRevenue>
    <us-gaap:ContractsRevenue contextRef="From2016-04-01to2016-09-30_custom_ESIMember" unitRef="USD" decimals="0">0</us-gaap:ContractsRevenue>
    <us-gaap:ContractsRevenue contextRef="From2015-04-01to2015-09-30_custom_AethlonMember" unitRef="USD" decimals="0">380874</us-gaap:ContractsRevenue>
    <us-gaap:ContractsRevenue contextRef="From2015-04-01to2015-09-30_custom_ESIMember" unitRef="USD" decimals="0">0</us-gaap:ContractsRevenue>
    <us-gaap:ContractsRevenue contextRef="From2016-07-01to2016-09-30" unitRef="USD" decimals="0">387438</us-gaap:ContractsRevenue>
    <us-gaap:ContractsRevenue contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">188366</us-gaap:ContractsRevenue>
    <us-gaap:OperatingIncomeLoss contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">-3358529</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">-2214332</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2016-04-01to2016-09-30_custom_AethlonMember" unitRef="USD" decimals="0">-3281530</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2016-04-01to2016-09-30_custom_ESIMember" unitRef="USD" decimals="0">-76999</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2015-04-01to2015-09-30_custom_AethlonMember" unitRef="USD" decimals="0">-1911219</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2015-04-01to2015-09-30_custom_ESIMember" unitRef="USD" decimals="0">-303113</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2016-07-01to2016-09-30" unitRef="USD" decimals="0">-2226678</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">-1124361</us-gaap:OperatingIncomeLoss>
    <us-gaap:ProfitLoss contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">-4400002</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">-2468265</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2016-04-01to2016-09-30_custom_AethlonMember" unitRef="USD" decimals="0">-4323003</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2016-04-01to2016-09-30_custom_ESIMember" unitRef="USD" decimals="0">-76999</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2015-04-01to2015-09-30_custom_AethlonMember" unitRef="USD" decimals="0">-2165152</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2015-04-01to2015-09-30_custom_ESIMember" unitRef="USD" decimals="0">-303113</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2016-07-01to2016-09-30" unitRef="USD" decimals="0">-2263254</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">-1251606</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">20612</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">18676</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2016-04-01to2016-09-30_custom_AethlonMember" unitRef="USD" decimals="0">10822</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2016-04-01to2016-09-30_custom_ESIMember" unitRef="USD" decimals="0">9790</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2015-04-01to2015-09-30_custom_AethlonMember" unitRef="USD" decimals="0">8886</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2015-04-01to2015-09-30_custom_ESIMember" unitRef="USD" decimals="0">9790</us-gaap:DepreciationAndAmortization>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2015-04-01to2015-09-30">On April 14, 2015, we completed a 1-for-50 reverse stock split. Accordingly, authorized common stock was reduced from 500,000,000 shares to 10,000,000 shares, and each 50 shares of outstanding common stock held by stockholders were combined into one share of common stock. </us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2016-04-01to2016-09-30" unitRef="Shares" decimals="INF">3289606</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2015-04-01to2015-09-30" unitRef="Shares" decimals="INF">2773483</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">56996</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">27641</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:ConvertibleDebt contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">662811</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">527780</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleNotesPayable contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">605815</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">500139</us-gaap:ConvertibleNotesPayable>
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">17486</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">74036</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrent contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">17486</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">74038</us-gaap:InterestPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">17830</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">62657</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2016-04-01to2016-09-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">417047</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2016-09-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">17500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2016-09-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">434547</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2016-09-30_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">11.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="AsOf2016-09-30_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">5.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2016-09-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">2171871</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2016-09-30_custom_ConvertibleNotes10November2014Amend2Member" unitRef="Shares" decimals="INF">30000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2016-04-01to2016-09-30_custom_JamesJoyceMember" unitRef="Shares" decimals="INF">634000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2016-04-01to2016-09-30_custom_RodneyKenleyMember" unitRef="Shares" decimals="INF">52000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2016-04-01to2016-09-30_custom_JamesFrakesMember" unitRef="Shares" decimals="INF">52000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2016-04-01to2016-09-30_custom_NonEmployeeDirectorsMember" unitRef="Shares" decimals="INF">16432</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2016-04-01to2016-09-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2016-03-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">6.68</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2016-09-30_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">5.37</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2016-09-30_custom_ConvertibleNotes10November2014Amend2Member" unitRef="USDPShares" decimals="INF">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">387438</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">372328</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="From2016-04-01to2016-09-30_custom_Milestone2613Member" unitRef="USD" decimals="0">193719</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="From2016-04-01to2016-09-30_custom_Milestone26143Member" unitRef="USD" decimals="0">193719</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="From2015-04-01to2015-09-30_custom_MilestoneM6Member" unitRef="USD" decimals="0">186164</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="From2015-04-01to2015-09-30_custom_Milestone2511Member" unitRef="USD" decimals="0">186164</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
    <us-gaap:PaymentsToAcquireProductiveAssets contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">2961</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">0</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets contextRef="From2016-04-01to2016-09-30_custom_AethlonMember" unitRef="USD" decimals="0">2961</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets contextRef="From2016-04-01to2016-09-30_custom_ESIMember" unitRef="USD" decimals="0">0</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets contextRef="From2015-04-01to2015-09-30_custom_AethlonMember" unitRef="USD" decimals="0">0</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets contextRef="From2015-04-01to2015-09-30_custom_ESIMember" unitRef="USD" decimals="0">0</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:InterestExpense contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">77433</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">252107</us-gaap:InterestExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">79000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">90000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:InterestExpenseDebt contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">30794</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">26390</us-gaap:InterestExpenseDebt>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2016-04-01to2016-09-30_custom_December2014WarrantsMember" unitRef="Percent" decimals="INF">.0070</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2016-04-01to2016-09-30_custom_December2014WarrantsMember">P3Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2016-04-01to2016-09-30_custom_December2014WarrantsMember" unitRef="Percent" decimals="INF">.915</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments contextRef="From2016-04-01to2016-09-30_custom_December2014WarrantsMember" unitRef="USD" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">27641</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">39441</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
    <us-gaap:InterestExpenseOther contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">78743</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">253933</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther contextRef="From2016-04-01to2016-09-30_custom_AethlonMember" unitRef="USD" decimals="0">78743</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther contextRef="From2016-04-01to2016-09-30_custom_ESIMember" unitRef="USD" decimals="0">0</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther contextRef="From2015-04-01to2015-09-30_custom_AethlonMember" unitRef="USD" decimals="0">253933</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther contextRef="From2015-04-01to2015-09-30_custom_ESIMember" unitRef="USD" decimals="0">0</us-gaap:InterestExpenseOther>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">377843</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">424267</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2016-07-01to2016-09-30" unitRef="USD" decimals="0">280860</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">207676</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ShareBasedCompensation contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">1573991</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">101421</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2016-07-01to2016-09-30" unitRef="USD" decimals="0">1523280</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">50711</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2016-04-01to2016-09-30_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USD" decimals="0">1523280</us-gaap:ShareBasedCompensation>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="From2016-04-01to2016-09-30" unitRef="USDPShares" decimals="INF">-.20</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="From2015-04-01to2015-09-30" unitRef="USDPShares" decimals="INF">-.01</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="From2016-07-01to2016-09-30" unitRef="USDPShares" decimals="INF">-.20</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="From2015-07-01to2015-09-30" unitRef="USDPShares" decimals="INF">-.01</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2016-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2016-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromConvertibleDebt contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">165031</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">66469</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">53294</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">-616889</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2016-04-01to2016-09-30_custom_ConvertibleNotes10November2014Member_custom_FairValueWarrantsMember" unitRef="USD" decimals="0">-287676</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2016-04-01to2016-09-30_custom_ConvertibleNotes10November2014Member_custom_BeneficialConversionFeatureMember" unitRef="USD" decimals="0">-325206</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2016-04-01to2016-09-30_custom_ConvertibleNotes10November2014Member_custom_DebtDiscountMember" unitRef="USD" decimals="0">75993</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2016-07-01to2016-09-30" unitRef="USD" decimals="0">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2016-04-01to2016-09-30_custom_ConvertibleNotes10November2014Amend2Member" unitRef="USD" decimals="0">-536889</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">18998</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">186276</us-gaap:AmortizationOfDebtDiscountPremium>
    <AEMD:SaleOfStockNewIssuesAggregateOfferingPrice contextRef="AsOf2016-09-30_custom_WainwrightMember" unitRef="USD" decimals="0">12500000</AEMD:SaleOfStockNewIssuesAggregateOfferingPrice>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">345841</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2016-04-01to2016-09-30_custom_December2014WarrantsMember" unitRef="USD" decimals="0">345841</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2016-07-01to2016-09-30" unitRef="USD" decimals="0">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">0</us-gaap:FairValueAdjustmentOfWarrants>
    <AEMD:FairValueOfWarrantsIssued contextRef="From2016-04-01to2016-09-30_custom_December2014WarrantsMember" unitRef="USD" decimals="0">111900</AEMD:FairValueOfWarrantsIssued>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">605815</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">0</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ProfessionalFees contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">1078731</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">927433</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="From2016-07-01to2016-09-30" unitRef="USD" decimals="0">510982</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">389207</us-gaap:ProfessionalFees>
    <us-gaap:LaborAndRelatedExpense contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">2158190</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">1056078</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="From2016-07-01to2016-09-30" unitRef="USD" decimals="0">1813003</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">597850</us-gaap:LaborAndRelatedExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">513681</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">611695</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2016-07-01to2016-09-30" unitRef="USD" decimals="0">290131</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">325670</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">3750602</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">2595206</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2016-07-01to2016-09-30" unitRef="USD" decimals="0">2614116</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">1312727</us-gaap:OperatingExpenses>
    <us-gaap:InterestAndDebtExpense contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">78743</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">253933</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="From2016-07-01to2016-09-30" unitRef="USD" decimals="0">36576</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">127245</us-gaap:InterestAndDebtExpense>
    <us-gaap:OtherExpenses contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">1041473</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">253933</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses contextRef="From2016-07-01to2016-09-30" unitRef="USD" decimals="0">36576</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">127245</us-gaap:OtherExpenses>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">-15400</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">-60623</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="From2016-07-01to2016-09-30" unitRef="USD" decimals="0">-7668</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">-27000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">-4384602</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">-2407642</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2016-07-01to2016-09-30" unitRef="USD" decimals="0">-2255586</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">-1224606</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2016-04-01to2016-09-30" unitRef="USDPShares" decimals="INF">-.57</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2015-04-01to2015-09-30" unitRef="USDPShares" decimals="INF">-.34</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2016-07-01to2016-09-30" unitRef="USDPShares" decimals="INF">-.29</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2015-07-01to2015-09-30" unitRef="USDPShares" decimals="INF">-.16</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2016-04-01to2016-09-30" unitRef="Shares" decimals="INF">7690369</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2015-04-01to2015-09-30" unitRef="Shares" decimals="INF">7167903</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2016-07-01to2016-09-30" unitRef="Shares" decimals="INF">7756883</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2015-07-01to2015-09-30" unitRef="Shares" decimals="INF">7610459</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">20612</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">18676</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">46639</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">225717</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">-5752</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">-6533</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">12507</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">35777</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">125842</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">-144533</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">-86750</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">58000</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">-1763693</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">-2238228</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">2961</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">-2961</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">0</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">266612</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">5591988</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2016-04-01to2016-09-30_custom_WainwrightMember" unitRef="USD" decimals="0">266612</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">199269</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">5591988</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">-1567385</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">3353760</us-gaap:CashPeriodIncreaseDecrease>
    <AEMD:DebtDiscountOnConvertibleNotesPayable contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">75994</AEMD:DebtDiscountOnConvertibleNotesPayable>
    <AEMD:DebtDiscountOnConvertibleNotesPayable contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">0</AEMD:DebtDiscountOnConvertibleNotesPayable>
    <AEMD:IssuanceOfSharesUnderVestedRestrictedStockUnits contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">30</AEMD:IssuanceOfSharesUnderVestedRestrictedStockUnits>
    <AEMD:IssuanceOfSharesUnderVestedRestrictedStockUnits contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">0</AEMD:IssuanceOfSharesUnderVestedRestrictedStockUnits>
    <AEMD:ReclassificationOfAccruedInterestToConvertibleNotesPayable contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">85031</AEMD:ReclassificationOfAccruedInterestToConvertibleNotesPayable>
    <AEMD:ReclassificationOfAccruedInterestToConvertibleNotesPayable contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">0</AEMD:ReclassificationOfAccruedInterestToConvertibleNotesPayable>
    <AEMD:CashlessExerciseOfWarrants contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">3</AEMD:CashlessExerciseOfWarrants>
    <AEMD:CashlessExerciseOfWarrants contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">5</AEMD:CashlessExerciseOfWarrants>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2016-04-01to2016-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;ORGANIZATION&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;Aethlon Medical, Inc. and subsidiary&#13;(&amp;#34;Aethlon&amp;#34;, the &amp;#34;Company&amp;#34;, &amp;#34;we&amp;#34; or &amp;#34;us&amp;#34;) is a medical device company focused on creating&#13;innovative devices that address unmet medical needs in cancer, infectious disease and other life-threatening conditions. At the&#13;core of our developments is the Aethlon ADAPT&amp;#8482; (Adaptive Dialysis-Like Affinity Platform Technology) system, a medical device&#13;platform that converges single or multiple affinity drug agents with advanced plasma membrane technology to create therapeutic&#13;filtration devices that selectively remove harmful particles from the entire circulatory system without loss of essential blood&#13;components. On June 25, 2013, the United States Food and Drug Administration (FDA) approved an Investigational Device Exemption&#13;(IDE) that allows us to initiate human feasibility studies of the Aethlon Hemopurifier&amp;#174; in the U.S. Under the feasibility&#13;study protocol, we plan to enroll ten end-stage renal disease patients who are infected with the Hepatitis C virus (HCV) to demonstrate&#13;the safety of Hemopurifier therapy. Successful completion of this study will allow us the opportunity to initiate pivotal studies&#13;that are required for market clearance to treat HCV and other disease conditions in the U.S.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;Successful outcomes of human trials&#13;will also be required by the regulatory agencies of certain foreign countries where we intend to sell this device. Some of our&#13;patents may expire before FDA approval or approval in a foreign country, if any, is obtained. However, we believe that certain&#13;patent applications and/or other patents issued more recently will help protect the proprietary nature of the Hemopurifier(R)&#13;treatment technology.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;In October 2013, our majority owned&#13;subsidiary, Exosome Sciences, Inc. (&amp;#8220;ESI&amp;#8221;), commenced operations with a focus on advancing exosome-based strategies&#13;to diagnose and monitor the progression of cancer, infectious disease and other life-threatening conditions.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;ESI is accounted for as a non-controlling&#13;interest as the Company has an 80% ownership interest in the subsidiary. Earnings or losses attributable to other stockholders&#13;of a consolidated affiliated company are classified separately as &amp;#34;noncontrolling interest&amp;#34; in the Company's consolidated&#13;statements of operations. Net loss attributable to noncontrolling interest reflects only its share of the after-tax earnings or&#13;losses of an affiliated company. Income taxes attributable to noncontrolling interest are determined using the applicable statutory&#13;tax rates in the jurisdictions where such operations are conducted. The Company's consolidated balance sheets reflect noncontrolling&#13;interests within the equity section of the consolidated balance sheets.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;Our common stock is traded on the&#13;Nasdaq Capital Market under the symbol &amp;#8220;AEMD.&amp;#8221;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING&#13;POLICIES&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;During the six months ended September&#13;30, 2016, there have been no changes to our significant accounting policies as described in our Annual Report on Form 10-K for&#13;the fiscal year ended March 31, 2016.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;The accompanying&#13;unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally&#13;accepted accounting principles (GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10&#13;of the Securities and Exchange Commission (SEC) Regulation S-X. Accordingly, they should be read in conjunction with the&#13;audited financial statements and notes thereto for the year ended March 31, 2016, included in the Company's Annual Report on&#13;Form 10-K filed with the SEC on June 29, 2016. The accompanying unaudited condensed consolidated financial statements include&#13;the accounts of Aethlon Medical, Inc. and its majority-owned subsidiary. All significant inter-company transactions and&#13;balances have been eliminated in consolidation. The unaudited condensed consolidated financial statements contain all normal&#13;recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the condensed&#13;consolidated balance sheet of the Company at September 30, 2016, the condensed consolidated statements of operations for the&#13;three and six months ended September 30, 2016, and the condensed consolidated statement of cash flows for the six months&#13;ended September 30, 2016. Estimates were made relating to useful lives of fixed assets, valuation allowances, the fair value&#13;of warrants, impairment of assets, share-based compensation expense and accruals for clinical trial and research and&#13;development expenses. Actual results could differ materially from those estimates. Certain amounts previously reported in the&#13;financial statements have been reclassified to conform to the current presentation. Such reclassifications did not affect net&#13;loss, equity or cash flows. The accompanying condensed consolidated balance sheet at March 31, 2016 has been derived from the&#13;audited consolidated balance sheet at March 31, 2016, contained in the above referenced 10-K. The results of operations for&#13;the three and six months ended September 30, 2016 are not necessarily indicative of the results to be expected for the full&#13;year or any future interim periods.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;On April 14, 2015, we completed a&#13;1-for-50 reverse stock split. Accordingly, authorized common stock was reduced from 500,000,000 shares to 10,000,000 shares, and&#13;each 50 shares of outstanding common stock held by stockholders were combined into one share of common stock. The accompanying&#13;condensed consolidated financial statements and accompanying notes have been retroactively revised to reflect such reverse stock&#13;split as if it had occurred on April 1, 2015. All share and per share amounts have been revised accordingly.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;On March 31, 2016, we filed a Certificate&#13;of Amendment to our Articles of Incorporation to increase our authorized common stock from 10,000,000 to 30,000,000 shares. Our&#13;stockholders approved the amendment at our annual meeting of stockholders held on March 29, 2016.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;LIQUIDITY AND GOING CONCERN&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;The accompanying condensed consolidated&#13;financial statements have been prepared assuming that we will continue as a going concern, which contemplates, among other things,&#13;the realization of assets and satisfaction of liabilities in the ordinary course of business. We have incurred continuing losses&#13;from operations and at September 30, 2016 had limited working capital and an accumulated deficit of approximately $90,887,000.&#13;These factors, among other matters, raise substantial doubt about our ability to continue as a going concern. A significant amount&#13;of additional capital will be necessary to advance the development of our products to the point at which they may become commercially&#13;viable. We intend to fund operations, working capital and other cash requirements for the twelve month period subsequent to September&#13;30, 2016 through debt and/or equity financing arrangements as well as through revenues and related cash receipts under our government&#13;contracts (see Note 11).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;We are currently addressing our liquidity&#13;issue by seeking additional investment capital through issuances of common stock under our existing S-3 registration statement&#13;and by applying for grants issued by government agencies in the United States. We believe that our cash on hand and funds expected&#13;to be received from additional debt and equity financing arrangements will be sufficient to meet our liquidity needs for the twelve&#13;month period through September 30, 2017. However, no assurance can be given that we will receive any funds in addition to the&#13;funds we have received to date (see Note 14).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;The successful outcome of future activities&#13;cannot be determined at this time and there is no assurance that, if achieved, we will have sufficient funds to execute our intended&#13;business plan or generate positive operating results.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;The consolidated financial statements&#13;do not include any adjustments related to this uncertainty and as to the recoverability and classification of asset carrying amounts&#13;or the amount and classification of liabilities that might result should the Company be unable to continue as a going concern.&lt;/font&gt;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2016-04-01to2016-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;Basic loss per share is computed by&#13;dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period&#13;of computation. The weighted average number of common shares outstanding for the three and six months ended September 30, 2016&#13;includes 184,500 vested restricted stock units that have not yet been issued. Diluted loss per share is computed similar to basic&#13;loss per share except that the denominator is increased to include the number of additional common shares that would have been&#13;outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses&#13;for all periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded&#13;as their effect would be antidilutive.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;As of September 30, 2016 and 2015,&#13;a total of 3,289,606 and 2,773,483 potential common shares, consisting of shares underlying outstanding stock options, warrants,&#13;unvested restricted stock units and convertible notes payable were excluded as their inclusion would be antidilutive.&lt;/font&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="From2016-04-01to2016-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;Our research and development costs&#13;are expensed as incurred. We incurred research and development expenses during the three and six month periods ended September&#13;30, 2016 and 2015, which are included in various operating expense line items in the accompanying condensed consolidated statements&#13;of operations. Our research and development expenses in those periods were as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;September 30,&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;September 30,&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="width: 66%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;Three months ended&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 13%; border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;280,860&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 13%; border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;207,676&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;Six months ended&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;377,843&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;424,267&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="From2016-04-01to2016-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;During the six months ended September&#13;30, 2016, we adopted Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) Accounting Standards Update (&amp;#8220;ASU&amp;#8221;)&#13;2015-03, the new accounting standard on imputation of interest, simplifying the presentation of debt issuance costs. As a result&#13;of the adoption of that pronouncement, our deferred financing costs at March 31, 2016 were reclassified from current assets to&#13;an offset against our convertible notes.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;Management is evaluating significant&#13;recent accounting pronouncements that are not yet effective for us, including the new accounting standard on improvements to employee&#13;share based payment accounting, ASU 2016-09 (Topic 718), the new accounting standard related to leases, ASU 2016-02 (Topic 842),&#13;the new accounting standard for recognition and measurement of financial assets and financial liabilities, ASU 2016-01, the new&#13;accounting standard on extraordinary and unusual items on income statements, ASU 2015-01, the new accounting standard related&#13;to presentation of financial statements - going concern qualifications, ASU 2014-15, and the new accounting standard on revenue&#13;recognition, ASU 2014-09 (Topic 606), and have not yet concluded whether any such pronouncements will have a significant effect&#13;on our future consolidated financial statements.&lt;/font&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2016-04-01to2016-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Common Stock Sales Agreement with&#13;H.C. Wainwright&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;On June 28, 2016, we entered into&#13;a Common Stock Sales Agreement (the &amp;#8220;Agreement&amp;#8221;) with H.C. Wainwright &amp;#38; Co., LLC (&amp;#8220;H.C. Wainwright&amp;#8221;)&#13;which establishes an at-the-market equity program pursuant to which we may offer and sell shares of our common stock from time&#13;to time as set forth in the Agreement. The Agreement provides for the sale of shares of our common stock having an aggregate offering&#13;price of up to $12,500,000 (the &amp;#8220;Shares&amp;#8221;).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;Subject to the terms and conditions&#13;set forth in the Agreement, H.C. Wainwright will use its commercially reasonable efforts consistent with its normal trading and&#13;sales practices to sell the Shares from time to time, based upon our instructions. We have provided H.C. Wainwright with customary&#13;indemnification rights, and H.C. Wainwright will be entitled to a commission at a fixed rate equal to three percent (3.0%) of&#13;the gross proceeds per Share sold. In addition, we have agreed to pay certain expenses incurred by H.C. Wainwright in connection&#13;with the Agreement, including up to $50,000 of the fees and disbursements of their counsel. The Agreement will terminate upon&#13;the sale of all of the Shares under the Agreement unless terminated earlier by either party as permitted under the Agreement (see&#13;Note 14).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;Sales of the Shares, if any, under&#13;the Agreement shall be made in transactions that are deemed to be &amp;#8220;at the market offerings&amp;#8221; as defined in Rule 415&#13;under the Securities Act, including sales made by means of ordinary brokers&amp;#8217; transactions, including on the Nasdaq Capital&#13;Market, at market prices or as otherwise agreed with H.C. Wainwright. We have no obligation to sell any of the Shares, and, at&#13;any time, we may suspend offers under the Agreement or terminate the Agreement.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;In July 2016, we commenced sales of&#13;common stock under our Common Stock Sales Agreement with H.C. Wainwright. In the three months ended September 30, 2016, we had&#13;raised net proceeds of $266,612 (net of $8,348 in commissions to H.C. Wainwright and $3,319 in other offering expenses) utilizing&#13;the sales agreement through the sale of 50,163 shares at an average price of $5.31 per share of net proceeds.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Warrant Issuances in July 2016&#13;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;In July 2016, we issued an aggregate&#13;of 2,660 shares of common stock to three investors upon the exercise of previously issued warrants. The warrants were exercised&#13;on a cashless or &amp;#8220;net&amp;#8221; basis. Accordingly, we did not receive any proceeds from such exercises. The cashless exercise&#13;of such warrants resulted in the cancellation of previously issued warrants to purchase an aggregate of 19,563 shares of common&#13;stock.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Restricted Stock Unit Grants to&#13;Directors and Executive Officers&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;During the three months ended September&#13;30, 2016, 30,131 Restricted Stock Units (&amp;#8220;RSUs&amp;#8221;) held by our outside directors were exchanged into the same number&#13;of shares of our common stock (see Note 9).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Amendment of November 2014 10%&#13;Convertible Notes&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;Under the Second Amendment&#13;and Extension of the November 2014 10% Convertible  Notes dated June 27, 2016 (See Note 5), we reduced the purchase price of&#13;47,125 Warrants from $8.40 per share to $5.00 per share. &amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;We also issued to the investors new&#13;warrants to purchase an aggregate of 30,000 shares of common stock with a purchase price of $5.00 per share of common stock. We&#13;issued the new warrants in substantially the same form as the prior Warrants, and the new warrants will expire on November 6,&#13;2019, the same date on which the prior warrants will expire (See Note 5).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Amendment of December 2014 Warrants&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;On June 27, 2016, we and certain investors&#13;(the &amp;#8220;Unit Investors&amp;#8221;) entered into Consent and Waiver and Amendment agreements (the &amp;#8220;CWAs&amp;#8221;), relating&#13;to an aggregate of 264,000 Warrants to Purchase Common Stock (the &amp;#8220;Unit Warrants&amp;#8221;) we had issued to the Unit Investors&#13;on December 2, 2014 pursuant to a Securities Purchase Agreement dated November 26, 2014 (the &amp;#8220;2014 SPA&amp;#8221;). In the CWAs,&#13;each of the Unit Investors provided its consent under certain restrictive provisions, and waived certain rights, including a right&#13;to participate in certain offerings made by us, under the 2014 SPA in order to facilitate the at-the-market equity program described&#13;above. Pursuant to the CWAs, we reduced the Exercise Price (as defined in the Unit Warrants) from $15.00 per share of common stock&#13;to $5.00 per share of common stock. At any time that the shares of common stock underlying the Unit Warrants are covered by an&#13;effective registration statement that permits the public resale of the shares, if the Unit Investors exercise the Unit Warrants,&#13;they must do so by a cash exercise, which could yield up to $1,320,000 in proceeds to us.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;On June 27, 2016, each of the Unit&#13;Investors also entered into a Consent and Waiver providing its consent under certain provisions, and waiving certain rights, including&#13;a right to participate in certain offerings made by us, under the 2015 SPA in order to facilitate the at-the market equity program&#13;described above.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;In accordance with GAAP, we measured&#13;the change in fair value that arose from the reduction in exercise price and recognized an expense of $345,841, which is included&#13;in other expenses in the accompanying condensed consolidated statements of operations.&lt;/font&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2016-04-01to2016-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;Convertible Notes Payable consisted&#13;of the following at September 30, 2016:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Principal&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Unamortized&#13;    &lt;/font&gt;&lt;font style="font-size: 8pt"&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;Discount&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Net&#13;    &lt;/font&gt;&lt;font style="font-size: 8pt"&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;Amount&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Accrued&#13;    &lt;/font&gt;&lt;font style="font-size: 8pt"&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;Interest&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Convertible Notes&#13;    Payable &amp;#8211; Current Portion:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="width: 49%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;November 2014 10% Convertible&#13;    Notes&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1pt solid"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;662,811&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1pt solid"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(56,996&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1pt solid"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;605,815&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1pt solid"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;17,486&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Total Convertible&#13;    Notes Payable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;662,811&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(56,996&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;605,815&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;17,486&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;During the six months ended September&#13;30, 2016, we recorded interest expense of $30,794 related to the contractual interest rates of our convertible notes, interest&#13;expense of $27,641 related to the amortization of deferred financing costs and interest expense of $18,998 related to the amortization&#13;of the note discount for a total interest expense of $77,433 related to our convertible notes in the six months ended September&#13;30, 2016. All of the unamortized discount at September 30, 2016 related to the note discount established upon the second amendment&#13;to the notes (see below).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;Convertible Notes Payable consisted&#13;of the following at March 31, 2016 (our most recent fiscal year end):&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;Principal&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;Unamortized &lt;br /&gt; Discount&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;Net &lt;br /&gt; Amount&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;Accrued &lt;br /&gt; Interest&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;Convertible Notes Payable &amp;#8211; Non-Current Portion:&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="width: 48%; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;November 2014 10% Convertible Notes&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;527,780&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(27,641&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;500,139&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;74,036&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;Total Convertible Notes Payable&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;527,780&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(27,641&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;500,139&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;74,036&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;The above table shows the retroactive&#13;application of $27,641 in note discounts representing the deferred financing costs of that same amount on March 31, 2016 due to&#13;the application of related to the application of the new accounting standard ASU 2015-03. All of the unamortized discount at March&#13;31, 2016 related to the deferred financing costs noted above.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;During the six months ended September&#13;30, 2015, we recorded interest expense of $26,390 related to the contractual interest rates of our convertible notes, interest&#13;expense of $186,276 related to the amortization of debt discount and interest expense of $39,441 related to the amortization of&#13;deferred financing costs for a total interest expense of $252,107 related to our convertible notes in the six months ended September&#13;30, 2015.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;NOVEMBER 2014 10% CONVERTIBLE NOTES&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;In November 2014, we entered into&#13;a subscription agreement with two accredited investors providing for the issuance and sale of (i) convertible promissory notes&#13;in the aggregate principal amount of $527,780 (the &amp;#8220;Notes&amp;#8221;) and (ii) five year warrants to purchase up to 47,125 shares&#13;of common stock at a fixed exercise price of $8.40 per share (the &amp;#8220;Warrants&amp;#8221;). These Notes bear interest at the annual&#13;rate of 10% and originally matured on April 1, 2016.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;The aggregate gross cash proceeds&#13;to us were $415,000 after subtracting legal fees of $35,000, a $27,780 due diligence fee and an original issuance discount of&#13;$50,000. We recorded deferred financing costs of $112,780 to reflect the legal fees, due diligence fee and original issuance discount&#13;and will amortize those costs over the life of the Notes using the effective interest method.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;These Notes are convertible at the&#13;option of the holders into shares of our common stock at a fixed price of $5.60 per share, for up to an aggregate of 94,246 shares&#13;of common stock. There are no registration requirements with respect to the shares of common stock underlying the Notes or the&#13;Warrants.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;The estimated relative fair value&#13;of Warrants issued in connection with the Notes was recorded as a debt discount and is amortized as additional interest expense&#13;over the term of the underlying debt. We recorded debt discount of $240,133 based on the relative fair value of these Warrants.&#13;In addition, as the effective conversion price of the Notes was less than market price of the underlying common stock on the date&#13;of issuance, we recorded an additional debt discount of $287,647 related to the beneficial conversion feature.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Initial Amendment of the November&#13;2014 10% Convertible Note Terms&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;On November 12, 2015, we entered into&#13;an amendment of terms (&amp;#8220;Amendment of Terms&amp;#8221;) with the two investors that participated in the November 2014 10% Convertible&#13;Notes. The Amendment of Terms modified the terms of the subscription agreement, Notes and Warrants held by those investors to,&#13;among other things, extended the maturity date of the Notes from April 1, 2016 to June 1, 2016, temporarily reduced the number&#13;of shares that we must reserve with respect to conversion of the Notes, and temporarily suspended the time period during which&#13;one of the investors may exercise its Warrants. In exchange for the investors&amp;#8217; agreements in the Amendment of Terms, we&#13;paid one of the investors a cash fee of $90,000, which we recorded as deferred financing costs and amortized over the remaining&#13;term of the notes.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Second Amendment and Extension&#13;of the November 2014 10% Convertible Notes&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;On June 27, 2016, we and certain investors&#13;entered into further Amendments (the &amp;#8220;Amendments&amp;#8221;) to the Notes and the Warrants. The Amendments provide that the&#13;Maturity Date (as defined in the Notes) was extended from June 1, 2016 to July 1, 2017 and that the conversion price per share&#13;of the Notes was reduced from $5.60 per share of common stock to $5.00 per share of common stock. In addition, we reduced the&#13;purchase price (as defined in the Warrants) from $8.40 per share to $5.00 per share of common stock. In connection with these&#13;modifications, each of the investors signed a Consent and Waiver providing its consent under certain restrictive provisions, and&#13;waiving certain rights, including a right to participate in certain offerings made by us, under a Securities Purchase Agreement&#13;dated June 23, 2015, (the &amp;#8220;2015 SPA&amp;#8221;) to which we, the investors and certain other investors are parties, in order&#13;to facilitate an at-the-market equity program (see Note 6).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;The Amendments also increase the principal&#13;amount of the Notes to $692,811 (in the aggregate) to (i)&amp;#160;include accrued and unpaid interest through June 15, 2016, and&#13;(ii) increase the principal amount by $80,000 (in the aggregate) as an extension fee for the extended maturity date of the Notes.&#13;With respect to each Note, we entered into an Allonge to Convertible Promissory Note (each, an &amp;#8220;Allonge&amp;#8221;) reflecting&#13;the changes in the principal amount, Maturity Date and conversion price of the Note.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;We also issued to the investors new&#13;warrants (the &amp;#8220;New Warrants&amp;#8221;) to purchase an aggregate of 30,000 shares of common stock with a Purchase Price (as&#13;defined in the New Warrants) of $5.00 per share of common stock. We issued the New Warrants in substantially the same form as&#13;the prior Warrants, and the New Warrants will expire on November 6, 2019, the same date on which the prior Warrants will expire.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;The modification of the Notes was&#13;evaluated under FASB Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) Topic No. 470-50-40, &amp;#8220;Debt Modification and Extinguishments&amp;#8221;.&#13;Therefore, according to the guidance, the instruments were determined to be substantially different, and the transaction qualified&#13;for extinguishment accounting. As a result, we recorded a loss on debt extinguishment of $536,889 and recognized and an extension&#13;fee expense of $80,000, which are included in other expenses in the accompanying condensed consolidated statements of operations.&#13;The debt extinguishment is comprised from the fair value of prior warrants issued in connection with the Notes of $287,676, as&#13;well as $325,206 related to beneficial conversion feature and offset by debt discount of $75,993. The beneficial conversion feature&#13;is a result of the effective conversion price of the new Notes being less than the market price of the underlying common stock&#13;on the date of modification.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;The following table shows the changes&#13;to the principal balance of the November 2014 10% Convertible Notes:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="5" style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Activity&#13;    in the November 2014 10% Convertible Notes &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="width: 84%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Initial principal balance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;527,780&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Increase in principal balance under the second&#13;    amendment (see above)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;165,031&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Conversions during the six months ended September&#13;    30, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(30,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Balance as of September 30, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;662,811&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&lt;/font&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2016-04-01to2016-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;DUE TO RELATED PARTIES&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;Historically, certain of our officers&#13;and other related parties have advanced us funds, agreed to defer compensation and/or paid expenses on our behalf to cover working&#13;capital deficiencies. There were no such related party transactions during the fiscal year ended March 31, 2016 except that we&#13;had accrued unpaid Board fees of $86,000 owed to our outside directors as of March 31, 2016. At September 30, 2016, we had unpaid&#13;Board fees of $28,250.&lt;/font&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2016-04-01to2016-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;Other current liabilities were comprised&#13;of the following items:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;September 30,&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;March 31,&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="width: 66%; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;Accrued interest&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;17,486&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;74,038&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;Other accrued liabilities&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;17,830&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;62,657&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;Total other current liabilities&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;35,316&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;136,695&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2016-04-01to2016-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;The following tables summarize share-based&#13;compensation expenses relating to Restricted Stock Units (&amp;#8220;RSU&amp;#8221;s) and options granted and the effect on basic and&#13;diluted loss per common share during the three and six month periods ended September 30, 2016 and 2015:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;Three Months &lt;br /&gt;&#13;    Ended &lt;br /&gt; September 30, &lt;br /&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;Three Months&lt;br /&gt; Ended&lt;br /&gt;&#13;    September 30, &lt;br /&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;Six Months &lt;br /&gt; Ended&#13;    &lt;br /&gt; September 30,&lt;br /&gt; 2016&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;Six Months&lt;br /&gt; Ended&#13;    &lt;br /&gt;September 30,&lt;br /&gt; 2015&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="width: 40%; text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;Vesting of stock options and restricted&#13;    stock units&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 11%; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,523,280&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 11%; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;50,711&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 11%; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,573,991&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 11%; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;101,421&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,523,280&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;50,711&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,573,991&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;101,421&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;Weighted average number of common shares&#13;    outstanding &amp;#8211; basic and diluted&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;7,756,883&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;7,610,459&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;7,690,369&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;7,167,903&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;Basic and diluted loss per common share&#13;    attributable to stock-based compensation expense&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(0.20&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(0.01&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(0.20&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(0.01&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;All of the stock-based compensation&#13;expense recorded during the six months ended September 30, 2016 and 2015, which totaled $1,573,991 and $101,421, respectively,&#13;is included in payroll and related expense in the accompanying condensed consolidated statements of operations.&amp;#160; Stock-based&#13;compensation expense recorded during the six months ended September 30, 2016 and 2015  represented an impact on basic and diluted&#13;loss per common share of $(0.20) in both periods.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;We review share-based compensation&#13;on a quarterly basis for changes to the estimate of expected award forfeitures based on actual forfeiture experience. The cumulative&#13;effect of adjusting the forfeiture rate for all expense amortization is recognized in the period the forfeiture estimate is changed.&#13;The effect of forfeiture adjustments for the six months ended September 30, 2016 was insignificant.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Restricted Stock Unit Grants to&#13;Directors and Executive Officers&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;On August 9, 2016, our Board of Directors&#13;(the &amp;#8220;Board&amp;#8221;) granted RSUs to certain of our officers and directors as set forth below. The RSUs represent the right&#13;to be issued on a future date shares of our common stock for vested RSUs. Our Compensation Committee recommended the grants based&#13;on a compensation assessment provided by a third-party compensation consulting firm engaged by us that developed a peer group&#13;of companies for market assessment and analyzed compensation at such companies.&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;The consultant recommended beneficial&#13;ownership targets, which we previously disclosed in our Proxy Statement filed on February 23, 2016, in connection with our Annual&#13;Meeting of Stockholders held on March 29, 2016. In connection with the Annual Meeting, our stockholders approved our Amended 2010&#13;Stock Incentive Plan, which included an increase in the number of shares available for grant under the plan in part to accommodate&#13;equity awards recommended by the Compensation Committee, and our stockholders approved our executive compensation as disclosed&#13;in the Proxy Statement pursuant to Item 402 paragraphs (m) through (q) of Regulation S-K.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;To Mr. James A. Joyce, an aggregate&#13;of 634,000 RSUs valued at $6.28 per share, based on the August 9, 2016 closing price of the common stock. 158,500 of the RSUs&#13;are deemed vested upon grant and an additional 39,625 RSUs will vest each quarter beginning on January 1, 2017. This grant is&#13;intended to increase Mr. Joyce&amp;#8217;s beneficial ownership of our common stock to 9.0%, which target was recommended in 2015&#13;and in June 2016 by the compensation consultant engaged by us. Previously, in 2004, the Board had approved a beneficial ownership&#13;target of 15% for Mr. Joyce. However, Mr. Joyce has agreed to the modified target of 9.0%.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;To Mr. Rodney S. Kenley, an aggregate&#13;of 52,000 RSUs valued at $6.28 per share, based on the August 9, 2016 closing price of the common stock. 13,000 of the RSUs are&#13;deemed vested upon grant and an additional 3,250 RSUs will vest each quarter beginning on January 1, 2017.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;To Mr. James B. Frakes, an aggregate&#13;of 52,000 RSUs valued at $6.28 per share, based on the August 9, 2016 closing price of the common stock. 13,000 of the RSUs are&#13;deemed vested upon grant and an additional 3,250 RSUs will vest each quarter beginning on January 1, 2017.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;To each of our non-employee directors,&#13;Mr. Franklyn S. Barry, Jr., Mr. Edward G. Broenniman and Dr. Chetan S. Shah, 16,432 RSUs valued at an aggregate of $105,000, based&#13;on the average of the closing prices of the common stock for the five trading days preceding and including August 9, 2016. These&#13;grants represent (a) $70,000 worth of RSUs representing two years of grants under the amended 2012 Non-Employee Directors Compensation&#13;Program (the &amp;#8220;2012 Program&amp;#8221;) because more than two years have elapsed since Messrs. Barry and Broenniman and Dr. Shah&#13;received grants under the program, all of which RSUs are deemed vested upon grant and (b) $35,000 worth of RSUs representing the&#13;grant covering the fiscal year ending March 31, 2017, of which one-quarter are deemed vested upon grant and the remaining portion&#13;will vest ratably at September 30, 2016, at December 31, 2016 and at March 31, 2017.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;The RSUs were granted under our Amended&#13;2010 Stock Incentive Plan and we recorded expense of $1,523,280 in the three months ended September 30, 2016 related to the RSU&#13;grants.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Changes to 2012 Non-Employee Directors&#13;Compensation Program&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;In July 2012, the Board approved the&#13;2012 Program, which modified and superseded the 2005 Directors Compensation Program that had been in effect previously. On June&#13;6, 2014, the Board approved certain changes to the 2012 Program, and on August 9, 2016, the Board approved further modifications&#13;to the program. Under the modified 2012 Program, in which only non-employee directors may participate, a new eligible director&#13;will receive an initial grant of $50,000 worth of RSUs or, at the discretion of the Board, options to acquire shares of Common&#13;Stock. RSUs granted under this provision will be valued based on the average of the closing prices of the Common Stock for the&#13;five trading days preceding and including the date of grant and will vest at a rate determined by the Board in its discretion.&#13;Options granted under this provision will be valued at the exercise price, which will be based on the average of the closing prices&#13;of the Common Stock for the five trading days preceding and including the date of grant. Such options will have a term of ten&#13;years and will vest at a rate determined by the Board in its discretion.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;At the beginning of each fiscal year,&#13;each existing director eligible to participate in the 2012 Program will receive a grant of $35,000 worth of RSUs or, at the discretion&#13;of the Board, options to acquire shares of Common Stock. RSUs granted under this provision will be valued based on the average&#13;of the closing prices of the Common Stock for the five trading days preceding and including the first day of the fiscal year (or&#13;preceding and including the date of grant, if such grant is not made on the first day of the fiscal year) and will vest at a rate&#13;determined by the Board in its discretion. Options granted under this provision will be valued at the exercise price, which will&#13;be based on the average of the closing prices of the Common Stock for the five trading days preceding and including the first&#13;day of the fiscal year (or preceding and including the date of grant, if such grant is not made on the first day of the fiscal&#13;year). Such options will have a term of ten years and will vest at a rate determined by the Board in its discretion.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;In lieu of per meeting fees,&#13;under the 2012 Program eligible directors will receive an annual Board retainer fee of $30,000. The modified 2012 Program&#13;also provides for the following annual retainer fees: Audit Committee Chair - $5,000, Compensation Committee chair - $5,000,&#13;Nominating Committee Chair - $5,000, Audit Committee member - $4,000, Compensation Committee member - $4,000 and Lead&#13;independent director (currently an open position) - $15,000.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;The RSU grants and the changes to&#13;the 2012 Program were approved and recommended by our Compensation Committee prior to approval by the Board.&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;RSUs outstanding that have vested&#13;and are expected to vest as of September 30, 2016 are as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;Number&#13;    of RSUs&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="width: 33%"&gt;&lt;font style="font-size: 8pt"&gt;Vested&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;184,500&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;Expected to vest&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;561,708&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;746,208&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;During the three months ended September&#13;30, 2016, 30,131 RSUs held by our outside directors were exchanged into the same number of shares of our common stock. As two&#13;of our three outside directors elected to return 40% of their RSU&amp;#8217;s in exchange for cash in order to pay their withholding&#13;taxes on the share issuances, 10,957 of the RSUs were cancelled and we paid a total of $67,343 in cash to those two outside directors.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Stock Option Activity&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;There were no stock option grants&#13;during the six months ended September 30, 2016 or September 30, 2015.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;Options outstanding that have vested&#13;and are expected to vest as of September 30, 2016 are as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number&#13;    of&lt;/b&gt;&lt;/font&gt;&lt;font style="font-size: 8pt"&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;font style="font-size: 8pt"&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;font style="font-size: 8pt"&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Term in&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Years&lt;/b&gt;&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="width: 58%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;417,047&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;11.20&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;4.77&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Expected to vest&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;17,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;7.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;434,547&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;There was no stock option activity&#13;during the six months ended September 30, 2016 other than the expiration of 4,000 stock options during the period.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;On September 30, 2016, our stock options&#13;had no intrinsic value since the closing price on that date of $5.02 per share was below the weighted average exercise price of&#13;our stock options.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;At September 30, 2016, there was approximately&#13;$3,509,367 of unrecognized compensation cost related to share-based payments, which is expected to be recognized over a weighted&#13;average period of 2.87 years.&lt;/font&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="From2016-04-01to2016-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;During the six months ended September&#13;30, 2016, we issued 30,000 warrants with an exercise price of $5.00 per share.&amp;#160;Those warrants were issued in connection with&#13;the Amendment of November 2014 Investment Documents (see Note 6).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;A summary of warrant activity during&#13;the six months ended September 30, 2016 is presented below:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Range&#13;    of&lt;/b&gt;&lt;/font&gt;&lt;font style="font-size: 8pt"&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;font style="font-size: 8pt"&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="width: 58%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Warrants outstanding at March&#13;    31, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2,164,094&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$2.10 -&#13;    $15.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;6.68&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(2,660&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$6.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;6.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Issued&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;30,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$5.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Cancelled/Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(19,563&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$6.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;6.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Warrants outstanding at September 30, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2,171,871&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$2.10&#13;    - $15.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5.37&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Warrants exercisable at September 30, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2,171,871&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$2.10&#13;    - $15.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5.37&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;The following outlines the significant&#13;weighted average assumptions used to estimate the fair value information presented, with respect to warrants utilizing the Binomial&#13;Lattice option pricing models at, and during the six months ended September 30, 2016:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="width: 70%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Risk free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 30%; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.70%&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: White"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Average expected life&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;3.5 years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(238,238,238)"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Expected volatility&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;91.5%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: White"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Expected dividends&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;None&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;The expected volatility was based&#13;on the historic volatility. The expected life of options granted was based on the &amp;#34;simplified method&amp;#34; as described in&#13;the SEC's guidance due to changes in the vesting terms and contractual life of current option grants compared to our historical&#13;grants.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;Based on the above assumptions, we&#13;valued the 30,000 new warrants issued during the six months ended September 30, 2016 at $111,900 and classified that fair value&#13;as equity.&lt;/font&gt;&lt;/p&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2016-04-01to2016-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;We entered into a contract with&#13;the Defense Advanced Research Projects Agency or, DARPA, on September 30, 2011. Under the DARPA award, we have been engaged to&#13;develop a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection that often results in the death&#13;of combat-injured soldiers. The award from DARPA was a fixed-price contract with potential total payments to us of $6,794,389&#13;over the course of five years. Fixed price contracts require the achievement of multiple, incremental milestones to receive&#13;the full award during each year of the contract. Under the terms of the contract, we performed certain incremental work&#13;towards the achievement of specific milestones against which we invoiced the government for fixed payment amounts.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;Originally, only the base year (year&#13;one of the contract) was effective for the parties; however, DARPA subsequently exercised its option on the remaining years of&#13;the contract. The milestones were comprised of planning, engineering and clinical targets, the achievement of which in some cases&#13;required the participation and contribution of third party participants under the contract. We commenced work under the contract&#13;in October 2011.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;In February 2014, DARPA reduced the&#13;scope of our contract in years three through five of the contract. The reduction in scope focused our research on exosomes, viruses&#13;and blood processing instrumentation. This scope reduction reduced the possible payments under the contract by $858,469 over years&#13;three through five.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;In the six months ended September&#13;30, 2016, we invoiced the U.S. Government for the final two milestones under our DARPA contract in the aggregate amount of $387,438.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;The details of those milestones were&#13;as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;Milestone 2.6.1.3 - Quantify the degree&#13;to which the MERS virus can be extracted from circulation in vitro using miniature Hemopurifiers. The milestone payment was $193,719.&#13;Management considers this milestone to be substantive as it was not dependent on the passage of time nor was it based solely on&#13;another party's efforts. We quantified the degree to which the MERS virus can be extracted from circulation in vitro using miniature&#13;Hemopurifiers. The report was accepted by the contracting officer's representative and the invoice was submitted thereafter.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;Milestone 2.6.1.4 &amp;#8211; Prepare&#13;and present Final Report for DARPA. The milestone payment was $193,719. Management considers this milestone to be substantive&#13;as it was not dependent on the passage of time nor was it based solely on another party's efforts. We prepared and presented the&#13;Final Report for DARPA. The report was accepted by the contracting officer's representative and the invoice was submitted thereafter.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;In the six months ended September&#13;30, 2015, we invoiced the U.S. Government for two milestones under our DARPA contract in the amount of $372,328.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;The details of those milestones were&#13;as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;Milestone M6 &amp;#8211; Define Aethlon&amp;#8217;s&#13;GMP manufacturing process and revise and upgrade Aethlon&amp;#8217;s quality procedures and policies to the current state of the art.&#13;The milestone payment was $186,164. Management considers this milestone to be substantive as it was not dependent on the passage&#13;of time nor was it based solely on another party's efforts. We demonstrated that defined our GMP manufacturing process and that&#13;we revised and upgraded our quality procedures and policies to the current state of the art for a company of our size. The report&#13;was accepted by the contracting officer's representative and the invoice was submitted thereafter.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;Milestone 2.5.1.1 - Complete Aethlon&amp;#8217;s&#13;GMP procedure and establish and maintain all GMP documentation for the company. The milestone payment was $186,164. Management&#13;considers this milestone to be substantive as it was not dependent on the passage of time nor was it based solely on another party's&#13;efforts. We demonstrated that we completed our GMP procedures and established and maintained all GMP documentation for the company.&#13;The report was accepted by the contracting officer's representative and the invoice was submitted thereafter.&lt;/font&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2016-04-01to2016-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;We operate our businesses principally&#13;through two reportable segments: Aethlon, which represents our therapeutic business activities, and ESI, which represents our&#13;diagnostic business activities. Our reportable segments have been determined based on the nature of the potential products being&#13;developed. We record discrete financial information for ESI and our chief operating decision maker reviews ESI&amp;#8217;s operating&#13;results in order to make decisions about resources to be allocated to the ESI segment and to assess its performance.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;Aethlon&amp;#8217;s revenue is generated&#13;primarily from government contracts to date and ESI does not yet have any revenues. We have not included any allocation of corporate&#13;overhead to the ESI segment.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;The following tables set forth certain&#13;information regarding our segments:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;Six Months Ended September&#13;    30,&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Revenues:&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="width: 66%; padding-left: 10pt"&gt;&lt;font style="font-size: 8pt"&gt;Aethlon&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;392,073&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;380,874&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font-size: 8pt"&gt;ESI&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 8pt"&gt;Total Revenues&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;392,073&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;380,874&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;Operating Losses:&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 8pt"&gt;Aethlon&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(3,281,530&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(1,911,219&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font-size: 8pt"&gt;ESI&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(76,999&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(303,113&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 8pt"&gt;Total Operating Loss&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(3,358,529&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(2,214,332&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;Net Losses:&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 8pt"&gt;Aethlon&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(4,323,003&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(2,165,152&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font-size: 8pt"&gt;ESI&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(76,999&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(303,113&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 8pt"&gt;Net Loss Before Non-Controlling&#13;    Interests&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(4,400,002&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(2,468,265&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Cash:&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 8pt"&gt;Aethlon&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;553,884&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,208,554&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font-size: 8pt"&gt;ESI&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,468&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;802&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 8pt"&gt;Total Cash&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;556,352&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,209,356&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;Total Assets:&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 8pt"&gt;Aethlon&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;914,179&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,677,989&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font-size: 8pt"&gt;ESI&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;36,656&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;27,486&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 8pt"&gt;Total Assets&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;950,835&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,705,475&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;Capital Expenditures:&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 8pt"&gt;Aethlon&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,961&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font-size: 8pt"&gt;ESI&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 8pt"&gt;Capital Expenditures&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,961&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;Depreciation and Amortization:&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 8pt"&gt;Aethlon&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;10,822&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8,886&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font-size: 8pt"&gt;ESI&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;9,790&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;9,790&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 8pt"&gt;Total Depreciation and&#13;    Amortization&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;20,612&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;18,676&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;Interest Expense:&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 8pt"&gt;Aethlon&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(78,743&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(253,933&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font-size: 8pt"&gt;ESI&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 8pt"&gt;Total Interest Expense&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(78,743&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(253,933&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2016-04-01to2016-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;LEASE COMMITMENTS&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;We currently rent approximately 2,600&#13;square feet of executive office space at 9635 Granite Ridge Drive, Suite 100, San Diego, CA 92123 at the rate of $6,054 per month&#13;on a four-year lease that expires in January 2019. We also rent approximately 1,700 square feet of laboratory space at 11585 Sorrento&#13;Valley Road, Suite 109, San Diego, California 92121 at the rate of $4,394 per month on a one-year lease that was recently extended&#13;to an expiration date of November 30, 2017.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;Our Exosome Sciences, Inc. subsidiary&#13;previously rented approximately 2,055 square feet of office and laboratory space at 11 Deer Park Drive, South Brunswick, NJ at&#13;the rate of $3,917 per month on a one-year lease that expired in October 2015. In October 2015, ESI relocated to a different suite&#13;at the same office complex. That new suite was comprised of approximately 541 square feet of office and laboratory space and is&#13;located at 9 Deer Park Drive, South Brunswick, NJ at the rate of $1,352 per month under a month to month lease basis. In January&#13;2016, we exercised our 30-day notice to terminate the ESI lease in New Jersey as part of a consolidation of our laboratory operations&#13;in San Diego and the ESI lease was terminated effective February 29, 2016.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;Rent expense, which is included in&#13;general and administrative expenses, approximated $79,000 and $90,000 for the six month periods ended September 30, 2016 and 2015,&#13;respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;LEGAL MATTERS&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;From time to time, claims are made&#13;against us in the ordinary course of business, which could result in litigation. Claims and associated litigation are subject&#13;to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting&#13;us from selling one or more products or engaging in other activities.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;The occurrence of an unfavorable outcome&#13;in any specific period could have a material adverse effect on our results of operations for that period or future periods. We&#13;are not presently a party to any pending or threatened legal proceedings.&lt;/font&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2016-04-01to2016-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;Management has evaluated events subsequent&#13;to September 30, 2016 through the date that the accompanying condensed consolidated financial statements were filed with the Securities&#13;and Exchange Commission for transactions and other events which may require adjustment of and/or disclosure in such financial&#13;statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;In October 2016, we collected $193,719&#13;from DARPA. That amount had been invoiced to DARPA for the achievement of a milestone in September 2016 and was classified as&#13;an account receivable as of September 30, 2016.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;Subsequent to September 30, 2016,&#13;we continued selling common stock under our Common Stock Sales Agreement with H.C. Wainwright (see Note 6). Between the period&#13;of October 1, 2016 through November 8, 2016, we raised net proceeds of $61,265 (after deducting $1,919 in commissions to H.C.&#13;Wainwright and $799 in other offering expenses) utilizing the sales agreement through the sale of 13,261 shares at an average&#13;price of $4.62 per share of net proceeds.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;On October 5, 2016, we entered into&#13;an amendment of the lease for our laboratory space at 11585 Sorrento Valley Road, Suite 109, San Diego, California 92121. Pursuant&#13;to the amendment, the lease term will be extended to November 30, 2017 and the rent will be $4,394 per month.&lt;/font&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock contextRef="From2016-04-01to2016-09-30">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;September 30,&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;September 30,&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="width: 66%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;Three months ended&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 13%; border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;280,860&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 13%; border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;207,676&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;Six months ended&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;377,843&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;424,267&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock>
    <us-gaap:ConvertibleDebtTableTextBlock contextRef="From2016-04-01to2016-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;Convertible Notes Payable consisted&#13;of the following at September 30, 2016:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Principal&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Unamortized&#13;    &lt;/font&gt;&lt;font style="font-size: 8pt"&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;Discount&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Net&#13;    &lt;/font&gt;&lt;font style="font-size: 8pt"&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;Amount&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Accrued&#13;    &lt;/font&gt;&lt;font style="font-size: 8pt"&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;Interest&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Convertible Notes&#13;    Payable &amp;#8211; Current Portion:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="width: 49%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;November 2014 10% Convertible&#13;    Notes&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1pt solid"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;662,811&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1pt solid"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(56,996&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1pt solid"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;605,815&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1pt solid"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;17,486&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Total Convertible&#13;    Notes Payable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;662,811&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(56,996&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;605,815&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;17,486&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;Convertible Notes Payable consisted&#13;of the following at March 31, 2016 (our most recent fiscal year end):&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;Principal&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;Unamortized &lt;br /&gt; Discount&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;Net &lt;br /&gt; Amount&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;Accrued &lt;br /&gt; Interest&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;Convertible Notes Payable &amp;#8211; Non-Current Portion:&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="width: 48%; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;November 2014 10% Convertible Notes&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;527,780&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(27,641&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;500,139&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;74,036&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;Total Convertible Notes Payable&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;527,780&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(27,641&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;500,139&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;74,036&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&lt;/font&gt;&lt;/p&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:ScheduleOfDebtConversionsTextBlock contextRef="From2016-04-01to2016-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="5" style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Activity&#13;    in the November 2014 10% Convertible Notes &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="width: 84%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Initial principal balance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;527,780&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Increase in principal balance under the second&#13;    amendment (see above)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;165,031&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Conversions during the six months ended September&#13;    30, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(30,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Balance as of September 30, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;662,811&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfDebtConversionsTextBlock>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="From2016-04-01to2016-09-30">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;September 30,&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;March 31,&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="width: 66%; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;Accrued interest&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;17,486&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;74,038&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;Other accrued liabilities&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;17,830&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;62,657&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;Total other current liabilities&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;35,316&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;136,695&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="From2016-04-01to2016-09-30_us-gaap_RestrictedStockMember">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;Three Months &lt;br /&gt;&#13;    Ended &lt;br /&gt; September 30, &lt;br /&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;Three Months&lt;br /&gt; Ended&lt;br /&gt;&#13;    September 30, &lt;br /&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;Six Months &lt;br /&gt; Ended&#13;    &lt;br /&gt; September 30,&lt;br /&gt; 2016&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;Six Months&lt;br /&gt; Ended&#13;    &lt;br /&gt;September 30,&lt;br /&gt; 2015&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="width: 40%; text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;Vesting of stock options and restricted&#13;    stock units&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 11%; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,523,280&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 11%; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;50,711&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 11%; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,573,991&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 11%; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;101,421&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,523,280&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;50,711&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,573,991&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;101,421&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5pt; text-indent: -5pt"&gt;&lt;font style="font-size: 8pt"&gt;Weighted average number of common shares&#13;    outstanding &amp;#8211; basic and diluted&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;7,756,883&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;7,610,459&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;7,690,369&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;7,167,903&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5pt; text-indent: -5pt"&gt;&lt;font style="font-size: 8pt"&gt;Basic and diluted loss per common share&#13;    attributable to stock-based compensation expense&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(0.20&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(0.01&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(0.20&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(0.01&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock contextRef="From2016-04-01to2016-09-30_us-gaap_StockOptionMember">&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number&#13;    of&lt;/b&gt;&lt;/font&gt;&lt;font style="font-size: 8pt"&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;font style="font-size: 8pt"&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;font style="font-size: 8pt"&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Term in&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Years&lt;/b&gt;&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="width: 58%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;417,047&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;11.20&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;4.77&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Expected to vest&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;17,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;7.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;434,547&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock contextRef="From2016-04-01to2016-09-30_us-gaap_RestrictedStockMember">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;Number&#13;    of RSUs&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="width: 33%"&gt;&lt;font style="font-size: 8pt"&gt;Vested&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;184,500&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;Expected to vest&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;561,708&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;746,208&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2016-04-01to2016-09-30_custom_December2014WarrantsMember">&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Range&#13;    of&lt;/b&gt;&lt;/font&gt;&lt;font style="font-size: 8pt"&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;font style="font-size: 8pt"&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="width: 58%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Warrants outstanding at March&#13;    31, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2,164,094&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$2.10 -&#13;    $15.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;6.68&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(2,660&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$6.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;6.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Issued&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;30,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$5.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Cancelled/Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(19,563&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$6.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;6.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Warrants outstanding at September 30, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2,171,871&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$2.10&#13;    - $15.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5.37&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Warrants exercisable at September 30, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2,171,871&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$2.10&#13;    - $15.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5.37&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2016-04-01to2016-09-30_custom_December2014WarrantsMember">&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="width: 70%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Risk free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 30%; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.70%&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: White"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Average expected life&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;3.5 years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(238,238,238)"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Expected volatility&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;91.5%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: White"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Expected dividends&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;None&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2016-04-01to2016-09-30">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;Six Months Ended September&#13;    30,&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Revenues:&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="width: 66%; padding-left: 10pt"&gt;&lt;font style="font-size: 8pt"&gt;Aethlon&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;392,073&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;380,874&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font-size: 8pt"&gt;ESI&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 8pt"&gt;Total Revenues&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;392,073&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;380,874&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;Operating Losses:&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 8pt"&gt;Aethlon&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(3,281,530&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(1,911,219&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font-size: 8pt"&gt;ESI&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(76,999&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(303,113&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 8pt"&gt;Total Operating Loss&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(3,358,529&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(2,214,332&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;Net Losses:&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 8pt"&gt;Aethlon&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(4,323,003&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(2,165,152&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font-size: 8pt"&gt;ESI&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(76,999&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(303,113&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 8pt"&gt;Net Loss Before Non-Controlling&#13;    Interests&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(4,400,002&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(2,468,265&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Cash:&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 8pt"&gt;Aethlon&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;553,884&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,208,554&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font-size: 8pt"&gt;ESI&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,468&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;802&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 8pt"&gt;Total Cash&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;556,352&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,209,356&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;Total Assets:&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 8pt"&gt;Aethlon&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;914,179&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,677,989&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font-size: 8pt"&gt;ESI&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;36,656&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;27,486&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 8pt"&gt;Total Assets&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;950,835&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,705,475&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;Capital Expenditures:&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 8pt"&gt;Aethlon&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,961&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font-size: 8pt"&gt;ESI&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 8pt"&gt;Capital Expenditures&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,961&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;Depreciation and Amortization:&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 8pt"&gt;Aethlon&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;10,822&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8,886&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font-size: 8pt"&gt;ESI&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;9,790&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;9,790&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 8pt"&gt;Total Depreciation and&#13;    Amortization&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;20,612&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;18,676&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;Interest Expense:&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 8pt"&gt;Aethlon&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(78,743&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(253,933&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font-size: 8pt"&gt;ESI&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 8pt"&gt;Total Interest Expense&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(78,743&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(253,933&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">30000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2016-04-01to2016-09-30_custom_ConvertibleNotes10November2014Amend2Member">2017-07-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="AsOf2016-09-30_custom_ConvertibleNotes10November2014Amend2Member" unitRef="USDPShares" decimals="INF">5.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="AsOf2016-09-30_custom_ConvertibleNotes10November2014Amend2Member" unitRef="USD" decimals="0">692811</us-gaap:DebtInstrumentCarryingAmount>
    <AEMD:WarrantExpirationDate contextRef="From2016-04-01to2016-09-30_custom_ConvertibleNotes10November2014Amend2Member">2019-11-06</AEMD:WarrantExpirationDate>
    <us-gaap:DeferredFinanceCostsGross contextRef="AsOf2016-09-30_custom_ConvertibleNotes10November2014Amend2Member" unitRef="USD" decimals="0">80000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">80000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="From2016-04-01to2016-09-30_custom_WainwrightMember" unitRef="USD" decimals="0">8348</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <AEMD:OtherOfferingExpenses contextRef="From2016-04-01to2016-09-30_custom_WainwrightMember" unitRef="USD" decimals="0">3319</AEMD:OtherOfferingExpenses>
    <us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1 contextRef="From2016-04-01to2016-09-30_custom_ThreeInvestorsMember" unitRef="Shares" decimals="INF">2660</us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1>
    <us-gaap:ConversionOfStockSharesConverted1 contextRef="From2016-04-01to2016-09-30_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">30131</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2016-04-01to2016-09-30_us-gaap_StockOptionMember">P4Y9M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2016-04-01to2016-09-30_us-gaap_StockOptionMember">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2016-09-30_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">746208</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <AEMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2016-09-30_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">561708</AEMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber>
    <AEMD:SharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares contextRef="From2016-04-01to2016-09-30_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">184500</AEMD:SharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares>
    <AEMD:SharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares contextRef="From2016-04-01to2016-09-30_custom_JamesJoyceMember" unitRef="Shares" decimals="INF">158500</AEMD:SharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares>
    <AEMD:SharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares contextRef="From2016-04-01to2016-09-30_custom_RodneyKenleyMember" unitRef="Shares" decimals="INF">13000</AEMD:SharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares>
    <AEMD:SharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares contextRef="From2016-04-01to2016-09-30_custom_JamesFrakesMember" unitRef="Shares" decimals="INF">13000</AEMD:SharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare contextRef="From2016-04-01to2016-09-30_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">-0.20</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare contextRef="From2016-07-01to2016-09-30_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">-.20</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2016-04-01to2016-09-30_custom_JamesJoyceMember" unitRef="USDPShares" decimals="INF">6.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2016-04-01to2016-09-30_custom_RodneyKenleyMember" unitRef="USDPShares" decimals="INF">6.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2016-04-01to2016-09-30_custom_JamesFrakesMember" unitRef="USDPShares" decimals="INF">6.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <AEMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue contextRef="From2016-04-01to2016-09-30_custom_NonEmployeeDirectorsMember" unitRef="USD" decimals="0">105000</AEMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="From2016-04-01to2016-09-30_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">10957</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="From2016-04-01to2016-09-30_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USD" decimals="0">67343</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2016-09-30_us-gaap_StockOptionMember" unitRef="USD" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2016-04-01to2016-09-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2015-04-01to2015-09-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="From2016-04-01to2016-09-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2016-09-30_us-gaap_StockOptionMember" unitRef="USD" decimals="0">3509367</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2016-04-01to2016-09-30_us-gaap_StockOptionMember">P2Y10M13D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2016-03-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">2164094</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2016-09-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">2171871</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2016-04-01to2016-09-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">2660</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations contextRef="From2016-04-01to2016-09-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">19563</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <AEMD:RangeOfExercisePricesWarrantsBeginning contextRef="From2016-04-01to2016-09-30_us-gaap_WarrantMember">$2.10-$15.00</AEMD:RangeOfExercisePricesWarrantsBeginning>
    <AEMD:RangeOfExercisePricesWarrantsExercised contextRef="From2016-04-01to2016-09-30_us-gaap_WarrantMember">6.25</AEMD:RangeOfExercisePricesWarrantsExercised>
    <AEMD:RangeOfExercisePricesWarrantsIssued contextRef="From2016-04-01to2016-09-30_us-gaap_WarrantMember">5.00</AEMD:RangeOfExercisePricesWarrantsIssued>
    <AEMD:RangeOfExercisePricesWarrantsCancelledExpired contextRef="From2016-04-01to2016-09-30_us-gaap_WarrantMember">6.25</AEMD:RangeOfExercisePricesWarrantsCancelledExpired>
    <AEMD:RangeOfExercisePricesWarrantsEnding contextRef="From2016-04-01to2016-09-30_us-gaap_WarrantMember">$2.10-$15.00</AEMD:RangeOfExercisePricesWarrantsEnding>
    <AEMD:RangeOfExercisePricesWarrantsExercisable contextRef="From2016-04-01to2016-09-30_us-gaap_WarrantMember">$2.10-$15.00</AEMD:RangeOfExercisePricesWarrantsExercisable>
    <AEMD:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised contextRef="From2016-04-01to2016-09-30_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">6.25</AEMD:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised>
    <AEMD:WeightedAverageExercisePriceWarrantsIssued contextRef="From2016-04-01to2016-09-30_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">5.00</AEMD:WeightedAverageExercisePriceWarrantsIssued>
    <AEMD:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelledExpired contextRef="From2016-04-01to2016-09-30_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">6.25</AEMD:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelledExpired>
    <AEMD:WeightedAverageExercisePriceWarrantsExercisable contextRef="AsOf2016-09-30_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">5.37</AEMD:WeightedAverageExercisePriceWarrantsExercisable>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">67343</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <AEMD:ConvertibleNotePayableAndAccruedInterestConvertedToCommonStock contextRef="From2016-04-01to2016-09-30" unitRef="USD" decimals="0">32321</AEMD:ConvertibleNotePayableAndAccruedInterestConvertedToCommonStock>
    <AEMD:ConvertibleNotePayableAndAccruedInterestConvertedToCommonStock contextRef="From2015-04-01to2015-09-30" unitRef="USD" decimals="0">0</AEMD:ConvertibleNotePayableAndAccruedInterestConvertedToCommonStock>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>aemd-20160930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.15b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: aethlon_10q%2D20160930.xfr; Date: 2016%2D11%2D08T22:13:26Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +Kopo7xRiXgen8uEbXpMOa2C+aPty552mYkxvmR4fZnq/yAiO/8fXi047dyGgSMK -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-roles="http://fasb.org/us-roles/2016-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:AEMD="http://aethlon.com/20160930" elementFormDefault="qualified" targetNamespace="http://aethlon.com/20160930">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://aethlon.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/StatementsOfCashFlowsUnaudited0" id="StatementsOfCashFlowsUnaudited0">
	  <link:definition>00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited0</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/NatureOfBusinessAndBasisOfPresentation" id="NatureOfBusinessAndBasisOfPresentation">
	  <link:definition>00000006 - Disclosure - 1. Nature of Business and Basis of Presentation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/LossPerCommonShare" id="LossPerCommonShare">
	  <link:definition>00000007 - Disclosure - 2. Loss per Common Share</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/ResearchAndDevelopmentExpenses" id="ResearchAndDevelopmentExpenses">
	  <link:definition>00000008 - Disclosure - 3. Research and Development Expenses</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/SignificantRecentAccountingPronouncements" id="SignificantRecentAccountingPronouncements">
	  <link:definition>00000009 - Disclosure - 4. Significant Recent Accounting Pronouncements</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/ConvertibleNotesPayable" id="ConvertibleNotesPayable">
	  <link:definition>00000010 - Disclosure - 5. Convertible Notes Payable</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/EquityTransactions" id="EquityTransactions">
	  <link:definition>00000011 - Disclosure - 6. Equity Transactions</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
	  <link:definition>00000012 - Disclosure - 7. Related Party Transactions</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/OtherCurrentLiabilities" id="OtherCurrentLiabilities">
	  <link:definition>00000013 - Disclosure - 8. Other Current Liabilities</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/StockCompensation" id="StockCompensation">
	  <link:definition>00000014 - Disclosure - 9. Stock Compensation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/Warrants" id="Warrants">
	  <link:definition>00000015 - Disclosure - 10. Warrants</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/DarpaContractAndRelatedRevenueRecognition" id="DarpaContractAndRelatedRevenueRecognition">
	  <link:definition>00000016 - Disclosure - 11. Darpa Contract and Related Revenue Recognition</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/Segments" id="Segments">
	  <link:definition>00000017 - Disclosure - 12. Segments</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000018 - Disclosure - 13. Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000019 - Disclosure - 14. Subsequent Events</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/ResearchAndDevelopmentExpensesTables" id="ResearchAndDevelopmentExpensesTables">
	  <link:definition>00000020 - Disclosure - 3. Research and Development Expenses (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/ConvertibleNotesPayableTables" id="ConvertibleNotesPayableTables">
	  <link:definition>00000021 - Disclosure - 5. Convertible Notes Payable (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/OtherCurrentLiabilitiesTables" id="OtherCurrentLiabilitiesTables">
	  <link:definition>00000022 - Disclosure - 8. Other Current Liabilities (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/StockCompensationTables" id="StockCompensationTables">
	  <link:definition>00000023 - Disclosure - 9. Stock Compensation (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/WarrantsTables" id="WarrantsTables">
	  <link:definition>00000024 - Disclosure - 10. Warrants (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/SegmentsTables" id="SegmentsTables">
	  <link:definition>00000025 - Disclosure - 12. Segments (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/NatureOfBusinessDetailsNarrative" id="NatureOfBusinessDetailsNarrative">
	  <link:definition>00000026 - Disclosure - 1. Nature of Business (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/LossPerCommonShareDetailsNarrative" id="LossPerCommonShareDetailsNarrative">
	  <link:definition>00000027 - Disclosure - 2. Loss per Common Share (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/ResearchAndDevelopmentExpenses-3.ResearchAndDevelopmentExpensesDetails" id="ResearchAndDevelopmentExpenses-3.ResearchAndDevelopmentExpensesDetails">
	  <link:definition>00000028 - Disclosure - 3. Research and Development Expenses - 3. Research and Development Expenses (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/ConvertibleNotesPayableDetails-ConvertibleNotesPayable" id="ConvertibleNotesPayableDetails-ConvertibleNotesPayable">
	  <link:definition>00000029 - Disclosure - 5. Convertible Notes Payable (Details - Convertible Notes Payable)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/ConvertibleNotesPayableDetails-ConvertibleNoteActivity" id="ConvertibleNotesPayableDetails-ConvertibleNoteActivity">
	  <link:definition>00000030 - Disclosure - 5. Convertible Notes Payable (Details - Convertible note activity)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/ConvertibleNotesPayableDetailsNarrative" id="ConvertibleNotesPayableDetailsNarrative">
	  <link:definition>00000031 - Disclosure - 5. Convertible Notes Payable (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/EquityTransactionsDetailsNarrative" id="EquityTransactionsDetailsNarrative">
	  <link:definition>00000032 - Disclosure - 6. Equity Transactions (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
	  <link:definition>00000033 - Disclosure - 7. Related Party Transactions (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/OtherCurrentLiabilitiesDetails" id="OtherCurrentLiabilitiesDetails">
	  <link:definition>00000034 - Disclosure - 8. Other Current Liabilities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/StockCompensationDetails-ShareBasedCompensation" id="StockCompensationDetails-ShareBasedCompensation">
	  <link:definition>00000035 - Disclosure - 9. Stock Compensation (Details - Share based compensation)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/StockCompensationDetails-RsusOutstanding" id="StockCompensationDetails-RsusOutstanding">
	  <link:definition>00000036 - Disclosure - 9. Stock Compensation (Details - RSU's outstanding)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest" id="StockCompensationDetails-OptionsVestedAndExpectedToVest">
	  <link:definition>00000037 - Disclosure - 9. Stock Compensation (Details - Options vested and expected to vest)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/StockCompensationDetailsNarrative" id="StockCompensationDetailsNarrative">
	  <link:definition>00000038 - Disclosure - 9. Stock Compensation (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/WarrantsDetails-WarrantActivity" id="WarrantsDetails-WarrantActivity">
	  <link:definition>00000039 - Disclosure - 10. Warrants (Details - Warrant activity)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/WarrantsDetails-Assumptions" id="WarrantsDetails-Assumptions">
	  <link:definition>00000040 - Disclosure - 10. Warrants (Details - Assumptions)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/WarrantsDetailsNarrative" id="WarrantsDetailsNarrative">
	  <link:definition>00000041 - Disclosure - 10. Warrants (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/DarpaContractAndRelatedRevenueRecognitionDetailsNarrative" id="DarpaContractAndRelatedRevenueRecognitionDetailsNarrative">
	  <link:definition>00000042 - Disclosure - 11. Darpa Contract and Related Revenue Recognition (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/SegmentsDetails" id="SegmentsDetails">
	  <link:definition>00000043 - Disclosure - 12. Segments (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlon.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000044 - Disclosure - 13. Commitments and Contingencies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="aemd-20160930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="aemd-20160930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="aemd-20160930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="aemd-20160930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <element id="AEMD_SaleOfStockNewIssuesAggregateOfferingPrice" name="SaleOfStockNewIssuesAggregateOfferingPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_FairValueOfWarrantsIssued" name="FairValueOfWarrantsIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_DebtDiscountOnConvertibleNotesPayable" name="DebtDiscountOnConvertibleNotesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_IssuanceOfSharesUnderVestedRestrictedStockUnits" name="IssuanceOfSharesUnderVestedRestrictedStockUnits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_ReclassificationOfAccruedInterestToConvertibleNotesPayable" name="ReclassificationOfAccruedInterestToConvertibleNotesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_CashlessExerciseOfWarrants" name="CashlessExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_WarrantExpirationDate" name="WarrantExpirationDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_OtherOfferingExpenses" name="OtherOfferingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_SharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares" name="SharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_RangeOfExercisePricesWarrantsBeginning" name="RangeOfExercisePricesWarrantsBeginning" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_RangeOfExercisePricesWarrantsExercised" name="RangeOfExercisePricesWarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_RangeOfExercisePricesWarrantsIssued" name="RangeOfExercisePricesWarrantsIssued" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_RangeOfExercisePricesWarrantsCancelledExpired" name="RangeOfExercisePricesWarrantsCancelledExpired" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_RangeOfExercisePricesWarrantsEnding" name="RangeOfExercisePricesWarrantsEnding" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_RangeOfExercisePricesWarrantsExercisable" name="RangeOfExercisePricesWarrantsExercisable" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_WeightedAverageExercisePriceWarrantsIssued" name="WeightedAverageExercisePriceWarrantsIssued" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelledExpired" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelledExpired" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_WeightedAverageExercisePriceWarrantsExercisable" name="WeightedAverageExercisePriceWarrantsExercisable" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_ConvertibleNotePayableAndAccruedInterestConvertedToCommonStock" name="ConvertibleNotePayableAndAccruedInterestConvertedToCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_VestingOfStockOptionsMember" name="VestingOfStockOptionsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_December2014WarrantsMember" name="December2014WarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_AethlonMember" name="AethlonMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_ESIMember" name="ESIMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_Milestone2613Member" name="Milestone2613Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_ConvertibleNotes10November2014Amend2Member" name="ConvertibleNotes10November2014Amend2Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_ConvertibleNotes10November2014Member" name="ConvertibleNotes10November2014Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_FairValueWarrantsMember" name="FairValueWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_BeneficialConversionFeatureMember" name="BeneficialConversionFeatureMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_DebtDiscountMember" name="DebtDiscountMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_WainwrightMember" name="WainwrightMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_UnPaidBoardFeesMember" name="UnPaidBoardFeesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_ThreeInvestorsMember" name="ThreeInvestorsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_JamesJoyceMember" name="JamesJoyceMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_RodneyKenleyMember" name="RodneyKenleyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_JamesFrakesMember" name="JamesFrakesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_NonEmployeeDirectorsMember" name="NonEmployeeDirectorsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_TwoOutsideDirectorsMember" name="TwoOutsideDirectorsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_Milestone26143Member" name="Milestone26143Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_MilestoneM6Member" name="MilestoneM6Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_Milestone2511Member" name="Milestone2511Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AEMD_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>aemd-20160930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.15b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: aethlon_10q%2D20160930.xfr; Date: 2016%2D11%2D08T22:13:26Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://aethlon.com/role/DocumentAndEntityInformation" xlink:href="aemd-20160930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/BalanceSheets" xlink:href="aemd-20160930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/BalanceSheetsParenthetical" xlink:href="aemd-20160930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/StatementsOfOperations" xlink:href="aemd-20160930.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/StatementsOfCashFlowsUnaudited0" xlink:href="aemd-20160930.xsd#StatementsOfCashFlowsUnaudited0" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/NatureOfBusinessAndBasisOfPresentation" xlink:href="aemd-20160930.xsd#NatureOfBusinessAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/LossPerCommonShare" xlink:href="aemd-20160930.xsd#LossPerCommonShare" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/ResearchAndDevelopmentExpenses" xlink:href="aemd-20160930.xsd#ResearchAndDevelopmentExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/SignificantRecentAccountingPronouncements" xlink:href="aemd-20160930.xsd#SignificantRecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/ConvertibleNotesPayable" xlink:href="aemd-20160930.xsd#ConvertibleNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/EquityTransactions" xlink:href="aemd-20160930.xsd#EquityTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/RelatedPartyTransactions" xlink:href="aemd-20160930.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/OtherCurrentLiabilities" xlink:href="aemd-20160930.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/StockCompensation" xlink:href="aemd-20160930.xsd#StockCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/Warrants" xlink:href="aemd-20160930.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/DarpaContractAndRelatedRevenueRecognition" xlink:href="aemd-20160930.xsd#DarpaContractAndRelatedRevenueRecognition" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/Segments" xlink:href="aemd-20160930.xsd#Segments" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/CommitmentsAndContingencies" xlink:href="aemd-20160930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/SubsequentEvents" xlink:href="aemd-20160930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/ResearchAndDevelopmentExpensesTables" xlink:href="aemd-20160930.xsd#ResearchAndDevelopmentExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/ConvertibleNotesPayableTables" xlink:href="aemd-20160930.xsd#ConvertibleNotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/OtherCurrentLiabilitiesTables" xlink:href="aemd-20160930.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/StockCompensationTables" xlink:href="aemd-20160930.xsd#StockCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/WarrantsTables" xlink:href="aemd-20160930.xsd#WarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/SegmentsTables" xlink:href="aemd-20160930.xsd#SegmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/NatureOfBusinessDetailsNarrative" xlink:href="aemd-20160930.xsd#NatureOfBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/LossPerCommonShareDetailsNarrative" xlink:href="aemd-20160930.xsd#LossPerCommonShareDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/ResearchAndDevelopmentExpenses-3.ResearchAndDevelopmentExpensesDetails" xlink:href="aemd-20160930.xsd#ResearchAndDevelopmentExpenses-3.ResearchAndDevelopmentExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/ConvertibleNotesPayableDetails-ConvertibleNotesPayable" xlink:href="aemd-20160930.xsd#ConvertibleNotesPayableDetails-ConvertibleNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/ConvertibleNotesPayableDetails-ConvertibleNoteActivity" xlink:href="aemd-20160930.xsd#ConvertibleNotesPayableDetails-ConvertibleNoteActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:href="aemd-20160930.xsd#ConvertibleNotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/EquityTransactionsDetailsNarrative" xlink:href="aemd-20160930.xsd#EquityTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="aemd-20160930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/OtherCurrentLiabilitiesDetails" xlink:href="aemd-20160930.xsd#OtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/StockCompensationDetails-ShareBasedCompensation" xlink:href="aemd-20160930.xsd#StockCompensationDetails-ShareBasedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/StockCompensationDetails-RsusOutstanding" xlink:href="aemd-20160930.xsd#StockCompensationDetails-RsusOutstanding" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest" xlink:href="aemd-20160930.xsd#StockCompensationDetails-OptionsVestedAndExpectedToVest" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/StockCompensationDetailsNarrative" xlink:href="aemd-20160930.xsd#StockCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/WarrantsDetails-WarrantActivity" xlink:href="aemd-20160930.xsd#WarrantsDetails-WarrantActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/WarrantsDetails-Assumptions" xlink:href="aemd-20160930.xsd#WarrantsDetails-Assumptions" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/WarrantsDetailsNarrative" xlink:href="aemd-20160930.xsd#WarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/DarpaContractAndRelatedRevenueRecognitionDetailsNarrative" xlink:href="aemd-20160930.xsd#DarpaContractAndRelatedRevenueRecognitionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/SegmentsDetails" xlink:href="aemd-20160930.xsd#SegmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="aemd-20160930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepositsAssets" xlink:label="loc_us-gaapDepositsAssets" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDepositsAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaapConvertibleLongTermNotesPayable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapConvertibleLongTermNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapLaborAndRelatedExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaapContractsRevenue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapContractsRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaapInterestAndDebtExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherExpenses" xlink:to="loc_us-gaapInterestAndDebtExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherExpenses" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherExpenses" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapOtherExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/StatementsOfCashFlowsUnaudited0" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited0">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableRelatedParties" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableRelatedParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashPeriodIncreaseDecrease" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/NatureOfBusinessAndBasisOfPresentation" xlink:title="00000006 - Disclosure - 1. Nature of Business and Basis of Presentation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/LossPerCommonShare" xlink:title="00000007 - Disclosure - 2. Loss per Common Share" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/ResearchAndDevelopmentExpenses" xlink:title="00000008 - Disclosure - 3. Research and Development Expenses" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/SignificantRecentAccountingPronouncements" xlink:title="00000009 - Disclosure - 4. Significant Recent Accounting Pronouncements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/ConvertibleNotesPayable" xlink:title="00000010 - Disclosure - 5. Convertible Notes Payable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/EquityTransactions" xlink:title="00000011 - Disclosure - 6. Equity Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/RelatedPartyTransactions" xlink:title="00000012 - Disclosure - 7. Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/OtherCurrentLiabilities" xlink:title="00000013 - Disclosure - 8. Other Current Liabilities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/StockCompensation" xlink:title="00000014 - Disclosure - 9. Stock Compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/Warrants" xlink:title="00000015 - Disclosure - 10. Warrants" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/DarpaContractAndRelatedRevenueRecognition" xlink:title="00000016 - Disclosure - 11. Darpa Contract and Related Revenue Recognition" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/Segments" xlink:title="00000017 - Disclosure - 12. Segments" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/CommitmentsAndContingencies" xlink:title="00000018 - Disclosure - 13. Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/SubsequentEvents" xlink:title="00000019 - Disclosure - 14. Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/ResearchAndDevelopmentExpensesTables" xlink:title="00000020 - Disclosure - 3. Research and Development Expenses (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/ConvertibleNotesPayableTables" xlink:title="00000021 - Disclosure - 5. Convertible Notes Payable (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000022 - Disclosure - 8. Other Current Liabilities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/StockCompensationTables" xlink:title="00000023 - Disclosure - 9. Stock Compensation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/WarrantsTables" xlink:title="00000024 - Disclosure - 10. Warrants (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/SegmentsTables" xlink:title="00000025 - Disclosure - 12. Segments (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/NatureOfBusinessDetailsNarrative" xlink:title="00000026 - Disclosure - 1. Nature of Business (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/LossPerCommonShareDetailsNarrative" xlink:title="00000027 - Disclosure - 2. Loss per Common Share (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/ResearchAndDevelopmentExpenses-3.ResearchAndDevelopmentExpensesDetails" xlink:title="00000028 - Disclosure - 3. Research and Development Expenses - 3. Research and Development Expenses (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/ConvertibleNotesPayableDetails-ConvertibleNotesPayable" xlink:title="00000029 - Disclosure - 5. Convertible Notes Payable (Details - Convertible Notes Payable)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/ConvertibleNotesPayableDetails-ConvertibleNoteActivity" xlink:title="00000030 - Disclosure - 5. Convertible Notes Payable (Details - Convertible note activity)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:title="00000031 - Disclosure - 5. Convertible Notes Payable (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/EquityTransactionsDetailsNarrative" xlink:title="00000032 - Disclosure - 6. Equity Transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000033 - Disclosure - 7. Related Party Transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/OtherCurrentLiabilitiesDetails" xlink:title="00000034 - Disclosure - 8. Other Current Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/StockCompensationDetails-ShareBasedCompensation" xlink:title="00000035 - Disclosure - 9. Stock Compensation (Details - Share based compensation)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/StockCompensationDetails-RsusOutstanding" xlink:title="00000036 - Disclosure - 9. Stock Compensation (Details - RSU's outstanding)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest" xlink:title="00000037 - Disclosure - 9. Stock Compensation (Details - Options vested and expected to vest)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/StockCompensationDetailsNarrative" xlink:title="00000038 - Disclosure - 9. Stock Compensation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/WarrantsDetails-WarrantActivity" xlink:title="00000039 - Disclosure - 10. Warrants (Details - Warrant activity)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/WarrantsDetails-Assumptions" xlink:title="00000040 - Disclosure - 10. Warrants (Details - Assumptions)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/WarrantsDetailsNarrative" xlink:title="00000041 - Disclosure - 10. Warrants (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/DarpaContractAndRelatedRevenueRecognitionDetailsNarrative" xlink:title="00000042 - Disclosure - 11. Darpa Contract and Related Revenue Recognition (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/SegmentsDetails" xlink:title="00000043 - Disclosure - 12. Segments (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlon.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000044 - Disclosure - 13. Commitments and Contingencies (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>aemd-20160930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.15b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: aethlon_10q%2D20160930.xfr; Date: 2016%2D11%2D08T22:13:26Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://aethlon.com/role/DocumentAndEntityInformation" xlink:href="aemd-20160930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/BalanceSheets" xlink:href="aemd-20160930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/BalanceSheetsParenthetical" xlink:href="aemd-20160930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/StatementsOfOperations" xlink:href="aemd-20160930.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/StatementsOfCashFlowsUnaudited0" xlink:href="aemd-20160930.xsd#StatementsOfCashFlowsUnaudited0" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/NatureOfBusinessAndBasisOfPresentation" xlink:href="aemd-20160930.xsd#NatureOfBusinessAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/LossPerCommonShare" xlink:href="aemd-20160930.xsd#LossPerCommonShare" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/ResearchAndDevelopmentExpenses" xlink:href="aemd-20160930.xsd#ResearchAndDevelopmentExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/SignificantRecentAccountingPronouncements" xlink:href="aemd-20160930.xsd#SignificantRecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/ConvertibleNotesPayable" xlink:href="aemd-20160930.xsd#ConvertibleNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/EquityTransactions" xlink:href="aemd-20160930.xsd#EquityTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/RelatedPartyTransactions" xlink:href="aemd-20160930.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/OtherCurrentLiabilities" xlink:href="aemd-20160930.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/StockCompensation" xlink:href="aemd-20160930.xsd#StockCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/Warrants" xlink:href="aemd-20160930.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/DarpaContractAndRelatedRevenueRecognition" xlink:href="aemd-20160930.xsd#DarpaContractAndRelatedRevenueRecognition" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/Segments" xlink:href="aemd-20160930.xsd#Segments" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/CommitmentsAndContingencies" xlink:href="aemd-20160930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/SubsequentEvents" xlink:href="aemd-20160930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/ResearchAndDevelopmentExpensesTables" xlink:href="aemd-20160930.xsd#ResearchAndDevelopmentExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/ConvertibleNotesPayableTables" xlink:href="aemd-20160930.xsd#ConvertibleNotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/OtherCurrentLiabilitiesTables" xlink:href="aemd-20160930.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/StockCompensationTables" xlink:href="aemd-20160930.xsd#StockCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/WarrantsTables" xlink:href="aemd-20160930.xsd#WarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/SegmentsTables" xlink:href="aemd-20160930.xsd#SegmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/NatureOfBusinessDetailsNarrative" xlink:href="aemd-20160930.xsd#NatureOfBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/LossPerCommonShareDetailsNarrative" xlink:href="aemd-20160930.xsd#LossPerCommonShareDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/ResearchAndDevelopmentExpenses-3.ResearchAndDevelopmentExpensesDetails" xlink:href="aemd-20160930.xsd#ResearchAndDevelopmentExpenses-3.ResearchAndDevelopmentExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/ConvertibleNotesPayableDetails-ConvertibleNotesPayable" xlink:href="aemd-20160930.xsd#ConvertibleNotesPayableDetails-ConvertibleNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/ConvertibleNotesPayableDetails-ConvertibleNoteActivity" xlink:href="aemd-20160930.xsd#ConvertibleNotesPayableDetails-ConvertibleNoteActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:href="aemd-20160930.xsd#ConvertibleNotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/EquityTransactionsDetailsNarrative" xlink:href="aemd-20160930.xsd#EquityTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="aemd-20160930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/OtherCurrentLiabilitiesDetails" xlink:href="aemd-20160930.xsd#OtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/StockCompensationDetails-ShareBasedCompensation" xlink:href="aemd-20160930.xsd#StockCompensationDetails-ShareBasedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/StockCompensationDetails-RsusOutstanding" xlink:href="aemd-20160930.xsd#StockCompensationDetails-RsusOutstanding" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest" xlink:href="aemd-20160930.xsd#StockCompensationDetails-OptionsVestedAndExpectedToVest" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/StockCompensationDetailsNarrative" xlink:href="aemd-20160930.xsd#StockCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/WarrantsDetails-WarrantActivity" xlink:href="aemd-20160930.xsd#WarrantsDetails-WarrantActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/WarrantsDetails-Assumptions" xlink:href="aemd-20160930.xsd#WarrantsDetails-Assumptions" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/WarrantsDetailsNarrative" xlink:href="aemd-20160930.xsd#WarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/DarpaContractAndRelatedRevenueRecognitionDetailsNarrative" xlink:href="aemd-20160930.xsd#DarpaContractAndRelatedRevenueRecognitionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/SegmentsDetails" xlink:href="aemd-20160930.xsd#SegmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="aemd-20160930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/StatementsOfCashFlowsUnaudited0" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited0" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/NatureOfBusinessAndBasisOfPresentation" xlink:title="00000006 - Disclosure - 1. Nature of Business and Basis of Presentation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/LossPerCommonShare" xlink:title="00000007 - Disclosure - 2. Loss per Common Share" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/ResearchAndDevelopmentExpenses" xlink:title="00000008 - Disclosure - 3. Research and Development Expenses" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/SignificantRecentAccountingPronouncements" xlink:title="00000009 - Disclosure - 4. Significant Recent Accounting Pronouncements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/ConvertibleNotesPayable" xlink:title="00000010 - Disclosure - 5. Convertible Notes Payable" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/EquityTransactions" xlink:title="00000011 - Disclosure - 6. Equity Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/RelatedPartyTransactions" xlink:title="00000012 - Disclosure - 7. Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/OtherCurrentLiabilities" xlink:title="00000013 - Disclosure - 8. Other Current Liabilities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/StockCompensation" xlink:title="00000014 - Disclosure - 9. Stock Compensation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/Warrants" xlink:title="00000015 - Disclosure - 10. Warrants" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/DarpaContractAndRelatedRevenueRecognition" xlink:title="00000016 - Disclosure - 11. Darpa Contract and Related Revenue Recognition" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/Segments" xlink:title="00000017 - Disclosure - 12. Segments" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/CommitmentsAndContingencies" xlink:title="00000018 - Disclosure - 13. Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/SubsequentEvents" xlink:title="00000019 - Disclosure - 14. Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/ResearchAndDevelopmentExpensesTables" xlink:title="00000020 - Disclosure - 3. Research and Development Expenses (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/ConvertibleNotesPayableTables" xlink:title="00000021 - Disclosure - 5. Convertible Notes Payable (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000022 - Disclosure - 8. Other Current Liabilities (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/StockCompensationTables" xlink:title="00000023 - Disclosure - 9. Stock Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/WarrantsTables" xlink:title="00000024 - Disclosure - 10. Warrants (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_December2014WarrantsMember" xlink:label="loc_AEMDDecember2014WarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_AEMDDecember2014WarrantsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_30" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/SegmentsTables" xlink:title="00000025 - Disclosure - 12. Segments (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/NatureOfBusinessDetailsNarrative" xlink:title="00000026 - Disclosure - 1. Nature of Business (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/LossPerCommonShareDetailsNarrative" xlink:title="00000027 - Disclosure - 2. Loss per Common Share (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/ResearchAndDevelopmentExpenses-3.ResearchAndDevelopmentExpensesDetails" xlink:title="00000028 - Disclosure - 3. Research and Development Expenses - 3. Research and Development Expenses (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/ConvertibleNotesPayableDetails-ConvertibleNotesPayable" xlink:title="00000029 - Disclosure - 5. Convertible Notes Payable (Details - Convertible Notes Payable)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/ConvertibleNotesPayableDetails-ConvertibleNoteActivity" xlink:title="00000030 - Disclosure - 5. Convertible Notes Payable (Details - Convertible note activity)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:title="00000031 - Disclosure - 5. Convertible Notes Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_ConvertibleNotes10November2014Amend2Member" xlink:label="loc_AEMDConvertibleNotes10November2014Amend2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_AEMDConvertibleNotes10November2014Amend2Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_ConvertibleNotes10November2014Member" xlink:label="loc_AEMDConvertibleNotes10November2014Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_AEMDConvertibleNotes10November2014Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="loc_us-gaapExtinguishmentOfDebtAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapExtinguishmentOfDebtAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="loc_us-gaapExtinguishmentOfDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapExtinguishmentOfDebtAxis" xlink:to="loc_us-gaapExtinguishmentOfDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="loc_us-gaapExtinguishmentOfDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapExtinguishmentOfDebtAxis" xlink:to="loc_us-gaapExtinguishmentOfDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_FairValueWarrantsMember" xlink:label="loc_AEMDFairValueWarrantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapExtinguishmentOfDebtTypeDomain" xlink:to="loc_AEMDFairValueWarrantsMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_BeneficialConversionFeatureMember" xlink:label="loc_AEMDBeneficialConversionFeatureMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapExtinguishmentOfDebtTypeDomain" xlink:to="loc_AEMDBeneficialConversionFeatureMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_DebtDiscountMember" xlink:label="loc_AEMDDebtDiscountMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapExtinguishmentOfDebtTypeDomain" xlink:to="loc_AEMDDebtDiscountMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestExpenseDebt_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaapDebtRelatedCommitmentFeesAndDebtIssuanceCosts_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtRelatedCommitmentFeesAndDebtIssuanceCosts_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestExpense_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_80" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount_80" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaapDeferredFinanceCostsGross_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsGross_80" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_80" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_WarrantExpirationDate" xlink:label="loc_AEMDWarrantExpirationDate_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AEMDWarrantExpirationDate_80" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_80" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="loc_us-gaapDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_80" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/EquityTransactionsDetailsNarrative" xlink:title="00000032 - Disclosure - 6. Equity Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaapCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapCounterpartyNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCounterpartyNameAxis" xlink:to="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCounterpartyNameAxis" xlink:to="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_WainwrightMember" xlink:label="loc_AEMDWainwrightMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_AEMDWainwrightMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_ThreeInvestorsMember" xlink:label="loc_AEMDThreeInvestorsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_AEMDThreeInvestorsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_December2014WarrantsMember" xlink:label="loc_AEMDDecember2014WarrantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_AEMDDecember2014WarrantsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_SaleOfStockNewIssuesAggregateOfferingPrice" xlink:label="loc_AEMDSaleOfStockNewIssuesAggregateOfferingPrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AEMDSaleOfStockNewIssuesAggregateOfferingPrice_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_OtherOfferingExpenses" xlink:label="loc_AEMDOtherOfferingExpenses_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AEMDOtherOfferingExpenses_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1" xlink:label="loc_us-gaapNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_60" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000033 - Disclosure - 7. Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_UnPaidBoardFeesMember" xlink:label="loc_AEMDUnPaidBoardFeesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_AEMDUnPaidBoardFeesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/OtherCurrentLiabilitiesDetails" xlink:title="00000034 - Disclosure - 8. Other Current Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/StockCompensationDetails-ShareBasedCompensation" xlink:title="00000035 - Disclosure - 9. Stock Compensation (Details - Share based compensation)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/StockCompensationDetails-RsusOutstanding" xlink:title="00000036 - Disclosure - 9. Stock Compensation (Details - RSU's outstanding)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_SharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares" xlink:label="loc_AEMDSharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AEMDSharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_AEMDShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AEMDShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_30" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest" xlink:title="00000037 - Disclosure - 9. Stock Compensation (Details - Options vested and expected to vest)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_30" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_30" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/StockCompensationDetailsNarrative" xlink:title="00000038 - Disclosure - 9. Stock Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_JamesJoyceMember" xlink:label="loc_AEMDJamesJoyceMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AEMDJamesJoyceMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_RodneyKenleyMember" xlink:label="loc_AEMDRodneyKenleyMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AEMDRodneyKenleyMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_JamesFrakesMember" xlink:label="loc_AEMDJamesFrakesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AEMDJamesFrakesMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_NonEmployeeDirectorsMember" xlink:label="loc_AEMDNonEmployeeDirectorsMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AEMDNonEmployeeDirectorsMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaapCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapCounterpartyNameAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCounterpartyNameAxis" xlink:to="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCounterpartyNameAxis" xlink:to="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsPerDilutedShare_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsPerDilutedShare_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_SharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares" xlink:label="loc_AEMDSharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AEMDSharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue" xlink:label="loc_AEMDShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AEMDShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_120" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapSharesPaidForTaxWithholdingForShareBasedCompensation_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesPaidForTaxWithholdingForShareBasedCompensation_120" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapAdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_120" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_120" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_120" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_120" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_120" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_120" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/WarrantsDetails-WarrantActivity" xlink:title="00000039 - Disclosure - 10. Warrants (Details - Warrant activity)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_RangeOfExercisePricesWarrantsBeginning" xlink:label="loc_AEMDRangeOfExercisePricesWarrantsBeginning_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AEMDRangeOfExercisePricesWarrantsBeginning_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_RangeOfExercisePricesWarrantsExercised" xlink:label="loc_AEMDRangeOfExercisePricesWarrantsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AEMDRangeOfExercisePricesWarrantsExercised_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_RangeOfExercisePricesWarrantsIssued" xlink:label="loc_AEMDRangeOfExercisePricesWarrantsIssued_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AEMDRangeOfExercisePricesWarrantsIssued_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_RangeOfExercisePricesWarrantsCancelledExpired" xlink:label="loc_AEMDRangeOfExercisePricesWarrantsCancelledExpired_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AEMDRangeOfExercisePricesWarrantsCancelledExpired_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_RangeOfExercisePricesWarrantsEnding" xlink:label="loc_AEMDRangeOfExercisePricesWarrantsEnding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AEMDRangeOfExercisePricesWarrantsEnding_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_RangeOfExercisePricesWarrantsExercisable" xlink:label="loc_AEMDRangeOfExercisePricesWarrantsExercisable_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AEMDRangeOfExercisePricesWarrantsExercisable_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" xlink:label="loc_AEMDClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AEMDClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_WeightedAverageExercisePriceWarrantsIssued" xlink:label="loc_AEMDWeightedAverageExercisePriceWarrantsIssued_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AEMDWeightedAverageExercisePriceWarrantsIssued_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelledExpired" xlink:label="loc_AEMDClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelledExpired_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AEMDClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelledExpired_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_WeightedAverageExercisePriceWarrantsExercisable" xlink:label="loc_AEMDWeightedAverageExercisePriceWarrantsExercisable_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AEMDWeightedAverageExercisePriceWarrantsExercisable_40" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/WarrantsDetails-Assumptions" xlink:title="00000040 - Disclosure - 10. Warrants (Details - Assumptions)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_December2014WarrantsMember" xlink:label="loc_AEMDDecember2014WarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_AEMDDecember2014WarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_20" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_20" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/WarrantsDetailsNarrative" xlink:title="00000041 - Disclosure - 10. Warrants (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_December2014WarrantsMember" xlink:label="loc_AEMDDecember2014WarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_AEMDDecember2014WarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapWarrantMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_FairValueOfWarrantsIssued" xlink:label="loc_AEMDFairValueOfWarrantsIssued_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AEMDFairValueOfWarrantsIssued_30" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/DarpaContractAndRelatedRevenueRecognitionDetailsNarrative" xlink:title="00000042 - Disclosure - 11. Darpa Contract and Related Revenue Recognition (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_Milestone2613Member" xlink:label="loc_AEMDMilestone2613Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AEMDMilestone2613Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_Milestone26143Member" xlink:label="loc_AEMDMilestone26143Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AEMDMilestone26143Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_MilestoneM6Member" xlink:label="loc_AEMDMilestoneM6Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AEMDMilestoneM6Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_Milestone2511Member" xlink:label="loc_AEMDMilestone2511Member_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AEMDMilestone2511Member_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaapRevenueRecognitionMilestoneMethodRevenueRecognized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueRecognitionMilestoneMethodRevenueRecognized_70" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/SegmentsDetails" xlink:title="00000043 - Disclosure - 12. Segments (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_AethlonMember" xlink:label="loc_AEMDAethlonMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_AEMDAethlonMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_ESIMember" xlink:label="loc_AEMDESIMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_AEMDESIMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaapContractsRevenue_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapContractsRevenue_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCash_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireProductiveAssets_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsToAcquireProductiveAssets_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciationAndAmortization_130" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpenseOther" xlink:label="loc_us-gaapInterestExpenseOther_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestExpenseOther_130" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlon.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000044 - Disclosure - 13. Commitments and Contingencies (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>aemd-20160930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.15b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: aethlon_10q%2D20160930.xfr; Date: 2016%2D11%2D08T22:13:26Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_December2014WarrantsMember" xlink:label="AEMD_December2014WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_December2014WarrantsMember" xlink:to="AEMD_December2014WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_December2014WarrantsMember_lbl" xml:lang="en-US">December 2014 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_AethlonMember" xlink:label="AEMD_AethlonMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_AethlonMember" xlink:to="AEMD_AethlonMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_AethlonMember_lbl" xml:lang="en-US">Aethlon [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_ESIMember" xlink:label="AEMD_ESIMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_ESIMember" xlink:to="AEMD_ESIMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_ESIMember_lbl" xml:lang="en-US">ESI [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_Milestone2613Member" xlink:label="AEMD_Milestone2613Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_Milestone2613Member" xlink:to="AEMD_Milestone2613Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_Milestone2613Member_lbl" xml:lang="en-US">Milestone 2.6.1.3</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_ConvertibleNotes10November2014Amend2Member" xlink:label="AEMD_ConvertibleNotes10November2014Amend2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_ConvertibleNotes10November2014Amend2Member" xlink:to="AEMD_ConvertibleNotes10November2014Amend2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_ConvertibleNotes10November2014Amend2Member_lbl" xml:lang="en-US">November 2014 10% Convertible Notes Second Amendment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_ConvertibleNotes10November2014Member" xlink:label="AEMD_ConvertibleNotes10November2014Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_ConvertibleNotes10November2014Member" xlink:to="AEMD_ConvertibleNotes10November2014Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_ConvertibleNotes10November2014Member_lbl" xml:lang="en-US">November 2014 10% Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_FairValueWarrantsMember" xlink:label="AEMD_FairValueWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_FairValueWarrantsMember" xlink:to="AEMD_FairValueWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_FairValueWarrantsMember_lbl" xml:lang="en-US">Fair Value of Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="us-gaap_ExtinguishmentOfDebtAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtAxis" xlink:to="us-gaap_ExtinguishmentOfDebtAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExtinguishmentOfDebtAxis_lbl" xml:lang="en-US">Extinguishment of Debt [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_BeneficialConversionFeatureMember" xlink:label="AEMD_BeneficialConversionFeatureMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_BeneficialConversionFeatureMember" xlink:to="AEMD_BeneficialConversionFeatureMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_BeneficialConversionFeatureMember_lbl" xml:lang="en-US">Beneficial Conversion Feature [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_DebtDiscountMember" xlink:label="AEMD_DebtDiscountMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_DebtDiscountMember" xlink:to="AEMD_DebtDiscountMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_DebtDiscountMember_lbl" xml:lang="en-US">Debt Discount [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_WainwrightMember" xlink:label="AEMD_WainwrightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_WainwrightMember" xlink:to="AEMD_WainwrightMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_WainwrightMember_lbl" xml:lang="en-US">H.C. Wainwright [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_CounterpartyNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_UnPaidBoardFeesMember" xlink:label="AEMD_UnPaidBoardFeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_UnPaidBoardFeesMember" xlink:to="AEMD_UnPaidBoardFeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_UnPaidBoardFeesMember_lbl" xml:lang="en-US">Unpaid Board Fees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_ThreeInvestorsMember" xlink:label="AEMD_ThreeInvestorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_ThreeInvestorsMember" xlink:to="AEMD_ThreeInvestorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_ThreeInvestorsMember_lbl" xml:lang="en-US">Three Investors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_JamesJoyceMember" xlink:label="AEMD_JamesJoyceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_JamesJoyceMember" xlink:to="AEMD_JamesJoyceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_JamesJoyceMember_lbl" xml:lang="en-US">James A. Joyce [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_RodneyKenleyMember" xlink:label="AEMD_RodneyKenleyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_RodneyKenleyMember" xlink:to="AEMD_RodneyKenleyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_RodneyKenleyMember_lbl" xml:lang="en-US">Rodney Kenley [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_JamesFrakesMember" xlink:label="AEMD_JamesFrakesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_JamesFrakesMember" xlink:to="AEMD_JamesFrakesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_JamesFrakesMember_lbl" xml:lang="en-US">James Frakes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_NonEmployeeDirectorsMember" xlink:label="AEMD_NonEmployeeDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_NonEmployeeDirectorsMember" xlink:to="AEMD_NonEmployeeDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_NonEmployeeDirectorsMember_lbl" xml:lang="en-US">Non-employee Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_Milestone26143Member" xlink:label="AEMD_Milestone26143Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_Milestone26143Member" xlink:to="AEMD_Milestone26143Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_Milestone26143Member_lbl" xml:lang="en-US">Milestone 2.6.1.4</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_MilestoneM6Member" xlink:label="AEMD_MilestoneM6Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_MilestoneM6Member" xlink:to="AEMD_MilestoneM6Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_MilestoneM6Member_lbl" xml:lang="en-US">Milestone M6 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_Milestone2511Member" xlink:label="AEMD_Milestone2511Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_Milestone2511Member" xlink:to="AEMD_Milestone2511Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_Milestone2511Member_lbl" xml:lang="en-US">Milestone 2.5.1.1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_DocumentAndEntityInformationAbstract" xlink:label="AEMD_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_DocumentAndEntityInformationAbstract" xlink:to="AEMD_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document And Entity Information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Is Entity a Well-known Seasoned Issuer?</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Is Entity a Voluntary Filer?</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Is Entity's Reporting Status Current?</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">TOTAL CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Patents and patents pending, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepositsAssets" xlink:label="us-gaap_DepositsAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssets" xlink:to="us-gaap_DepositsAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssets_lbl" xml:lang="en-US">Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Due to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Convertible notes payable, net - current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">TOTAL CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">NONCURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US">Convertible notes payable, net - less current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES (Note 13)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, par value $0.001 per share; 30,000,000 shares authorized as of September 30, 2016 and March 31, 2016; 7,711,811 and 7,622,393 shares issued and outstanding as of September 30, 2016 and March 31, 2016, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Aethlon Medical Inc. stockholders' (deficit) equity before noncontrolling interests</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US">Noncontrolling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Total (deficit) equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock par value (in Dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">REVENUES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="us-gaap_ContractsRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractsRevenue" xlink:to="us-gaap_ContractsRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractsRevenue_lbl" xml:lang="en-US">Government contract revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">OPERATING EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US">Payroll and related expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">OPERATING LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">OTHER EXPENSE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="us-gaap_InterestAndDebtExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDebtExpense" xlink:to="us-gaap_InterestAndDebtExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndDebtExpense_lbl" xml:lang="en-US">Interest and other debt expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on debt extinguishment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Warrant repricing expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Total other expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">NET LOSS BEFORE NONCONTROLLING INTERESTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">LOSS ATTRIBUTABLE TO NONCONTROLLING INTERESTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted loss per common share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average number of common shares outstanding - basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt discount and deferred financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl" xml:lang="en-US">Due to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from the issuance of common stock, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US">Cash paid for tax withholding on vested restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="us-gaap_CashPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashPeriodIncreaseDecrease" xlink:to="us-gaap_CashPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net (decrease) increase in cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Cash_2_lbl" xml:lang="en-US">Cash at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Cash_3_lbl" xml:lang="en-US">Cash at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental disclosures of non-cash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_ConvertibleNotePayableAndAccruedInterestConvertedToCommonStock" xlink:label="AEMD_ConvertibleNotePayableAndAccruedInterestConvertedToCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_ConvertibleNotePayableAndAccruedInterestConvertedToCommonStock" xlink:to="AEMD_ConvertibleNotePayableAndAccruedInterestConvertedToCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_ConvertibleNotePayableAndAccruedInterestConvertedToCommonStock_lbl" xml:lang="en-US">Convertible note payable and accrued interest converted to common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_DebtDiscountOnConvertibleNotesPayable" xlink:label="AEMD_DebtDiscountOnConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_DebtDiscountOnConvertibleNotesPayable" xlink:to="AEMD_DebtDiscountOnConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_DebtDiscountOnConvertibleNotesPayable_lbl" xml:lang="en-US">Debt discount on convertible notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_IssuanceOfSharesUnderVestedRestrictedStockUnits" xlink:label="AEMD_IssuanceOfSharesUnderVestedRestrictedStockUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_IssuanceOfSharesUnderVestedRestrictedStockUnits" xlink:to="AEMD_IssuanceOfSharesUnderVestedRestrictedStockUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_IssuanceOfSharesUnderVestedRestrictedStockUnits_lbl" xml:lang="en-US">Issuance of shares under vested restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_ReclassificationOfAccruedInterestToConvertibleNotesPayable" xlink:label="AEMD_ReclassificationOfAccruedInterestToConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_ReclassificationOfAccruedInterestToConvertibleNotesPayable" xlink:to="AEMD_ReclassificationOfAccruedInterestToConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_ReclassificationOfAccruedInterestToConvertibleNotesPayable_lbl" xml:lang="en-US">Reclassification of accrued interest to convertible notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_CashlessExerciseOfWarrants" xlink:label="AEMD_CashlessExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_CashlessExerciseOfWarrants" xlink:to="AEMD_CashlessExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_CashlessExerciseOfWarrants_lbl" xml:lang="en-US">Cashless exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">Nature of Business and Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Loss per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xml:lang="en-US">Research and Development [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xml:lang="en-US">Research and Development Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xml:lang="en-US">Significant Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Convertible Notes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityAbstract_2_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Equity Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">Other Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="us-gaap_RevenueRecognitionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionAbstract" xlink:to="us-gaap_RevenueRecognitionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionAbstract_lbl" xml:lang="en-US">Revenue Recognition [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Darpa Contract and Related Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Segments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_lbl" xml:lang="en-US">Research and Development Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl" xml:lang="en-US">Convertible notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDebtConversionsTextBlock" xlink:label="us-gaap_ScheduleOfDebtConversionsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtConversionsTextBlock" xlink:to="us-gaap_ScheduleOfDebtConversionsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtConversionsTextBlock_lbl" xml:lang="en-US">Changes to principal balance of Convertible Note</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xml:lang="en-US">Share based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_lbl" xml:lang="en-US">Options vested and expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Warrant activity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Assumptions used</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Segment reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Potential common shares excluded from earnings per share calculation due to being antidilutive</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US">Convertible notes payable, principal</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Unamortized discount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Convertible notes payable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_2_lbl" xml:lang="en-US">Convertible notes payable, current portion</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_2_lbl" xml:lang="en-US">Convertible notes payable, noncurrent portion</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ConvertibleDebt_2_lbl" xml:lang="en-US">Convertible debt, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Increase in principal balance under the second amendment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Conversions during the period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ConvertibleDebt_3_lbl" xml:lang="en-US">Convertible debt, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:to="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_lbl" xml:lang="en-US">Amortization of deferred financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Total interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Debt maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Stock purchase price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Debt carrying amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsGross" xlink:to="us-gaap_DeferredFinanceCostsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xml:lang="en-US">Debt issuance cost</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_WarrantExpirationDate" xlink:label="AEMD_WarrantExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_WarrantExpirationDate" xlink:to="AEMD_WarrantExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_WarrantExpirationDate_lbl" xml:lang="en-US">Warrant expiration date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Loss on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xml:lang="en-US">Extension fee expense</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_SaleOfStockNewIssuesAggregateOfferingPrice" xlink:label="AEMD_SaleOfStockNewIssuesAggregateOfferingPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_SaleOfStockNewIssuesAggregateOfferingPrice" xlink:to="AEMD_SaleOfStockNewIssuesAggregateOfferingPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_SaleOfStockNewIssuesAggregateOfferingPrice_lbl" xml:lang="en-US">Sale of stock, new issues, aggregate offering price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from sale of stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Commissions</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_OtherOfferingExpenses" xlink:label="AEMD_OtherOfferingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_OtherOfferingExpenses" xlink:to="AEMD_OtherOfferingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_OtherOfferingExpenses_lbl" xml:lang="en-US">Other offering expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1_lbl" xml:lang="en-US">Warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Restricted stock units exchanged</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xml:lang="en-US">Fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other accrued liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_2_lbl" xml:lang="en-US">Total other current liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl" xml:lang="en-US">Basic and diluted loss per common share attributable to stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_SharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares" xlink:label="AEMD_SharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_SharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares" xlink:to="AEMD_SharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_SharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares_lbl" xml:lang="en-US">RSU's vested</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber" xlink:label="AEMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber" xlink:to="AEMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">RSU's expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Total RSU's outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Options vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Options expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Total options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price options vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price options expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual term options vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual term options expected to vest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_3_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" xml:lang="en-US">Stock-based compensation per share effect on diluted loss per common share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">RSU's granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">RSU per share, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue" xlink:label="AEMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue" xlink:to="AEMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue_lbl" xml:lang="en-US">RSU's granted, value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US">RSU's cancelled for withholding taxes, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US">RSU's cancelled for withholding taxes, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Stock options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Stock options expired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Intrinsic value of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Unrecognized compensation cost amortization period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2_lbl" xml:lang="en-US">Warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US">Warrants cancelled/expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Warrants outstanding, ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Warrants exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_RangeOfExercisePricesWarrantsBeginning" xlink:label="AEMD_RangeOfExercisePricesWarrantsBeginning" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_RangeOfExercisePricesWarrantsBeginning" xlink:to="AEMD_RangeOfExercisePricesWarrantsBeginning_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_RangeOfExercisePricesWarrantsBeginning_lbl" xml:lang="en-US">Range of exercise prices, warrants beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_RangeOfExercisePricesWarrantsExercised" xlink:label="AEMD_RangeOfExercisePricesWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_RangeOfExercisePricesWarrantsExercised" xlink:to="AEMD_RangeOfExercisePricesWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_RangeOfExercisePricesWarrantsExercised_lbl" xml:lang="en-US">Range of exercise prices, warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_RangeOfExercisePricesWarrantsIssued" xlink:label="AEMD_RangeOfExercisePricesWarrantsIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_RangeOfExercisePricesWarrantsIssued" xlink:to="AEMD_RangeOfExercisePricesWarrantsIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_RangeOfExercisePricesWarrantsIssued_lbl" xml:lang="en-US">Range of exercise prices, warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_RangeOfExercisePricesWarrantsCancelledExpired" xlink:label="AEMD_RangeOfExercisePricesWarrantsCancelledExpired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_RangeOfExercisePricesWarrantsCancelledExpired" xlink:to="AEMD_RangeOfExercisePricesWarrantsCancelledExpired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_RangeOfExercisePricesWarrantsCancelledExpired_lbl" xml:lang="en-US">Range of exercise prices, warrants cancelled/expired</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_RangeOfExercisePricesWarrantsEnding" xlink:label="AEMD_RangeOfExercisePricesWarrantsEnding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_RangeOfExercisePricesWarrantsEnding" xlink:to="AEMD_RangeOfExercisePricesWarrantsEnding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_RangeOfExercisePricesWarrantsEnding_lbl" xml:lang="en-US">Range of exercise prices, warrants ending</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_RangeOfExercisePricesWarrantsExercisable" xlink:label="AEMD_RangeOfExercisePricesWarrantsExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_RangeOfExercisePricesWarrantsExercisable" xlink:to="AEMD_RangeOfExercisePricesWarrantsExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_RangeOfExercisePricesWarrantsExercisable_lbl" xml:lang="en-US">Range of exercise prices, warrants exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Weighted average exercise price, warrants beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" xlink:label="AEMD_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" xlink:to="AEMD_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised_lbl" xml:lang="en-US">Weighted average exercise price, warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_WeightedAverageExercisePriceWarrantsIssued" xlink:label="AEMD_WeightedAverageExercisePriceWarrantsIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_WeightedAverageExercisePriceWarrantsIssued" xlink:to="AEMD_WeightedAverageExercisePriceWarrantsIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_WeightedAverageExercisePriceWarrantsIssued_lbl" xml:lang="en-US">Weighted average exercise price, warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelledExpired" xlink:label="AEMD_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelledExpired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelledExpired" xlink:to="AEMD_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelledExpired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelledExpired_lbl" xml:lang="en-US">Weighted average exercise price, warrants cancelled/expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xml:lang="en-US">Weighted average exercise price, warrants ending</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_WeightedAverageExercisePriceWarrantsExercisable" xlink:label="AEMD_WeightedAverageExercisePriceWarrantsExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_WeightedAverageExercisePriceWarrantsExercisable" xlink:to="AEMD_WeightedAverageExercisePriceWarrantsExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_WeightedAverageExercisePriceWarrantsExercisable_lbl" xml:lang="en-US">Weighted average exercise price, warrants exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Average expected life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xml:lang="en-US">Expected dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_FairValueOfWarrantsIssued" xlink:label="AEMD_FairValueOfWarrantsIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_FairValueOfWarrantsIssued" xlink:to="AEMD_FairValueOfWarrantsIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AEMD_FairValueOfWarrantsIssued_lbl" xml:lang="en-US">Fair value of warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xml:lang="en-US">Revenue recognition</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractsRevenue" xlink:to="us-gaap_ContractsRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractsRevenue_2_lbl" xml:lang="en-US">Revenues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Losses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_3_lbl" xml:lang="en-US">Net Losses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US">Capital Expenditures</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpenseOther" xlink:label="us-gaap_InterestExpenseOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseOther_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Rent expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelledExpired" xlink:to="AEMD_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelledExpired_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AEMD_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelledExpired_doc" xml:lang="en-US">Weighted average exercise price, warrants cancelled/expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" xlink:to="AEMD_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AEMD_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised_doc" xml:lang="en-US">Weighted average exercise price, warrants exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_RangeOfExercisePricesWarrantsBeginning" xlink:to="AEMD_RangeOfExercisePricesWarrantsBeginning_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AEMD_RangeOfExercisePricesWarrantsBeginning_doc" xml:lang="en-US">Range of exercise prices, warrants beginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_RangeOfExercisePricesWarrantsCancelledExpired" xlink:to="AEMD_RangeOfExercisePricesWarrantsCancelledExpired_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AEMD_RangeOfExercisePricesWarrantsCancelledExpired_doc" xml:lang="en-US">Range of exercise prices, warrants cancelled/expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_RangeOfExercisePricesWarrantsEnding" xlink:to="AEMD_RangeOfExercisePricesWarrantsEnding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AEMD_RangeOfExercisePricesWarrantsEnding_doc" xml:lang="en-US">Range of exercise prices, warrants ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_RangeOfExercisePricesWarrantsExercisable" xlink:to="AEMD_RangeOfExercisePricesWarrantsExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AEMD_RangeOfExercisePricesWarrantsExercisable_doc" xml:lang="en-US">Range of exercise prices, warrants exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_RangeOfExercisePricesWarrantsExercised" xlink:to="AEMD_RangeOfExercisePricesWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AEMD_RangeOfExercisePricesWarrantsExercised_doc" xml:lang="en-US">Range of exercise prices, warrants exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_RangeOfExercisePricesWarrantsIssued" xlink:to="AEMD_RangeOfExercisePricesWarrantsIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AEMD_RangeOfExercisePricesWarrantsIssued_doc" xml:lang="en-US">Range of exercise prices, warrants issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_ReclassificationOfAccruedInterestToConvertibleNotesPayable" xlink:to="AEMD_ReclassificationOfAccruedInterestToConvertibleNotesPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AEMD_ReclassificationOfAccruedInterestToConvertibleNotesPayable_doc" xml:lang="en-US">Reclassification of accrued interest to convertible notes payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_WeightedAverageExercisePriceWarrantsExercisable" xlink:to="AEMD_WeightedAverageExercisePriceWarrantsExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AEMD_WeightedAverageExercisePriceWarrantsExercisable_doc" xml:lang="en-US">Weighted average exercise price, warrants exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_WeightedAverageExercisePriceWarrantsIssued" xlink:to="AEMD_WeightedAverageExercisePriceWarrantsIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AEMD_WeightedAverageExercisePriceWarrantsIssued_doc" xml:lang="en-US">Weighted average exercise price, warrants issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_SaleOfStockNewIssuesAggregateOfferingPrice" xlink:to="AEMD_SaleOfStockNewIssuesAggregateOfferingPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AEMD_SaleOfStockNewIssuesAggregateOfferingPrice_doc" xml:lang="en-US">Sale of stock, new issues, aggregate offering price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_FairValueOfWarrantsIssued" xlink:to="AEMD_FairValueOfWarrantsIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AEMD_FairValueOfWarrantsIssued_doc" xml:lang="en-US">Fair value of warrants issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_IssuanceOfSharesUnderVestedRestrictedStockUnits" xlink:to="AEMD_IssuanceOfSharesUnderVestedRestrictedStockUnits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AEMD_IssuanceOfSharesUnderVestedRestrictedStockUnits_doc" xml:lang="en-US">Issuance of shares under vested restricted stock units</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_CashlessExerciseOfWarrants" xlink:to="AEMD_CashlessExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AEMD_CashlessExerciseOfWarrants_doc" xml:lang="en-US">Cashless exercise of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_WarrantExpirationDate" xlink:to="AEMD_WarrantExpirationDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AEMD_WarrantExpirationDate_doc" xml:lang="en-US">Warrant expiration date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_OtherOfferingExpenses" xlink:to="AEMD_OtherOfferingExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AEMD_OtherOfferingExpenses_doc" xml:lang="en-US">Other offering expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_SharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares" xlink:to="AEMD_SharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AEMD_SharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares_doc" xml:lang="en-US">Number of RSU's vested,</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber" xlink:to="AEMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AEMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber_doc" xml:lang="en-US">Number of RSU's expected to vest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue" xlink:to="AEMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AEMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue_doc" xml:lang="en-US">RSU's granted, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AEMD_ConvertibleNotePayableAndAccruedInterestConvertedToCommonStock" xlink:to="AEMD_ConvertibleNotePayableAndAccruedInterestConvertedToCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AEMD_ConvertibleNotePayableAndAccruedInterestConvertedToCommonStock_doc" xml:lang="en-US">Convertible note payable and accrued interest converted to common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_2_lbl" xml:lang="en-US">Other Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Related Parties</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2_lbl" xml:lang="en-US">Payments Related to Tax Withholding for Share-based Compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashPeriodIncreaseDecrease" xlink:to="us-gaap_CashPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Cash, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_2_lbl" xml:lang="en-US">Schedule of Research and Development Assets Acquired Other than Through Business Combination [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock_2_lbl" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_2_lbl" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_2_lbl" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1_2_lbl" xml:lang="en-US">Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Warrants Issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_2_lbl" xml:lang="en-US">Interest Payable, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseOther_2_lbl" xml:lang="en-US">Interest Expense, Other</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>aemd-20160930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.15b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: aethlon_10q%2D20160930.xfr; Date: 2016%2D11%2D08T22:13:26Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://aethlon.com/role/DocumentAndEntityInformation" xlink:href="aemd-20160930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/BalanceSheets" xlink:href="aemd-20160930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/BalanceSheetsParenthetical" xlink:href="aemd-20160930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/StatementsOfOperations" xlink:href="aemd-20160930.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/StatementsOfCashFlowsUnaudited0" xlink:href="aemd-20160930.xsd#StatementsOfCashFlowsUnaudited0" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/NatureOfBusinessAndBasisOfPresentation" xlink:href="aemd-20160930.xsd#NatureOfBusinessAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/LossPerCommonShare" xlink:href="aemd-20160930.xsd#LossPerCommonShare" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/ResearchAndDevelopmentExpenses" xlink:href="aemd-20160930.xsd#ResearchAndDevelopmentExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/SignificantRecentAccountingPronouncements" xlink:href="aemd-20160930.xsd#SignificantRecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/ConvertibleNotesPayable" xlink:href="aemd-20160930.xsd#ConvertibleNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/EquityTransactions" xlink:href="aemd-20160930.xsd#EquityTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/RelatedPartyTransactions" xlink:href="aemd-20160930.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/OtherCurrentLiabilities" xlink:href="aemd-20160930.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/StockCompensation" xlink:href="aemd-20160930.xsd#StockCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/Warrants" xlink:href="aemd-20160930.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/DarpaContractAndRelatedRevenueRecognition" xlink:href="aemd-20160930.xsd#DarpaContractAndRelatedRevenueRecognition" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/Segments" xlink:href="aemd-20160930.xsd#Segments" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/CommitmentsAndContingencies" xlink:href="aemd-20160930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/SubsequentEvents" xlink:href="aemd-20160930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/ResearchAndDevelopmentExpensesTables" xlink:href="aemd-20160930.xsd#ResearchAndDevelopmentExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/ConvertibleNotesPayableTables" xlink:href="aemd-20160930.xsd#ConvertibleNotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/OtherCurrentLiabilitiesTables" xlink:href="aemd-20160930.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/StockCompensationTables" xlink:href="aemd-20160930.xsd#StockCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/WarrantsTables" xlink:href="aemd-20160930.xsd#WarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/SegmentsTables" xlink:href="aemd-20160930.xsd#SegmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/NatureOfBusinessDetailsNarrative" xlink:href="aemd-20160930.xsd#NatureOfBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/LossPerCommonShareDetailsNarrative" xlink:href="aemd-20160930.xsd#LossPerCommonShareDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/ResearchAndDevelopmentExpenses-3.ResearchAndDevelopmentExpensesDetails" xlink:href="aemd-20160930.xsd#ResearchAndDevelopmentExpenses-3.ResearchAndDevelopmentExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/ConvertibleNotesPayableDetails-ConvertibleNotesPayable" xlink:href="aemd-20160930.xsd#ConvertibleNotesPayableDetails-ConvertibleNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/ConvertibleNotesPayableDetails-ConvertibleNoteActivity" xlink:href="aemd-20160930.xsd#ConvertibleNotesPayableDetails-ConvertibleNoteActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:href="aemd-20160930.xsd#ConvertibleNotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/EquityTransactionsDetailsNarrative" xlink:href="aemd-20160930.xsd#EquityTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="aemd-20160930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/OtherCurrentLiabilitiesDetails" xlink:href="aemd-20160930.xsd#OtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/StockCompensationDetails-ShareBasedCompensation" xlink:href="aemd-20160930.xsd#StockCompensationDetails-ShareBasedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/StockCompensationDetails-RsusOutstanding" xlink:href="aemd-20160930.xsd#StockCompensationDetails-RsusOutstanding" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest" xlink:href="aemd-20160930.xsd#StockCompensationDetails-OptionsVestedAndExpectedToVest" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/StockCompensationDetailsNarrative" xlink:href="aemd-20160930.xsd#StockCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/WarrantsDetails-WarrantActivity" xlink:href="aemd-20160930.xsd#WarrantsDetails-WarrantActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/WarrantsDetails-Assumptions" xlink:href="aemd-20160930.xsd#WarrantsDetails-Assumptions" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/WarrantsDetailsNarrative" xlink:href="aemd-20160930.xsd#WarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/DarpaContractAndRelatedRevenueRecognitionDetailsNarrative" xlink:href="aemd-20160930.xsd#DarpaContractAndRelatedRevenueRecognitionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/SegmentsDetails" xlink:href="aemd-20160930.xsd#SegmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlon.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="aemd-20160930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_DocumentAndEntityInformationAbstract" xlink:label="loc_AEMDDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AEMDDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AEMDDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AEMDDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AEMDDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AEMDDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AEMDDocumentAndEntityInformationAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AEMDDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AEMDDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AEMDDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AEMDDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AEMDDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AEMDDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AEMDDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AEMDDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepositsAssets" xlink:label="loc_us-gaapDepositsAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapDepositsAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaapConvertibleLongTermNotesPayable" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapConvertibleLongTermNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenuesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaapContractsRevenue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_us-gaapContractsRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapLaborAndRelatedExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaapInterestAndDebtExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestAndDebtExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/StatementsOfCashFlowsUnaudited0" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited0">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableRelatedParties" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableRelatedParties" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashPeriodIncreaseDecrease" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_2" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCash_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_ConvertibleNotePayableAndAccruedInterestConvertedToCommonStock" xlink:label="loc_AEMDConvertibleNotePayableAndAccruedInterestConvertedToCommonStock" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_AEMDConvertibleNotePayableAndAccruedInterestConvertedToCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_DebtDiscountOnConvertibleNotesPayable" xlink:label="loc_AEMDDebtDiscountOnConvertibleNotesPayable" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_AEMDDebtDiscountOnConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_IssuanceOfSharesUnderVestedRestrictedStockUnits" xlink:label="loc_AEMDIssuanceOfSharesUnderVestedRestrictedStockUnits" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_AEMDIssuanceOfSharesUnderVestedRestrictedStockUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_ReclassificationOfAccruedInterestToConvertibleNotesPayable" xlink:label="loc_AEMDReclassificationOfAccruedInterestToConvertibleNotesPayable" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_AEMDReclassificationOfAccruedInterestToConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_CashlessExerciseOfWarrants" xlink:label="loc_AEMDCashlessExerciseOfWarrants" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_AEMDCashlessExerciseOfWarrants" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/NatureOfBusinessAndBasisOfPresentation" xlink:title="00000006 - Disclosure - 1. Nature of Business and Basis of Presentation">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/LossPerCommonShare" xlink:title="00000007 - Disclosure - 2. Loss per Common Share">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/ResearchAndDevelopmentExpenses" xlink:title="00000008 - Disclosure - 3. Research and Development Expenses">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="loc_us-gaapResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/SignificantRecentAccountingPronouncements" xlink:title="00000009 - Disclosure - 4. Significant Recent Accounting Pronouncements">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/ConvertibleNotesPayable" xlink:title="00000010 - Disclosure - 5. Convertible Notes Payable">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/EquityTransactions" xlink:title="00000011 - Disclosure - 6. Equity Transactions">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/RelatedPartyTransactions" xlink:title="00000012 - Disclosure - 7. Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/OtherCurrentLiabilities" xlink:title="00000013 - Disclosure - 8. Other Current Liabilities">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/StockCompensation" xlink:title="00000014 - Disclosure - 9. Stock Compensation">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/Warrants" xlink:title="00000015 - Disclosure - 10. Warrants">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/DarpaContractAndRelatedRevenueRecognition" xlink:title="00000016 - Disclosure - 11. Darpa Contract and Related Revenue Recognition">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="loc_us-gaapRevenueRecognitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueRecognitionAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/Segments" xlink:title="00000017 - Disclosure - 12. Segments">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/CommitmentsAndContingencies" xlink:title="00000018 - Disclosure - 13. Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/SubsequentEvents" xlink:title="00000019 - Disclosure - 14. Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/ResearchAndDevelopmentExpensesTables" xlink:title="00000020 - Disclosure - 3. Research and Development Expenses (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:label="loc_us-gaapScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/ConvertibleNotesPayableTables" xlink:title="00000021 - Disclosure - 5. Convertible Notes Payable (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaapConvertibleDebtTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapConvertibleDebtTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDebtConversionsTextBlock" xlink:label="loc_us-gaapScheduleOfDebtConversionsTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDebtConversionsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000022 - Disclosure - 8. Other Current Liabilities (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="loc_us-gaapOtherCurrentLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/StockCompensationTables" xlink:title="00000023 - Disclosure - 9. Stock Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/WarrantsTables" xlink:title="00000024 - Disclosure - 10. Warrants (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_December2014WarrantsMember" xlink:label="loc_AEMDDecember2014WarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_AEMDDecember2014WarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/SegmentsTables" xlink:title="00000025 - Disclosure - 12. Segments (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/NatureOfBusinessDetailsNarrative" xlink:title="00000026 - Disclosure - 1. Nature of Business (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/LossPerCommonShareDetailsNarrative" xlink:title="00000027 - Disclosure - 2. Loss per Common Share (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/ResearchAndDevelopmentExpenses-3.ResearchAndDevelopmentExpensesDetails" xlink:title="00000028 - Disclosure - 3. Research and Development Expenses - 3. Research and Development Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/ConvertibleNotesPayableDetails-ConvertibleNotesPayable" xlink:title="00000029 - Disclosure - 5. Convertible Notes Payable (Details - Convertible Notes Payable)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaapConvertibleLongTermNotesPayable" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapConvertibleLongTermNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/ConvertibleNotesPayableDetails-ConvertibleNoteActivity" xlink:title="00000030 - Disclosure - 5. Convertible Notes Payable (Details - Convertible note activity)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapConvertibleDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapConvertibleDebt_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:title="00000031 - Disclosure - 5. Convertible Notes Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_ConvertibleNotes10November2014Amend2Member" xlink:label="loc_AEMDConvertibleNotes10November2014Amend2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_AEMDConvertibleNotes10November2014Amend2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_ConvertibleNotes10November2014Member" xlink:label="loc_AEMDConvertibleNotes10November2014Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_AEMDConvertibleNotes10November2014Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="loc_us-gaapExtinguishmentOfDebtAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapExtinguishmentOfDebtAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="loc_us-gaapExtinguishmentOfDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapExtinguishmentOfDebtAxis" xlink:to="loc_us-gaapExtinguishmentOfDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_FairValueWarrantsMember" xlink:label="loc_AEMDFairValueWarrantsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapExtinguishmentOfDebtTypeDomain" xlink:to="loc_AEMDFairValueWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_BeneficialConversionFeatureMember" xlink:label="loc_AEMDBeneficialConversionFeatureMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapExtinguishmentOfDebtTypeDomain" xlink:to="loc_AEMDBeneficialConversionFeatureMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_DebtDiscountMember" xlink:label="loc_AEMDDebtDiscountMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapExtinguishmentOfDebtTypeDomain" xlink:to="loc_AEMDDebtDiscountMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestExpenseDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaapDebtRelatedCommitmentFeesAndDebtIssuanceCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaapDeferredFinanceCostsGross" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_WarrantExpirationDate" xlink:label="loc_AEMDWarrantExpirationDate" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AEMDWarrantExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="loc_us-gaapDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/EquityTransactionsDetailsNarrative" xlink:title="00000032 - Disclosure - 6. Equity Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaapCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapCounterpartyNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCounterpartyNameAxis" xlink:to="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_WainwrightMember" xlink:label="loc_AEMDWainwrightMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_AEMDWainwrightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_ThreeInvestorsMember" xlink:label="loc_AEMDThreeInvestorsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_AEMDThreeInvestorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_December2014WarrantsMember" xlink:label="loc_AEMDDecember2014WarrantsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_AEMDDecember2014WarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_SaleOfStockNewIssuesAggregateOfferingPrice" xlink:label="loc_AEMDSaleOfStockNewIssuesAggregateOfferingPrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AEMDSaleOfStockNewIssuesAggregateOfferingPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_OtherOfferingExpenses" xlink:label="loc_AEMDOtherOfferingExpenses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AEMDOtherOfferingExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1" xlink:label="loc_us-gaapNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000033 - Disclosure - 7. Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_UnPaidBoardFeesMember" xlink:label="loc_AEMDUnPaidBoardFeesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_AEMDUnPaidBoardFeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/OtherCurrentLiabilitiesDetails" xlink:title="00000034 - Disclosure - 8. Other Current Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/StockCompensationDetails-ShareBasedCompensation" xlink:title="00000035 - Disclosure - 9. Stock Compensation (Details - Share based compensation)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsPerBasicAndDilutedShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/StockCompensationDetails-RsusOutstanding" xlink:title="00000036 - Disclosure - 9. Stock Compensation (Details - RSU's outstanding)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_SharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares" xlink:label="loc_AEMDSharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AEMDSharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_AEMDShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AEMDShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest" xlink:title="00000037 - Disclosure - 9. Stock Compensation (Details - Options vested and expected to vest)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/StockCompensationDetailsNarrative" xlink:title="00000038 - Disclosure - 9. Stock Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_JamesJoyceMember" xlink:label="loc_AEMDJamesJoyceMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AEMDJamesJoyceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_RodneyKenleyMember" xlink:label="loc_AEMDRodneyKenleyMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AEMDRodneyKenleyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_JamesFrakesMember" xlink:label="loc_AEMDJamesFrakesMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AEMDJamesFrakesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_NonEmployeeDirectorsMember" xlink:label="loc_AEMDNonEmployeeDirectorsMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AEMDNonEmployeeDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaapCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapCounterpartyNameAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCounterpartyNameAxis" xlink:to="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsPerDilutedShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_SharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares" xlink:label="loc_AEMDSharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AEMDSharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue" xlink:label="loc_AEMDShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AEMDShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapSharesPaidForTaxWithholdingForShareBasedCompensation" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapAdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/WarrantsDetails-WarrantActivity" xlink:title="00000039 - Disclosure - 10. Warrants (Details - Warrant activity)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_RangeOfExercisePricesWarrantsBeginning" xlink:label="loc_AEMDRangeOfExercisePricesWarrantsBeginning" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AEMDRangeOfExercisePricesWarrantsBeginning" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_RangeOfExercisePricesWarrantsExercised" xlink:label="loc_AEMDRangeOfExercisePricesWarrantsExercised" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AEMDRangeOfExercisePricesWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_RangeOfExercisePricesWarrantsIssued" xlink:label="loc_AEMDRangeOfExercisePricesWarrantsIssued" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AEMDRangeOfExercisePricesWarrantsIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_RangeOfExercisePricesWarrantsCancelledExpired" xlink:label="loc_AEMDRangeOfExercisePricesWarrantsCancelledExpired" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AEMDRangeOfExercisePricesWarrantsCancelledExpired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_RangeOfExercisePricesWarrantsEnding" xlink:label="loc_AEMDRangeOfExercisePricesWarrantsEnding" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AEMDRangeOfExercisePricesWarrantsEnding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_RangeOfExercisePricesWarrantsExercisable" xlink:label="loc_AEMDRangeOfExercisePricesWarrantsExercisable" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AEMDRangeOfExercisePricesWarrantsExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" xlink:label="loc_AEMDClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AEMDClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_WeightedAverageExercisePriceWarrantsIssued" xlink:label="loc_AEMDWeightedAverageExercisePriceWarrantsIssued" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AEMDWeightedAverageExercisePriceWarrantsIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelledExpired" xlink:label="loc_AEMDClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelledExpired" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AEMDClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelledExpired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_WeightedAverageExercisePriceWarrantsExercisable" xlink:label="loc_AEMDWeightedAverageExercisePriceWarrantsExercisable" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AEMDWeightedAverageExercisePriceWarrantsExercisable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/WarrantsDetails-Assumptions" xlink:title="00000040 - Disclosure - 10. Warrants (Details - Assumptions)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_December2014WarrantsMember" xlink:label="loc_AEMDDecember2014WarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_AEMDDecember2014WarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/WarrantsDetailsNarrative" xlink:title="00000041 - Disclosure - 10. Warrants (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_December2014WarrantsMember" xlink:label="loc_AEMDDecember2014WarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_AEMDDecember2014WarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_FairValueOfWarrantsIssued" xlink:label="loc_AEMDFairValueOfWarrantsIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AEMDFairValueOfWarrantsIssued" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/DarpaContractAndRelatedRevenueRecognitionDetailsNarrative" xlink:title="00000042 - Disclosure - 11. Darpa Contract and Related Revenue Recognition (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="loc_us-gaapRevenueRecognitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueRecognitionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_Milestone2613Member" xlink:label="loc_AEMDMilestone2613Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AEMDMilestone2613Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_Milestone26143Member" xlink:label="loc_AEMDMilestone26143Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AEMDMilestone26143Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_MilestoneM6Member" xlink:label="loc_AEMDMilestoneM6Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AEMDMilestoneM6Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_Milestone2511Member" xlink:label="loc_AEMDMilestone2511Member" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AEMDMilestone2511Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaapRevenueRecognitionMilestoneMethodRevenueRecognized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueRecognitionMilestoneMethodRevenueRecognized" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/SegmentsDetails" xlink:title="00000043 - Disclosure - 12. Segments (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_AethlonMember" xlink:label="loc_AEMDAethlonMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_AEMDAethlonMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20160930.xsd#AEMD_ESIMember" xlink:label="loc_AEMDESIMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_AEMDESIMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaapContractsRevenue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapContractsRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireProductiveAssets" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsToAcquireProductiveAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpenseOther" xlink:label="loc_us-gaapInterestExpenseOther" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestExpenseOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlon.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000044 - Disclosure - 13. Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6731821232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Nov. 08, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_AEMD_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AETHLON MEDICAL INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000882291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--03-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Is Entity a Well-known Seasoned Issuer?</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Is Entity a Voluntary Filer?</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Is Entity's Reporting Status Current?</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,725,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AEMD_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AEMD_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AEMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6732331920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 556,352<span></span>
</td>
<td class="nump">$ 2,123,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">193,719<span></span>
</td>
<td class="nump">199,471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">66,469<span></span>
</td>
<td class="nump">53,294<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
<td class="nump">816,540<span></span>
</td>
<td class="nump">2,376,502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">22,969<span></span>
</td>
<td class="nump">36,038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patents and patents pending, net</a></td>
<td class="nump">89,579<span></span>
</td>
<td class="nump">94,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssets', window );">Deposits</a></td>
<td class="nump">21,747<span></span>
</td>
<td class="nump">22,415<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">950,835<span></span>
</td>
<td class="nump">2,529,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">384,728<span></span>
</td>
<td class="nump">244,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="nump">58,362<span></span>
</td>
<td class="nump">145,112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable, net - current portion</a></td>
<td class="nump">605,815<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">35,316<span></span>
</td>
<td class="nump">136,695<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="nump">1,084,221<span></span>
</td>
<td class="nump">526,611<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>NONCURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible notes payable, net - less current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">500,139<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">1,084,221<span></span>
</td>
<td class="nump">1,026,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES (Note 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.001 per share; 30,000,000 shares authorized as of September 30, 2016 and March 31, 2016; 7,711,811 and 7,622,393 shares issued and outstanding as of September 30, 2016 and March 31, 2016, respectively</a></td>
<td class="nump">7,711<span></span>
</td>
<td class="nump">7,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">90,811,302<span></span>
</td>
<td class="nump">88,047,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(90,886,645)<span></span>
</td>
<td class="num">(86,502,043)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Aethlon Medical Inc. stockholders' (deficit) equity before noncontrolling interests</a></td>
<td class="num">(67,632)<span></span>
</td>
<td class="nump">1,552,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="num">(65,754)<span></span>
</td>
<td class="num">(50,354)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total (deficit) equity</a></td>
<td class="num">(133,386)<span></span>
</td>
<td class="nump">1,502,366<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 950,835<span></span>
</td>
<td class="nump">$ 2,529,116<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4590271-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568740-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6719129296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued</a></td>
<td class="nump">7,711,811<span></span>
</td>
<td class="nump">7,622,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding</a></td>
<td class="nump">7,711,811<span></span>
</td>
<td class="nump">7,622,393<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6730051760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Government contract revenue</a></td>
<td class="nump">$ 387,438<span></span>
</td>
<td class="nump">$ 188,366<span></span>
</td>
<td class="nump">$ 392,073<span></span>
</td>
<td class="nump">$ 380,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="nump">510,982<span></span>
</td>
<td class="nump">389,207<span></span>
</td>
<td class="nump">1,078,731<span></span>
</td>
<td class="nump">927,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Payroll and related expenses</a></td>
<td class="nump">1,813,003<span></span>
</td>
<td class="nump">597,850<span></span>
</td>
<td class="nump">2,158,190<span></span>
</td>
<td class="nump">1,056,078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">290,131<span></span>
</td>
<td class="nump">325,670<span></span>
</td>
<td class="nump">513,681<span></span>
</td>
<td class="nump">611,695<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">2,614,116<span></span>
</td>
<td class="nump">1,312,727<span></span>
</td>
<td class="nump">3,750,602<span></span>
</td>
<td class="nump">2,595,206<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
<td class="num">(2,226,678)<span></span>
</td>
<td class="num">(1,124,361)<span></span>
</td>
<td class="num">(3,358,529)<span></span>
</td>
<td class="num">(2,214,332)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER EXPENSE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Interest and other debt expenses</a></td>
<td class="nump">36,576<span></span>
</td>
<td class="nump">127,245<span></span>
</td>
<td class="nump">78,743<span></span>
</td>
<td class="nump">253,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">616,889<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrant repricing expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">345,841<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Total other expense</a></td>
<td class="nump">36,576<span></span>
</td>
<td class="nump">127,245<span></span>
</td>
<td class="nump">1,041,473<span></span>
</td>
<td class="nump">253,933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">NET LOSS BEFORE NONCONTROLLING INTERESTS</a></td>
<td class="num">(2,263,254)<span></span>
</td>
<td class="num">(1,251,606)<span></span>
</td>
<td class="num">(4,400,002)<span></span>
</td>
<td class="num">(2,468,265)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">LOSS ATTRIBUTABLE TO NONCONTROLLING INTERESTS</a></td>
<td class="num">(7,668)<span></span>
</td>
<td class="num">(27,000)<span></span>
</td>
<td class="num">(15,400)<span></span>
</td>
<td class="num">(60,623)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS</a></td>
<td class="num">$ (2,255,586)<span></span>
</td>
<td class="num">$ (1,224,606)<span></span>
</td>
<td class="num">$ (4,384,602)<span></span>
</td>
<td class="num">$ (2,407,642)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted loss per common share</a></td>
<td class="num">$ (.29)<span></span>
</td>
<td class="num">$ (.16)<span></span>
</td>
<td class="num">$ (.57)<span></span>
</td>
<td class="num">$ (.34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding - basic and diluted</a></td>
<td class="nump">7,756,883<span></span>
</td>
<td class="nump">7,610,459<span></span>
</td>
<td class="nump">7,690,369<span></span>
</td>
<td class="nump">7,167,903<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and construction contracts, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of expenditures for salaries, wages, profit sharing and incentive compensation, and other employee benefits, including equity-based compensation, and pension and other postretirement benefit expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488393&amp;loc=d3e606610-122999<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 225<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=6488370&amp;loc=d3e13550-115849<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6731800016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited0 - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (4,400,002)<span></span>
</td>
<td class="num">$ (2,468,265)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">20,612<span></span>
</td>
<td class="nump">18,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">1,573,991<span></span>
</td>
<td class="nump">101,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrant repricing expense</a></td>
<td class="nump">345,841<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="nump">616,889<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and deferred financing costs</a></td>
<td class="nump">46,639<span></span>
</td>
<td class="nump">225,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">5,752<span></span>
</td>
<td class="nump">6,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(12,507)<span></span>
</td>
<td class="num">(35,777)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and other current liabilities</a></td>
<td class="nump">125,842<span></span>
</td>
<td class="num">(144,533)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Due to related parties</a></td>
<td class="num">(86,750)<span></span>
</td>
<td class="nump">58,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="num">(1,763,693)<span></span>
</td>
<td class="num">(2,238,228)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(2,961)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
<td class="num">(2,961)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock, net</a></td>
<td class="nump">266,612<span></span>
</td>
<td class="nump">5,591,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Cash paid for tax withholding on vested restricted stock units</a></td>
<td class="num">(67,343)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="nump">199,269<span></span>
</td>
<td class="nump">5,591,988<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashPeriodIncreaseDecrease', window );">Net (decrease) increase in cash</a></td>
<td class="num">(1,567,385)<span></span>
</td>
<td class="nump">3,353,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash at beginning of period</a></td>
<td class="nump">2,123,737<span></span>
</td>
<td class="nump">855,596<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash at end of period</a></td>
<td class="nump">556,352<span></span>
</td>
<td class="nump">4,209,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_AEMD_ConvertibleNotePayableAndAccruedInterestConvertedToCommonStock', window );">Convertible note payable and accrued interest converted to common stock</a></td>
<td class="nump">32,321<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_AEMD_DebtDiscountOnConvertibleNotesPayable', window );">Debt discount on convertible notes payable</a></td>
<td class="nump">75,994<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_AEMD_IssuanceOfSharesUnderVestedRestrictedStockUnits', window );">Issuance of shares under vested restricted stock units</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_AEMD_ReclassificationOfAccruedInterestToConvertibleNotesPayable', window );">Reclassification of accrued interest to convertible notes payable</a></td>
<td class="nump">85,031<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_AEMD_CashlessExerciseOfWarrants', window );">Cashless exercise of warrants</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AEMD_CashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cashless exercise of warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AEMD_CashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AEMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AEMD_ConvertibleNotePayableAndAccruedInterestConvertedToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible note payable and accrued interest converted to common stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AEMD_ConvertibleNotePayableAndAccruedInterestConvertedToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AEMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AEMD_DebtDiscountOnConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AEMD_DebtDiscountOnConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AEMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AEMD_IssuanceOfSharesUnderVestedRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares under vested restricted stock units</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AEMD_IssuanceOfSharesUnderVestedRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AEMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AEMD_ReclassificationOfAccruedInterestToConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of accrued interest to convertible notes payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AEMD_ReclassificationOfAccruedInterestToConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AEMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6723095728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>1. Nature of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of Business and Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">ORGANIZATION</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">Aethlon Medical, Inc. and subsidiary
(&#34;Aethlon&#34;, the &#34;Company&#34;, &#34;we&#34; or &#34;us&#34;) is a medical device company focused on creating
innovative devices that address unmet medical needs in cancer, infectious disease and other life-threatening conditions. At the
core of our developments is the Aethlon ADAPT&#8482; (Adaptive Dialysis-Like Affinity Platform Technology) system, a medical device
platform that converges single or multiple affinity drug agents with advanced plasma membrane technology to create therapeutic
filtration devices that selectively remove harmful particles from the entire circulatory system without loss of essential blood
components. On June 25, 2013, the United States Food and Drug Administration (FDA) approved an Investigational Device Exemption
(IDE) that allows us to initiate human feasibility studies of the Aethlon Hemopurifier&#174; in the U.S. Under the feasibility
study protocol, we plan to enroll ten end-stage renal disease patients who are infected with the Hepatitis C virus (HCV) to demonstrate
the safety of Hemopurifier therapy. Successful completion of this study will allow us the opportunity to initiate pivotal studies
that are required for market clearance to treat HCV and other disease conditions in the U.S.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">Successful outcomes of human trials
will also be required by the regulatory agencies of certain foreign countries where we intend to sell this device. Some of our
patents may expire before FDA approval or approval in a foreign country, if any, is obtained. However, we believe that certain
patent applications and/or other patents issued more recently will help protect the proprietary nature of the Hemopurifier(R)
treatment technology.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">In October 2013, our majority owned
subsidiary, Exosome Sciences, Inc. (&#8220;ESI&#8221;), commenced operations with a focus on advancing exosome-based strategies
to diagnose and monitor the progression of cancer, infectious disease and other life-threatening conditions.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">ESI is accounted for as a non-controlling
interest as the Company has an 80% ownership interest in the subsidiary. Earnings or losses attributable to other stockholders
of a consolidated affiliated company are classified separately as &#34;noncontrolling interest&#34; in the Company's consolidated
statements of operations. Net loss attributable to noncontrolling interest reflects only its share of the after-tax earnings or
losses of an affiliated company. Income taxes attributable to noncontrolling interest are determined using the applicable statutory
tax rates in the jurisdictions where such operations are conducted. The Company's consolidated balance sheets reflect noncontrolling
interests within the equity section of the consolidated balance sheets.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">Our common stock is traded on the
Nasdaq Capital Market under the symbol &#8220;AEMD.&#8221;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">During the six months ended September
30, 2016, there have been no changes to our significant accounting policies as described in our Annual Report on Form 10-K for
the fiscal year ended March 31, 2016.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">The accompanying
unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally
accepted accounting principles (GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10
of the Securities and Exchange Commission (SEC) Regulation S-X. Accordingly, they should be read in conjunction with the
audited financial statements and notes thereto for the year ended March 31, 2016, included in the Company's Annual Report on
Form 10-K filed with the SEC on June 29, 2016. The accompanying unaudited condensed consolidated financial statements include
the accounts of Aethlon Medical, Inc. and its majority-owned subsidiary. All significant inter-company transactions and
balances have been eliminated in consolidation. The unaudited condensed consolidated financial statements contain all normal
recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the condensed
consolidated balance sheet of the Company at September 30, 2016, the condensed consolidated statements of operations for the
three and six months ended September 30, 2016, and the condensed consolidated statement of cash flows for the six months
ended September 30, 2016. Estimates were made relating to useful lives of fixed assets, valuation allowances, the fair value
of warrants, impairment of assets, share-based compensation expense and accruals for clinical trial and research and
development expenses. Actual results could differ materially from those estimates. Certain amounts previously reported in the
financial statements have been reclassified to conform to the current presentation. Such reclassifications did not affect net
loss, equity or cash flows. The accompanying condensed consolidated balance sheet at March 31, 2016 has been derived from the
audited consolidated balance sheet at March 31, 2016, contained in the above referenced 10-K. The results of operations for
the three and six months ended September 30, 2016 are not necessarily indicative of the results to be expected for the full
year or any future interim periods.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">On April 14, 2015, we completed a
1-for-50 reverse stock split. Accordingly, authorized common stock was reduced from 500,000,000 shares to 10,000,000 shares, and
each 50 shares of outstanding common stock held by stockholders were combined into one share of common stock. The accompanying
condensed consolidated financial statements and accompanying notes have been retroactively revised to reflect such reverse stock
split as if it had occurred on April 1, 2015. All share and per share amounts have been revised accordingly.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">On March 31, 2016, we filed a Certificate
of Amendment to our Articles of Incorporation to increase our authorized common stock from 10,000,000 to 30,000,000 shares. Our
stockholders approved the amendment at our annual meeting of stockholders held on March 29, 2016.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">LIQUIDITY AND GOING CONCERN</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">The accompanying condensed consolidated
financial statements have been prepared assuming that we will continue as a going concern, which contemplates, among other things,
the realization of assets and satisfaction of liabilities in the ordinary course of business. We have incurred continuing losses
from operations and at September 30, 2016 had limited working capital and an accumulated deficit of approximately $90,887,000.
These factors, among other matters, raise substantial doubt about our ability to continue as a going concern. A significant amount
of additional capital will be necessary to advance the development of our products to the point at which they may become commercially
viable. We intend to fund operations, working capital and other cash requirements for the twelve month period subsequent to September
30, 2016 through debt and/or equity financing arrangements as well as through revenues and related cash receipts under our government
contracts (see Note 11).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">We are currently addressing our liquidity
issue by seeking additional investment capital through issuances of common stock under our existing S-3 registration statement
and by applying for grants issued by government agencies in the United States. We believe that our cash on hand and funds expected
to be received from additional debt and equity financing arrangements will be sufficient to meet our liquidity needs for the twelve
month period through September 30, 2017. However, no assurance can be given that we will receive any funds in addition to the
funds we have received to date (see Note 14).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">The successful outcome of future activities
cannot be determined at this time and there is no assurance that, if achieved, we will have sufficient funds to execute our intended
business plan or generate positive operating results.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">The consolidated financial statements
do not include any adjustments related to this uncertainty and as to the recoverability and classification of asset carrying amounts
or the amount and classification of liabilities that might result should the Company be unable to continue as a going concern.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6887756304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>2. Loss per Common Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss per Common Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">Basic loss per share is computed by
dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period
of computation. The weighted average number of common shares outstanding for the three and six months ended September 30, 2016
includes 184,500 vested restricted stock units that have not yet been issued. Diluted loss per share is computed similar to basic
loss per share except that the denominator is increased to include the number of additional common shares that would have been
outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses
for all periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded
as their effect would be antidilutive.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">As of September 30, 2016 and 2015,
a total of 3,289,606 and 2,773,483 potential common shares, consisting of shares underlying outstanding stock options, warrants,
unvested restricted stock units and convertible notes payable were excluded as their inclusion would be antidilutive.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6723099856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>3. Research and Development Expenses<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">Research and Development Expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">Our research and development costs
are expensed as incurred. We incurred research and development expenses during the three and six month periods ended September
30, 2016 and 2015, which are included in various operating expense line items in the accompanying condensed consolidated statements
of operations. Our research and development expenses in those periods were as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt">September 30,</font></td><td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt">September 30,</font></td><td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">2016</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">2015</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; padding-bottom: 2.5pt"><font style="font-size: 8pt">Three months ended</font></td><td style="width: 2%; padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 13%; border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">280,860</font></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 2%; padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 13%; border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">207,676</font></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">Six months ended</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">377,843</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">424,267</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23218-108380<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6887710688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>4. Significant Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Significant Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">During the six months ended September
30, 2016, we adopted Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Update (&#8220;ASU&#8221;)
2015-03, the new accounting standard on imputation of interest, simplifying the presentation of debt issuance costs. As a result
of the adoption of that pronouncement, our deferred financing costs at March 31, 2016 were reclassified from current assets to
an offset against our convertible notes.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">Management is evaluating significant
recent accounting pronouncements that are not yet effective for us, including the new accounting standard on improvements to employee
share based payment accounting, ASU 2016-09 (Topic 718), the new accounting standard related to leases, ASU 2016-02 (Topic 842),
the new accounting standard for recognition and measurement of financial assets and financial liabilities, ASU 2016-01, the new
accounting standard on extraordinary and unusual items on income statements, ASU 2015-01, the new accounting standard related
to presentation of financial statements - going concern qualifications, ASU 2014-15, and the new accounting standard on revenue
recognition, ASU 2014-09 (Topic 606), and have not yet concluded whether any such pronouncements will have a significant effect
on our future consolidated financial statements.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Change in Accounting Principle<br> -URI http://asc.fasb.org/extlink&amp;oid=6507316<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Direct Effects of a Change in Accounting Principle<br> -URI http://asc.fasb.org/extlink&amp;oid=66092750<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22583-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Indirect Effects of a Change in Accounting Principle<br> -URI http://asc.fasb.org/extlink&amp;oid=6515603<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22580-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.10-01.(b)(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=27015980&amp;loc=d3e46468-122699<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Accounting Change<br> -URI http://asc.fasb.org/extlink&amp;oid=6503790<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22499-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Retrospective Application<br> -URI http://asc.fasb.org/extlink&amp;oid=6523989<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=68064558&amp;loc=d3e765-108305<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=68064558&amp;loc=d3e725-108305<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6723109616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>5. Convertible Notes Payable<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Notes Payable</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">Convertible Notes Payable consisted
of the following at September 30, 2016:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Principal</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Unamortized
    </font><font style="font-size: 8pt"><br />
    <font style="font-family: Times New Roman, Times, Serif">Discount</font></font></td>
    <td style="text-align: center"><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Net
    </font><font style="font-size: 8pt"><br />
    <font style="font-family: Times New Roman, Times, Serif">Amount</font></font></td>
    <td style="text-align: center"><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Accrued
    </font><font style="font-size: 8pt"><br />
    <font style="font-family: Times New Roman, Times, Serif">Interest</font></font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt"><font style="font: 8pt Times New Roman, Times, Serif">Convertible Notes
    Payable &#8211; Current Portion:</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 49%"><font style="font: 8pt Times New Roman, Times, Serif">November 2014 10% Convertible
    Notes</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; border-bottom: black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; border-bottom: black 1pt solid; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">662,811</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 2%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; border-bottom: black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; border-bottom: black 1pt solid; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">(56,996</font></td>
    <td style="width: 1%"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td>
    <td style="width: 2%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; border-bottom: black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; border-bottom: black 1pt solid; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">605,815</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 2%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; border-bottom: black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; border-bottom: black 1pt solid; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">17,486</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt"><font style="font: 8pt Times New Roman, Times, Serif">Total Convertible
    Notes Payable</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">662,811</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">(56,996</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">605,815</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">17,486</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">During the six months ended September
30, 2016, we recorded interest expense of $30,794 related to the contractual interest rates of our convertible notes, interest
expense of $27,641 related to the amortization of deferred financing costs and interest expense of $18,998 related to the amortization
of the note discount for a total interest expense of $77,433 related to our convertible notes in the six months ended September
30, 2016. All of the unamortized discount at September 30, 2016 related to the note discount established upon the second amendment
to the notes (see below).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">Convertible Notes Payable consisted
of the following at March 31, 2016 (our most recent fiscal year end):</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Principal</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Unamortized <br /> Discount</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Net <br /> Amount</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Accrued <br /> Interest</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left"><font style="font-size: 8pt">Convertible Notes Payable &#8211; Non-Current Portion:</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 48%; padding-bottom: 1pt"><font style="font-size: 8pt">November 2014 10% Convertible Notes</font></td><td style="width: 2%; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">527,780</font></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 2%; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">(27,641</font></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="width: 2%; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">500,139</font></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 2%; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">74,036</font></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font-size: 8pt">Total Convertible Notes Payable</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">527,780</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">(27,641</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">500,139</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">74,036</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">The above table shows the retroactive
application of $27,641 in note discounts representing the deferred financing costs of that same amount on March 31, 2016 due to
the application of related to the application of the new accounting standard ASU 2015-03. All of the unamortized discount at March
31, 2016 related to the deferred financing costs noted above.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">During the six months ended September
30, 2015, we recorded interest expense of $26,390 related to the contractual interest rates of our convertible notes, interest
expense of $186,276 related to the amortization of debt discount and interest expense of $39,441 related to the amortization of
deferred financing costs for a total interest expense of $252,107 related to our convertible notes in the six months ended September
30, 2015.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">NOVEMBER 2014 10% CONVERTIBLE NOTES</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">In November 2014, we entered into
a subscription agreement with two accredited investors providing for the issuance and sale of (i) convertible promissory notes
in the aggregate principal amount of $527,780 (the &#8220;Notes&#8221;) and (ii) five year warrants to purchase up to 47,125 shares
of common stock at a fixed exercise price of $8.40 per share (the &#8220;Warrants&#8221;). These Notes bear interest at the annual
rate of 10% and originally matured on April 1, 2016.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">The aggregate gross cash proceeds
to us were $415,000 after subtracting legal fees of $35,000, a $27,780 due diligence fee and an original issuance discount of
$50,000. We recorded deferred financing costs of $112,780 to reflect the legal fees, due diligence fee and original issuance discount
and will amortize those costs over the life of the Notes using the effective interest method.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">These Notes are convertible at the
option of the holders into shares of our common stock at a fixed price of $5.60 per share, for up to an aggregate of 94,246 shares
of common stock. There are no registration requirements with respect to the shares of common stock underlying the Notes or the
Warrants.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">The estimated relative fair value
of Warrants issued in connection with the Notes was recorded as a debt discount and is amortized as additional interest expense
over the term of the underlying debt. We recorded debt discount of $240,133 based on the relative fair value of these Warrants.
In addition, as the effective conversion price of the Notes was less than market price of the underlying common stock on the date
of issuance, we recorded an additional debt discount of $287,647 related to the beneficial conversion feature.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt"><b>Initial Amendment of the November
2014 10% Convertible Note Terms</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">On November 12, 2015, we entered into
an amendment of terms (&#8220;Amendment of Terms&#8221;) with the two investors that participated in the November 2014 10% Convertible
Notes. The Amendment of Terms modified the terms of the subscription agreement, Notes and Warrants held by those investors to,
among other things, extended the maturity date of the Notes from April 1, 2016 to June 1, 2016, temporarily reduced the number
of shares that we must reserve with respect to conversion of the Notes, and temporarily suspended the time period during which
one of the investors may exercise its Warrants. In exchange for the investors&#8217; agreements in the Amendment of Terms, we
paid one of the investors a cash fee of $90,000, which we recorded as deferred financing costs and amortized over the remaining
term of the notes.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt"><b>Second Amendment and Extension
of the November 2014 10% Convertible Notes</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">On June 27, 2016, we and certain investors
entered into further Amendments (the &#8220;Amendments&#8221;) to the Notes and the Warrants. The Amendments provide that the
Maturity Date (as defined in the Notes) was extended from June 1, 2016 to July 1, 2017 and that the conversion price per share
of the Notes was reduced from $5.60 per share of common stock to $5.00 per share of common stock. In addition, we reduced the
purchase price (as defined in the Warrants) from $8.40 per share to $5.00 per share of common stock. In connection with these
modifications, each of the investors signed a Consent and Waiver providing its consent under certain restrictive provisions, and
waiving certain rights, including a right to participate in certain offerings made by us, under a Securities Purchase Agreement
dated June 23, 2015, (the &#8220;2015 SPA&#8221;) to which we, the investors and certain other investors are parties, in order
to facilitate an at-the-market equity program (see Note 6).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">The Amendments also increase the principal
amount of the Notes to $692,811 (in the aggregate) to (i)&#160;include accrued and unpaid interest through June 15, 2016, and
(ii) increase the principal amount by $80,000 (in the aggregate) as an extension fee for the extended maturity date of the Notes.
With respect to each Note, we entered into an Allonge to Convertible Promissory Note (each, an &#8220;Allonge&#8221;) reflecting
the changes in the principal amount, Maturity Date and conversion price of the Note.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">We also issued to the investors new
warrants (the &#8220;New Warrants&#8221;) to purchase an aggregate of 30,000 shares of common stock with a Purchase Price (as
defined in the New Warrants) of $5.00 per share of common stock. We issued the New Warrants in substantially the same form as
the prior Warrants, and the New Warrants will expire on November 6, 2019, the same date on which the prior Warrants will expire.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">The modification of the Notes was
evaluated under FASB Accounting Standards Codification (&#8220;ASC&#8221;) Topic No. 470-50-40, &#8220;Debt Modification and Extinguishments&#8221;.
Therefore, according to the guidance, the instruments were determined to be substantially different, and the transaction qualified
for extinguishment accounting. As a result, we recorded a loss on debt extinguishment of $536,889 and recognized and an extension
fee expense of $80,000, which are included in other expenses in the accompanying condensed consolidated statements of operations.
The debt extinguishment is comprised from the fair value of prior warrants issued in connection with the Notes of $287,676, as
well as $325,206 related to beneficial conversion feature and offset by debt discount of $75,993. The beneficial conversion feature
is a result of the effective conversion price of the new Notes being less than the market price of the underlying common stock
on the date of modification.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">The following table shows the changes
to the principal balance of the November 2014 10% Convertible Notes:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td colspan="5" style="border-bottom: black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif">Activity
    in the November 2014 10% Convertible Notes </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 84%"><font style="font: 8pt Times New Roman, Times, Serif">Initial principal balance</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">527,780</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><font style="font: 8pt Times New Roman, Times, Serif">Increase in principal balance under the second
    amendment (see above)</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">165,031</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><font style="font: 8pt Times New Roman, Times, Serif">Conversions during the six months ended September
    30, 2016</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">(30,000</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><font style="font: 8pt Times New Roman, Times, Serif">Balance as of September 30, 2016</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">662,811</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt"></font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6887578848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>6. Equity Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity Transactions</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt"><b>Common Stock Sales Agreement with
H.C. Wainwright</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">On June 28, 2016, we entered into
a Common Stock Sales Agreement (the &#8220;Agreement&#8221;) with H.C. Wainwright &#38; Co., LLC (&#8220;H.C. Wainwright&#8221;)
which establishes an at-the-market equity program pursuant to which we may offer and sell shares of our common stock from time
to time as set forth in the Agreement. The Agreement provides for the sale of shares of our common stock having an aggregate offering
price of up to $12,500,000 (the &#8220;Shares&#8221;).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">Subject to the terms and conditions
set forth in the Agreement, H.C. Wainwright will use its commercially reasonable efforts consistent with its normal trading and
sales practices to sell the Shares from time to time, based upon our instructions. We have provided H.C. Wainwright with customary
indemnification rights, and H.C. Wainwright will be entitled to a commission at a fixed rate equal to three percent (3.0%) of
the gross proceeds per Share sold. In addition, we have agreed to pay certain expenses incurred by H.C. Wainwright in connection
with the Agreement, including up to $50,000 of the fees and disbursements of their counsel. The Agreement will terminate upon
the sale of all of the Shares under the Agreement unless terminated earlier by either party as permitted under the Agreement (see
Note 14).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">Sales of the Shares, if any, under
the Agreement shall be made in transactions that are deemed to be &#8220;at the market offerings&#8221; as defined in Rule 415
under the Securities Act, including sales made by means of ordinary brokers&#8217; transactions, including on the Nasdaq Capital
Market, at market prices or as otherwise agreed with H.C. Wainwright. We have no obligation to sell any of the Shares, and, at
any time, we may suspend offers under the Agreement or terminate the Agreement.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">In July 2016, we commenced sales of
common stock under our Common Stock Sales Agreement with H.C. Wainwright. In the three months ended September 30, 2016, we had
raised net proceeds of $266,612 (net of $8,348 in commissions to H.C. Wainwright and $3,319 in other offering expenses) utilizing
the sales agreement through the sale of 50,163 shares at an average price of $5.31 per share of net proceeds.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt"><b>Warrant Issuances in July 2016
</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">In July 2016, we issued an aggregate
of 2,660 shares of common stock to three investors upon the exercise of previously issued warrants. The warrants were exercised
on a cashless or &#8220;net&#8221; basis. Accordingly, we did not receive any proceeds from such exercises. The cashless exercise
of such warrants resulted in the cancellation of previously issued warrants to purchase an aggregate of 19,563 shares of common
stock.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt"><b>Restricted Stock Unit Grants to
Directors and Executive Officers</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">During the three months ended September
30, 2016, 30,131 Restricted Stock Units (&#8220;RSUs&#8221;) held by our outside directors were exchanged into the same number
of shares of our common stock (see Note 9).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt"><b>&#160;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt"><b>Amendment of November 2014 10%
Convertible Notes</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">Under the Second Amendment
and Extension of the November 2014 10% Convertible  Notes dated June 27, 2016 (See Note 5), we reduced the purchase price of
47,125 Warrants from $8.40 per share to $5.00 per share. &#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">We also issued to the investors new
warrants to purchase an aggregate of 30,000 shares of common stock with a purchase price of $5.00 per share of common stock. We
issued the new warrants in substantially the same form as the prior Warrants, and the new warrants will expire on November 6,
2019, the same date on which the prior warrants will expire (See Note 5).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt"><b>Amendment of December 2014 Warrants</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">On June 27, 2016, we and certain investors
(the &#8220;Unit Investors&#8221;) entered into Consent and Waiver and Amendment agreements (the &#8220;CWAs&#8221;), relating
to an aggregate of 264,000 Warrants to Purchase Common Stock (the &#8220;Unit Warrants&#8221;) we had issued to the Unit Investors
on December 2, 2014 pursuant to a Securities Purchase Agreement dated November 26, 2014 (the &#8220;2014 SPA&#8221;). In the CWAs,
each of the Unit Investors provided its consent under certain restrictive provisions, and waived certain rights, including a right
to participate in certain offerings made by us, under the 2014 SPA in order to facilitate the at-the-market equity program described
above. Pursuant to the CWAs, we reduced the Exercise Price (as defined in the Unit Warrants) from $15.00 per share of common stock
to $5.00 per share of common stock. At any time that the shares of common stock underlying the Unit Warrants are covered by an
effective registration statement that permits the public resale of the shares, if the Unit Investors exercise the Unit Warrants,
they must do so by a cash exercise, which could yield up to $1,320,000 in proceeds to us.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">On June 27, 2016, each of the Unit
Investors also entered into a Consent and Waiver providing its consent under certain provisions, and waiving certain rights, including
a right to participate in certain offerings made by us, under the 2015 SPA in order to facilitate the at-the market equity program
described above.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">In accordance with GAAP, we measured
the change in fair value that arose from the reduction in exercise price and recognized an expense of $345,841, which is included
in other expenses in the accompanying condensed consolidated statements of operations.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74567-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6888055648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>7. Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">DUE TO RELATED PARTIES</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">Historically, certain of our officers
and other related parties have advanced us funds, agreed to defer compensation and/or paid expenses on our behalf to cover working
capital deficiencies. There were no such related party transactions during the fiscal year ended March 31, 2016 except that we
had accrued unpaid Board fees of $86,000 owed to our outside directors as of March 31, 2016. At September 30, 2016, we had unpaid
Board fees of $28,250.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6723094352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>8. Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Other Current Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">Other current liabilities were comprised
of the following items:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt">September 30,</font></td><td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt">March 31,</font></td><td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">2016</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">2016</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left"><font style="font-size: 8pt">Accrued interest</font></td><td style="width: 2%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">17,486</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 2%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">74,038</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><font style="font-size: 8pt">Other accrued liabilities</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">17,830</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">62,657</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font-size: 8pt">Total other current liabilities</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">35,316</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">136,695</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6887652624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>9. Stock Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">The following tables summarize share-based
compensation expenses relating to Restricted Stock Units (&#8220;RSU&#8221;s) and options granted and the effect on basic and
diluted loss per common share during the three and six month periods ended September 30, 2016 and 2015:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Three Months <br />
    Ended <br /> September 30, <br />2016</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Three Months<br /> Ended<br />
    September 30, <br />2015</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Six Months <br /> Ended
    <br /> September 30,<br /> 2016</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Six Months<br /> Ended
    <br />September 30,<br /> 2015</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 40%; text-align: left; padding-bottom: 1pt"><font style="font-size: 8pt">Vesting of stock options and restricted
    stock units</font></td><td style="width: 2%; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 11%; border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">1,523,280</font></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 2%; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 11%; border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">50,711</font></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 2%; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 11%; border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">1,573,991</font></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 2%; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 11%; border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">101,421</font></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font-size: 8pt">Total stock-based compensation expense</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">1,523,280</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">50,711</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">1,573,991</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">101,421</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font-size: 8pt">Weighted average number of common shares
    outstanding &#8211; basic and diluted</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">7,756,883</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">7,610,459</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">7,690,369</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">7,167,903</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font-size: 8pt">Basic and diluted loss per common share
    attributable to stock-based compensation expense</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">(0.20</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">(0.01</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">(0.20</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">(0.01</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">)</font></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">All of the stock-based compensation
expense recorded during the six months ended September 30, 2016 and 2015, which totaled $1,573,991 and $101,421, respectively,
is included in payroll and related expense in the accompanying condensed consolidated statements of operations.&#160; Stock-based
compensation expense recorded during the six months ended September 30, 2016 and 2015  represented an impact on basic and diluted
loss per common share of $(0.20) in both periods.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">We review share-based compensation
on a quarterly basis for changes to the estimate of expected award forfeitures based on actual forfeiture experience. The cumulative
effect of adjusting the forfeiture rate for all expense amortization is recognized in the period the forfeiture estimate is changed.
The effect of forfeiture adjustments for the six months ended September 30, 2016 was insignificant.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt"><b>Restricted Stock Unit Grants to
Directors and Executive Officers</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">On August 9, 2016, our Board of Directors
(the &#8220;Board&#8221;) granted RSUs to certain of our officers and directors as set forth below. The RSUs represent the right
to be issued on a future date shares of our common stock for vested RSUs. Our Compensation Committee recommended the grants based
on a compensation assessment provided by a third-party compensation consulting firm engaged by us that developed a peer group
of companies for market assessment and analyzed compensation at such companies.&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">The consultant recommended beneficial
ownership targets, which we previously disclosed in our Proxy Statement filed on February 23, 2016, in connection with our Annual
Meeting of Stockholders held on March 29, 2016. In connection with the Annual Meeting, our stockholders approved our Amended 2010
Stock Incentive Plan, which included an increase in the number of shares available for grant under the plan in part to accommodate
equity awards recommended by the Compensation Committee, and our stockholders approved our executive compensation as disclosed
in the Proxy Statement pursuant to Item 402 paragraphs (m) through (q) of Regulation S-K.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">To Mr. James A. Joyce, an aggregate
of 634,000 RSUs valued at $6.28 per share, based on the August 9, 2016 closing price of the common stock. 158,500 of the RSUs
are deemed vested upon grant and an additional 39,625 RSUs will vest each quarter beginning on January 1, 2017. This grant is
intended to increase Mr. Joyce&#8217;s beneficial ownership of our common stock to 9.0%, which target was recommended in 2015
and in June 2016 by the compensation consultant engaged by us. Previously, in 2004, the Board had approved a beneficial ownership
target of 15% for Mr. Joyce. However, Mr. Joyce has agreed to the modified target of 9.0%.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">To Mr. Rodney S. Kenley, an aggregate
of 52,000 RSUs valued at $6.28 per share, based on the August 9, 2016 closing price of the common stock. 13,000 of the RSUs are
deemed vested upon grant and an additional 3,250 RSUs will vest each quarter beginning on January 1, 2017.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">To Mr. James B. Frakes, an aggregate
of 52,000 RSUs valued at $6.28 per share, based on the August 9, 2016 closing price of the common stock. 13,000 of the RSUs are
deemed vested upon grant and an additional 3,250 RSUs will vest each quarter beginning on January 1, 2017.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">To each of our non-employee directors,
Mr. Franklyn S. Barry, Jr., Mr. Edward G. Broenniman and Dr. Chetan S. Shah, 16,432 RSUs valued at an aggregate of $105,000, based
on the average of the closing prices of the common stock for the five trading days preceding and including August 9, 2016. These
grants represent (a) $70,000 worth of RSUs representing two years of grants under the amended 2012 Non-Employee Directors Compensation
Program (the &#8220;2012 Program&#8221;) because more than two years have elapsed since Messrs. Barry and Broenniman and Dr. Shah
received grants under the program, all of which RSUs are deemed vested upon grant and (b) $35,000 worth of RSUs representing the
grant covering the fiscal year ending March 31, 2017, of which one-quarter are deemed vested upon grant and the remaining portion
will vest ratably at September 30, 2016, at December 31, 2016 and at March 31, 2017.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">The RSUs were granted under our Amended
2010 Stock Incentive Plan and we recorded expense of $1,523,280 in the three months ended September 30, 2016 related to the RSU
grants.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt"><b>Changes to 2012 Non-Employee Directors
Compensation Program</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">In July 2012, the Board approved the
2012 Program, which modified and superseded the 2005 Directors Compensation Program that had been in effect previously. On June
6, 2014, the Board approved certain changes to the 2012 Program, and on August 9, 2016, the Board approved further modifications
to the program. Under the modified 2012 Program, in which only non-employee directors may participate, a new eligible director
will receive an initial grant of $50,000 worth of RSUs or, at the discretion of the Board, options to acquire shares of Common
Stock. RSUs granted under this provision will be valued based on the average of the closing prices of the Common Stock for the
five trading days preceding and including the date of grant and will vest at a rate determined by the Board in its discretion.
Options granted under this provision will be valued at the exercise price, which will be based on the average of the closing prices
of the Common Stock for the five trading days preceding and including the date of grant. Such options will have a term of ten
years and will vest at a rate determined by the Board in its discretion.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">At the beginning of each fiscal year,
each existing director eligible to participate in the 2012 Program will receive a grant of $35,000 worth of RSUs or, at the discretion
of the Board, options to acquire shares of Common Stock. RSUs granted under this provision will be valued based on the average
of the closing prices of the Common Stock for the five trading days preceding and including the first day of the fiscal year (or
preceding and including the date of grant, if such grant is not made on the first day of the fiscal year) and will vest at a rate
determined by the Board in its discretion. Options granted under this provision will be valued at the exercise price, which will
be based on the average of the closing prices of the Common Stock for the five trading days preceding and including the first
day of the fiscal year (or preceding and including the date of grant, if such grant is not made on the first day of the fiscal
year). Such options will have a term of ten years and will vest at a rate determined by the Board in its discretion.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">In lieu of per meeting fees,
under the 2012 Program eligible directors will receive an annual Board retainer fee of $30,000. The modified 2012 Program
also provides for the following annual retainer fees: Audit Committee Chair - $5,000, Compensation Committee chair - $5,000,
Nominating Committee Chair - $5,000, Audit Committee member - $4,000, Compensation Committee member - $4,000 and Lead
independent director (currently an open position) - $15,000.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">The RSU grants and the changes to
the 2012 Program were approved and recommended by our Compensation Committee prior to approval by the Board.&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">RSUs outstanding that have vested
and are expected to vest as of September 30, 2016 are as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td><td style="font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Number
    of RSUs</font></td><td style="padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 33%"><font style="font-size: 8pt">Vested</font></td><td style="width: 2%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">184,500</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><font style="font-size: 8pt">Expected to vest</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">561,708</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">Total</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">746,208</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">During the three months ended September
30, 2016, 30,131 RSUs held by our outside directors were exchanged into the same number of shares of our common stock. As two
of our three outside directors elected to return 40% of their RSU&#8217;s in exchange for cash in order to pay their withholding
taxes on the share issuances, 10,957 of the RSUs were cancelled and we paid a total of $67,343 in cash to those two outside directors.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt"><b>&#160;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt"><b>Stock Option Activity</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">There were no stock option grants
during the six months ended September 30, 2016 or September 30, 2015.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">Options outstanding that have vested
and are expected to vest as of September 30, 2016 are as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Number
    of</b></font><font style="font-size: 8pt"><br />
    <font style="font-family: Times New Roman, Times, Serif"><b>Shares</b></font></font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted</b></font><font style="font-size: 8pt"><br />
    <font style="font-family: Times New Roman, Times, Serif"><b>Average</b></font><br />
    <font style="font-family: Times New Roman, Times, Serif"><b>Exercise</b></font><br />
    <font style="font-family: Times New Roman, Times, Serif"><b>Price</b></font></font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted</b></font><font style="font-size: 8pt"><br />
    <font style="font-family: Times New Roman, Times, Serif"><b>Average</b></font><br />
    <font style="font-family: Times New Roman, Times, Serif"><b>Remaining</b></font><br />
    <font style="font-family: Times New Roman, Times, Serif"><b>Contractual</b></font><br />
    <font style="font-family: Times New Roman, Times, Serif"><b>Term in</b></font><br />
    <font style="font-family: Times New Roman, Times, Serif"><b>Years</b></font></font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 58%"><font style="font: 8pt Times New Roman, Times, Serif">Vested</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">417,047</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">11.20</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">4.77</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><font style="font: 8pt Times New Roman, Times, Serif">Expected to vest</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">17,500</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">5.00</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">7.00</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><font style="font: 8pt Times New Roman, Times, Serif">Total</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">434,547</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">There was no stock option activity
during the six months ended September 30, 2016 other than the expiration of 4,000 stock options during the period.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">On September 30, 2016, our stock options
had no intrinsic value since the closing price on that date of $5.02 per share was below the weighted average exercise price of
our stock options.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">At September 30, 2016, there was approximately
$3,509,367 of unrecognized compensation cost related to share-based payments, which is expected to be recognized over a weighted
average period of 2.87 years.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65895303&amp;loc=d3e17540-113929<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6887713728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>10. Warrants<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Warrants</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">During the six months ended September
30, 2016, we issued 30,000 warrants with an exercise price of $5.00 per share.&#160;Those warrants were issued in connection with
the Amendment of November 2014 Investment Documents (see Note 6).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">A summary of warrant activity during
the six months ended September 30, 2016 is presented below:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Amount</b></font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Range
    of</b></font><font style="font-size: 8pt"><br />
    <font style="font-family: Times New Roman, Times, Serif"><b>Exercise</b></font><br />
    <font style="font-family: Times New Roman, Times, Serif"><b>Price</b></font></font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted</b></font><font style="font-size: 8pt"><br />
    <font style="font-family: Times New Roman, Times, Serif"><b>Average</b></font><br />
    <font style="font-family: Times New Roman, Times, Serif"><b>Exercise</b></font><br />
    <font style="font-family: Times New Roman, Times, Serif"><b>Price</b></font></font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 58%"><font style="font: 8pt Times New Roman, Times, Serif">Warrants outstanding at March
    31, 2016</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">2,164,094</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$2.10 -
    $15.00</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">6.68</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><font style="font: 8pt Times New Roman, Times, Serif">Exercised</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">(2,660</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$6.25</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">6.25</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><font style="font: 8pt Times New Roman, Times, Serif">Issued</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">30,000</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$5.00</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">5.00</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><font style="font: 8pt Times New Roman, Times, Serif">Cancelled/Expired</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">(19,563</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$6.25</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">6.25</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><font style="font: 8pt Times New Roman, Times, Serif">Warrants outstanding at September 30, 2016</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">2,171,871</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$2.10
    - $15.00</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">5.37</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><font style="font: 8pt Times New Roman, Times, Serif">Warrants exercisable at September 30, 2016</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">2,171,871</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$2.10
    - $15.00</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">5.37</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">The following outlines the significant
weighted average assumptions used to estimate the fair value information presented, with respect to warrants utilizing the Binomial
Lattice option pricing models at, and during the six months ended September 30, 2016:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="background-color: rgb(238,238,238)">
    <td style="width: 70%"><font style="font: 8pt Times New Roman, Times, Serif">Risk free interest rate</font></td>
    <td style="width: 30%; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">0.70%&#160;&#160;</font></td></tr>
<tr style="background-color: White">
    <td><font style="font: 8pt Times New Roman, Times, Serif">Average expected life&#160;</font></td>
    <td style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">3.5 years</font></td></tr>
<tr style="background-color: rgb(238,238,238)">
    <td><font style="font: 8pt Times New Roman, Times, Serif">Expected volatility&#160;&#160;</font></td>
    <td style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">91.5%</font></td></tr>
<tr style="background-color: White">
    <td><font style="font: 8pt Times New Roman, Times, Serif">Expected dividends&#160;</font></td>
    <td style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">None</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">The expected volatility was based
on the historic volatility. The expected life of options granted was based on the &#34;simplified method&#34; as described in
the SEC's guidance due to changes in the vesting terms and contractual life of current option grants compared to our historical
grants.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">Based on the above assumptions, we
valued the 30,000 new warrants issued during the six months ended September 30, 2016 at $111,900 and classified that fair value
as equity.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6441202&amp;loc=d3e80720-113993<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41620-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624163-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5579240-113959<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4D<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624177-113959<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35736893&amp;loc=d3e80784-113994<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41641-113959<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5579245-113959<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624258-113959<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35736893&amp;loc=d3e80748-113994<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5708775-113959<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5708773-113959<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5580258-113959<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624181-113959<br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6886632&amp;loc=d3e76258-113986<br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41638-113959<br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6604452384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>11. Darpa Contract and Related Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Darpa Contract and Related Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">We entered into a contract with
the Defense Advanced Research Projects Agency or, DARPA, on September 30, 2011. Under the DARPA award, we have been engaged to
develop a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection that often results in the death
of combat-injured soldiers. The award from DARPA was a fixed-price contract with potential total payments to us of $6,794,389
over the course of five years. Fixed price contracts require the achievement of multiple, incremental milestones to receive
the full award during each year of the contract. Under the terms of the contract, we performed certain incremental work
towards the achievement of specific milestones against which we invoiced the government for fixed payment amounts.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">Originally, only the base year (year
one of the contract) was effective for the parties; however, DARPA subsequently exercised its option on the remaining years of
the contract. The milestones were comprised of planning, engineering and clinical targets, the achievement of which in some cases
required the participation and contribution of third party participants under the contract. We commenced work under the contract
in October 2011.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">In February 2014, DARPA reduced the
scope of our contract in years three through five of the contract. The reduction in scope focused our research on exosomes, viruses
and blood processing instrumentation. This scope reduction reduced the possible payments under the contract by $858,469 over years
three through five.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">In the six months ended September
30, 2016, we invoiced the U.S. Government for the final two milestones under our DARPA contract in the aggregate amount of $387,438.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">The details of those milestones were
as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">Milestone 2.6.1.3 - Quantify the degree
to which the MERS virus can be extracted from circulation in vitro using miniature Hemopurifiers. The milestone payment was $193,719.
Management considers this milestone to be substantive as it was not dependent on the passage of time nor was it based solely on
another party's efforts. We quantified the degree to which the MERS virus can be extracted from circulation in vitro using miniature
Hemopurifiers. The report was accepted by the contracting officer's representative and the invoice was submitted thereafter.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">Milestone 2.6.1.4 &#8211; Prepare
and present Final Report for DARPA. The milestone payment was $193,719. Management considers this milestone to be substantive
as it was not dependent on the passage of time nor was it based solely on another party's efforts. We prepared and presented the
Final Report for DARPA. The report was accepted by the contracting officer's representative and the invoice was submitted thereafter.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">In the six months ended September
30, 2015, we invoiced the U.S. Government for two milestones under our DARPA contract in the amount of $372,328.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">The details of those milestones were
as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">Milestone M6 &#8211; Define Aethlon&#8217;s
GMP manufacturing process and revise and upgrade Aethlon&#8217;s quality procedures and policies to the current state of the art.
The milestone payment was $186,164. Management considers this milestone to be substantive as it was not dependent on the passage
of time nor was it based solely on another party's efforts. We demonstrated that defined our GMP manufacturing process and that
we revised and upgraded our quality procedures and policies to the current state of the art for a company of our size. The report
was accepted by the contracting officer's representative and the invoice was submitted thereafter.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">Milestone 2.5.1.1 - Complete Aethlon&#8217;s
GMP procedure and establish and maintain all GMP documentation for the company. The milestone payment was $186,164. Management
considers this milestone to be substantive as it was not dependent on the passage of time nor was it based solely on another party's
efforts. We demonstrated that we completed our GMP procedures and established and maintained all GMP documentation for the company.
The report was accepted by the contracting officer's representative and the invoice was submitted thereafter.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6887588688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>12. Segments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">We operate our businesses principally
through two reportable segments: Aethlon, which represents our therapeutic business activities, and ESI, which represents our
diagnostic business activities. Our reportable segments have been determined based on the nature of the potential products being
developed. We record discrete financial information for ESI and our chief operating decision maker reviews ESI&#8217;s operating
results in order to make decisions about resources to be allocated to the ESI segment and to assess its performance.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">Aethlon&#8217;s revenue is generated
primarily from government contracts to date and ESI does not yet have any revenues. We have not included any allocation of corporate
overhead to the ESI segment.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">The following tables set forth certain
information regarding our segments:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Six Months Ended September
    30,</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">2016</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">2015</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><font style="font-size: 8pt">Revenues:</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; padding-left: 10pt"><font style="font-size: 8pt">Aethlon</font></td><td style="width: 2%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">392,073</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 2%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">380,874</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 8pt">ESI</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">&#8211;</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">&#8211;</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"><font style="font-size: 8pt">Total Revenues</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">392,073</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">380,874</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><font style="font-size: 8pt">Operating Losses:</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt"><font style="font-size: 8pt">Aethlon</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">(3,281,530</font></td><td style="text-align: left"><font style="font-size: 8pt">)</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">(1,911,219</font></td><td style="text-align: left"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 8pt">ESI</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">(76,999</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">(303,113</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"><font style="font-size: 8pt">Total Operating Loss</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">(3,358,529</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">(2,214,332</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left"><font style="font-size: 8pt">Net Losses:</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><font style="font-size: 8pt">Aethlon</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">(4,323,003</font></td><td style="text-align: left"><font style="font-size: 8pt">)</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">(2,165,152</font></td><td style="text-align: left"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 8pt">ESI</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">(76,999</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">(303,113</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"><font style="font-size: 8pt">Net Loss Before Non-Controlling
    Interests</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">(4,400,002</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">(2,468,265</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><font style="font-size: 8pt">Cash:</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt"><font style="font-size: 8pt">Aethlon</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">553,884</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">4,208,554</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 8pt">ESI</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">2,468</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">802</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"><font style="font-size: 8pt">Total Cash</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">556,352</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">4,209,356</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left"><font style="font-size: 8pt">Total Assets:</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><font style="font-size: 8pt">Aethlon</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">914,179</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">4,677,989</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 8pt">ESI</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">36,656</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">27,486</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"><font style="font-size: 8pt">Total Assets</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">950,835</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">4,705,475</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><font style="font-size: 8pt">Capital Expenditures:</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt"><font style="font-size: 8pt">Aethlon</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">2,961</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">&#8211;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 8pt">ESI</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">&#8211;</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">&#8211;</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"><font style="font-size: 8pt">Capital Expenditures</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">2,961</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">&#8211;</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left"><font style="font-size: 8pt">Depreciation and Amortization:</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><font style="font-size: 8pt">Aethlon</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">10,822</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">8,886</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 8pt">ESI</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">9,790</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">9,790</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"><font style="font-size: 8pt">Total Depreciation and
    Amortization</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">20,612</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">18,676</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><font style="font-size: 8pt">Interest Expense:</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt"><font style="font-size: 8pt">Aethlon</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">(78,743</font></td><td style="text-align: left"><font style="font-size: 8pt">)</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">(253,933</font></td><td style="text-align: left"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 8pt">ESI</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">&#8211;</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">&#8211;</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"><font style="font-size: 8pt">Total Interest Expense</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">(78,743</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">(253,933</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">)</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8981-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9038-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 33<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8971-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8595-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8380-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 35<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8984-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9031-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8538-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8864-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8924-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6722983024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>13. Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">LEASE COMMITMENTS</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">We currently rent approximately 2,600
square feet of executive office space at 9635 Granite Ridge Drive, Suite 100, San Diego, CA 92123 at the rate of $6,054 per month
on a four-year lease that expires in January 2019. We also rent approximately 1,700 square feet of laboratory space at 11585 Sorrento
Valley Road, Suite 109, San Diego, California 92121 at the rate of $4,394 per month on a one-year lease that was recently extended
to an expiration date of November 30, 2017.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">Our Exosome Sciences, Inc. subsidiary
previously rented approximately 2,055 square feet of office and laboratory space at 11 Deer Park Drive, South Brunswick, NJ at
the rate of $3,917 per month on a one-year lease that expired in October 2015. In October 2015, ESI relocated to a different suite
at the same office complex. That new suite was comprised of approximately 541 square feet of office and laboratory space and is
located at 9 Deer Park Drive, South Brunswick, NJ at the rate of $1,352 per month under a month to month lease basis. In January
2016, we exercised our 30-day notice to terminate the ESI lease in New Jersey as part of a consolidation of our laboratory operations
in San Diego and the ESI lease was terminated effective February 29, 2016.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">Rent expense, which is included in
general and administrative expenses, approximated $79,000 and $90,000 for the six month periods ended September 30, 2016 and 2015,
respectively.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">LEGAL MATTERS</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">From time to time, claims are made
against us in the ordinary course of business, which could result in litigation. Claims and associated litigation are subject
to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting
us from selling one or more products or engaging in other activities.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">The occurrence of an unfavorable outcome
in any specific period could have a material adverse effect on our results of operations for that period or future periods. We
are not presently a party to any pending or threatened legal proceedings.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73718637&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6887588688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>14. Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">Management has evaluated events subsequent
to September 30, 2016 through the date that the accompanying condensed consolidated financial statements were filed with the Securities
and Exchange Commission for transactions and other events which may require adjustment of and/or disclosure in such financial
statements.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">In October 2016, we collected $193,719
from DARPA. That amount had been invoiced to DARPA for the achievement of a milestone in September 2016 and was classified as
an account receivable as of September 30, 2016.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">Subsequent to September 30, 2016,
we continued selling common stock under our Common Stock Sales Agreement with H.C. Wainwright (see Note 6). Between the period
of October 1, 2016 through November 8, 2016, we raised net proceeds of $61,265 (after deducting $1,919 in commissions to H.C.
Wainwright and $799 in other offering expenses) utilizing the sales agreement through the sale of 13,261 shares at an average
price of $4.62 per share of net proceeds.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">On October 5, 2016, we entered into
an amendment of the lease for our laboratory space at 11585 Sorrento Valley Road, Suite 109, San Diego, California 92121. Pursuant
to the amendment, the lease term will be extended to November 30, 2017 and the rent will be $4,394 per month.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6596571232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>3. Research and Development Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock', window );">Research and Development Expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt">September 30,</font></td><td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt">September 30,</font></td><td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">2016</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">2015</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; padding-bottom: 2.5pt"><font style="font-size: 8pt">Three months ended</font></td><td style="width: 2%; padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 13%; border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">280,860</font></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 2%; padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 13%; border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">207,676</font></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">Six months ended</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">377,843</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">424,267</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature and amounts of capitalized costs of a research and development nature that were acquired in a transaction other than a business combination, the amount of such assets charged to expense during the period, and identification of the income statement caption in which the charges are included.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6613959216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>5. Convertible Notes Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Convertible notes payable</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">Convertible Notes Payable consisted
of the following at September 30, 2016:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Principal</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Unamortized
    </font><font style="font-size: 8pt"><br />
    <font style="font-family: Times New Roman, Times, Serif">Discount</font></font></td>
    <td style="text-align: center"><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Net
    </font><font style="font-size: 8pt"><br />
    <font style="font-family: Times New Roman, Times, Serif">Amount</font></font></td>
    <td style="text-align: center"><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Accrued
    </font><font style="font-size: 8pt"><br />
    <font style="font-family: Times New Roman, Times, Serif">Interest</font></font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt"><font style="font: 8pt Times New Roman, Times, Serif">Convertible Notes
    Payable &#8211; Current Portion:</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 49%"><font style="font: 8pt Times New Roman, Times, Serif">November 2014 10% Convertible
    Notes</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; border-bottom: black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; border-bottom: black 1pt solid; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">662,811</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 2%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; border-bottom: black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; border-bottom: black 1pt solid; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">(56,996</font></td>
    <td style="width: 1%"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td>
    <td style="width: 2%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; border-bottom: black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; border-bottom: black 1pt solid; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">605,815</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 2%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; border-bottom: black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; border-bottom: black 1pt solid; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">17,486</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt"><font style="font: 8pt Times New Roman, Times, Serif">Total Convertible
    Notes Payable</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">662,811</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">(56,996</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">605,815</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">17,486</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">Convertible Notes Payable consisted
of the following at March 31, 2016 (our most recent fiscal year end):</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Principal</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Unamortized <br /> Discount</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Net <br /> Amount</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Accrued <br /> Interest</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left"><font style="font-size: 8pt">Convertible Notes Payable &#8211; Non-Current Portion:</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 48%; padding-bottom: 1pt"><font style="font-size: 8pt">November 2014 10% Convertible Notes</font></td><td style="width: 2%; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">527,780</font></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 2%; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">(27,641</font></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="width: 2%; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">500,139</font></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 2%; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">74,036</font></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font-size: 8pt">Total Convertible Notes Payable</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">527,780</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">(27,641</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">500,139</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">74,036</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt"></font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtConversionsTextBlock', window );">Changes to principal balance of Convertible Note</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td colspan="5" style="border-bottom: black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif">Activity
    in the November 2014 10% Convertible Notes </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 84%"><font style="font: 8pt Times New Roman, Times, Serif">Initial principal balance</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">527,780</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><font style="font: 8pt Times New Roman, Times, Serif">Increase in principal balance under the second
    amendment (see above)</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">165,031</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><font style="font: 8pt Times New Roman, Times, Serif">Conversions during the six months ended September
    30, 2016</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">(30,000</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><font style="font: 8pt Times New Roman, Times, Serif">Balance as of September 30, 2016</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">662,811</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtConversionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information on an original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. The information may be presented entirely or partially in this block of text or in the associated elements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtConversionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6723040928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>8. Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Other current liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt">September 30,</font></td><td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt">March 31,</font></td><td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">2016</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">2016</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left"><font style="font-size: 8pt">Accrued interest</font></td><td style="width: 2%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">17,486</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 2%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">74,038</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><font style="font-size: 8pt">Other accrued liabilities</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">17,830</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">62,657</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font-size: 8pt">Total other current liabilities</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">35,316</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">136,695</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6719541744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>9. Stock Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock', window );">Options vested and expected to vest</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Number
    of</b></font><font style="font-size: 8pt"><br />
    <font style="font-family: Times New Roman, Times, Serif"><b>Shares</b></font></font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted</b></font><font style="font-size: 8pt"><br />
    <font style="font-family: Times New Roman, Times, Serif"><b>Average</b></font><br />
    <font style="font-family: Times New Roman, Times, Serif"><b>Exercise</b></font><br />
    <font style="font-family: Times New Roman, Times, Serif"><b>Price</b></font></font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted</b></font><font style="font-size: 8pt"><br />
    <font style="font-family: Times New Roman, Times, Serif"><b>Average</b></font><br />
    <font style="font-family: Times New Roman, Times, Serif"><b>Remaining</b></font><br />
    <font style="font-family: Times New Roman, Times, Serif"><b>Contractual</b></font><br />
    <font style="font-family: Times New Roman, Times, Serif"><b>Term in</b></font><br />
    <font style="font-family: Times New Roman, Times, Serif"><b>Years</b></font></font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 58%"><font style="font: 8pt Times New Roman, Times, Serif">Vested</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">417,047</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">11.20</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">4.77</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><font style="font: 8pt Times New Roman, Times, Serif">Expected to vest</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">17,500</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">5.00</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">7.00</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><font style="font: 8pt Times New Roman, Times, Serif">Total</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">434,547</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Share based compensation expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Three Months <br />
    Ended <br /> September 30, <br />2016</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Three Months<br /> Ended<br />
    September 30, <br />2015</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Six Months <br /> Ended
    <br /> September 30,<br /> 2016</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Six Months<br /> Ended
    <br />September 30,<br /> 2015</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 40%; text-align: left; padding-bottom: 1pt"><font style="font-size: 8pt">Vesting of stock options and restricted
    stock units</font></td><td style="width: 2%; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 11%; border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">1,523,280</font></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 2%; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 11%; border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">50,711</font></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 2%; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 11%; border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">1,573,991</font></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 2%; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 11%; border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">101,421</font></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font-size: 8pt">Total stock-based compensation expense</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">1,523,280</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">50,711</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">1,573,991</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">101,421</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5pt; text-indent: -5pt"><font style="font-size: 8pt">Weighted average number of common shares
    outstanding &#8211; basic and diluted</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">7,756,883</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">7,610,459</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">7,690,369</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">7,167,903</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5pt; text-indent: -5pt"><font style="font-size: 8pt">Basic and diluted loss per common share
    attributable to stock-based compensation expense</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">(0.20</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">(0.01</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">(0.20</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">(0.01</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">)</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock', window );">Options vested and expected to vest</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td><td style="font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Number
    of RSUs</font></td><td style="padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 33%"><font style="font-size: 8pt">Vested</font></td><td style="width: 2%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">184,500</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><font style="font-size: 8pt">Expected to vest</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">561,708</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">Total</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">746,208</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan.  Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the following for fully vested share options (or share units) and share options expected to vest at the date of the latest statement of financial position: the number, weighted-average exercise price (or conversion ratio), aggregate intrinsic value (except for nonpublic entities), and weighted-average remaining contractual term of options (or share units) currently exercisable (or convertible).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6888079904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>10. Warrants (Tables) - December 2014 Warrants [Member]<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Warrant activity</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Amount</b></font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Range
    of</b></font><font style="font-size: 8pt"><br />
    <font style="font-family: Times New Roman, Times, Serif"><b>Exercise</b></font><br />
    <font style="font-family: Times New Roman, Times, Serif"><b>Price</b></font></font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted</b></font><font style="font-size: 8pt"><br />
    <font style="font-family: Times New Roman, Times, Serif"><b>Average</b></font><br />
    <font style="font-family: Times New Roman, Times, Serif"><b>Exercise</b></font><br />
    <font style="font-family: Times New Roman, Times, Serif"><b>Price</b></font></font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 58%"><font style="font: 8pt Times New Roman, Times, Serif">Warrants outstanding at March
    31, 2016</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">2,164,094</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$2.10 -
    $15.00</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">6.68</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><font style="font: 8pt Times New Roman, Times, Serif">Exercised</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">(2,660</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$6.25</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">6.25</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><font style="font: 8pt Times New Roman, Times, Serif">Issued</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">30,000</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$5.00</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">5.00</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><font style="font: 8pt Times New Roman, Times, Serif">Cancelled/Expired</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">(19,563</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$6.25</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">6.25</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><font style="font: 8pt Times New Roman, Times, Serif">Warrants outstanding at September 30, 2016</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">2,171,871</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$2.10
    - $15.00</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">5.37</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><font style="font: 8pt Times New Roman, Times, Serif">Warrants exercisable at September 30, 2016</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">2,171,871</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$2.10
    - $15.00</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">5.37</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions used</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="background-color: rgb(238,238,238)">
    <td style="width: 70%"><font style="font: 8pt Times New Roman, Times, Serif">Risk free interest rate</font></td>
    <td style="width: 30%; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">0.70%&#160;&#160;</font></td></tr>
<tr style="background-color: White">
    <td><font style="font: 8pt Times New Roman, Times, Serif">Average expected life&#160;</font></td>
    <td style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">3.5 years</font></td></tr>
<tr style="background-color: rgb(238,238,238)">
    <td><font style="font: 8pt Times New Roman, Times, Serif">Expected volatility&#160;&#160;</font></td>
    <td style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">91.5%</font></td></tr>
<tr style="background-color: White">
    <td><font style="font: 8pt Times New Roman, Times, Serif">Expected dividends&#160;</font></td>
    <td style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">None</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=AEMD_December2014WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=AEMD_December2014WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6722978272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>12. Segments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Segment reporting</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Six Months Ended September
    30,</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">2016</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">2015</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><font style="font-size: 8pt">Revenues:</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; padding-left: 10pt"><font style="font-size: 8pt">Aethlon</font></td><td style="width: 2%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">392,073</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 2%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">380,874</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 8pt">ESI</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">&#8211;</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">&#8211;</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"><font style="font-size: 8pt">Total Revenues</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">392,073</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">380,874</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><font style="font-size: 8pt">Operating Losses:</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt"><font style="font-size: 8pt">Aethlon</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">(3,281,530</font></td><td style="text-align: left"><font style="font-size: 8pt">)</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">(1,911,219</font></td><td style="text-align: left"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 8pt">ESI</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">(76,999</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">(303,113</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"><font style="font-size: 8pt">Total Operating Loss</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">(3,358,529</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">(2,214,332</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left"><font style="font-size: 8pt">Net Losses:</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><font style="font-size: 8pt">Aethlon</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">(4,323,003</font></td><td style="text-align: left"><font style="font-size: 8pt">)</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">(2,165,152</font></td><td style="text-align: left"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 8pt">ESI</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">(76,999</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">(303,113</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"><font style="font-size: 8pt">Net Loss Before Non-Controlling
    Interests</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">(4,400,002</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">(2,468,265</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><font style="font-size: 8pt">Cash:</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt"><font style="font-size: 8pt">Aethlon</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">553,884</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">4,208,554</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 8pt">ESI</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">2,468</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">802</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"><font style="font-size: 8pt">Total Cash</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">556,352</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">4,209,356</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left"><font style="font-size: 8pt">Total Assets:</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><font style="font-size: 8pt">Aethlon</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">914,179</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">4,677,989</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 8pt">ESI</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">36,656</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">27,486</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"><font style="font-size: 8pt">Total Assets</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">950,835</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">4,705,475</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><font style="font-size: 8pt">Capital Expenditures:</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt"><font style="font-size: 8pt">Aethlon</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">2,961</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">&#8211;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 8pt">ESI</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">&#8211;</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">&#8211;</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"><font style="font-size: 8pt">Capital Expenditures</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">2,961</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">&#8211;</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left"><font style="font-size: 8pt">Depreciation and Amortization:</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><font style="font-size: 8pt">Aethlon</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">10,822</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">8,886</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 8pt">ESI</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">9,790</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">9,790</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"><font style="font-size: 8pt">Total Depreciation and
    Amortization</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">20,612</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">18,676</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><font style="font-size: 8pt">Interest Expense:</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt"><font style="font-size: 8pt">Aethlon</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">(78,743</font></td><td style="text-align: left"><font style="font-size: 8pt">)</font></td><td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">(253,933</font></td><td style="text-align: left"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 8pt">ESI</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">&#8211;</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">&#8211;</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"><font style="font-size: 8pt">Total Interest Expense</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">(78,743</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">(253,933</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">)</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8813-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6719054240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>1. Nature of Business (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">On April 14, 2015, we completed a 1-for-50 reverse stock split. Accordingly, authorized common stock was reduced from 500,000,000 shares to 10,000,000 shares, and each 50 shares of outstanding common stock held by stockholders were combined into one share of common stock. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (90,886,645)<span></span>
</td>
<td class="num">$ (86,502,043)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6719436288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>2. Loss per Common Share (Details Narrative) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential common shares excluded from earnings per share calculation due to being antidilutive</a></td>
<td class="nump">3,289,606<span></span>
</td>
<td class="nump">2,773,483<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6719472016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>3. Research and Development Expenses - 3. Research and Development Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 280,860<span></span>
</td>
<td class="nump">$ 207,676<span></span>
</td>
<td class="nump">$ 377,843<span></span>
</td>
<td class="nump">$ 424,267<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6730112080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>5. Convertible Notes Payable (Details - Convertible Notes Payable) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible notes payable, principal</a></td>
<td class="nump">$ 662,811<span></span>
</td>
<td class="nump">$ 527,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized discount</a></td>
<td class="num">(56,996)<span></span>
</td>
<td class="num">(27,641)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable, net</a></td>
<td class="nump">605,815<span></span>
</td>
<td class="nump">500,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued interest</a></td>
<td class="nump">17,486<span></span>
</td>
<td class="nump">74,036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable, current portion</a></td>
<td class="nump">605,815<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible notes payable, noncurrent portion</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 500,139<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e603758-122996<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6719476304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>5. Convertible Notes Payable (Details - Convertible note activity)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt, beginning balance</a></td>
<td class="nump">$ 527,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Increase in principal balance under the second amendment</a></td>
<td class="nump">165,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversions during the period</a></td>
<td class="num">(30,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt, ending balance</a></td>
<td class="nump">$ 662,811<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6732259872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>5. Convertible Notes Payable (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,794<span></span>
</td>
<td class="nump">$ 26,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,998<span></span>
</td>
<td class="nump">186,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,641<span></span>
</td>
<td class="nump">39,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Total interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,433<span></span>
</td>
<td class="nump">252,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(616,889)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Extension fee expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=AEMD_ConvertibleNotes10November2014Amend2Member', window );">November 2014 10% Convertible Notes Second Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul.  01,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Stock purchase price per share</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt carrying amount</a></td>
<td class="nump">$ 692,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 692,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance cost</a></td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_AEMD_WarrantExpirationDate', window );">Warrant expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov.  06,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (536,889)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=AEMD_ConvertibleNotes10November2014Member', window );">November 2014 10% Convertible Notes [Member] | Fair Value of Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(287,676)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=AEMD_ConvertibleNotes10November2014Member', window );">November 2014 10% Convertible Notes [Member] | Beneficial Conversion Feature [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(325,206)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=AEMD_ConvertibleNotes10November2014Member', window );">November 2014 10% Convertible Notes [Member] | Debt Discount [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AEMD_WarrantExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant expiration date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AEMD_WarrantExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AEMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the charge against earnings during the period for commitment fees and debt issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=AEMD_ConvertibleNotes10November2014Amend2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=AEMD_ConvertibleNotes10November2014Amend2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=AEMD_ConvertibleNotes10November2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=AEMD_ConvertibleNotes10November2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAxis=AEMD_FairValueWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAxis=AEMD_FairValueWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAxis=AEMD_BeneficialConversionFeatureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAxis=AEMD_BeneficialConversionFeatureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAxis=AEMD_DebtDiscountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAxis=AEMD_DebtDiscountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6730182208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>6. Equity Transactions (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 266,612<span></span>
</td>
<td class="nump">$ 5,591,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">345,841<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=AEMD_December2014WarrantsMember', window );">December 2014 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Restricted stock units exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=AEMD_WainwrightMember', window );">H.C. Wainwright [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_AEMD_SaleOfStockNewIssuesAggregateOfferingPrice', window );">Sale of stock, new issues, aggregate offering price</a></td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_AEMD_OtherOfferingExpenses', window );">Other offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=AEMD_ThreeInvestorsMember', window );">Three Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AEMD_OtherOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other offering expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AEMD_OtherOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AEMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AEMD_SaleOfStockNewIssuesAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of stock, new issues, aggregate offering price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AEMD_SaleOfStockNewIssuesAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AEMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=AEMD_December2014WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=AEMD_December2014WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=AEMD_WainwrightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=AEMD_WainwrightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=AEMD_ThreeInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=AEMD_ThreeInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6719578464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>7. Related Party Transactions (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="nump">$ 58,362<span></span>
</td>
<td class="nump">$ 145,112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=AEMD_UnPaidBoardFeesMember', window );">Unpaid Board Fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="nump">$ 28,250<span></span>
</td>
<td class="nump">$ 86,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=AEMD_UnPaidBoardFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=AEMD_UnPaidBoardFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6719117680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>8. Other Current Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">$ 17,486<span></span>
</td>
<td class="nump">$ 74,038<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">17,830<span></span>
</td>
<td class="nump">62,657<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total other current liabilities</a></td>
<td class="nump">$ 35,316<span></span>
</td>
<td class="nump">$ 136,695<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6732376576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>9. Stock Compensation (Details - Share based compensation) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="nump">$ 1,523,280<span></span>
</td>
<td class="nump">$ 50,711<span></span>
</td>
<td class="nump">$ 1,573,991<span></span>
</td>
<td class="nump">$ 101,421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding - basic and diluted</a></td>
<td class="nump">7,756,883<span></span>
</td>
<td class="nump">7,610,459<span></span>
</td>
<td class="nump">7,690,369<span></span>
</td>
<td class="nump">7,167,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Basic and diluted loss per common share attributable to stock-based compensation expense</a></td>
<td class="num">$ (.20)<span></span>
</td>
<td class="num">$ (.01)<span></span>
</td>
<td class="num">$ (.20)<span></span>
</td>
<td class="num">$ (.01)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6887971248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>9. Stock Compensation (Details - RSU's outstanding) - Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2016 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_AEMD_SharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares', window );">RSU's vested</a></td>
<td class="nump">184,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_AEMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber', window );">RSU's expected to vest</a></td>
<td class="nump">561,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Total RSU's outstanding</a></td>
<td class="nump">746,208<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AEMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of RSU's expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AEMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AEMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AEMD_SharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of RSU's vested,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AEMD_SharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AEMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6879515504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>9. Stock Compensation (Details - Options vested and expected to vest) - Options [Member]<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Options vested</a></td>
<td class="nump">417,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options expected to vest</a></td>
<td class="nump">17,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total options outstanding</a></td>
<td class="nump">434,547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price options vested | $ / shares</a></td>
<td class="nump">$ 11.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options expected to vest | $ / shares</a></td>
<td class="nump">$ 5.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term options vested</a></td>
<td class="text">4 years 9 months 7 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term options expected to vest</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the weighted-average exercise price (at which grantees can acquire the shares reserved for issuance) for exercisable stock options that are fully vested or expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options that are exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6732079920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>9. Stock Compensation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 1,523,280<span></span>
</td>
<td class="nump">$ 50,711<span></span>
</td>
<td class="nump">$ 1,573,991<span></span>
</td>
<td class="nump">$ 101,421<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AEMD_JamesJoyceMember', window );">James A. Joyce [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSU's granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">634,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">RSU per share, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_AEMD_SharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares', window );">RSU's vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AEMD_RodneyKenleyMember', window );">Rodney Kenley [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSU's granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">RSU per share, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_AEMD_SharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares', window );">RSU's vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AEMD_JamesFrakesMember', window );">James Frakes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSU's granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">RSU per share, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_AEMD_SharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares', window );">RSU's vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AEMD_NonEmployeeDirectorsMember', window );">Non-employee Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSU's granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_AEMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue', window );">RSU's granted, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Stock-based compensation per share effect on diluted loss per common share</a></td>
<td class="num">$ (.20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Stock options expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value of stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 3,509,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,509,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,523,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_AEMD_SharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares', window );">RSU's vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Restricted stock units exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">RSU's cancelled for withholding taxes, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">RSU's cancelled for withholding taxes, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AEMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>RSU's granted, value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AEMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AEMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AEMD_SharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of RSU's vested,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AEMD_SharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AEMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of adjustment to stockholders' equity associated with an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20187-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For net-share settlement of share-based awards when the employer settles employees' income tax withholding obligations, this element represents the number of shares the employees use to repay the employer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AEMD_JamesJoyceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AEMD_JamesJoyceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AEMD_RodneyKenleyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AEMD_RodneyKenleyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AEMD_JamesFrakesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AEMD_JamesFrakesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AEMD_NonEmployeeDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AEMD_NonEmployeeDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6719221760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>10. Warrants (Details - Warrant activity) - Warrants [Member]<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning | shares</a></td>
<td class="nump">2,164,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised | shares</a></td>
<td class="num">(2,660)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Warrants issued | shares</a></td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Warrants cancelled/expired | shares</a></td>
<td class="num">(19,563)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending | shares</a></td>
<td class="nump">2,171,871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable | shares</a></td>
<td class="nump">2,171,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_AEMD_RangeOfExercisePricesWarrantsBeginning', window );">Range of exercise prices, warrants beginning</a></td>
<td class="text">$2.10-$15.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_AEMD_RangeOfExercisePricesWarrantsExercised', window );">Range of exercise prices, warrants exercised</a></td>
<td class="text">6.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_AEMD_RangeOfExercisePricesWarrantsIssued', window );">Range of exercise prices, warrants issued</a></td>
<td class="text">5.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_AEMD_RangeOfExercisePricesWarrantsCancelledExpired', window );">Range of exercise prices, warrants cancelled/expired</a></td>
<td class="text">6.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_AEMD_RangeOfExercisePricesWarrantsEnding', window );">Range of exercise prices, warrants ending</a></td>
<td class="text">$2.10-$15.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_AEMD_RangeOfExercisePricesWarrantsExercisable', window );">Range of exercise prices, warrants exercisable</a></td>
<td class="text">$2.10-$15.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price, warrants beginning | $ / shares</a></td>
<td class="nump">$ 6.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_AEMD_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised', window );">Weighted average exercise price, warrants exercised | $ / shares</a></td>
<td class="nump">6.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_AEMD_WeightedAverageExercisePriceWarrantsIssued', window );">Weighted average exercise price, warrants issued | $ / shares</a></td>
<td class="nump">5.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_AEMD_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelledExpired', window );">Weighted average exercise price, warrants cancelled/expired | $ / shares</a></td>
<td class="nump">6.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price, warrants ending | $ / shares</a></td>
<td class="nump">5.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_AEMD_WeightedAverageExercisePriceWarrantsExercisable', window );">Weighted average exercise price, warrants exercisable | $ / shares</a></td>
<td class="nump">$ 5.37<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AEMD_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelledExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price, warrants cancelled/expired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AEMD_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelledExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AEMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AEMD_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price, warrants exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AEMD_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AEMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AEMD_RangeOfExercisePricesWarrantsBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Range of exercise prices, warrants beginning</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AEMD_RangeOfExercisePricesWarrantsBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AEMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AEMD_RangeOfExercisePricesWarrantsCancelledExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Range of exercise prices, warrants cancelled/expired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AEMD_RangeOfExercisePricesWarrantsCancelledExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AEMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AEMD_RangeOfExercisePricesWarrantsEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Range of exercise prices, warrants ending</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AEMD_RangeOfExercisePricesWarrantsEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AEMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AEMD_RangeOfExercisePricesWarrantsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Range of exercise prices, warrants exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AEMD_RangeOfExercisePricesWarrantsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AEMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AEMD_RangeOfExercisePricesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Range of exercise prices, warrants exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AEMD_RangeOfExercisePricesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AEMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AEMD_RangeOfExercisePricesWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Range of exercise prices, warrants issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AEMD_RangeOfExercisePricesWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AEMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AEMD_WeightedAverageExercisePriceWarrantsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price, warrants exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AEMD_WeightedAverageExercisePriceWarrantsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AEMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AEMD_WeightedAverageExercisePriceWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price, warrants issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AEMD_WeightedAverageExercisePriceWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AEMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6888156352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>10. Warrants (Details - Assumptions) - December 2014 Warrants [Member]<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Average expected life</a></td>
<td class="text">3 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">91.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments', window );">Expected dividends</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=AEMD_December2014WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=AEMD_December2014WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6629904176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>10. Warrants (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=AEMD_December2014WarrantsMember', window );">December 2014 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_AEMD_FairValueOfWarrantsIssued', window );">Fair value of warrants issued | $</a></td>
<td class="nump">$ 111,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Warrants issued | shares</a></td>
<td class="nump">30,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AEMD_FairValueOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AEMD_FairValueOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AEMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=AEMD_December2014WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=AEMD_December2014WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6879572880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>11. Darpa Contract and Related Revenue Recognition (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Revenue recognition</a></td>
<td class="nump">$ 387,438<span></span>
</td>
<td class="nump">$ 372,328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=AEMD_Milestone2613Member', window );">Milestone 2.6.1.3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Revenue recognition</a></td>
<td class="nump">193,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=AEMD_Milestone26143Member', window );">Milestone 2.6.1.4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Revenue recognition</a></td>
<td class="nump">$ 193,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=AEMD_MilestoneM6Member', window );">Milestone M6 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Revenue recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=AEMD_Milestone2511Member', window );">Milestone 2.5.1.1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Revenue recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 186,164<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 28<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=68058744&amp;loc=SL6892177-166501<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=AEMD_Milestone2613Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=AEMD_Milestone2613Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=AEMD_Milestone26143Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=AEMD_Milestone26143Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=AEMD_MilestoneM6Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=AEMD_MilestoneM6Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=AEMD_Milestone2511Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=AEMD_Milestone2511Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6719289440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>12. Segments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Revenues</a></td>
<td class="nump">$ 387,438<span></span>
</td>
<td class="nump">$ 188,366<span></span>
</td>
<td class="nump">$ 392,073<span></span>
</td>
<td class="nump">$ 380,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Losses</a></td>
<td class="num">(2,226,678)<span></span>
</td>
<td class="num">(1,124,361)<span></span>
</td>
<td class="num">(3,358,529)<span></span>
</td>
<td class="num">(2,214,332)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Losses</a></td>
<td class="num">(2,263,254)<span></span>
</td>
<td class="num">(1,251,606)<span></span>
</td>
<td class="num">(4,400,002)<span></span>
</td>
<td class="num">(2,468,265)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">556,352<span></span>
</td>
<td class="nump">4,209,356<span></span>
</td>
<td class="nump">556,352<span></span>
</td>
<td class="nump">4,209,356<span></span>
</td>
<td class="nump">$ 2,123,737<span></span>
</td>
<td class="nump">$ 855,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">950,835<span></span>
</td>
<td class="nump">4,705,475<span></span>
</td>
<td class="nump">950,835<span></span>
</td>
<td class="nump">4,705,475<span></span>
</td>
<td class="nump">$ 2,529,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Capital Expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,961<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,612<span></span>
</td>
<td class="nump">18,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78,743)<span></span>
</td>
<td class="num">(253,933)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=AEMD_AethlonMember', window );">Aethlon [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">392,073<span></span>
</td>
<td class="nump">380,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,281,530)<span></span>
</td>
<td class="num">(1,911,219)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,323,003)<span></span>
</td>
<td class="num">(2,165,152)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">553,884<span></span>
</td>
<td class="nump">4,208,554<span></span>
</td>
<td class="nump">553,884<span></span>
</td>
<td class="nump">4,208,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">914,179<span></span>
</td>
<td class="nump">4,677,989<span></span>
</td>
<td class="nump">914,179<span></span>
</td>
<td class="nump">4,677,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Capital Expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,961<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,822<span></span>
</td>
<td class="nump">8,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78,743)<span></span>
</td>
<td class="num">(253,933)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=AEMD_ESIMember', window );">ESI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(76,999)<span></span>
</td>
<td class="num">(303,113)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(76,999)<span></span>
</td>
<td class="num">(303,113)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">2,468<span></span>
</td>
<td class="nump">802<span></span>
</td>
<td class="nump">2,468<span></span>
</td>
<td class="nump">802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">$ 36,656<span></span>
</td>
<td class="nump">$ 27,486<span></span>
</td>
<td class="nump">36,656<span></span>
</td>
<td class="nump">27,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Capital Expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,790<span></span>
</td>
<td class="nump">9,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and construction contracts, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4D<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624177-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph -4<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=AEMD_AethlonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=AEMD_AethlonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=AEMD_ESIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=AEMD_ESIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6592931488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>13. Commitments and Contingencies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense</a></td>
<td class="nump">$ 79,000<span></span>
</td>
<td class="nump">$ 90,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>60
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M9*U0R%JAD+5"(6OU1E8V_+MW]@Q02P,$%     @ &HIJ24AU!>[%    *P(
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MK:1O;?2QS=%;@=[*T5N!WLK16X'>RM%;@=[*T5N!WLK16X'>RM%;@=[*T=N
MWL;1VX#>QM';@-Y&VBM!FR4<O0WH;1R]#>AM'+T-Z&T<O0WH;1R]#>AM'+T-
MZ&T<O3W0VW/T]D!OS]'; [T]1V\/]/:DO6ZTV<W1VU_H'>MJ"-NG-!S:?;QV
MS;?AL.@"[YC>3^'Z*>>IL.%"ZS2N%-SY>/5WZSSU,\3]^ENV^@!02P,$%
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M?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8.9_
M[/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*$IY"
M&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X2O2Q
MS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y"M-2
MD&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#0X=Y
M>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0HGQ,
MC$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55ORL+YJ
M/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SCYL=Q
M3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7=\%@
M\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#NDI &
M$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A%W+C
M[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF8$O#
M>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->YA,L
M0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_2P=\
M'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!U4#E
M/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04    "  :
MBFI)SCB5]48"  !Z"@  #0   'AL+W-T>6QE<RYX;6S-5EMKVS 4_BM"&:.%
M$=L)3>EJ&T8A,-C*H'GH6Y%MV1;HXLER9O?73Q?'=@)9T^Z6O.CHTSG?^70D
MYRBL54?Q0XFQ BVCO(Y@J53UT?/JM,0,U7-18:Y7<B$94GHJ"Z^N)$99;8(8
M]1:^O_(8(AS&(6_8FJD:I*+A*H++ 0(N_DYD.()/%^^_-T+=O@-NG'V8S?RG
MR]M#_,(N7$+@.#YG$0Q65] [G73N^\>)S>(!^>J5Y+_B/J"^-M1>7Z XS 4?
MZ[2 #HC#^AEL$=7^@7%/!142*'T06H-%.&+8>=PA2A))#)@C1FCGX(4![-GU
M?HQP(6UNE^$PS]P?,\DBB:#?_TY/EXSL=C#;(Y3N;T\#<5@AI;#D:ST!O;WI
M*KTY+CAV(JW?"]Z%1%VPN)H$V$'G383,L!PR!W 'Q2'%N=(!DA2E&96HC'2A
ME&#:R @J!$?44.XB>D/3IIC2!_.E/.9[W&T.G(\Y8Q\"HV)GZD+TYG@-;%&]
M*9OCGM*^C1>T^9! 1Z.JHMTG2@K.L!/KH+7H9R_1!T?HXQ#M6$$I)'G6_N8B
MI!K $H(MEHJD4^2'1-4&MZJ_P5Z;'U/XUBW_34U_OFJC&GT%_W5Y_FORZ=G8
MSQ >Z#GA*.X;EF"YMO_-KQ>VO#Y79::QG:VTU?E*.]L#7=[\IC*O;PR3[K/7
M>P84) VABO"=!&1>"_=&-MUK"V/?T9Q9.[8<NZI0HA^">UDT689SU%#UC6R%
MLHL1'.TO1GZP&KPV T4$1_LKSDC#;JR"\;49_P102P,$%     @ &HIJ23S#
M55<6!   V@X   \   !X;"]W;W)K8F]O:RYX;6R5EU%OFSH4@/^*Q5/OPPA@
MDK;1,FE=NGLK=5W51-NS TYCU=C,-FFW7W^/G60[-!YJG@ #G^WCSP?.>SM]
MUN9II?43>6FDLE,S2S;.M=/1R%8;WC";ZI8KN+?6IF$.+LWC2*_7HN)S774-
M5VY49-ED9+AD3FAE-Z*UR9YFWT*SK>&LMAO.72-WL(8)E7QX;Z=K(?DW;BR
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MI7WI^J^ZKP2\SH"+KCZ/;V>F5T2;_P%02P,$%     @ &HIJ21XX30[X P
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M--F;0_W2C#_L]9O!,<@IX<XVP_P_V;T,HVV7D#1IZU_^>.[FX]7_HA6&A0,
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MW<<F7:F4.!R6![*^TNH=4$L#!!0    ( !J*:DE:MO@YI0$  +$#   8
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M)Q(:%\(;'YMTI5+BL#\^D/F5EE]02P,$%     @ &HIJ21T7W=RE 0  L0,
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M>  =H@/?/GO84S+X][,E$CH7PL\^-NE*I<3AN#Z0[976_P!02P,$%     @
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M0KCSL4E7*B4.A^6!K*^T^@=02P,$%     @ &HIJ28/I[#ZE 0  L0,  !D
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MO7L_6R*AM3Y\<+&.5RHF%L?U@6ROM/H'4$L#!!0    ( !J*:DG ')()I@$
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M:J&@-P)[HJ'9T?O5=I][1 #\$3"9LSWQW@^(;S[X5>]HXBV A,IZ!>Z6(SR
ME%[(%7Z?-3]+>N+Y_J3^%+IU[@_<P /*OZ*VG3.;4%)#PT=I7W%ZAKF%6R]8
MH33A2ZK16%0G"B6*?\15]&&=XI]L,].N$]*9D"Z$31*,QT+!YB.WO"PT3L0,
MW)_=:NO@VHLX9>*\&==VT-2A\;(XEJOUNF!'+W2!B<3]C%D0S*E?+9'2:_0T
MT-.?Z=DE/8L.LU@]SWX6R"\%\BB0!X$S_C?(/I^GL/E2@YV-5(%NP\TQI,*Q
MMW&B2W:YG/=I.))/>%D,O(7?7+>B-^2 UAULF'^#:,&53VYN*>G<\UD""8WU
MV[7;ZWBC8F!Q.+V/Y9&6_P%02P,$%     @ &HIJ29=S=X'$ 0  O 0  !D
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M7=,:%R!Y1A9>U0GH=2=[I*#>X\-J5R0.X0&_.YCTS1PY[R<IW]SB9[7'D;,
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MONVL7R!5219>W0N0IE<2:6CV^"G9'7*/"(!?/4SF:HY\]J-2;[[X4>\Q]1&
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MV_3 N0*-CV=YA!H]9:<-A8,RRU*OA1L\;J-X/X[1:9;7_P%02P,$%     @
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M8QB*88!)9S!><T?*C"7+G!SEY,#)9CB@(3DI\BL.4H&""@"Q&5!Q&ZA$026
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M^UHL!8/:N.G.SE6X0*$PLI^?@^5-*OX"4$L#!!0    ( !J*:DGRC^$&R0$
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M[]O.N  I<K+PZIZ#T+T42$&SQ;O5IDP=P@-^]3#IBSERW@]2?KC%2[W%D;,
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M-UW;N0K//"R,'$Y-N_PYBK]02P,$%     @ &HIJ29=?I=D@1   "/X  !0
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MR;.WJW 82V.&%.FJR%+T5C<8K4UYT3A/NJ"3)*Y*XO>._<.K)P4_(^P6!0
MH.>HW()N\L-T>GE$[(WP*%H[2XF<+!1DG$;'B5"+V0J6 [ UC/Y(CTU94X4O
ME.S@.IS#X9K RNP3'Q2%\B-FVX?7LY,CS")!J8]?7!__(Y@+M#E4RI_HP &C
M0;%=+5AC" @  ,>?MS'CN5ZATN"NA2NN@0U6PB'8P%($2>.9HC"9K[8+AGF1
M+9911CDH$ZU<W1#VB"C%^O:D"5N\S\,662"A:*!];W  S99F1-H/2_=CDNX%
MB30%%<,E(4*08RU4,-<G"^9&<5'"3S('3T'O 3Y*2^:#LL8X;_OS=HK<#Y5
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M4OXY:3V7#17:R%Y.337 SC++_8:L5SP:W]::8+C0G(SE)5FY=4[6U^J2,S<
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M8%V"ZEQ]:[)[QT-V-CW:M/.JRLX>]7++X6E]AU'1!G@Z59JN._:[@W8%Y<;
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MO%NZ$%YXE[ZX1<HO?+S <#(8%1PXG%O"I02"61A#P/P=YQZ0@^'([_5[%!/
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M%5_Z@I=1Z4M?JK4!E4=VR*8OF^MCN3^;.4DK/D[#)85!IKI:P-P-!U8@MOS
MNO0PGC^12^YT>G4Y]?'T*A#NN"YX>HY35&R;";XZ4%(#P-Z4Y"9*D0(JW(3
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MX1V,)B;%5NXDK/;?V+]KD:_<7C(M[]WLA^D[[_WTY@9]J6^KEP_,5T&TY@)
MS/]6.N:U-<%*TW/=!@JUI5+LI2A7P428K9U+3W2073(!0B3+$I2[E%B@GZ"I
M,[[<05%=^3V3T386-982J?C6LF7P &>,AA#@[QPC(3)W,@>)XW-2>X#7>\9A
MCFM>!&NPSF&AZ*N!?^ ,@A4-F.!-"S_#))S9 $=R']U&9)5L=<?JD+0VODXR
MY5)-8SUA\0E&DCG>(OF KN6&.CHM*]5A8\##FBT@BJ(A8"*0DJ+&&Y.\>D26
M%,VP8('WN+B-L21&1'94H;./X!$WW*2DMU1W*7&:YRB^E#C7OEG,XM9-\A)N
MXRTEFPEG]\)*T-;D.Z*E2R;VDJR:]WVZM4/"DM[LH=;.+S^PR\Y_;C#'@8CE
M]_:^KI"'MD%2Q+0:,G*[PB^8)>E[P_=HL62-9:?9$L5/N>&(:?]A._%*0VS)
M>#ZQ5V_0V;E-"FVO1=F,5%P&3R8J;WOX,+91-\6%5?BH%S055LDZE5UG6<CI
MVP16DK>M@PW*YB.('!,'ME.UJ1WDB;B\-3\K!8(#Q^\6N?D<AJ.18+19,D%&
MEPKS56.23,"):0VYRP7\JSUQ7SVRERN*,:-'4_S7NC*AE.OX)LP?$40V"1C=
MTAKJG1(2&N7+O;BHZ3:%88=,QT.^;7[!05[8R0%:S9.&6Q54^5:%T63/.Q5$
MMWG^3H4.&/%@Q]7=J6!O #KHMX;=8LOBXIT*%Q8W!PXPPIWW3=^'(N01_TH:
M0H,R[GV&,FX;/NN*8+,,WUD$54:9&W<^V48J%1W;J6R/[24]91V_PFY[+9LY
M11T!V+%'X)CIWHR'-^0K*EN9]:TYB^12^,OQ"]U4:U+ AD;_SK!-UC3=6D=^
MIM)#O='('_?1'=3O]@%-1I5>F8-6S54 TI^T:2_?NV_0%<P8#\!']]IT\WSZ
M$JB:5J2UF;&OU:6YMNU#;&Z-5J?ZNKWS,-?9R=*BU/@:JK<J*+T,]"OH9JN7
MW/'@M=KC+G3G=K8#[W" WJLA^1Z&[0%\.S!=4;4OJ3* 7L&^ ^TXN]VP+/7<
M/43B77-EP)S[=Q7Z21PU0!H!;"#;O!8$*#GJ7@143P-5[NLC)PZ@>I\[3^)5
M9IW>1'>8K0&J5P;J?@-5:,1I]%![D6%YRKVHX.^7&NYQJ>&NILI?PFG_@_8P
M;F3(NC#MG][3'JL-I.5WZ?%"D<U2B==>4/R/6)E6S<XN-<]L AK?J=?<$;?:
MUOGOW8S_7^MF_$*J^((:Y%T5<H;NO>.F&WN:D/ACJ=YK/]GT]X*N?]>"KO(A
M3DN%6A66]K>M?]J59=(HHG2Z2:K332H/_#U,_O<P^=_#Y/_WALE;WKE)>'JC
M,ZD.3R6+]AS9'P9%4$A]N#[U#@\J0R %HFN=-9IL ZQFOQM,8F\*MLS*PRH1
MDR=LD_<"KW,,:'X\:%,^4&F*TE6:P3:_3U)=&.]<#DB!6R[8(!>LW)7M7B@(
M(KQ3_I+SSZBT:M N]/&P$J5X9[?T"RGT:-9%0+=R01D65\9ATP5C9< " WZG
M]2+M0J4WZX^'%UFYE<8DL!6T.6P7PN$W@@J(C)@NMK+.Q'FP,D4"4F]*F6\>
M)GB2W@;S?I8S[=C;S^<FN]R)>LX@"V>0!F5^MU],0_6X^:$=:VETG_G68B^_
MXSI=%N+>>L&X<5AYNFSOOF T;=-*.]"7K".)GWGY<P"/DQ@-MT;SV+2,[K7'
MD2S"V]QWNN6)[Z3\RLL<+=9E73]UQ<?"T8OGURFAPX9%[@?-?7BWD1O:@L+I
M*SCE"C#@6OA,([I6'UZ&= >]1,^(;V;5&"3+L:BTGDK2%/)#,OA0_=I&V;T.
M6]0MW-Z8B]W)&H;<QUM9OH^WT3 [1="L4:!2%XZ@XC;\_O?;50OL</6;WV#,
MHAEMI(;8\./Z"ZE*E]XV/DWKFF,39.+@Z[J3HV=T^R<ZI*:&*U+(WV25EA*B
M:@#>PLMO"0*3SSD.#7WOG[VW6/S_$S6S "1XUG!^X>AO;$=[YV3>AJPQ?:5)
M".XFN-$TZ+#ES?C^B,)=AB^B]LOBQ>(2:B3MH_SH6]LDQ/:7J6GJ\R*W1=.M
M9NA@.=KG+==I9KJOE9\OQY(;/8'N_GW**R.\INL6;:]V">82@=4F?')LN/YV
MOTHLN-Z]:&] ;5KLSKLO7X8%']S[%M^&8?.DNQWUSZMGC9[U>N;?Z%K?TXUN
MU8@F)^^.M3:]4GYN3]^E]U+?97D>,-KPWJZZK]N=RM?/0@1([-N"/PQ!\7GT
M6-"\ZHT.GHWC$O6_/1.H$(RHK/K%^]XC1G+D/+;7G@^\[\2*JM]]<<ZF7_>#
M0%)M3E@MUWJF$5T1!/_LV?5_[E"5+H@O&M2VTG#[$W$+W)V@ZTN'B(F.4XZH
M_>_7F/"YTY"6=R_$OWW8\74#8Z@HCH7;E9JE)9&,-)RJ^=&]X*7I*;Y0AV_3
M:9R(U\-7S.Q0A9QF_?82@[T6[[/^L2^\'->%3?+<R:/K5>I2SZ[=#TGJ>XU9
M5>@X60X&5D7RKL:.+WNZ>/%AO<'9%4+JM#4E=7JUI,0'8AN^8DJ8TT#6HP:R
M?@/A[_ERO352C)19AEX.?1W9[YZ-EQ78J.L,^.<FUE6*_A#[?.91:7+V[',&
M+M_I^HEG7RFL7EP$^RZ=])"FARDF*-5$#K_'1'4]C %612/!8-<QA[H^8UP#
MV<]XM]X,W>/%"NP_9^&UPGC_'==DUCTG?^N.XTOD>=TQ?*7Q#!5\C<'J2.6K
M;%J3T%>$H-!9\XA-C,T)!W]&1D!#L+C\&,6.*RZ[NE!RQ;,O(F,H$J/J:ZO$
MFRO*4J<UJ,Y>#4?O!S&K6^WC&JX_BWHOAX.\C5RUZ1Q>WF?RY<$V'"!M;AY9
MZ;7UW /]Y@?>#QMW6NU9T@B30B;!\VZ#]T':TEFL@P8 U!A=Q5!_11,U8?AZ
M0XN#SQ4'3TWTN.H$VQ$^;G2XS^K-?AW[;8(EAGX;X?Q<R?-+4:TND/9=EN7?
M_Q]02P$"% ,4    "  :BFI)LO,XU=(!  #E&P  $P              @ $
M    6T-O;G1E;G1?5'EP97-=+GAM;%!+ 0(4 Q0    ( !J*:DE(=07NQ0
M "L"   +              "  0,"  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M !J*:DD9(\'7O $  $$;   :              "  ?$"  !X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( !J*:DGHH2\<!@,  -X+   0
M              "  >4$  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
M&HIJ2?KJ$-4^ 0  :0,  !$              ( !&0@  &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ &HIJ29E<G",0!@  G"<  !,
M ( !A@D  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  :BFI)SCB5
M]48"  !Z"@  #0              @ ''#P  >&PO<W1Y;&5S+GAM;%!+ 0(4
M Q0    ( !J*:DD\PU57%@0  -H.   /              "  3@2  !X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    "  :BFI)A3+&-V<"  "^"   &
M        @ %[%@  >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ &HIJ23\(C!S) P  )1$  !@              ( !&!D  'AL+W=O<FMS
M:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( !J*:DF">A! W@$  &(%   8
M              "  1<=  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"
M% ,4    "  :BFI)ZI4GB3@$   N$@  &               @ $K'P  >&PO
M=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ &HIJ21XX30[X P
M<Q(  !@              ( !F2,  'AL+W=O<FMS:&5E=',O<VAE970U+GAM
M;%!+ 0(4 Q0    ( !J*:DFSP2*THP$  +$#   8              "  <<G
M  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  :BFI)&\P,
M]Z0!  "Q P  &               @ &@*0  >&PO=V]R:W-H965T<R]S:&5E
M=#<N>&UL4$L! A0#%     @ &HIJ25JV^#FE 0  L0,  !@
M ( !>BL  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( !J*
M:DDEE<4MI0$  +$#   8              "  54M  !X;"]W;W)K<VAE971S
M+W-H965T.2YX;6Q02P$"% ,4    "  :BFI)'1?=W*4!  "Q P  &0
M        @ $P+P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0
M   ( !J*:DE]#P\LI@$  + #   9              "  0PQ  !X;"]W;W)K
M<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ &HIJ24HH,L^E 0  L0,
M !D              ( !Z3(  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q0
M2P$"% ,4    "  :BFI)LMO(8:4!  "Q P  &0              @ '%-
M>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( !J*:DF@G_LR
MI@$  +$#   9              "  :$V  !X;"]W;W)K<VAE971S+W-H965T
M,30N>&UL4$L! A0#%     @ &HIJ28/I[#ZE 0  L0,  !D
M ( !?C@  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  :
MBFI) @'8[*4!  "Q P  &0              @ %:.@  >&PO=V]R:W-H965T
M<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( !J*:DG ')()I@$  +$#   9
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M970R,2YX;6Q02P$"% ,4    "  :BFI):U/B4:<!  "P P  &0
M    @ &110  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (
M !J*:DF7<W>!Q $  +P$   9              "  6]'  !X;"]W;W)K<VAE
M971S+W-H965T,C,N>&UL4$L! A0#%     @ &HIJ2:H!>%^I 0  U0,  !D
M             ( !:DD  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"
M% ,4    "  :BFI)E6XL?J8!  "Q P  &0              @ %*2P  >&PO
M=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( !J*:DGX<Q(XY@$
M .T$   9              "  2=-  !X;"]W;W)K<VAE971S+W-H965T,C8N
M>&UL4$L! A0#%     @ &HIJ20^>P<?1 0  200  !D              ( !
M1$\  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  :BFI)
MXB?1N@,"  !W!0  &0              @ %,40  >&PO=V]R:W-H965T<R]S
M:&5E=#(X+GAM;%!+ 0(4 Q0    ( !J*:DDK#^F)%0(  '0&   9
M      "  893  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%
M  @ &HIJ22MDWW#A 0  [@0  !D              ( !TE4  'AL+W=O<FMS
M:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "  :BFI)O?T=RD(#   5#@
M&0              @ 'J5P  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+
M 0(4 Q0    ( !J*:DF2)F3"F@(  ,H)   9              "  6-;  !X
M;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ &HIJ22/HN9^W
M 0  /P0  !D              ( !-%X  'AL+W=O<FMS:&5E=',O<VAE970S
M,RYX;6Q02P$"% ,4    "  :BFI)V+VG:=D!  #.!   &0
M@ $B8   >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( !J*
M:DE'&Z[J3P(  "D'   9              "  3)B  !X;"]W;W)K<VAE971S
M+W-H965T,S4N>&UL4$L! A0#%     @ &HIJ2<2+,;;! 0  100  !D
M         ( !N&0  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
M    "  :BFI)%\Z:@@ "  #7!0  &0              @ &P9@  >&PO=V]R
M:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( !J*:DGBWR[AB0,  &,0
M   9              "  >=H  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL
M4$L! A0#%     @ &HIJ2;'Q-KJ= @  9 H  !D              ( !IVP
M 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    "  :BFI)OR4%
M4,<!  "?!   &0              @ %[;P  >&PO=V]R:W-H965T<R]S:&5E
M=#0P+GAM;%!+ 0(4 Q0    ( !J*:DGRC^$&R0$  %X$   9
M  "  7EQ  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @
M&HIJ23V!KND: @  L 8  !D              ( !>7,  'AL+W=O<FMS:&5E
M=',O<VAE970T,BYX;6Q02P$"% ,4    "  :BFI)"]"4,H($  !0%@  &0
M            @ '*=0  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4
M Q0    ( !J*:DFSW16\RP$  $4$   9              "  8-Z  !X;"]W
M;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ &HIJ29=?I=D@1
M"/X  !0              ( !A7P  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L%
3!@     U #4 90X  -?       $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.5.0.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>46</ContextCount>
  <ElementCount>170</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>23</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/StatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited0</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/StatementsOfCashFlowsUnaudited0</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited0</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Disclosure - 1. Nature of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/NatureOfBusinessAndBasisOfPresentation</Role>
      <ShortName>1. Nature of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - 2. Loss per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/LossPerCommonShare</Role>
      <ShortName>2. Loss per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - 3. Research and Development Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/ResearchAndDevelopmentExpenses</Role>
      <ShortName>3. Research and Development Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - 4. Significant Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/SignificantRecentAccountingPronouncements</Role>
      <ShortName>4. Significant Recent Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - 5. Convertible Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://aethlon.com/role/ConvertibleNotesPayable</Role>
      <ShortName>5. Convertible Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - 6. Equity Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/EquityTransactions</Role>
      <ShortName>6. Equity Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - 7. Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/RelatedPartyTransactions</Role>
      <ShortName>7. Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - 8. Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/OtherCurrentLiabilities</Role>
      <ShortName>8. Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - 9. Stock Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/StockCompensation</Role>
      <ShortName>9. Stock Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - 10. Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/Warrants</Role>
      <ShortName>10. Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - 11. Darpa Contract and Related Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/DarpaContractAndRelatedRevenueRecognition</Role>
      <ShortName>11. Darpa Contract and Related Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - 12. Segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/Segments</Role>
      <ShortName>12. Segments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - 13. Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/CommitmentsAndContingencies</Role>
      <ShortName>13. Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - 14. Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/SubsequentEvents</Role>
      <ShortName>14. Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - 3. Research and Development Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/ResearchAndDevelopmentExpensesTables</Role>
      <ShortName>3. Research and Development Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aethlon.com/role/ResearchAndDevelopmentExpenses</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - 5. Convertible Notes Payable (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://aethlon.com/role/ConvertibleNotesPayableTables</Role>
      <ShortName>5. Convertible Notes Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aethlon.com/role/ConvertibleNotesPayable</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - 8. Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/OtherCurrentLiabilitiesTables</Role>
      <ShortName>8. Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aethlon.com/role/OtherCurrentLiabilities</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - 9. Stock Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/StockCompensationTables</Role>
      <ShortName>9. Stock Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aethlon.com/role/StockCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - 10. Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/WarrantsTables</Role>
      <ShortName>10. Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aethlon.com/role/Warrants</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - 12. Segments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/SegmentsTables</Role>
      <ShortName>12. Segments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aethlon.com/role/Segments</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - 1. Nature of Business (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/NatureOfBusinessDetailsNarrative</Role>
      <ShortName>1. Nature of Business (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlon.com/role/NatureOfBusinessAndBasisOfPresentation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - 2. Loss per Common Share (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/LossPerCommonShareDetailsNarrative</Role>
      <ShortName>2. Loss per Common Share (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlon.com/role/LossPerCommonShare</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - 3. Research and Development Expenses - 3. Research and Development Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/ResearchAndDevelopmentExpenses-3.ResearchAndDevelopmentExpensesDetails</Role>
      <ShortName>3. Research and Development Expenses - 3. Research and Development Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - 5. Convertible Notes Payable (Details - Convertible Notes Payable)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://aethlon.com/role/ConvertibleNotesPayableDetails-ConvertibleNotesPayable</Role>
      <ShortName>5. Convertible Notes Payable (Details - Convertible Notes Payable)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlon.com/role/ConvertibleNotesPayableTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - 5. Convertible Notes Payable (Details - Convertible note activity)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://aethlon.com/role/ConvertibleNotesPayableDetails-ConvertibleNoteActivity</Role>
      <ShortName>5. Convertible Notes Payable (Details - Convertible note activity)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlon.com/role/ConvertibleNotesPayableTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - 5. Convertible Notes Payable (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://aethlon.com/role/ConvertibleNotesPayableDetailsNarrative</Role>
      <ShortName>5. Convertible Notes Payable (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlon.com/role/ConvertibleNotesPayableTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - 6. Equity Transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/EquityTransactionsDetailsNarrative</Role>
      <ShortName>6. Equity Transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlon.com/role/EquityTransactions</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - 7. Related Party Transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>7. Related Party Transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlon.com/role/RelatedPartyTransactions</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - 8. Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/OtherCurrentLiabilitiesDetails</Role>
      <ShortName>8. Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlon.com/role/OtherCurrentLiabilitiesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - 9. Stock Compensation (Details - Share based compensation)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/StockCompensationDetails-ShareBasedCompensation</Role>
      <ShortName>9. Stock Compensation (Details - Share based compensation)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlon.com/role/StockCompensationTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - 9. Stock Compensation (Details - RSU's outstanding)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/StockCompensationDetails-RsusOutstanding</Role>
      <ShortName>9. Stock Compensation (Details - RSU's outstanding)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlon.com/role/StockCompensationTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - 9. Stock Compensation (Details - Options vested and expected to vest)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest</Role>
      <ShortName>9. Stock Compensation (Details - Options vested and expected to vest)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlon.com/role/StockCompensationTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - 9. Stock Compensation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/StockCompensationDetailsNarrative</Role>
      <ShortName>9. Stock Compensation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlon.com/role/StockCompensationTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - 10. Warrants (Details - Warrant activity)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/WarrantsDetails-WarrantActivity</Role>
      <ShortName>10. Warrants (Details - Warrant activity)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlon.com/role/WarrantsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - 10. Warrants (Details - Assumptions)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/WarrantsDetails-Assumptions</Role>
      <ShortName>10. Warrants (Details - Assumptions)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlon.com/role/WarrantsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - 10. Warrants (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/WarrantsDetailsNarrative</Role>
      <ShortName>10. Warrants (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlon.com/role/WarrantsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - 11. Darpa Contract and Related Revenue Recognition (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/DarpaContractAndRelatedRevenueRecognitionDetailsNarrative</Role>
      <ShortName>11. Darpa Contract and Related Revenue Recognition (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlon.com/role/DarpaContractAndRelatedRevenueRecognition</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - 12. Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/SegmentsDetails</Role>
      <ShortName>12. Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlon.com/role/SegmentsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="aemd-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - 13. Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlon.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>13. Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlon.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>44</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>aemd-20160930.xml</File>
    <File>aemd-20160930.xsd</File>
    <File>aemd-20160930_cal.xml</File>
    <File>aemd-20160930_def.xml</File>
    <File>aemd-20160930_lab.xml</File>
    <File>aemd-20160930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>66
<FILENAME>0001683168-16-000543-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001683168-16-000543-xbrl.zip
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M*(CY*_9N\UGR;G>LFN5;X \XMQ5*%MY36U=Y=MKUIAZ@63S=/&1\:CFVU/>
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MPX93UXEFS!8KAET=R#;FVGGWP4*WA!T/% .WZW6C+OX5 HIH;<Y^:23RAEO
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M*B\X$\LKCF()-]%6I2R54@RUN'CN0G5Z+4/*YZE;A=ITDPP*;OQA!,OE6#
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M!DIIWZEWWHI!,YD7"(J(6SV,.:5L8U83)2/,,'::C6=E\M8%?PL!*:I>R/S
ME>EAJV.UV[ (9JV,&RT=YX)29#%%M KC;L'.N<,/HM,&$WT_;BR\0'8Z"KC8
M\UAU@<#Z6^VLQM(^'P3YW5X6],PT5U+3MJ<9;>0PE]=(93[(4K*\2:LW"Q-,
M_9(QX*ADQ@SA5$FVW@>8H6:PSY_/,L;<+)UG#3L10 <;#8XZ3CBF&QE@))T
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M;)BYO7>7K<^0O3VWHAX*05:@]([,][;<HF O+"^Q\]N5^YSR.(CSW;,F/FR
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MXG=^P"CJF+@UT<,-\][QL>4.12X:!O@?_.!/%68;6%,GHA1<].9QL.5EAE_
MA:?8\UD8#\89*!]U;W#&QIHIQP_/S]PYYC\&H*U4YAR!,+;L)'8JXZ8??;Q'
MG%QDZ74H(N0_I%<G_3@*,0/%=@(^$-%W>C8[78V=YG6#(#\T3BNF(RAFIFR
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M\CQXP/!C9\HBF(1C<W%A9SY@$U90W7X<4O]FJC0E>QT#0WX+_!^/V+E:V(#
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M91?P* X\[#XH?9).P+2NTY1!C<%9"9FXE&F%8[H'$I"W"V,'C_)5O(J!-P\
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MT^6DJVHR5_]I)]G.]1HLM9C@*&*A[]$2/TVNO<J+DJXSY%N)0FX)M<U:6US
MW!8J]^%E2TI1W?NNA:(Q>BS%'7O#;M^LM7\Z>B9-T&D[V)C:L\-CPN%7WULL
MCIZ,K7-,%@Z?WS[BVCY>G"9H9#NHL1-&?H E 9('18?SC#BC7E?2\*'..?!]
M,ISJ+"50T6Q]")W)U!7MT2<\&OMV\@OV9;%Y. B<.[J82Y#@NS<79_\%0\>.
MC4%FL&4X&D>JF[4C)L +N63B\& B6E[C)6U9-#R!4_8;SS;ZH2OP5B!,-BQ%
MH-8M32SQ5'6E=PE('W5:6W?^?<8>QOO<! Y9OZ(9N;S7[0$(B9DK[V27+"9B
M17"J-DVC+UO.#UR86G 85:I([6Z" ;B,_Q4C*R_ GE9R8(,: ;/U!J[Y/?=B
M?BU*)"!:OOFN,WBLB@JLQ7"_@Q B@U5VXK.2[9Z]Q'_.A]P+.3NU[U%XV.P:
M3EMX=0B[WO\!0BQDIR/N#1Z9'QCL_/3ZVZF!?#S'9V:-??>HFQZ.BL\Q"QC7
MIEH%U)?JCG,/@!I9(Y(D!((-5'?]*7;&&X,E..5PDAN E+O'(QLU][-C66;%
M\0:H?$4M@Y!/0P?08P'W8D>].]?W;6!!;F$C@J$L5T#L[0\CF!<L]]B-$FEH
M<TLB 86>/[FSD.!_Q(BO$+O_\2 4HIP6 2< ?R)7105$V-#YP>T345LA@UDV
M]6&^"(Z?LMF?*@N"RXE#T?O/Z/9;1K/7%Q#<2ZP-0+:&M+PA;"E9]X-]PIE8
M=J80U@-[-!"8L09C!_"H2C%,8*'.U.4&HBR@KP&,B>."!O#IN(YX'7"8(V&#
M8>RZ<JE2NG 8E4!0S0W5W#J=A3*9>8 H/N4!'N&Q?@H/(@O0K@/SX =_BKE]
MG#/,6P:>\M&AH$-NC6 D.(*) BM8!,.[]YV!%)DCQ*1'[V.3QZ% G$ _L^B6
M>*6EEH%T%3CP@N6ZC[C'76J)26:*8(0W^%]I__!9JK^EC<&'M/?N19M-*D=E
M!:@!/K"Q_P#454*$A?%="#P,I(%Y5+$2$%:8&R",#ZDM ]5816P(51(IRY*X
M4S4^$3TXP6H):%  =>I:'@YBH 1R/,Z)R84ZA-$'N%T!71S+]^0PHZSHXX%P
MF&!WSY"+XE!R&]KI4@?.5/BM$A/+N8M5Z:YH[ 0V/?>8/DT.K&1+I6OZG98P
MX226<<?D/$5  %A7@\B7U5?,BL67@'3IL4_\+HBQN@J6JE'L*!0-T9'@"0?^
ME*==:J6 !TP+)A1]:>&_?CP:"W$])R9OB7EA6*(^\@Z-.?0'Y/[$@0.E;'TL
MV.,C<\':[IT@5@R&7$3*#32 /^ A51IS$FN+6 VG<D(Y?#JCMB102O F^OD2
M;33/2]C:]W6OW3-:G;ZH3R4<'V*WS:ZWXK+E7%:ZG).NR;[7;FKLMZPZ(S6-
MTIE:!&O"3E 2V4FPLLZM),I&HX"/T,LN=""9(,U>UV@U>Q455_@"; [&BRMM
M'*R2-:-EU)'I.39,W0>.ORATLD:M4S-K37;"_CL&G>@,'Z6E#MPK#55?ZF'\
M_LO%]8V0E-AL&ZOK 5J0[;FTU@=.,(A=2PE?.(@&:(!3\ <TOA6!L<_^QB?^
M% S>86KP)P1.3$<T;%Z;_:;1-?LU@N2+Y<$IAGZ$W8:]NDDG@!!.WQ8E_]#,
MB7 Y=.('\T;6"HU@85-.1%2&SA2.Y>@+1U9SL&<Z;/H'\8YP%<'!A(.QY'M2
M,X@JH61-_!>97GX !B[:#7\)##I2G @<LNWCCP#)P6' IP"+."H-!BCTJ'&\
MKFTH@#@$^YX'_X7'&1GFLP2F/%N>^4@HTD" R8D316))<-"#8UU0B:\26ZLE
MG8R]AFE^@.,]1Y]>8F1(_,-Q$U7,M2 @ZAU2*H6V!EMK6R@)NIVMP99MBZE8
ML\VT!6LVW[*E5QQ]!""5,JO:!<VJDL:49D)U&T:S49E0E0EU+'+^2R<CXL\Y
MG!<X.^71V 6C0?W2_2#.=+]]^0:3>?$08T"!J&!-1TP25@&_Q^JQ^#&>C@++
MSAT(+0V*C]&K-I@$XNTI^NX=X6LD&2GC2B#TH^2H#!):F%/+=$NO@Q65UM0M
M!4TNY0C>1+?88 7AL5Q4AJ8*X(1^<=!?CFM\7"9-2;S;.N+%$!MBFH2=)4)Y
MWJ/R;" GZ0I.0%$IN:/8SHU:&\PV$TY$6,_;Y='RO9PP!M$!QK#N7"<<TU_H
M0B4OO.6ZQ(RV+,LL['OE7Y#<L=S:F]^1!,(A#D*S.Y( 6;XK'\0J$9OIUIS9
M4PGNY#Y4V,,_"^$OD6J'-AO36.W*^.IL0/:&CW"!PAP&(*LZ[YN'9/TI#T@L
M ]_=X5D:- #'XMP8W)QBX$5Y6\G/BK:IX"#*T0P%1<+W2@RH3@,)TX0TLAY*
M5;.H^N$.K@"YZN+F,O]U$9=UK)'GAPM&J+$K<E[/0:8%>L'JX\&$]DPFT<43
MCA>IF-)@*6Q!=%QC<PQ5WEP&A[E-6QF;)V!X$M@P0%&(OE# &KRJ9POC3H2E
MT1+)=3]V^%#B'7>:S0=.B ].K#]Y0-J6/X3X2L:L25Z049XD>$R)K"C2\/UD
MM!!S.F+L#!'"I .AC4'H 47]@>H5@>M%T"2RQ-[V,0\$L8N!+QDTQ4#\[E7D
M,[."\XS30,@\K'\_XAYM/9&_!1L.)G! AY"K2PL<IQ%V( WU<)&;!20^%_KJ
MD4>"S]&.DE,(;4/?XB.PG=W8)NWQJ)A A@"!B6';8 JQBOV/N97''Q4';'0Y
M@003*$M.EF\T5GD(,F*:2@R,C02VN,\0I#+V:):U=CJ_GKX_F]Z?O?4SGY<_
MD[]?='F+TOD/T0S!/5BAC*0$>B=!]'S>;W(IHFPAC1GP;IP?[(MPAEWD.,,0
MK&;=. 8LN<O2N5\HAS3VP"%+[S'OE_XO!-V+R\,<]W;;=E68&:#E$31/M^KH
M.10;;+M'YRZD586;@U8&E$91IP,VD=J]+A]*VZCL4:60D)!3-O98S3U[1Q'7
M5W3NQ;?.<V=JEJK>/C-7L]\PZMW%=?NVO;:R&JXBW"+"]>I&K[NX0<9A"+?O
M%C YRG\3F8(.K",P.O+76J9&WRZWY/9J!>8"0E'7M:FP/S14+/!"66 O-M+L
M$E*IIE;:J+7GA5VCA+"[I8M5ZCBQ'KH)B,.P/4V=6U5G!RJ[) 2[,\$6<,&A
MA%Y%_RW0OXPE=Q#Z'YD'Y.#'_ 4R>E>;;N<NA'TMJ"+(41'D((9,T25<)<D&
MGWV,[1_*W5FQ5K77GP%!#N68V9%?]UBYJZ YN393O6D:C9YIM)N+B[MN91V+
MFZB\;/2;1M\TC8;9/R#Z#]6]J7*L/E6OVIMNQ^CW"_+L5CUJ*^1(1?5=4KU9
M;QJFN:9C:7=DW[<ILC=7:O;(LA[:*X?:Y@XU,)*:[9[1;JPI\3;TJ:TI\RK*
M;X'R#;#-6D:SV3@^RA^DETMU>'\.A_>*($=&D$.;,$57\Y5'E?OT"?)719 C
M(\A>?2Z5SW2[3CLP"!M-HUXO>!*N?*;;17_#,#MMPVP7M,F/UOBN\E)?JB.M
M<I^^1*H_8_?I,:2?JK,)^\B'?L#95]\[.8/' M]U5<D(!.Q2=@RK'*KE]\&V
MW&HMHU7'3BI'Z%:K*+]CAVJK ^9.9\W+N,?N4*VR4E_ZR;XBR)$1Y!CB)&=6
M.*X\ID^):RJ"'!E!JH339^&]:[>;1J]7\'+22]WBNR9"RVC4>T:[?11DJ-)/
M*T]:.?:E,^3:^*]N]#]IXO?6=1H]D9O\1YF)BN>7];!>.<TV=YJUVQVC633<
M65WH?W;T1W.M#QRP9KW()W.EO\I&?9$G^XH@1T:00YLQY6R3TS#DN97!*PX[
M6@ZK"')D!*GR47?'4KOVYO7-EF%V=WR#_*GOZ]V[5#O=KM'O'049JNS4RL&V
M?OFXCM%9]ZA9N5>?.O4;7:/5.U[J/Y=D5?WHLAZR*\?:YHZU?KMN])J'246L
M'*N'IW_+Z-;;1JM[S!Q09:56Y_N*(,^.($==*_7,FCIHGUS\P![0#K:&K1RL
M3XJ]*H(<&4&J]-5GX>9K&/V.>0S\]'))(!94HJ7+\6_L*GWU);G82C-PY66M
M6.!INEJ/+)DU[URS'OXK[]OFWK<2ME3E>WUVU-]8!#X9[VN5UOHB3_P508Z,
M((<V:(JNYIQ/ SYPK,CQ/69Y-CN=^ #?O^F+R@W[E%BN(LB1$:3*<]T=2^W:
M\6?6C5YCQT4_G_JVWC4->D:O:';8\6_D*L7UA;K?^D:W7[#A7>5[K8C_U+RN
MQY/@.GN42>#1CS3KT:+RP6W! ULW.F955^"EDM_L&9WN<R\J4.6^OO0S?T60
M(R/(4>>^JO+P(D@<\LKA^I18JR+(D1&DRGM]%GZ_-]V>T6U5#:\.@OM&NVGT
MFX=$?I7D6GG9GE^&8\4"+YX%#IT3LC//Z^PQ9CT*5%ZV+;0\*F,Z59VNG@W9
M2UEMA^QS]2ZR8*GXU<_OXO!D9%G3]S=\-.%>=,VG&*?Q1N=..'#], [X+8#T
MT?4'?_[ZG_^!-/U9O7+F3R9.A&^%IYZ-G??@/>X-'![FO,T&\ #\<<V'O[SZ
M%/B31MWLG-1;)W4S\L7G_DFS_NI7A'"J+U58@>S6F?"0?>4/[-J?6)XAOC#8
M#0^<X0<VL8*1 UBK2R0ZGLWQW7JM[7B%67L.B],4<PI]FP!7%)#/%Z<W%^SL
MZLN7R]LO%U]O;W8.V49H6R(1#H3 WSD;Q$$ :W$?&?Z/6=-IX/]P)E;$X:N&
MT:G7":+PK]@*.!MR'C%_R/@//H@CYY[#'T-GP%DXM>"_5L3ZG6:;_198'AQK
MV+5CCS@[#^!! #+&K\QZ'3Y:'CMW^,@WV-DIZS?,1A/?C<:<!3 SSO"Z8]3;
M+3;E 9L X&." L.E;.C'P<DCMP+8^U;(X2UXE?^8.J#8F>.QOUL>P K U\U^
MC<$2+3?T\U9G&MUZG<VLS+5 _%F1#P,D:S+-=J_-;GS"E$^0_--R7?X(9+#L
M=&7][,I 0@W]P',L6J$YM\*6T>QK*V2T.M_C<XM[L$* ?R#(!/S'@?U$T#CR
M&4Q(BQ?19%L._M6_YY,[&+H)Z 9,=&O5WBBW-Z[B *Q$/_0GG-V N/8&.-JE
M-ZBQ,+X+'=L!)B.(I@&_=_PXE'N(VW.[J-YNS_*9W#>8R)S/<NR< _F^6<&?
MR0;R8^"2CT'LA0_.X$^#??T[/"KX0.<K4+!FMPA?B4UCXZ:Y&D0^L@NP2KL&
MJ\Q\8;"+FTM8&V@H"Y>'7,=L9SCDM*M"9'\"0W)X:$T2P3#P)U.7_ZBQ6YS1
M _+0X\33^%O@A# B@)W%6;MEEL(8?.F$!(,"$F5141QF]Z6);04T_,&A!CY;
M\B]8O/@@$'EGA4Y(&)-RAX! 56VP!XZ",AB()<:X&4]LZY%Y?H0K@9'@-#)Q
M/)P8(4 LBU&!(LC)?^=!"%(&4#6U D*"A18"'4'%?D>\P, :0GP G'X3Z("1
M$IE$:,I.A&1(@+ 9!YH.2*Y_XG>!$*-]$B"=YR- C@/@8Y%SU[B%N3@. \N.
MG<$8MA)PX,"-;1(.! [8K,!7+K&090._.&&$?';/U<L @[:';?:ZVS?JH&#Q
MC=?].GT&?2@DA/-#[B+@5L>W0T8Z#18QC3)ZJT.ODQ B,$#'3P6'NH^[Y\@G
MK+X^7_QV^IE].;V]O;BN[.*2R,.3%XM@#)+1\'^##5S+F80,%=+$LJ6Z&UF.
M%T8L)KL3^1I.SB!)06H.0"J'I$[NXM#Q>!BJO06_N#8HTS!V(WS-=2)G1 *[
MQL[D)+C'PM#'%$'8%.D3-#U8'W_ %E#VG^.-A1J.P4()(H H@K,EC1%[0^L>
M] *<8T%+1*!N>2CG]P=@^!LP%D $*@#V(H\0;MN:6"-$W1"!-F![>I9+ \+.
M=;P_8!+2+0PV^MBY<R+50QYP,$2LA9SZRJ.]@:],L.<\/&O'@XC&X-[(&N$#
ML'0?4 :*%;>S@W,\'Q6S)SZ]198;B"/<@+@-5'T.U94E8'EH,/&! Y:4E+R2
M'\86"'(P<8#A @?%O'V/MH<T"-"$1#-#<&U(5D=B9DBA#E:4'!'^',9814 )
M=SR%B0T#WX'Q PS!0W&:L<BR>223$H"C @3(/3ABP $:#S< 'P%(P$4#SO'G
MA8R2>FK*N5UFG38W8.#SOV)X^^(>AZC\,VNQYQ?+ V&"1 #^ A5_;[FQ,#,)
MJW2.$FA6PBQ'_P,?^/%H3.+5%I:R--BM 1X@@&V08X P-EHAMF8@PQ\@QBR@
M.K!/&,$7Q!!@E^.QPG'A]P<G$D/?<-A&)(4$IX+XO/@Q&%O -8R8*0Q1 !.O
M!Y876E(.XH-"CLE%"2D_L? P^%<,YRO82W_$(?&BV*'V.QC$3K@0)2')X016
MX7%)X*W$8DF^RQY?Q4%LX+LN2#*T2\U^T^B:?0*)=-;YZ?6W4WE"M29^3/QJ
MLSO./2#.O0^'-3KTTG.)#6L-Q@[0/*$KFP!'A1$J/CQT)9R<6+%TY'5!L8/X
MQ0.JXC1B9)P4?3S./0ENBX3L_':H;-XE(*5BF^7*$G&$(&9 ?1 #$92Y I($
M;" 8&X6\./"CPCL37]_0US<6T)>=C@(NB$ZRXV^U,U!O8'4]4!R$O0DY9U]]
MD%.=MS7VD4</R$7(+T(9"C_F,&%0<T;,)8Z[GI$R;V"1"P%L-*4%0^$C-8U&
MI\W>6$-0VPP.4&!EX6I>FT;?[",;#A+1%2).$%J"0(.8SF?=?C^UR'ST[. X
MZF3WEL61XSK_QN^$@P<Q8268T&4T_H; F4V S63AV$*_+.XL8'0P*D C2*^9
M,Y!^T%I'N%OH6?Q*7VC%\<N<E*FD:VO\PBG,C6=WZ:Y&W .E;"6LD%#" 832
M;,:#M,#OS=;P>=?8-S@'Q5:JX4ER*E ,#1#T0L&6<EV0NXF3&WEVSI6=N+$"
ML0O%*[/N]-4VXD(K;\X<'(QA:[G\:G@-=JL5#,9@4YZ#['?]*2[CE!H6G Y(
MW=M7N(= EWBW8E=\E = D"5WZ&:#O;B>/4D!238 B27CHK^\JK^BOY%BZN]L
M$!?5GC4-@674IP^ ,3L:(T/6?_K BC)GFKY!H*Q(",E+]MA>X'S+P\W$X0%1
M@$_OEU>-!)EZP'E FZNP2M*5T+X65.%GZQE.>V#H@V3=%2+F![8\&ZXH>"C0
MC@$'+P?=:[;PV#JZ]YU0*%5<I_/3@E3"XAXVL'&%02%C%,4P*@%H;#K_VFED
M2LG_M(";]II1IH!IEH>FW,WM7MWH=0J6,= P=.!;W!6S'(19ZMWB%[T/S2P'
MN6I2BOEN5$BWE)RL<FRWS]C-;M?H'2BUNBI@<7CZMQHMH]'I'C']"^5:[\SI
M,I^B[9$0!1#.^5UTB[!4$;^U_)$:*LD)'K)OUJ-P6_E>Z(013QS@Z, ;^J[K
M/Z!7V8IR_/4Y10:>;N K]=[IWKI9;U[II62<>0N=?L?DO=O/N'E'[1FA>[?L
M3M\*-Q9!5L!C^BUPO($SM=R2&FI]C]I6+GKO>LKC(,YWSQ(%U[B= 3"S@@*B
M]RY@[^96.??>T)HX[N/[ G!AA@H&A.>Q>9S4?+$,])5'1\4XIY.*;9X VYP.
M!D%\9#)'W8Q>AWF.SM.Q80GCC0D\9P8G<RMS6*L"P,[$%3SV#771LEX&FR]@
M%QOH$%4BGOV<%9XK/#^G.5\$GK>DO5;ZZ>69O]7_:7,+5B57->IFBYGUGYBF
MNY+IA0XKA^HD8G+ Z-5=P<!Y46PM=NXNA:R_$K(RWMZBP'8Z#:-G+FXE>"1D
M:U0,<B &>=/N&/W^X@#HN@Q2=/[%Y5@JACE*ANG4VR!1%N<451+EA3.(V35:
M2QHA[8\_CL"/L#R2712CHFS=0IM,^1,V-(./).J^]\VRU2C\;NVRPY"L8I0#
M,LIZ]MENY%!96ZUBG$-*F+7LM$K"O#A&6<M>VS7%<FRW-#_L\%D_<V!7MU&W
MD?WU!3/\6%-=AWZ#=U(G?AC)PH=LZ(1@LC,J8<<]^^WN<\-V1(CJ%N?+NH6U
M.@-LCXAX(3C7$KMH?I4LP19G5E6TV!$MOO(H2X-%24H5!79$ 9ENE*7"XGR?
M%W%!=-W[#8M-'#VCYZOOG13.ZMFR6MWN>E]H?[:*(!5!*H)4!'E"!-EKYE$O
MYQYT"9M@:=;1BFRC/'CR;L[O(YULU;WY+?0M*W=I/B?LN[W.9>U&]_]O[\IZ
MVT:2\/L"^Q\$(P/D@79XDPJR >0C \^.+4-V$N0IH,FVS1V*]/!(HOGUVTU2
M-RGQ9I.LQ6 12Q2[JK[J[JKJZBI&4<M75VBTAQUH2(,:\A9KB"RF'VTVHB$9
MNWN!8C2Y=+ LPPEC6#I 0U)(442&%<H78QEN<\RL3.YE%&7,)-JBB=)3VTZ7
M[<AE7D'9EM[AG\MX@HZH?8$]EVD$T[YW^.<Q?"@KUM1"KL4>G7M]7P[4<DJO
MZTV>C7X:ELHO6Y^[DQ5^UH>24L;B"*FH92^$$+9^6JPHB=MH98@/[A=-:-%$
MCR%2Q?*7HJYMTS?#;D=QV@@FS=)L/6^*?PO7+TOS7O"N2U@IM/KDR&/V>.=N
MLZ1&]\OKK.XNVY;NZ6W<325L#8)(EZ;5X.N.%&'3%.T1S_JL>>9U*77=DZ6&
M'%Y9P@9$UNLDU"EEEF6VK(@V=O:1$;BK+C8[%6O7%0A7XR\K$5*B/06WXV:&
MK^4*C!#VC2TI_O*77&A?@<_CM3:M;1C-^LN?\?3<NT@@J?T[@ VY<TFU=],<
MHUU7*JR_&Z>\_6EJCZ85]E(L44L7\N0;2;;I13>?KLAG=<FE0=E IZ,<0$*G
M(Q!W-WRBG7A#V.FH:!QX>4' S'4GH)5J*PWVGBD<T3]RJ[9JU@JGM0!N"2<Q
M*F6X-9+6>SS%),<Z&;H"I*=UN*98:V> AA4ZQPEC!?E5>:=F;=E5>$E2A8*I
M)8WFW 'Z-: O\XPL%>P'! EUV1+JHL[I>GSIK_2J!YD5%?1!DQBAJ%\ B36=
MAY\39$8>%^R 2TT;M$R!U=UH+"ES8#E>X*+IT_V+YJ)SS4/&A3-_1;87-D.;
MN*YF/R-R^NJ=+];/W&F+L+G:3\TU\L9MO\?#?Y]A'](U=1\9]S[^^4T8$H2H
M+B563Z.1F:A_\HT3GK*2Y_?ZEER%1Z^;7^V<7VU^15&@9VCH;2%TM>SPN@?G
M0>QH:4<^!.Q(/]Z$>1=#MTE9\KS;^@;F74O8983N('*TS+J60N,BFQ"D*Q7A
M^H+M&Y)$Y#SAAXA]Y+SZ87*19ALC=V7\K,B*'@ILTX=K[<7BNGE)R><H,!(O
M,#S<; <E2:=%8AGE0,(.:,C@-00O(XK C,>@)* DZ4K"<HS(=T)%*#EY+!"+
M#^VMTT<2S\)V^SKH-4*_R+_ACOM!OFN-R>8SM2 JWSL-R&-' ?R]@S^GD00:
MT#\-R&,!47$LU_2U-MI2X%-,M;HF74_J<0(@  @  H!T"!"://[UQ^2A]Z/U
MOK]LVW2:PQ;[B@@JR!AIF!/M&8WL(#PM<YY(@&#NV"./I,!X*YJ=P/=\S28$
M;%7V?]0\4P_/>0S3"OSH$'R AF0EN:U555!B%$EF5%6@V*8$56A(%62.940)
MRJF!*C#RF&4$&50!5('A9(49LS1O$!!T  L>  %  !  9%" ]#?H<+X;*QA9
MCN>-7LD]P8V@P[H>HN^[YF,079'QG1&D,=!ZAO66/>/;26& 0NUM@LY"=?[A
M@0XS?8"@TSC3LUP7KOCF[U[%_&.O3'OC-+HA0V[.(&-B&U?8A"%W9!X<\M'5
M+^3JIA?>:2Y2,7)U\SB\;QR-E7SKN).5^>N:S;6M$@F7Y?+4#CY25#&D+,M-
M;_S;1_*/VV"KJ+/S%)+^N&)BDZ-CLK 2[KPF_NY)FYO6XGT>.N^C,\ATXEK$
M="BZLCPIIE1%)M'Y]0'J:ALZ7J1;&?O.-?5# \/$@(G1VL28H;EFVMB*:&/P
M"_P[5]/]0+/:&/X!N?.1:;<Q]#>DN=1LE@GF^1 LO;K]S#ICW-V6$$B^;^_M
MLN0++'\55?>0U/)]QZ*H1$Z8:&JP5O5(NV6-JVEZ(G(*PXKI=4AIX9Z&D;+*
MM&C+O'H0YKA#T7+ZI=[=D6J:L6<*#=.UHMVEMNY;RV V.;3_<:A_ @7=MOK<
M+0[O+U+I9G'T&%75*FG>G:)Z>*2SP8'3O$^0%0RE#3 :=!/*RB>L)$,)^B7:
M)C9'0BWVAR R4F:/H6N3FYY%@U9.NO;>+DL^86U.; W:< 9(US)0FJM]+_6B
M]'WXBI_AV2(9W3(:+D.8<,J:0%)]I9[W<E-&L_O/Q5ME11JQ13U]CGB!,*\@
M9 XH'(GF)KV]&[WP"E;V+-G,4!4/.M7M,$G)I9$<*U/F&-&Q&=ZTJ=^_=FB2
MS#$*F['18T<+K^998LM77"TFRLZGJE-UQUV4&;ZH4E/3[:IU[T)_049@D>1Y
M8KV_8/,)N=[5WX'I+VX='WW5""F^-W5G!!POMYN@!QZ6^/=+I(>. ?Y&7+X3
M$M;;\]LIR[6<S/%:'ID(CRO*>Q@NH4SL,[+*T']- !*Q!ZVED(@-$X,^)Z+"
M=+RE0;15A%'S1S>:J[^LAA<XYG!;.EI2<[J>!,0SG"PR[%BDGO\^CE0/IF_X
M,XX=G:[&?L/E2,X8@MC[EIDIG\GIL0'(Y%MG\D461-9D\,[9LK7E$[WE&5DN
MFU&4=;#T,@D 3\IJ))_QZ7U@NRVUIE?J.E;G%L!IT$DH*Y]KSPM@3<XM-H%E
M6$BYI0:.-P-,@.[.&MP*.'7;PT7R"+(*[$*SR8$4,MY=_7HUW=P7*-O(;: ]
MGZ(B6YP;,Y*<7NV\.1W):JB#3M2M$WD< $ C4R9G77M;\\I!G6YTR#=).ZVX
M1Z]^F-$QPF9XGI.*AK6]_]=">893.$95TDMZ=MOV'BRPX2G&BIK3?*<8 T.Y
MH<VJ =2E,Z'Y&X%U.VJ5[4)HG>K8O5UH"'=:![T;#0%@V)7RH=WHSE0[^K3L
M3HG9]46SVP^DR2=FXV^48?>^:%809?%[7C"//BMVQ;;+N?.5)-<I;/FTE)GI
M_35Z<A$:F20M%7G^R-7\]%Y"AV]ELK_5DNO*GF%6-_2^I'W6H!T69[^&+9K"
MZWZ6^80J.8.J2+3"F31:K"KG5B#*)F(LJ\N3/QP+KR467J]R:4=CTAUS9])O
MU"OI2IR&^<,TD&UX-,GPUK$/MC;+N=-5L$$=V/[0,WGG#+TZV 6TGZ_M)\>=
MAV\[7\1?YMWG:BD6$6U;67>[M%VL]6H1[92&D$_2U;VJ.A#WYJ_1#?[XQ1M=
MV0:>FRO/?9WQSC(T2*E **3W&L(WH"$'@S?-XC\0<:>?B=$]W6KN#3Y#/Y =
M(._]8?&TI0:U],*E]G5]DTTCZ5"Q423+O^UV_"6V45;Y3)#_8CEVMD6B4Y6&
M,O9@K*3 D##F&59)3U:JFK>"590 N#W@5)91E?1;@>T UW;Q'&Z_BWB>->7J
M_IH&HZ-\8E(G*T-%A*@\QQ4W?YL3 ZC 0%6 DNIW<=6H[<6.S['8A;7#1DMW
MHIBX.U]$C()^U[E,L%9JAP'^M>*?QY*CHG9<RQ&0UMW\E#6ZKDE7>PBA*88
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M.W3K*KD\P0L\MYQ-I:BIF;$"4%7#U(=WOQY=RWQ/_A__^7]02P,$%     @
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M/D4V_87[GH?MX(4N>/P?4$L#!!0    ( !J*:DG",F7/9 T  #6?   5
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MX^/CP&</^)$%W_C 83!VMRP*'++AA4FX$#"_CD??_WXP/1B-WXR.)J/!TUS
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M--O\Y7?JLT"A-UD^W]*^0-R@#<L48YT%4[7GB>_6J=?,E%WW4B@V8__;RC%
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M7MZR&J8@N5HY*V5&5.A\UO7\2Q)"2N1,LZ[]J5#J@DF C(5LZ\8:C.V6JU[
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M;DX52^@?39K%!/-7$@$1WRSR.:$!KY?Q(A0BSY+4)\V2FH,@ .X%]#,OZK<
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M?/7V2T'N> ^K5;JUE972 D*/5D$EB+[*4,51O%^ "DDCHHFA^8S,HX])JHZ
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M=/KN&QA@LSK?&?,4QWQ6 _1$QNK<!=(Y2^V:,'M$7C,@FF2N/8Q,R;9;J=.
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M I;R(F^9[?[1RT*?[H;#:),K\W:-7$ZKG-B9T"A[HF<!X\7L]&PCD%&Q($7
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MP#E/O3CS^%H?!CQK9<9>ZMH9HX0F-K>1%SLCF@$6/0\8Z%DJ*H9+>$TXQM<
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M>H^3X@Y8S)0:4Q55+ZOW7&#V@ >+$&?9AGI85G%=,[UVD.%ZM=/9O/:2QUH
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M#__BL[J:47FA:_!HC-4G#V)?V*'Q]EQGJ_J>FX'WG@^\F#V3%W1/PQ[45N6
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MB=*KP#H<A&C5,U57/^+A)4D/U'^Z(O]&?BY_(O^@/4Y^^?]02P,$%     @
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M\.#Y$OH)DV#T(N*$J0J62E,@'#^9!X>$:\3C:3I_;\@\C+C)F,8L*T^IDAY
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MU4X;G+8$$(:AJ(GR*3J(Y1VP4YSZ1&M5"(8BI:X7(&.M3;4 $_V9+:L%K/G
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M#^T/E754.Y.&PHYOL/<F1_RD]K3\46%HL+)B1Y4G+M_N6RDMJTC,L#C)=(2
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MLWX  &%E;60M,C Q-C Y,S N>'-D4$L! A0#%     @ &HIJ2<(R9<]D#0
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I;60M,C Q-C Y,S!?<')E+GAM;%!+!08     !@ & (H!  !X#@$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
